Pre-meeting Courses: Annual Scientific Sessions: Exhibits:

Transcription

1 program book Pre-meeting Courses: Friday, November 14 Saturday, November 15, 2014 Annual Scientific Sessions: Saturday, November 15 Wednesday, November 19, 2014 Exhibits: Sunday, November 16 Tuesday, November 18, 2014

2 IMPORTANT LOCATIONS ACR Office ; Telephone: (617) Attendee Lounge... Ballroom Lobby Business Center... Level 1: North Lobby Career Connection... Exhibit Hall A: Discovery Center (Booth #731) Child Care.... Call for Location; Telephone: (617) Coat/Baggage Check.... Level 1: Northeast Lobby A (near 154) Concierge Center... Level 1: North Lobby Discovery Center.... Exhibit Hall A (Booth #731) Exhibit Hall... Exhibit Hall A First Aid... Level 1: North Lobby Foundation Booth... Exhibit Hall A: Discovery Center (Booth #731) Foundation Donors Lounge.... Boardroom (Suite 201) Hotel Reservations... Exhibit Level: Registration Industry-Supported Symposia Information... Level 1: North Lobby Innovation Theater Exhibit Hall A (Booths #139 and #1401) Lost and Found... ACR Office (260) Membership Booth... Exhibit Level: Registration Newsroom ; Telephone: (617) Nursing Mothers Room A Overflow Rooms , 204 and 259 Poster Hall.... Exhibit Hall B Prayer Room Recharge Areas... Attendee Lounge, Technology Center and Wi-Fi Way Registration... Exhibit Level: East Registration Restaurant Reservations Level 1: North Lobby Ribbon Distribution... Exhibit Level: Registration Shuttle Bus... Level 1 (near 156) Simple Tasks... Exhibit Hall A: Discovery Center (Booth #731) Speaker Ready Room Technology Center... Level 1: North Lobby Visitor Information... Level 1: North Lobby Wheelchairs... Order through ScootAround, Inc.; Telephone: (888) Wi-Fi Way... Exhibit Hall A Special Needs If you require special arrangements, please contact the ACR Office (260); Telephone: (617) Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder. *All important locations are located in the Boston Convention and Exhibition Center.

3 program book ABOUT THE ANNUAL MEETING Participation Statement This Annual Meeting is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare professionals arriving at their own conclusions and consequent application. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the College for reliance on any information presented during these educational activities. The College does not guarantee, warrant or endorse any commercial products or services. The ACR s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians, scientists and other health professionals in order to improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal diseases. The Annual Meeting program s content was developed through a planning process that included a practice gap analysis that identified educational needs in knowledge, competence and/or performance. Planners took professional activities, practice setting, ABIM recertification requirements and physician attributes into account and have designed this activity to obtain desired outcomes in terms of improved physician competence and performance. Global Learning Objectives At the conclusion of the 2014 ACR/ARHP Annual Meeting, participants should be able to: Identify recent developments in the diagnosis and management of patients with rheumatic diseases; Outline new technologies for the treatment of rheumatologic problems; Describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible solutions; Utilize new research data to improve the quality of care of patients with rheumatic diseases; and Summarize recent rheumatology research findings. Printing of this publication is supported by Amgen, Inc. This publication was printed by an FSC validated printer on eco-friendly paper.

4 TABLE OF CONTENTS POLICIES Copyright Materials Policy...11 Photographs and Video Recording Policy...11 Media...11 Embargo Policy...12 Abstract Reprint Policy...12 MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices...13 Children...13 Child Care...13 Nursing Mothers Room...13 Exhibit Hall...13 Meeting Room Capacity/Imortant First Safety Information...13 Photoograpy and Videotaping...13 Name Badges...13 No Smoking...13 MEETING NAVIGATION GUIDE Tracks and State CME Designations...14 Session Formats...14 Abstract Formats...14 Abstract Categories...14 MEETING SERVICES Annual Meeting App...17 Discovery Center...17 Membership Booth...18 Lost and Found...18 Newsroom...18 Attendee Lounge...18 Concierge Center...18 Registration...18 Shuttle Bus...20 Speaker Ready Room...20 Wi-Fi Way and Recharge Access...20 Rheumatology Research Foundation Donors Lounge...20 SPECIAL OFFERS SessionSelect...19 What Would Make the Meeting Better?...20 Medical Bag...20 POSTER SESSIONS Poster Session Presenter Instructions...21 Poster Presenter No-shows...21 Guided Poster Tours...21 ACR/ARHP Annual Meeting Program Pre-Meeting Program Friday, November 14, 2014 Pre-Meeting Courses ACR Musculoskeletal Ultrasound Course for Rheumatologists Day One of Two...22 ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 ACR Basic Research Conference: Emerging Perspectives on the Microbiome in the Rheumatic Diseases Day One of Two...23 ACR Clinical Research Conference: Patient-Centered Outcomes in Rheumatology Day One of Two...24 ACR/ABIM Maintenance of Certification Learning Session 2014 Update in Rheumatology...25 Saturday, November 15, 2014 Pre-Meeting Courses ACR Musculoskeletal Ultrasound Course for Rheumatologists Day Two of Two...25 ACR Clinical Research Conference: Patient-Centered Outcomes in Rheumatology Day Two of Two...26 ACR Practice Management Pre-meeting Course...27 ACR Review Course...28 ACR Basic Research Conference: Emerging Perspectives on the Microbiome in the Rheumatic Diseases Day Two of Two...29 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions...30 AAMC Medical Education Research Certificate (MERC) Workshop...31 Scientific Sessions ACR/ARHP Opening Lecture and Awards Opening Lecture: P4 Medicine Is Transforming Health Care: A Longitudinal, Framingham-like Study of 100,000 Well Patients Over Years...31 ACR/ARHP Opening Reception...31 Sunday, November 16, 2014 ACR Sessions Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Pediatric Rheumatology Town Hall...32 Year in Review...32 ACR/ARHP Networking Event ACR/ARHP First-time Attendee Orientation...32 ACR Meet the Professor Sessions Basic Immunology for Clinical Rheumatologists (001)...32 Crystal: Diagnosis and Management of Gout (002)...32 Cutaneous Vasculitis (003)...33 Fibromyalgia 2014: Update on Management (004)...33 Macrophage Activation Syndrome (005)...33 Pain: Evaluation and Treatment of Back Pain (006)...33 Psoriatic Arthritis (007)...33 Reactive Arthritis: An Update (008)...33 Rheumatoid Arthritis: Challenging Cases (009)...33 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (010)...33 ACR Workshops Joint Injection Techniques (201)...33 Nail Calicoscopy (202)...34 Tai Chi in Rheumatic Disease (203) Program Book

5 TABLE OF CONTENTS ACR Sessions CARE: Maintenance of Certification Session One of Three Vasculitits...34 Current Understanding of Malignancies in Connective Tissue Diseases...34 Ethics and Rheumatology...34 Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 Osteoporosis: Current Concepts for the Clinician...35 Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 The Microbiome in Health and Disease...35 When Pills Are Not Enough: Multidisciplinary Approaches to Pediaric Pain and Hyperrmobility...35 ACR Poster Session A and Poster Tours Abstracts (#1-814)...36 ACR Sessions ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Advocacy: Meet the Expert...36 Sarcoidosis in Social Media Boot Camp: Twitter Basics...37 ARHP Sessions ARHP Keynote Address: Happiness From the Inside Out...37 Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing. ACR Workshops Beyond Musculoskeletal Ultrasound for Rheumatologists (204)...37 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Histopathology of Rheumatic Lung Disease (206) Synovial Fluid Analysis and Crystal Identification (207)...38 ACR Sessions Bone Biology...38 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 ARHP Sessions Affordable Care Act...38 Immunology Boot Camp I: The Basics of Targeted Therapies...38 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain?...38 ACR Plenary Session I: Discovery 2014 Abstracts (# )...39 ARHP Networking Event ARHP Networking Forum...42 ACR Meet the Professor Sessions Ankylosing Spondylitis: 2014 Update (011)...43 Ankylosing Spondylitis: Disease Modification (012)...43 Dermatological Manifestations of Rheumatic Diseases (013)...43 Hereditary Angioedema Update (014)...43 Pediatric Systemic Lupus Erythematosus (015)...43 Rheumatoid Arthritis: Biological Agents (016)...43 Systemic Lupus Erythematosus: Novel Treatments (017)...43 Vaccinations for Patients on Biologic Therapies (018)...43 Vasculitis: Update (019)...44 What is Not Central Nervous Angiitis: Making the Right Diagnosis (020)...44 ACR Sessions ACR Knowledge Bowl: Preliminary Round...42 Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Axial Spondyloarthritis Guidelines...44 Gout Management in How the Gut Primes the Immune System...44 Practice Issues: The Road to I Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 The Butterfly Effect: Lupus Rashes and Their Mimics...45 ACR Workshops Advanced Musculoskeletal Ultrasound (208)...45 Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 ACR Sessions Autoimmunity in Immunodeficiency...45 Educator: Medical Education: The Year in Review...45 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 ACR Concurrent Abstract Sessions Epidemiology and Public Health I: Drug and Vaccine Safety (# )...46 Metabolic and Crystal Arthropathies I: Clinical Aspects (# )...47 Miscellaneous Rheumatic and Inflammatory Diseases (# )...47 Rheumatoid Arthritis Clinical Aspects I: Cardiovascular Disease Risk (# )...48 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Malignancy and Infection (# )...48 Spondylarthropathies and Psoriatic Arthritis I Novel Treatments Axial Spondyloarthritis (# )...49 Systemic Lupus Erythematosus Animal Models (# )...50 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Cardiovascular Disease and Pregancy (# )...50 Systemic Lupus Erythematosus Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury (# )...51 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy (# )...51 Vasculitis I (# )...52 ARHP Sessions Google Minefield: Empowering Patients to Evaluate Online Resources Program Book 3

6 TABLE OF CONTENTS Practical Practice Management Session One: Improve Quality and Efficiency...53 Sports Medicine for the Rheumatology Provider...53 Young Adults with Rheumatic Disease: The Patient Perspective...54 ARHP Concurrent Abstract Session Exemplary Abstracts (# )...54 ACR Workshops Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210)...55 Muscle Involvement in Rheumatic Diseases (211)...55 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212)...55 Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213)...55 ACR Sessions Therapeutic Targeting of the Innate Immune System...55 Thieves Market: Show Me Your Best Cases...55 ACR Concurrent Abstract Sessions Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives (# )...56 Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease (# )...56 Imaging of Rheumatic Diseases: Ultrasound (# )...57 Muscle Biology,Myositis and Myopathies (# )...58 Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety (# )...58 Pain: Basic and Clinical Aspects I (# )...59 Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (# )...60 Rheumatoid Arthritis Animal Models I (# )...61 Rheumatoid Arthritis Clinical Aspects II: Remission and De-escalation of Therapy (# )...61 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis Early in Development (# )...62 Spondylarthropathies and Psoriatic Arthritis II Novel Treatments Psoriatic Arthritis (# )...63 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Lupus Nephritis (# )...63 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I (# )...65 ACR Meet the Professor Sessions Crystal: Diagnosis and Management of Gout (021)...66 Infections with Biologics (022)...66 Inflammatory Eye Disease/Uveitis (023)...66 Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (024)...66 Polymyalgia Rheumatica (025)...66 Pulmonary Hypertension in the Rheumatic Diseases (026)...66 Rheumatoid Arthritis: Biological Agents (027)...66 Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (028)...67 Systemic Lupus Erythematosus: Novel Treatments (029)...67 Vitamin D and Bone Health (030)...67 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Epidemiology and Public Health (# )...67 ARHP Sessions Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Multidisciplinary Management of Scleroderma...68 Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 ARHP Concurrent Abstract Session Osteoarthritis (# )...68 Industry-Supported Post-Meeting Symposia...69 Monday, November 17, 2014 ACR Sessions Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Meniscus Biology in Osteoarthritis...69 Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Gene-Environment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 ARHP Sessions Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Update on Findings from Large Registries: Emphasis on Health Disparities in Rheumatioid Arthritis...70 What Are Biosimilars?...70 ACR Meet the Professor Sessions Ankylosing Spondylitis: 2014 Update (031)...70 Basic Immunology for Clinical Rheumatologists (032)...70 Controversies in Sjögren s Syndrome (033)...70 Dermatological Manifestations of Rheumatic Diseases (034)...70 Osteoarthritis: Update 2014 (035)...71 Pregnancy and Rheumatic Diseases (036)...71 Reactive Arthritis: An Update (037)...71 Rheumatoid Arthritis: Challenging Cases (038)...71 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (039)...71 Vasculitis: Update (040)...71 ACR/ARHP Workshops Advanced Musculoskeletal Ultrasound (214)...71 Complementary and Alternative Therapies in Rheumatic Disease (215)...71 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216)...72 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (217) Program Book

7 TABLE OF CONTENTS ACR Sessions CARE: Maintenance of Certification Session Two of Three...72 Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of Disease-modifying Antirheumatic Drugs (DMARDs) and Biologics in the Perioperative Period...72 Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Practical Use of Registries...73 Practice Issues: Practice Success in an Environment of Transition...73 Strategies for Academic Success: The Roadmap From Mentee to Mentor...73 Systems Biology of Lupus Nephritis...73 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 ACR/ARHP Poster Session B, Thieves Market Posters and Poster Tours Abstracts (# )...74 ACR Sessions Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy...75 Legislative Update: Chat with Congress...75 Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Social Media Boot Camp: Blogging for Beginners...75 ARHP Session ARHP Distinguished Lectuer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease...75 Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing. ACR Workshops Histopathology of Vasculitis (218)...76 Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Musculoskeletal Ultrasound (220)...76 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221)...76 ACR Sessions ACR Immunology Update: Innate Lymphoid Cells...76 ACR Knowledge Bowl: Final Round...76 ARHP Sessions Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain...77 Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Stats Boot Camp: Statistical Analysis of Ordinal Data...77 ACR Plenary Session II: Discovery 2014 Abstracts (# )...77 ARHP Networking Event ARHP Networking at Noon...81 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (041)...81 Pediatric Rheumatology for Adult Rheumatologists (042)...81 Psoriatic Arthritis (043)...81 Rheumatoid Arthritis: Biological Agents (044)...82 Rheumatoid Arthritis: Challenging Cases (045)...82 Scleroderma Mimics (046)...82 Still s Disease and Autoinflammatory Syndromes (047)...82 Systemic Lupus Erythematosus: Central Nervous System (048)...82 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049)...82 Vasculitis Mimics (050)...82 ACR Sessions Classification Criteria for Gout...82 Classification Criteria for Myositis...83 Neonatal Lupus: From Bench to Bedside...83 Rheumatology On the Street...83 Telomeres, Telomerase and the Aging Immune System...83 ACR Workshops Joint Injection Techniques (222)...83 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223)...83 Synovial Fluid Analysis and Crystal Identification (224)...83 ACR Sessions Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Forefronts in Lupus Nephritis...84 Insight into Lung Fibrosis...84 ACR Concurrent Abstract Sessions Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more (# )...84 Health Services Research: Improving Clinical Practice (# )...85 Innate Immunity and Rheumatic Disease (# )...85 Osteoarthritis Clinical Aspects I: Imaging in Osteoarthritis (# )...86 Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus (# )...86 Quality Measures and Quality of Care (# )...87 Rheumatoid Arthritis Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery (# )...88 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis (# )...89 Spondylarthropathies and Psoriatic Arthritis III Clinical Aspects Psoriatic Arthritis (# )...90 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus (# )...90 Vasculitis II (# )...91 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Pediatric Rheumatology (# )...92 ARHP Sessions Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Biomarkers in Rheumatic Care Program Book 5

8 TABLE OF CONTENTS 6 Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Thriving with Rheumatic Disease: Cultivating Resilience...93 ACR/ARHP Workshops Dermatopathology of Rheumatic Diseases (225)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, toward Better Clinical Decisions and Outcomes (227)...94 Musculoskeletal Ultrasonography: Basic (228)...94 ACR Session Clinicopathologic Conference...94 ACR Sessions Career Opportunities in Rheumatology: Making a Choice...94 Curbside Consults Ask the Experts...94 Fibrotic Complications of Scleroderma...95 The Role of Bone in the Pathogenesis of Osteoarthritis...95 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 ACR Concurrent Abstract Sessions Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus (# )...95 Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives (# )...96 Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity (# )...96 Imaging of Rheumatic Diseases: X-Ray, MRI and CT (# )...97 Pediatric Rheumatology Pathogenesis and Genetics (# )...98 Rheumatoid Arthritis Clinical Aspects IV: Promising Biomarkers (# )...99 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Cardiovascular and Other Systems (# )...99 Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis (# ) ACR Meet the Professor Sessions Antiphospholipid Syndrome (051) Behçet s Syndrome (052) Immunodeficiency Syndromes (053) Infections with Biologics (054) Myopathy: Issues in Diagnosis and Treatment (055) Pulmonary Manifestations of Rheumatic Disease (056) Raynaud s and Digital Ischemia (057) Safety of Drugs Used to Treat Rheumatoid Arthritis (058) Systemic Lupus Erythematosus: Lupus Nephritis (059) Vasculitis Factors That Influence Disease Patterns (060) Program Book ARHP Sessions Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Role of Nutrition in Rheumatic Diseases The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond ARHP Concurrent Abstract Session Health Disparities/Social Determinants of Health (# ) Study Groups ACR Musculoskeletal Ultrasound Study Group Antiphospholipid Syndrome Task Force Study Group Capillaroscopy in Rheumatic Diseases Study Group Childhood Vasculitis Study Group Clinical Anatomy Study Group Crystal Study Group Degos Disease Study Group Hypermobility Study Group Interstitial Lung Disease Group Macrophage Activation Syndrome (MAS) Study Group Myositis Study Group Osteoarthritis Study Group Pediatric Rheumatologists Interested in Medial Education Study Group The Why and How of Disease Criteria Study Group Veterans Affairs Rheumatology Study Group Tuesday, November 18, 2014 ACR Sessions Glycosylation and Glycan Binding Proteins in Immune Function Hepatitis C in Patient Access to Biologics Across the Globe ARHP Sessions Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything ACR Meet the Professor Sessions Antiphospholipid Syndrome (061) Controversies in Sjögren s Syndrome (062) Footwear in Orthoarthritis (063) Osteoporosis: Novel Treatments (064) Pediatrics: Periodic Fevers in Children (065) Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066) Safety of Drugs Used to Treat Rheumatoid Arthritis (067) Systemic Lupus Erythematosus: Central Nervous System (068) Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069) Vasculitis Factors That Influence Disease Patterns (070) ACR/ARHP Workshops Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229) Basic Statistical Concepts for the Medical Researcher (230)...110

9 TABLE OF CONTENTS Joint Injections (Knee, Ankle, Shoulder and Wrist) (231) Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232) ACR Sessions Bioenergetics and Energy Regulation CARE: Maintenance of Certification Session Three of Three Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required Macrophages Gone Wild Myositis Mimics: Clinical and Molecular Diagnosis Rheumatology Research Foundation: Special Session Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases ACR/ARHP Poster Session C, Late-Breaking and Thieves Market Posters and Poster Tours Abstracts (# ) ACR Sessions ACR-EULAR R Guidelines Metainflammation Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges ARHP Sessions Mycobacterium Infections in Immunocompromised Patients RheumChat Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing ACR Workshops Musculoskeletal Ultrasound (233) Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234) X-Ray Challenges in Rheumatic Diseases (235) ACR Sessions Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases Protecting Bone Health in Pediatric Rheumatic Diseases ARHP Sessions Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Providing Evidence for Mid-Level Providers in Rheumatology Practice ACR Plenary Session III: Discovery 2014 Abstracts (# ) ACR Meet the Professor Sessions Antiphospholipid Syndrome (071) Challenging Cases in Osteoporosis Management (072) Crystal: Diagnosis and Management of Gout (073) Non-surgical Treatments for Osteoarthritis (074) Osteoarthritis: Update 2014 (075) Psoriatic Arthritis (076) Spondylarthropathy: An Update (077) Systemic Lupus Erythematosus: Lupus Nephritis (078) Temporal Arteritis (079) Vaccinations for Patients on Biologic Therapies (080) ACR Sessions Clinical Issues Associated with the Use of Methotrexate Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others New Regulatory T Cells Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside ARHP Sessions Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease Pharmacotherapy: What s New in Rheumatology Study Groups ACR-EULAR Study Group: Toward A New Understanding of Myositis Through International Collaboration Autoantibodies in Diagnosis and Follow-Up of Rheumatic Diseases Study Group Behçet s Disease Study Group Biosimilars in Theumatology: Update Study Group Closing the Gap Psoriasis to Psoriatic Arthritis Study Group Global Musculoskeletal Health Initiatives Study Group High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging in Arthritis Study Group Juvenile Arthritis Workgroup (JAW) Study Group Latin American Study Group Neuroendocrine Immunology Pediatric Rheumatology Imaging Study Group Polymyalgia Rheumatica Study Group Sjögren s Syndrome Study Group ACR/ARHP Workshops Dermatopathology of Rheumatic Diseases (236) Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237) Musculoskeletal Ultrasonography: Basic (238) The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-specific Measurements (239) ACR Session ACR Business Meeting ACR Sessions Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Novel Regulatory Cell Subsets Psoriatic Arthritis: Skin, Entheses and Joints ACR Concurrent Abstract Sessions ACR Late-Breaking Abstract Session Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship (# ) Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis (# ) Program Book 7

10 TABLE OF CONTENTS Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I (# ) Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease (# ) Rheumatoid Arthritis Clinical Aspects V: Mortality and Other Outcomes (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage 2013 Lee C. Howley, Sr. Prize (# ) Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis Late in Development (# ) Spondylarthropathies and Psoriatic Arthritis IV Clinical Aspects Axial Spondyloarthritis (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus (# ) Systemic Lupus Erythematosus Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis (# ) T cell Biology and Targets in Autoimmune Disease (# ) Vasculitis III (# ) ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Rehabilitation (# ) ARHP Sessions Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Treatment Considerations in Chronic Pain ACR Workshops Getting Electronic Health Records Right (240) Systemic Sclerosis: How to Perform Skin Scores (241) Ultrasound Injection Guidance (242) ACR Sessions Autophagy in Rheumatic Diseases Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond ACR Concurrent Abstract Sessions Antiphospholipid Syndrome (# ) B cell Biology and Targets in Autoimmune Disease (# ) Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II (# ) Education (# ) Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis (# ) Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies (# ) Pediatric Rheumatology Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases (# ) Rheumatoid Arthritis Animal Models II (# ) Rheumatoid Arthritis Clinical Aspects VI: Impact of Treatment and Other Interventions (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes (# ) Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes (# ) Sjögren s Syndrome I: Clinical Perspectives (# ) Spondylarthropathies and Psoriatic Arthritis V Clinical Aspects and Treatment (# ) ACR Meet the Professor Sessions Adult Inflammatory Myopathy (081) Behçet s Syndrome (082) Calcium Crystal Arthritis (083) Juvenile Dermatomyositis (084) Myopathy: Issues in Diagnosis and Treatment (085) Pregnancy and Rheumatic Diseases (086) Pulmonary Manifestations of Rheumatic Disease (087) Raynaud s and Digital Ischemia (088) Rheumatoid Arthritis: Challenging Cases (089) Temporal Arteritis (090) ARHP Sessions Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Successful Aging in Rheumatic Disease ARHP Concurrent Abstract Session Epidemiology/Public Health (# ) Industry-Supported Post-Meeting Symposia Wednesday, November 19, 2014 ACR Sessions Co-Stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases Rheumatology Roundup: Highlights from the 2014 Annual Meeting ARHP Sessions Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Rheumatic Manifestations of Malignancy ACR Sessions Complement in Rheumatic Disease Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Primary Angiitis of the Central Nervous System and Its Mimics Program Book

11 TABLE OF CONTENTS ACR Concurrent Abstract Sessions Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation (# ) Genetics, Genomics and Proteomics II: Genetics of Autoimmunity (# ) Metabolic and Crystal Arthropathies II: Mechanisms of Disease (# ) Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation (# ) Rheumatoid Arthritis Clinical Aspects VII: New Aspects of Monitoring Disease (# ) Sjögren s Syndrome II: Insights into Pathophysiology (# ) Spondylarthropathies and Psoriatic Arthritis VI Imaging and Biomarkers (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: CNS and Other Clinical Aspects (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics II (# ) ARHP Sessions Exercise Adherence in Arthritis: The Role of Technology Nothing About Us Without Us: Engaging Patients in Rheumatology Research ARHP Concurrent Abstract Sessions Clinical Practice/Patient Care (# ) Innovations in Rheumatologic Care (# ) ACR Sessions Inflammation and Atherothrombosis Advances in Molecular Profiling and Relevance to Autoimmune Disease Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment ARHP Sessions Work and Worker Health: Easy Accommodations Keep People With Arthritis Employed Industry-Supported Post-Meeting Symposia ACR Poster Session A Antiphospholipid Syndrome (#1-18) Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling (#19-39) Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More (#40-73) Genetics, Genomics and Proteomics I (#74-93) Health Services Research (#94-118) Imaging of Rheumatic Diseases: Ultrasound (# ) Metabolic and Crystal Arthropathies: Clinical Aspects (# ) Orthopedics, Low Back Pain and Rehabilitation (# ) Osteoarthritis Clinical Aspects: Imaging and Biomechanics (# ) Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis (# ) Pain: Basic and Clinical Aspects (# ) Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (# ) Pediatric Rheumatology Pathogenesis and Genetics (# ) Rheumatoid Arthritis Animal Models (# ) Rheumatoid Arthritis Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis (# ) Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis (# ) Sjögren s Syndrome: Pathophysiology (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment I (# ) Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology (# ) Systemic Lupus Erythematosus Animal Models (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: Treatment and Management Studies (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (# ) Vasculitis (# ) ACR/ARHP Poster Session B B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases (# ) Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis (# ) Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis (# ) Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes (# ) Epidemiology and Public Health (ARHP): Epidemiology and Public Health (# ) Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus (# ) Genetics, Genomics and Proteomics II (# ) Health Services Research (ACR) (# ) Health Services Research (ARHP): Health Services Research (# ) Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI) (# ) Innate Immunity and Rheumatic Disease: Signaling Mechanisms (# ) Metabolic and Crystal Arthropathies: Mechanisms of Disease (# ) Miscellaneous Rheumatic and Inflammatory Diseases (# ) Program Book 9

12 TABLE OF CONTENTS 10 Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype (# ) Osteoarthritis Clinical Aspects: Epidemiology and Pathogenesis (# ) Pediatric Rheumatology Clinical and Therapeutic Aspects (ARHP): Pediatrics (# ) Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR) (# ) Psychology/Social Sciences (ARHP) (# ) Quality Measures and Quality of Care (# ) Rheumatoid Arthritis Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality (# ) Rheumatoid Arthritis Clinical Aspects (ARHP): Clinical Practice/Patient Care (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis (# ) Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment II (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies (# ) Systemic Lupus Erythematosus Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (# ) T cell Biology in Rheumatoid Arthritis and Other Arthritis (# ) Vasculitis (# ) ACR/ARHP Poster Session C B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases (# ) Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis (# ) Education (ACR) (# ) Education (ARHP): Education/Community Programs (# ) Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment (# ) Epidemiology and Public Health (ARHP) (# ) Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus (# ) Genetics, Genomics and Proteomics (# ) Health Services Research (# ) Imaging of Rheumatic Diseases: Various Imaging Techniques (# ) Infections, Infection-related Biomarkers and Impact of Biologic Therapies (# ) Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors (# ) Miscellaneous Rheumatic and Inflammatory Diseases (# ) Program Book Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy (# ) Osteoarthritis Clinical Aspects: Therapeutics (# ) Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes (# ) Pediatric Rheumatology Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases (# ) Quality Measures and Quality of Care (# ) Rehabilitation Sciences (ARHP) (# ) Research Methodology (ARHP) (# ) Rheumatoid Arthritis Animal Models (# ) Rheumatoid Arthritis Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches (# ) Rheumatoid Arthritis Clinical Aspects (ARHP): Clinical Practice/Patent Care (# ) Rheumatoid Arthritis Human Etiology and Pathogenesis (# ) Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis (# ) Sjögren s Syndrome: Clinical Science (# ) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment III (# ) Systemic Lupus Erythematosus Clinical Aspects and Treatment: Epidemiology, Women s Health, Cardiovascular and CNS (# ) Systemic Lupus Erythematosus Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants (# ) Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response (# ) T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity (# ) Vasculitis (# ) INNOVATION THEATER LISTING INDUSTRY-SUPPORTED POST MEETING SYMPOSIA CERTIFICATES OF CME CREDIT OR PARTICIPATION Accredidation Statements Evaluations, CME Credit and Cerfiticates When Claiming CME Credit Conflict of Interest and Disclosure RECOGNITIONS ACR/ARHP Annual Meeting Leadership Exhibitors Supporter Acknowledgements INDICIES ACR/ARHP Annual Meeting Planning Committee Disclosures ACR/ARHP Abstract Category Chair and Reviwer Disclosures Invited Speaker Moderator Index ACR/ARHP Abstract Author Index ACR/ARHP Abstract Moderator Disclosure Index...346

13 The most comprehensive online collection of rheumatology-related images. Serving as a centralized resource for clinicians, researchers and health care professionals, the Rheumatology Image Bank provides invaluable assistance in self-study or the education of others. Start your visual exploration of rheumatology today at Stop by the ACR s Discovery Center, located in Exhibit Hall A (Booth #731), or the Concierge Center, located in the North Lobby, and speak with staff to learn more about the Rheumatology Image Bank and all it can offer you. The ACR would like to thank the following company for their generous support of the Rheumatology Image Bank: general information COPYRIGHT MATERIALS POLICY The Annual Meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. Information displayed or presented at all sessions during the Annual Meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced or distributed without the written permission of the ACR and the presenter. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. Use of American College of Rheumatology s Name The names, insignias, logos and acronyms of the ACR, the ARHP and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the written permission of the College. PHOTOGRAPHS AND VIDEO RECORDING POLICY As a courtesy to our presenters, ACR policy does not permit photographs or recordings during educational sessions, including poster sessions. The only exception to this is for registered media, who should review their registration materials for more information. MEDIA Credentialed media attend the Annual Meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to Meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the Exhibit Hall. Press who would like general photos of the Exhibit Hall can obtain these after the meeting from the ACR. Attendees who have questions about the ACR s media policies should contact the ACR Public Relations department at [email protected] Program Book 11

14 general information EMBARGO POLICY Accepted abstracts are made available to the public online in advance of the meeting and are published in a special supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 4:30 pm Eastern Time on Saturday, November 15, Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. ABSTRACT REPRINT POLICY Copyright law covers all Annual Meeting abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means, except as permitted under section 107 and 108 of the United States Copyright Act, without the prior permission of the publisher. For the purposes of this statement, the term ACR abstracts refers to all Annual Meeting abstracts as published in Arthritis & Rheumatology and posted online, including the abstracts accepted for presentation during ARHP sessions and the latebreaking category. For the purposes of this statement, the term ACR posters refers to the accepted abstracts as presented during the Annual Meeting. All ACR posters are the property of the ACR or the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author. For the purposes of this statement, the term reproduce includes all forms of reproduction including, but not limited to, print, electronic and photographed formats. For the purposes of this statement, the term presenting author refers to the author who is designated as the individual who will present the work during the ACR Annual Meeting, as identified through the abstract submission process. Approval Process Excerpts of ACR abstracts or ACR abstracts in their entirety may not be reproduced without the prior written permission of the publisher. Permission requests and other permission inquiries should be addressed to: Permissions Department c/o John Wiley & Sons, Inc. 111 River Street Hoboken, NJ Fax: (201) aa! Commercial entities seeking permission to reprint must obtain all materials from the author and/or publisher John Wiley & Sons, Inc. ACR cannot provide any materials. Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination During the Annual Meeting Following approval (see approval process), an exhibiting organization may: Disseminate copies of individual ACR abstracts from its exhibit space. Booklets of abstracts (e.g., two or more) may not be produced. Disseminate information summaries (title/date/time/ poster number) of ACR abstracts from its exhibit space. Summaries may not reference company or product names. Requests for approval must be submitted in writing to [email protected]. Presenting authors may disseminate individual copies of their ACR poster during their assigned poster presentation time. Dissemination must be limited to the area directly in front of their assigned poster space and may not interfere with other poster presentations. Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination After the Annual Meeting Following approval (see approval process above), the ACR permits ACR abstracts to be reprinted and disseminated following the Annual Meeting. Booklets of abstracts (e.g., two or more) must include the following statement on the front of the booklet: Abstracts reprinted from the ACR/ARHP Annual Meeting held November 14-19, The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company). Booklets cannot contain corporate or product logos or any advertisements. No exceptions Program Book

15 general information ACR Posters Following approval from the ACR and the presenting author, copies of ACR poster presentation images may be reproduced. IMPORTANT: The ACR does not retain and cannot provide poster presentation images. Requests to reproduce individual ACR posters or booklets of posters (e.g., two or more) must be submitted via to Poster reproduction requests must include the following: Abstract ID Number Abstract title Presenting author s name A copy of presenting author s written approval (Please Note: An approval from the presenting author is acceptable). The following statement must be listed under each poster reprint: Poster reprinted from the ACR/ARHP Annual Meeting held November 14-19, The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company). Use of the ACR Scientific Program Content Information displayed or presented at all sessions during the Annual Meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced or distributed without the written permission of the ACR and the presenter. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices As a courtesy to meeting attendees, electronic devices must be operated in silent/vibrate mode within educational sessions; devices that beep, ring, etc. are prohibited. Cell phone conversations are not permitted in meeting rooms. Children For safety reasons, strollers are not permitted in the exhibit hall and all children must be accompanied by an adult. Only registered attendees will be permitted into meeting rooms. Child Care KiddieCorp is providing child care services for our attendees during meeting hours. If you did not reserve space in advance, you can inquire about space availability by calling (617) Nursing Mothers Room During scientific session hours, a staffed Nursing Mothers room will be available in Room 162-A. This room will have a private seating area, a refrigerator and a bulletin board for information exchange, advice and suggestions. Exhibit Hall Located in Hall A, you will find the latest technology and services demonstrated or on display in the exhibit hall. See page 252 for more information. Exhibit Hall hours: Sunday, November :00 AM 5:00 Monday, November :00 AM 5:00 Tuesday, November :00 AM 2:30 Meeting Room Capacity/Important Fire Safety Information Attendance at scientific sessions is on a first-come, first-served basis. Rooms which have reached the maximum capacity may be closed according to local fire and safety regulations. Standing in the aisle or against the walls is not permitted. If overcrowding occurs, staff/security personnel will close the session. Sessions closed due to overcrowding may be redirected to an overflow room or made available on SessionSelect within 24 hours following the session. See page 19 for more information on SessionSelect. Photography and Videotaping Photographers will be present at the meeting. Registration and attendance at, or participation in, ACR meetings and other activities constitutes an agreement by the registrant for the ACR s use and distribution (both now and in the future) of the registrant or attendee s image or voice in photographs, videotapes, electronic reproductions and audio tapes of such events and activities. Visual reproduction of sessions is prohibited without prior written permission of the ACR. The ACR reserves the rights to audio and video reproduction at the 2014 ACR/ARHP Annual Meeting. See copyrighted materials policy for more information on page 11. Name Badges For security reasons, your badge will be required for admittance to all sessions, exhibits, social events and shuttle buses. Please wear your badge so it can be easily seen at all times. Lost badges should be reported to the registration staff immediately. No Smoking All meeting facilities at the convention center, hotel meeting rooms and other venues have been designated as non-smoking areas Program Book 13

16 general information MEETING NAVIGATION GUIDE Use the following track icons to help you identify the most relevant content based on your specialty. PRIMARY TRACKS Basic Science Business/Administration Clinical Practice Clinical Science Exhibits and Industry-Supported Sessions provide attendees with an opportunity to learn about the latest technological advances in the treatment of rheumatic diseases within the exhibit hall via various exhibitions and non-cme sessions in the Innovation Theater, as well as evening and post-meeting symposia. Meet the Professor Sessions provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. Networking Events provide unique opportunities to socialize and network with peers in smaller group settings. 14 Educators Ed Pd PrM FIT Pediatrics Ed Pd PrM FIT Sd PrM FIT Fellows-In-Training 2014 Program Book SECONDARY TRACKS Practice Management STATE CME DESIGNATIONS Pain Management The ACR designates certain sessions for pain management credit as required by the Medical Board of California (AB487). This designation is identified by the icon shown and will be placed next to the session title. Patient Safety The ACR designates certain sessions that will satisfy patient safety/risk management requirements of the Medical Board of Pennsylvania. This designation is identified by the icon shown and will be placed next to the session title. SESSION FORMATS ACR Sessions provide an update on the most recent developments in the field of rheumatology and provide instruction to improve patient care. Developments from other specialties and practical patient management skills will be emphasized. ARHP Sessions offer educational programs of interest to various health professionals. Concurrent sessions include invited speakers; peer-reviewed programs and lectures; and research and special interest abstract sessions. ACR and ARHP Concurrent Abstract Sessions provide a platform for the presentation of the most up-to-date basic science and clinical research data in the field of rheumatology. Sessions are grouped by topic or theme and include short oral presentations of high scoring accepted abstracts. Poster Sessions include accepted abstracts not selected for oral presentation. Poster sessions are arranged by topic/category. Presenters are required to accompany their posters during designated poster presentation times. Pre-Meeting Courses offer attendees, with a specific interest, a unique learning opportunity. A separate registration is required. Study Groups bring together attendees with a common interest in one disease, a group of related disorders or a specialized field of study for discussion and dissemination of information. Workshops foster Hands-On learning, and provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. ABSTRACT FORMATS Late-Breaking Session features truly late-breaking research. Oral Presentations are the main forum for didactic presentation of original research related to rheumatic diseases. Plenary Sessions highlight abstracts of significant novelty and importance. There will be three theme-based sessions offered. Poster Presentations feature poster displays of abstracts, while facilitating one-on-one interaction between the presenter and the audience. Poster Tours are small groups guided by experts in a particular field. Each tour will highlight selected posters of novel or recent developments within an abstract category. There is no additional cost to participate, although a separate registration is required. ABSTRACT CATEGORIES ACR Basic Science 1. B-cell Biology and Targets in Autoimmune Disease: B-lymphocyte differentiation, B-cell subsets, plasma cells, autoantigens, autoreactive B-cells and tissue injury. 2. Biology and Pathology of Bone and Joint: joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.

17 general information 3. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis: cytokines, chemokines and their receptors; downstream signaling effects and biologic pathways; cell-cell recognition and adhesion molecules, cell matrix interactions, matrix characteristics and properties, lymphoid organogenesis. 4. Genetics, Genomics and Proteomics: techniques, strategies and observations related to disease susceptibility and expression; bioinformatics and systems biology. 5. Innate Immunity and Rheumatic Disease: dendritic cells, antigen presentation, auto-inflammatory pathogenesis, pattern recognition receptors and their ligands, NK cells, complement and Fc receptors. 6. Pain Basic Aspects: studies on pain mechanisms, animal models of pain and pain physiology. 7. Pediatric Rheumatology Pathogenesis and Genetics: pathological, genetic and other laboratory-based aspects of pediatric rheumatology conditions. 8. Rheumatoid Arthritis Animal Models: animal models of inflammatory synovitis, mechanisms and treatment. 9. Rheumatoid Arthritis Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis. 10. Spondylarthropathies Psoriatic Arthritis Pathogenesis, Etiology: etiology and pathogenesis, including genetics, reactive arthritis and animal models. 11. Systemic Lupus Erythematosus Animal Models: animal models, mechanisms and treatment. 12. Systemic Lupus Erythematosus Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis. 13. Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics: cellular and molecular mechanisms, biomarkers. 14. T-cell Biology and Targets in Autoimmune Disease: T-lymphocyte antigens and subpopulations, cognate interactions, T-lymphocyte activation and proliferation. CLINICAL 15. Antiphospholipid Syndrome: pathophysiology, presentation and management. 16. Education: research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education including associated health training. 17. Epidemiology and Public Health: descriptive and/or analytical studies of populations. 18. Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: regional pain syndromes, local diseases of muscle, ligament and tendon, fibromyalgia. 19. Health Services Research: delivery of care affecting patients with rheumatic disease; health systems and health care economic and ultization analysis. 20. Imaging of Rheumatic Diseases: radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound and computed tomography (CT). 21. Infection-related Rheumatic Disease: musculoskeletal manifestations of infectious disease, infectious arthritis and pathogenesis. 22. Metabolic and Crystal Arthropathies: crystal-induced arthritis, metabolic conditions including endocrine abnormalities. 23. Miscellaneous Rheumatic and Inflammatory Diseases: rheumatic manifestations and therapy of less common and even rare illnesses not included in other categories (e.g., RS3PE, reticulohistiocytosis, SAPHO). 24. Muscle Biology, Myositis and Myopathies: muscle biology, inflammatory and non-inflammatory muscle disease. 25. Orthopedics, Low Back Pain and Rehabilitation: orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine. 26. Osteoarthritis Clinical Aspects: patient-oriented studies of osteoarthritis, including treatment, diagnosis and outcomes. 27. Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: patient-oriented studies of bone structure and integrity and its change in various disease states. 28. Pain Clinical Aspects: studies on pain evaluation, pain management and pain-related functional imaging. NEW! 29. Pediatric Rheumatology Clinical and Therapeutic Aspects: clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions. 30. Quality Measures and Quality of Care: development and use of tools to measure or quantify healthcare processes, outcomes, patient perceptions, organizational structures and/or systems relating to healthcare goals including safety, effectiveness, patient centricity, equity and timeliness. NEW! 31. Rheumatoid Arthritis Clinical Aspects: clinical aspects of rheumatoid arthritis. Should not contain any treatment studies. 32. Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: treatment of human rheumatoid arthritis including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only. 33. Sjögren s Syndrome: pathophysiology, presentation and treatment Program Book 15

18 Stop by the Discovery Center to learn what s new at the College! We re located in the center of the Exhibit Hall (Booth #731). L E A R N C O N N E C T E N G A G E S E E Get details about our 2015 educational activities Find answers to your coding and billing questions Talk with ACR staff about The Lupus Initiative, CME activities, registries, MOC tools, and more Get Social by meeting with a social media mentor Speak with key representatives from the ACR and ARHP journals Hear about the Foundation s programs and initiatives Learn about the latest advocacy efforts and how you can get involved Enroll in the ACR Rheumatology Musculoskeletal Ultrasound Certification Program Demo popular online tools and resources View and order the latest Rodnan Commemorative Gout Print Collect complimentary product brochures, publications and patient education materials Discovery Center Hours: Sunday, November :00 am 5:00 pm Monday, November :00 am 5:00 pm Tuesday, November :00 am 2:30 pm

19 general information 34. Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: small molecule and biologic therapies of spondyloarthropathies, reactive arthritis and psoriatic arthritis. 35. Systemic Lupus Erythematosus Clinical Aspects and Treatment: diagnosis, clinical manifestations, outcomes, and treatment, including new small molecules, biologics and gene therapy. Human lupus only. 36. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics: clinical aspects of these syndromes and of treatments. 37. Vasculitis: genetics, etiology, pathogenesis, polygmatic rheumatica, presentation and management. ARHP 38. Clinical Practice/Patient Care: care of patients, practice management, medication monitoring/adherence and complementary and alternative strategies. 39. Education/Community Programs: patient education, professional education, community-based programs and public health programs. 40. Epidemiology and Public Health: descriptive and analytical studies of health status and health outcomes of populations and patient groups. 41. Health Services Research: health care systems and delivery, economic evaluations, quality improvements and analysis. 42. Pediatrics: pediatric practice and patient care. 43. Psychology/Social Sciences: social, emotional and behavioral factors affecting patients, families and providers. 44. Rehabilitation Sciences: physical therapy, occupational therapy, exercise programs, splinting/orthotics and other rehabilitation services. 45. Research Methodology: quantitative and qualitative studies, new assessment tools and methodology, new analytical techniques and research study management. MEETING SERVICES Annual Meeting App Everything You Need, in One Place Search the program, retrieve syllabi, view abstracts and access recorded sessions on SessionSelect. See page 19 for more information on SessionSelect. NEW! Discovery Center The Spot for All Things ACR, ARHP and the Foundation! Discovery Center Hours: Sunday, November : 0 0 AM 5:00 Monday, November : 0 0 AM 5:00 Tuesday, November : 0 0 AM 2:30 Located in the center of Exhibit Hall A, Booth #731, the Discovery Center is designed to highlight all of the College s exceptional programs and services. ACR s professional staff is on hand to demonstrate online tools and resources, introduce new initiatives of the College that are under way, provide information and answer any questions you may have. The Discovery Center has it all in one place! See page 16 for more information. Look for these specific areas in the Discovery Center: Advocacy Get the most up-to-date information on the legislative and regulatory issues affecting your profession. We have talking points on all ACR legislative priorities and tips on how to get more involved with the ACR s advocacy efforts. You can also receive information on RheumPAC the ACR s political action committee. Education Learn about ACR/ARHP educational offerings and upcoming meetings in 2015 and beyond. You can also demo online products, tools and training programs like SessionSelect, Advanced and Fundamentals of Rheumatology Courses and the popular Rheumatology Image Bank. Rheumatology Research Foundation Learn about the latest activities the Foundation is doing to ensure the future of rheumatology. View and order the latest poster in the Rodnan Commemorative Gout Print poster series, and hear about Foundation programs and initiatives. Practice Management & Coding Visit with ACR certified coders and practice management experts for any coding, billing, insurance or practice management questions. We have all the resources you need for an efficient rheumatology practice. You can also pick up the latest copy of the ACR s monthly RheumWATCH. Take advantage of the new Annual Meeting App! Publications The editorial office staff of the Arthritis & Rheumatology and Arthritis Care & Research journals will be available to answer questions concerning online article submission and article review processes for the journals Program Book 17

20 general information Simple Tasks Learn how the ACR s Simple Tasks campaign is educating lawmakers and referring physicians and others who influence rheumatology on the severity of inflammatory rheumatic diseases and the importance of rheumatologists and rheumatology health professionals in the treatment of those diseases. You can also learn how you can get involved in the Campaign in Action initiative. Quality & Informatics Learn how enrollment in the Rheumatology Clinical Registry can benefit you by providing Hands-On measurement tools and reports that enable you to comparatively assess the quality and outcome of rheumatologic care you provide. Plan on attending interactive demonstrations of this tool offered throughout the meeting. Certification Need help navigating Maintenance of Certification? We have answers to help steer your route to success with the American Board of Internal Medicine s Maintenance of Certification program. An ABIM representative will be on site to help answer your questions. Musculoskeletal Ultrasound Certification Interested in certifying in ultrasound? The ACR is providing a voluntary pathway for physicians, physician assistants and nurse practitioners who perform ultrasound as part of their practice in rheumatology to demonstrate competence to patients, peers and payers through its first certification program. Lost and Found Found items should be returned to the ACR Office, Room 260. If you are looking for a lost item, go to the ACR Office or call (617) Newsroom Located in Room 252, use of the Newsroom is limited to media representatives with press passes. Attendee Lounge Located in the Ballroom Lobby, attendees are welcome to relax and enjoy seating while networking with colleagues, checking and recharging their laptops or smartphones. Concierge Center Need directions to your next session or interested in discovering all things ACR? Stop by the Concierge Center located in the center of the North Lobby (Level 1). Staff is on hand to assist you and answer general questions about the Annual Meeting, ACR/ ARHP events, programs, resources and services of the College and we re happy to give directions to your next session, too. Concierge Center Hours: Friday, November :3 0 AM 6:00 Saturday, November :3 0 AM 6:30 Sunday, November :3 0 AM 6:00 Monday, November :3 0 AM 6:00 Tuesday, November :3 0 AM 6:00 Wednesday, November : 0 0 AM 1:00 Career Connection Employers and candidates are encouraged to take advantage of the online Career Connection to post position openings, search nationwide rheumatology career opportunities and much more. Career Fair On Friday, November 14 from 6:00 8:00 pm, potential employers and candidates can meet in the Grand Ballroom C-D-E at the Westin Boston Waterfront and enjoy complimentary hors d oeuvres and beverages while discussing career opportunities. During this time, employers who have registered for the Career Fair can distribute handouts, flyers or business cards to potential candidates. aa A Take-Away Gift Just for You! Come by the Discovery Center and take home a meeting souvenir get your picture taken with one of the landmarks of Boston and discover where the 2015 ACR/ARHP Annual Meeting will be held! Membership Booth Located in Registration (Exhibit Level), this is the place to go if you want to become a member, pay dues, reinstate your membership, learn more about member benefits and awards or volunteer to serve on a committee. Registration Registration counters are located in East Registration (Exhibit Level). Registration Hours: Friday, November :3 0 AM 6:00 Saturday, November :3 0 AM 6:30 Sunday, November :3 0 AM 6:00 Monday, November : 0 0 AM 6:00 Tuesday, November :00 AM 6:00 Wednesday, November : 0 0 AM 1: Program Book

21 Get On-Demand Annual Meeting Education with SessionSelect! ATTENDEE BONUS! Your Annual Meeting registration fee gives you FREE access to the online content of the 2014 Annual Meeting in SessionSelect for one year! Starting on Monday (November 17), you can view fully-synchronized presentations online, complete with speaker slides and audio, within 24 hours from the completion of the live session just as if you were actually attending each session. Take advantage of the most convenient way to experience education from the Annual Meeting at your own pace. With SessionSelect you can: Stay up to date on the most relevant information and research pertaining to rheumatic diseases Apply session information to your practice to enhance your knowledge, competence and performance Watch and learn 24/7 View content on your mobile device or download MP3 files for listening to audio on-the-go To learn more about SessionSelect or to view a demo, be sure to stop by the ACR s Discovery Center, located in Exhibit Hall A (Booth #731), or the Concierge Center, located in the North Lobby, or go to Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access. CME credit is not available for viewing 2014 sessions online.

22 general information Shuttle Bus Shuttle service will be provided to and from the Boston Convention and Exhibition Center and ACR hotels that are designated as non-walking hotels. On Friday, Saturday and Wednesday, service operates continuously. On Sunday through Tuesday, service operates from 6:30-10:30 am and 2:30-6:30 pm. Full shuttle service information will be posted in ACR hotel lobbies and at the shuttle bus entrances of the convention center. This service is complimentary for attendees and registered guests who booked their rooms through ACR Housing. Attendees who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass at the ACR registration counter for $50. Speaker Ready Room Located in Room 206, check-in is expected of all speakers and oral abstract presenters (excluding Meet the Professor and Workshop speakers, as well as poster presenters). Plan to check in at least 3 hours prior to your presentation time. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual technicians will be available to assist you. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems and make corrections as necessary before your presentation. Speaker Ready Room Hours: Friday, November :3 0 AM 6:00 Saturday, November :3 0 AM 6:30 Sunday, November :3 0 AM 6:00 Monday, November :3 0 AM 8:00 Tuesday, November :3 0 AM 6:00 Wednesday, November : 0 0 AM 12:30 Wi-Fi Way and Recharge Access Complimentary Wi-Fi access is available in all rooms of the convention center. Recharge areas will be available in Wi-Fi Way (Exhibit Hall A), the Attendee Lounge (Ballroom Lobby) and the Technology Center (North Lobby). Rheumatology Research Foundation Donors Lounge Experience the perks of supporting the Rheumatology Research Foundation while at the 2014 ACR/ARHP Annual Meeting in Boston! Attendees with access are invited to enjoy a hot breakfast every morning and gourmet coffee service throughout the day. Located in the Boardroom, the Donors Lounge is a great place to check your between sessions or catch up on work at our private computer stations. Donors are also invited to relax, watch television and network with their colleagues. Eligible donors will be able to get into the lounge with the 2014 Donors Lounge Access Pass. Passes will be distributed on site to individuals who have donated a total of $500 or more during fiscal year 2014 (July 1, 2013 through June 30, 2014). Donors Lounge Hours: Saturday, November Noon 5:00 Sunday, November : 0 0 AM 6:00 Monday, November : 0 0 AM 6:00 Tuesday, November : 0 0 AM 6:00 Wednesday, November : 0 0 AM 12:30 SPECIAL OFFERS AT THE ANNUAL MEETING SessionSelect no need to miss a session! Within 24 hours of virtually every live session at the Annual Meeting, video recordings of the presentations, including oral abstracts, will be available through SessionSelect. As an attendee benefit, you get FREE online access for one year to hundreds of hours of Annual Meeting content over $500 of added value. See page 19 for more information. Please Note: Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access. CME credit is not available for viewing 2014 sessions through SessionSelect. What Would Make This Meeting Better? You ve got ideas to share, and we ve made it easy for you to share them. Tweet your idea using the #ACR2014 hashtag. Submit your session proposal or topic idea for the 2015 meeting at ACRannualmeeting.org. Medical Bag Don t forget to pick up a Medical Bag prior to visiting the exhibits. Each bag contains special offers and invitations from our exhibitors and will be distributed from the exhibition entrance while supplies last Program Book

23 general information POSTER SESSIONS Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and will remain displayed in the poster hall (Exhibit Hall B) from 9:00 am - 4:00 pm, Sunday, November 16 - Tuesday, November 18. Poster presenters will be available at their poster from 9:00-11:00 am. One poster session will be held each day; however, there is no poster session on Wednesday. Poster presentations will be unopposed during the 10:00-11:00 am hour. The number on the poster boards refers to the abstract presentation number, and this number will change for each poster session. Late-breaking abstract posters will be available for viewing Sunday, November 16 - Tuesday, November 18. Late-breaking abstract presenting authors will be available at their posters on Tuesday, November 18 from 9:00 am - 11:00 pm Thieves Market posters will be presented on Monday, November 17 and Tuesday, November 18. NEW THIS YEAR! aa Two new ACR clinical science abstract categories have been introduced: Pain: Clinical Aspects and Quality Measures and Quality of Care.! The abstract supplement will no longer be offered in the flash drive version. All attendees will be able to easily access the abstract supplement publication online. Posters must be mounted by 8:30 am of the designated poster session and dismantled after 4:00 pm as outlined in the abstract acceptance notification. Posters not dismantled by 5:00 pm each day will be recycled. Poster storage will not be available in the poster hall. In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00-11:00 am for poster presentations to answer questions from attendees. Poster presenter ribbons will be available in the Speaker Ready Room (Room 206). Poster Presenter No-shows Please Note: The ACR will be monitoring posters during the presentation hours in an effort to make certain the College is meeting the educational needs and expectations of attendees. Poster Sessions - Sunday, November 16 through Tuesday, November 18 from 9:00 am - 4:00 pm Set Up:... 7:00 8:30 AM Presentation: :00 11:00 AM Poster Tours:... 9:00 9:45 AM 10:15 11:00 AM Posters to remain up until 4:00 pm Poster pick up:... 4:00 6:30 ACR Removal:... 6:30 * * The ACR will remove and promptly recycle all posters not picked up by 6:30 pm each day. Guided Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. Although there is no fee to participate, pre-registration is required and each tour is limited to 20 registered scientific attendees. If you would like to participate and have not registered, you can check tour availability and request a ticket at registration, located in East Registration on the Exhibit Level. If you registered in advance of the meeting, your ticket is located on the back of your name badge. Once you have your ticket, it is important that you collect your headset from the Poster Tour Kiosk and meet your group 10 minutes before your tour departs from the entrance of the poster hall, located in Exhibit Hall B. Poster tour reservations will be released to stand-by attendees five minutes before the tour Program Book 21

24 FRIDAY november 14, 2014 Great Meetings Come from Great Ideas! Call for Proposals: Submit your session idea or study group topic for the 2015 ACR/ARHP Annual Meeting at ACRannualmeeting.org TODAY! We are looking for proposals that: Reflect clinical innovation and cutting edge research. Convey best practices. Present evidence-based medicine. Stimulate discussion and challenge mind-sets. Tell us about learning models that: Address challenges in your area of practice. Create opportunities to share information across geographical demographics. Encourage collaboration between subspecialities Promote partnership among physicians and health professionals. Relevant topics may include: Technological advances impacting practice. World-wide trends in patient care. Outcomes assessment and holistic treatment. Deadline for submissions is Friday, November 21, 2014 acr/arhp scientific sessions FRIDAY, NOVEMBER 14, 2014 PRE-MEETING COURSES ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY ONE OF TWO 7:45 am 5:30 pm 109 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. demonstrate proper ultrasound exam technique and procedure guidance, applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound Moderator: Eugene Y. Kissin, MD Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin, MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED; Alicia Weeks, MD 7:00 7:45 am Continental Breakfast 7:45 am Introduction Eugene Y. Kissin, MD 8:00 am Principles of Musculoskeletal Ultrasound for Rheumatologists Jay B. Higgs, MD Program Book

25 scientific sessions 8:30 am Introduction to Typical Sonographic Findings and Tissue Characteristics in Rheumatology Clara Lin, MD 9:15 9:30 am Morning Break 9:30 11:30 am Hand and Wrist 4:30 5:30 pm Pediatrics 4:30 pm Lecture: Pediatric Anatomy in Musculoskeletal Ultrasound Johannes Roth, MD 5:00 pm Hands-On Scanning: The Upper Extremity in Pediatrics Bethany A. Marston, MD and Johannes Roth, MD FRIDAY november 14, :30 am Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Eugene Y. Kissin, MD 10:00 am Live Demonstration: Hand and Wrist Eugene Y. Kissin, MD 10:15 am Hands-On Scanning: The Hand and Wrist All Faculty 11:30 am 12:30 pm Boxed Lunch 12:30 2:15 pm The Elbow 12:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Amy M. Evangelisto, MD 1:00 pm Live Demonstration: Scanning of the Elbow Amy M. Evangelisto, MD 1:15 pm Hands-On Scanning: The Elbow All Faculty 2:15 2:30 pm Afternoon Break 2:30 4:30 pm The Shoulder 2:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Gurjit S. Kaeley, MBBS, MRCP 3:00 pm Live Demonstration: Scanning of the Shoulder Gurjit S. Kaeley, MBBS, MRCP 3:15 pm Hands-On Scanning: The Shoulder All Faculty ACR ADVANCED RHEUMATOLOGY CODING COURSE: DEVELOPING EXPERTS IN RHEUMATOLOGY CODING AND ICD-10-CM 9:00 am 5:00 pm 257 A Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. This course is not eligible for CME credit. 8:00 9:00 am Continental Breakfast Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCS-P and Melesia Tillman, CPC, CPC-I, CRHC, CHA exhibit proficiency in adjudicating claims for accurate medical coding for diagnoses, procedures and services in physicianbased settings demonstrate knowledge of medical coding rules and regulations including compliance and reimbursement evaluate, revise and focus physician educational efforts and queries to meet documentation requirements for medical necessity and ICD-10-CM identify the impact ICD-10-CM will have on organizations and workflow implement strategies that will improve clinical documentation and facilitate a smooth transition to ICD-10-CM recognize how ICD-10-CM documentation requirements will affect principal diagnosis selection, additional diagnosis reporting and diagnosis sequencing ACR BASIC RESEARCH CONFERENCE: EMERGING PERSPECTIVES ON THE MICROBIOME IN THE RHEUMATIC DISEASES DAY ONE OF TWO 1:00 6:10 pm 210 B Admission to the Basic Research Conference requires a separate registration. describe underlying principles and evidence demonstrating how the microbiome may affect immune development and thresholds of immune responsiveness 2014 Program Book 23

26 scientific sessions FRIDAY november 14, examine the technologic and bioinformatics tools that are used to provide quantitative data that enable correlations with host phenotypes and alterations (or dysbioses) within the microbiome describe disease states that may be affected by microbial dysbioses 1:00 1:45 pm Keynote Lecture: Microbiome and Host Immune Defenses Speaker: Dan Littmann, MD, PhD 1:45 4:00 pm Session I: Overview of General Principles Moderator: Heidi H. Kong, MD, MHSc 1:45 pm Culture Independent Surveys of Microbiomes Rob Knight, PhD 2:15 pm Surveys of Human Populations and Families Jack Gilbert, PhD 2:45 pm Analysis and Models of Microbiomes Eric A. Franzosa, PhD 3:15 pm Multi-Omics Janet Jansson, PhD 3:45 pm Afternoon Break 4:00 6:10 pm Session II: The Microbiome and Regional Immunity Moderator: Susan A. Boackle, MD 4:00 pm Microbial Molding of Mucosal Immunity Hiroshi Kiyono, DDS, PhD 4:30 pm Microbiome and Lung Susan Lynch, PhD 5:00 pm Microbial Regulation of Responses in the Skin Heidi H. Kong, MD, MHSc 5:30 pm Immunity at the Barriers Yasmine Belkaid, PhD 6:00 pm Questions and Answers 6:10 7:00 pm Networking Reception Reception combined with ACR Clinical Research Conference participants Program Book ACR CLINICAL RESEARCH CONFERENCE: PATIENT-CENTERED OUTCOMES IN RHEUMATOLOGY DAY ONE OF TWO 1:00 6:00 pm 205 B Admission to the ACR Clinical Research Conference requires a separate registration. define the role of patient-centered outcomes from the perspectives of clinical researchers, patients, caregivers and other stakeholders define the contribution of patient-centered outcomes in a learning health care system describe the case for patient-reported outcomes in clinical care and identify strategies to overcome barriers to use identify and select key variables to consider in selection of patient-reported outcomes measures incorporate patient-reported outcomes results into shared decision making in their respective clinical settings 1:00 4:00 pm Session I: Methodology and Development Moderators: Esi Morgan DeWitt, MD, MSCE 1:00 pm Patient-Centered Outcome Research: Why Methods Matter Sherine E. Gabriel, MD, MSc 1:15 pm Modern Methods in Patient-Reported Outcomes Measure Development Karon Cook, PhD 2:00 pm Advances in Comparative Effectiveness Research Methods in Rheumatoid Arthritis Jeffrey R. Curtis, MD, MPH, MS 2:30 pm Patient-Centered Outcomes Research Institute (PCORI) and Patients as Partners in Research Joe V. Selby, MD, MPH 3:00 pm Nothing About Me Without Me : Including the Patient in Outcomes Research Leslie Kelly-Hall 3:30 pm Questions and Answers 3:45 pm Afternoon Break 4:00 6:00 pm Session II: Translating Patient-Centered Outcomes to the Real World Setting Moderator: Sherine E. Gabriel, MD, MSc

27 scientific sessions 4:00 pm The Role of Patient-Centered Outcomes in a Learning Health System L. Charles Bailey, MD, PhD 4:30 pm How New Treatments Show They Are Working Laure Gossec, MD, PhD 5:00 pm Learning Health System and Patient-Centered Outcomes in Pediatric Rheumatology Esi M. Morgan DeWitt, MD, MSCE 5:30 pm Questions and Answers 5:45 pm Wrap-Up Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE 6:00 7:00 pm Networking Reception Reception combined with ACR Basic Research Conference participants. ACR/ABIM MAINTENANCE OF CERTIFICATION LEARNING SESSION 2014 UPDATE IN RHEUMATOLOGY 1:00 6:00 pm 258 B Admission to the ACR/ABIM Maintenance of Certification Learning Session requires a separate registration. Learn in an interactive environment as clinical experts lead you through 30 case-based questions from ABIM s 2014 Update in Rheumatology Module. After the session, submit your answers online to the ABIM to receive 10 medical knowledge points for the Maintenance of Certification program. assess strengths and weaknesses in rheumatology medical base knowledge state major developments in rheumatology over the past ten years satisfy a self-evaluation requirement for the American Board of Internal Medicine Maintenance of Certification program 2:40 3:00 pm Afternoon Break 3:00 4:30 pm Session II: Questions from 2014 Update Speaker: Seetha U. Monrad, MD 4:30 6:00 pm Session III: Questions from 2014 Update Speaker: Erika H. Noss, MD, PhDSATURDAY, NOVEMBER 15, 2014 SATURDAY, NOVEMBER 17, 2014 PRE-MEETING COURSES ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY TWO OF TWO 7:15 am 5:50 pm 109 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Eugene Y. Kissin, MD Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin, MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED; Alicia Weeks, MD demonstrate proper ultrasound exam technique and procedure guidance, applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound SATURDAY november 15, :00 pm Introduction Carol A. Langford, MD, MHS 1:10 2:40 pm Session I: Questions from 2014 Update Speaker: Carol A. Langford, MD, MHS 6:45 7:15 am Continental Breakfast 7:15 am Opening Remarks Eugene Y. Kissin, MD 7:30 9:15 am The Hip 7:30 am Lecture: Standard Scans, Sonographic Anatomy and Basic 2014 Program Book 25

28 scientific sessions Sonographic Pathology Midori Jane Nishio, MD of Procedures Janak R. Goyal, MD SATURDAY november 15, :00 am Live Demonstration: Scanning of the Hip Midori Jane Nishio, MD 8:15 am Hands-On Scanning: The Hip All Faculty 9:15 9:30 am Morning Break 9:30 11:30 am The Knee 9:30 am Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Gary A. Kunkel, MD 10:00 am Live Demonstration: Scanning of the Knee Gary A. Kunkel, MD 10:15 am Hands-On Scanning: The Knee All Faculty 11:30 am 12:30 pm Boxed Lunch 12:30 pm 2:30 pm Foot and Ankle 12:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Ralf G. Thiele, MD, RhMSUS 1:00 pm Live Demonstration: Scanning of Foot and Ankle Ralf G. Thiele, MD, RhMSUS 1:15 pm Hands-On Scanning: Foot and Ankle All Faculty 2:30 pm ACR Musculoskeletal Ultrasound Course for Rheumatologists Billing, Coding and Report Generation Paul J. DeMarco, MD 3:00 pm 3:15 pm Afternoon Break 3:15 pm 5:00 pm Ultrasound Needle Guidance 3:15 pm Lecture: Evidence Base and Technique of Ultrasound Guidance 3:45 pm Panel Discussion Implementing Musculoskeletal Ultrasound in the Practice of Rheumatology Catherine Bakewell, MD; Paul J. DeMarco, MD; Eugene Y. Kissin, MD; and Ralf G. Thiele, MD, RhMSUS 4:15 pm Hands-On Scanning: Ultrasound Guidance of Procedures All Faculty 5:00 5:50 pm Pediatrics 5:00 pm Lecture: The Lower Extremity in Pediatrics Johannes Roth, MD 5:20 pm Hands-On Scanning: Pediatrics Bethany A. Marston, MD and Johannes Roth, MD ACR CLINICAL RESEARCH CONFERENCE: PATIENT-CENTERED OUTCOMES IN RHEUMATOLOGY DAY TWO OF TWO 7:45 am 4:30 pm 205 B Admission to the ACR Clinical Research Conference requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. define the role of patient-centered outcomes from the perspectives of clinical researchers, patients, caregivers and other stakeholders define the contribution of patient-centered outcomes in a learning health care system describe the case for patient-reported outcomes in clinical care and identify strategies to overcome barriers to use identify and select key variables to consider in selection of patient reported outcomes measures incorporate patient-reported outcomes results into shared decision making in their respective clinical settings 7:00 7:45 am Continental Breakfast 7:45 8:00 am Introduction Speakers: Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE 8:00 9:30 am Session III: Research Perspective Moderator: Kenneth G. Saag, MD, MSc Program Book

29 scientific sessions 8:00 am Patient-Centered Outcomes Research in ANCA-Associated Vasculitis Peter A. Merkel, MD, MPH 2:00 4:30 pm Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials Moderator: Dinesh Khanna, MD 8:30 am Patient-Centered Outcomes Research in Pediatrics Angelo Ravelli, MD 9:00 am Patient-Centered Outcomes Research in Scleroderma Dinesh Khanna, MD, MSc 9:30 am 1:00 pm Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs) Moderator: Nora G. Singer, MD 2:00 pm The Patient-Reported Outcomes Measurement Information System in Rheumatology James P. Witter, MD, PhD 2:30 2:50 pm Afternoon Break 2:50 pm Incorporating Patient-Centered Outcomes (PCOs) in Product Development: Industry Perspective Arijit X. Ganguli, MBA, PhD SATURDAY november 15, :30 am Use of Patient-Reported Outcomes in Rheumatology Clinical Practice Clifton O. Bingham III, MD 10:00 am Passive Patient-Reported Outcomes: Biosensors and Social Media to Track Patient Outcomes Brennan Spiegel, MD, MSHS 10:30 10:45 am Morning Break 10:45 am Shared Decision Making: Incorporating Patient-Centered Outcomes Liana Fraenkel, MD, MPH 11:15 am Family Communication The Next Frontier for Improving Patient Satisfaction Richard Siegrist, Jr., MBA, MS, CPA 11:45 am Big Data and the Point of Care Kenneth D. Mandl, MD, MPH 12:15 1:00 pm Boxed Lunch 1:00 2:00 pm Session V: Patient Perspective Moderator: Sherine E. Gabriel, MD, MSc 1:00 pm Importance of Patient-Centered Outcomes From the Patient s Viewpoint Kelly Young, BA 1:30 pm Parent Engagement in Care and Research Judy K. Crosby, JD 3:20 pm Abstract Presentations 3:50 pm Questions and Answers 4:00 pm Wrap-Up Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE ACR PRACTICE MANAGEMENT PRE-MEETING COURSE 8:00 am 4:00 pm 257 A Admission to the ACR Practice Management Pre-meeting Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Nilsa Cruz 7:00 8:00 am Continental Breakfast 8:00 9:00 am Customer Service That Rocks: Boost Patient Satisfaction Speaker: Brandi Young, DNP identify steps to achieve outstanding patient satisfaction results and discover reliable methods for dealing with demanding patients outline breaking through ordinary communication and outdated work habits and improve overall customer service from check-in to check-out discuss specific techniques to implement for over-the-phone or in-person communications to calm upset patients 9:00 9:30 am Morning Break 2014 Program Book 27

30 scientific sessions SATURDAY november 15, :30 10:30 am Improve Time-of-Service Collections From the Front End Speaker: Mark Painter discuss why it is important to move from a back-end collections strategy to a front-end strategy identify all that should be collected at the time of service and the difference it will make in collections (e.g., co-insurance, co-pay, self-pay) define the practice collection process and what it means to the practice bottom line identify tactics, tools and technologies to optimize collections from self-pay patients and reduce days in accounts receivable 10:30 11:30 am Managing Denials in a Complex Reimbursement Environment Speaker: Mark Painter identify how to set up a tracking mechanism to collect data on denials improve front and back office processes to prevent future denials determine root causes, patterns and process breakdowns responsible for denials, and explaining how establishing corrective steps may reduce the volume of denied claims and write-offs 11:30 am 12:30 pm Boxed Lunch 12:30 1:30 pm Ins and Outs of an Effective Compliance Plan Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM discuss how to structure an effective anti-corruption compliance program. identify the vital elements of an effective compliance program discuss the role of a compliance office in fighting fraud and implementing a compliance program 1:30 2:00 pm Afternoon Break 2:00 3:00 pm Increase Team Performance and Productivity Speaker: Mark Painter discuss how to reduce staff conflict and build a team with a common purpose and shared vision identify the elements of building a high-performance team discuss the key principles of team dynamics, such as balance, conflict management and team alignment to provide practical insight into productivity and team success 3:00 4:00 pm Take Your Appeals to the Next Level Speaker: Jessica Farrell, PharmD identify how to customize appeal letters for Level II appeals so no higher level appeals are rejected identify the steps to appeal for all carriers, which forms to use and proven strategies for successful appeals discuss how to craft effective appeals letters and get your claims paid ACR REVIEW COURSE 8:00 am 4:00 pm Exhibit Hall C Admission to the ACR Review Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderators: Simon M. Helfgott, MD and Kristine M. Lohr, MD, MS 6:30 8:00 am Continental Breakfast 8:00 8:45 am Pregnancy Management and Outcome in Systemic Lupus Erythematosus Speaker: Lisa R. Sammaritano, MD review the key clinical issues related to pregnancy in the lupus patient discuss some of the more common clinical challenges facing the rheumatologist and obstetrician formulate some recommendations regarding the management of pregnancy and the role of the rheumatologist 8:45 9:30 am The Diagnosis and Management of Macrophage Activation Syndrome Speaker: Alexei A. Grom, MD identify the clinical features of macrophage activation syndrome review the steps required to establish the diagnosis, using lab and clinical criteria discuss treatment options for macrophage activation syndrome 9:30 10:15 am Interstitial Lung Disease in Rheumatic Disease: A Focused Review Speaker: Aryeh Fischer, MD evaluate patterns of interstitial lung disease (ILD) and the clinical landscape of ILD disease in rheumatic diseases Program Book

31 scientific sessions review the evaluation of rheumatic patients with ILD and the evaluation for occult rheumatic diseases in those presenting with presumed idiopathic ILD outline the management of ILD in patients with rheumatic disease 10:15 10:45 am Morning Break 10:45 11:30 am Genomics for the Clinician Speaker: Soumya Raychaudhuri, MD, PhD review how genomics affects the clinician s understanding of specific rheumatic diseases such as rheumatoid arthritis discuss the future role of genomics and how it may fit into the rheumatology practice of tomorrow 11:30 am 12:15 pm Management of Salivary Gland Involvement in Sjögren s Syndrome Speaker: Alan N. Baer, MD describe salivary gland anatomy and methods to assess function and structure recognize symptoms and signs of salivary gland disease and MALT lymphoma in Sjögren s syndrome recommend management of salivary hypofunction and MALT lymphoma in Sjögren s syndrome 12:15 1:15 pm Boxed Lunch 1:15 2:00 pm Management of Pseudogout: Insights for Clinicians Speaker: Geraldine M. McCarthy, MD describe the clinical features of calcium pyrophosphate dihydrate (CPPD) crystal-associated arthropathy formulate a diagnostic approach to CPPD arthropathy and screening for predisposing metabolic disease manage CPPD arthropathy 2:00 2:45 pm Assessing Disease and Managing Large Vessel Vasculitis Speaker: Kenneth J. Warrington, MD recognize the presentations of Takayasu arteritis and giant cell arteritis describe vascular involvement in large vessel vasculitis recommend short- and long-term management of large vessel vasculitis 2:45 3:15 pm Afternoon Break 3:15 4:00 pm Rheumatoid Arthritis Therapy After Diagnosis of Malignancy Speaker: Iain B. McInnes, PhD discuss interactions of medications used to treat rheumatoid arthritis and malignancy discuss the risks and benefits of rheumatoid arthritis treatment in the setting of malignancy modify rheumatoid arthritis treatment in the setting of malignancy ACR BASIC RESEARCH CONFERENCE: EMERGING PERSPECTIVES ON THE MICROBIOME IN THE RHEUMATIC DISEASES DAY TWO OF TWO 8:00 am 4:30 pm 210 B Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. describe underlying principles and evidence demonstrating how the microbiome can affect immune development and thresholds of immune responsiveness examine the technologic and bioinformatics tools that are used to provide quantitative data that enable correlations with host phenotypes and alterations (or dysbioses) within the microbiome describe disease states that may be affected by microbial dysbioses 7:00 8:00 am Continental Breakfast 8:00 10:30 am Session III: Mechanisms of Immune Activation and Regulation Moderator: Kevin D. Deane, MD, PhD 8:00 am Mechanisms of Immune Activation and Regulation Andrew Gewirtz, PhD 8:30 am Microbiome and Gut T Cell Signaling June L. Round, PhD 9:00 am Microbiota and Tumor Immunity Romina Goldszmid, PhD 9:30 am The Microbiome as a Potential Risk Factor for Psoriatic Arthritis Anne Barton, PhD SATURDAY november 15, Program Book 29

32 scientific sessions SATURDAY november 15, :00 am Questions and Answers 10:10 10:30 am Morning Break 10:30 am 1:30 pm Session IV: Microbiome and Rheumatic Disease Moderator: Gregg J. Silverman, MD 10:30 am Microbiome and Psoriatic Arthritis James T. Rosenbaum, MD 11:00 am Microbiome and Rheumatoid Arthritis Jose U. Scher, MD 11:30 am Microbiome and Inflammatory Bowel Disease Jonathan Braun, MD, PhD Noon GALT Mediated Regulation of Immunologic Tolerance and Systemic Lupus Erythematosus Jo Spencer, PhD 12:30 pm Questions and Answers ARHP CLINICAL FOCUS COURSE: DIAGNOSTIC IMAGING USE IN DIFFERENTIAL DIAGNOSIS FOR COMMON RHEUMATIC AND MUSCULOSKELETAL CONDITIONS 8:00 am 4:30 pm 254 A Admission to the ARHP Clinical Focus Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Karen Huisinga, MN, ARNP review the concepts of common, patient-specific rheumatic differential diagnosis develop basic knowledge of diagnostic imaging focusing on plain film, MRI and ultrasound define the role, utilization and limitations of diagnostic imaging in plain film, MRI and ultrasound in the clinical setting identify the appropriate imaging modality to apply in the clinical setting 7:00 8:00 am Continental Breakfast 8:00 am Introduction Karen Huisinga, MN, ARNP 30 12:45 1:30 pm Boxed Lunch 1:30 4:30 pm Session V: Prospects for Manipulating Disease Through the Microbiome Moderator: Jose U. Scher, MD 1:30 pm Consequences for Disease and Health of Shifting the Microbiome: Antibiotics, Probiotics and Nutriceuticals David A. Mills, MS, PHD 2:00 pm Treatment of Inflammatory Bowel Disease With Nematodes Joel Weinstock, MD 2:30 pm Manipulating the Urogenital Microbiome of Women Gregor Reid, PhD, MBA 3:00 3:15 pm Afternoon Break 3:15 pm Fecal Transplants Michael J. Sadowsky, PhD 3:45 pm Abstract Presentations 4:20 pm Wrap-Up Heidi H. Kong, MD, MHSc and Rob Knight, PhD 2014 Program Book 8:15 9:00 am Diagnostic Imaging: A Tool for Differential Diagnosis Michael D. Ross, PT, DHSc, OCS 9:00 11:00 am Plain Film 9:00 am Outlining the Value of Plain Film Michael D. Ross, PT, DHSc, OCS 9:45 10:00 am Morning Break 10:00 am Plain Film Case Presentation Michael D. Ross, PT, DHSc, OCS 10:45 am Plain Film Questions and Answer 11:00 am 1:30 pm Ultrasound 11:00 am Outline the Value of Ultrasound Patrick Astourian, MPAS, PA-C 11:45 am 12:30 pm Boxed Lunch 12:30 pm Ultrasound Case Presentations Patrick Astourian, MPAS, PA-C

33 scientific sessions 1:15 pm Ultrasound Case Questions and Answer 1:30 3:30 pm Magnetic Resonance Imaging (MRI) 1:30 pm Outlining the Value of MRI Stacy Smith, MD SCIENTIFIC SESSIONS ACR/ARHP OPENING LECTURE AND AWARDS 4:30 6:15 pm Exhibit Hall C Moderators: Joseph Flood, MD, ACR President and Karen L. Smarr, PhD, ARHP President 2:15 2:30 pm Afternoon Break 2:30 3:15 pm MRI Case Presentations Stacy Smith, MD 3:15 3:30 pm MRI Case Questions and Answer 3:30 4:30 pm Audience Response Interactive Session 4:15 pm Wrap-Up AAMC MEDICAL EDUCATION RESEARCH CERTIFICATE (MERC) WORKSHOP 9:00 am 4:00 pm 204 A This workshop is not eligible for CME credit. 9:00 am Noon Formulating Research Questions and Designing Studies Speaker: Karen Richardson-Nassif, PhD write a FINER (feasible, interesting, novel, ethical, relevant) educational research question specify an educational research area of interest evaluate whether they need Institutional Review Board approval for their study select the correct design for their research question 4:30 pm ACR Presidential Address 5:00 pm Recognition of 2014 ACR Masters Recognition of 2014 ACR Awards of Distinction Recipients Recognition of 2014 ARHP Merit Awards Recipients Recognition of 2014 ACR Distinguished Fellows Awards Recipients Recognition of 2014 Rheumatology Research Foundation Corporate Roundtable Donors 5:30 6:15 pm Opening Lecture: P4 Medicine Is Transforming Health Care: A Longitudinal, Framingham-like Study of 100,000 Well Patients Over Years Speaker: Leroy Hood, MD, PhD review systems medicine and how its technologies and strategies are changing medicine describe how P4 medicine differs from evidence-based medicine explain the power of a longitudinal, Framingham-like 100,000 person wellness study for optimizing wellness for each individual and for studying wellness to disease transitions at the earliest stage ACR/ARHP OPENING RECEPTION 6:15 9:00 pm Ballroom East and West SUNDAY november 16, 2014 Noon 1:00 pm Boxed Lunch SUNDAY, NOVEMBER 16, :00 4:00 pm Measuring Educational Outcomes With Reliability and Validity Speaker: Karen Richardson-Nassif, PhD identify three types of reliability (inter-rater, test-retest and internal consistency) match types of reliability with appropriate statistical measures describe the relationship between reliability and validity describe multiple forms of evidence for validity select an approach to reliability and validity assessment for a particular study ACR SESSIONS 7:30 8:30 am 253 B Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action Moderator: Wael N. Jarjour, MD Speaker: Bruce N. Cronstein, MD 2014 Program Book 31

34 scientific sessions SUNDAY november 16, 2014 review methotrexate-putative mechanisms of action in rheumatoid arthritis and gene expression data in methotrexate-naïve patients before and after treatment review hydroxychloroquine mechanisms of action including discussion of effects on autophagy and TLR signaling in rheumatoid arthritis and lupus review rituximab-recognized mechanisms of action and immune phenotypic changes in rheumatoid arthritis 104 B Pediatric Rheumatology Town Hall Moderator: Anna Huttenlocher, MD delineate the American Board of Pediatrics Maintenance of Certification program clarify the ACGME milestones for pediatrics identify current work initiated for pediatric rheumatology by the ACR 7:30 am Update on the Modifications to the American Board of Pediatrics Maintenance of Certification Program C. Egla Rabinovich, MD, MPH 7:50 am Update on Accreditation Council for Graduate Medical Education Pediatric Milestones Marilynn G. Punaro, MD NETWORKING EVENT 7:30 8:30 am 102 A ACR/ARHP First-time Attendee Orientation First-time annual meeting attendees are invited to an orientation to learn the ins and outs of the annual meeting. Dr. Audrey Uknis, ACR Immediate Past President and Dr. Jan Richardson, ARHP Immediate Past President, will assist you in planning how to get the most out of your first annual meeting. This session is not eligible for CME credit. Coffee and tea will be provided. Moderators: Audrey B. Uknis, MD and Jan K. Richardson, PT, PhD, OCS ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. 8:10 am American College of Rheumatology Update and Pediatric Awards Polly J. Ferguson, MD Exhibit Hall C Year in Review Moderator: Chester V. Oddis, MD discuss selected recent publications on the pathophysiological basis of rheumatic diseases by literature review of important publications describe selected treatment modalities for rheumatic diseases from the recent published literature evaluate how these new advances may impact the practice of rheumatology 7:30 am Clinical Perspective S. Louis Bridges Jr., MD, PhD 8:00 am Basic Science Perspective Cornelia M. Weyand, MD, PhD Westin Paine (Lobby) *Basic Immunology for Clinical Rheumatologists (001) Speaker: John Atkinson, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity Westin Otis (Lobby) Crystal: Diagnosis and Management of Gout (002) Speaker: Theodore R. Fields, MD recall the various published guidelines for diagnosis of gout, including the most recent and appreciate the input that, when appropriate, can be added with ultrasound and Dual Energy CT scanning appreciate the challenges in gout patient education and medication adherence recall the 2012 ACR guidelines for gout management and appreciate those issues that still remain controversial or unresolved discuss the types of agents in the pipeline for future gout therapy and potential future approaches to gout management Program Book

35 scientific sessions Westin Hancock (Lobby) Cutaneous Vasculitis (003) Speaker: Ruth Ann Vleugels, MD, MPH use the cutaneous exam to help distinguish between small and medium-sized vasculitides observe the histopathological features of cutaneous vasculitis, which lead directly to clinical disease observable on the skin identify vasculitis mimickers with cutaneous involvement define the role of dermatologists in the diagnosis, work-up and management of cutaneous vasculitides Westin Revere (Lobby) Fibromyalgia 2014: Update on Management (004) Speaker: Daniel J. Clauw, MD identify newly proposed biological mechanisms for fibromyalgia and centralized pain discuss the role of central nervous system dysfunction in the pathogenesis of fibromyalgia describe the drug and non-drug treatments that are effective in fibromyalgia Westin Stone (Lobby) *Macrophage Activation Syndrome (005) Speaker: Alexei A. Grom, MD recognize the signs and symptoms of macrophage activation syndrome (MAS) in rheumatology recognize markedly distinct nature of the systemic form of juvenile idiopathic arthritis and the fact that MAS most frequently occurs in patients with this disease discuss current treatment approaches in MAS Westin Webster (Lobby) Pain: Evaluation and Treatment of Back Pain (006) Speaker: Rajiv Dixit, MD describe the clinically relevant anatomy of the lumbar spine clinically evaluate a patient with acute or chronic back pain or a patient with an associated nerve root compression syndrome formulate a rational and cost effective management plan with a clear understanding of surgical indications Westin Alcott (Mezzanine) Reactive Arthritis: An Update (008) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis Westin Douglas (Mezzanine) *Rheumatoid Arthritis: Challenging Cases (009) Speaker: Daniel Furst, MD, MPH discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Faneuil (Mezzanine) *Systemic Lupus Erythematosus: Difficult-to-Treat Systemic Lupus Erythematosus (010) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of systemic lupus erythematosus examine management strategies for refractory cutaneous manifestations of systemic lupus erythematosus discuss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias ACR WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. SUNDAY november 16, 2014 Westin Adams (Mezzanine) *Psoriatic Arthritis (007) Speaker: Dafna D. Gladman, MD discuss advances in diagnosis and classification of psoriatic arthritis determine if patients with psoriatic arthritis should be treated aggressively determine treatment options for patients with psoriatic arthritis 152 *Joint Injection Techniques (201) Speaker: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures perform common joint and soft tissue injections on upper and lower extremities 2014 Program Book 33

36 scientific sessions SUNDAY november 16, *Nailfold Capillaroscopy (202) Speaker: Maurizio Cutolo, MD 154 distinguish between normal nailfold capillary array and early/advanced microvascular changes that allows the early differential diagnosis between primary and secondary Raynaud s phenomenon by using nailfold videocapillaroscopy (NVC) identify the early scleroderma pattern, the predictive/ prognostic value of NVC for the SSc clinical complications (by models/indexes) as linked to the NVC patterns quantify the microvascular lesions distinguish between the difference of combined predictive value of the NVC patterns and nuclear antibodies, the links with peripheral blood changes, as well as the effects of systemic sclerosis therapeutic treatments on NVC patterns Tai Chi in Rheumatic Disease (203) Speaker: Mary L. Jurisson, MD describe the practice of tai chi and qigong and advise patients of its evidence-based benefits and risks practice 1 or 2 qigong exercises independently describe some of the simplified curricula ACR SESSIONS 8:30 10:00 am 52 A CARE: Maintenance of Certification Session One of Three Vasculitis All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) vasculitis questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Carol A. Langford, MD, MHS assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program Ballroom East Current Understanding of Malignancies in Connective Tissue Diseases Moderator: Dinesh Khanna, MD review the mechanisms of cancer-associated autoimmune diseases discuss data related to associations of scleroderma and idiopathic inflammatory myopathies with malignancy and relationships with autoantibodies 8:30 am Idiopathic Inflammatory Myopathies Whom Should We Screen for Malignancy? Frederick W. Miller, MD, PhD 9:00 am Scleroderma Whom Should We Screen for Malignancy? Ami A. Shah, MD, MHS 9:30 am Cancers and Autoimmune Disease What Is the Link? Antony Rosen, MD 254 A Ethics and Rheumatology Ed Pd Ed PrM Eth Pd FIT PrM FIT Moderators: Robert H. Shmerling, MD and Jane Kang, MD develop knowledge and skills to address ethical conflicts that arise in rheumatologic practice and research recognize how social and cultural perspectives affect the approach to ethical decision making identify key ethical issues concerning social media for health professionals in general and rheumatologists in particular 8:30 am Ethical Challenges in Rheumatologic Research Arthur L. Caplan, PhD 9:00 am Ethics Concerns of the ACR Membership C. Ronald MacKenzie, MD 9:30 am Ethical Challenges Posed By Social Media Elizabeth A. Kitsis, MD, MBE 257 A Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts Ed Pd PrM FIT Moderators: Joan M. Bathon, MD, Editor, Arthritis & Rheumatology and Marian T. Hannan, DSc, MPH, Editor, Arthritis Care & Research peer-review scientific manuscripts within a field of interest assess one s own work prior to submission in terms of clarity of message and importance of the findings Program Book

37 scientific sessions describe the requirements and scientific preferences of the journals of the ACR 8:30 am Outline and Key Points of Conducting a Review Joan M. Bathon, MD and Marian T. Hannan, DSc, MPH 8:50 am Panel Presentation: Reviewing Clinical Science Articles Karen H. Costenbader, MD, MPH explain how to effectively respond to allegations of overpayments identify ways to improve workflow to handle the everincreasing number of multi-payer audits identify automated tools for tracking the status of individual claims appraise the types of audits to expect and key areas that each audit program may target (i.e., medical necessity, documentation, etc.) 9:00 am Panel Presentation: Reviewing Translational Articles Richard J. Bucala, MD, PhD 9:10 am Panel Presentation: Reviewing Genetics/Genome-Wide Association Study Articles S. Louis Bridges Jr., MD, PhD 9:20 am Panel Presentation: Reviewing From a Biostatistics Perspective Michael P. LaValley, PhD 9:30 am Questions and Answers Exhibit Hall C Osteoporosis: Current Concepts for the Clinician Moderator: Margaret R. Wilkes, MD discuss etiologies, diagnosis and management of low bone density in premenopausal women describe secondary causes of low bone density in men and treatment strategies for male osteoporosis review current data for best practice regarding utilization of bone turnover markers and duration of antiresorptive therapy in the treatment of osteoporosis 8:30 am Osteoporosis in Young Women Elizabeth J. Shane, MD 9:00 am Osteoporosis in Men Benjamin Z. Leder, MD 9:30 am Antiresorptive Therapies and Utilization of Bone Turnover Markers in the Management of Osteoporosis Karen E. Hansen, MD, MS 160 B Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation Moderator: Douglas White, MD, PhD Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM discuss the scope and purpose of the RAC, ZIPC and CERT contractors and audits trends for each program 258 B The Microbiome in Health and Disease Moderator: Robert A. Colbert, MD, PhD review the skin microbiome system and its role in dermatologic and systemic diseases evaluate the interactions between the microbiome and host gender in disease predisposition examine the role of the microbiome in inflammatory arthritides 8:30 am The Skin Microbiome Elizabeth A. Grice, PhD 9:00 am Gender, Microbiome and Autoimmunity Jayne Danska, PhD 9:30 am The Microbiome in Inflammatory Arthritides Jose U. Scher, MD 104 B When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility Ed Pd PrM FIT Moderators: Laura E. Schanberg, MD and Kenneth N. Schikler, MD describe novel insights in juvenile fibromyalgia diagnosis and prognosis effectively diagnose hypermobility syndromes and discuss prognosis recognize the value and the role of medications in the management of non-inflammatory musculoskeletal pains in children and adolescents 8:30 am Juvenile Fibromyalgia: Diagnosis, Severity and Prognosis Susmita Kashikar-Zuck, PhD 9:00 am The Spectrum of Pediatric Hypermobility A Geneticist s Viewpoint Brad Tinkle, MD, PhD 2014 Program Book 35 SUNDAY november 16, 2014

38 scientific sessions 9:30 am Integrated Management of Non-Inflammatory Musculoskeletal Pain in Children Kenneth Goldschneider, MD ACR POSTER SESSION A AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # 1 814). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Metabolic and Crystal Arthropathies Poster Tour (308) Tour Guide: N. Lawrence Edwards, MD Past President s Picks Poster Tour (309) Tour Guide: David G. Borenstein, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (310) Tour Guide: Jennifer Barton, MD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (311) Tour Guide: Megan E. B. Clowse, MD, MPH Vasculitis Poster Tour (312) Tour Guide: Robert F. Spiera, MD SUNDAY november 16, 2014 Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Fellows Only: How to Navigate the Poster Hall (301) Tour Guide: Calvin R. Brown, Jr, MD Pain: Basic and Clinical Aspects (302) Tour Guide: Anne-Marie Malfait, MD, PhD Past President s Picks Poster Tour (303) Tour Guide: Mary K. Crow, MD Past President s Picks Poster Tour (304) Tour Guide: Michael Weinblatt, MD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (305) Tour Guide: Iain B. McInnes, PhD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (306) Tour Guide: Diane L. Kamen, MD, MS 10:15 11:00 am Antiphospholipid Syndrome Poster Tour (307) Tour Guide: Pier Luigi Meroni, MD ACR SESSIONS 9:00 10:00 am 210 B ACR Immunology Update: New Immunology of the Spondyloarthropathies Moderator: Gregg J. Silverman, MD Speaker: Christopher T. Ritchlin, MD, MPH review the demographics and common clinical presentations for these conditions appraise insights gained from genetic surveys and evolving insights into cellular and molecular pathogenesis discuss recent advances in clinical trials with new therapeutic agents 102 A Advocacy: Meet the Expert A Senator s Perspective on Advocacy Best Practices Moderator: William F. Harvey, MD, MSc Speaker: The Honorable Tim Hutchinson (U.S. House ; U.S. Sen ) review how rheumatologists can interact with elected officials locally review how rheumatologists can interact with elected officials nationally appraise effective and ineffective ways of approaching elected officials Ballroom West Sarcoidosis in 2014 Moderator: Elana J. Bernstein, MD, MSc discuss the diagnosis and management of cardiac sarcoidosis discuss the diagnosis and management of neurosarcoidosis 9:00 am Cardiac Sarcoidosis Daniel Culver, DO Program Book

39 scientific sessions 9:30 am Neurosarcoidosis Nadera J. Sweiss, MD 153 B Social Media Boot Camp: Twitter Basics Moderator: Paul Sufka, MD create an Twitter account recognize proper and improper usage of tweeting in professional environments identify whom to follow, e.g., rheumatologists and other interesting people in medicine identify and define a hashtag demonstrate how to tweet demonstrate how to retweet or favorite noteworthy information 9:00 am Introduction Paul Sufka, MD 9:05 am Why Tweet? Ronan Kavanagh, MD, MRCP (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am, 12:30 1:15 pm and 2:30 3:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm, 1:30 2:15 pm and 3:30 4:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. SUNDAY november 16, :30 am How to Tweet Christopher E. Collins, MD 9:55 am Question and Answer ARHP SESSION 9:00 10:00 am 107 B ARHP Keynote Address: Happiness from the Inside Out Moderator: Afton L. Hassett, PsyD Speaker: Cynthia Coney, MEd, CAPP identify the three stages patients may traverse after a diagnosis of chronic illness list at least three personal strengths that resilient people exhibit apply resiliency skills into personal and professional lives EXHIBITS 10:00 am 5:00 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 11:00 am and 2:00 3:00 pm. 159 *Beyond Musculoskeletal Ultrasound for Rheumatologists (204) Speaker: Minna J. Kohler, MD identify non-musculoskeletal uses of ultrasound in rheumatology patients. recognize some common ultrasound abnormalities in patients with rheumatic diseases. recognize the importance of proper ultrasound transducer selection and system settings to obtain adequate ultrasound images. apply introductory ultrasound scanning techniques for nonmusculoskeletal scanning. apply introductory ultrasound scanning techniques to assess for vasculitis 152 *Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes administer the physical examination of the lower extremities on healthy volunteers 2014 Program Book 37

40 scientific sessions SUNDAY november 16, Histopathology of Rheumatic Lung Disease (206) Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD appraise the basic patterns of lung injury as seen microscopically compare pathologic findings in rheumatologic lung diseases with their idiopathic counterparts distinguish histologic features of drug induced lung injury from rheumatologic injury Synovial Fluid Analysis and Crystal Identification (207) Speakers: Brian F. Mandell, MD, PhD; Gilda M. Clayburne, MLT and Lan Chen, MD, PhD prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid ACR SESSIONS 11:00 am Noon 210 B Bone Biology Moderators: George C. Tsokos, MD and Steven R. Goldring, MD Speaker: Laurie H. Glimcher, MD review how the skeleton remodels itself continuously through bone formation and resorption establish familiarity with the signaling pathways that operate in osteoblasts recognize the need for new therapeutics to treat low bone mass 11:20 am Presentation of the New ACR Rheumatoid Arthritis Guidelines Jasvinder A. Singh, MD, MPH 11:50 am Questions and Answers Kenneth G. Saag, MD, MSc ARHP SESSIONS 11:00 am Noon 257 A Affordable Care Act Moderator: Daniel F. Battafarano, DO Speaker: Angela K. Golden, DNP describe the changes that the Affordable Care Act will have on health care explain how reimbursement will be affected by the Affordable Care Act summarize the changes of the Affordable Care Act that will impact rheumatology directly 52 A Immunology Boot Camp I: The Basics of Targeted Therapies Moderators: Deborah McCloskey, RN, BSN and Brandi Young, DNP, FNP-C Speaker: Troy R. Torgerson, MD, PhD describe the basic building blocks of the immune system summarize the components of innate immunity, including sensing self and foreign explain the body s immediate response to an antigen Ballroom East New ACR Recommendations for the Management of Rheumatoid Arthritis Moderators: S. Louis Bridges Jr., MD, PhD and Raveendhara R. Bannuru, MD describe the recommended treatment approach for patients with rheumatoid arthritis outline the ACR s recommendations for use of non-biologic and biologic disease-modifying agents in the treatment of rheumatoid arthritis explain the ACR s recommendations for use of corticosteroids in the treatment of rheumatoid arthritis 11:00 am Overview of Guideline Development, Including Methods and Literature Review Timothy E. McAlindon, MD, MPH, MRCP 254 A What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain? Moderator: Daniel J. Clauw, MD explain some of the basic principles of brain neurochemistry and brain connectivity and how these are altered in chronic pain describe how brain neurotransmitters and connectivity patterns may be altered by pharmacologic and nonpharmacologic treatment recognize how neuroimaging outcomes can be used to guide clinical decision making 11:00 am Pharmacologic Neuroimaging in Chronic Pain Richard E. Harris, PhD Program Book

41 scientific sessions 11:30 am Neuroplastic Response to Non-Pharmacologic Treatment in Chronic Pain Vitaly Napadow, PhD ACR PLENARY SESSION I DISCOVERY :00 am 12:30 pm Conclusion: We identify ch2b as an antigenic target of the ACPA immune response and our findings suggest that intra-articular histone citrullination can link innate immunity via NETosis and adaptive immunity via generation of citrullinated histone immune complexes. The generation of citrullinated histone antigens during low grade articular inflammation provides a potential mechanism for the conversion from asymptomatic ACPA seropositivity to clinical RA. Exhibit Hall C ACR Plenary Session I: Discovery 2014 Moderators: Joseph Flood, MD and Chester V. Oddis, MD 11:00 am Rheumatology Research Foundation Corporate Roundtable Awards 11:15 am 815. Netosis Induced Histone Citrullination Facilitates Onset and Propagation of Rheumatoid Arthritis Dong Hyun Sohn and Jeremy Sokolove, VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are characteristic of rheumatoid arthritis however, their presence years before onset of clinical RA is perplexing. Although multiple putative citrullinated antigens have been identified, including citrullinated products of NETosis, no studies have demonstrated the capacity of these antigens to initiate inflammatory arthritis. We sought to identify citrullinated products of NETosis targeted by the RA immune response and with the capacity to drive inflammatory arthritis. Methods: We performed proteomic analysis of human NETs to identify all citrullinated proteins including those targeted as part of the RA immune response. Using a combination of ELISA and IHC we compared RA and OA serum, synovial fluid and synovial tissue for levels of histone 2B (H2B), anti-h2b antibodies, as well as H2B-containing immune complexes. Using macrophage activation assays we assessed the effect of histone citrullination on immunostimulatory capacity and evaluated the stimulatory capacity of native and citrullinated H2B-containing immune complexes. Finally, we immunized mice with citrullinated H2B (ch2b) with and without the induction of low grade collagen induced arthritis to assess the potential for anti-ch2b antibodies to mediate arthritis in vivo. Results: Proteomic interrogation of NET-derived proteins, RA serum, synovium and synovial fluid identified robust targeting of NET-derived citrullinated histones by the ACPA immune response. Over 90% of RA patients have anti-ch2b antibodies and over half have measurable levels of synovial fluid H2B immune complexes. We observe that histone citrullination increases innate immunostimulatory capacity and that immune complexes containing citrullinated histones both activate macrophage cytokine production and propagate NETosis. Finally, we demonstrate that autoimmunity to ch2b is arthritogenic, both by primary immunization as well as immune serum transfer, but only in the setting of underlying low grade articular inflammation. Disclosures: D. H. Sohn, None; J. Sokolove, None. 11:30 am 816. TRNT1 Missense Mutations Define a New Periodic Fever Syndrome Angeliki Giannelou, National Institute for Arthritis and Musculoskeletal and Skin Diseases,Bethesda, MD Background/Purpose: Two thirds of the 1700 patients seen at our NIH clinic for autoinflammatory diseases do not have a genetic diagnosis. Whole exome sequencing permits analysis of most of the protein coding regions of the human genome. Methods: With the use of whole exome sequencing and candidate gene screening, we identified five children from four unrelated families, who had unexplained autoinflammatory disease and shared mutations in one common gene. One family from Saudi Arabia was consanguineous with two affected daughters. The second family of mixed Czech and British background had one affected boy. The third and fourth families were of mixed European ancestry from the United States and each family had one affected daughter. We performed additional experiments in patients samples including flow cytometry, immunophenotyping, cytokine profiling, mitochondria related function and ribosomal assembly assays. Protein function was studied with morpholino knockdowns in zebrafish embryos. Results: All patients carried missense recessive mutations in one common gene, the TRNT1 (trna Nucleotidyl Transferase, SUNDAY november 16, Program Book 39

42 scientific sessions SUNDAY november 16, 2014 CCA-Adding, 1), on chromosome 3. The two affected Saudi Arabian sisters were homozygous for a p.h215r missense mutation, while the other three children were compound heterozygous for a missense mutation, p. I223T or p. R99W and one shared mutation p.d163v. The p.h215r mutation was not found in any public database neither in 1061 Arab control DNA samples. From the three Caucasian mutations, the p.r99w was novel whereas the p. I223T and p.d163v were found at a very low allele frequency (<0.001) at the NHLBI exomedatabase. All mutations affect highly conserved amino acid residues and are predicted to be damaging to the protein function. All children had recurrent episodes of high fevers with negative sepsis work up that occurred in association with microcytic anemia and a spectrum of multisystem features. Neurologic involvement ranged from mild developmental delay to nystagmus, hypotonia, optic nerve atrophy and sensorineural hearing loss. Other variables manifestations include dysmorphic features, musculoskeletal and gastrointestinal symptoms, B cell immunodeficiency and hypogammaglobulinemia. Studies performed so far, point towards a maturation defect of the B cell lineage in the bone marrow, as a possible cause of the observed immunodeficiency. Preliminary data from cytokine analysis in two patients have shown elevated levels of the proinflammatory cytokines interleukin 6 and type 1interferon, suggesting possible therapeutic targets. Knockdown of the zebrafish TRNT1 homologue caused hydrocephaly, defects in tail development, anemia and a reduction in the number of hair cells present in the lateral line, that has function resembling human inner ear. Conclusion: The CCA-adding TRNT1 enzyme catalyzes the addition of the CCA terminus to the 3 prime end of all trnas precursors, a step that is essential for trna aminoacylation and protein synthesis. The discovery that missense mutations in this essential and ubiquitously expressed gene cause a newly defined periodic fever syndrome, will allow further understanding of mechanisms underlying inflammation. Disclosures: A. Giannelou, None. matched by age, gender and calendar year. Cox regression was used to calculate hazard ratios (HR) to determine baseline risk factors for increased mortality in the BeSt population. Results: During 10 years, 72 of 508 patients died at a mean age of 75 years. No difference in survival was observed between the treatment strategies (p=0.805) (figure), with 16/126, 15/121, 21/133 and 20/128 deaths in arm 1 to 4, respectively. Based on the general Dutch population, 62 deaths were expected and 72 deaths occurred, resulting in an overall SMR of 1.16 (95% confidence interval, CI ). Comparing the general population to each of the treatment strategies resulted in a SMR (95% CI) of 1.00 ( ), 1.02 ( ), 1.30 ( ) and 1.32 ( ) in arm 1 to 4, respectively. In the BeSt population, baseline age (HR 1.13, 95% CI ), male gender (HR 1.78, 95% CI ), smoking at baseline (HR 5.19, 95% CI ) and health assessment questionnaire at baseline (HR 1.89, 95% CI ) were associated with an increased risk of mortality. Randomization arm was not associated with an increased risk of mortality (arm 1 as reference category; arm 2 HR 0.99, 95% CI ; arm 3 HR 1.27, 95% CI ; arm 4 HR 1.25, 95% CI ). Conclusion: After 10 years of continued tight controlled treatment in patients with rheumatoid arthritis in the BeSt study, the survival rate was comparable to the general Dutch population, without differences between the treatment strategies. Higher age, male gender, smoking and worse functional ability were associated with an increased risk of mortality within our study population. These results suggest that treatment targeted at DAS 2.4 prevents increased mortality previously associated with RA and that the medication used in these strategies does not increase mortality :45 am 817. Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years I.M. Markusse, Leiden University Medical Center, Leiden, Netherlands Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of treatto-target therapy in patients with early RA, to compare these survival rates with the general population and to define risk factors for mortality during the 10 years duration of the BeSt study. Methods: The BeSt study enrolled 508 Dutch patients with recent-onset active RA (1987 criteria) who were randomized to: sequential monotherapy, step-up therapy, initial combination including either prednisone or infliximab. During 10 years, all patients were treated-to-target, aiming at a disease activity score (DAS) 2.4. Kaplan-Meier curves and the log-rank test were used to compare survival rates in the four treatment strategies. Standardized mortality ratios (SMR) were calculated to compare the BeSt population to the general Dutch population, 2014 Program Book Disclosures: I. M. Markusse, None. Noon 818. Incident Rheumatoid Arthritis and Risk of Mortality Among Women Followed Prospectively from 1976 to 2010 in the Nurses Health Study Jeffrey A. Sparks, Brigham and Women s Hospital, Harvard Medical School, Boston, MA Background/Purpose: RA has been associated with increased mortality compared to general population estimates. Previous studies were limited due to the inability to directly compare RA patients to controls, short follow-up and lack of detailed data on clinical, lifestyle and serologic factors. We evaluated mortality among women followed prospectively prior to RA diagnosis, directly comparing to women without RA. Methods: We conducted a study of RA and mortality among 121,700 women followed from 1976 to 2010 in the Nurses Health Study (NHS). Incident RA was validated by medical record

43 scientific sessions review according to the 1987 ACR RA criteria and classified by serostatus. Women who reported RA or other connective tissue diseases before the start of NHS were excluded. Women were followed from cohort entry to death or end of follow-up and were censored for loss to follow-up. Deaths were validated by the National Death Index; death certificate and medical record review determined cause of death. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD), cancer and respiratory mortality for women with RA compared to women without RA. We obtained HRs for mortality by RA duration and serologic RA phenotype. Models were adjusted for age, demographics and other mortality factors, including physical activity, smoking, obesity, comorbidities and family history of cancer, CVD and diabetes. Results: We validated 960 incident RA cases and identified 25,699 deaths in 34 years of NHS follow-up. Of the 261 deaths among women with RA, 75 (29%) were from cancer, 58 (22%) were from CVD and 43 (16%) were from respiratory causes. Compared to women without RA, women with RA had increased all-cause mortality that remained significant after adjusting for age and other mortality factors (HR 2.07, 95% CI , Table). Mortality was significantly increased for seropositive (HR 2.33, 95% CI ) and seronegative RA (HR 1.60, 95% CI ) compared to non-ra women. Each five years of RA duration conferred a 32% (95% CI 27-36%) increased mortality compared to non-ra. Women with RA had significantly increased risk for mortality from CVD (HR 1.87, 95% CI ), cancer (HR 1.35, 95% CI ) and respiratory (HR 4.50, 95% CI ) causes compared to women without RA. Respiratory mortality for women with seropositive RA was sixfold higher than non-ra women (HR 6.23, 95% CI ). Conclusion: In 34 years of prospective follow-up, women diagnosed with RA had a two-fold increased risk of death from any cause compared to women without RA. Respiratory mortality was six-fold higher in seropositive RA and women with RA were significantly more likely to die from CVD and cancer than women without RA. Respiratory mortality appears to be an important but understudied cause of death in RA. These findings provide evidence of high RA mortality burden that is unexplained by traditional mortality predictors. Table. Hazard ratios for all-cause and cause-specific mortality in RA serologic phenotypes among women in the Nurses Health Study, (n = 119,264). All-cause mortality Ageadjusted HR Multivariable HR (95% CI)* (95% CI) CVD-specific mortality Multivariable HR (95% CI)* Cancerspecific mortality Multivariable HR (95% CI)* Respiratoryspecific mortality Multivariable HR (95% CI)* All RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.42 ( ) 2.07 ( ) 1.87 ( ) 1.35 ( ) 4.50 ( ) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.16 (1.13- (per 5 years) 1.20) 1.32 ( ) 1.24 ( ) 1.22 ( ) 1.55 ( ) Seropositive RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.54 ( ) 2.33 ( ) 1.80 ( ) 1.25 ( ) 6.23 ( ) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.20 (1.15- (per 5 years) 1.25) 1.38 ( ) 1.26 ( ) 1.23 ( ) 1.69 ( ) Seronegative RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.15 ( ) 1.60 ( ) 1.84 ( ) 1.40 ( ) 1.97 ( ) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.08 (1.02- (per 5 years) 1.15) 1.20 ( ) 1.19 ( ) 1.18 ( ) 1.23 ( ) * Adjusted for age, questionnaire period, US region, race/ethnicity, education, husband s education, body mass index (<18.5, , , 30), cigarette smoking pack-years (never, 0-10, , >20), post-menopausal hormone use, physical activity, healthy eating index, cancer, cardiovascular disease, diabetes mellitus, family history of diabetes, family history of cancer, family history of myocardial infarction <60 years of age and aspirin use through follow-up. Modifiable factors were adjusted up to RA diagnosis (cigarette smoking pack-years, physical activity and body mass index). Among women with RA, there were a total of 43 respiratory deaths that were due to pneumonia (11), emphysema (8), chronic interstitial lung disease (5), asthma (1) and other respiratory diseases (18). Disclosures: J. A. Sparks, None. 12:15 pm 819. Secukinumab, a Monoclonal Antibody to Interleukin- 17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing Dominique L. Baeten, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands Background/Purpose: A phase 2, proof-of-concept study indicated that secukinumab, an anti IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk) 6. We present Wk 16 and Wk 52 efficacy and safety data from MEASURE 1 (NCT ), a phase 3 study assessing secukinumab vs. placebo (PBO) in patients (pts) with AS. Methods: Pts with active AS fulfilling modified New York Criteria and BASDAI 4, despite current or previous therapy with NSAIDs, DMARDs and/or anti-tnf agents, were randomized to receive: i.v. secukinumab 10 mg/kg (Wk 0, 2, 4) followed by s.c. secukinumab 75 mg every 4 wks (10 IV 75 SC), s.c. secukinumab 150 mg every 4 wks (10 IV 150 SC), or PBO on same i.v. and s.c. schedules. Endpoints included ASAS20 at Wk 16 (primary), ASAS40, hscrp, ASAS 5/6, BASDAI, SF-36 PCS, ASQoL and ASAS partial remission. Statistical analyses followed a pre-defined hierarchical hypothesis testing strategy to adjust for multiplicity. PBO pts were re-randomized to secukinumab 75 mg or 150 mg s.c. based on ASAS20 response at Wk 16, with nonresponders switched at Wk 16 and responders at Wk 24. Results: Baseline characteristics of the 371 randomized pts were similar between study arms: mean age years, mean disease duration years, mean BASDAI , ~27% inadequate response to anti-tnf agents (TNF-IR). The study met its primary efficacy endpoint with a significantly higher ASAS20 response at Wk 16 in the 10 IV 75 SC (59.7%) and 10 IV 150 SC (60.8%) groups vs. PBO (28.7%; P < 0.01 for each dose); ASAS20 response rates in TNF-naïve pts were 60.0%, 66.3% and 32.6% and in the TNF-IR pts were 58.8%, 45.5% and 18.2%, in 2014 Program Book 41 SUNDAY november 16, 2014

44 SUNDAY november 16, 2014 scientific sessions the 10 IV 75 SC, 10 IV 150 SC and PBO groups, respectively (P< 0.01 vs. PBO). Significant improvements with both doses of secukinumab vs. PBO were observed for all pre-specified secondary endpoints at Wk 16 (Table), with responses sustained through Wk 52. Onset of action of secukinumab was rapid, with significant improvements in ASAS20, ASAS40, hscrp, ASAS5/6 and BASDAI seen at Wk 1. Through to Wk 16, drug exposure levels were similar in the secukinumab groups due to the i.v. loading doses. Secukinumab was generally well tolerated. At Wk 16, 66.9% of pts in the 10 IV 75 SC group and 69.6% in the 10 IV 150 SC group experienced an AE, vs. 55.7% on PBO; SAE rates were 1.6%, 2.4% and 4.1%, respectively. Through Wk 52 visit of the last pt (average exposure [range]: [8 757] days), AE/SAE rates were 76.5%/10.1% and 85.1%/9.4% for pts receiving secukinumab 75 or 150 mg s.c., respectively, at any point in the study. Table. Summary of 16-week efficacy results Week 16 Data Secukinumab 10 mg/kg i.v. 75 mg s.c. (N = 124) Secukinumab 10 mg/kg i.v. 150 mg s.c. (N = 125) Placebo (N = 122) ASAS20 response 59.7%* 60.8%* 28.7% ASAS40 response 33.1%* 41.6%* 13.1% hscrp, post-baseline to baseline ratio (LSM±SE) 0.45 ± 1.092* 0.40 ± 1.090* 0.97 ± ASAS5/6 45.2%* 48.8%* 13.1% BASDAI, mean change from baseline score (LSM±SE) ± 0.175* ± 0.172* ± SF-36 PCS, mean change from baseline score (LSM±SE) 5.64 ± 0.595* 5.57 ± 0.586* 0.96 ± ASQoL, mean change from baseline ± 0.424* score (LSM±SE) ± 0.420* ± ASAS partial remission 16.1%* 15.2%* 3.3% *P<0.01 vs. placebo Prespecified hierarchical statistical testing strategy used to account for multiplicity. Missing data for categorical variables were imputed as nonresponse ASAS, Assessment of SpondyloArthritis International Society Criteria; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; hscrp, high-sensitivity C-reactive protein; LSM, least square mean; SE, standard error; NS, not significant; SF-36 PCS, short form 36 physical component summary Conclusion: The selective IL-17A inhibitor secukinumab provided rapid and significant improvement of signs and symptoms in pts with active AS, regardless of prior anti-tnf exposure. Improvements were observed from Wk 1 and sustained through 52 wks. Secukinumab was well tolerated through 52 wks with no unexpected safety findings. Disclosures: D. L. Baeten, Research grants from Boehringer Ingelheim, Janssen, MSD, Novartis, Pfizer, 2, 9, Consulting fees from AbbVie, Boehringer Ingelheim, BMS, Eli Lilly, Jannsen, MSD, Novartis, Pfizer, Roche, UCB, 5. ARHP NETWORKING EVENT 12:30 2:15 pm Commonwealth Ballroom Networking Forum All ARHP attendees are invited to this kick-off forum for the annual meeting. A box lunch will be provided for the first 250 people. You will have an opportunity to meet and network with other health professionals. Discipline tables will be arranged to help facilitate connections. This session is not eligible for CME credit. ACR SESSION 12:45 2:15 pm Ballroom West ACR Knowledge Bowl: Preliminary Round Moderator: Rebecca L. Manno, MD, MHS identify key images that are important to recognize in clinical practice describe factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Competing Teams: Bourbon Street Bunions Nirupa J. Patel, MD; Kenneth Van Dyke, DO and Joseph Martinez, MD Complement ary Medicine! Sobia Hassan, BM BS, MRCP; Maria Antonelli, MD and Santosh Bhusal, MD Combat Rheumatology Ramon Arroyo, MD; Joshua Scott, DO, MS, BS and Ian Ward, MD Drugs ANCAnna Help Your GPA Soumya Chatterjee, MD, MS; Piyush Poddar, MD and David Theis, DO, BA Healing Hinges Kenneth J. Warrington, MD; Megan L. Krause, MD and Abha G. Singh, MBBS Motor City Road Runners Alireza Meysami, MD; Reshma Khan, MD and Reshma Marri, BS, MD Rheumatology Research Unit Rosa Daniela Grembiale, MD; Francesco Ursini, PhD, MD and Saverio Naty, MD Rheumawiz Rohini Samant, MBBS, MD; Piyush Joshi, MBBS, MD and Yathish GC, MBBS, MD Sweet Bones Alabama Laura B. Hughes, MD, MSPH; Xena Whittier, MD, MS, BA and Jenny Lin, MD Team Galveston Vijaya Murthy, MD; Rajani Rudrangi, MD and Niharika Ganti, MD Team Ireland John J. Carey, CCD, MS; Richard Conway, BAO, BCh, MB, MRCPI and Orla Ni Mhuircheartaigh, BAO, BCh, MB, MRCPI The Bauer Rumble Robert P. Friday, MD, PhD; Sara Schoenfeld, MD and Zachary Wallace, MD Program Book

45 scientific sessions The Brooklyn Rheuminators Deana M. Lazaro, MD; Nina Ramessar, MBBS and Jigar Shah, MD The Hawkeyes Namrata Singh, MBBS; Bharat Kumar, MD and Vijay Aluri, MD Triple Therapy: Triple Threat Ted R. Mikuls, MD, MSPH; Manpreet Sethi, MBBS; and Priyanka Vashisht, MD Westin Revere (Lobby) Hereditary Angioedema Update (014) Speaker: Peter Deane, MD discuss the pathophysiology of hereditary angioedema discuss the proper approach to the patient with angioedema discuss current treatment options The Honey Badgers Andrew Östör, MD; Andra Negoescu, MD; and Elena Nikiphorou, MRCP, MD (Res), PGCME ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Ankylosing Spondylitis: 2014 Update (011) Speaker: Lianne S. Gensler, MD discuss the spectrum of axial spondyloarthritis, including ankylosing spondylitis discuss the early diagnosis of ankylosing spondylitis and axial spondyloarthritis describe clinical and radiographic outcome measures used in clinical trials and practice summarize axial spondyloarthritis treatment options and evaluate the impact of treatment on outcomes Westin Otis (Lobby) *Ankylosing Spondylitis: Disease Modification (012) Speaker: Joachim Sieper, MD outline what is known about the pathophysiology of disease modification in spondyloarthritis review outcomes relevant to the concept of disease modification in spondyloarthritis and assess their relevance to clinical practice review therapeutic issues relevant to the concept of disease modification discuss assessment of disease modification clinical trial Westin Hancock (Lobby) *Dermatological Manifestations of Rheumatic Diseases (013) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatic disease construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatic diseases Westin Stone (Lobby) *Pediatric Systemic Lupus Erythematosus (015) Speaker: Kelly A. Rouster-Stevens, MD, MS discuss the epidemiology of pediatric systemic lupus erythematosus describe the differences in organ involvement between pediatric and adult systemic lupus erythematosus discuss the management and treatment of pediatric systemic lupus erythematosus review consensus treatment plans for the induction of proliferative lupus nephritis in pediatric patients discuss novel biomarkers that in the future may be beneficial in managing pediatric systemic lupus erythematosus Westin Webster (Lobby) *Rheumatoid Arthritis: Biological Agents (016) Speaker: Edward C. Keystone, MD describe recent trends in the use of biologics to improve outcomes and utility describe strategies to reduce costs of biologics discuss emerging biologics, including biosimilars and their advantage for the therapeutic algorithm Westin Adams (Mezzanine) *Systemic Lupus Erythematosus: Novel Treatments (017) Speaker: Susan Manzi, MD, MPH describe the history of therapeutic agents and the rationale for further drug development in lupus review new data to support standard therapies for management of lupus discuss the newest therapies approved for lupus and those currently under investigation Westin Alcott (Mezzanine) *Vaccinations for Patients on Biologic Therapies (018) Speaker: Jeffrey R. Curtis, MD, MPH, MS recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety 2014 Program Book 43 SUNDAY november 16, 2014

46 scientific sessions SUNDAY november 16, 2014 Westin Douglas (Mezzanine) *Vasculitis: Update (019) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size discuss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities Westin Faneuil (Mezzanine) *What Is Not Central Nervous Angiitis: Making the Right Diagnosis (020) Speaker: Leonard H. Calabrese, DO list and elaborate on the diagnostic criteria for primary angiitis of the central nervous system discuss the test operating characteristic of commonly employed neurodiagnostics, i.e., magnetic resonance, angiography, cerebrospinal fluid analysis, etc. list and appraise diagnostic heuristics for the recognition and diagnosis of primary angiitis of the central nervous system and the separation of mimics that can confound the diagnosis ACR SESSIONS 1:00 2:00 pm 254 A Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences Moderator: Salahuddin Kazi, MD Speaker: Steven K. Magid, MD recognize common errors in electronic health record systems and how to prevent these issues evaluate legal and social implications of unintended consequences in electronic health records review approaches to mitigate electronic health record related errors using a strategic set of solutions 157 B Axial Spondyloarthritis Guidelines Moderators: John D. Reveille, MD and Atul A. Deodhar, MD describe the ACR-SAA-SPARTAN recommendations for management of patients with axial spondyloarthritis/ ankylosing spondylitis review the process and methods used in the development of the new ACR-SAA-SPARTAN guidelines 1:00 pm Overview of Guidelines Development, Including Methods and Literature Review Liron Caplan, MD, PhD 1:25 pm Presentation of the Draft ACR-SAA-SPARTAN Axial Spondyloarthritis/Ankylosing Spondylitis Guidelines Michael M. Ward, MD 1:50 pm Questions and Answers Exhibit Hall C Gout Management Edin 2014 Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and Alan N. Baer, MD describe the effective management of gout in the setting of chronic kidney disease discuss the current best treatment for tophaceous gout and emerging therapies 1:00 pm Effective Management of Gout in the Setting of Renal Disease Lisa K. Stamp, PhD 1:30 pm Tophaceous Gout: Past, Present and the Future of Therapeutics Tuhina Neogi, MD, PhD 102 A How the Gut Primes the Immune System Moderator: Wael N. Jarjour, MD Speaker: Hilde Cheroutre, PhD examine the collaboration of the intestinal host-microbial interface and the innate and adaptive immune system in the detection and regulation of microbial populations and maintaining homeostasis examine the effects of disruption of the intestinal-host microbial interface and its contribution to chronic inflammatory disease 151 A Practice Issues: The Road to I10 Moderator: Douglas White, MD, PhD describe the challenges in the physician practice and the workflow for staff and patients identify any productivity loss due to coding backlogs discuss delays in turnaround time due to training assess performance in the new environment discuss any reimbursement disruptions and the flow of denials and/or adjustments for claims billed with ICD-9 codes for the earlier part of the year 1:00 pm The Advocacy Movement William F. Harvey, MD, MSc Program Book

47 scientific sessions 1:20 pm Physician s Perspective of ICD-10 Jonathan Kay, MD 1:40 pm Process and Strategy From the Coder s Viewpoint Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 104 B Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease Eth Moderator: Linda Bockenstedt, MD Speaker: Robert Terkeltaub, MD evaluate novel translational vision and action in the science and practice of rheumatology, by reviewing lucid examples of Dr. Malawista s seminal works and their evolving fate recognize the power of clinical observation and creative thinking in fleshing out etiopathogenesis, epidemiology and treatment of rheumatic diseases, exemplified by Lyme disease and gout appraise phagocyte innate immune responses to exogenous infectious and endogenous particulate danger signals and how nuances in macrophage differentiation and function orchestrate inflammatory responses and can be therapeutically corralled in rheumatic disease Ballroom East The Butterfly Effect: Lupus Rashes and Their Mimics Moderators: Elana J. Bernstein, MD, MSc and Meenakshi Jolly, MD, MS Speaker: Bonnie T. Mackool, MD, MSPH identify mimics of lupus rashes distinguish between lupus rashes and their mimics discuss the management of lupus rashes, including the treatment of rashes refractory to initial therapy 159 *Advanced Musculoskeletal Ultrasound (208) Speaker: Jay B. Higgs, MD 152 demonstrate improvement in their techniques for performing selected musculoskeletal ultrasound examinations use practical knowledge of ultrasound technology to improve image quality Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes perform the physical examination of the lower extremities on healthy volunteers ACR SESSIONS 2:30 4:00 pm 52 A Autoimmunity in Immunodeficiency Moderators: Nora G. Singer, MD and Jose Carlos Crispin Acuna, MD describe the presence of autoimmune manifestations in patients with primary immunodeficiency discuss the molecular basis for the development of autoimmunity in primary immunodeficiency consider therapeutic approaches for autoimmune manifestations in patients with primary immunodeficiency 2:30 pm Autoimmunity and Autoimmune Diseases in Primary Immunodeficiencies Erin Janssen, MD, PhD SUNDAY november 16, 2014 ACR WORKSHO 1:15 3:15 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. 3:15 pm The Abnormal Regulation of B-Cell Tolerance in Patients with Autoimmune Disease and Primary Immunodeficiencies Eric Meffre Sr., PhD 102 A Educator: Medical Education: The Year in Review Ed Pd PrM FIT Moderators: Deana M. Lazaro, MD and Michael J. Battistone, MD Speaker: Andrew R. Hoellein, MD recognize the major research reports and scholarship in the field of medical education over the past year 2014 Program Book 45

48 scientific sessions SUNDAY november 16, 2014 translate results of educational research to their own educational programs formulate ideas for educational research at their own institution 205 B New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines Ed Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and Timothy E. McAlindon, MD, MPH, MRCP summarize the evidence regarding weight loss in the management of osteoarthritis assess the role of arthroscopic debridement in treatment of osteoarthritis discuss how to reconcile differences between recent osteoarthritis treatment guidelines from the ACR, AAOS and other leading organizations 2:30 pm Weight Loss in the Management of Osteoarthritis: Lessons From Randomized Trials Stephen P. Messier, PhD 3:00 pm Arthroscopic Debridement and Meniscal Tear Surgery in Osteoarthritis Patients: Who Needs It and When and When Not to Do It Jeffrey N. Katz, MD, MSc 3:30 pm Recommendations for Management of Osteoarthritis: Can We Reconcile Differences? Marc C. Hochberg, MD, MPH, MACP Exhibit Hall C The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus Moderator: Elana J. Bernstein, MD, MSc identify predictors of response to belimumab discuss the efficacy of belimumab in the treatment of systemic lupus erythematosus evaluate the limitations of belimumab in the treatment of systemic lupus erythematosus describe the safety issues with belimumab discuss the outcomes and limitations of the BLISS-52 and BLISS-76 trials 2:30 pm Pro Perspective Bevra H. Hahn, MD 3:05 pm Pro Rebuttal David A. Isenberg, MD 3:13 pm Con Perspective David A. Isenberg, MD 3:48 pm Con Rebuttal Bevra H. Hahn, MD 3:56 pm Pro Final Bevra H. Hahn, MD 3:58 pm Con Final David A. Isenberg, MD ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm 253 B Epidemiology and Public Health I: Drug and Vaccine Safety Moderators: Kaleb Michaud, PhD and Cynthia S. Crowson, MS 2:30 pm 820. Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination Huifeng Yun 1, Shuo Yang 2, Lang Chen 2, Fenglong Xie 2, K. L. Winthrop 3, John Baddley 2, Kenneth G. Saag 4, Jasvinder Singh 2 and Jeffrey R. Curtis 2, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 Oregon Health and Science University, Portland, OR, 4 The University of Alabama at Birmingham, Birmingham, AL 2:45 pm 821. Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update Christina D Chambers 1, Diana L Johnson 2, Yunjun Luo 2, Ronghui Xu 1 and Kenneth L Jones 2, 1 University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, 2 University of California San Diego Department of Pediatrics, La Jolla, CA Pharmaceuticals, 2, Sandoz, 2, Sanofi-Aventis Pharmaceutical, 2, Teva Pharmaceuticals, 2, UCB, 2. 3:00 pm 822. Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study Deepan Dalal 1, Maureen Dubreuil 2, Yuqing Zhang 2, Christine Peloquin 2, Tuhina Neogi 2, Hyon Choi 2 and David T. Felson 2, 1 Boston Medical Center, Boston, MA, 2 Boston University School of Medicine, Boston, MA 3:15 pm 823. Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol Alina Soare, Carina Mihai, Ana Maria Gherghe, Rucsandra Dobrota, Raida Oneata, Simona Pintilie, Mihaela Milicescu, Program Book

49 scientific sessions Ioan Ancuta, Andrei Martin, Mariana Sasu, Claudia Ciofu, Liviu Macovei, Victor Stoica and Mihai Bojinca, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania 3:30 pm 824. Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom 3:45 pm 825. Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time and How High Are They? Elizabeth V. Arkema, Karolinska Institutet, Stockholm, Sweden Disclosures: E. V. Arkema, None. 104 B Metabolic and Crystal Arthropathies I: Clinical Aspects Moderators: N. Lawrence Edwards, MD and Janitzia Vazquez- Mellado, MD PhD 2:30 pm 826. Comparison of Classification Criteria for Gout Using Monosodium Urate Crystal Identification By a Certified Examiner As the Gold-Standard in a Large Multi-National Study William Taylor 1, Nicola Dalbeth 2, Jaap Fransen 3, Tuhina Neogi 4, H. Ralph Schumacher Jr. 5 and Tim Jansen 6, 1 University of Otago Wellington, Wellington, New Zealand, 2 University of Auckland, Auckland, New Zealand, 3 Radboud University, Nijmegen, Netherlands, 4 Boston University School of Medicine, Boston, MA, 5 University of Pennsylvania VA Medical Center, Philadelphia, PA, 6 Radboud University Medical Center, Nijmegen, Netherlands 2:45 pm 827. Gout and the Risk of Alzheimer s Disease: A Population- Based Cohort Study Na Lu 1, Yuqing Zhang 1, Alberto Ascherio 2, Miguel Hernan 2, Tuhina Neogi 1, Maureen Dubreuil 3 and Hyon Choi 4, 1 Boston University School of Medicine, Boston, MA, 2 Harvard School of Public Health, Boston, MA, 3 Boston University Medical Center, Boston, MA, 4 Harvard Medical School, Boston, MA 3:00 pm 828. Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study Nicola Dalbeth 1, Meaghan House 1, Opetaia Aati 1, Paul Tan 1, Christopher Franklin 1, Anne Horne 1, Gregory Gamble 1, Lisa K. Stamp 2, Anthony Doyle 1 and Fiona M. McQueen 1, 1 University of Auckland, Auckland, New Zealand, 2 University of Otago, Christchurch, New Zealand 3:15 pm 829. Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome Mariano Andrés 1, María Amparo Quintanilla 1, Francisca Sivera 1, Paloma Vela 2 and Juan Miguel Ruiz-Nodar 3, 1 Hospital General Universitario de Elda, Alicante, Spain, 2 Universidad Miguel Hernández, Alicante, Spain, 3 Hospital General Universitario de Alicante, Alicante, Spain 3:30 pm 830. Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Raymond P. Warrell Jr. 1, Anna Klukovits 2, Keith Barnes 3, Chitkala Satyanarayana 4, Chris Cheeseman 5 and John Piwinski 1, 1 Relburn- Metabolomics, Inc., Westfield, NJ, 2 SOLVO Biotechnology, Budapest, Hungary, 3 AMRI, Albany, NY, 4 AMRI, Singapore, Singapore, 5 University of Alberta, Alberta, AB 3:45 pm 831. Bisphosphonates and Risk of Acute Pseudogout: A Case- Control Study in the Clinical Practice Research Datalink (CPRD) Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Keele University, Keele, United Kingdom 160 B Miscellaneous Rheumatic and Inflammatory Diseases Moderators: Mehrdad Maz, MD and Isabelle Koné-Paut, MD 2:30 pm 832. NOD2-Associated Autoinflammatory Disease: The Largest Cohort Study Qingping Yao, Min Shen, Christine McDonald, Felicitas Lacbawan and Bo Shen, Cleveland Clinic, Cleveland, OH 2:45 pm 833. Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry Hal M. Hoffman 1, Jasmin B. Kuemmerle-Deschner 2, Philip N. Hawkins 3, T. van der Poll 4, Ulrich A. Walker 5, Ken Abrams 6 and Hugh H. Tilson 7, 1 University of California at San Diego, La Jolla, CA, 2 University Hospital Tuebingen, Tuebingen, Germany, 3 University College London Medical School, London, United Kingdom, 4 University of Amsterdam, Amsterdam, Netherlands, 5 Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 6 Novartis Pharmaceutical Corporation, East Hanover, NJ, 7 University of North Carolina, Chapel Hill, NC 3:00 pm 834. Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still s Disease and Systemic Onset Juvenile Idiopathic Arthritis Holger Kudela 1, Susanne Drynda 2, Anke Lux 3, Gerd Horneff 4 and Joern Kekow 2, 1 Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, 2 Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, 3 Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, 4 Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany SUNDAY november 16, Program Book 47

50 scientific sessions SUNDAY november 16, :15 pm 835. Relapsing Polychondritis Can Be Characterized By 3 Different Clinical Phenotypes: Analysis of a Series of 142 Patients Jeremie Dion 1, Nathalie Costedoat-Chalumeau 1, Damien Sène 2, Judith Cohen-Bittan 3, Gaëlle Leroux 3, Charlotte Dion 4, Camille Francès 5 and Jean-Charles Piette 3, 1 National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, Paris, France, 2 Hopital Lariboisière, service de Médecine Interne, Paris, France, 3 CHU Pitié-Salpêtrière, Paris, France, 4 Ecole des hautes études en sciences sociales, Paris, France, 5 Hôpital Tenon, Paris Cedex 20, France 3:30 pm 836. Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years Aryeh Fischer 1, Virginia D. Steen 2, Steven Nathan 3, Hunter Gillies 4, James Tislow 4 and Chris Blair 4, 1 National Jewish Health, Denver, CO, 2 Georgetown University Medical Center, Washington, DC, 3 Inova Medical Group, Falls Church, VA, 4 Gilead Sciences, Inc., Foster City, CA 3:45 pm 837. Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab Eamonn Molloy 1 and Leonard H. Calabrese 2, 1 St Vincent University Hospital, Dublin, Ireland, 2 Cleveland Clinic Foundation, Cleveland, OH Ballroom East Rheumatoid Arthritis Clinical Aspects I: Cardiovascular Disease Risk Moderators: Grant H. Louie, MD, MHS and Jon Giles, MD, MPH 2:30 pm 838. The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare? Elena Myasoedova 1, Arun K. Chandran 1, Birkan İlhan 2, Brittny T. Major 1, C. John Michet 1, Eric L. Matteson 1 and Cynthia S. Crowson 1, 1 Mayo Clinic, Rochester, MN, 2 Marmara University School of Medicine, Istanbul, Turkey 2:45 pm 839. Cardiovascular Risk with NSAIDs in Rheumatoid Arthritis: An Analysis Using Routinely Collected Data Fowzia Ibrahim 1, Antigoni Grigoriou 2, Khaldoun Chaabo 2, David L. Scott 2, Sophia Steer 2 and James Galloway 2, 1 King s College London, Department of Rheumatology, London, United Kingdom, 2 King s College Hospital, Department of Rheumatology, London, London, United Kingdom 3:00 pm 840. Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen- Specific Anti-Citrullinated Protein Antibodies and Mortality in Rheumatoid Arthritis E. Blair Solow 1, Fang Yu 2, Geoffrey M. Thiele 3, Jeremy Sokolove 4, William H. Robinson 5, Zachary M. Pruhs 3, Kaleb Michaud 3, Alan R. Erickson 3, Harlan Sayles 3, Gail S. Kerr 6, Angelo L. Gaffo 7, Liron Caplan 8, Lisa A. Davis 8, Grant W. Cannon 9, Andreas M. Reimold 10, Joshua Baker 11, Pascale Schwab 12, Daniel Anderson 3 and Ted R. Mikuls 3, 1 UT Southwestern Medical Center, Dallas, TX, 2 University of Nebraska Medical Center, Omaha, NE, 3 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4 VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 5 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 7 Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, 8 Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, 9 Salt Lake City VA and University of Utah, Salt Lake City, UT, 10 Dallas VA and University of Texas Southwestern, Dallas, TX, 11 University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 12 Oregon Health & Science University, Portland, OR 3:15 pm 841. Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non- Rheumatoid Arthritis Patients J An 1, E Alemao 2, K Reynolds 3, H Kawabata 2, D H Solomon 4, K P Liao 4 and T C Cheetham 3, 1 Western University of Health Sciences, Pomona, CA, 2 Bristol-Myers Squibb, Princeton, NJ, 3 Kaiser Permanente Southern California, Pasadena, CA, 4 Brigham and Women s Hospital, Boston, MA 3:30 pm 842. Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? Jie Zhang 1, Shuo Yang 2, Lang Chen 2, Fenglong Xie 2, Huifeng Yun 3, Paul M. Muntner 2, Emily Levitan 2, Monica Safford 2, Kenneth G. Saag 4, Jasvinder Singh 2 and Jeffrey R. Curtis 2, 1 Univ. of Alabama at Birmingham, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 4 The University of Alabama at Birmingham, Birmingham, AL 3:45 pm 843. Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis Kevin Byram, Annette Oeser, MacRae F. Linton, Sergio Fazio, C Michael Stein and Michelle Ormseth, Vanderbilt University, Nashville, TN Ballroom West Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Malignancy and Infection Moderators: Stephen A. Paget, MD and Peter C. Taylor, MD, PhD 2:30 pm 844. Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Followup in a US Observational Study Program Book

51 scientific sessions Kenneth G. Saag 1, Kevin L. Winthrop 2, D E Furst 3, Kimberly Alexander 4, Angelika Jahreis 5, Carol Chung 6 and Kurt Oelke 7, 1 The University of Alabama at Birmingham, Birmingham, AL, 2 Oregon Health & Science University, Portland, OR, 3 University of California at Los Angeles, Los Angeles, CA, 4 Genentech, Inc., South San Francisco, CA, 5 Genentech, South San Francisco, CA, 6 Genentech, Inc, South San Francisco, CA, 7 Rheumatic Disease Center, Glendale, WI 2:45 pm 845. The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication Layla Saliba 1, Guillaume Moulis 2, Malak Aboutaam 3, Grégory Pugnet 2, Vanessa Rousseau 1, Leila Chebane 1, Nadine Petitpain 4, Bernadette Baldin 5, Jean-Louis Montastruc 1 and Haleh Bagheri 1, 1 Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, 2 Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, 3 Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, 4 Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, 5 Nice University Hospital, Pharmacovigilance Regional Center, Nice, France 3:00 pm 846. Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden Pauline Raaschou 1, Julia F Simard 2, Charlotte Asker-Hagelberg 3, Johan Askling 4 and the ARTIS Study group 5, 1 Karolinska Institutet, Stockholm, Sweden, 2 Stanford School of Medicine, Stanford, CA, 3 Swedish Medical Products Agency, SE Uppsala, Sweden, 4 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5 Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden 3:15 pm 847. Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy Seung-Hyeon Bae, Doo-Ho Lim, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3:30 pm 848. Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients René Cordtz 1, Lene Mellemkjær 2, Bente Glintborg 1, Merete Lund Hetland 3 and Lene Dreyer 1, 1 Copenhagen University Hospital Gentofte, Hellerup, Denmark, 2 The Danish Cancer Society, Copenhagen, Denmark, 3 Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark 3:45 pm 849. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years J. Wollenhaupt 1, J. Silverfield 2, E.B. Lee 3, S.P. Wood 4, K. Terry 4, H. Nakamura 5, K. Kwok 6, A. Anisfeld 6, C. Nduaka 4, R. Riese 4 and L. Wang 4, 1 Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2 Healthpoint Medical Group, Tampa, FL, 3 Seoul National University, Seoul, South Korea, 4 Pfizer Inc, Groton, CT, 5 Pfizer Inc, Tokyo, Japan, 6 Pfizer Inc, New York, NY 210 B Spondyloarthropathies and Psoriatic Arthritis I Novel Treatments for Axial Spondyloarthritis Moderators: Atul A. Deodhar, MD and Lianne S. Gensler, MD 2:30 pm 850. Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib Jacqueline E. Paramarta 1, Maureen C. Turina 1, Tanja F. Heijda 1, Iris C. Blijdorp 2, Troy Noordenbos 1, Nataliya Yeremenko 1 and Dominique L. Baeten 2, 1 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2 Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands 2:45 pm 851. A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study Jakub Zavada 1, Michal Uher 2, Katarina Sisol 3, Sarka Forejtova 3, Katerina Jarosova 3, Herman F. Mann 4, Jiri Vencovsky 5 and Karel Pavelka 6, 1 Charles University, Prague, Czech Republic, 2 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, 3 Institute of Rheumatology, Prague, Czech Republic, 4 Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 5 Institute of Rheumatology and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6 Institute of Rheumatology, Praha, Czech Republic 3:00 pm 852. Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Joachim Sieper 1, Martin Rudwaleit 2, Désirée M. van der Heijde 3, Walter P. Maksymowych 4, Maxime Dougados 5, Philip Mease 6, Jürgen Braun 7, Atul A. Deodhar 8, Bengt Hoepken 9, Tommi Nurminen 9 and Robert B. M. Landewé 10, 1 Charité Universitätsmedizin Berlin, Berlin, Germany, 2 Endokrinologikum, Berlin, Germany, 3 Leiden University Medical Center, Leiden, Netherlands, 4 University of Alberta, Edmonton, AB, 5 Université Paris René Descartes and Hôpital Cochin, Paris, France, 6 Swedish Medical Center and University of Washington, Seattle, WA, 7 Ruhr-University Bochum, Herne, Germany, 8 Oregon Health and Sciences University, Portland, OR, 9 UCB Pharma, Monheim, Germany, 10 Amsterdam Rheumatology Center, Amsterdam, Netherlands SUNDAY november 16, Program Book 49

52 scientific sessions SUNDAY november 16, :15 pm 853. Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis a Study from the ARTIS and Danbio Registers Johan Askling 1, Lene Dreyer 2, Merete Lund Hetland 3, Lennart Jacobsson 4, Lars-Erik Kristensen 5, Bente Glintborg 6,. ARTIS and DANBIO study groups 7 and Karin Hellgren 1, 1 Karolinska Institutet, Stockholm, Sweden, 2 Gentofte University Hospital, Hellreup, Denmark, 3 Glostrup University Hospital, Glostrup, Denmark, 4 Sahlgrenska Academy, Gothenburg, Sweden, 5 Lund University, Lund, Sweden, 6 Gentofte University Hospital, Gentofte, Denmark, 7 Karolinska Institutet, Stockholm, Sweden 3:30 pm 854. Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial Chi Chiu Mok, Angela Li, Kar Li Chan and Ling Yin Ho, Tuen Mun Hospital, Hong Kong, Hong Kong 3:45 pm 855. Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non- Radiographic Axial Spondyloarthritis Treated with Etanercept WP Maksymowych 1, S Wichuk 1, H Jones 2, A Szumski 2, L Marshall 2, J Bukowski 2 and RG Lambert 1, 1 University of Alberta, Edmonton, AB, 2 Pfizer Inc., Collegeville, PA 153 B Systemic Lupus Erythematosus Animal Models Moderators: Keith B. Elkon, MD and Ram P. Singh, PhD 2:30 pm 856. A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus Silvio M. Vieira, Andrew Yu, Michael Hiltesperger, Odelya E. Pagovich, Eleni Tiniakou, William Ruff, John Sterpka and Martin Kriegel, Yale School of Medicine, New Haven, CT 2:45 pm 857. Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors Chaim O. Jacob, Ning Yu and William Stohl, University of Southern California Keck School of Medicine, Los Angeles, CA 3:00 pm 858. ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets Li Chun Wang 1, Stuart Perper 1, Annette Schwartz 1, Christian Goess 1, Liz O connor 1, Dawna Hartman 1, Candace Graff 1, Andrew Souers 2, Joel Leverson 2, Steven Elmore 2 and Lisa Olson 1, 1 AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2 AbbVie Inc, North Chicago, IL 3:15 pm 859. TGF-β3-Producing CD4 + CD25 - LAG3 + Regulatory T Cells Control B Cell Responses Tomohisa Okamura 1, Kaoru Morita 1, Mariko Inoue 1, Toshihiko Komai 1, Yukiko Iwasaki 1, Shuji Sumitomo 1, Shinichiro Nakachi 1, Hirofumi Shoda 2, Keishi Fujio 2 and Kazuhiko Yamamoto 1, 1 Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, 2 The University of Tokyo, Tokyo, Japan 3:30 pm 860. Inhibition of G Protein βγ Signaling Inhibits Nephritis in Lupus Prone Mice Teresa Owen, Javier Rangel-Moreno, Jesi To, Bruce Goldman, Alan Smrcka and Jennifer H. Anolik, University of Rochester, Rochester, NY 3:45 pm 861. Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus Clayton Sontheimer and Keith B. Elkon, University of Washington, Seattle, WA 258 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Cardiovascular Disease and Pregnancy Moderators: Wendy Marder, MD and Eliza Chakravarty, MD, MS 2:30 pm 862. Risk Factors for Changes in Subclinical Atherosclerosis As Measured By Carotid Intima Media Thickness (IMT) and Plaque over 5 Years in Women with Systemic Lupus Erythematosus (SLE) Apinya Lertratanakul 1, Peggy W. Wu 1, Alan Dyer 1, William Pearce 1, Emma Barinas-Mitchell 2, Trina Thompson 2 and Rosalind Ramsey- Goldman 3, 1 Northwestern University, Chicago, IL, 2 University of Pittsburgh, Pittsburgh, PA, 3 Northwestern University and Feinberg School of Medicine, Chicago, IL 2:45 pm 863. Metabolic Syndrome in Young Premenopausal Female Lupus Patients Is Mainly Influenced By Therapies Luciana Muniz 1, Rosa M.R. Pereira 1, Thiago Silva 1, Eloisa Bonfá 2 and Eduardo Ferreira Borba 1, 1 University of São Paulo, São Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 3:00 pm 864. Association of Coronary Artery Calcification with Brown and White Pericardial Adipose Tissue in SLE Kelly J. Shields, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA 3:15 pm 865. Cardiovascular Events Prior to or Early after Diagnosis of SLE Murray B. Urowitz 1, Dafna D. Gladman 1, Nicole Anderson 1, Dominique Ibanez 1 and Systemic Lupus International Collaborating Clinics (SLICC) 2, 1 University of Toronto, Toronto Western Hospital, Toronto, ON, 2 University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON Program Book

53 scientific sessions 3:30 pm 866. Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus Aikaterini Thanou 1, Stavros Stavrakis 2, John Dyer 2, Stan Kamp 1, Melissa E. Munroe 1, David Albert 3, Judith A. James 1 and Joan T. Merrill 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3 AliveCor, Inc., San Francisco, CA 3:45 pm 867. Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy Sara K. Tedeschi, Hongshu Guan, Alexander Fine, Bonnie L. Bermas and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 107 B Systemic Lupus Erythematosus Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury Moderators: Robert M. Clancy, PhD and Susan Boackle, MD 2:30 pm 868. Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, University of Michigan, Ann Arbor, MI 2:45 pm 869. UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex Myles J. Lewis 1, Simon Vyse 1, Adrian M. Shields 2, Sebastian Boeltz 2, Patrick Gordon 2, Timothy D. Spector 2, Paul J. Lehner 3, Henning Walczak 4 and Timothy J. Vyse 2, 1 Queen Mary University of London, London, United Kingdom, 2 King s College London, London, United Kingdom, 3 University of Cambridge, Cambridge, United Kingdom, 4 University College London, London, United Kingdom 3:00 pm 870. IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus Yiu Tak Leung 1, Lihua Shi 2, Kelly Maurer 2, Li Song 2, Zhe Zhang 3, Michelle Petri 4 and Kathleen E. Sullivan 2, 1 University of Pennsylvania, Philadelphia, PA, 2 The Children s Hospital of Philadelphia, Philadelphia, PA, 3 Bioinformatics, Children s Hospital of Philadelphia, Philadelphia, PA, 4 Johns Hopkins University School of Medicine, Baltimore, MD 3:15 pm 871. Antimalarials Regulate TLR7/8 Mediated Macrophage Activation Via Epigenetic Modification at the TNFα Promoter Androo J. Markham 1, Mark Halushka 2, Cristiana Guiducci 3, Robert M. Clancy 1 and Jill P. Buyon 1, 1 New York University School of Medicine, New York, NY, 2 John Hopkins Pathology, Baltimore, MD, 3 Dynavax Technologies, Berkeley, CA 3:30 pm 872. Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia Danieli Andrade 1, Mimi Kim 2, Luz P. Blanco 3, S. Ananth Karumanchi 4, Gloria Koo 1, Patricia M. Redecha 1, Kyriakos A. Kirou 1, Angela M. Alvarez 5, Melissa J. Mulla 5, Mary K. Crow 1, Vikki Abrahams 5, Mariana J. Kaplan 3 and Jane E. Salmon 1, 1 Hospital for Special Surgery, New York, NY, 2 Albert Einstein College of Medicine, Bronx, NY, 3 National Institutes of Health, Bethesda, MD, 4 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5 Yale School of Medicine, New Haven, CT 3:45 pm 873. The Second Messenger, Cyclic GMP-AMP Dinucleotide (cgamp) and the Enzyme, Cyclic GMP-AMP Synthase (cgas), Are Expressed in Systemic Lupus Erythematosus Jie An, Joshua Woodward, Reynold Karr, Thomas H. Teal and Keith B. Elkon, University of Washington, Seattle, WA 157 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Moderators: Sindhu R. Johnson, MD, PhD and Christopher P. Denton, MD, PhD 2:30 pm 874. Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial Dinesh Khanna 1, Christopher P. Denton 2, Jacob M. van Laar 3, Angelika Jahreis 4, Sabrina Cheng 4, Helen Spotswood 5, Jeffrey Siegel 4 and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS 6, 1 University of Michigan Health System, Ann Arbor, MI, 2 University College London Medical School, London, United Kingdom, 3 University Medical Center Utrecht, Utrecht, Netherlands, 4 Genentech, South San Francisco, CA, 5 Roche Products Ltd., Welwyn Garden City, United Kingdom, 6 University of California, Los Angeles, CA 2:45 pm 875. Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials Rennie L. Rhee 1, Nicole B. Gabler 1, Amy Praestgaard 1, Peter A. Merkel 2 and Steven M. Kawut 1, 1 University of Pennsylvania, Philadelphia, PA, 2 Vasculitis Center, University of Pennsylvania, Philadelphia, PA 3:00 pm 876. SAR100842, an Antagonist of Lysophosphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study Dinesh Khanna 1, Christopher P. Denton 2, Alexandre Jagerschmidt 3, Martine Jasson 4, Oliver Distler 5 and Yannick Allanore 6, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 UCL Medical School Royal Free Campus, London, United Kingdom, 3 Sanofi-Aventis, Chilly-Mazarin, France, 4 Sanofi-Aventis, Paris, France, 5 Zurich University Hospital, Zurich, SUNDAY november 16, Program Book 51

54 scientific sessions SUNDAY november 16, 2014 Switzerland, 6 Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France 3:15 pm 877. Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts Tomoaki Higuchi 1, Yasushi Kawaguchi 1, Kae Takagi 1, Akiko Tochimoto 1, Yuko Ota 1, Yasuhiro Katsumata 1, Takahisa Gono 1, Masanori Hanaoka 1, Yuko Okamoto 1, Hidenaga Kawasumi 1 and Hisashi Yamanaka 2, 1 Tokyo Women s Medical University, Tokyo, Japan, 2 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 3:30 pm 878. Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment D. James Haddon 1, Hannah Wand 1, Paul J. Utz 1, Robert F. Spiera 2, Jessica K. Gordon 2 and Lorinda Chung 3, 1 Stanford University School of Medicine, Stanford, CA, 2 Hospital for Special Surgery, New York, NY, 3 Stanford University School of Medicine, Palo Alto, CA 3:45 pm 879. Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up Eleonora Zaccara 1, Domenico Sambataro 2, Wanda Maglione 1, Gianluca Sambataro 1, Francesco Onida 3, Claudio Annaloro 3, Giorgia Saporiti 3, Elena Tagliaferri 3, Agostino Cortelezzi 3, Rosaria Giordano 3, Claudio Vitali 4 and Nicoletta Del Papa 2, 1 Osp. G. Pini, Milano, Italy, 2 Istituto G.Pini, Milan, Italy, 3 Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, 4 Istituto San Giuseppe, Lecco, Italy 156 B Vasculitis I Moderators: Maria C. Cid, MD. PhD and Kenneth J. Warrington, MD 2:30 pm 880. An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis Francisco David Carmona 1, Sarah Mackie 2, Jose Ezequiel Martin 1, John Taylor 2, Augusto Vaglio 3, Lara Bossini-Castillo 1, Santos Castañeda 4, Maria C. Cid 5, José Hernández-Rodríguez 5, Roser Solans 6, Ricardo Blanco 7, Lorenzo Beretta 8, Claudio Lunardi 9, Marco A. Cimmino 10, Cisca Wijmenga 11, Torsten Witte 12, Julia Holle 13, Frank Moosig 13, Verena Schönau 14, Andre Franke 15, Øyvind Palm 16, Andreas P. Diamantopoulos 17, Benedicte A. Lie 18, Simon Carette 19, David Cuthbertson 20, Gary S. Hoffman 21, Nader A. Khalidi 22, Curry L. Koening 23, Carol A. Langford 24, Carol McAlear 25, Larry Moreland 26, Paul A. Monach 27, Christian Pagnoux 19, Philip Seo 28, Antoine G. Sreih 29, Kenneth J. Warrington 30, Steven R. Ytterberg 30, Colin T. Pease 31, Andrew Gough 32, Michael Green 33, Lesley Hordon 34, Stephen Jarrett 35, Richard Watts 36, Sarah Levy 37, Yusuf Patel 38, Sanjeet Kamath 39, Bhaskar Dasgupta 40, Paul IW. de Bakker 41, Bobby P.C. Koeleman 41, Jennifer H. Barrett 2, Carlo Salvarani 42, Peter A. Merkel 25, Miguel A. Gonzalez-Gay 7, Ann W. Morgan 2 and Javier Martin 1, 1 Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 2 University of Leeds, Leeds, United Kingdom, 3 University Hospital of Parma, Parma, Italy, 4 Hospital Universitario de La Princesa, IISP, Madrid, Spain, 5 Hospital Clínic University of Barcelona, Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBA), Barcelona, Spain, 6 Hospital Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain, 7 Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, 8 Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 9 Università degli Studi di Verona, Verona, Italy, 10 University of Genova, Genova, Italy, 11 University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, 12 Hannover Medical School, Hannover, Germany, 13 Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, 14 Universitätsklinikum Erlangen, Erlangen, Germany, 15 Christian-Albrechts-University of Kiel, Kiel, Germany, 16 Oslo University Hospital and University of Oslo, Oslo, Norway, 17 Hospital of Southern Norway Trust, Kristiansand, Norway, 18 University of Oslo and Oslo University Hospital, Oslo, Norway, 19 University of Toronto, Toronto, ON, 20 University of South Florida, Tampa, FL, 21 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 22 St. Joseph s Hospital, McMaster University, Hamilton, ON, 23 University of Utah, Salt Lake City, UT, 24 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 25 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 26 Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, 27 Vasculitis Center, Boston University School of Medicine, Boston, MA, 28 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 29 The University of Pennsylvania, Philadelphia, PA, 30 Mayo Clinic, Rochester, MN, 31 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 32 Harrogate and District Foundation Trust, Harrogate, United Kingdom, 33 York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 34 Mid Yorkshire Hospitals NHS Trust, Dewsbury, United Kingdom, 35 Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom, 36 Ipswich Hospital NHS Trust, Ipswich, United Kingdom, 37 Croydon Health Service NHS Trust, Croydon, United Kingdom, 38 Hull and East Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom, 39 Staffordshire and Stoke-on-Trent Partnership NHS Trust, Staffordshire, United Kingdom, 40 Southend University Hospital, Essex, United Kingdom, 41 University Medical Center Utrecht, Utrecht, Netherlands, 42 Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy 2:45 pm 881. DNA Methylation Analysis of the Temporal Artery Microenvironment Reveals a Robust T Cell Signature and Suggests a Role for TNF-α in Giant Cell Arteritis Patrick S. Coit, Lindsey B. De Lott, Bin Nan, Victor M. Elner and Amr H. Sawalha, University of Michigan, Ann Arbor, MI Program Book

55 3:00 pm 882. A Signature of micrornas Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis Stefania Croci, Alessandro Zerbini, Luigi Boiardi, Francesco Muratore, Alessandra Bisagni, Giulia Pazzola, Luca Cimino, Antonio Moramarco, Davide Nicoli, Enrico Farnetti, Bruno Casali, Alberto Cavazza, Maria Parmeggiani and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy 3:15 pm 883. Accuracy of High Resolution MRI of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Study Maxime Rhéaume 1, Ryan Rebello 2, Christian Pagnoux 3, Simon Carette 3, Marie Clements-Baker 4, Violette Cohen-Hallaleh 2, David Doucette-Preville 2, B. Stanley Jackson 5, Sam Salama 6, George Ioannidis 7 and Nader A. Khalidi 8, 1 Division of Rheumatology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 2 Department of Radiology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 3 University of Toronto, Toronto, ON, 4 Queens University, Kingston, ON, 5 Department of Surgery, St. Joseph s Hospital, McMaster University, Hamilton, ON, 6 Department of Pathology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 7 St Joseph s Healthcare Hamilton, Hamilton, ON, 8 St. Joseph s Hospital, McMaster University, Hamilton, ON 3:30 pm 884. Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis Lorraine O Neill 1, Jennifer McCormick 2, Wei Gao 2, Conor Murphy 3, Geraldine M. McCarthy 4, Douglas J. Veale 1, Ursula Fearon 2 and Eamonn S. Molloy 1, 1 St. Vincent s University Hospital, Dublin 4, Ireland, 2 Translational Rheumatology Research Group, Dublin, Ireland, 3 Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 4 Mater Misericordiae University Hospital, Dublin 7, Ireland 3:45 pm 885. A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-il17 mab), Canakinumab (anti-il-1 b mab), or Corticosteroids on Initial Disease Activity Scores in Patients with R, Followed By an Open-Label Extension to Assess Safety and Effect Duration Eric L. Matteson 1, Bhaskar Dasgupta 2, Wolfgang A. Schmidt 3, Carlo Salvarani 4, Nagui Gendi 5, Mauro Galeazzi 6, Sylvie Stitah 7, Yue Li 7, Marie-Anne Valentin 7, Bolan Linghu 8 and Stephen J. Oliver 7, 1 Mayo Clinic, Rochester, MN, 2 Southend University Hospital, Essex, United Kingdom, 3 Immanuel Krankenhaus, Berlin, Germany, 4 Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, 5 Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, 6 Università di Siena, Siena, Italy, 7 Novartis Pharma AG, Basel, Switzerland, 8 Novartis Pharma AG, Cambridge, MA ARHP SESSIONS 2:30 4:00 pm scientific sessions 255 Google Minefield: Empowering Patients to Evaluate Online Resources Ed Pd PrM Ed FIT Pd PrM FIT identify quality resources for patients regarding arthritis education describe process of online search for arthritis education resources evaluate health literacy of online content to selectively identify content that meets the needs of specific patients/ consumers 2:30 pm Online Patient Resources for Arthritis and Strategies to Locate Quality Information and Usability Maura D. Iversen, BSc, DPT, SD, MPH 3:15 pm Empowering Patients to Navigate the Google Minefield Laura E. Ray, MA, MLS 256 Practical Practice Management Session One: Improve Quality and Efficiency Moderators: Lee Anderson, BSN and Brandi Young, DNP recognize the links between quality improvement initiatives and payment reform apply techniques in quality measurement to drive practice improvement in rheumatology utilize tools created by the ACR, including the Rheumatology Clinical Registry (RCR) and the Rheumatology Informatics System for Effectiveness (RISE) Registry, to successfully report quality measures for their practices 2:30 pm Payment Reform: What s Coming? Robert Warren, MD, PhD, MPH 3:00 pm Quality Improvement in Rheumatology Jinoos Yazdany, MD, MPH 151 A Sports Medicine for the Rheumatology Provider Moderator: Judy Foxworth, PhD, PT identify mechanisms of injury of common sports medicine injuries of both the shoulder and knee of the older athlete discuss medical/surgical management of common sports medicine injuries of the knee and shoulder with special consideration of athletes with osteoarthritis present evidence of best practices for rehabilitation for older athletes with common shoulder and knee injuries with rheumatic disease 2014 Program Book 53 SUNDAY november 16, 2014

56 scientific sessions SUNDAY november 16, :30 pm Most Common Sports Medicine Injuries of the Older Athlete Karl Fields, MD 3:15 pm Special Considerations for Sports Participation for Those with Rheumatic Disease James J. Irrgang, ATC, PhD, PT 254 A Young Adults with Rheumatic Disease: The Patient Perspective Ed Pd PrM FIT Moderator: Sandra Mintz, BSN enhance their knowledge of the multifaceted experiences of living with a rheumatic disease discuss the importance of patient advocacy and how to help develop it at any age employ tips towards engaging patients and providing them opportunities to develop their toolset for living with a rheumatic disease 2:30 pm Patient Perspective Jennifer R. Horonjeff, MS 3:15 pm Young Adults with Rheumatic Disease: The Patient Perspective Kiana Johnson, PhD ARHP CONCURRENT ABSTRACT SESSION 2:30 4:00 pm Gil 10, Mariana Salcedo 11 and Gustavo Citera 1, 1 Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2 Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, 3 Hospital Britanico, Buenos Aires, Argentina, 4 British Hospital, Buenos Aires, Argentina, 5 Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, 6 Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 7 Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, 8 Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, 9 Hospital Señor del Milagro, Salta, Argentina, 10 Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, 11 Consultorio Privado, San Nicolás, Argentina 3:00 pm 888. Annual Medical Care Expenditures Among US Adults with Gout, Miriam G. Cisternas 1, Louise Murphy 2, David J. Pasta 3, Edward H. Yelin 4 and Charles Helmick 2, 1 MGC Data Services, Carlsbad, CA, 2 Centers for Disease Control and Prevention, Atlanta, GA, 3 DMA Corporation, Palo Alto, CA, 4 University of California, San Francisco, San Francisco, CA 3:15 pm 889. Exercise, Manual Therapy and Use of Booster Sessions in Physical Therapy for Knee OA: A Multi-Center Randomized Clinical Trial G Kelley Fitzgerald 1, Julie Fritz 2, John Childs 3, Gerard P. Brennan 4, Douglas P. Landsittel 5, Brett Neilson 6, Alexandra Gil 1 and J. Haxby Abbott 7, 1 University of Pittsburgh, Pittsburgh, PA, 2 University of Utah, Salt Lake City, UT, 3 US Army-Baylor University, Schertz, TX, 4 Intermountain Healthcare, Murray, UT, 5 University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, 6 Henry M. Jackson Foundation, Bethesda, MD, 7 University of Otago, Dunedin, New Zealand 257 A Exemplary Abstracts Moderators: Scott Hasson, Pt, PhD and Robert M. McLean, MD 2:30 pm 886. Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status? Nancy A. Baker 1, Heather Eng 2, Juan (June) Feng 2, Jason Lyons 2, Yong Gil Hwang 1, Kimberly P. Liang 1 and Larry W. Moreland 1, 1 University of Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 2:45 pm 887. The Impact of Inadequate Health Literacy on Disease Activity in Patients with Rheumatoid Arthritis Maria Celeste Orozco 1, Maria Florencia Marengo 1, Christian A. Waimann 1, Ana Inés Marcos 2, Amelia Granel 2, Sofia Velez 3, Federico Zazzetti 3, Juan C. Barreira 4, Paula Kohan 5, Oscar L. Rillo 6, María Victoria Collado 7, Graciela Gómez 8, Ricardo V. Juárez 9, Veronica Lencina 9, Andrea D Orazio 10, Gustavo Rodriguez 3:30 pm 890. Test of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Item Profile in a Large Cohort of Rheumatic Disease Patients Patricia P. Katz 1, Sofia Pedro 2 and Kaleb Michaud 3, 1 University of California, San Francisco, San Francisco, CA, 2 National Data Bank, Wichita, KS, 3 University of Nebraska Medical Center and National Data Bank, Omaha, NE 3:45 pm 891. Randomized Clinical Trial of Group Vs. Individual Physical Therapy for Knee Osteoarthritis Kelli D. Allen 1, Dennis Bongiorni 2, Hayden B. Bosworth 3, Cynthia Coffman 3, Santanu Datta 3, David Edelman 3, Jennifer H. Lindquist 2, Eugene Oddone 3 and Helen Hoenig 3, 1 Durham VA Medical Center and University of North Carolina at Chapel Hill, Durham, NC, 2 Durham VA Medical Center, Durham, NC, 3 Durham VA Medical Center and Duke University Medical Center, Durham, NC Program Book

57 scientific sessions ACR WORKSHO 4:00 6:00 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. demonstrate the mechanism leading to mechanical neck and lumbar pain and the approach at the bedside to discerning the mechanisms and its treatment demonstrate how to more easily determine joint swelling particularly in the metacarpophalangeal joint, proximal interphalangeal joint and wrists ACR SESSIONS 4:30 6:00 pm 52 A Therapeutic Targeting of the Innate Immune System Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210) Speaker: Walter P. Maksymowych, MD recognize typical active and structural lesions of spondyloarthritis recognize complicated/subtle lesions of spondyloarthritis recognize lesions that may mimic spondyloarthritis recognize pitfalls in the interpretation of MRI in spondyloarthritis Muscle Involvement in Rheumatic Diseases (211) Speaker: Sakir Humayun Gultekin, MD identify the histologic abnormalities of steroid myopathy, polymyositis, dermatomyositis and inclusion body myositis examine the major differential diagnostic possibilities in possible myositis cases interpret the findings in the muscle biopsy pathology report 154 *Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212) Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold assess limitations of the Fracture Risk Assessment Algorithm in clinical practice Moderator: Betsy Barnes, PhD describe mechanisms and molecules involved in activation of the innate immune system identify new potential therapeutic targets to maintain immune tolerance recognize the multifunctional role of high mobility group box 1 (HMBG1) in inflammation 4:30 pm High Mobility Group Box 1 as Chemokine and Cytokine Helena E. Harris 5:00 pm Dendric Cells in Tolerance and Immune Activation Michel C. Nussenzweig, MD, PhD 5:30 pm Activation of the Immune System by Intracellular Nucleic Acids Tracy McGaha, PhD Ballroom East Thieves Market: Show Me Your Best Cases Moderators: Rula Hajj-Ali, MD; N. Lawrence Edwards, MD and Rebecca L. Manno, MD, MHS compare their diagnostic and management approaches of selected clinical problems with those of other rheumatologists and the presenters recognize unusual presentations of common diseases identify and recognize essential mimics of the rheumatic diseases 4:30 pm Image Competition Presentation Erika H. Noss, MD SUNDAY november 16, Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213) Speaker: Edward C. Keystone, MD describe the concept of referred pain and its presentation with neck and lumbar disorders 4:50 pm Case Presentation 1: A Rapid Decline Kevin Wei, MD PhD 5:00 pm Case Presentation 2: An Uncommon Cause of a Common Presentation David McCormick, MB, BaO, BCh, MRCP 2014 Program Book 55

58 scientific sessions SUNDAY november 16, :10 pm Case Presentation 3: Groundhog Day P. W. James Russell, MB, BChir 5:20 pm Case Presentation 4: It is Not a Simple Headache Catherine E. Najem, MD 5:30 pm Case Presentation 5: Lesions in the Spine A Diagnostic Dilemma Mehwish Khan, MBBS, MD 5:40 pm Case Presentation 6: The Nose Knows Sarah Goglin, MD ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm 104 B Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Moderators: Laurence A. Bradley, PhD and Leslie J. Crofford, MD 4:30 pm 892. Symptom Increase in Fibromyalgia Is Not Consistent with the Central Sensitization or Central Hyperresponsiveness Hypothesis Frederick Wolfe 1, Brian T. Walitt 2, Johannes Rasker 3, Robert S. Katz 4 and Winfried Häuser 5, 1 National Data Bank for Rheumatic Diseases, Wichita, KS, 2 Washington Hospital Center, Washington, DC, 3 University Twente, Enschede, Netherlands, 4 Rush Medical College, Chicago, IL, 5 Klinikum Saarbrücken, Saarbrücken, Germany 4:45 pm 893. Polysymptomatic Distress Categories for Clinical and Research Use Frederick Wolfe 1, Brian T. Walitt 2, Johannes Rasker 3, Robert S. Katz 4 and Winfried Häuser 5, 1 National Data Bank for Rheumatic Diseases, Wichita, KS, 2 Washington Hospital Center, Washington, DC, 3 University Twente, Enschede, Netherlands, 4 Rush Medical College, Chicago, IL, 5 Klinikum Saarbrücken, Saarbrücken, Germany 5:00 pm 894. Small Fiber Neuropathy in Women with Fibromyalgia. a Clinical-Pathological Correlation Using Confocal Corneal Biomicroscopy Manuel Ramírez-Fernández 1, Laura-Aline Martinez-Martinez 2, Angelica Vargas-Guerrero 2, Manuel Martínez-Lavín 2, Everardo Hernandez Quintela 1 and Jorge Velazco-Caspia 1, 1 Asociación para Evitar la Ceguera en México, Mexico City, Mexico, 2 Instituto Nacional de Cardiologia, Mexico City, Mexico 5:15 pm 895. The Fibromyalgia Syndrome and Widespread Pain Frequency in Active Duty U.S. Service Members with Posttraumatic Stress Disorder Bernard Hildebrand Jr. 1, Jay B. Higgs 1, Douglas Williamson 2, Edna Foa 3, Patricia Resick 4, Jim Mintz 2, Antoinette Brundige 2, Kevin Kelly 5, Adam Borah 5, Stacey Young-McCaughan 2, Brett Litz 6, Elizabeth Hembree 3 and Alan Peterson 2, 1 San Antonio Military Medical Center, JBSA Fort Sam Houston, TX, 2 The University of Texas Health Science Center at San Antonio, San Antonio, TX, 3 University of Pennsylvania, Philadelphia, PA, 4 Duke University, Durham, NC, 5 Carl R. Darnall Army Medical Center, Fort Hood, TX, 6 VA Boston Healthcare System, Boston, MA 5:30 pm 896. Development of Fibromyalgia and Polysymptomatic Distress Definitions in the National Health Interview Survey Brian Walitt 1, Richard Nahin 2, Robert S. Katz 3, Martin J. Bergman 4 and Frederick Wolfe 5, 1 MedStar Health, Washington, DC, 2 National Institutes of Health, Bethesda, MD, 3 Rush Medical College, Chicago, IL, 4 Taylor Hospital, Ridley Park, PA, 5 National Data Bank for Rheumatic Diseases, Wichita, KS 5:45 pm 897. Resting State Functional Connectivity Differs Between Chronic Fatigue Syndrome Patients and Healthy Controls Jason Craggs 1, Charles Gay 1, Andrew O Shea 1, Ricky Madhavan 1, Donald Price 1, Michael Robinson 1 and Roland Staud 2, 1 University of Florida, Gainesville, FL, 2 Univ of Florida Med Ctr/JHMHC, Gainesville, FL 151 A Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease Moderators: Edward H. Yelin, PhD and Katherine Liao, MD, MPH 4:30 pm 898. Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting J An 1, K Reynolds 2, E Alemao 3, H Kawabata 3, D H Solomon 4, K P Liao 4 and T C Cheetham 2, 1 Western University of Health Sciences, Pomona, CA, 2 Kaiser Permanente Southern California, Pasadena, CA, 3 Bristol-Myers Squibb, Princeton, NJ, 4 Brigham and Women s Hospital, Boston, MA 4:45 pm 899. Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis Laura Plantinga 1, Cristina M. Drenkard 1, Rachel Patzer 1, William McClellan 1, Stephen Pastan 1 and S. Sam Lim 2, 1 Emory University, Atlanta, GA, 2 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA Program Book

59 scientific sessions 5:00 pm 900. Race and Sex Specific Incidence Rates and Predictors of Total Knee Arthroplasty: Data from the Osteoarthritis Initiative, 7 Years Follow up Jamie E. Collins, Bhushan Deshpande, Jeffrey N. Katz and Elena Losina, Brigham and Women s Hospital, Boston, MA 5:15 pm 901. Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target? Robert Morlock 1, David M. Kern 2, Ozgur Tunceli 2, Siting Zhou 2, Laura Horne 3, Sulabha Ramachandran 3 and Hyon Choi 4, 1 Ardea Biosciences, San Diego, CA, 2 HealthCore, Inc., Wilmington, DE, 3 AstraZeneca, Wilmington, DE, 4 Harvard Medical School, Boston, MA 5:30 pm 902. Co-Management for Children with JIA: A Survey of Primary Care Providers Regarding Current Practices and Willingness to Provide Services Amanda Mroczek, Gary Freed and Meredith Riebschleger, University of Michigan, Ann Arbor, MI 5:45 pm 903. Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries Jinoos Yazdany 1, Candace H. Feldman 2, Hongshu Guan 3 and Karen H. Costenbader 3, 1 University of California, San Francisco, San Francisco, CA, 2 Brigham and Women s Hospital, Boston, MA, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 210 B Imaging of Rheumatic Diseases: Ultrasound Moderators: Jay B. Higgs, MD and Wolfgang A. Schmidt, MD 904. Ultrasound Synovitis Reflects Synovial Inflammation at a Histopathological Level Nora Ng, Stephen Kelly, Frances Humby, Maria DiCicco, Vidalba Rocher, Rebecca Hands, Michele Bombardieri and Costantino Pitzalis, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom 4:45 pm 905. First Step in the Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis: A Data Driven Approach Anna-Birgitte Aga 1, Hilde Berner Hammer 1, Inge C. Olsen 1, Till Uhlig 1, Tore K. Kvien 1, Désirée van der Heijde 2, Elisabeth Lie 1, Espen A. Haavardsholm 1 and the Arctic study Group 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Leiden University Medical Center, Leiden, Netherlands 5:00 pm 906. How Long Does Sonographic Joint Activity Continue in Clinically Remittive Joints of Patients with Rheumatoid Arthritis? Miriam Gärtner, Farideh Alasthi, Gabriela Supp, Peter Mandl, Josef Smolen and Daniel Aletaha, Medical University of Vienna, Vienna, Austria 5:15 pm 907. Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis Hilde B. Hammer and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway 5:30 pm 908. Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission Emanuela Bellis 1, Greta Carrara 2, Carlo Alberto Scirè 2, Alessandra Bortoluzzi 3, Alberto Batticciotto 4, Antonella Adinolfi 5, Giovanni Cagnotto 6, Marta Caprioli 7, Marco Canzoni 8, Francesco Cavatorta 9, Fulvia Ceccarelli 10, Orazio De Lucia 11, Valentina Di Sabatino 12, Antonella Draghessi 13, Georgios Filippou 12, Ilaria Farina 3, Maria Cristina Focherini 14, Paola Frallonardo 15, Alessandra Gabba 16, Angelica Gattamelata 10, Marwin Gutierrez 13, Luca Idolazzi 17, Filippo Luccioli 18, Pierluigi Macchioni 19, Marco Massarotti 20, Claudio Mastaglio 21, Luana Menza 21, Giulia Mirabelli 18, Maurizio Muratore 22, Simone Parisi 23, Valentina Picerno 12, Matteo Piga 24, Roberta Ramonda 25, Bernd Raffeiner 15, Daniela Rossi 26, Paola Rossini 27, Garifallia Sakellariou 28, Crescenzio Scioscia 29, Carlo Venditti 30, Annamaria Iagnocco 10 and Marco Matucci-Cerinic 31, 1 Ospedale Mauriziano, Turin, Italy, 2 Italian Society for Rheumatology, Milan, Italy, 3 A.O.U. S.Anna di Cona, Ferrara, Italy, 4 L.Sacco University Hospital, Milan, Italy, 5 Policlinico le Scotte, Siena, Italy, 6 IRCCS Policlinico San Matteo, Pavia, Italy, 7 Istituto di Cura Città di Pavia, Pavia, Italy, 8 A.O. Sant Andrea, Rome, Italy, 9 A.O.U.P. Santa Chiara, Trento, Italy, 10 Sapienza University of Rome, Rome, Italy, 11 Orthopedic Institute Gaetano Pini, Milano, Italy, 12 University of Siena, Siena, Italy, 13 Università Politecnica delle Marche, Jesi, Italy, 14 Ospedale Infermi, Rimini, Italy, 15 University of Padova, Padova, Italy, 16 A.O.U. di Cagliari, Cagliari, Italy, 17 Ospedale Civile Maggiore, Verona, Italy, 18 University of Perugia, Perugia, Italy, 19 Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 20 Istituto Clinico Humanitas, Rozzano, Italy, 21 Moriggia-Pelascini, Gravedona, Italy, 22 Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, 23 A.O. Città della Salute e della Scienza di Torino, Turin, Italy, 24 Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 25 University of Padua, Padova, Italy, 26 University of Turin, Turin, Italy, 27 P.O. Destra Secchia, Pieve di Coriano, Italy, 28 Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation/University of Pavia, Pavia, Italy, 29 University of Bari, Bari, Italy, 30 A.O. Rummo, Benevento, Italy, 31 University of Florence, Florence, Italy SUNDAY november 16, Program Book 57

60 scientific sessions SUNDAY november 16, :45 pm 909. A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using Ultrasound Assessment Jennifer Piper 1, Ana Sofia Serafim 1, Cristina Ponte 1, Surjeet Singh 2, Bhaskar Dasgupta 3, Wolfgang A. Schmidt 4, Eugene McNally 5, Andreas P. Diamantopoulos 6, Andrew Hutchings 7 and Raashid Luqmani 8, 1 University of Oxford, Oxford, United Kingdom, 2 Sciences, Oxford, England, 3 Southend University Hospital, Essex, United Kingdom, 4 Immanuel Krankenhaus, Berlin, Germany, 5 Oxford University, Oxford, United Kingdom, 6 Hospital of Southern Norway Trust, Kristiansand, Norway, 7 London School of Hygiene and Tropical Medicine, London, United Kingdom, 8 Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom 160 B Muscle Biology, Myositis and Myopathies Moderator: Megan Curran, MD 4:30 pm 910. The Selective Sphingosine-1-Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial Katalin Danko 1, Jiri Vencovsky 2, Ingrid E. Lundberg 3, Anthony A Amato 4, Chester V. Oddis 5, Maria Molnar 6, Antonette Mallari Moher 7, Laurence Colin 8, Florian Muellershausen 9, David Lee 9 and Peter Gergely 9, 1 University of Debrecen, Hungary, Debrecen, Hungary, 2 Charles University, Prague, Czech Republic, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4 Brigham and Women s Hospital and Harvard Medical School, Boston, MA, 5 University of Pittsburgh, Pittsburgh, PA, 6 Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, 7 Novartis Institutes for Biomedical Research (former employee), Basel, Switzerland, 8 Novartis Pharma, Basel, Switzerland, 9 Novartis Institutes for Biomedical Research, Basel, Switzerland 4:45 pm 911. Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-Kb-Mediated Inflammation Nicholas A. Young 1, Lai-Chu Wu 1, Michael Bruss 1, Wael N. Jarjour 1 and Dana P. Ascherman 2, 1 The Ohio State University Wexner Medical Center, Columbus, OH, 2 Miami VAMC, Miami, FL 5:00 pm 912. A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clinical Trials Rohit Aggarwal 1, Lisa G. Rider 2, Nicolino Ruperto 3, Nastaran Bayat 2, Brian Erman 4, Brian M. Feldman 5, Adam M. Huber 6, Chester V. Oddis 1, Ingrid E. Lundberg 7, Anthony A. Amato, MD 8, Robert G. Cooper, MD, FRCP 9, Hector Chinoy 10, Maryam Dastmalchi 11, David Fiorentino 12, David Isenberg 13, James D. Katz 14, Andrew L. Mammen 15, Marianne de Visser 16, Steven R. Ytterberg 17, Katalin Danko 18, Luca Villa 19, Mariangela Rinaldi 19, Howard Rockette 1, Peter A. Lachenbruch 20, Frederick W. Miller 2 and Jiri Vencovsky, MD, DSc 21, 1 University of Pittsburgh, Pittsburgh, PA, 2 Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3 Istituto Giannina Gaslini, Genoa, Italy, 4 Social and Scientific Systems, Inc., Durham, NC, 5 The Hospital for Sick Children, Toronto, ON, 6 IWK Health Centre, Halifax, NS, 7 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 8 Brigham and Women s Hospital and Harvard Medical School, Boston, MA, 9 University of Liverpool, Liverpool, United Kingdom, 10 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 11 Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 12 Stanford University, Redwood City, CA, 13 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 14 NIH, Bethesda, MD, 15 Johns Hopkins University, Baltimore, MD, 16 Academic Medical Centre, Amsterdam, Netherlands, 17 Mayo Clinic, Rochester, MN, 18 University of Debrecen, Hungary, Debrecen, Hungary, 19 IRCCS Istituto G. Gaslini, Genova, Italy, 20 NIEHS, NIH, Bethesda, MD, 21 Charles University, Prague, Czech Republic 5:15 pm 913. Long Term Outcomes of Patients with Moderate Creatine Kinase (CK) Elevation Seen in a Rheumatology Clinic Lyudmila Kirillova 1, Abraham Tacang 1, Andrea Berger 2, Thomas M. Harrington 1 and Androniki Bili 1, 1 Geisinger Health System, Danville, PA, 2 Center for Health Research, Geisinger Health System, Danville, PA 5:30 pm 914. A Predictive Model of Disease Outcome in Rituximab- Treated Myositis Patients Using Clinical Features, Autoantibodies and Serum Biomarkers Jeannette Olazagasti 1, Cynthia S. Crowson 1, Molly S. Hein 1, Consuelo Lopez de Padilla 1, Rohit Aggarwal 2, Chester V. Oddis 2 and Ann M. Reed 1, 1 Mayo Clinic, Rochester, MN, 2 University of Pittsburgh, Pittsburgh, PA 5:45 pm 915. Increased Risk of Myocardial Infarction in Dermatomyositis and Polymyositis: A General Population- Based Cohort Study Kateryna Vostretsova 1, Erin Carruthers 2, Eric C. Sayre 2, John Esdaile 2 and J Antonio Avina-Zubieta 3, 1 University of British Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada, Richmond, BC, 3 University of British Columbia, Department of Experimental Medicine, Vancouver, BC 153 B Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Moderators: Simpson Bobo Tanner, MD and Chad Deal, MD Program Book

61 scientific sessions 4:30 pm 916. Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density MR McClung 1, A Chines 2, JP Brown 3, A Diez-Perez 4, H Resch 5, J Caminis 6, MA Bolognese 7, S Goemaere 8, HG Bone 9, JR Zanchetta 10, J Maddox 2, O Rosen 2, S Bray 11 and A Grauer 2, 1 Oregon Osteoporosis Center, Portland, OR, 2 Amgen Inc., Thousand Oaks, CA, 3 Laval University and CHU de Québec Research Centre, Quebec City, QC, 4 Autonomous University of Spain, Barcelona, Spain, 5 St. Vincent Hospital, Vienna, Austria, 6 UCB, Raleigh, NC, 7 Bethesda Health Research Center, Bethesda, MD, 8 Ghent University Hospital, Ghent, Belgium, 9 Michigan Bone and Mineral Clinic, Detroit, MI, 10 Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 11 Amgen Ltd., Cambridge, United Kingdom 4:45 pm 917. Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab: Results from the Pivotal Phase 3 Fracture Study Extension Nelson B. Watts 1, John T. Grbic 2, Michael McClung 3, Socrates Papapoulos 4, David Kendler 5, Christence S. Teglbjaerg 6, Lawrence O Connor 7, Rachel B. Wagman 7, Eric Ng 7, Nadia S. Daizadeh 7 and Pei-Ran Ho 7, 1 Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, 2 Columbia University, New York, NY, 3 Oregon Osteoporosis Center, Portland, OR, 4 Leiden University Medical Center, Leiden, Netherlands, 5 University of British Columbia, Vancouver, BC, 6 Center for Clinical and Basic Research, Ballerup, Denmark, 7 Amgen Inc., Thousand Oaks, CA 5:00 pm 918. Findings from Denosumab (Prolia ) Postmarketing Safety Surveillance for Serious Infections W Golden 1, DB Crittenden 1, M Uhart 1, RB Wagman 1, C Stehman-Breen 1, S Papapoulos 2 and NB Watts 3, 1 Amgen Inc., Thousand Oaks, CA, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH 5:15 pm 919. Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65 Akhila Balasubramanian 1, Sally Wade 2, Robert A Adler 3, Celia Fang (Lin) 4, Michael Maricic 5, Cynthia O Malley 1, Kenneth G. Saag 6 and Jeffrey R. Curtis 6, 1 Amgen, Inc., Thousand Oaks, CA, 2 Wade Outcomes Research and Consulting, Salt Lake City, UT, 3 Hunter Holmes McGuire VA Medical Center, Richmond, VA, 4 Amgen, Thousand Oaks, CA, 5 Catalina Pointe Rheumatology, Tucson, AZ, 6 The University of Alabama at Birmingham, Birmingham, AL 5:30 pm 920. Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis Eric Orwoll 1, Silvano Adami 2, Neil Binkley 3, Roland Chapurlat 4, Bente Langdahl 5, Steven Doleckyj 6, Hilde Giezek 7, Boyd Scott 8 and Arthur Santora 8, 1 Oregon Health and Science University, Portland, OR, 2 Rheumatology Department, University of Verona, Verona, Italy, 3 University of Wisconsin, Madison, WI, 4 Hopital Edouard Herriot, Lyon, France, 5 Aarhus University Hospital, Aarhus, Denmark, 6 Merck & Co., Inc., Whitehouse Station, NJ, 7 MSD Belgium, Brussels, Belgium, 8 Merck Sharp & Dohme Corp., Whitehouse Station, NJ 5:45 pm 921. Comparison of Infection Rates in Patients Receiving Denosumab, Denosumab and Biologics and Biologics Alone in a Suburban Rheumatology Clinic Sajina Prabhakaran 1 and Charles Pritchard 2, 1 Drexel University College of Medicine, Philadelphia, PA, 2 Drexel University College of Medicine, Willow Grove, PA 156 B Pain: Basic and Clinical Aspects I Moderators: Yvonne C. Lee, MD and Martin K. Lotz, MD and Camilla Svensson, PhD 4:30 pm 922. A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain Rachel E. Miller 1, Shingo Ishihara 1, Phuong Tran 1, Richard J. Miller 2 and Anne-Marie Malfait 1, 1 Rush University Medical Center, Chicago, IL, 2 Northwestern University, Chicago, IL 4:45 pm 923. Phenotypes of Osteoarthritis-Related Knee Pain and Their Transitions over Time: The Osteoarthritis Initiative Na Lu 1, Tuhina Neogi 1, K. Douglas Gross 1, Jingbo Niu 1, Hyon Choi 2 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA 5:00 pm 924. Characteristics of Pain Flares in Knee Osteoarthritis Susan L. Murphy 1, Angela K. Lyden 1, Arnold Gammaitoni 2, David A. Williams 3, Daniel J. Clauw 1, J. Ryan Scott 1 and Kristine Phillips 1, 1 University of Michigan, Ann Arbor, MI, 2 Zogenix, Inc, San Diego, CA, 3 Univ of MI Hlth System-Lobby M, Ann Arbor, MI 5:15 pm 925. Cortical Reorganization after Duloxetine Treatment- Related Pain Decrease in Knee Osteoarthritis Pascal Tetreault, Marwan Baliki, Etienne Vachon-Presseau, Renita Evonne Yeasted, Thomas J. Schnitzer and A. Vania Apkarian, Northwestern University, Chicago, IL SUNDAY november 16, Program Book 59

62 scientific sessions SUNDAY november 16, :30 pm 926. Does a Family History of Total Knee Replacement for Knee Osteoarthritis Influence Knee Pain and Structural Progression? a Prospective Longitudinal Cohort Study Feng Pan 1, Hussain Khan 1, Changhai Ding 1, Tania Winzenberg 1, Johanne Martel-Pelletier 2, Jean-Pierre Pelletier 2, Flavia Cicuttini 3 and Graeme Jones 1, 1 Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, 2 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 3 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 5:45 pm 927. Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice a New Potential Role for TRPA1 in Gout Lauri J Moilanen, Mari Hämäläinen, Lauri Lehtimäki, Riina Nieminen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland 253 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Moderators: Murray H. Passo, MD and Andrew S. Zeft, MD, MSCE Ed Pd PrM FIT 4:30 pm 928. A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthriti: Preliminary Data from 6,940 Patients Alessandro Consolaro 1, Amita Aggarwal 2, Troels Herlin 3, Olga Vougiouka 4, Rubén Burgos-Vargas 5, Ilonka Orban 6, Nahid Shafaie 7, Maria Trachana 8, Lidia Rutkowska-Sak 9, Ingrida Rumba-Rozenfelde 10, Dimitrina Mihaylova 11, Alberto Martini 1 and Angelo Ravelli 12, 1 Istituto Giannina Gaslini, Genova, Italy, 2 Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3 Aarhus University Hospital, Aarhus, Denmark, 4 P. A. Kyriakou Children s Hospital of Athens University, Athens, Greece, 5 Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 6 National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 7 Tehran University of Medical Sciences, Tehran, Iran, 8 Aristotle University, Thessaloniki, Greece, 9 Institute of Rheumatology, Warsaw, Poland, 10 University of Latvia, Riga, Latvia, 11 University Children Hospital, Sofia, Bulgaria, 12 Istituto Giannina Gaslini and University of Genova, Genova, Italy dupont Hospital for Children, Thomas Jefferson University, Wilmington, DE, 4 Rutgers Biomedical and Health Sciences, Newark, NJ 5:00 pm 930. An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis Hermine I. Brunner 1, Nicola Ruperto 2, Isabelle Koné-Paut 2, Bo Magnusson 2, Seza Ozen 2, Flavio Sztajnbok 2, Jordi Anton 2, Judith Barash 2, Reinhard Berner 2, Fabrizia Corona 2, Karine Lheritier 3, Corine Gaillez 3, Alberto Martini 2 and Daniel Lovell 1, 1 PRCSG, Cincinnati, OH, 2 PRINTO-Istituto Gaslini, Genova, Italy, 3 Novartis Pharma AG, Basel, Switzerland 5:15 pm 931. Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients N.M. Wulffraat 1, N. Ruperto 2, H.I. Brunner 3, S. Oliveira 2, Y. Uziel 2, K. Nistala 2, R. Cimaz 2, M. Ferrandiz 2, B. Flato 2, M.L. Gamir 2, I. Koné-Paut 2, C. Gaillez 4, K. Lheritier 4, K. Abrams 5, A. Martini 2 and D.J. Lovell 3, 1 UMC Utrecht, Utrecht, Netherlands, 2 PRINTO- Istituto Gaslini, Genova, Italy, 3 PRCSG, Cincinnati, OH, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ 5:30 pm 932. MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis Janneke Anink 1, Marieke H. Otten 1, Lisette W.A. van Suijlekom- Smit 1, Marion A.J. Van Rossum 2, Koert M. Dolman 3, Esther P.A. Hoppenreijs 4, Rebecca ten Cate 5, Simona Ursu 6, Lucy R Wedderburn 7, Gerd Horneff 8, Thomas Vogl 9, Dirk Föll 10, Johannes Roth 9 and Dirk Holzinger 11, 1 Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands, 2 Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, 3 St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4 Radboud University Medical Center, Nijmegen, Netherlands, 5 Leiden University Medical Center, Leiden, Netherlands, 6 Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 7 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 8 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 9 Institute of Immunology University of Muenster, Muenster, Germany, 10 University Children s Hospital Muenster, Muenster, Germany, 11 University Hospital Muenster, Muenster, Germany 4:45 pm 929. Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study Daniel B. Horton 1, Frank I. Scott IV 2, Kevin Haynes 1, Mary E. Putt 1, Carlos D. Rose 3, James D. Lewis 1 and Brian L. Strom 4, 1 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2 Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, 3 Division of Rheumatology, Nemours A.I. 5:45 pm 933. A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results Hermine I. Brunner 1, Nicolino Ruperto 2, N Tzaribachev 3, Gerd Horneff 4, Carine Wouters 5, Violeta Vladislava Panaviene 2, Vyacheslav Chasnyk 6, Carlos Abud-Mendoza 7, Ruben Cuttica 8, Andreas Reiff 9, M Maldonado-Velázquez 1, Nadina Rubio-Pérez 10, Program Book

63 scientific sessions Rik Joos 11, V Keltsev 12, Evgeny Nasonov 13, Daniel Kingsbury 14, M Bandeira 15, Earl Silverman 16, F Weller-Heinemann 10, A van Royen-Kerkhof 17, Alan M. Mendelsohn 18, Lilianne Kim 18, Daniel Lovell 19 and A Martini 20, 1 PRCSG, Cincinnati, OH, 2 Istituto Giannina Gaslini, Genoa, Italy, 3 PRINTO & PRCSG, Bramstedt, Germany, 4 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 5 University Hosp Gasthuisberg, Leuven, Belgium, 6 Novartis Pharma, Saint-Petersburg, Russia, 7 Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 8 Hospital de Ninos Pedro de Elizalde, Capital Federal, Argentina, 9 Children s Hospital of Los Angeles, Los Angeles, CA, 10 PRINTO, Genoa, Italy, 11 UZ Gent, Gent, Belgium, 12 Paediatric Rheumatology International Trials Organisation IRCCS [PRINTO], Genoa, Italy, 13 State Institute of Rheumatology of RAMS, Moscow, Russia, 14 Randall Children s Hospital at Legacy Emanuel, Portland, OR, 15 Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, 16 Hosp for Sick Children, Toronto, ON, 17 Department of Pediatric Immunology & Rheumatology, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 18 Janssen Research & Development, LLC., Spring House, PA, 19 Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 20 Istituto Gaslini-PRINTO, Genova, Italy 107 B Rheumatoid Arthritis Animal Models I Moderators: Peter A. Nigrovic, MD and Ewa Cairns, PhD 4:30 pm 934. Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction Echoe M. Bouta 1, Igor Kuzin 2, Karen de Mesy-Bentley 1, Ronald Wood 3, Homaira Rahimi 4, Rui-Cheng Ji 5, Christopher T. Ritchlin 3, Andrea Bottaro 2, Lianping Xing 1 and Edward M. Schwarz 1, 1 University of Rochester, Rochester, NY, 2 Cooper Medical School, Camden, NJ, 3 University of Rochester Medical Center, Rochester, NY, 4 University of Rochester/Golisano Children s Hospital, Rochester, NY, 5 Oita University, Oita, Japan 4:45 pm 935. Targeting Glycolysis in Rheumatoid Arthritis Monica Guma 1, Alessia Lodi 2, Ajit Divakaruni 1, Anne Murphy 1, Stefano Tiziani 2 and Gary S. Firestein 3, 1 University of California, San Diego, La Jolla, CA, 2 University of Texas at Austin, Austin, TX, 3 University of California at San Diego School of Medicine, La Jolla, CA 5:00 pm 936. Active Invasion of Periodontal Bacteria into Synovial Joint Exacerbates Collagen-Induced Arthritis in Disease-Prone B10 Riii Mice Sasanka Chukkapalli 1, Mercedes Rivera-Kweh 1, Irina Velsko 1, Indraneel Bhattacharyya 1, S. John Calise 2, Edward Chan 1, Minoru Satoh 3 and Lakshmyya Kesavalu 1, 1 College of Dentistry, University of Florida, Gainesville, FL, 2 University of Florida, Gainesville, FL, 3 Univ. Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan 5:15 pm 937. A Unique Role for IL-18 Receptor-α in Monocyte Migration in RA and K/BxN Serum Transfer Arthritis W. Alexander Stinson 1, Phillip L. Campbell 1, Jeffrey Ruth 1, Gautam Edhayan 1, Ray A. Ohara 1, Nicholas Lepore 1, Alisa E. Koch 2, David A. Fox 1 and M. Asif Amin 1, 1 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2 Department of Veteran s Affairs and University of Michigan, Ann Arbor, MI 5:30 pm 938. C1q Is Mandatory for Disease Development in Experimental Arthritis and Expression of Its Receptors Correlates with Disease Activity in Patients Matthieu Ribon 1, Julie Mussard 1, Roxane Herve 1, Marina Botto 2, Marie-Christophe Boissier 3 and Patrice Decker 1, 1 INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 2 Imperial College, London, United Kingdom, 3 INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France 5:45 pm 939. Prenatal Methyl-Rich Diet Decreases Inflammation in Collagen Induced Arthritis Sanjay Garg 1, Dipak R. Patel 2 and Raymond Yung 2, 1 University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 2 University of Michigan, Ann Arbor, MI Exhibit Hall C Rheumatoid Arthritis Clinical Aspects II: Remission and De-Escalation of Therapy Moderators: Clifton O. Bingham III, MD and Kimme Hyrich, MD, PhD 4:30 pm 940. Study of Reduction of Therapy in Patients with Rheumatoid Arthritis in Ongoing Remission Judith Haschka 1, Jürgen Rech 1, Matthias Englbrecht 1, Stephanie Finzel 1, Michaela Reiser 1, Axel J. Hueber 1, Arnd Kleyer 1, Hans- Peter Tony 2, Martin Fleck 3, Karin Manger 4, Wolfgang Ochs 5, Jörg Wendler 6, Hanns-Martin Lorenz 7, Hubert Nüßlein 8, Rieke Alten 9, Winfried Demary 10 and Georg Schett 1, 1 University of Erlangen- Nuremberg, Erlangen, Germany, 2 University Hospital Würzburg, Würzburg, Germany, 3 Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, 4 Rheumatology Practice Bamberg, Bamberg, Germany, 5 Rheumatology Practice Bayreuth, Bayreuth, Germany, 6 Rheumatology Practice Erlangen, Erlangen, Germany, 7 University of Heidelberg, Heidelberg, Germany, 8 Rheumatology Practice Nuremberg, Nuremberg, Germany, 9 Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 10 Rheumatolgy Practice Hildesheim, Hildesheim, Germany 4:45 pm 941. Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success Tarun S. Sharma 1, Lyudmila Kirillova 2, Andrea Berger 3 and Eric D. Newman 2, 1 Geisinger Medical Center, Danville, PA, 2 Geisinger Health System, Danville, PA, 3 Center for Health Research, Geisinger Health System, Danville, PA 2014 Program Book 61 SUNDAY november 16, 2014

64 scientific sessions SUNDAY november 16, :00 pm 942. ACR/EULAR Remission in RA patients in Clinical Practice Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry Merete Lund Hetland, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark 5:15 pm 943. Improvements in the Proportion of Patients Achieving DAS, CDAI and SDAI Remission By Omitting the Patient Global Assessment (PtGA): an Analysis from a Prospective, Observational Registry Philip Baer 1, WG Bensen 2, Carter Thorne 3, Boulos Haraoui 4, Denis Choquette 5, Regan Arendse 6, John Kelsall 7, Maqbool Sheriff 8, John S. Sampalis 9, Emmanouil Rampakakis 9, Francois Nantel 10, May Shawi 10, Allen J Lehman 10, Susan Otawa 10 and Edward Keystone 11, 1 Private Practice, Scarborough, ON, 2 St Joseph s Hospital and McMaster University, Hamilton, ON, 3 Southlake Regional Health Centre, Newmarket, ON, 4 University of Montreal Hospital Centre, Montreal, QC, 5 Institut de rhumatologie de Montréal (IRM), Montréal, QC, 6 University of Saskatchewan, Saskatoon, SK, 7 The Mary Pack Arthritis Centre, Vancouver, BC, 8 Nanaimo Regional General Hospital, Nanaimo, BC, 9 JSS Medical Research, Montreal, QC, 10 Janssen Inc., Toronto, ON, 11 Mount Sinai Hospital, University of Toronto, Toronto, ON 5:30 pm 944. Predict the Chance of Remission for Your RA Patient in Real Life Till Uhlig 1, Vibeke Norvang 1, Elisabeth Lie 1, Erik Rødevand 2, Knut Mikkelsen 3, Åse S. Lexberg 4, Synøve Kalstad 5 and Tore K. Kvien 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 St. Olavs Hospital, Trondheim, Norway, 3 Revmatismesykehuset, Lillehammer, Norway, 4 Vestre Viken Hospital, Drammen, Norway, 5 University Hospital of Northern Norway, Tromsø, Norway 5:45 pm 945. Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy Thomas Schau 1, Michael Gottwald 2, Christian Butter 1 and Michael Zaenker 2, 1 Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, 2 Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany Ballroom West Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis Early in Development Moderators: Vivian P. Bykerk, MD and Iain B. McInnes, PhD 4:30 pm 946. Phase 1 Study of Immunotherapy Using Autoantigen- Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis Young Bin Joo 1, Jun-Eui Park 2, Chan-Bum Choi 3, Jeongim Choi 1, Jin-ah Jang 2, Minkyu Heo 2, Hak-yeop Kim 2, Hye-Soon Lee 1, Yong- Soo Bae 4 and Sang-Cheol Bae 5, 1 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2 JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, 3 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4 Sungkyunkwan University, Suwon, South Korea, 5 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 4:45 pm 947. Efficacy and Safety of NNC , an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Juan D. Cañete 1, Piotr Leszczynski 2, Rikke Riisbro 3 and Klaus S. Frederiksen 3, 1 Hospital Clínic of Barcelona, Barcelona, Spain, 2 Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, 3 Novo Nordisk A/S, Søborg, Denmark 5:00 pm 948. A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate Alan J. Kivitz 1, Anna Zubrzycka-Sienkiewicz 2, Sergio R. Gutierrez- Ureña 3, Jeffrey Poiley 4, Rita Kristy 5, Kathyjo Shay 5 and Jay P. Garg 5, 1 Altoona Center for Clinical Research, Duncansville, PA, 2 ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, 3 Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, 4 Arthritis Associates, Orlando, FL, 5 Astellas Pharma Global Development, Northbrook, IL 5:15 pm 949. Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study Rumen M. Stoilov 1, Rodina N. Licheva 2, Mariyana K. Mihaylova 3, Tatiana Reitblat 4, Emil A. Dimitrov 1, Krasimira M. Shimbova 1, Girish Bhatia 5, Amit Pispati 6, Alexandra Gurman- Balbir 7, B R Bagaria 5, Boytcho A. Oparanov 2, Sari Fishman 8, Zivit Harpaz 8, Motti Farbstein 8, Shira Cohen 8, Michael H. Silverman 8 and Pnina Fishman 8, 1 Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Clinic of Rheumatology, Sofia, Bulgaria, 2 Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, 3 3Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, 4 Barzilai Medical Center,, Ashkelon, Israel, 5 Malpani Multispeciality Hospital, Mumbai, India, 6 Bhatia Hospital Medical Research Society, Mumbai, India, 7 Rambam Medical Center, Haifa, Israel, 8 CanFite Biopharma Ltd, Petah Tikva, Israel 5:30 pm 950. Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis Soi-Cheng Law 1, Hendrik Nel 2, Ahmed Mehdi 2, Kim-Anh Le Cao 2 and Ranjeny Thomas 1, 1 Univ of Queensland, Brisbane, Australia, 2 University of Queensland, Brisbane, Australia Program Book

65 scientific sessions 5:45 pm 951. Safety, Tolerability and Functional Activity of ABT-122, a Dual TNF- and IL-17A Targeted DVD-Ig, Following Single-Dose Administration in Healthy Subjects Heikki Mansikka 1, Melanie Ruzek 2, Margaret Hugunin 2, Alexander Ivanov 2, Alyssa Brito 2, Anca Clabbers 2, Carolyn Cuff 2, Chung-Ming Hsieh 2, Martin Okun 1, Renee Heuser 1, David Carter 1, Barbara Hendrickson 1, Dipak Pisal 1, Sandra Goss 1, Jia Liu 1, Charles Locke 1, Nasser Khan 1 and Robert Padley 1, 1 AbbVie, Inc, North Chicago, IL, 2 AbbVie, Inc, Worcester, MA 258 B Spondyloarthropathies and Psoriatic Arthritis II Novel Treatments for Psoriatic Arthritis Moderators: Philip Mease, MD and Eric Ruderman, MD 4:30 pm 952. A Phase IIb, Randomized, Double-Blind, Placebo- Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis Philip Mease 1, A B Gottlieb 2, A Berman 3, E Drescher 4, J Xing 5, S Banerjee 5 and R Wong 5, 1 Swedish Medical Center and University of Washington, Seattle, WA, 2 Tufts Medical Center and Tufts University School of Medicine, Boston, MA, 3 Centro Médico Privado de Reumatología, Tucuman, Argentina, 4 Csolnoky Ferenc Hospital, Veszprém, Hungary, 5 Bristol-Myers Squibb, Princeton, NJ 4:45 pm 953. Secukinumab, a Human Anti Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo- Controlled Study Philip Mease 1, Iain B. McInnes 2, Bruce Kirkham 3, Arthur Kavanaugh 4, Proton Rahman 5, Désirée van der Heijde 6, Robert Landewé 7, Peter Nash 8, Luminita Pricop 9, Jiacheng Yuan 9, Hanno Richards 10 and Shephard Mpofu 10, 1 Swedish Medical Center and University of Washington, Seattle, WA, 2 University of Glasgow, Glasgow, United Kingdom, 3 Guy s and St Thomas NHS Foundation Trust, London, United Kingdom, 4 UCSD School of Medicine, La Jolla, CA, 5 Memorial University of Newfoundland, St. John s, NF, 6 Leiden University Medical Center, Leiden, Netherlands, 7 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 8 University of Queensland, Brisbane, Australia, 9 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10 Novartis Pharma AG, Basel, Switzerland 5:00 pm 954. Secukinumab, a Monoclonal Antibody to Interleukin- 17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Désirée van der Heijde 1, Robert B. M. Landewé 2, Philip Mease 3, Iain B. McInnes 4, Philip G. Conaghan 5, Luminita Pricop 6, Gregory Ligozio 6, Hanno Richards 7 and Shephard Mpofu 7, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 3 Swedish Medical Center, Seattle, WA, 4 University of Glasgow, Glasgow, United Kingdom, 5 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7 Novartis Pharma AG, Basel, Switzerland 5:15 pm 955. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial Peter Schafer 1, Peng Chen 2, Lorraine Fang 2, Andrew Wang 2 and Rajesh Chopra 1, 1 Celgene Corporation, Summit, NJ, 2 Celgene Corporation, Warren, NJ 5:30 pm 956. Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada Proton Rahman 1, Saeed Shaikh 2, Michael Starr 3, William Bensen 4, Denis Choquette 5, Wojciech Olszynski 6, Maqbool Sheriff 7, Michel Zummer 8, Emmanouil Rampakakis 9, John S. Sampalis 9, Allen J Lehman 10, Susan Otawa 10, Francois Nantel 10, Vincent Letourneau 10 and May Shawi 10, 1 Memorial University of Newfoundland, St. John s, NF, 2 McMaster University, Hamilton, ON, 3 Montreal General Hospital, Montreal, QC, 4 Division of Rheumatology, McMaster University, Hamilton, ON, 5 Notre Dame Hospital, Montreal, QC, 6 University of Saskatchewan, Saskatoon, SK, 7 Nanaimo Regional General Hospital, Nanaimo, BC, 8 Université de Montréal, Montreal, QC, 9 JSS Medical Research, Montreal, QC, 10 Janssen Inc., Toronto, ON 10:15 am 957. Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity? Debora Russo 1, Carla G.S. Saad 2, Ana C.M. Ribeiro 1, Cláudia Goldeinstein-Schainberg 2, Percival D Sampaio-Barros 2, Celio R. Gonçalves 2, Eloisa Bonfá 1 and Julio C. B. Moraes 2, 1 University of Sao Paulo, Sao Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 205 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Lupus Nephritis Moderators: Maria Dall Era, MD and Cynthia Aranow, MD 4:30 pm 958. The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Longterm Immunosuppression of Lupus Nephritis Farah Tamirou 1, David D Cruz 2, Shirish Sangle 3, Philippe Remy 4, Carlos Vasconcelos 5, Christoph Fiehn 6, Maria del Mar Ayala Gutierrez 7, Inge-Margrethe Gilboe 8, Maria Tektonidou 9, Daniel Blockmans 10, Isabelle Ravelingien 11, Véronique le Guern 12, SUNDAY november 16, Program Book 63

66 scientific sessions SUNDAY november 16, 2014 Geneviève Depresseux 1, Loïc Guillevin 13, Ricard Cervera 14 and Frédéric A. Houssiau 15, 1 Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium, 2 Louis Coote Lupus Unit, St Thomas Hospital, London, United Kingdom, 3 St Thomas Hospital, London, United Kingdom, 4 Hôpital Henri Mondor, Créteil, France, 5 Hospital Geral Santo Antonio, Porto, Portugal, 6 ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, 7 Hospital Regional Universitario Carlos Haya, Malaga, Spain, Malaga, Spain, 8 Oslo University Hospital Rikshospitalet, Oslo, Norway, 9 First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 10 UZ Leuven, Leuven, Belgium, 11 Onze-Lieve- Vrouwzienkenhuis, Aalst, Belgium, 12 Hôpital Cochin, Paris, France, 13 Hôpital Cochin, University Paris V Descartes, Paris, France, 14 Hospital Clínic of Barcelona, Barcelona, Spain, 15 Université catholique de Louvain, Brussels, Belgium 4:45 pm 959. Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort Guillermo J. Pons-Estel 1, Gaobin Bao 2, Bernado Pons-Estel 3, Daniel Wojdyla 4, Veronica Saurit 5, Alejandro J. Alvarellos 6, Francisco Caeiro 7, Emilia I. Sato 8, Enrique R. Soriano 9, Lilian Tereza Costallat 10, Oscar Neira 11, Antonio A. Iglesias- Gamarra 12, Gil Reyes Llerena 13, Mario Cardiel 14, Eduardo M. Acevedo-Vásquez 15, Rosa Chacon 16 and Cristina M. Drenkard 2, 1 Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 2 Emory University, Atlanta, GA, 3 Hospital Provincial de Rosario, Rosario, Argentina, 4 Universidad Nacional de Rosario, Argentina, Rosario, Argentina, 5 Hospital Privado de Córdoba, Córdoba, Argentina, 6 Hospital Privado Córdoba, Córdoba, Argentina, 7 Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 8 Escola Paulista de Medicina Universidade Federal de São Paulo, Sao Paulo, Brazil, 9 Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires and Fundacion Catoggio, Buenos Aires, Argentina, 10 Unicamp, Campinas, Brazil, 11 Univ of Chile Hosp Salvador, Santiago, Chile, 12 Professor- Universidad Nacional de Colombia, Bogota, Colombia, 13 Centro de Investigaciones Médico Quirúrgicas (CIMEQ), La Habana, Cuba, 14 Secretaría de Salud de Michoacán, Morelia, Mexico, 15 Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 16 Hospital Universitario, Centro Nacional de Enfermedades Reumáticas and Hospital de Clínicas Caracas, Caracas, Venezuela 5:00 pm 960. Allogeneic Mesenchymal Stem Cell Transplantation for Lupus Nephritis Patients Refractory to Conventional Therapy Dandan Wang, Huayong Zhang, Xuebing Feng and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 5:15 pm 961. Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study John G. Hanly for the Systemic Lupus International Collaborating Clinics 1, Aidan O Keeffe 2, Li Su 3, Murray B. Urowitz 4, Juanita Romero-Diaz 5, Caroline Gordon 6, Sang-Cheol Bae 7, Sasha R Bernatsky 8, Ann E. Clarke 9, Daniel J. Wallace 10, Joan T. Merrill 11, David A. Isenberg 12, Anisur Rahman 13, Ellen M. Ginzler 14, Paul Fortin 15, Dafna D. Gladman 4, Jorge Sanchez-Guerrero 16, Michelle A. Petri 17, Ian Bruce 18, Mary Anne Dooley 19, Rosalind Ramsey- Goldman 20, Cynthia Aranow 21, Graciela S. Alarcon 22, Barri Fessler 22, Kristjan Steinsson 23, Ola Nived 24, Gunnar Sturfelt 24, Susan Manzi 25, Munther A. Khamashta 26, Ronald F. van Vollenhoven 27, Asad Zoma 28, Manuel Ramos-Casals 29, Guillermo Ruiz-Irastorza 30, S. Sam Lim 31, Thomas Stoll 32, Murat Inanc 33, Kenneth C. Kalunian 34, Diane L. Kamen 35, Peter Maddison 36, Christine A. Peschken 37, Søren Jacobsen 38, Anca Askanase 39, Jill P. Buyon 40, Chris Theriault 41, Kara Thompson 41 and Vernon Farewell 3, 1 Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, 2 MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, 3 MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 Instituto Nacional de Ciencias Médicas y Nutricion, Mexico City, Mexico, 6 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8 Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, 9 Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, 10 Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 11 Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12 Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 13 University College London, London, United Kingdom, 14 SUNY-Downstate Medical Center, Brooklyn, NY, 15 Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, 16 Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, 17 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 18 Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 19 Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 20 Northwestern University and Feinberg School of Medicine, Chicago, IL, 21 Feinstein Institute for Medical Research, Manhasset, NY, 22 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 23 Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, 24 Department of Rheumatology, University Hospital Lund, Lund, Sweden, 25 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 26 Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 27 Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 28 Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Program Book

67 scientific sessions United Kingdom, 29 Josep Font Autoimmune Diseases Laboratory, IDIBA, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 30 Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 31 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 32 Kantonsspital Geissbergstr, Schaffhausen, Switzerland, 33 Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 34 UCSD School of Medicine, La Jolla, CA, 35 Medical University of South Carolina, Charleston, SC, 36 Ysbyty Gwynedd Bangor, North Wales, United Kingdom, 37 University of Manitoba, Winnipeg, MB, 38 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 39 Columbia University Medical Center, New York, NY, 40 New York University School of Medicine, New York, NY, 41 Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS 5:30 pm 962. A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis Jasvinder Singh 1, Alomgir Hossain 2, Ahmed Kotb 2 and George Wells 3, 1 University of Alabama at Birmingham, Birmingham, AL, 2 University of Ottawa, Ottawa, ON, 3 University of Ottawa Heart Institute, Ottawa, ON 5:45 pm 963. Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept Sarah Goglin 1, David Wofsy 1, Miriam G. Cisternas 2 and Maria Dall Era 1, 1 University of California, San Francisco, San Francisco, CA, 2 MGC Data Services, Carlsbad, CA 157 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I Moderators: Jessica K. Gordon, MD, MSc and Robert Lafyatis, MD 4:30 pm 964. Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients Claire Emson 1, Martin Decaris 1, Michelle Gatmaitan 1, Flora Luo 1, Dan Holochwost 1, Simplicia FloraCruz 1, Thomas Angel 1, Kelvin Li 1, Marc Hellerstein 1, Fredrick M. Wigley 2, Scott Turner 1 and Francesco Boin 2, 1 KineMed Inc., Emeryville, CA, 2 Johns Hopkins University School of Medicine, Baltimore, MD 4:45 pm 965. Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis Swati Bhattacharyya 1, Wenxia Wang 1, Zenshiro Tamaki 1, Yasuhiro Tsukimi 2, Masashi Yamasaki 2 and John Varga 3, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 3 Northwestern University Feinberg School of Medicine, Chicago, IL 5:00 pm 966. Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism Feng Fang 1, Roberta G. Marangoni 1, Xingchun Zhou 2, Wen Hong 2, Boping Ye 2, Asano Yoshihide 3, Shinichi Sato 3, Yuri Masui 3, Chengning Zhang 1, Katja Lakota 1, Jun Wei 1, Monique E. Hinchcliff 1, Philipp Scherer 4, Laszlo Otvos 5 and John Varga 6, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 China Pharmaceutical University, Nanjing, China, 3 University of Tokyo, Tokyo, Japan, 4 University of Texas Southwestern Medical Center, Dallas, TX, 5 Temple University, Philadelphia, PA, 6 Northwestern University Feinberg School of Medicine, Chicago, IL 5:15 pm 967. Mir-145 Protects Against Skin Fibrosis in Vivo by targeting TGF-β Signaling Serena Vettori 1, Christian Beyer 2, Matthias Brock 1, Naoki Iwamoto 1, Britta Maurer 1, Michelle Trenkmann 1, Astrid Jüngel 1, Renate E. Gay 1, Maurizio Calcagni 3, Gabriele Valentini 4, Steffen Gay 1, Joerg H. W. Distler 2 and Oliver Distler 1, 1 Zurich University Hospital, Zurich, Switzerland, 2 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, 3 Division of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland, 4 Second University of Naples, Napoli, Italy 5:30 pm 968. Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation Justin Gillespie 1, Emma C. Derrett-Smith 2, Michael McDermott 1, Paul Emery 3, Christopher P Denton 2 and Francesco Del Galdo 3, 1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2 UCL Medical School Royal Free Campus, London, United Kingdom, 3 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 5:45 pm 969. Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation Alexander Misharin 1, Carla M. Cuda 2, Luisa Morales-Nebreda 3, Gokhan Mutlu 1, GR Scott Budinger 3 and Harris R. Perlman 2, 1 Northwestern University, Chicago, IL, 2 Northwestern University Feinberg School of Medicine, Chicago, IL, 3 Northwestern University, Feinberg School of Medicine, Chicago, IL SUNDAY november 16, Program Book 65

68 scientific sessions SUNDAY november 16, 2014 ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) Crystal: Diagnosis and Management of Gout (021) Speaker: Saima Chohan, MD review diagnostic criteria for gout assess treatment options for hyperuricemia, acute and chronic gout assess the current ACR recommendations for the treatment of acute and chronic manifestations of gout Westin Otis (Lobby) *Infections with Biologics (022) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction Westin Hancock (Lobby) *Inflammatory Eye Disease/Uveitis (023) Speaker: Sergio Schwartzman, MD review the clinical manifestations of inflammatory eye disease encountered by rheumatologists discuss diagnostic pearls for the evaluation of someone with inflammatory eye disease discuss the treatment paradigms used for the inflammatory eye diseases Westin Revere (Lobby) Pediatrics: Difficult-to-Treat Juvenile Idiopathic Arthritis (024) Ed Pd PrM FIT Speaker: Thomas J. A. Lehman, MD discuss the differences in the treatment of the difficult situations for the different subtypes of juvenile idiopathic arthritis recognize some of the complications of the disease and appropriate management explain the difficulties posed by non-adherence and inadequate decision making Westin Stone (Lobby) Polymyalgia Rheumatica (025) Speaker: Antoine G. Sreih, MD distinguish the clinical subtleties of polymyalgia rheumatica and outline an evaluative process that can help differentiate it from other inflammatory conditions and identify manifestations of giant cell arteritis discuss the new EULAR/ACR classification criteria and the scoring algorithm for polymyalgia rheumatica review the therapeutic strategies used for the treatment of polymyalgia rheumatica, including the range of glucocorticoid regimens, other disease modifying therapies, steroid-sparing approaches and new investigative drugs Westin Webster (Lobby) Pulmonary Hypertension in the Rheumatic Diseases (026) Speaker: James R. Seibold, MD describe the World Health Organization classification of pulmonary hypertension and how to recognize the frequent overlap of these syndromes in the clinical setting of connective tissue disease discuss the utility, sensitivity and specificity of non-invasive screening tests and algorithms for determining which patients are appropriate for right heart catheterization explain the benefits, risks, costs and effects on outcome of the available therapies for pulmonary arterial hypertension Westin Adams (Mezzanine) *Rheumatoid Arthritis: Biological Agents (027) Speaker: Josef Smolen, MD describe similarities and differences between approved biological agents in terms of efficacy and safety discuss issues around biosimilars assess the place of biologicals in the therapeutic cascade according to the updated EULAR management recommendations appraise the potential of induction therapy with biologics followed by withdrawal of the biologic as a potential future treatment approach Westin Alcott (Mezzanine) *Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow Ed Pd (028) PrM FIT Speakers: Alexandru F. Kimel, MD prepare for their first job search Program Book

69 scientific sessions assess expectation when starting out (perceptions versus reality) adapt to new practice styles and build a referral base identify ways to ensure long term success and personal life balance Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Novel Treatments (029) Speaker: Liz Lightstone, MD, PhD review immunosuppressive therapy of lupus nephritis classes II-V, including novel biologics discuss the management of lupus nephritis in pregnancy discuss novel approaches to improving adherence to therapy in lupus nephritis describe the use of reno-protective and anti-proteinuria therapies in lupus nephritis outline the future research agenda for clinical trials in lupus nephritis Westin Faneuil (Mezzanine) Vitamin D and Bone Health (030) Speaker: Nancy E. Lane, MD state current Food and Nutrition Board recommendations for vitamin D intake in older men and women recall evidence-based medicine conclusions regarding vitamin D and osteoporotic fracture identify the range of serum 25(OH)D levels believed optimal for bone health Dan Caspi 7 and Ori Elkayam 8, 1 Tel Aviv medical center, Tel Aviv, Israel, 2 Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel, 4 Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, 5 Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, 6 Department of rheumatology. Tel Aviv Medical Center, Tel Aviv, Israel, 7 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 8 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel 5:00 pm 972. Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, Eric Y Yen 1, Magda Shaheen 2, Jennifer MP Woo 1, Deborah K. McCurdy 1 and Ram Raj Singh 3, 1 UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2 Charles R. Drew University of Medicine and Science, Los Angeles, CA, 3 UCLA Division of Rheumatology, Los Angeles, CA 5:15 pm 973. Relation of Pelvic Drop during Walking to Risk of Incident Medial Knee Osteoarthritis: The Multicenter Osteoarthritis Study K. Douglas Gross 1, Emily K. Quinn 2, Michael C. Nevitt 3, James C. Torner 4, Cora E. Lewis 5 and David T. Felson 1, 1 Boston University School of Medicine, Boston, MA, 2 Boston University, Boston, MA, 3 UCSF (University of California, San Francisco), San Francisco, CA, 4 University of Iowa, Iowa City, Iowa City, IA, 5 The University of Alabama at Birmingham, Birmingham, AL SUNDAY november 16, 2014 ACR/ARHP COMBINED ABSTRACT SESSION 4:30 6:00 pm 109 A ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Moderator: Elizabeth G. Salt, PhD 4:30 pm 970. Risk of Developing Antiphospholipid Syndrome Following Infection: A Systematic Review and Meta-Analysis of Observational Studies Noha Abdel-Wahab 1, Maria A. Lopez-Olivo 1, Saurabh Talathi 2 and Maria E. Suarez-Almazor 1, 1 The University of Texas, MD Anderson Cancer Center, Houston, TX, 2 The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 4:45 pm 971. The Long-Term Efficacy of an Anti-Pneumococcal Polysaccharide Vaccine (PV23, Pneumovax) Among Autoimmune Inflammatory Rheumatic Patients Adi Broyde 1, Uri Arad 2, Noa Madar-Balakinski 2, Daphna Paran 3, Ilana Kaufman 4, Ira Litinsky 5, David Levartovsky 6, Irena Wigler 2, 5:30 pm 974. Obesity Paradox in Osteoarthritis Progression What Effects Are We Measuring? Qiong Louie-Gao 1, Hyon K Choi 1, David T. Felson 2, Tuhina Neogi 1, Uyen Sa D.T. Nguyen 1, Na Lu 1 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 University of Manchester, Manchester, United Kingdom 5:45 pm 975. Chronic Pain Predicts Reduced Physical Activity in a Large Population Cohort Study Kathryn Remmes Martin, Marcus Beasley, Gary J. Macfarlane and Daniel Whibley, University of Aberdeen, Aberdeen, United Kingdom 2014 Program Book 67

70 scientific sessions SUNDAY november 16, 2014 ARHP SESSIONS 4:30 6:00 pm 255 Say What? : Implications of Adolescent Development and Behavior in Communicating with Health Care Providers Ed Pd PrM FIT Moderator: Thuy T. Beam, BSN, RN Speakers: Kiana Johnson, PhD and Courtney Wells, MPH, MSW evaluate the cultural competency skills of professionals working with adolescents with rheumatic diseases recognize the developmental needs of adolescents with rheumatic diseases use knowledge of adolescent development and behavior to learn how to talk with adolescents develop comfort in speaking with adolescent patients 254 A Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations Eth Moderator: Catherine L. Backman, PhD define mobile health/ehealth and evaluate its utilization in the care of people with arthritis examine mobile health applications and identify functionality options to enhance consumer and health care provider utilization outline potential and actual ethical situations that may arise in the era of ehealth 4:30 pm Take Two Apps and Call Me in the Morning: An Overview of Mobile Health Applications to Improve Quality of Care Elizabeth A. Breeden, PharmD 5:00 pm State of the Science: A Conversation on Digital Resources to Support Self-Management Linda C. Li, PhD, PT and Maura D. Iversen, BSc, DPT, SD, MPH 5:30 pm The e-patient: Engaged, Empowered, Equipped, Enabled and Ethical? Anne F. Townsend, MA, PhD 102 A Multidisciplinary Management of Scleroderma Moderator: Deborah McCloskey, RN, BSN explain the medical management for the skin, vascular and organ involvement in scleroderma 256 describe the rehabilitation interventions used by occupational and physical therapists to manage functional disability in scleroderma discuss the management of psychosocial issues that can occur in scleroderma 4:30 pm Targeted Therapy for Systemic Sclerosis Virginia D. Steen, MD 5:00 pm Rehabilitation Techniques to Improve Function in Scleroderma Janet L. Poole, OTR, PhD 5:30 pm Managing Psychosocial Challenges in Scleroderma Vanessa L. Malcarne, PhD Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits Moderator: Karen Huisinga, MN, ARNP review the latest national HIPAA requirements evaluate current pre-audit preventive measures and strategies for responding to audits develop an up-to-date small practice compliance plan 4:30 pm HIPAA in 2014: Don t Forget Research, Quality Measures and Electronic Medical Records Bruce Toppin, JD 5:15 pm Audits, Affordable Care Act, ICD-10 I m at the End of the Rope Karen Zupko, BS ARHP CONCURRENT ABSTRACT SESSION 4:30 6:00 pm 257 A Osteoarthritis Moderators: Sara R. Piva, PhD, PT and Jan K. Richardson, PT, PhD 4:30 pm 976. Measurement Properties of the Health Assessment Questionnaire Disability Index (HAQ-DI) in Patients with Generalized Osteoarthritis (GOA) Nienke Cuperus 1, Elien A.M. Mahler 1, Thea Vliet Vlieland 2, Thomas Hoogeboom 3 and Cornelia H.M. van den Ende 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 Leiden University Medical Center, Leiden, Netherlands, 3 CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands Program Book

71 4:45 pm 977. Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans Kelli D. Allen 1, Hayden B. Bosworth 2, Amy Jeffreys 1, Cynthia Coffman 2, Santanu Datta 2, Jennifer McDuffie 3, Eugene Oddone 2, Jennifer Strauss 3 and William S. Yancy Jr. 3, 1 Durham VA Medical Center, Durham, NC, 2 Durham VA Medical Center and Duke University Medical Center, Durham, NC, 3 Duke University Medical Center, Durham, NC 5:00 pm 978. Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis Rebecca Cleveland 1, Jordan B. Renner 2, Joanne M. Jordan 3 and Leigh F. Callahan 4, 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 University of North Carolina Department of Radiology, Chapel Hill, NC, 3 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC 5:15 pm 979. Genome-Wide Association Study for Severe Radiographic Knee Osteoarthritis Youfang Liu 1, Michelle Yau 2, Laura Yerges-Armstrong 3, Braxton Mitchell 3, Rebecca D. Jackson 4, Marc C. Hochberg 3, Shad Smith 1, William Maixner 1, Luda Diatchenko 5 and Joanne M. Jordan 6, 1 University of North Carolina, Chapel Hill, NC, 2 University of Maryland, Baltimore,, MD, 3 University of Maryland School of Medicine, Baltimore, MD, 4 The Ohio State University, Columbus, OH, 5 McGill University, Montreal, QC, 6 University of North Carolina Dept of Epidemiology, Chapel Hill, NC 5:30 pm 980. Annual Medical Care Expenditures Among US Adults with Osteoarthritis, Miriam G. Cisternas 1, Louise Murphy 2, David J. Pasta 3, Daniel H. Solomon 4 and Charles G. Helmick 2, 1 MGC Data Services, Carlsbad, CA, 2 Centers for Disease Control and Prevention, Atlanta, GA, 3 DMA Corporation, Palo Alto, CA, 4 Brigham and Women s Hospital, Boston, MA 5:45 pm 981. The Effect of Compression Gloves in Hand Osteoarthritis: A Pre-Post-Test Trial Alison Hammond 1, Yeliz Prior 1, Vivienne Jones 1, Mary Dooley 2, Yvonne Hough 3 and Angela Jacklin 4, 1 University of Salford, Greater Manchester, United Kingdom, 2 Southport & Formby District Hospital, Southport, United Kingdom, 3 St Helens Hospital, St Helens, United Kingdom, 4 Stepping Hill Hospital, Stockport, United Kingdom scientific sessions INDUSTRY-SUPPORTED SYMPOSIA 6:30 9:30 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. ACR SESSIONS 7:30 8:30 am MONDAY, NOVEMBER 17, A Educator: Cultivating the Competent Medical Educator: A Growing Concern Moderator: Kenneth S. O Rourke, MD Speaker: Kelley M. Skeff, MD, PhD Ed Pd PrM FIT discuss the major aspects of effective teaching in medical school and clinical environments describe proposed competencies for medical educators based on this framework describe personal goals for improving teaching effectiveness 104 B Meniscus Biology in Osteoarthritis Moderator: Richard F. Loeser, MD Speaker: Robert Brophy, MD review the normal function of the meniscus in stabilizing the joint appraise how meniscal injury contributes to osteoarthritis pathogenesis describe the pro-inflammatory mediators produced by the meniscus that could promote osteoarthritis Ballroom East Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Gene-Environment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis Moderator: David R. Karp, MD, PhD Speaker: Lars Klareskog, MD, PhD critically evaluate studies on genetic and environmental/life style risk factors for RA and other rheumatic diseases appraise the power of such studies for identifying subsets of disease with different etiologies, molecular pathologies, disease course and response to therapy MONDAY november 17, Program Book 69

72 scientific sessions MONDAY november 17, 2014 recognize the effects of genes and environment/life style in clinical practice to advise patients and their relatives in avoiding and ameliorating disease critically evaluate the potentials of tolerizing therapies as future options for prevention and treatment of rheumatoid arthritis ARHP SESSIONS 7:30 8:30 am 151 A Stats Boot Camp: The Effect Size: What Is It and How Can You Use It? Moderator: Uyen Sa D.T. Nguyen, DSc, MPH Speaker: Nancy A. Baker, MPH, OTR, OTR/L distinguish between effect size and statistical significance define common effect sizes calculate and interpret common effect sizes discuss practical uses of effect sizes 255 Update on Findings from Large Registries: Emphasis on Health Disparities in Rheumatoid Arthritis Moderator: Scott Hasson, PT, PhD Speaker: Jeffrey D. Greenberg, MD, MPH discuss the incidence and prevalence of rheumatoid arthritis in ethnic populations describe disease severity and clinical course of disease among different ethnic groups discuss who are the medically underserved in this patient population 153 B What Are Biosimilars? Moderator: Susan Chrostowski, MS, ANP-C, RN summarize the basic concept of biosimilar drugs discuss the development, clinical trial and approval process for biosimilar drugs evaluate how the availability of biosimilars may affect their rheumatology practice and patient care approaches 7:30 am What Are Biosimilars? Lee S. Simon, MD ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Ankylosing Spondylitis: 2014 Update (031) Speaker: Lianne S. Gensler, MD discuss the spectrum of axial spondyloarthritis, including ankylosing spondylitis discuss the early diagnosis of ankylosing spondylitis and axial spondyloarthritis describe clinical and radiographic outcome measures used in clinical trials and practice summarize axial spondyloarthritis treatment options and understand the impact of treatment on outcomes Westin Otis (Lobby) *Basic Immunology for Clinical Rheumatologists (032) Speaker: John Atkinson, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity Westin Hancock (Lobby) Controversies in Sjögren s Syndrome (033) Speaker: Frederick Vinino, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients 8:00 am Where Are We Now with Biosimilars? Vibeke Strand, MD Westin Revere (Lobby) Dermatological Manifestations of Rheumatic Diseases (034) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatic disease Program Book

73 scientific sessions construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatic diseases Westin Stone (Lobby) Osteoarthritis: Update 2014 (035) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis Westin Webster (Lobby) *Pregnancy and Rheumatic Diseases (036) Speaker: Eliza Chakravarty, MD, MS describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy Westin Adams (Mezzanine) Reactive Arthritis: An Update (037) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis Westin Alcott (Mezzanine) Rheumatoid Arthritis: Challenging Cases (038) Speaker: Daniel Furst, MD, MPH discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Difficult-to-Treat Systemic Lupus Erythematosus (039) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of systemic lupus erythematosus including: examine management strategies for refractory cutaneous manifestations of systemic lupus erythematosus discuss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias Westin Faneuil (Mezzanine) *Vasculitis: Update (040) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size discuss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities ACR/ARHP WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August *Advanced Musculoskeletal Ultrasound (214) Speaker: Jay B. Higgs, MD 161 demonstrate improvement in their techniques for performing selected musculoskeletal ultrasound examinations use practical knowledge of ultrasound technology to improve image quality Complementary and Alternative Therapies in Rheumatic Disease (215) Speaker: Donald M. Marcus, MD describe the differences between the regulation of dietary supplements and conventional medications and to inform patients about current evidence concerning their efficacy and safety inform patients about the efficacy of acupuncture and chiropractic manipulation for relief of musculoskeletal pain and osteoarthritis 2014 Program Book 71 MONDAY november 17, 2014

74 scientific sessions MONDAY november 17, Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216) Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold address limitations of the Fracture Risk Assessment Algorithm in clinical practice The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (217) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP define the importance of using disease activity measurement tools in daily practice, the barriers which hinder routine widespread use and how these barriers can be overcome in nearly any practice setting learn and practice several of the most common and wellrecognized disease activity measurement tools used in rheumatology care, including the Disease Activity Score for 28 Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for rheumatoid arthritis; the Psoriatic Arthritis Response Criteria (PsARC) for psoriatic arthritis; measurements of spine and hip flexibility as well as the Ankylosing Spondylitis Disease Activity Score (AS-DAS) for spondyloarthropathies; and the modified Rodnan skin score for systemic sclerosis ACR SESSIONS 8:30 10:00 am 52 A CARE: Maintenance of Certification Session Two of Three Seronegative Spondyloarthropathies and Infectious Diseases All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) seronegative spondyloarthropathies and infectious diseases questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Atul A. Deodhar, MD, MRCP assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program Exhibit Hall C Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics and Management of Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics in the Perioperative Ed Period Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and James R. O Dell, MD review the findings of comparative effectiveness of biologics and oral small molecules from registries and direct comparator trials for treatment discuss the comparative harms of biologics and oral small molecules from registries and direct comparator trials for treatment with biologics summarize how to manage biologics and traditional diseasemodifying antirheumatic drugs in the perioperative period 8:30 am Comparative Efficacy and Effectiveness of Biologics: Head-to- Head Trials vs. Registry Studies Arthur Kavanaugh, MD 9:00 am Comparative Harms of Biologics: How to Best Learn from the Data? William G. Dixon, MRCP, PhD 9:30 am Perioperative Management of Biologics and Traditional Disease-Modifying Antirheumatic Drugs Susan M. Goodman, MD 107 B Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art Ed Pd PrM FIT Moderators: Kelly A. Rouster-Stevens, MD, MS and Angela Robinson, MD, MPH review the latest information on the pathogenesis of juvenile dermatomyositis review the different clinical phenotypes of juvenile dermatomyositis review cutting-edge developments in treatments and outcome measures for juvenile dermatomyositis 8:30 am Pathogenesis of Juvenile Dermatomyositis Ann M. Reed, MD Program Book

75 scientific sessions 9:00 am The Clinical and Autoantibody Phenotypes of Juvenile Myositis Lisa G. Rider, MD 9:30 am Outcome Assessment and Advances in Therapies Adam M. Huber, MD, MSc 204 A Practical Use of Registries Moderator: Melissa Francisco describe the importance of data collection and synthesis in evidence-based care evaluate the importance of their role as a participant in the Rheumatology Informatics System for Effectiveness registry develop strategies for participating in the registry and accessing collective data as a part of improving patient care 8:30 pm Rheumatology Informatics System for Effectiveness and Its Applications Salahuddin Kazi, MD 156 B Strategies for Academic Success: The Roadmap From Mentee to Mentor Ed Pd PrM FIT Moderators: Flavia V. Castelino, MD and Darcy S. Majka, MD identify the necessary measures for a productive menteementor relationship develop time management and organizational skills for academic success develop a strategy to transition from a mentored relationship to independence 8:30 am Your Role as a Mentee S. Louis Bridges Jr., MD, PhD 8:50 am Effective Time Management Leena Sharma, MD 9:20 am Transitioning to Independence Liana Fraenkel, MD, MPH 8:45 pm The Value of Participating Registries Jeffrey R. Curtis, MD, MPH, MS 9:00 am RISE Demonstration Tim Parr 109 A Practice Issues: Practice Success in an Environment of Transition Moderator: Suzanne Moore, MD review the next steps for Physician Quality Reporting System (PQRS), Electronic Prescribing (erx) and Electronic Health Record (EHR) Incentive Programs discover how to avoid penalties review ways to avoid Health Insurance Portability and Accountability Act (HIPAA) violations 9:40 am Panel Discussion 253 B Systems Biology of Lupus Nephritis Moderators: Shu Man Fu, MD, PhD and Vasileios C. Kyttaris, MD review how a systems analysis of mouse and human renal gene expression analysis can lead to the identification of major pathogenic cell populations and pathways evaluate how a single cell characterization of local renal immune responses can lead to identification of disease amplification mechanisms describe how to identify and test novel disease biomarkers 8:30 am Stage Specific Systems Analysis of Lupus Nephritis: From Mice to Men Anne Davidson, MBBS MONDAY november 17, :30 am Physician Quality Reporting System (PQRS) Reporting Made Easy Robert Warren, MD, PhD, MPH 9:00 am Health Insurance Portability and Accountability Act (HIPAA) A Guide to Compliance Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 9:00 am Systems Analysis of the Immunoglobulin Gene Repertoire in Nephritic Kidneys Suggests Local Antigenic Drive Marcus R. Clark, MD 9:30 am Proteomic Analysis of Lupus Urines Leads to the Identification of Potential Renal Biomarkers Chandra Mohan, MD, PhD 9:30 am The Fundamentals of Value-Based Modifier Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 2014 Program Book 73

76 scientific sessions MONDAY november 17, 2014 Ballroom West The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be? Moderators: Dinesh Khanna, MD and N. Lawrence Edwards, MD describe the development and content of the recent ACR Gout Guidelines examine the components of the guidelines that have generated concern and controversy examine the historic success of guideline implementation and which factors influence this success 8:30 am An Overview of the 2012 ACR Gout Management Guidelines John D. FitzGerald, MD, PhD 9:00 am Strengths, Weakness and Controversies of the Gout Guidelines Kenneth G. Saag, MD, MSc 9:30 am The Trouble With Guidelines Implementation and What We Can Do About It Robert T. Keenan, MD, MPH ACR/ARHP POSTER SESSION B, THIEVES MARKET POSTERS AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # ). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Poster Hall (Exhibit Hall B) Thieves Market Posters TM 1. Friday Evening Consult...Vasculitis? Manpreet Sethi, MBBS TM 2. Numbness Matters Nandita Gatla, MD TM 3. Scary Salmonella Yathish GC, MBBS, MD TM 4. When Oral and Genital Ulcers Are Not Behçet s... Kim M. Wu, MD TM Year-Old Woman With Fever and Anasarca Kensuke Nakanishi, MD TM 6. A Case of An Orbital Mass Namrata Singh, MBBS TM 7. Arthritis Mutilans in a Teenage Girl from Panama Vidya Raman, MD Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Epidemiology and Health Services Research Poster Tour (313) Tour Guide: Cheryl Barnabe, MD, MSc Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster Tour (314) Tour Guide: Daniel J. Claw, MD Imaging of Rheumatic Diseases Poster Tour (315) Tour Guide: Wolfgang A. Schmidt, MD Pediatric Rheumatology: Clinical Aspects Poster Tour (316) Tour Guide: Bryce A. Binstadt, MD, PhD Rheumatoid Arthritis: Clinical Aspects Poster Tour (317) Tour Guide: Merete Lund Hetland, DMSc, MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Poster Tour (318) Tour Guide: Robert Lafyatis, MD 10:15 11:00 am Pediatric Rheumatology: Clinical Aspects Poster Tour (319) Tour Guide: Lisa F. Imundo, MD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (320) Tour Guide: Vivian P. Bykerk, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (321) Tour Guide: Grant H. Louie, MD, MHS Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (322) Tour Guide: Robert D. Inman, MD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (323) Tour Guide: Eliza Chakravarty, MD Vasculitis Poster Tour (324) Tour Guide: Kenneth J. Warrington, MD Program Book

77 scientific sessions ACR SESSIONS 9:00 10:00 am 104 B Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy Moderator: Lindsey A. Criswell, MD, MPH Speaker: Ranjeny Thomas, MBBS, MD review the molecular mechanisms whereby HLA-DRB1 contributes to the pathogenesis of rheumatoid arthritis appraise subtle differences in the structure of HLA-DR molecules permitting the binding of specific autoantigens describe the rationale for contemporary approaches to peptide specific immunotherapy for the treatment of rheumatoid arthritis 102 A Legislative Update: Chat with Congress Moderator: David Goddard, MD describe the latest developments in federal health policy discuss legislative initiatives currently before Congress appraise how legislative outcomes could affect the rheumatology community 9:00 am Congressional Update Speaker to be Determined 9:30 am Legislative Update William F. Harvey, MD, MSc 153 B Social Media Boot Camp: Blogging for Beginners Moderator: Ronan Kavanagh, MD, MRCP describe a blog and its relevance in professional social engagement identify the challenges and opportunities of communicating through blogs in a public environment evaluate appropriate content for blogging define self-hosting vs. writing for an established platform create a basic blog in WordPress produce strategies for basic blog promotion and building readership 9:00 am Introduction Ronan Kavanagh, MD, MRCP 9:05 am Why Blog: An Overview Philip Gardiner, MD 9:30 am How to Blog Paul Sufka, MD 9:55 am Question and Answer ARHP SESSION 9:00 10:00 am 254 A ARHP Distinguished Lecturer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease MONDAY november 17, 2014 Ballroom East Prosthetic Device Infections, or Infection as a Threat to the Bionic Man Moderator: Kenneth S. O Rourke, MD Speaker: James E. Peacock Jr., MD define the utilization of prosthetic devices in musculoskeletal diseases and the risk of infection associated with those devices describe the pathogenesis of prosthetic device infection, including the bacterial elaboration of extracellular glycocalyx (biofilm) and how it impacts the choice and duration of antibiotic therapy discuss the management strategies for infected joint prostheses, including the impact of immunosuppressive medications on the development and outcome of treatment Moderator: Afton L. Hassett, PsyD Speaker: Monique A. Gignac, PhD describe factors beyond health symptoms and treatment that are important in understanding the behaviors and perceptions of patients with rheumatic diseases in living with and managing their disease help patients find ways to maintain social participation in diverse roles and activities in terms of physical health and well-being develop strategies in combination with patients to promote the maintenance of social participation and further promote health and well-being 2014 Program Book 75

78 scientific sessions MONDAY november 17, 2014 EXHIBITS 10:00 am 5:00 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 11:00 am and 2:00 3:00 pm. (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am, 12:30 1:15 pm and 2:30 3:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm, 1:30 2:15 pm and 3:30 4:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm 154 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Histopathology of Vasculitis (218) Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD describe histological features of normal blood vessels distinguish pathologic reactions to vascular injury identify histological features of major vasculitis syndromes 152 *Knee Braces, Foot Orthoses and Shoe Gear for Managing Knee Osteoarthritis (219) Speakers: Howard J. Hillstrom, PhD and Kelly D. Krohn, MD review the biomechanical rationale for the use of knee braces and foot orthoses for knee osteoarthritis discuss the clinical data to support these modalities apply these modalities to their patients 159 *Musculoskeletal Ultrasound (220) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 161 demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221) Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis ACR SESSIONS 11:00 am Noon 52 A ACR Immunology Update: Innate Lymphoid Cells Moderator: Leonard H. Sigal, MD Speaker: Hergen Spits, MD, PhD provide an overview of human innate lymphoid cells subsets discuss development and plasticity of innate lymphoid cells subsets discuss the possible roles of innate lymphoid cells in human diseases Ballroom West ACR Knowledge Bowl: Final Round Moderator: Rebecca L. Manno, MD, MHS identify key images that are important to recognize in clinical practice describe factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Competing Teams: Portlandumabs Defending 2013 ACR Knowledge Bowl Champions Cailin H. Sibley, MD; Navid Mehraban, MD and Daniela Ghetie, MD Winners from the 2014 ACR Knowledge Bowl: Preliminary Round View the full list of competing 2014 Knowledge Bowl Teams on page Program Book

79 scientific sessions ARHP SESSIONS 11:00 am Noon ACR PLENARY SESSION II DISCOVERY :00 am 12:30 pm 259 A Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain Moderator: Kenneth N. Schikler, MD Speaker: Daniel J. Clauw, MD summarize the research-based evidence for the benefits to medicinal marijuana and cannabinoids for treating chronic pain review the research-based evidence for the risks to medicinal marijuana and cannabinoids enhance patient and provider education by using contemporary scientific knowledge to clarify the appropriate position of this class of drugs in the overall treatment algorithms for chronic pain 257 A Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency Moderator: Benjamin J Smith, PA-C Speaker: Troy R. Torgerson, MD, PhD describe mechanisms of tolerance review the cellular changes responsible for autoimmunity describe the relevance of genetic predisposition for rheumatic diseases recognize when the immune system fails to recognize threats and mount an appropriate response 254 A Stats Boot Camp: Statistical Analysis of Ordinal Data Moderator: Michael P. LaValley, PhD identify the ubiquity of ordinal data and contrast it with continuous data review contingency table analysis of ordinal data describe common statistical models for ordinal outcome data interpret and report results generated by ordinal data methods 11:00 am Ordinal Data: Overview and Contingency Table Analysis Todd A. Schwartz, DrPH 11:30 am Statistical Modeling of Ordinal Data Rebecca J. Cleveland, PhD Exhibit Hall C ACR Plenary Session II: Discovery 2014 Moderators: Eric L. Matteson, MD, MPH and Mary E. Cronin, MD 11:00 am The Sting Pathway Regulates Bone Remodeling in a Model of Autoimmune Disease Rebecca Baum, University of Massachusetts Medical School, Worcester, MA Background/Purpose: Cytosolic DNA sensors detect viral and bacterial DNA, inducing inflammatory cytokines and type I IFNs via the adaptor stimulator of interferon genes (STING) to clear infection. The STING pathway also responds to endogenous DNA from dying cells and contributes to autoimmune disease. We have identified a potentially important role for cytosolic DNA sensor pathways in bone by studying a mouse that develops inflammatory polyarthritis and articular erosions in the setting of DNA accrual. In this model, DNA accumulates in macrophages due to deletion of the lysosomal endonuclease DNaseII and is detected by cytosolic sensors that signal through STING. Type I IFNs in DNaseII-/- mice lead to anemia-related embryonic lethality; thus co-deletion of the type I IFN receptor is required (DNaseII/IFN-IR double deficient, (DKO) mouse). We investigated the impact of DNA and of the STING pathway in bone in this model of autoimmune disease. Methods: STING-/- mice were intercrossed with DKO mice to generate STING/DNaseII/IFN-IR triple knock out (TKO) mice. uct was performed on TKO, DKO and control femurs from 6-16 month-old mice. Mesenchymal colony forming unit (CFU) assays were used to determine the number of osteoblast precursor cells in bone. uct was performed on femurs from 6 month-old STING-/- and littermate controls. Finally, RNA from wild type (WT) osteoblasts was analyzed for the expression of cytosolic DNA sensors. To determine the potential for osteoblasts to respond directly to DNA, MC3T3 osteoblast-lineage cells were transfected with poly(da:dt) and RNA was analyzed by qpcr. Results: Inflammatory cytokines in the DKO model would be expected to induce bone loss in the axial skeleton, as well as articular erosions. Paradoxically, we found that bone accumulates in long bones, with significant replacement of the marrow cavity by 16 months. CFU assays demonstrate increased osteoblast precursor numbers and osteoid is also significantly increased in DKO compared to controls (13,881 vs. 424 µm2, p=0.02). Surprisingly, ectopic bone forms in DKO spleens, a site of DNA accrual in macrophages. We thus sought to define the contribution of cytosolic DNA sensor pathways to bone accrual. STING deficiency almost completely abrogates both arthritis and bone accrual in the spleen and long bones of DKO mice (BV/TV: Het = 0.44%, DKO = 11.47%, TKO = 1.99%, p<0.02 compared to DKO). STING also contributes to bone homeostasis, independent of DNaseII deficiency, as revealed by uct performed on femurs from STING-/- and littermate controls (BV/TV: STING-/- = 1.39%, WT = 0.62%, p=0.011). Furthermore, cytosolic DNA sensors are MONDAY november 17, Program Book 77

80 scientific sessions MONDAY november 17, 2014 expressed in osteoblasts and expression of several sensors is increased in osteoblasts upon transfection with a DNA ligand. Conclusion: The STING pathway plays a role in bone remodeling in situations of DNA accrual as well as in bone homeostasis. Cytosolic DNA sensors are expressed in differentiating osteoblasts and expression is upregulated by DNA. These findings have relevance to SLE and other autoimmune diseases in which DNA plays a pathogenic role. Discovery of new pathways linking bone and the immune system may identify new targets for the treatment of bone loss in inflammatory autoimmune diseases. Disclosures: R. Baum, None. 11:15 am Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-Over Group in the Extension of the Denosumab Pivotal Fracture Trial JP Bilezikian, College of Physicians and Surgeons, Columbia University, New York, NY and JP Brown, CHU de Québec Research Centre and Laval University, Quebec City, QC Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone, including the radius, a skeletal site not responsive to most osteoporosis treatments. Here, we evaluated changes over time in radius BMD and wrist fracture incidence during 3 years of placebo (Pbo) and up to 5 subsequent years of DMAb therapy in FREEDOM and its Extension (EXT). Methods: We evaluated 2207 women who received Pbo during FREEDOM (3 years) and enrolled in the EXT to receive DMAb 60 mg Q6M (cross-over group); all women received daily calcium and vitamin D. A subset of these women (n=115) participated in a distal radius DXA substudy and were evaluated at baseline and during FREEDOM and EXT. Analysis of mean percentage changes in BMD over time from FREEDOM and EXT baselines consisted of a repeated measure model. Wrist fracture rates (per 100 subject-years), rate ratios and 95% CI were computed. Results: At FREEDOM baseline, the mean (SD) 1/3 radius T-score was 2.53 (1.18). During FREEDOM, daily calcium and vitamin D alone was associated with a progressive and significant loss of BMD at the 1/3 radius ( 1.2%); however, during EXT, DMAb halted and reversed bone loss (Figure). With 5 years of DMAb treatment, a significant gain in BMD (1.5% at EXT Year 5) was observed, compared with EXT baseline. The wrist fracture rate during the Pbo period in FREEDOM was 1.02 ( ) per 100 subject-years. During the first 3 years of EXT, BMD recovered to the original baseline levels in response to DMAb and the wrist fracture rate remained comparable to the FREEDOM Pbo rate (Table); with 2 additional years of DMAb treatment, BMD increased further and the wrist fracture rate declined to levels significantly lower than the FREEDOM Pbo rate (rate ratio=0.57, 95% CI= ; p=0.03). Conclusion: In untreated women with postmenopausal osteoporosis, cortical bone density at the radius declined significantly. DMAb treatment for 3 years fully reversed this bone loss and 2 additional years of treatment resulted in further BMD gains that translated to significantly lower wrist fracture rates, highlighting the clinical importance of reversing cortical bone loss. Disclosures: J. Bilezikian, NIH, Amgen Inc., N, 2, Columbia University, 3, Merck, Amgen Inc., N, Lilly, Johnson&Johnson, 5, Elsevier Press, 7; J. Brown, Actavis, Amgen Inc., Eli Lilly, Merck, Novartis, 2, Amgen Inc., Eli Lilly, 5, Amgen Inc., Eli Lilly, 8. 11:30 am Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6 and Is a Target for SSc Therapy Flavia V. Castelino, Massachusetts General Hospital, Boston, MA Background/Purpose: Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously implicated LPA and its receptor, LPA1 in SSc pathogenesis.1 Here we studied the role of ATX in SSc dermal fibrosis using the bleomycin (BLM) mouse model and skin biopsy samples from SSc patients and healthy controls. We evaluated the role of IL-6, a cytokine implicated in SSc, in mediating ATX-induced fibrosis. Additionally, we investigated the therapeutic potential of targeting ATX, by using a novel ATX inhibitor, PAT-048 in this model. Methods: BLM or saline (PBS) was administered subcutaneously to C57Bl/6 mice daily for 3, 7, 14 and 28 days. 6mm dermal punch biopsies were obtained and ATX levels were measured by qpcr and ELISA. ATX inhibition with PAT-048 (20mg/kg oral gavage daily) was assessed in the model. PAT-048 was administered concurrently with BLM or PBS for 28 days, or initiated at 7 or 14 days after BLM. Dermal thickness was measured using H&E-stained sections. Collagen was visualized by Masson s trichrome stain and quantified by hydroxyproline measurement. Skin IL-6 expression was evaluated by immunohistochemistry (IHC). The effect of LPA-induced ATX expression was tested on human dermal fibroblasts transfected with IL-6 sirna. Additionally, healthy and SSc dermal fibroblasts were stimulated with LPA and IL-6 in vitro and IL-6 and ATX induction were evaluated by ELISA, respectively. Skin ATX expression was measured in SSc patients and healthy controls by qpcr and IL-6 expression by IHC. Results: ATX expression at both the mrna and protein level was increased at Day 3 after BLM injection (3-fold increase, p=0.05) suggesting a role for ATX early in fibrosis. Treatment with PAT-048 attenuated BLM-induced dermal fibrosis in all treatment groups (50% reduction, Day 28, p=0.01) and reduced IL-6 expression in the dermis. In vitro studies of human dermal fibroblasts showed that LPA-induced ATX expression was Program Book

81 scientific sessions attenuated with sirna knock-down of IL-6 (65% reduction, p<0.05). SSc fibroblasts demonstrated increased LPA-induced IL-6 expression and increased IL-6-induced ATX expression, compared to healthy fibroblasts. Furthermore, ATX expression was increased in SSc skin (n=7) compared to healthy controls (n=5; 3-fold increase, p=0.006) and IL-6 expression by IHC was increased in SSc skin compared to healthy controls (n=3 per group). Conclusion: We demonstrate that ATX has an important role in SSc fibrosis. Pharmacologic inhibition of ATX with a novel inhibitor, PAT-048, attenuated dermal fibrosis and IL-6 expression. Knock-down of IL-6 in fibroblasts in vitro abrogated LPA-induced ATX expression, suggesting an autocrine loop for ATX/LPA/IL-6 signaling. Both ATX and IL-6 are increased in SSc skin compared to healthy controls and LPA-induced IL-6 and IL-6- induced ATX expression are increased in SSc fibroblasts, further supporting an ATX/LPA/IL-6 autocrine loop in SSc. Targeting ATX may thus be an effective new therapeutic strategy for SSc fibrosis. Reference: Castelino FV et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of LPA1 in a mouse model of scleroderma. Arth Rheum, 2011; 63(5): Disclosures: F. V. Castelino, None. 11:45 am One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study Elana J. Bernstein, Columbia University College of Physicians & Surgeons, New York, NY Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease and/or pulmonary hypertension. However, many transplant programs are hesitant to offer lung transplantation (LTx) to those with SSc due to concerns about extra-pulmonary involvement that might affect short- and long-term survival. However, survival data for lung transplantation in SSc are sparse. The primary aim of this study was to determine whether adults with SSc have higher 1-year mortality rates after LTx compared to those with interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH) not due to SSc. We hypothesized that adults with SSc would have higher 1-year mortality rates after LTx than those with ILD or PAH not due to SSc. Methods: We performed a retrospective cohort study of adults who underwent double or single LTx in the United States between May 4, 2005 (the date of implementation of the lung allocation score) and September 14, Data were provided by the United Network for Organ Sharing, a non-profit organization that records data on all solid organ transplants performed in the US. Subjects were included if they were at least 18 years of age at the time of LTx; had a diagnosis of SSc, ILD, or PAH; and were transplanted at a center that has performed at least 1 LTx for SSc. Subjects were excluded if they had received a heart-lung transplant; if they received a LTx from a living donor; or if they had missing data on survival time. We modeled diagnosis (SSc) as the independent binary variable of interest in stratified Cox regression models where survival time was the dependent variable, adjusting for recipient, donor and procedural factors (Table 1). We used multiple imputation to account for missing covariate data. Results: A total of 3763 adults were transplanted during the study period and met inclusion criteria: 229 with SSc, 201 with PAH and 3333 with ILD (Table 1). The 1-year unadjusted mortality rate following LTx per 100 person-years was 21.4 among adults with SSc, 19.0 among adults with PAH and 17.8 among adults with ILD. A diagnosis of SSc was associated with a multivariable-adjusted 48% relative increase in the 1-year mortality rate compared to a diagnosis of ILD (HR 1.48, 95% CI ). However, a diagnosis of SSc was not associated with a relative increase in the 1-year mortality rate compared to a diagnosis of PAH (HR 0.85, 95% CI ). Conclusion: Adults with SSc had a 48% increased risk of death at 1 year following LTx compared to adults with ILD, but no increase in risk of death at 1 year compared to adults with PAH. Rather than denying SSc patients LTx because of their SSc diagnosis, variables need to be identified that will enable risk stratification of these patients prior to LTx, with particular attention to modifiable risk factors. MONDAY november 17, Program Book 79

82 scientific sessions MONDAY november 17, 2014 Table 1: Recipient Characteristics and Covariates Recipient Characteristics SSc N = 229 PH N = 201 ILD N = 3333 Age, years 53 (44-59) 46 (34-57) 62 (56-66) Female sex 135 (58.95%) 126 (62.69%) 941 (28.23%) Race/Ethnicity White 162 (70.74%) 161 (80.10%) 2782 (83.47%) Black 38 (16.59%) 17 (8.46%) 199 (5.97%) Hispanic 25 (10.92%) 17 (8.46%) 261 (7.83%) Asian 3 (1.313%) 5 (2.49%) 67 (2.01%) Other 1 (0.44%) 1 (0.50%) 24 (0.72%) LAS score ( ) ( ) ( ) Height, cm (10.29) (9.62) (9.56) Body mass index (kg/m 2 ) (4.21) (4.36) (3.99) Steroid use 117 (52.00%) N = 225 Pulmonary artery systolic pressure, mmhg Forced vital capacity, %predicted 48 (37-66) N = (34-60) N = (23.20%) N = (68-98) N = (60-87) N = (53.75%) N = (32-48) N = ( ) N = 3300 Creatinine, mg/dl 0.8 ( ) 1.0 ( ) 0.9 ( ) N = 3322 Extracorporeal membrane 11 (4.80%) 5 (2.49%) 50 (1.50%) oxygenation Mechanical ventilation 23 (10.04%) 6 (2.99%) 232 (6.96%) Oxygen requirement, L/ min 5 (3-6) N = (2-6) N = (3-6) N = 3310 Covariates adjusted for in Cox regression models Recipient factors Age; Sex; Race/Ethnicity; LAS score; Height; BMI; Steroid use; Pulmonary artery systolic pressure; Forced vital capacity; Creatinine; Extracorporeal membrane oxygenation; Mechanical ventilation Donor factors Age; Sex; Height; Body mass index; PaO 2 on FiO 2 of 1.0; Pulmonary infection; 20 Pack-years smoking; Heavy alcohol use; Cause of death Procedural factors Ischemic time; Single vs. bilateral transplant; Transplant center; Distance from donor hospital to transplant center; Recipient-donor sex mismatch; CMV mismatch (D+/R-); 3 HLA mismatches * Data presented as mean (SD), median (IQR) and frequency (percentage) ** LAS = lung allocation score; PaO 2 = arterial oxygen tension; FiO 2 = fraction of inspired oxygen; CMV = cytomegalovirus; D+ = donor positive; R- = recipient negative; HLA = human leukocyte antigen Disclosures: E. J. Bernstein, None. Noon Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjögren s Syndromelike Disease in Mice Paulina Kaplonek and Umesh Deshmukh, Oklahoma Medical Research Foundation, Oklahoma City, OK Background/Purpose: Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren s syndrome (SS) patients. This study was undertaken to investigate the role of Ro52 induced immune responses in the pathogenesis of SS in an experimental mouse model system. Methods: New Zealand Mixed (NZM) 2758 mice were immunized with mouse Ro52, adsorbed on to alum adjuvant. Control mice were injected either with Maltose binding protein (MBP) or only with alum. Mice were monitored for anti-ro52 antibody production, sialoadenitis, serum cytokine levels and pilocarpine induced salivation. Antibody binding to salivary gland cells was analyzed in vivo and in vitro by immunofluorescence. Sera from immunized mice were passively transferred into untreated or alum injected NZM2758 mice. Internalization of antibodies by live cells was investigated by using the salivary gland cell line SCA9-15. Clinical data from the Oklahoma pss patient cohort that met the AECG classification criteria for SS was analyzed for anti-ro reactivity, minor labial salivary gland biopsy focus scores and xerostomia. Results: By day 30 post-immunization, Ro52 immunized mice generated immunoprecipitating anti-ro52 antibodies and they had the maximum drop in saliva production. The glandular dysfunction in these mice was significantly associated with the level of anti-ro52 antibody. Both Ro52 immunized and control mice showed evidence for very mild sialoadenitis. However, only Ro52 immunized mice had antibody deposition in their salivary glands. Passive transfer of Ro52 immune sera induced salivary gland dysfunction in the recipient mice, only if the recipients were pre primed with alum. The levels of IL-1α and CXCL1 were significantly upregulated in alum injected mice, indicative of the inflammasome pathway activation. In vitro, antibodies from Ro52 immune sera were internalized by SCA9-15 cells and the antibodies recognized cytoplasmic Ro52. The antibody internalization was inhibited by Cytochalasin D treatment, indicating it to be an active uptake process. Amongst the 298 pss patients in Oklahoma cohort, 28 patients (9.3%) were anti- Ro positive and had a focus score of 0; and 37 anti-ro positive patients (12%) had a focus score of >0 but <1. Several of these patients have dry mouth and dry eyes Conclusion: Our data show for the first time that antibodies induced by Ro52 are capable of inducing salivary gland dysfunction and this phenomenon is dependent on the activation of innate immunity. The mouse model presented in this study mimics a subset (22%) of pss patients in our cohort, who are biopsy negative (or have low focus scores) and are anti- Ro antibody positive. In this group of patients, in the absence of sialoadenitis, it is possible that salivary gland dysfunction is caused by autoantibodies. Our data also suggests that antibody deposition within the salivary glands might be an important step for the induction of glandular dysfunction. Overall this study suggests that down modulation of autoantibody responses should constitute a major therapeutic strategy for the treatment of SS. Disclosures: P. Kaplonek, None; U. Deshmukh, None. 12:15 pm Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25hiFoxP3+ regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue? Naomi I Maria, Erasmus Medical Center, Immunology, Rotterdam, Netherlands Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO the rate-limiting enzyme in tryptophan (TRP) catabolism is driven in part by type I and type II IFNs. Systemic overactivation of IFN-signaling is evident in Primary Sjögrens syndrome (pss) and could shift the delicate regulatory balance towards a more auto-reactive state in these patients. Interestingly Program Book

83 scientific sessions aberrant systemic TRP catabolism, resulting in a shift from neuroprotective towards neurotoxic downstream metabolites, has been associated with mood disturbances as well as neurophsychiatric consequences and possibly contributes to symptoms of fatigue and depression in pss. Here we investigate the role of IDO and downstream TRP catabolism in pss and hypothesize an increase in Tregs, in concordance with increased IDO-activity in IFNpositive pss patients. Methods: In a Cohort of 20 Healthy controls (HC), 18 IFNnegative and 21 IFNpositive pss patients, diagnosed according to the 2002 American-European criteria, CD4+CD45RO+ T helper (Th) memory cell populations defined by chemokine receptor expression: CD25hiFoxP3+ Tregs, CCR6+CCR4+CXCR3-CCR10- Th17, CCR6+CCR4+CXCR3 CCR10+ Th22, CCR6-CXCR3+CCR4- Th1 and CCR6-CXCR3 CCR4+ Th2- cells were analyzed by flow cytometry in peripheral blood mononuclear cells (PBMCs). Analysis of TRP and Kynurenine (KYN) were performed simultaneously in serum using HPLC. CD14+ monocyte mrna-expression of IDO1and downstream enzymes was assessed using real-time quantitative PCR, to investigate the direction of downstream TRP catabolism in pss. Results: Activity of IDO (p=0.0054) as determined by measuring levels of the KYN/TRP-ratio in sera and CD25hiFoxP3+ Tregs (p=0.039) were significantly increased in IFNpositive pss patients. In addition, CD25hiFoxP3+ Tregs significantly correlated with the KYN/TRP-ratio (p=0.002;r=0.509) as well as the IFNscore (p=0.011;r=0.375). Peripheral monocytes showed an upregulation of IDOexpression (p<0.0001) in IFNpositive pss, also highly correlating with the IFNscore (p<0.0001;r=0.816). Interestingly the neuroprotective downstream enzymes KAT1 (p=0.0003), KAT3 (p=0.016) and KAT4 (p=0.04) were downregulated, whereas the neurotoxic enzymes KMO (p=0.0057) and KYNU (p=0.0001) which convert KYN into the neutoxic metabolite Quinolinic acid were upregulated in these patients, suggesting a skew towards neurotoxicity. Conclusion: Here we find enhanced IDO activity in coherence with increased CD25hiFoxP3+ Tregs and evidence for a shift towards production of more neurotoxic metabolites previously associated with sickness behavior in IFNpositive pss. This imbalance towards neurodegenerative effects might contribute to increased fatigue and depressive symptoms in these patients. However, whether this shift in Tregs reflects an immune rescuemechanism or increases tolerance to self remains unknown. Intervening in these IFN and IDO-induced imbalances offers new possibilities for therapeutic interventions. Disclosures: N. I. Maria, None. ARHP NETWORKING EVENT Noon 2:00 pm Commonwealth Ballroom ARHP Networking at Noon Sit down with your colleagues over a complimentary lunch and participate in open discussion on various research, practice and clinical topics. Each roundtable discussion will be facilitated by a rheumatology expert. All ARHP attendees are welcome to participate in this event. This session is not eligible for CME credit. ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Adult Inflammatory Myopathy (041) Speaker: Robert L. Wortmann, MD review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies Westin Otis (Lobby) Pediatric Rheumatology for Adult Rheumatologists (042) Speaker: Daniel Lovell, MD, MPH identify how the evaluation of children with rheumatic diseases may be different from that of adults identify the evaluation and treatment of arthralgia in children diagnose the various forms of arthritis that are unique to children describe current treatment of chronic arthritis in children Westin Hancock (Lobby) *Psoriatic Arthritis (043) Speaker: Dafna D. Gladman, MD discuss advances in diagnosis and classification of psoriatic arthritis appraise if patients with psoriatic arthritis should be treated aggressively choose treatment options for patients with psoriatic arthritis MONDAY november 17, Program Book 81

84 scientific sessions MONDAY november 17, 2014 Westin Revere (Lobby) *Rheumatoid Arthritis: Biological Agents (044) Speaker: Edward C. Keystone, MD describe recent trends in the use of biologics to improve outcomes and utility describe strategies to reduce costs of biologics discuss emerging biologics, including biosimilars and their advantage for the therapeutic algorithm Westin Stone (Lobby) *Rheumatoid Arthritis: Challenging Cases (045) Speaker: Stephen A. Paget, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Webster (Lobby) Scleroderma Mimics (046) Speaker: Faye N. Hant, DO, MSCR present an overview of scleroderma-like conditions review the clinical phenotypes and classification of scleroderma create a differential diagnosis for conditions that may mimic features of scleroderma discuss features of specific scleroderma mimics and strategies to distinguish them explain potential diagnostic and initial management/ treatment of these conditions Westin Adams (Mezzanine) *Still s Disease and Autoinflammatory Syndromes (047) Speaker: John J. Cush, MD describe the clinical features of Still s disease and other febrile syndromes describe the immunogenetic mechanisms and treatment for adult Still s disease and related syndromes Westin Alcott (Mezzanine) *Systemic Lupus Erythematosus: Central Nervous System (048) Speaker: Cynthia Aranow, MD identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus Westin Faneuil (Mezzanine) *Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans Webster (Mezzanine) Vasculitis Mimics (050) Speaker: Peter A. Merkel, MD, MPH discuss the broad categories and specific entities that constitute clinical mimics of vasculitis distinguish the subtleties of mimics of vasculitis including common clinical situations of mimics in a patient with a known diagnosis of vasculitis develop a methodology for clinically evaluating patients with possible vasculitis with particular attention to differentiating mimics from true vasculitis ACR SESSIONS 1:00 2:00 pm 205 B Classification Criteria for Gout Moderators: Jasvinder A. Singh, MD, MPH and Nicola Dalbeth, MBChB, MD recognize the limitations of existing classification criteria and why new criteria are needed review the latest evidence related to various imaging modalities and clinical parameters for classification of gout identify the key elements of the new proposed preliminary gout classification criteria 1:00 pm Gout Classification Criteria: Where Have We Been and Where Do We Need to Go? Tim L. Jansen, MD, PhD 1:10 pm Key Clinical Considerations in Developing New Gout Classification Criteria William Taylor, PhD, MBChB 1:35 pm The Proposed New Preliminary Gout Classification Criteria Tuhina Neogi, MD, PhD Program Book

85 scientific sessions 107 B Classification Criteria for Myositis Moderators: Chester V. Oddis, MD and Lisa G Rider, MD discuss the history of and differences between criteria used in myositis describe the new classification criteria for myositis appraise how to use the new classification criteria in clinical settings and research 1:00 pm History of Classification Criteria for Idiopathic Inflammatory Myopathies Frederick W. Miller, MD, PhD 1:25 pm New Classification Criteria for Idiopathic Inflammatory Myopathies Ingrid E. Lundberg, MD, PhD discuss how cellular senescence impacts cell function and the immune system determine how current research on families with telomere syndromes informs biology of normal aging process and how it impacts the immune system ACR WORKSHO 1:15 3:15 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. 1:50 pm Panel Discussion Ballroom East Neonatal Lupus: From Bench to Bedside Moderators: Elana J. Bernstein, MD, MSc and Rennie N. G. Howard, MD Speaker: Jill P. Buyon, MD identify pregnant women at risk for having babies affected by neonatal lupus and describe the clinical manifestations of neonatal lupus discuss the pathogenesis of heart block in neonatal lupus and describe the diagnostic evaluation of heart block due to neonatal lupus discuss the treatment of congenital heart block Ballroom West Rheumatology on the Street Moderator: Kristine M. Lohr, MD, MS Speaker: Jonathan D. Graf, MD summarize medical complications associated with certain types of illicit drug use describe the rheumatic manifestations of cocaine use review an update of the clinical manifestations and autoantibody profiles associated with levamisole toxicity 52 A Telomeres, Telomerase and the Aging Immune System Moderator: Leonard H. Sigal, MD Speaker: Jonathan Alder, PhD describe current concepts of telomeres and telomerase biology 152 *Joint Injection Techniques (222) Speakers: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures practice common joint and soft tissue injections on upper and lower extremities Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223) Speaker: Walter P. Maksymowych, MD recognize typical active and structural lesions of spondyloarthritis recognize complicated/subtle lesions of spondyloarthritis recognize lesions that may mimic spondyloarthritis recognize pitfalls in the interpretation of magnetic resonance imaging in spondyloarthritis Synovial Fluid Analysis and Crystal Identification (224) Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, PhD; and Gilda M. Clayburne, MLT prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid MONDAY november 17, Program Book 83

86 scientific sessions ACR SESSIONS 2:30 4:00 pm 205 B Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk Moderators: Shreyasee Amin, MD CM, MPH and Alan N. Baer, MD describe the central and peripheral nervous system manifestations of Sjögren s syndrome recognize the different presenting manifestations of lymphoma, including of mucosa-associated lymphoid tissue (MALT) lymphoma, in patients with Sjögren s syndrome outline the approach for evaluating patients with Sjögren s syndrome who have neurologic manifestations or symptoms of lymphoma 2:30 pm Neurological Complications of Sjögren s Syndrome: Central Nervous System Manifestations Julius Birnbaum, MD, MHS 52 A Insight into Lung Fibrosis Moderators: John Varga, MD and Flavia V. Castelino, M.D. review classification and biology of lung fibrosis recognize immune dysregulation in lung fibrosis review cell-based approaches to lung regeneration 2:30 pm Insight into Lung Fibrosis Timothy Blackwell, MD 3:00 pm Immune Networks of Lung Fibrosis Thomas Wynn, PhD 3:30 pm Lung Regeneration and Cell-Based Therapies Darrell Kotton, MD ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm MONDAY november 17, :00 pm Neurological Complications of Sjögren s Syndrome: Peripheral Nervous System Manifestations Julius Birnbaum, MD, MHS 3:30 pm Lymphoma and Sjögren s: What the Clinician Should Know Elke Theander, MD, PhD Ballroom East Forefronts in Lupus Nephritis Moderator: George Stojan, MD recognize the pitfalls of current lupus nephritis treatment guidelines discuss the emerging role of Rituxan challenge the dogma of the need for steroid use in lupus nephritis 2:30 pm Clinical Pearls and Pitfalls in Diagnosis and Management of Lupus Nephritis Michelle Petri, MD, MPH 2:45 pm Guidelines for Lupus Nephritis More Recommendations than Data? Derek M. Fine, MD 3:00 pm The Parable of the Lost Sheep The Rituximab Redemption Liz Lightstone, MD, PhD 2014 Program Book 253 B Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and More Moderators: Jeffrey N. Katz, MD, MSc and Catherine Hill, MD, MBBS 2:30 pm Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative Jing Song 1, Lee A. Lindquist 1, Rowland W. Chang 1, Pamela A. Semanik 2, Linda S. Ehrlich-Jones 3, Jungwha Lee 1, Min-Woong Sohn 1 and Dorothy D. Dunlop 1, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Rush University Medical Center, Chicago, IL, 3 Rehabilitation Institute of Chicago, Chicago, IL 2:45 pm The Association of Knee Shape with Sex: The Osteoarthritis Initiative Barton L. Wise 1, Lisa Kritikos 1, Felix Liu 2, Neeta Parimi 2, John A. Lynch 2, Yuqing Zhang 3 and Nancy E. Lane 1, 1 Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, 2 University of California at San Francisco, San Francisco, CA, 3 Boston University School of Medicine, Boston, MA 3:00 pm Are Outcomes after Total Knee Arthroplasty Worsening over Time? a Time-Trends Study of Activity Limitation and Pain Outcomes Jasvinder A Singh 1 and David Lewallen 2, 1 University of Alabama and VA Medical Center, Birmingham, AL, 2 Mayo Clinic college of medicine, Rochester, MN

87 scientific sessions 3:15 pm Knee Osteoarthritis and All-Cause Mortality: The Wuchuan Osteoarthritis Study Qiang Liu 1, Xu Tang Sr. 2, Jingbo Niu 3, Xu Wu 2, Yan Ke 4, Jian Huang 5, Rujun Li 4, Hu Li 4, Xin Zhi 4, Kai Wang 4, Zhengming Cao 1 and Jianhao Lin 2, 1 Arthritis Institute, People s Hospital, Peking University, Beijing, China, 2 Peking University Health Science Center, Beijing, China, 3 Boston University, Boston, MA, 4 Peking University People s Hospital, Beijing, China, 5 The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China 3:30 pm Increased Mortality in Ankylosing Spondylitis Results from a National Population Based Study Sofia Exarchou 1, Elisabeth Lie 2, Johan Askling 3, Helena Forsbladd Elia 4, Carl Turesson 1, Lars Erik Kristensen 5 and Lennart T. Jacobsson 2, 1 Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 3 Clinical Epidemiology Unit, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4 Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 5 Lund University, Malmö, Sweden 3:45 pm Prevalence and Associating Factors with Atypical Femoral Fractures: An Asian Single Center Based Case-Control Study Dam Kim 1, Yoon-Kyoung Sung 1, Soo-Kyung Cho 1, Minkyung Han 1 and Yee-Suk Kim 2, 1 Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2 Hanyang University Hospital, Seoul, South Korea 160 B Health Services Research: Improving Clinical Practice Moderators: Una Makris, MD and Elena Losina, PhD 2: WITHDRAWN 2:45 pm Problems with Fee for Service Payments for Academic Rheumatology Practices: A Need for Payment Reform: Allen P. Anandarajah 1 and Christopher T. Ritchlin 2, 1 Univ of Rochester Medical Ctr, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY 3:00 pm Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis Di Dong 1, Wei Chuen Tan-Koi 2, Gim Gee Teng 3, Eric Finkelstein 4 and Cynthia Sung 4, 1 Duke-NUS Graduate Medical School, Singapore, Singapore, 2 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 3 Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, 4 Duke-NUS Graduate Medical School, Singapore, Singapore, Singapore 3:15 pm Is Team Care Better? a Comparison of Rheumatoid Arthritis Disease Activity Among Patients Cared for in Practices with Nurse Practitioners and Physicians Assistants Versus Rheumatologist Only DH Solomon 1, Liana Fraenkel 2, Bing Lu 1, Erika Brown 1, Peter Hsun Tsao 3, Elena Losina 1, Jeffrey N. Katz 1 and Asaf Bitton 1, 1 Brigham and Women s Hospital, Boston, MA, 2 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 3:30 pm Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety and Wasted Health Care Resources Sahar Eivaz Mohammadi 1, Imam H Shaik 1, Parag Chevli 1, Fernando Gonzalez-Ibarra 1, Sohini Sarkar 1, Saurav Acharya 1, Prerna Dogra 1, Hesam Hekmatjou 2, Maushmi Savjani 2, Waheed Abdul 2 and Valentin Marian 1, 1 Jersey City Medical Center- Barnabas Health, Jersey City, NJ, 2 St. George s University SOM, St. George s, Grenada 3:45 pm The Burden of Depression on Healthcare Utilization in a Population-Based Cohort of Patients with Systemic Lupus Erythematosus Alfredo Aguirre 1, Gaobin Bao 1, S. Sam Lim 2 and Cristina Drenkard 1, 1 Emory University, Atlanta, GA, 2 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA 156 B Innate Immunity and Rheumatic Disease Moderators: Philip L. Cohen, MD and Edward M. Behrens, MD 2:30 pm Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome Yin Liu 1, Adriana Almeida de Jesus 2, Bernadette Marrero 1, Dan Yang 3, Gina A. Montealegre Sanchez 2, Steve Brooks 1, Zuoming Deng 2, Amy Paller 4, Manfred Boehm 3 and Raphaela Goldbach- Mansky 2, 1 NIAMS/NIH, Bethesda, MD, 2 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3 National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 4 Northwestern University Feinberg School of Medicine, Chicago, IL 2:45 pm DNA Sensors Regulate Inflammation in a Model of Autoimmune Arthritis Rebecca Baum 1, Shruti Sharma 1, Sudesh Pawaria 1, Susan Carpenter 2, Katherine A. Fitzgerald 1, Ann Marshak-Rothstein 1 MONDAY november 17, Program Book 85

88 scientific sessions and Ellen M. Gravallese 3, 1 University of Massachusetts Medical School, Worcester, MA, 2 University of California, San Francisco, San Francisco, CA, 3 UMass Memorial Medical Center, Worcester, MA Boston, MA, 2 Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 3 Tufts Medical Center, Boston, MA, 4 Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI MONDAY november 17, :00 pm RNA-Containing Immune Complexes Shift Human Neutrophils from Phagocytosing Cells to Efficient Releasers of Oxidized DNA in a Process Requiring Crosstalk Between Tolllike Receptors and Fc Gamma Receptor IIa Christian Lood 1, Xizhang Sun 1, Lena Tanaka 1, Andrew Oberst 2, Jeffrey Ledbetter 3 and Keith B. Elkon 1, 1 University of Washington, Seattle, WA, 2 Department of Immunology, University of Washington, Seattle, WA, 3 Division of Rheumatology, University of Washington, Seattle, WA 3:15 pm STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation Jehad H. Edwan 1, Raphaela Goldbach-Mansky 2 and Robert A. Colbert 3, 1 NIAMS NIH, Bethesda, MD, 2 NIH Building 10 Room 6D47B, Bethesda, MD, 3 NIAMS/NIH, Bethesda, MD 3:30 pm Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice Tom Ederveen 1, Rebecca Rogier 1, Jos Boekhorst 1, Harm Wopereis 2, Johan Garssen 2, Sacha van Hijum 1, Fons A.J. van de Loo 1, Marije I. Koenders 1, Wim B. van den Berg 1 and Shahla Abdollahi-Roodsaz 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Danone Research, Wageningen, Netherlands 3:45 pm Connecting Two Pathways through Ca 2+ Signaling: NLRP3 Inflammasome Activation Induced By a Hypermorphic PLCG2 Mutation Jae Jin Chae 1, Yong Hwan Park 1, Chung Park 2, Il-Young Hwang 2, Patrycja Hoffmann 1, John Kehrl 2, Ivona Aksentijevich 1 and Daniel L. Kastner 1, 1 National Human Genome Research Institute, Bethesda, MD, 2 National Institute of Allergy and Infectious Diseases, Bethesda, MD 104 B Osteoarthritis Clinical Aspects I: Imaging in Osteoarthritis Moderators: Grace H. Lo, MD, MSc and Leena Sharma, MD 2:45 pm WITHDRAWN 3:00 pm Discordance of Hip Pain with Radiographic Hip Osteoarthritis: The Osteoarthritis Initiative Chan Kim 1, Michael C. Nevitt 2, Pia M. Jungmann 3, Irina Tolstykh 4, Nancy E. Lane 5, Thomas M. Link 4 and David T. Felson 6, 1 Boston University, Boston, MA, 2 UCSF (University of California, San Francisco), San Francisco, CA, 3 Technische Universitaet Muenchen, Munich, Germany, 4 University of California, San Francisco, San Francisco, CA, 5 Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, 6 University of Manchester, Manchester, United Kingdom 3:15 pm The Co-Occurrence Patterns of MRI Lesions and Incident Knee Osteoarthritis: The MOST Study Jingbo Niu 1, David T. Felson 2, Tuhina Neogi 2, Michael C. Nevitt 3, Cora E. Lewis 4, James Torner 5, Ali Guermazi 2, Frank Roemer 6 and Yuqing Zhang 2, 1 Boston University, Boston, MA, 2 Boston University School of Medicine, Boston, MA, 3 UCSF (University of California, San Francisco), San Francisco, CA, 4 University of Alabama, Birmingham, Birmingham, AL, 5 University of Iowa, Iowa City, IA, 6 Klinikum Augsburg, Augsburg, Germany 3:30 pm Increasing Synovitis and Bone Marrow Lesions Are Associated with Incident Joint Tenderness in Hand Osteoarthritis Ida K. Haugen 1, Barbara Slatkowsky-Christensen 1, Pernille Boyesen 1, Sølve Sesseng 1, Désirée van der Heijde 1 and Tore K. Kvien 2, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 PsAID taskforce, EULAR, Zurich, Switzerland 3:45 pm Inflammation Is Associated with Erosive Progression in Patients with Hand Osteoarthritis: A Prospective Ultrasonography Study Marion C. Kortekaas 1, Wing Yee Kwok 2, Monique Reijnierse 2, Theo Stijnen 2 and Margreet Kloppenburg 2, 1 Flevoziekenhuis, Almere-Stad, Netherlands, 2 Leiden University Medical Center, Leiden, Netherlands. 2:30 pm Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative Michael P. Lavalley 1, Grace H. Lo 2, Lori Lyn Price 3, Jeffrey Driban 3, Charles Eaton 4 and Timothy E. McAlindon 3, 1 Boston University, 157 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus Ed Pd PrM FIT Moderators: Mical Cidon, MD and Lisa F. Imundo, MD Program Book

89 scientific sessions 2:30 pm A Randomized Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Improvement in Disease Activity and Fatigue Scores Glauce Lima, Juliane Paupitz, Liliam Takayama, Eloisa Bonfa and Rosa M R Pereira, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 2:45 pm Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus Patricia Vega-Fernandez 1, Shana Vanderburgh 2, Deborah M. Levy 3, Frank A. Zelko 4, Eyal Muscal 5, Natasha M. Ruth 6, Adam M. Huber 7, Marisa S. Klein-Gitelman 8, Kasha Wiley 9, Wenjie Zheng 9, Lori B. Tucker 10, Tresa Roebuck-Spencer 11, Jun Ying 2 and Hermine Brunner 12, 1 Cincinnati Children s Hospital, Cincinnati, OH, 2 University of Cincinnati, Cincinnati, OH, 3 The Hospital for Sick Children and University of Toronto, Toronto, ON, 4 Northwestern University Feinberg School of Medicine, Chicago, IL, 5 Texas Children s Hospital, Houston, TX, 6 Medical University of South Carolina, Charleston, SC, 7 IWK Health Centre, Halifax, NS, 8 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, 9 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 10 BC Children s Hospital and University of British Columbia, Vancouver, BC, 11 University of Oklahoma, Norman, OK, 12 PRCSG, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 3:00 pm A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children Khalid Abulaban 1, Michael Bennett 1, Marisa Klein-Gitelman 2, Stacy P. Ardoin 3, Kelly A. Rouster-Stevens 4, Lori B. Tucker 5, Kasha Wiley 6, Shannen Nelson 7, Karen Onel 8, Nora G. Singer 9, Kathleen M. O Neil 10, Elizabeth Brooks 11, B Anne Eberhard 12, Lawrence K. Jung 13, Lisa F. Imundo 14, Tracey Wright 15, David Witte 16, Jun Ying 17, Prasad Devarajan 1 and Hermine I. Brunner 7, 1 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 2 Anne & Robert H Lurie Children s Hospital of Chicago, Chicago, IL, 3 Ohio State University College of Medicine, Columbus, OH, 4 Emory University School of Medicine, Atlanta, GA, 5 BC Children s Hospital and University of British Columbia, Vancouver, BC, 6 Cincinnati Children s Hospital Medical Center, c, OH, 7 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 8 University of Chicago Hospitals, Chicago, IL, 9 Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 10 Riley Hospital for Children, Indianapolis, IN, 11 Univ Hospitals of Cleveland, Cleveland, OH, 12 Cohen Children s Medical Center, Lake Success, NY, 13 Children s National Medical Center, Washington, DC, 14 Columbia University Medical Center, New York, NY, 15 UT Southwestern Medical Center, Dallas, TX, 16 Cincinnati Children s Hospital, Cincinnati, OH, 17 University of Cincinnati, Cincinnati, OH 3:15 pm Anti-Ro and Anti-La Antibodies in the General Pregnant Population Evelyn V. Rozenblyum 1, Sharon Sukhdeo 1, Edgar Jaeggi 2, Lisa Hornberger 3, Philip Wyatt 4, Carl A. Laskin 5 and Earl D. Silverman 6, 1 University of Toronto, Toronto, ON, 2 The Hospital for Sick Children, University of Toronto, Toronto, ON, 3 Stollery Children s Hospital, Edmonton, ON, 4 North York General Hospital, Toronto, ON, 5 University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, 6 The Hospital for Sick Children, Toronto, ON 3:30 pm Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate Nicole Ling, Isabel E. Allen, Erica F. Lawson and Emily von Scheven, University of California, San Francisco, San Francisco, CA 3:45 pm Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System Ummara Shah 1, Amit Saxena 1, Sara Sahl 1, Deborah Friedman 2, Jill P. Buyon 1 and Peter M. Izmirly 1, 1 New York University School of Medicine, New York, NY, 2 New York Medical College, Valhalla, NY 153 B Quality Measures and Quality of Care Moderators: Eric D. Newman, MD and Jinoos Yazdany, MD MPH 2:30 pm A Novel Population Care Model in Rheumatoid Arthritis Significant Improvement in Quality and Reduction in Cost of Care Eric D. Newman 1, William T. Ayoub 2, David M. Pugliese 3, Chelsea Cedeno 1, Jason Brown 1, Thomas M. Harrington 1, Thomas P. Olenginski 1, Androniki Bili 1, Alfred E. Denio 1, Lisa L. Schroeder 1, Dennis Torretti 1, Tarun Sharma 1, Lyudmila Kirillova 1, Susan Mathew 1, Jonida Cote 1, Brian Oppermann 2, Cynthia Sullivan 2, Shantanu Bishwal 4, Brian DelVecchio 3 and Howard Aylward 2, 1 Geisinger Health System, Danville, PA, 2 Geisinger Health System, State College, PA, 3 Geisinger Health System, Wilkes-Barre, PA, 4 Geisinger Health System, Wilkes Barre, PA 2:45 pm Monitoring Patients with Rheumatoid Arthritis in Routine Care Experiences from a Treat-to-Target Strategy Using the Danbio Registry Merete Lund Hetland 1, Dorte Vendelbo Jensen 2 and Niels Steen Krogh 3, 1 DANBIO, Glostrup Hospital, Glostrup, Denmark, 2 DANBIO, Glostrup, Denmark, 3 ZiteLab ApS, Copenhagen, Denmark MONDAY november 17, Program Book 87

90 scientific sessions MONDAY november 17, :00 pm National Quality Forum Measure Achievement and Costs in Rheumatoid Arthritis Patients in a Large Managed Care Population Roxanne Meyer 1, Susan C. Bolge 2, Joseph Tkacz 3, Brenna Brady 3 and Charles Ruetsch 4, 1 Janssen Scientific Affairs, Horsham, PA, 2 Janssen Scientific Affairs, LLC, Horsham, PA, 3 Health Analytics, LLC, Columbia, MD, 4 Health Analytics LLC, Columbia, MD 3:15 pm Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA) Jessica Widdifield 1, Claire Bombardier 2, Jacqueline Young 1, Noah Ivers 2, R. Liisa Jaakkimainen 3, Sasha Bernatsky 4, J. Michael Paterson 1, J. Carter Thorne 5, Pooneh S.Akhavan 6, Debra Butt 1, Vandana Ahluwalia 7 and Karen Tu 1, 1 Institute for Clinical Evaluative Sciences, Toronto, ON, 2 University of Toronto, Toronto, ON, 3 Sunnybrook Health Sciences Centre, Toronto, ON, 4 McGill University Health Centre, Montreal, QC, 5 Southlake Regional Health Centre, Newmarket, Newmarket, ON, 6 Mount Sinai Hospital, Toronto, ON, 7 William Osler Health Center, Brampton, ON 3:30 pm Uptake of the American College of Rheumatology s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data Natalie Fisk 1, Melissa Francisco 1, Jinoos Yazdany 2 and Salahuddin Kazi 3, 1 American College of Rheumatology, Atlanta, GA, 2 University of California, San Francisco, San Francisco, CA, 3 UT Southwestern Medical Center, Dallas, TX 3:45 pm Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture Robert A. Overman 1 and Chad L. Deal 2, 1 University of North Carolina, Chapel Hill, NC, 2 Cleveland Clinic, Cleveland, OH 210 B Rheumatoid Arthritis Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Moderators: Lin Brown, MD and Jennifer Barton, MD 2:30 pm Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy Stephen Lindsey 1, Brandi Oufnac 2 and Holly Walker 2, 1 Ochsner Clinic Baton Rouge, Baton Rouge, LA, 2 Ochsner Health Systems, Baton Rouge, LA 2:45 pm First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis Louise Mercer 1, Xavier Mariette 2, William Dixon 1, Eva Baecklund 3, Karin Hellgren 4, Lene Dreyer 5, Merete Lund Hetland 6, Lene Mellemkjær 7, Kimme Hyrich 8, Anja Strangfeld 9, Angela Zink 10, Helena Canhao 11, Fernando Martins 12, Victoria Hernández 13, Florence Tubach 14, Jacques-Eric Gottenberg 15, Jacques Morel 16, Jakub Zavada 17, Piet van Riel 18, Axel Finckh 19, Florenzo Iannone 20, Johan Askling 4 and Joachim Listing 9, 1 The University of Manchester, Manchester, United Kingdom, 2 Université Paris-Sud, Le Kremlin Bicêtre, France, 3 Uppsala University, Uppsala, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Copenhagen University Hospital at Gentofte, Gentofte, Denmark, 6 DANBIO, Glostrup Hospital, Glostrup, Denmark, 7 The Danish Cancer Society, Copenhagen, Denmark, 8 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 9 German Rheumatism Research Center, Berlin, Germany, 10 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 11 Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, 12 Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, 13 BIOBADASER Registry, Madrid, Spain, 14 Universite Paris Diderot, Paris, France, 15 Department of rheumatology CHU, Strasbourg, France, 16 Universite Montpellier, Montpellier, France, 17 Charles University, Prague, Czech Republic, 18 Radboud University Medical Centre, Nijmegen, Netherlands, 19 University of Geneva, Geneva, Switzerland, 20 Reumatologia Universita e Policlinico di Bari, Bari, Italy 3:00 pm No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers Louise Mercer 1, Johan Askling 2, Pauline Raaschou 2, William Dixon 1, Lene Dreyer 3, Merete Lund Hetland 4, Lene Mellemkjær 5, Anja Strangfeld 6, Angela Zink 7, Florenzo Iannone 8, Axel Finckh 9, Jakub Zavada 10, Helena Canhao 11, Fernando Martins 12, Xavier Mariette 13, Jacques Morel 14, Jacques-Eric Gottenberg 15, Adele Green 1, Victoria Hernández 16, Florence Tubach 17, Piet van Riel 18, Kimme Hyrich 19 and Joachim Listing 6, 1 The University of Manchester, Manchester, United Kingdom, 2 Karolinska Institutet, Stockholm, Sweden, 3 Copenhagen University Hospital at Gentofte, Gentofte, Denmark, 4 DANBIO, Glostrup Hospital, Glostrup, Denmark, 5 The Danish Cancer Society, Copenhagen, Denmark, 6 German Rheumatism Research Center, Berlin, Germany, 7 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 8 Reumatologia Universita e Policlinico di Bari, Bari, Italy, 9 University of Geneva, Geneva, Switzerland, 10 Charles University, Prague, Czech Republic, 11 Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, 12 Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, 13 Université Paris-Sud, Le Kremlin Bicêtre, France, 14 Universite Montpellier, Montpellier, France, 15 Department of rheumatology CHU, Strasbourg, France, 16 BIOBADASER Registry, Madrid, Spain, 17 Universite Paris Diderot, Paris, France, 18 Radboud University Medical Centre, Nijmegen, Netherlands, 19 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom Program Book

91 scientific sessions 3:15 pm Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis Frank I Scott 1, Ronac Mamtani 1, Colleen Brensinger 1, Kevin Haynes 2, Zelma ChiesaFuxench 1, Huifeng Yun 3, Jie Zhang 4, Lang Chen 5, Fenglong Xie 5, David Margolis 1, James D. Lewis 2 and Jeffrey R. Curtis 6, 1 University of Pennsylvania, Philadelphia, PA, 2 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 4 Univ. of Alabama at Birmingham, Birmingham, AL, 5 University of Alabama at Birmingham, Birmingham, AL, 6 The University of Alabama at Birmingham, Birmingham, AL 3:30 pm Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy M Kumar 1, L Ray 1, S Vemuri 2 and T Simon 1, 1 Bristol-Myers Squibb, Hopewell, NJ, 2 Bristol-Myers Squibb, Plainsboro, NJ Johannes W.J. Bijlsma 4, Bart van den Bemt 1 and Alfons A. den Broeder 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 3 Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 4 University Medical Center Utrecht, Utrecht, Netherlands 3:00 pm Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data Jeffrey R. Curtis 1, Melvin Churchill 2, Alan Kivitz 3, Laura Gauer 4, Christopher Herrem 4, David Carter 5, Jeffrey Melin 4 and Yusuf Yazici 6, 1 The University of Alabama at Birmingham, Birmingham, AL, 2 Arthritis Center of Nebraska, Lincoln, NE, 3 Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 4 UCB Pharma, Smyrna, GA, 5 UCB Pharma, Brussels, Belgium, 6 New York University Hospital for Joint Diseases, New York, NY 3:45 pm Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease Elena Nikiphorou 1, Lewis Carpenter 1, Sam Norton 2, Josh Dixey 3, Patrick Kiely 4, David Walsh 5 and Adam Young 6, 1 University of Hertfordshire, Hatfield, United Kingdom, 2 King s College London, London, United Kingdom, 3 New Cross Hospital, Wolverhampton, United Kingdom, 4 St. Georges Healthcare NHS Trust, London, United Kingdom, 5 University of Nottingham, Nottingham, United Kingdom, 6 ERAS, St Albans City Hospital, St Albans, United Kingdom Exhibit Hall C Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Moderators: Maarten Boers, MD, MSc, PhD and Mark C. Genovese, MD 2:30 pm High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry Kazuki Yoshida 1, Mitsumasa Kishimoto 2, Helga Radner 1, Kazuo Matsui 3, Masato Okada 2, Yukihiko Saeki 4, Daniel H. Solomon 1 and Shigeto Tohma 5, 1 Brigham and Women s Hospital, Boston, MA, 2 St. Luke s International Hospital, Tokyo, Japan, 3 Kameda Medical Center, Kamogawa, Japan, 4 Osaka-Minami Medical Center, Osaka, Japan, 5 Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan 2:45 pm Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis Noortje van Herwaarden 1, Aatke van der Maas 1, Michiel Minten 1, Frank H.J. van den Hoogen 2, Ronald F. van Vollenhoven 3, 3:15 pm Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial Gerd Burmester 1, William Rigby 2, Ronald F. van Vollenhoven 3, Jonathan Kay 4, Andrea Rubbert-Roth 5, Ricardo Blanco 6, Ariella Kelman 7, Sophie Dimonaco 8 and Nina Mitchell 8, 1 Charité- Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2 Geisel School of Medicine at Dartmouth, Lebanon, NH, 3 Karolinska Institute, Stockholm, Sweden, 4 UMass Memorial Medical Center, Worcester, MA, 5 University of Cologne, Cologne, Germany, 6 Hospital Marques de Valdecilla, Santander, Spain, 7 Genentech, South San Francisco, CA, 8 Roche Products Ltd., Welwyn Garden City, United Kingdom 3:30 pm The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients Michael Shapiro 1 and Yair Levy 2, 1 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2 Meir Medical Center, Kfar Saba, Israel 3:45 pm Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate Josef S. Smolen 1, David Collier 2, Annette Szumski 3, Heather Jones 3 and Lisa Marshall 3, 1 PsAID taskforce, EULAR, Zurich, Switzerland, 2 Amgen, Inc., Thousand Oaks, CA, 3 Pfizer Inc., Collegeville, PA 2014 Program Book 89 MONDAY november 17, 2014

92 scientific sessions MONDAY november 17, B Spondyloarthropathies and Psoriatic Arthritis III Clinical Aspects of Psoriatic Arthritis Moderators: Arthur Kavanaugh, MD and Enrique R. Soriano, MD, MSc 2:30 pm Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition Karen M. Fagerli 1, Louise K. Mercer 2, Kath D. Watson 2, Jonathon Packham 3, Deborah Symmons 4, Kimme L. Hyrich 5 and. On behalf of the BSRBR 6, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 3 Institute of Science and Technology in Medicine, Keele, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 6 British Society for Rheumatology, London, United Kingdom 2:45 pm Risk of Malignancy Among Medicare Psoriasis/Psoriatic Arthritis Patients Huifeng Yun 1, Kevin L. Winthrop 2, Lang Chen 3, Wilson Smith 3, Benjamin Chan 4, Fenglong Xie 3, Allison Taylor 3 and Jeffrey R. Curtis 3, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 Oregon Health & Science University, Portland, OR, 3 University of Alabama at Birmingham, Birmingham, AL, 4 Oregon Health and Science University, Portland, OR 3:00 pm The Incidence and Risk Factors for Psa in Patients with Psoriasis a Prospective Cohort Study Lihi Eder 1, Amir Haddad 1, Hua Shen 2, Cheryl Rosen 1, Vinod Chandran 1, Richard J. Cook 2 and Dafna D. Gladman 3, 1 University of Toronto, Toronto Western Hospital, Toronto, ON, 2 University of Waterloo, Waterloo, ON, 3 Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON 3:15 pm Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience Robert Kalb 1, David Fiorentino 2, Mark Lebwohl 3, Craig Leonardi 4, John Toole 5, Kavitha Goyal 6, Steve Calabro 6, Wayne Langholff 7 and Steve Fakharzadeh 8, 1 SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, 2 Stanford University, Redwood City, CA, 3 Mount Sinai Medical Center, New York, NY, 4 Central Dermatology, St. Louis, MO, 5 University of Manitoba, Dermadvances Research, Winnipeg, MB, 6 Janssen Services, LLC, Horsham, PA, 7 Janssen Research and Development, LLC, Spring House, PA, 8 Janssen Services, LLC, Spring House, PA 2014 Program Book 3:30 pm Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study Katelynn Wilton 1, Floranne C. Ernste 1, Cynthia S. Crowson 2, Eric L. Matteson 2, Hilal Maradit Kremers 2 and Marta Sánchez- Menéndez 3, 1 Mayo Clinic Rochester, Rochester, MN, 2 Mayo Clinic, Rochester, MN, 3 Centro Medico de Asturias, Oviedo, Spain 3:45 pm Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry Philip Mease 1, David Collier 2, Chitra Karki 3, Guo Li 4, Bojena Bitman 5 and Jeffrey D. Greenberg 6, 1 Swedish Medical Center, Seattle, WA, 2 Amgen, Inc., Thousand Oaks, CA, 3 Corrona, LLC., Southborough, MA, 4 Axio Research LLC, Seattle, WA, 5 Amgen, Inc., San Francisco, CA, 6 New York University School of Medicine, New York, NY Ballroom West Systemic Lupus Erythematosus Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Moderators: S. Sam Lim, MD, MPH and Iris Navarro-Millan, MD 2:30 pm Systemic Lupus Erythematosus Patients Have Increased Risk of Short Term Adverse Events after Total Hip Arthroplasty Jordan Roberts 1, Lisa A. Mandl 2, Edwin Su 2, David J. Mayman 2, Mark P. Figgie 2, Arielle Fein 2, Yuo-Yu Lee 2, Ummara Shah 3 and Susan M. Goodman 2, 1 Weill Cornell Medical College, New York, NY, 2 Hospital for Special Surgery, New York, NY, 3 New York University School of Medicine, NYC, NY 2:45 pm Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE) Ripneet Puar 1, Carol A. Hitchon 1, David B. Robinson 1, Hani El-Gabalawy 1, Navjot Dhindsa 1 and Christine A. Peschken 2, 1 University of Manitoba, Winnipeg, MB, 2 University of Manitoba, Canada, Winnipeg, MB 3:00 pm National Hospitalization Trends in Lupus Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Infections Sara G. Murray, Gabriela Schmajuk, Laura Trupin, Lianne S. Gensler and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA 3:15 pm Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use Shih-Yin Chen 1, Chan-Bum Choi 2, Qian Li 3, Wei-Shi Yeh 1, Yuan- Chi Lee 4, Amy H Kao 1 and Matthew H. Liang 5, 1 Biogen Idec,

93 scientific sessions Cambridge, MA, 2 VA Healthcare System, Boston, MA, 3 Evidera, Lexington, MA, 4 Formerly of Evidera, Lexington, MA, 5 Harvard Medical School, Boston, MA 3:30 pm Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 3:45 pm Age-Specific Predictors of Mortality in SLE Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 107 B Vasculitis II Moderators: Robert F. Spiera, MD and Sebastian H. Unizony, MD 2:30 pm Serum Calprotectin and Disease Relapse in ANCA- Associated Vasculitis Juliana B Draibe 1, Ruth J. Pepper 1, Peter A. Merkel 2, Alan D. Salama 1 and for The RAVE-ITN Investigators 3, 1 University College London, London, United Kingdom, 2 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 3 Immune Tolerance Network, San Francisco, CA 2:45 pm The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis Antoine G. Sreih 1, Rana Ezzeddine 2, Juan Fan 3, Lin Leng 3, Simon Carette 4, David Cuthbertson 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Carol A. Langford 8, Carol McAlear 9, Paul Monach 10, Philip Seo 11, Ulrich Specks 12, Steven R. Ytterberg 12, Peter A. Merkel 13 and Richard Bucala 14, 1 The University of Pennsylvania, Philadelphia, PA, 2 Bristol-Myers Squibb, Wallingford, CT, 3 Yale University, New Haven, CT, 4 University of Toronto, Toronto, ON, 5 University of South Florida, Tampa, FL, 6 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 7 St. Joseph s Hospital, McMaster University, Hamilton, ON, 8 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 9 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 10 Boston University, Boston, MA, 11 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 12 Mayo Clinic, Rochester, MN, 13 Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14 Yale University School of Med, New Haven, CT 3:00 pm The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA- Associated Vasculitis Peter C. Grayson 1, Carmelo Carmona-Rivera 1, Lijing Xu 2, Noha Lim 2, Adam Asare 2, Deborah J. Phippard 2, Mariana J. Kaplan 1, Peter A. Merkel 3 and Paul A. Monach 4, 1 National Institutes of Health, Bethesda, MD, 2 Immune Tolerance Network, Bethesda, MD, 3 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 4 Vasculitis Center, Boston University School of Medicine, Boston, MA 3:15 pm CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Pirow Bekker 1, David Jayne 2, Annette Bruchfeld 3, Matthias Schaier 4, Kazimierz Ciechanowski 5, Lorraine Harper 6, Michel Jadoul 7, Mårten Segelmark 8, Daina Selga 9, Istvan Szombati 10, Michael Venning 11, Christian Hugo 12, Paul L. van Daele 13, Ondrej Viklicky 14, Antonia Potarca 15 and Thomas J. Schall 15, 1 Chemocentryx, Inc., Mountain View, CA, 2 Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 3 Karolinska Institute, Stockholm, Sweden, 4 University of Heidelberg, Heidelberg, Germany, 5 Pomeranian Medical University, Szczecin, Poland, 6 University of Birmingham, Birmingham, United Kingdom, 7 Cliniques Saint-Luc, Brussels, Belgium, 8 Linkoping University, Linkoping, Sweden, 9 Lund University, Lund, Sweden, 10 Budaclinic, Budapest, Hungary, 11 Manchester University, Manchester, United Kingdom, 12 Dresden University, Dresden, Germany, 13 Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 14 Instit of Clin and Exp Med, Prague, Czech Republic, 15 ChemoCentryx, Inc., Mountain View, CA 3:30 pm Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of Comparing Azathioprine Vs Methotrexate for Remission-Maintenance in 126 Patients Xavier Puéchal 1, Christian Pagnoux 2, Elodie Perrodeau 3, Mohamed Hamidou 4, Jean-Jacques Boffa 5, Xavier Kyndt 6, François Lifermann 7, Thomas Papo 8, Dominique Merrien 9, Amar Smail 10, Philippe Delaval 11, Catherine Hanrotel-Saliou 12, Bernard Imbert 13, Chahéra Khouatra 14, Marc Lambert 15, Charles Leské 16, Kim Heang Ly 17, Edouard Pertuiset 18, Pascal Roblot 19, Marc Ruivard 20, Jean-François Subra 21, Jean-Francois Viallard 22, Benjamin Terrier 1, Pascal Cohen 1, Luc Mouthon 1, Philippe Ravaud 3 and Loïc Guillevin for the French Vasculitis Study Group 1, 1 National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, Paris, France, 2 University of Toronto, Toronto, ON, 3 Epidemiology, Université Paris-Descartes, Paris, Paris, France, 4 CHU Hôtel Dieu, Nantes, Nantes, France, 5 Hôpital Tenon, Paris, Paris, France, 6 CH, Valenciennes, Valenciennes, France, 7 CH Côte d Argent, Dax, Dax, France, 8 Bichat Hospital, Paris, Paris, France, 9 CH Compiègne-Noyon, Compiègne, France, 10 CHU Amiens Nord, Amiens, France, 11 CHU Rennes Sud, Rennes, France, 12 CHU Cavale Blanche, Brest, Brest, France, 13 CHU, Grenoble, Grenoble, France, 14 CHU Louis Pradel, Lyon, Lyon, France, 15 Internal Medicine University Lille Hospital, Lille, Lille, France, 16 CH, Cholet, Cholet, France, 17 CHU Dupuytren, Limoges, Limoges, France, 18 René Dubos Hospital, Pontoise, France, 19 CHU, Poitiers, Poitiers, 2014 Program Book 91 MONDAY november 17, 2014

94 scientific sessions France, 20 CHU Estaing, Clermont Ferrand, Clermont Ferrand, France, 21 CHU, Angers, Angers, France, 22 Hôpital Haut-Lévêque, Bordeaux, CHU Bordeaux, France 3:45 pm Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study Neda Amiri 1, Natasha Dehghan 1, Eric C. Sayre 2, Kamran Shojania 1 and J. Antonio Avina-Zubieta 2, 1 University of British Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada, Richmond, BC ACR/ARHP COMBINED ABSTRACT SESSION 2:30 4:00 pm 3:15 pm Child Pain, Function and Psychological Outcomes in an Intensive Interdisciplinary Pediatric Pain Rehabilitation Program Cara Hoffart, Rawni Anderson, Amy Chapman, Brandi Dorton, Danielle Feltrop, Misty Wilson and Dustin Wallace, Children s Mercy Hospital, Kansas City, MO 3:30 pm Children and Parent Satisfaction in the Pediatric Rheumatology Clinic: Patient Orientated Quality Service Measures Jenny Tekano 1, Lori B. Tucker 2 and Audrea Chen 3, 1 BC Children s Hospital, Vancouver, BC, 2 BC Children s Hospital and University of British Columbia, Vancouver, BC, 3 research student, Vancouver, BC MONDAY november 17, A ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Ed Pd PrM FIT Moderators: Marisa S. Klein-Gitelman, MD, MPH and Bryce A. Binstadt, MD, PhD 2:30 pm Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis Debbie Ehrmann Feldman 1, Evelyne Vinet 2, Sasha Bernatsky 3, Ciaran Duffy 4, Elizabeth Hazel 5, Marie-Pierre Sylvestre 1, Garbis Meshefedjian 6 and Anick Bérard 1, 1 Université de Montréal, Montréal, QC, 2 McGill University Health Center, Montreal, QC, 3 McGill University, Montreal, QC, 4 Children s Hospital of Eastern Ontario, Ottawa, ON, 5 McGill University Health Center, Montreal, QC, 6 Public Health Department of Montreal, Montreal, QC 2:45 pm Mandibular Movement in Healthy Individuals from 4-17 Years of Age Peter Stoustrup 1, Kasper Dahl Kristensen 2, Annelise Küseler 3, Thomas Klit Pedersen 4 and Troels Herlin 4, 1 University of Aarhus, Aarhus C, Denmark, 2 Specialist Oral Health Center for Western Norway, Rogaland Stavanger, Norway, 3 Aarhus University, Aarhus, Denmark, 4 Aarhus University Hospital, Aarhus, Denmark 3:00 pm Can DAS 28 at 3 Months after the 1 st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients? Tomohiro Kubota 1, Syuji Takei 2, Tsuyoshi Yamatou 3, Tomokazu Nagakura 4, Hiroyuki Imanaka 3, Yukiko Nonaka 3, Tomoko Takezaki 3, Harumi Akaike 3 and Mio Matsuura 5, 1 Kagoshima University Hospital, Kagoshima City, Japan, 2 Kagoshima University, Kagoshima, Japan, 3 Kagoshima University Hospital, Kagoshima, Japan, 4 House of Meguminoseibo, Usuki, Japan, 5 Kagoshima University, Kagoshima-Shi, Japan 3:45 pm Puberty and Disease Activity in JIA Philomine A. van Pelt 1, Aike.a. Kruize 2, Anita C.S. Hokken- Koelega 3, Radboud JEM Dolhain 4, Johannes WJ Bijlsma 5 and Nico M. Wulffraat 5, 1 Erasmus MC, Rotterdam, Netherlands, 2 University Medical Center Utrecht, Utrecht, Netherlands, 3 Erasmus Medical Center- Sophia Children s Hospital, Rotterdam, Netherlands, 4 Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 5 University Medical Centre Utrecht, Utrecht, Netherlands ARHP SESSIONS 2:30 4:00 pm 257 A Alternative Medicine: Presenting the Evidence for Rheumatic Conditions Moderators: Deborah McCloskey, RN, BSN and Lisa Shelton, BSc, BSN, RN evaluate the mounting evidence to support the use of acupuncture for a variety of chronic pain conditions in rheumatology describe the regulatory differences between dietary supplements, medical foods and drug products discuss safety and efficacy data on dietary supplements and medical foods utilized for rheumatic conditions 2:30 pm Efficacy of Acupuncture for Treatment of Chronic Pain Richard E. Harris, PhD 3:15 pm Dietary Supplements in Rheumatology James Torr, PharmD Program Book

95 scientific sessions 254 A Biomarkers in Rheumatic Care Moderators: Jennifer L. Trizuto, MPT and Chokkalingam Siva, MD recognize what biomarkers are explain how biomarkers can be useful tools with diagnostic and prognostic utility identify the obstacles in the validation of candidate biomarkers 2:30 pm Biomarkers in Rheumatic Care Richard D. Brasington, MD 3:00 pm Biomarkers in the Assessment of Lupus Disease Activity Chaim Putterman, MD express the importance of positive affect experiences in promoting resilience recognize how resilience can promote successful adaptation to the stresses of chronic illness 2:30 pm Temperament and Affect Balance Style: Maximizing Strengths to Promote Resilience Kim Sibille, PhD 3:00 pm Identifying Modifiable Biopsychosocial Pathways of Resilience to Chronic Illness Alex Zautra, PhD 3:30 pm Valued Life Activities and Psychological Well-Being Patricia P. Katz, PhD 256 3:30 pm Biomarkers in the Assessment of Vasculitis Peter A. Merkel, MD, MPH Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section Moderator: Robert R. McLean, DSc, MPH recognize the importance of the Specific Aims section of a research proposal describe the essential elements of a compelling Specific Aims section develop Specific Aims that effectively sell a research idea and form a partnership with reviewers enhance Specific Aims in current development based on direct feedback given by experienced investigators during breakout group review sessions 2:30 pm How to Develop a Convincing Specific Aims Section Kelli D. Allen, PhD 3:05 pm Common Pitfalls of Specific Aims and How to Avoid Them Linda C. Li, PhD, PT 3:40 pm Review of Attendees In Progress Specific Aims in Small Breakout Groups Led by Speakers Kelli D. Allen, PhD; Linda C. Li, PhD, PT 255 Thriving with Rheumatic Disease: Cultivating Resilience Moderator: Hazel L. Breland, PhD, OTR/L explain the importance of preserving valued life activities to maintain psychological well-being ACR/ARHP WORKSHO 4:00 6:00 pm 161 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Dermatopathology of Rheumatic Diseases (225) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice 152 *Joint Injections (Knee, Ankle, Shoulder and Wrist) (226) Speakers: Jemima Albayda, MD and Pari Basharat, MD describe indications for lower extremity joint injection and aspiration identify anatomic landmarks for injection of the knee and ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics MONDAY november 17, Program Book 93

96 scientific sessions MONDAY november 17, MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, Toward Better Clinical Decisions and Outcomes (227) Speaker: Theodore Pincus, MD summarize the rationale for the use of MDHAQ/RAPID3 and RHEUMDOC to help establish an agenda or road map for the encounter proficiency in scoring RAPID3 and interpretation using RHEUMDOC in using different levels of scores for clinical decisions recognize how to use other components of MDHAQ beyond RAPID3, including RADAI self-report joint count (rheumatoid arthritis disease activity index), review of systems and recent medical history and RHEUMDOC help improve doctor-patient communication and save time for the doctor. 159 *Musculoskeletal Ultrasonography: Basic (228) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP explain basic concepts of ultrasound physics assess how to perform a proper ultrasound examination identify various tissues in an ultrasound image ACR SESSION 4:30 5:30 pm Md Pd PrM FIT Ballroom East Clinicopathologic Conference: A 17-Year-Old Young Woman with Chronic Ankle and Back Pain Moderators: Simon M. Helfgott, MD and Derrick J. Todd, MD, PhD assess chronic ankle and back pain in adolescent patients determine the differences between inflammatory and noninflammatory joint pain synthesize clinical, radiologic and pathologic data in formulating a diagnosis 4:30 pm Case Presentation Derrick J. Todd, MD, PhD 4:45 pm Radiologic Findings Barbara N. Weissman, MD 5:05 pm Histologic Findings Margaret Seton, MD Ed Pd PrM FIT 5:15 am Guest Speaker Ronald Laxer, MD ACR SESSIONS 4:30 6:00 pm 204 A Career Opportunities in Rheumatology: Making a Choice Moderators: Marcy B. Bolster, MD and Kristine M. Lohr, MD, MS discuss examples of different career paths available to rheumatologists explain the pros and cons of the various career paths in rheumatology 4:30 pm Basic Research Ellen M. Gravallese, MD 4:47 pm Clinical Research Jane E. Salmon, MD 5:04 pm Clinician Educator Kenneth S. O Rourke, MD 5:21 pm Private Practice David G. Borenstein, MD 5:38 pm Industry Primal P. Kaur, MD 5:55 pm Questions and Answers Ballroom West Curbside Consults Ask the Experts Moderators: Rula Hajj-Ali, MD, Rebecca L. Manno, MD, MHS and N. Lawrence Edwards, MD compare the personal management approaches of selected clinical problems with those of the presenters develop an approach to evaluating and managing patients with a new diagnosis of granulomatosis with polyangiitis devise an approach to evaluating and managing patients with cryoglobulinemic vasculitis describe therapeutic options for common but difficult complications of the antiphospholipid syndrome Program Book

97 scientific sessions 4:30 pm A New Diagnosis of Granulomatosis with Polyangiitis: How Do I Treat This Patient? Carol A. Langford, MD 5:00 pm The Role of Wnt Signaling in Bone and Cartilage in Osteoarthritis Rik Lories, PhD, MD 5:00 pm Cryoglobulinemic Vasculitis...Help! Patrice Cacoub, MD 5:30 pm Antiphospholipid Syndrome: How Do I Approach This Patient? Robert Roubey, MD 160 B Fibrotic Complications of Scleroderma Moderators: Dinesh Khanna, MD and Virginia D. Steen, MD review the management of early skin involvement in systemic scleroderma discuss the management of lung fibrosis in systemic scleroderma explain the management of heart involvement in systemic scleroderma 4:30 pm Skin Fibrosis in Systemic Sclerosis Current Management Strategies Oliver Distler, MD 5:00 pm Management of Interstitial Lung Disease Whom to Treat Philip J. Clements, MD, MPH 5:30 pm Primary Cardiac Involvement in Systemic Sclerosis Management Strategies Yannick Allanore, MD, PhD 5:30 pm Transforming Growth Factor Beta (TGF-ß), Bone Marrow Mesenchymal Stem Cells and Osteoarthritis Xu Cao, Phd 205 B Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management Moderators: Kerry Stone, MD and Rodney Tehrani, MD Ed Pd PrM FIT develop a rational treatment approach to fibromyalgia develop a rational approach to the diagnosis and treatment of low back pain describe the etiologies and diagnosis of amplified musculoskeletal pain syndrome develop a multidisciplinary approach for the treatment of amplified musculoskeletal pain syndrome 4:30 pm Fibromyalgia Don L. Goldenberg, MD 5:00 pm Low Back Pain Rajiv Dixit, MD 5:30 pm Amplified Musculoskeletal Pain Syndrome David D. Sherry, MD ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm MONDAY november 17, A The Role of Bone in the Pathogenesis of Osteoarthritis Moderator: Richard F. Loeser, MD describe the relationship between bone marrow lesions and pain and disease progression in osteoarthritis define the biological and mechanical factors that regulate bone remodeling in osteoarthritis appraise how transforming growth factor beta in bone activates mesenchymal stem cells that contribute to osteoarthritis pathogenesis 4:30 pm The Relationship of Bone Marrow Lesions to Pain and Progression in Osteoarthritis David T. Felson, MD, MPH 253 B Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus Moderators: Evelyne Vinet, MD and Dorothy D. Dunlop, PhD 4:30 pm Gout in Older Adult Mara McAdams-DeMarco 1, Anna Kottgen 2, Bridget Burke 3, Andrew Law 4, Josef Coresh 1 and Alan N. Baer 5, 1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2 University Hospital Freiburg, Freiburg, Germany, 3 Johns Hopkins University, Baltimore, MD, 4 Johns Hopkins, Baltimore, MD, 5 Johns Hopkins University School of Medicine, Baltimore, MD 4:45 pm Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study Gim Gee Teng 1, An Pan 2, Jian-Min Yuan 3 and Woon-Puay Koh 4, 1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 2 Saw Swee Hock School 2014 Program Book 95

98 scientific sessions MONDAY november 17, of Public Health, National University of Singapore, Singapore, Singapore, 3 Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute and Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 4 Duke-NUS Graduate Medical School Singapore, Singapore, Singapore 5:00 pm Obesity Paradox in Recurrent Gout a Metrological Clarification and Remedy Uyen Sa D.T. Nguyen 1, Qiong Louie-Gao 1, Yuqing Zhang 1, David T. Felson 1, Michael P. Lavalley 2 and Hyon Choi 3, 1 Boston University School of Medicine, Boston, MA, 2 Boston University, Boston, MA, 3 Harvard Medical School, Boston, MA 5:15 pm Can Allopurinol Survival Impact Reverse Depending on Patients Characteristics? a Propensity-Score-Based Subgroup Analysis Na Lu 1, Hyon Choi 2, Maureen Dubreuil 3, Qiong Louie-Gao 1 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Boston University Medical Center, Boston, MA 5:30 pm Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses Health Studies Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks, Elizabeth W. Karlson and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 5:45 pm Pregnancy Outcomes in SLE: Before and after Elizabeth V. Arkema 1, Kristin Palmsten 2, Christopher Sjöwall 3, Elisabet Svenungsson 4, Jane E. Salmon 5 and Julia F Simard 6, 1 Karolinska Institutet, Stockholm, Sweden, 2 University of California, San Diego, La Jolla, CA, 3 Linköping University, Linköping, Sweden, 4 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5 Hospital for Special Surgery, New York, NY, 6 Stanford School of Medicine, Stanford, CA 104 B Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives Moderators: Muhammad Yunus, MD and Lisa Suter, MD 4:30 pm A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study William Pridgen 1, Carol Duffy 2, Judith Gendreau 3 and R Michael Gendreau 3, 1 Innovative Med Concepts, Tuscaloosa, AL, 2 University of Alabama, Tuscaloosa, AL, 3 Gendreau Consulting, LLC, Poway, CA 2014 Program Book 4:45 pm The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain Andrew Clair and Birol Emir, Pfizer Inc, New York, NY 5:00 pm Moderate Alcohol Consumption Is Associated with Lower Risk (and severity) of Chronic Widespread Pain: Results from a Population-Based Study Gary J. Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom 5:15 pm Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia Robert S. Katz 1 and Jessica L. Polyak 2, 1 Rush Medical College, Chicago, IL, 2 Rheumatology Associates, Chicago, IL 5:30 pm Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice Sonali N. Shah 1, Rachel Halpern 2, Joseph C. Cappelleri 3, Elizabeth T. Masters 4, Andrew G. Clair 1, Cori Blauer-Peterson 2 and Damon Van Voorhis 5, 1 Pfizer, Inc., New York, NY, 2 Optum, Eden Prairie, MN, 3 Pfizer, Inc., Groton, CT, 4 Pfizer Inc, New York, NY, 5 Optum Life Sciences, Eden Prairie, MN 5: WITHDRAWN 156 B Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Moderators: Patrick Gaffney, MD and Amr Sawalha, MD 4:30 pm Differential DNA Methylation Associated with Rheumatoid Arthritis in Disease Discordant Monozygotic Twins Amy Webster 1, Flore Zufferey 2, Darren Plant 3, Anne Barton 4, Frances Williams 2 and Jane Worthington 5, 1 Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2 Dept Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom, 3 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, 5 The University of Manchester, Manchester, United Kingdom 4:45 pm Integrative Omics Profiling Reveals Dysregulated Novel Pathways Mediated By micrornas and DNA Methylation in Osteoarthritis Kathleen M. Fisch 1, Ryuichiro Akagi 2, Oscar Alvarez-Garcia 1, Takeshi Teramura 1, Yuta Muramatsu 1, Masahiko Saito 3, Stuart

99 scientific sessions Duffy 1, Shawn Grogan 1, Takahisa Sasho 4, Darryl D Lima 1, Andrew I. Su 1 and Martin K. Lotz 1, 1 The Scripps Research Institute, La Jolla, CA, 2 The Scripps Research Institute, San Diego, CA, 3 Toho University Sakura Medical Center, Sakura, Japan, 4 Chiba University School of Medicine, Chiba, Japan Indianapolis, IN, 5 Daiich Sankyo Co. Ltd, Tokyo, Japan, 6 Daiichi Sankyo Co. Ltd, Tokyo, Japan, 7 University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, 8 Leiden University Medical Center, Leiden, Netherlands, 9 Keio University School of Medicine, Tokyo, Japan 5:00 pm A Novel Monocyte-Specific Transcript Underlies the Chromosome 21q22 Intergenic Genetic Association in Ankylosing Spondylitis Katelin Haynes, Tony Kenna, Evgeny Glazov, Matthew A. Brown and Gethin Thomas, University of Queensland Diamantina Institute, Brisbane, Australia 5:15 pm Genome-Wide DNA Methylation Analysis of Twin Pairs Discordant for Systemic Sclerosis Reveals Distinct Signatures in Blood and Dermal Fibroblasts Paula S. Ramos 1, Rick Jordan 2, James Lyons-Weiler 2, Thomas A. Medsger Jr. 2 and Carol A. Feghali-Bostwick 1, 1 Medical University of South Carolina, Charleston, SC, 2 University of Pittsburgh, Pittsburgh, PA 5:30 pm PU.1, Mitf and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation Heather Carey 1, Sankha Ghosh 1, Eason Hildreth III 1, Jennifer Cabrera 1, Dias Kurmashev 1, Wael N. Jarjour 2, Ramiro Toribio 1, Sudarshana Sharma 1 and Michael Ostrowski 1, 1 The Ohio State University, Columbus, OH, 2 The Ohio State University Wexner Medical Center, Columbus, OH 5:45 pm Rheumatoid Arthritis (RA)-Associated Risk Allele LBH Alters the Function of a Differentially Methylated LBH Enhancer Deepa Hammaker 1, Gary S. Firestein 2, Wei Wang 3, John W. Whitaker 4 and Anna-Karin Ekwall 5, 1 University of California San Diego, La Jolla, CA, 2 University of California at San Diego School of Medicine, La Jolla, CA, 3 UCSD, La Jolla, CA, 4 UCSD, San Diego, CA, 5 UC San Diego, La Jolla, CA 52 A Imaging of Rheumatic Diseases: X-Ray, MRI and CT Moderators: Charles Peterfy, MD, PhD and Orrin M. Troum, MD 4:30 pm Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis Naoki Ishiguro 1, Yoshiya Tanaka 2, Hisashi Yamanaka 3, Toshiyuki Yoneda 4, Takeshi Ohira 5, Naoki Okubo 6, Harry K. Genant 7, Desiree van der Heijde 8 and Tsutomu Takeuchi 9, 1 Nagoya University Graduate School of Medicine, Nagoya, Japan, 2 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 4 Indiana University School of Medicine, 4:45 pm Early MRI Endpoints Provide a Valid Measure of Structural Damage While Reducing Study Duration and Participant Numbers in Rheumatoid Arthritis Clinical Trials Joshua Baker 1, Philip G. Conaghan 2, Paul Emery 3, Daniel Baker 4 and Mikkel Østergaard 5, 1 Philadelphia VA Medical Center, Philadelphia, PA, 2 University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4 Janseen R&D, Spring House, PA, 5 Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark 5:00 pm In Vivo Visualization of Cortical Microchannels in Metacarpal Bones in Patients with Cutaneous Psoriasis By High Resolution Peripheral Computed tomography - Detecting Cortical Pathologies before the Clinical Onset of Psoriatic Arthritis David Simon, Francesca Faustini, Arnd Kleyer, Judith Haschka, David Werner, Axel J. Hueber, Michael Sticherling, Georg Schett and Juergen Rech, University of Erlangen-Nuremberg, Erlangen, Germany 5:15 pm Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation WP Maksymowych 1, S Wichuk 1, H Jones 2, A Szumski 2, L Marshall 2, J Bukowski 2 and RG Lambert 1, 1 University of Alberta, Edmonton, AB, 2 Pfizer Inc., Collegeville, PA 5:30 pm Is It Worth to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis Manouk de Hooge 1, Jean-Baptiste Pialat 2, Antoine Feydy 3, Monique Reijnierse 1, Pascal Claudepierre 4, Alain Saraux 5, Maxime Dougados 3 and Désirée van der Heijde 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Hôpital Edouard Herriot, Lyon, France, 3 Descartes University, Cochin Hospital, Paris, France, 4 Henri Mondor Teaching Hospital, Creteil, France, 5 CHU de la Cavale Blanche, Brest Cedex, France 5:45 pm Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis Pamela Weiss 1, Rui Xiao 2 and Nancy Chauvin 1, 1 Children s Hospital of Philadelphia, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, PA 2014 Program Book 97 MONDAY november 17, 2014

100 scientific sessions MONDAY november 17, B Pediatric Rheumatology Pathogenesis and Genetics Ed Pd PrM FIT Moderators: Karyl Barron, MD, PhD and Nora G. Singer, MD 4:30 pm Validation of a Novel IFN-Regulated Gene Score As Biomarker in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Patients on Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept Hanna Kim 1, Steve Brooks 2, Yin Liu 1, Adriana Almeida de Jesus 1, Gina A. Montealegre Sanchez 1, Dawn C. Chapelle 1, Nicole Plass 1, Yan Huang 1 and Raphaela Goldbach-Mansky 1, 1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2 NIAMS/NIH, Bethesda, MD 4:45 pm Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma Kathryn S. Torok 1, Katherine Kurzinski 2, Christina Kelsey 3, Kelsey Magee 4, Jonathan Yabes 4, Abbe N. Vallejo 4, Thomas A. Medsger Jr. 4 and Carol A. Feghali-Bostwick 5, 1 Children s Hospital of Pittsburgh of UC, Pittsburgh, PA, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3 University of Pittsburgh/UC, Pittsburgh, PA, 4 University of Pittsburgh, Pittsburgh, PA, 5 Medical University of South Carolina, Charleston, SC 5:00 pm Identification of autoinflammatory interferonopathies? a New Class of Autoinflammatory Conditions? Adriana Almeida de Jesus 1, Zuoming Deng 1, Stephen Brooks 2, Yin Liu 1, Hanna Kim 1, Gina A. Montealegre Sanchez 1, Dawn C. Chapelle 1, Yan Huang 1, Philip Hashkes 3, Gulnara Nasrullayeva 4, Maria Teresa Terreri 5, Bita Arabshahi 6, Marilynn G. Punaro 7, Lakshmi N. Moorthy 8, Adam Reinhardt 9, Clovis A. Silva 10, Emilia I. Sato 11, Vibke Lilleby 12, Thomas Fleisher 13 and Raphaela Goldbach- Mansky 1, 1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2 NIAMS/NIH, Bethesda, MD, 3 Shaare Zedek Medical Center, Jerusalem, Israel, 4 Azerbaijan Medical University, Baku, Azerbaijan, 5 University of Federal De Sao Paulo, Sao Paulo, Brazil, 6 Inova Fairfax Hospital for Children, Fairfax, VA, 7 University of Texas Southwestern Medical Center, Dallas, TX, 8 Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, 9 Children s Specialty Physicians, Omaha, NE, 10 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 11 Escola Paulista de Medicina Universidade Federal de São Paulo, Sao Paulo, Brazil, 12 Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 13 National Institutes of Health, Bethesda, MD 5:15 pm Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis Julia Rood 1, Portia Kreiger 2, Erietta Stelekati 1, E. John Wherry 1 and Edward M. Behrens 3, 1 Perelman School of Medicine at the 2014 Program Book University of Pennsylvania, Philadelphia, PA, 2 Alfred I. dupont Hospital for Children, Wilmington, DE, 3 The Children s Hospital of Philadelphia, Philadelphia, PA 5:30 pm HLA-DRB1*1101, Regulatory Variants of the MHC and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis Michael J. Ombrello 1, Elaine F. Remmers 2, Ioanna Tachmazidou 3, Alexei Grom 4, Dirk Föll 5, Alberto Martini 6, Marco Gattorno 7, Seza Ozen 8, Sampath Prahalad 9, Andrew S. Zeft 10, John F. Bohnsack 11, Norman T. Ilowite 12, Jane L. Park 13, Elizabeth D. Mellins 13, Ricardo A. G. Russo 14, Claudio A. Len 15, Sheila K. Feitosa de Oliveira 16, Rae SM Yeung 17, Lucy R. Wedderburn 18, Jordi Anton 19, Tobias Schwarz 20, Buhm Han 21, Richard H. Duerr 22, Jean-Paul Achkar 10, M. Ilyas Kamboh 22, Kenneth M. Kaufman 23, Leah C. Kottyan 4, Dalila Pinto 24, Stephen Scherer 17, Marta E. Alarcón-Riquelme 25, Elisa Docampo Martinez 26, Xavier Estivill 27, Ahmet Gul 28, Colleen Satorius 29, Paul I.W. de Bakker 30, Soumya Raychaudhuri 21, Carl D. Langefeld 31, Susan D. Thompson 4, Eleftheria Zeggini 3, Wendy Thomson 32, Daniel L. Kastner 29, Patricia Woo 33 and International Childhood Arthritis Genetics (INCHARGE) Consortium, 1 National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3 The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 University Children s Hospital Muenster, Muenster, Germany, 6 University of Genova, Genova, Italy, 7 Instituto Giannina Gaslini, Genoa, Italy, 8 Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 9 Emory University School of Medicine, Atlanta, GA, 10 Cleveland Clinic, Cleveland, OH, 11 University of Utah, Salt Lake City, UT, 12 Albert Einstein College of Medicine, Bronx, NY, 13 Stanford University Medical Center, Stanford, CA, 14 Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 15 Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, 16 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 17 The Hospital for Sick Children, Toronto, ON, 18 University College London (UCL) Institute of Child Health, London, United Kingdom, 19 Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, 20 University of Wuerzburg, Wuerzburg, Germany, 21 Broad Institute of MIT and Harvard, Cambridge, MA, 22 University of Pittsburgh, Pittsburgh, PA, 23 Cincinnati Children s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 24 Icahn School of Medicine at Mount Sinai, New York, NY, 25 Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 26 GIGA-Université de Liège, LIege, Belgium, 27 Center for Genomic Regulation, Barcelona, Spain, 28 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 29 National Human Genome Research Institute, Bethesda, MD, 30 University Medical Center Utrecht, Utrecht, Netherlands, 31 Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 32 Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 33 University College London, London, United Kingdom

101 scientific sessions 5:45 pm Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sjia). High Levels in Patients and a Role in a Murine MAS Model Claudia Bracaglia 1, Ivan Caiello 1, Kathy De Graaf 2, Giovanni D Ario 2, Florence Guilhot 2, Walter Ferlin 2, Lidia Meli 1, Giusi Prencipe 1, Sergio Davì 3, Grant Schulert 4, Angelo Ravelli 5, Alexei Grom 4, Cristina De Min 2 and Fabrizio De Benedetti Sr. 1, 1 Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2 Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 3 Istituto Giannina Gaslini, Genova, Italy, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Istituto Giannina Gaslini and University of Genova, Genova, Italy 258 B Rheumatoid Arthritis Clinical Aspects IV: Promising Biomarkers Moderators: S. Louis Bridges Jr., MD, PhD and Kristen Demoruelle, MD 4:30 pm Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity Michelle Ormseth 1, Cecilia P. Chung 1, Joseph F. Solus 1, Annette M. Oeser 1, Margery A. Connelly 2, Jim Otvos 2 and C Michael Stein 1, 1 Vanderbilt University, Nashville, TN, 2 LipoScience, Inc., Raleigh, NC 4:45 pm Change in η Expression in Early RA Patients Treated with DMARDs Corresponds with Change in DAS28 and Good EULAR Responses Dirkjan van Schaardenburg 1, Mairead Murphy 2, Yuan Gui 2, Samina Turk 1, Walter P. Maksymowych 3 and Anthony Marotta 2, 1 Reade, Amsterdam, Netherlands, 2 Augurex Life Sciences Corp., North Vancouver, BC, 3 University of Alberta, Edmonton, AB 5:00 pm Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis M. Kristen Demoruelle 1, Anthony Kahr 1, Mark C. Parish 1, Marie L. Feser 1, Ryan W. Gan 2, Jason R. Kolfenbach 1, William R. Gilliland 3, Jess D. Edison 3, Michael H. Weisman 4, James R. O Dell 5, Ted R. Mikuls 6, Richard M. Keating 7, Peter K. Gregersen 8, Jane H. Buckner 9, Jill M. Norris 2, V. Michael Holers 1 and Kevin D. Deane 1, 1 University of Colorado School of Medicine, Aurora, CO, 2 Colorado School of Public Health, Aurora, CO, 3 Walter Reed National Military Medical Center, Bethesda, MD, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 5 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7 Scripps Clinic, La Jolla, CA, 8 Feinstein Institute for Medical Research, Manhasset, NY, 9 Benaroya Research Institute at Virginia Mason, Seattle, WA 5:15 pm Within-Day Variation and Influence of Physical Exercise on Circulating Galectin-3 in Patients with Rheumatoid Arthritis and Healthy Individuals Saida Farah Issa 1, Anne Friesgaard Christensen 2, Tine Lottenburger 2, Kirsten Junker 3, Hanne M. Lindegaard 1, Kim Hoerslev-Petersen 4 and Peter Junker 1, 1 Department of Rheumatology, Odense University Hospital, Odense, Denmark, 2 Department of Rheumatology, Vejle Hospital, Vejle, Denmark, 3 Institute of Molecular Medicine, Cardiovascular & Renal Research, University of Southern Denmark, Odense, Denmark, 4 Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark 5:30 pm IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis Atsuma Nishiwaki 1, Hitomi Kobayashi 1, Yasuyuki Kobayashi 2, Isamu Yokoe 1, Noboru Kitamura 1, Hidetake Shiraiwa 1, Takamasa Nozaki 1, Hirotake Inomata 1, Natsumi Ikumi 1, Kaita Sugiyama 1, Yousuke Nagasawa 1 and Masami Takei 3, 1 Nihon University School of Medicine, Tokyo, Japan, 2 St.Marianna University School of Medicine, Kawasaki, Japan, 3 Nihon University School of Medicine, Itabashi Tokyo, Japan 5:45 pm Clinical Evaluation of Anti-Aminoacyl trna Synthase Antibodies in Rheumatoid Arthritis Patients Masakazu Matsushita, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Juntendo University School of Medicine, Tokyo, Japan Exhibit Hall C Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Cardiovascular and Other Systems Moderators: Gerd Burmester, MD and Alan K. Matsumoto, MD 4:30 pm Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014 A. Marren 1, Y. Chen 1, D. Frazier 2 and J. Geier 3, 1 Pfizer Inc, Collegeville, PA, 2 Pfizer Inc, Groton, CT, 3 Pfizer Inc, New York, NY 4:45 pm Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Alper van Sijl 1, Mamas Mamas 2, Mark Lunt 3,. BSRBR Control Centre Consortium 4, Kath Watson 5, Deborah P. Symmons 4 and Kimme L. Hyrich 6, 1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2 Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; MONDAY november 17, Program Book 99

102 scientific sessions MONDAY november 17, 2014 Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, 3 University of Manchester, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 5 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom 5:00 pm Risk of Hypersensitivity Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics Huifeng Yun 1, Fenglong Xie 2, Lang Chen 2, James Lewis 3 and Jeffrey R. Curtis 2, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 University of Pennsylvania, Philadelphia, PA 5:15 pm Disease Modifying Anti-Rheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients with Early Rheumatoid Arthritis: A Retrospective Cohort Study Rishi Desai, Wesley Eddings, Katherine Liao, DH Solomon and Seoyoung C. Kim, Brigham and Women s Hospital, Boston, MA 5:30 pm Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency Shunsuke Mori, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan 5:45 pm Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases Silvia Rollefstad 1, Eirik Ikdahl 1, Jonny Hisdal 2, Inge C. Olsen 1, Ingar Holme 3, Hilde Berner Hammer 1, Knut T. Smerud 4, G Kitas 5, Terje R. Pedersen 6, Tore K. Kvien 7 and Anne Grete Semb 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Uslo University Hospital-Aker, Oslo, Norway, 3 Oslo University Hospital, Oslo, Norway, 4 Smerud Medical Research International AS, Oslo, Norway, 5 The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, 6 University of Oslo, Oslo, Norway, 7 PsAID taskforce, EULAR, Zurich, Switzerland 153 B Spondyloarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines Moderators: Christopher T. Ritchlin, MD, MPH and Robert D. Inman, MD 4:30 pm IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis Anita T. Shaw 1, Yukiko Maeda 1, Catherine Manning 1 and Ellen M. Gravallese 2, 1 University of Massachusetts Medical School, Worcester, MA, 2 UMass Memorial Medical Center, Worcester, MA 4:45 pm IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R + /CD4 + and γδ T Cells Erika Suzuki, Ritu Sarin, Emanual Maverakis and Iannis E. Adamopoulos, University of California at Davis, Sacramento, CA 5:00 pm Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice Leonie M. van Duivenvoorde 1, Melissa N. van Tok 1 and Dominique L. Baeten 2, 1 Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 2 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 5:15 pm IL-23 Expression and Activation of Autophagy in Synovium and PBMCs of HLA-B27 Positive Patients with Ankylosing Spondylitis Barbara Neerinckx, Shea Carter and Rik Lories, KU Leuven, Leuven, Belgium 5:30 pm IL23 Overexpression Demonstrates Gut-Joint Inflammation Link and Increased Expression of Spondyloarthopathy Associated Genes In Vivo Donald Souza II, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 5:45 pm HLA-B27 Expression Shapes the Intestinal Microbiota Mark Asquith 1, Phoebe Lin 1, Tejpal Gill 2, Justine Debelius 3, Patrick Stauffer 1, Sean Davin 1, Gail Ackermann 3, Robert A. Colbert 2, Rob Knight 3 and James Rosenbaum 4, 1 Oregon Health and Science University, Portland, OR, 2 NIAMS/NIH, Bethesda, MD, 3 University of Colorado Boulder, Boulder, CO, 4 Legacy Hospital, Portland, OR 210 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Moderators: Diane L. Kamen, MD, MS and Anca D. Askanase, MD 4:30 pm Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins Laurence S Magder 1, Eric Zollars 2, Jadwiga Bienkowska 3, Chris Stebbins 4, Carrie Wager 4, Linda Burkly 4, Nicolas Wisniacki 5, Ann Ranger 4 and Michelle Petri 2, 1 University of Maryland School of Medicine, Baltimore, MD, 2 Johns Hopkins University School of Medicine, Baltimore, MD, 3 Biogen Idec Inc., Cambridge, MA, 4 Biogen Idec, Cambridge, MA, 5 Formerly with Biogen Idec, Cambridge, MA Program Book

103 scientific sessions 4:45 pm The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus Joan T. Merrill 1, Aikaterini Thanou 1, Stan Kamp 1, John Conklin 2, Derren Barken 2 and Thierry Dervieux 2, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Exagen Diagnostics, Inc., Vista, CA 5:00 pm Hydroxychloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples Rufei Lu 1, Adam Przebinda 1, Melissa E. Munroe 2, Joel M. Guthridge 2, Joan T. Merrill 2 and Judith A. James 2, 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 5:15 pm Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10 John A. Reynolds 1, David W. Ray 2, Yvonne Alexander 3 and Ian N. Bruce 4, 1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, 2 Institute of Human Development, The University of Manchester, Manchester, United Kingdom, 3 Manchester Metropolitan University, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom 5:30 pm Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus Rosalind Ramsey-Goldman 1, Richard Furie 2, Chaim Putterman 3, Anka Askanase 4, Jill P. Buyon 5, Kenneth Kalunian 6, W. Winn Chatham 7, E Massarotti 8, Kyriakos A. Kirou 9, A. Weinstein 10, Puja Chitkara 11, Susan Manzi 12, Joe Ahearn 13, Leilani Wolover 14, John Conklin 14, Tyler O Malley 14, Claudia Ibarra 14, Derren Barken 14 and Thierry Dervieux 14, 1 Northwestern University, Chicago, IL, 2 North Shore-LIJ Health System, Great Neck, NY, 3 Albert Einstein College of Medicine, Bronx, NY, 4 Colombia University, New York, NY, 5 New York University School of Medicine, New York, NY, 6 UCSD School of Medicine, La Jolla, CA, 7 University of Alabama at Birmingham, Birmingham, AL, 8 Brigham and Women s Hospital, Boston, MA, 9 Hospital for Special Surgery, New York, NY, 10 Washington Hospital Center, Washington, DC, 11 Sharp Memorial Hospital, San Diego, CA, 12 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 13 West Penn Allegheny Health System, Pittsburgh, PA, 14 Exagen Diagnostics, Inc., Vista, CA 5:45 pm Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients Moez Jallouli 1, Lionel Galicier 2, Olivier Aumaître 3, Camille Francès 4, Véronique Le-Guern 5, F. Lioté 6, Amar Smail 7, Nicolas Limal 8, L. Perard 9, H. Desmurs-Clavel 10, Du Boutin 11, B. Asli 12, Jean Emmanuel Kahn 13, Jacques Pourrat 14, Laurent Sailler 15, F. Ackermann 13, T. Papo 16, Karim Sacre 17, O. Fain 18, J. Stirnemann 18, Patrice Cacoub 1, Gaëlle Leroux 1, Judith Cohen-Bittan 1, Js Hulot 19, Zahir Amoura 20, Jean-Charles Piette 1 and Nathalie Costedoat- Chalumeau 5, 1 CHU Pitié-Salpêtrière, Paris, France, 2 Hopital St Louis, AP-HP, Paris, France, 3 Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France, 4 Hôpital Tenon, Paris Cedex 20, France, 5 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, 6 Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris- Cité, Paris, France, 7 CHU Amiens Nord, Amiens, France, 8 Hôpital Henri Mondor, APHP, Creteil, France, 9 Hospices Civils de Lyon, groupement Hospitalier Edouard Herriot, Lyon, France, 10 Hospice civils de Lyon, Lyon, France, 11 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 12 Hopital Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, 13 Hopital Foch, Suresnes, France, 14 CHU Toulouse, Hopital Rangueil, University of Paul Sabatier, Toulouse, France, 15 CHU Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse, France, 16 Hopital Bichat Claude Bernard, University of Paris Diderot, Sorbonne Paris cité, Paris, France, 17 University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 18 Hopital Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris, France, 19 CHU Pitié-Salpêtrière, UC, University Paris 6, Paris, France, 20 Pitié-Salpêtrière Hospital (AP-HP), Paris, France 107 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Moderator: Robyn T. Domsic, MD, MPH and Laura K. Hummers, MD 4:30 pm Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis Jerome Avouac 1, Laetitia Morardet 2, Maya Sammour 3, Andre Kahan 2, Antoine Feydy 3 and Yannick Allanore 1, 1 Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, 2 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3 Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France MONDAY november 17, Program Book 101

104 scientific sessions MONDAY november 17, :45 pm A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil Ami A. Shah 1, Elena Schiopu 2, Soumya Chatterjee 3, Mary Ellen Csuka 4, Tracy Frech 5, Avram Goldberg 6, Robert F. Spiera 7, Stanford L. Peng 8 and Virginia D. Steen 9, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Michigan, Ann Arbor, MI, 3 Cleveland Clinic, Cleveland, OH, 4 Medical College of Wisconsin, Milwaukee, WI, 5 University of Utah, Salt Lake City, UT, 6 North Shore-LIJ Health System, Great Neck, NY, 7 Hospital for Special Surgery, New York, NY, 8 Benaroya Research Institute/Virginia Mason, Seattle, WA, 9 Georgetown University Medical Center, Washington, DC 5:00 pm A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic Sclerosis Vanessa Smith 1, Maurizio Cutolo 2, Ariane Herrick 3, Oliver Distler 4, Mike Becker 5, Emma Beltran 6, Patrick Carpentier 7, Clodoveo Ferri 8, Murat Inanc 9, Panayiotis Vlachoyiannopoulos 10, Harbajan Chadha-Boreham 11, Emmanuelle Cottreel 11, Thomas Pfister 11, Daniel Rosenberg 11 and Juan Torres, on behalf of the CAP study investigators 12, 1 Ghent University Hospital, Ghent, Belgium, 2 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 3 Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4 Zurich University Hospital, Zurich, Switzerland, 5 Charité University Hospital, Berlin, Germany, 6 Hospital La Fe, Valencia, Spain, 7 La Tronche Hospital, Grenoble, France, 8 University of Modena & Reggio E, Moderna, Italy, 9 Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 10 School of Medicine, National University of Athens, Athens, Greece, 11 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 12 Syntax for Science SL, Basel, Switzerland 5:15 pm Echocardiographic Phenomics for Novel Classification of Cardiac Involvement in Systemic Sclerosis Monique Hinchcliff, Vistasp Daruwalla, Lauren Beussink-Nelson, Sofia Podlusky, Mary A. Carns, John Varga and Sanjiv J. Shah, Northwestern University Feinberg School of Medicine, Chicago, IL 5:30 pm The Value of Repeated Nailfold Capillaroscopy in Raynaud s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands B. de Boer 1, J. Meijs 1, J. van Aken 2, T.W.J. Huizinga 1, A.a. Schouffoer 3 and J.K. de Vries-Bouwstra 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Spaarne Ziekenhuis, Hoofddorp, Netherlands, 3 Haga Hospital, The Hague, Netherlands 2014 Program Book 5:45 pm Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Lesley Ann Saketkoo 1, Matthew R. Lammi 2, Aryeh Fischer 3, Jerry A. Molitor 4 and Virginia D. Steen 5, 1 Louisiana State University Health Sciences Center, New Orleans, LA, 2 Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 3 National Jewish Health, Denver, CO, 4 University of Minnesota, Minneapolis, MN, 5 Georgetown University Medical Center, Washington, DC ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) Antiphospholipid Syndrome (051) Speaker: Doruk Erkan, MD review the spectrum of antiphospholipid syndrome explain the diagnostic utility of antiphospholipid antibody tests discuss the management of persistently antiphospholipid antibody-positive patients with different antiphospholipid antibody-related clinical manifestation Westin Otis (Lobby) *Behçet s Syndrome (052) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome Westin Hancock (Lobby) Immunodeficiency Syndromes (053) Speaker: Troy R. Torgerson, MD, PhD review the immunology and clinical manifestations of the major immune deficiency syndromes that both adult and pediatric rheumatologists might encounter discuss the diagnostic evaluation for someone suspected of having an immune deficiency syndrome illustrate therapeutic options with cases

105 scientific sessions Westin Revere (Lobby) *Infections with Biologics (054) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction Westin Stone (Lobby) *Myopathy: Issues in Diagnosis and Treatment (055) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies describe the importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease Westin Alcott (Mezzanine) *Safety of Drugs Used to Treat Rheumatoid Arthritis (058) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Lupus Nephritis (059) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis Westin Webster (Lobby) *Pulmonary Manifestations of Rheumatic Disease (056) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease Westin Adams (Mezzanine) Raynaud s and Digital Ischemia (057) Speaker: Fredrick M. Wigley, MD discuss the current understanding of the pathogenesis of Raynaud s phenomenon classify type of Raynaud s phenomenon and differentiate it from mimickers describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of an autoimmune rheumatic disease discuss current options and evidence for treatment of Raynaud s phenomenon, threatened digital ischemia and digital ulcers Westin Faneuil (Mezzanine) Vasculitis Factors That Influence Disease Patterns (060) Speaker: Gary S. Hoffman, MD review advances in diagnosis and staging of vasculitis and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis ARHP SESSIONS 4:30 6:00 pm 254 A Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation Moderator: Judy Foxworth, PhD, PT differentiate total knee arthroplasty prosthesis types and surgical techniques evaluate predictors of success following total knee arthroplasty implement best practices in a rehabilitation program for total knee arthroplasty MONDAY november 17, Program Book 103

106 scientific sessions 4:30 pm Innovations in Total Knee Arthroplasty Jason Lang, MD 5:00 pm Predictors for Best Outcome After Total Knee Arthroplasty Chad M. Brummett, MD 5:00 pm Diet and Nutritional Supplements in Rheumatoid Arthritis Susanna Proudman, MBBS, PhD 5:30 pm Diet in Gout Hyon Choi, MD, PhD MONDAY november 17, :30 pm Best Practice Rehabilitation Following Total Knee Arthroplasty Sara R. Piva, PhD, PT From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Moderator: Jasvinder A. Singh, MD, MPH recognize the relative importance of immune mechanisms in the onset of atherosclerosis among patients with inflammatory rheumatic diseases review the generalizability of such mechanisms to people without inflammatory rheumatic diseases evaluate the role of oxidative stress in non-autoimmune diseases and autoimmune diseases on the incidence of atherosclerosis 4:30 pm Immunological Underpinnings of Atherosclerosis Cornelia M. Weyand, MD, PhD 5:00 pm Atherosclerotic Cardiovascular Diseases and Oxidative Stress: The Case of Crystalline Arthritis Eswar Krishnan, MD 255 The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond Ed Pd PrM FIT Moderator: Lori B. Tucker, MD summarize the research-based evidence for the benefits and risks to medicinal cannabis on young adults evaluate environmental and psychosocial factors that may drive a request for physician-approved medicinal cannabis by young adults discuss the medicolegal implications for rheumatologists and for patients in this era of increasing demand for medicinal cannabis 4:30 pm A Prescription for Herbal Cannabis: Primum Non Nocere Mary-Ann Fitzcharles, MBChB, MD 5:15 pm Medicolegal Considerations for Herbal Cannabis Use in Rheumatology Practice Peter A. Ste-Marie, BA, LLB ARHP CONCURRENT ABSTRACT SESSION 4:30 6:00 pm 104 5:30 pm Innate Immunity and Atherosclerosis in Inflammatory Rheumatic Diseases Mariana J. Kaplan, MD 257 A Role of Nutrition in Rheumatic Diseases Moderators: Susan J. Bartlett, PhD and Carole V. Dodge, OT, CHT summarize current scientific evidence underlying the role of nutrition in rheumatic diseases discuss the role of diet and nutritional supplements in managing rheumatoid arthritis care recognize how the intake of various foods and drinks may affect patients with gout 4:30 pm Role of Nutrition in Rheumatic Diseases- An Overview Shivani Sahni, PhD 2014 Program Book 109 Health Disparities/Social Determinants of Health Ed Pd PrM FIT Moderators: Jillian A. Rose, LCSW and Leigh F. Callahan, PhD 4:30 pm Increasing Access to Inflammatory Arthritis Education in Rural and Remote Communities Using Telemedicine Carol Kennedy 1, Kelly Warmington 2, Carol Flewelling 1, Rachel Shupak 1, Angelo Papachristos 3, Caroline Jones 4, Dorcas Beaton 5, Sydney Brooks 6 and Denise Linton 1, 1 St. Michael s Hospital, Toronto, ON, 2 The Hospital for Sick Children, Toronto, ON, 3 St Michael s Hospital, Toronto, ON, 4 St. Michael s Hospital, Aurora, ON, 5 Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, 6 The Arthritis Society, Ontario Division, Toronto, ON 4:45 pm Getting a Grip on Arthritis Online: Web-Based Continuing Education Supports the Dissemination of Arthritis Clinical Practice Guidelines Among Rural/Remote Primary Care Providers Sydney Lineker 1, Mary Bell 2, Lisa Fleet 3, Elizabeth M. Badley 4, Vernon Curran 3, Marlene Del Pino 5, Fran Kirby 3, Anne Lyddiatt 6,

107 scientific sessions Lynn Moore 1, Karla Simmons 3, Raquel Sweezie 1, Peter Tugwell 7 and Ed Ziesmann 1, 1 The Arthritis Society, Toronto, ON, 2 Sunnybrook Health Sciences Ctr, Toronto, ON, 3 Memorial University, St. John s, NF, 4 Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5 Health Canada, Regina, SK, 6 Patient Partners in Arthritis, Toronto, ON, 7 Institute of Population Hlth, Ottawa, ON 5:00 pm Examining Why Minority Women Are Risk Averse : A Qualitative Study Sonal Bhalla 1, Kristin Mattocks 2 and Liana Fraenkel 3, 1 Yale- New Haven Hospital, New Haven, CT, 2 VA Central Western Massachusetts Healthcare System, University of Massachusetts Medical School, Leeds, MA, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 5:15 pm Racial Disparities in Attitude Towards Treatment in Young Women Raluca Cozmuta 1, Sonal Bhalla 2 and Liana Fraenkel 3, 1 Yale University School of Medicine, New Haven, CT, 2 Yale University, New Haven, CT, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 5:30 pm Ageism, Fear and Competing Co-Morbidities Why Older Patients May Not Seek Care for Restricting Back Pain: A Qualitative Study Una Makris 1, Robin Higashi 2, Emily Marks 2, Liana Fraenkel 3, Joanna Sale 4 and CM Reid 5, 1 Dallas VA Medical Ctr, Dallas, TX, 2 UT Southwestern Medical Center, Dallas, TX, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 4 University of Toronto, St. Michael s Hospital, Toronto, ON, 5 Weill Cornell Medical College, New York City, NY 5:45 pm Model Examining Factors Related to Physicians Ratings of Disease Activity in Patients with RA Julia R. Ayeroff 1, Sarah R. Ormseth 2, David Hardy 3, Michael R. Irwin 2, Michael H. Weisman 4 and Perry M. Nicassio 2, 1 University of Southern California, Los Angeles, CA, 2 University of California, Los Angeles, Los Angeles, CA, 3 Loyola Marymount University, Los Angeles, CA, 4 Cedars-Sinai Medical Center, Los Angeles, CA ACR STUDY GROU 6:30 7:45 pm Study Groups are non-cme activities open to all attendees. 109 A ACR Musculoskeletal Ultrasound Study Group 6:30 pm The American End of the Tendon and Enthesis Ralf G. Thiele, MD 6:45 pm The European End of the Tendon and Enthesis George A. W. Bruyn, MD, PhD 7:00 pm Sonographic Evaluation of the Enthesis and Enthesopathy Maria-Antonietta d Agostino, MD, PhD 7:15 pm Ultrasound Assessment of Dactylitis Gurjit S. Kaeley, MBBS, MRCP 7:30 pm Closing Statements 157 B Antiphospholipid Syndrome Task Force Study Group 6:30 pm Introduction Past, Present and Future of Antiphospholipid Syndrome Task Forces Doruk Erkan, MD 6:35 pm 2013 Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force Report Maria Laura Bertolaccini, MD, PhD 6:50 pm 2013 Antiphospholipid Syndrome Clinical Diagnostics Task Force Report Roger A. Levy, MD 7:05 pm 2013 Antiphospholipid Syndrome Obstetric Diagnostics and Treatment Task Force Report Ware D. Branch, MD 7:20 pm 2016 Antiphospholipid Syndrome Diagnostic and Classification Criteria Task Force Update MG Tektonidou, MD 7:30 pm 2013/2016 Antiphospholipid Syndrome Treatment Trends Task Force Report/Update Danieli Andrade, MD 256 Capillaroscopy in Rheumatic Diseases Study Group 6:30 pm Evaluation Tools for Microcirculation Analysis: Morphology Versus Flow Ariane L. Herrick, MD 6:50 pm Capillaroscopy in Systemic Sclerosis: Clinical Applications Vanessa Smith, MD, PhD MONDAY november 17, Program Book 105

108 scientific sessions 7:05 pm Capillaroscopy in Systemic Sclerosis: Basic Science Maurizio Cutolo, MD 7:25 pm Practical Issues in Videocapillaroscopy Including Scoring Systems and Links with Other Diagnostic Tools Alberto Sulli, MD 255 Childhood Vasculitis Study Group 6:30 pm Childhood Vasculitis in North American and Europe Marinka Twilt, MD 6:55 pm Childhood Vasculitis in South Africa Christiaan Scott, MD 7:10 pm Potential Role of Uricosuric Agents in the Contemporary Management of Gout Peter A. Simkin, MD 107 B Degos Disease Study Group 6:30 pm The Pathology of Degos Cynthia Magro, MD 6:55 pm Parvovirus Infection: Effects on Endothelium Stanley J. Naides, MD 7:20 pm Formation of Degos Registry J. Patrick Whelan, MD, PhD MONDAY november 17, :20 pm Childhood Vasculitis in India Sathish Kumar 259 A Clinical Anatomy Study Group 6:30 pm Clinical Anatomy: An Unmet Need in Rheumatology Training Robert A. Kalish, MD 6:45 pm The Clinical Anatomy Program at Los Angeles County Christine Evelyn, MD 7:00 pm Ultrasonography as a Teaching Tool of Musculoskeletal Anatomy Karina D. Torralba, MD, MAppSc 7:15 pm Development and Experience of the Mexican Group for the Study of Clinical Anatomy (GMAC) Pablo Villasenor Ovies, MD 7:30 pm A Clinical Scholar s Perspective Richard S. Panush, MD 102 A Crystal Study Group 6:30 pm Introduction Naomi Schlesinger, MD 6:35 pm Forms of Monosodium Urate Crystal (MSUC) Deposits in Tissue Eliseo Pascual, MD, PhD 104 B Hypermobility Study Group 6:30 pm Joint Hypermobility Syndrome and the Impact on Day to Day Functioning in Children Amanda Kirby, MBBS, MRCGP, PhD 6:55 pm Joint Hypermobility and Autonomic Hyperactivity: Relevance to Neurodevelopmental Disorders Jessica Eccles, MB, BCh, MA, MSc, MRCPsych 7:20 pm Dysautonomia and Fatigue in Hypermobility Nelly Ninis, MRCP, MD 7:45 pm Physical Therapy Management of Adolescents with Postural Orthostatic Tachycardia Syndrome and Ehlers Danlos Syndrome Hypermobility Type Jane Simmonds, MCSP, MMACP 160 B Intestinal Lung Disease Study Group 6:30 pm Emerging and Adjunctive Therapies for Intestinal Lung Disease Due to Connective Tissue Disease: Lessons from Idiopathic Pulmonary Fibrosis Trials Aryeh Fischer, MD 7:00 pm Appropriate Utilization of Imaging in Intestinal Lung Disease Associated with Connective Tissue Disease Rachna Madan, MD Program Book

109 scientific sessions 156 B Macrophage Activation Syndrome Study Group 6:30 pm The Genetics of Macrophage Activation Syndrome/ Haemophagocytic Lymphohistiocytosis in Adults Lisa Filipovich, MD 6:55 pm The Propensity to Develop Macrophage Activation Syndrome in the Setting of Systemic Lupus Erythematosus W. Winn Chatham, MD 7:20 pm Macrophage Activation Syndrome Along the Spectrum of Juvenile Idiopathic Arthritis and Adult-Onset Still s-disease Peter A. Nigrovic, MD 7:05 pm Incorporating Active Learning Techniques into Your Teaching Presentations Kristen Hayward, MD, MS 7:40 pm Wrap-Up Kristen Hayward, MD, MS 254 A The Why and How of Disease Criteria Study Group 6:30 pm Is an n of 1 Trail of Low Dose Prednisone and Methotrexate More Definitive and Cost-Effective than an Extensive and Expensive Evaluation to Meet Criteria? Theodore Pincus, MD 153 B Myositis Study Group 6:30 pm Introduction Ignacio Garcia-De La Torre, MD 6:35 pm Update on the Pathogenesis of Inclusion Body Myositis Steven A. Greenberg, MD 7:10 pm Novel Therapeuptic Approaches for Inclusion Body Myositis Thomas E. Lloyd, MD, PhD 257 A Osteoarthritis Study Group 6:30 pm Introduction Carla R. Scanzello, MD, PhD 6:35 pm In-Vitro Models of Cartilage Injury and Post-Traumatic Osteoarthritis George Dodge, PhD 7:10 pm Anterior Cruciate Ligament Injury and Osteoarthritis: Biomarkers and Therapeutic Approaches Richard Frobell, PT, PhD 6:55 pm Criteria for Systemic Vasculitis: Diagnosis vs. Classification or One and the Same? Hasan Yazici, MD 7:20 pm Criteria for Defining Rheumatoid Arthritis: Is New Always Better? Yusuf Yazici, MD 204 A Veterans Affairs Rheumatology Study Group 6:30 pm Utilization of Computerized Patient Record System Templates to Capture Patient Outcomes During Clinical Practice Mathilde Pioro, MD 6:55 pm Opportunities for Participation in Veterans Affairs (VA) Rheumatology Research Through Involvement in VA Disease Specific Registries Elizabeth Chang, MD 7:20 pm Rheumatology Field Advisory Update: How to Use Available Productivity Measures to Optimizing Veterans Affairs Practice Grant W. Cannon, MD MONDAY november 17, A Pediatric Rheumatologists Interested in Medial Education Study Group 6:30 pm Development of a Peer Review Process for Educational Materials Submitted to Ouch My Leg! Megan L. Curran, MD 2014 Program Book 107

110 scientific sessions TUESDAY november 18, 2014 ACR SESSIONS 7:30 8:30 am TUESDAY, NOVEMBER 18, B Glycosylation and Glycan Binding Proteins in Immune Function Moderator: Leonard H. Sigal, MD Speaker: Sean Ryan, PhD identify roles for protein glycosylation in immune function identify roles for glycan binding molecules in immune function describe the importance of glycans and their binding partners in health and disease Ballroom West Hepatitis C in 2014 Moderator: Elana J. Bernstein, MD, MSc Speaker: Raymond T. Chung, MD describe the natural history of hepatitis C infection describe the extrahepatic manifestations of hepatitis C infection discuss which patients are appropriate for therapy and how to predict response to therapy describe available treatment regimens and novel/investigative treatment regimens for hepatitis C infection 151 A Patient Access to Biologics Across the Globe Moderators: Joseph Flood, MD and Maurizio Cutolo, MD discuss the access to biologics for patients in various regions of the world locate the areas where patients access differs significantly identify potential solutions to overcome identified barriers to providing biologics 7:30 am Intro and Overview of International League of Associations for Rheumatology (ILAR) Joseph Flood, MD; Maurizio Cutolo, MD Ed Pd PrM FIT 8:00 am Patient Access to Biologics in African League of Associations for Rheumatology (AFLAR) Regions Olufemi Adelowo, MD 8:10 am Patient Access to Biologics in Asian Pacific League of Association for Rheumatology (APLAR) Regions Kevin Pile, MD 8:20 am Question and Answers ARHP SESSIONS 7:30 8:30 am 254 A Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders Moderator: Shawn Rose, MD, PhD Speaker: Michelle Petri, MD, MPH review the mechanisms contributing to involvement of the central nervous system summarize the diagnostic criteria and screening tools used to identify the presence of psychiatric and cognitive deficits and whether they are due to active central nervous system systemic lupus erythematosus or other factors recognize the range of cognitive changes and psychiatric disorders found in systemic lupus erythematosus patients 257 A Muscle and Adipose Tissue in Rheumatic Diseases: Location Is Everything Moderator: Kelli D. Allen, PhD Speaker: Jon T. Giles, MD, MPH differentiate between abnormal body composition phenotypes (sarcopenia, overfat and sarcopenic obesity) summarize the relationships between muscle and adipose tissue in rheumatoid arthritis evaluate the implications of fat and muscle distribution on disease-associated outcomes in rheumatic diseases 7:40 am Patient Access to Biologics in Pan American League of Associations for Rheumatology (PANLAR) Regions Carlos Pineda, MD, MSc 7:50 am Patient Access to Biologics in The European League Against Rheumatism (EULAR) Regions Maurizio Cutolo, MD ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August Program Book

111 scientific sessions Westin Paine (Lobby) Antiphospholipid Syndrome (061) Speaker: Alana B. Levine, MD review classification criteria for antiphospholipid syndrome review non-criteria manifestations of antiphospholipid syndrome discuss the management of obstetric antiphospholipid syndrome, catastrophic antiphospholipid syndrome and difficult cases posed by the audience review of current international research efforts in antiphospholipid syndrome Westin Otis (Lobby) Controversies in Sjögren s Syndrome (062) Speaker: Frederick Vinino, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients relate the pathogenesis of these syndromes to knowledge of the various gene functions discuss the treatment rationale based on the pathogenesis and to expand on practical issues in the management of these patients Westin Webster (Lobby) *Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066) Speaker: J. Timothy Harrington, MD discuss outcome measures used in rheumatoid arthritis integrate outcome measures into an office-based practice Westin Adams (Mezzanine) Safety of Drugs Used to Treat Rheumatoid Arthritis (067) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill Westin Hancock (Lobby) Footwear in Orthoarthritis (063) Speaker: Najia Shakoor, MD, MS establish the biomechanical pathophysiology of osteoarthritis discuss the impact of footwear choice on biomechanics of the lower extremity discuss the impact of footwear choice on clinical conditions at the knees and feet Westin Revere (Lobby) Osteoporosis: Novel Treatments (064) Speaker: Linda Russell, MD review the basic biology of bone as it relates to treatment examine the potential benefits and risks of antiresorptive therapies discuss the potential benefits and risks of anabolic therapies review the current knowledge and understanding of how to pick the best therapy for each patient and for how long to treat each patient with osteoporosis Westin Stone (Lobby) Pediatrics: Periodic Fevers in Children (065) Speaker: Daniel L. Kastner, MD, PhD Ed Pd PrM FIT describe the differential diagnosis and expanding spectrum of these syndromes Westin Alcott (Mezzanine) Systemic Lupus Erythematosus: Central Nervous System (068) Speaker: Meggan Mackey, MD, MS identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus Westin Douglas (Mezzanine) Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans TUESDAY november 18, Program Book 109

112 scientific sessions Westin Faneuil (Mezzanine) Vasculitis: Factors that Influence Disease Patterns (070) Speaker: Gary S. Hoffman, MD identify anatomic landmarks for injection of the knee and ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics TUESDAY november 18, 2014 review advances in diagnosis and staging of vasculitis and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis ACR/ARHP WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August *Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229) Speaker: Jay B. Higgs, MD use practical knowledge of ultrasound technology to improve image quality recognize common pathology patterns in musculoskeletal ultrasound 154 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T1- and T2-weighted, fat-saturated, STIR and contrast-enhanced) and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging ACR SESSIONS 8:30 10:00 am 253 B Bioenergetics and Energy Regulation Moderator: Antonio La Cava, MD, PhD describe the relationship between metabolism and apoptosis recognize the interactions between metabolism and activation of both the innate and adaptive immune response recognize the beneficial effects of reactive oxygen species 8:30 am Homeostatic Mechanisms of the Mitochondria Richard Siegel, MD, PhD 9:15 am Homeostatic Mechanisms of the Mitochondria Navdeep S. Chandel, PhD 161 Basic Statistical Concepts for the Medical Researcher (230) Speakers: Dorothy D. Dunlop, PhD and Jungwha Lee, PhD, MPH identify factors influencing sample size and power interpret confidence intervals, odds ratio and relative risk identify factors that confound study results 152 *Joint Injections (Knee, Ankle, Shoulder and Wrist) (231) Speakers: Jemima Albayda, MD and Pari Basharat, MD describe indications for lower extremity joint injection and aspiration 52 A CARE: Maintenance of Certification Session Three of Three Rheumatoid Arthritis All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) rheumatoid arthritis questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Jonathan Kay, MD Program Book

113 scientific sessions assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program 102 A Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required Ed Pd PrM FIT Moderator: Kenneth S. O Rourke, MD Speaker: William Iobst, MD discuss the importance of direct observation for assessment of clinical skills summarize the status of evaluation skills describe strategies for direct observation and rater training methods 104 B Macrophages Gone Wild Ed Pd PrM FIT Moderators: Randy Q. Cron, MD, PhD and Karyl Barron, MD review the pathophysiology of macrophage activation syndrome recognize new classification criteria for macrophage activation syndrome discuss macrophage activation syndrome outside of the context of systemic juvenile idiopathic arthritis 8:30 am Inside the World of a Killer: Understanding the Pathogenesis of Macrophage Activation Syndrome Edward M. Behrens, MD 9:00 am Diagnosis of Macrophage Activation Syndrome in the Age of Biologics Angelo Ravelli, MD 9:30 am Macrophage Activation Syndrome Independent of Systemic Juvenile Idiopathic Arthritis Rayfel Schneider, MBBCh Ballroom East Myositis Mimics: Clinical and Molecular Diagnosis Moderator: Alan N. Baer, MD review muscle diseases which may mimic adult-onset polymyositis describe diagnostic features of a myopathy suggestive of a muscular dystrophy or metabolic myopathy create an approach to the diagnosis of unusual forms of myopathy that may mimic polymyositis 8:30 am Differential Diagnosis of Polymyositis Andrew L. Mammen, MD, PhD 9:15 am Molecular Diagnosis of Adult-Onset Muscular Dystrophy and Metabolic Myopathies Anthony A. Amato, MD 153 B Rheumatology Research Foundation Special Session: Disease Targeted Research Moderator: Anne Davidson, MBBS review functional differences among large numbers of fibroblast-like synoviocytes and determine if the differences are genetically determined describe how to use the blood level of high density lipoprotein as a powerful determinant for predicting risk for cardiovascular disease in patients with rheumatoid arthritis describe the role of innate immune receptors in osteoclast development and how they relate to bone loss during inflammation 8:30 am Synovial Fibroblast Phenotypes After Activation Bv TNF/lL-17 Michael B. Brenner, MD 9:00 am Dysfunctional High-Density Lipoprotein, Rheumatoid Arthritis and Cardiovascular Disease Subramaniam Pennathur, MD 9:30 am Regulation of Osteoclasts During Inflammation Julia F. Charles, MD, PhD Exhibit Hall C Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases define the clinical aspects and epidemiology of cardiovascular disease in systemic rheumatic diseases, particularly rheumatoid arthritis interpret mechanisms of cardiovascular disease in patients with rheumatoid arthritis generate pragmatic guidance for the evaluation and management of cardiovascular disease in patients with rheumatoid arthritis TUESDAY november 18, Program Book 111

114 scientific sessions TUESDAY november 18, :30 am Epidemiology of Cardiovascular Disease in Rheumatoid Arthritis and Other Rheumatic Diseases Sherine E. Gabriel, MD, MSc 9:00 am Cardio-Rheumatology: Approach to the Patient Anne Grete Semb, MD, PhD 9:30 am Which Tests Should Be Done and When? Sharon Mulvagh, MD ACR/ARHP POSTER SESSION C, Late- Breaking and THIEVES MARKET POSTERS AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # ). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Poster Hall (Exhibit Hall B) Thieves Market Posters TM 8. Acute Onset of Headaches, Dysarthria, Vision Changes in a 17 y/o Male Angela Bryan, MD TM 9. Discharged but Not Better for Long Aixa Toledo-Garcia, MD TM 10. Masquerader of Adult Still s Michael Thomas Avery, DO TM 11. Refractory Knee Joint Swelling in a Patient With Systemic Lupus Erythematosus Minyoung Her, MD TM 12. The Thin Young Man -- Ed Oberle Edward J. Oberle, MD TM 13. Whispers of Disease Rikitha Menezes, MD Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Osteoarthritis Clinical Aspects Poster Tour (325) Tour Guide: Grace H. Lo, MD, MSc Quality Measures and Quality of Care Poster Tour (326) Tour Guide: Gabriela Schmajuk, MD, MS Rheumatoid Arthritis: Clinical Aspects Poster Tour (327) Tour Guide: Inmaculada Del Rincon, MD, MSc Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (328) Tour Guide: Joseph A. Markenson, MD Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (329) Tour Guide: Philip Mease, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (330) Tour Guide: Laura K. Hummers, MD, ScM 10:15 11:00 am Epidemiology and Health Services Research Poster Tour (331) Tour Guide: Kaleb Michaud, PhD Health Services Research Poster Tour (332) Tour Guide: Salahuddin Kazi, MD, PhD Rheumatoid Arthritis: Human Etiology and Pathogenesis Poster Tour (333) Tour Guide: David S. Pisetsky, MD, PhD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (334) Tour Guide: Jonathan Kay, MD Rheumatology 360 Poster Tour (335) Tour Guide: Eric L. Matteson, MD Spondyolarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (336) Tour Guide: John D. Reveille, MD Program Book

115 scientific sessions ACR SESSIONS 9:00 10:00 am ARHP SESSIONS 9:00 10:00 am 107 B ACR-EULAR Polymyalgia Rheumatica Guidelines Moderators: Steven E. Carsons, MD and Andy Abril, MD review the approach to polymyalgia, the relevant investigations, differential diagnosis and overlap with other conditions, classification criteria review Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and available evidence for polymyalgia rheumatica therapies, prognostic factors, values and preferences of patients and professionals on polymyalgia rheumatica review ACR-EULAR polymyalgia rheumatica treatment guidelines including glucocorticoids, disease modifiers, biologic agents and future research agenda and clinical trials 9:00 am Polymyalgia: What Does It Mean? Bhaskar Dasgupta, MD 204 A Mycobacterium Infections in Immunocompromised Patients Moderator: Susan Richmond, MS, PA-C recognize the risk of non-tuberculosis mycobacterium infection in immunosuppressed patients evaluate tuberculosis risk factors in immunosuppressed patients and recognize the need to maintain vigilance for tuberculosis during treatment with immunosuppressants review available screening tests, including the Tuberculin Skin Test, Quantiferon-Gold and TB-spot 9:00 am Evaluating Tuberculosis Risk in Immunocompromised Patients Lisa Shelton, BSc, BSN, RN 9:15 am Mycobacterium Infections in Immunocompromised Patients Kevin L. Winthrop, MD, MPH 9:20 am Polymyalgia Rheumatica: Grading the Evidence Christian Dejaco, MD, PhD 9:40 am Polymyalgia Rheumatica: Treatment Guidelines and Next Steps Eric L. Matteson, MD, MPH 156 B Metainflammation Speaker: Gökhan S. Hotamisligil, PhD, MD review metabolic aspects of inflammation discuss metabolic pathways 210 B Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges Moderator: Michael Maricic, MD Speaker: Roland Baron, DDS, MD review the mechanisms regulating bone homeostasis and the process of bone remodeling evaluate the effects of anti-resorptive and osteo-anabolic drugs and the differences between them review the mode of action and anticipated effects of molecules currently in development for the treatment of osteoporosis 157 B RheumChat Moderator: Afton L. Hassett, PsyD describe the newest science and the oldest debates in the field of pain research describe a potential means by which autoimmune disorders may be cured discuss the intersection of research and clinical care in the context of history, health policy and technology 9:00 am Pain! Sean Mackey, MD, PhD 9:12 am Jumping Across the Knowledge Gap: The Roles of Significance and Innovation in Rheumatology Research Marian T. Hannan, DSc, MPH 9:24 am It s Time that We Started to Talk About Cure in Severe Autoimmune Disease Troy R. Torgerson, MD, PhD 9:36 am Did We Care More When We Knew Less? Andrew A. Guccione, DPT, PhD TUESDAY november 18, Program Book 113

116 scientific sessions TUESDAY november 18, A Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies Moderator: Alyssa B. Dufour, PhD review when to use the prevalence ratio and when to use the odds ratio recognize with the regression models that can generate the prevalence odds ratio explain the methodological issues that may arise when estimating prevalence ratios analyze data using the prevalence ratio with popular statistical packages 9:00 am Regression Models for Prevalence Ratios Kamil E. Barbour, PhD 9:30 am Examples of the Prevalence Ratio vs. the Odds Ratio in Rheumatology Research Yvonne M. Golightly, PT, MS, PhD EXHIBITS 10:00 am 2:30 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning refreshments from 10:00 11:00 am. (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am and 12:30 1:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm and 1:30 2:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August Musculoskeletal Ultrasound (233) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types based on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234) Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis X-Ray Challenges in Rheumatic Diseases (235) Speaker: Donald J. Flemming, MD describe the potential causes and exacerbating factors of the disease discuss the appropriate use of laboratory testing and imaging modalities design an efficacious, safe and cost-effective therapeutic strategy ACR SESSIONS 11:00 am Noon 253 B Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases Moderator: Dana P. Ascherman, MD Speaker: Paolo Bianco, MD review the biology of MSCs and differences from hematopoietic stem cells (HSCs) appraise anti-inflammatory versus remodeling properties associated with MSCs define limitations in pre-clinical models, barriers in clinical application 104 B Protecting Bone Health in Pediatric Rheumatic Diseases Ed Pd PrM FIT Moderators: Stacy P. Ardoin, MD, MS and Kelly A. Rouster- Stevens, MD, MS Speaker: Jon M. Burnham, MD, MSCE Program Book

117 scientific sessions evaluate threats to bone health in children with rheumatic diseases review effects of rheumatic diseases and their therapies on bone density, structure, strength and fracture risk describe best practices for bone health monitoring and preventive measures, such as calcium and vitamin D supplementation and bisphosphonate use ARHP SESSIONS 11:00 am Noon explain the characteristics of rheumatology practices with and without mid-level providers in the scope of the treat-to-target concept discuss the research that has been done in regards to midlevel providers in rheumatology practice describe the role of a mid-level provider in rheumatology care 11:00 am Study Comparing Practices with and without Midlevel Providers Daniel H. Solomon, MD, MPH 257 A Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions Eth Moderator: Barbara A. Slusher, PA-C, MSW Speaker: Troy R. Torgerson, MD, PhD compare several biologic treatment options for active rheumatoid arthritis differentiate existing treatment options for systemic lupus erythematosus when hydroxychloroquine is not enough discuss how psoriasis and psoriatic arthritis differ from rheumatoid arthritis when anti-tnfs fail to control active inflammation examine treatment considerations for refractory myopathies Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Moderator: Donah Z. Crawford, BS, MA discuss the state of the science on positive emotions and pain determine the mechanistic links between dopaminergic neurotransmission, reward-related behaviors and coping with chronic pain introduce the role of social relations in pain adaptation and a promising new intervention in social intelligence that may build social resourcefulness among patients with chronic pain 11:00 am Mechanisms of Positive Emotion and Reward in Chronic Pain Patrick Finan, PhD 11:30 am The Importance of Social Relations in Positive Emotion and Resilience to Chronic Pain Alex Zautra, PhD Providing Evidence for Mid-Level Providers in Rheumatology Practice Moderator: Kori A. Dewing, DNP, ARNP 11:15 am The Role of Mid-level Providers in Rheumatology Care Benjamin J. Smith, PA-C ACR PLENARY SESSION III DISCOVERY :00 am 12:30 pm Exhibit Hall C ACR Plenary Session III: Discovery 2014 Moderators: John Varga, MD and Mary K. Crow, MD 11:00 am Cost-Effectiveness of Adding Etanercept Vs. Sulfasalazine and Hydroxychloroquine to Methotrexate Therapy: A Randomized Noninferiority Trial Nick Bansback, University of British Columbia, Vancouver, BC Background/Purpose: To estimate the incremental costeffectiveness of etanercept plus methotrexate versus a triple regimen of disease-modifying anti rheumatic drugs (methotrexate, sulfasalazine and hydroxychloroquine) over 24 weeks and 48 weeks in patients with active rheumatoid arthritis despite methotrexate therapy (RACAT). Methods: In this double blind, noninferiority trial 353 patients were randomized to etanercept plus methotrexate or a triple regimen. After 24 weeks of treatment patients not achieving a DAS28 improvement of 1.2 were switched in a blinded fashion to the other therapy. Quality Adjusted Life Years (QALYs) were estimated using US societal values from the EQ-5D instrument which was measured every 24 weeks. Costs of drugs, hospitalizations, procedures, tests, visits and lost productivity were prospectively tracked and monetized from a societal perspective in 2014 US dollars. Incremental costeffectiveness ratios were calculated using standard procedures assuming an intent-to-treat analysis, with missing data analyzed using multiple imputation and uncertainty assessed using bootstrapping. Results: Both strategies showed significant improvements in EQ-5D, with etanercept providing marginally more accumulated QALYs (0.358 vs over 24 weeks and vs over 48 weeks for etanercept and triple regimen strategies respectively). The etanercept strategy accumulated substantially higher drug costs even considering the switches between treatments at 24 weeks ($11,286 vs $369 cumulative costs from 0 to 24 weeks and $19,625 vs $3,721 cumulative costs from 0 to 48 weeks for 2014 Program Book 115 TUESDAY november 18, 2014

118 scientific sessions etanercept and triple regimen respectively). The differences in other health care and productivity costs across strategies were negligible. The resultant incremental cost-effectiveness ratios for etanercept vs. triple regimen were $2.7 million/qaly (95%CI 0.87 to ) gained over 24 weeks and $0.95 million/qaly (95%CI 0.41 to ) over 48 weeks. Conclusion: This economic evaluation based on a prospective tracking of resource use and QALY measurement in a blinded, randomized trial demonstrates that the additional costs associated with using etanercept prior to a triple regimen does not provide good value for money at generally acceptable willingness to pay thresholds. A limitation of the study is its short time frame. However, even when considering the long-term perspective, since the incremental benefits are so small, even under the most optimistic scenarios imaginable, etanercept has only a small probability of being cost-effective compared to triple therapy. Given the opportunity cost associated with all health care spending, adapting a triple regimen prior to etanercept would free up scarce health dollars for use on alternative health care interventions that provide greater health benefits. 5 ACPAs were reverted to the germ line sequences and the corresponding antibodies were also expressed for the above tests. Results: The relative frequencies of circulating plasmablasts were significantly higher in RA patients than in healthy donors ( p = ). About 19.5% of circulating plasmablast-derived recombinant antibodies from CCP-positive RA patients, but none from the CCP-negative RA patient or healthy donors, specifically recognized citrullinated RA autoantigens ( p = ). The immunoglobulin genes encoding these ACPAs were highly mutated with increased replacement/silent mutation ratios, suggesting that the generation of ACPAs involved active antigen selection. Interestingly, 63% of these ACPAs cross-reacted with the outer membrane antigens and/or citrullinated enolase from P. gingivalis. Germ-line reversions of some ACPAs completely eliminated their reactivity to citrullinated RA autoantigens but retained their reactivity to P. gingivalis antigens. Conclusion: These results suggest that circulating plasmablasts in RA patients produce ACPAs and this process may be, in part, initiated by the anti-p. gingivalis immune responses. Disclosures: S. Li, None. TUESDAY november 18, 2014 Disclosures: N. Bansback, None. 11:15 am Autoantibodies from Single Circulating Plasmablasts React with Citrullinated Antigens and Porphyromonas Gingivalis in Rheumatoid Arthritis Song Li, University of Nebraska Medical Center, Omaha, NE Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) and also believed to play a pathogenic role in RA. Porphyromonas gingivalis (P. gingivalis), a Gram negative oral pathogen associated with periodontitis, has long been speculated as a trigger for the anti-citrulline autoimmune responses in RA patients. However, the detail relation between ACPA and P. gingivalis is still unclear. Methods: In this study, we made 195 recombinant monoclonal antibodies from anti-cyclic citrullinated peptide (CCP)-positive RA patients (N=6), 23 recombinant monoclonal antibodies from CCP-negative RA patients (N=1) and 110 recombinant monoclonal antibodies from healthy controls (N=4) using a single cell-based antibody cloning approach. All the 7 RA patients satisfied the 2010 ACR classification criteria. Monoclonal ACPAs were determined by commercial anti-ccp test and fine specificity with 3 synthesized citrullinated peptides. Cross-reactivity of ACPA to P. gingivalis was tested by ELISA against P. gingivalis outer membrane protein and citrullinated peptide from P. gingivalis enolase. Immunoglobulin genes of 11:30 am Effect of Synovitis, Effusion and Bone Marrow Lesions on Development of Sensitization in Knee OA: The Multicenter Osteoarthritis Study Tuhina Neogi, Boston University School of Medicine, Boston, MA Background/Purpose: Alterations in the peripheral and central nervous systems including sensitization are thought to play an important role in the pain experience in knee OA. While sensitization could occur due to an underlying predisposition, it is hypothesized that joint inflammation and/or tissue injury in OA could provide sufficient peripheral nociceptive input to cause sensitization. We previously reported that radiographic knee OA severity or duration do not appear to be related to sensitization. However, whether specific MRI lesions related to inflammation (e.g., synovitis, effusion), or mechanical load or remodeling related to noninflammatory tissue injury (e.g., bone marrow lesions (BMLs)) are risk factors for development of sensitization is not yet known. Methods: The Multicenter Osteoarthritis (MOST) Study is a NIHfunded longitudinal cohort of persons with or at risk of knee OA. Subjects had x-rays and MRIs (1.0 T) of each knee obtained at each study visit and a standardized somatosensory evaluation of mechanical temporal summation and pressure pain thresholds (PPT) at the patella at 60- and 84-months. Temporal summation was defined by increased pain during repeated mechanical stimulation (1 Hz x 30-sec) with a 60g monofilament. PPT was assessed with an algometer (1 cm2 tip, 0.5 Kg/sec) as the point at which the subject felt the pressure change to slight pain. Lower PPT indicates more sensitivity. Synovitis, effusion and BMLs on MRIs were scored using WORMS (one knee per person); these lesions were considered to be present if their score was 1 in any subregion. In sensitivity analyses, we assessed the sum of BML scores across all knee subregions as a measure of BML burden. We assessed the relation of presence of synovitis, effusion and BMLs at 60-mo to incident temporal Program Book

119 scientific sessions summation in the same knee at 84-mo among those who did not have temporal summation at 60-mo and to change in PPT in the same knee between 60- and 84-mo in the whole sample using logistic and linear regression, respectively, adjusted for relevant potential confounders, including OA severity. Results: There were 1111 subjects (mean age 66.9, mean BMI 29.7, 62% female) in the whole sample. 22.6% developed incident temporal summation at the 84-mo visit and the range in change of PPT between the 60- and 84-mo visits was to 7.15 kg/cm2. Presence of synovitis was associated with a significant decrease in PPT (i.e., more sensitized) over 24 mo, while effusion was significantly associated with incident temporal summation (Table). BML presence or burden were not associated with temporal summation or PPT. Conclusion: Inflammation, as evidenced by synovitis or effusion, may drive the occurrence of sensitization in knee OA. In contrast, BMLs do not appear to contribute to sensitization in knee OA. Early targeting of inflammation in knee OA may be a reasonable strategy to test for its ability to prevent occurrence of sensitization, thereby reducing pain severity in knee OA. MRI Lesion at 60-mo Presence of synovitis Presence of effusion Presence of BMLs Sum of BMLs ( BML burden ) (per unit increase) Incident Temporal Summation at 84-mo (N=716) Prevalence of MRI Lesion 62% 67% 79% Range: 0-19 Adjusted* OR (95% CI) 1.12 (0.75, 1.66), p= (1.01, 2.36), p= (0.56, 1.49), p= (0.92, 1.07), p=0.9 Change in PPT (60- to 84-mo) (N=1111) Prevalence of MRI Lesion 60% 66% 79% Range: 0-19 Adjusted* Beta (95% CI) (-0.52, -0.08), p= (-0.28, 0.19), p= (-0.25, 0.31), p= (-0.05, 0.04), p=0.8 * Analyses adjusted for age, sex, BMI, clinic site, race, catastrophizing, depressive symptoms, widespread pain, KL grade Disclosures: T. Neogi, None. 11:45 am Contribution at the Spinal Level of Innate and Adaptive Immunity to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice Sarah Woller, UCSD, La Jolla, CA Background/Purpose: Individuals with arthritis frequently develop persistent pain despite adequate treatment of synovitis. There is a need to better understand the mechanisms underlying pain occurring with arthritis. Recently, it has been shown that Toll-like receptor 4 (TLR4) mediates the transition from acute to chronic pain in a murine model of arthritis. Rather than developing persistent pain, animals deficient in TLR4 showed an attenuation of the late phase of pain. This receptor is unique in signaling through both MyD88-dependent and independent pathways. In order to further understand the role of TLR signaling, we examined the development of arthritis and persistent pain in mice deficient in these adaptor proteins. Methods: Adult arthritic K/BxN mice were bled and the sera pooled. 100μl of the pooled sera was injected into recipient mice on Days 0 and 2. Clinical arthritis scores and mechanical reactivity, using the up-down method of von Frey testing, were assessed over a period of 28 days in male C57Bl/6, Tlr4-/-, Triflps2, Myd88-/-, Tnf-/- and Ifnar1-/- mice. Spinal cords were collected from WT and Tlr4-/- arthritic mice and changes in gene expression were measured using nanostring ncounter analysis. Behavioral data were analyzed using repeated measures ANOVAs and Duncan New Multiple Range post-hoc analyses when appropriate. Results: As shown previously, WT mice develop a persistent increase in mechanical reactivity that outlasts the period of inflammation; the 50% withdrawal thresholds dropped from 1.66 at baseline to 0.74 on day 28. In addition, Tlr4- /- mice develop an initial increase in reactivity, which resolves concurrent with inflammation (WT AUC 13.2 and TLR4 AUC 9.7, p<.05). MyD88 and TRIF play distinct roles in the development of pain: mice lacking MyD88 do not develop swelling or allodynia (AUC 2.6, p<0.01), while those deficient in TRIF develop a prolonged allodynia (AUC 12.2), similar to WT animals and outlasting the period of inflammation. NanoString ncounter analysis of 516 immune genes in the spinal cords of WT and Tlr4-/- mice harvested on Day 10 of arthritis showed differences in expression levels of IL2, RANKL, IFNβ and TNF transcripts. Therefore, we also examined the development of pain resulting from arthritis in Rag1-/-, Ifnar1-/- and Tnf-/- mice. In the Tnf-/- mice there was an attenuated development of pain (AUC 8.0, p<.001), the Rag1 (10.0, p<.05) mice developed pain, which resolved with the resolution of inflammation similar to Tlr4-/- mice and Ifnar1-/- mice developed pain that was not different than the WT mice (AUC 12.2). Conclusion: These results suggest that pain can persist after resolution of inflammation. The innate and adaptive immune systems appear to have distinct roles in the development of the chronic pain state and this pain cannot be attributed solely to increased TNF or IFNβ transcription. Disclosures: S. Woller, None. Noon Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland Background/Purpose: The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of Hox genes along proximaldistal and anterior-posterior body axes is critical for proper limb development. Adult skin fibroblasts retain the positional embryonic Hox code and exhibit major anatomic differences in their transcriptome, defining their unique positional identities. Synovial fibroblasts (SF) in the joints of RA patients drive joint destruction and inflammation locally. We hypothesized that SF from different joints show a joint specific, positional gene expression pattern, which can predispose joints to develop certain types of arthritides, like RA or osteoarthritis (OA). Methods: SF were derived from knees, shoulders and metacarpophalangeal joints (MCPs) of RA and OA patients (n=9 each) undergoing joint replacement surgery. SF were obtained TUESDAY november 18, Program Book 117

120 scientific sessions TUESDAY november 18, 2014 also from front paws, ankles and knees of wildtype (wt) and TNF transgenic (TNFtg) mice (n=7 each). Total RNA was extracted and RNA sequencing was performed with the Illumina HiSeq 2000 sequencing system followed by hierarchical clustering. Functional annotation clustering of mrnas was done using Database for Annotation, Visualization and Integrated Discovery (DAVID). Positionally expressed RNAs were validated by qpcr. Results: Unsupervised hierarchical cluster analysis showed clustering of SF according to anatomic joint localization rather than disease. The positional embryonic HOX code was retained in SF, clearly differentiating between different joints. Among the Hox cluster residing long noncoding RNAs, HOTTIP was expressed in distal, MCP-derived SF and HOTAIR in posterior, knee-derived SF. Several positionally expressed mrnas, e.g.hoxc8 and HOXD13, were differentially expressed in MCP-derived RA and OA SF. DAVID analysis showed positional enrichment of GOTERM limb development, anterior/posterior patterning, cartilage development, extracellular region part, cell adhesion, regulation of transcription. While some outliers where found when clustering was based on mrna expression, clustering of SF into knee, shoulder and MCPs was perfect when based on mir expression. For example, mir-24 was positionally expressed in shoulder, mir-34c in MCP and mir-137 in kneederived SF, irrespective of disease. The positional expression of these mirs was confirmed in wt and TNFtg mice. Interestingly, mir-204 and mir-146a were positionally expressed in MCPs of OA but not of RA patients. These mirs were indeed positional also in wt mice but their MCP specific expression in humans correlated to ankle specific expression in wt mice. In addition, their expression was significantly changed in ankles of TNFtg compared to wt mice. Conclusion: SF from joints of different anatomic sites exhibit particularly different mrna and mir expression patterns suggesting that functionally unique subsets of SF populate different joints. The existence of positionally imprinted risk signatures of SF may account for the susceptibility of certain synovial joints to develop RA in humans and mice and may have major implications for synovial disease pathways operating early in RA. Disclosures: C. Ospelt, IMI BTCure, EuroTEAM, IAR, CABMM start-up grant, 2. 12:15 pm Aortitis: Outcomes from a Cohort of 196 Patients Alison Clifford, Cleveland Clinic Foundation, Cleveland, OH Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease, or in isolation. In patients with focal isolated aortitis (FIA), surgery alone may be curative; however, new vascular lesions have been reported to develop in between 5-47% of cases. The risk of progression to systemic disease and optimal management strategy for FIA patients is uncertain. Methods: Patients with biopsy-proven aortitis, diagnosed following thoracic aortic surgery at the Cleveland Clinic between 1996 and 2012, were retrospectively reviewed. Patients were classified into clinical subgroups [Giant cell arteritis (GCA), Takayasu s arteritis (TAK), Focal Isolated Aortitis (FIA) or Other] at the time of surgery using pre-defined criteria. Symptoms, pathology, laboratory and imaging results were recorded at surgery and over time using a standardized database. Patients with FIA at surgery were followed for progression to systemic disease and outcomes of clinical subgroups were compared. Results: Of 7,551 patients who underwent thoracic aortic surgery between , 196 patients with biopsy-proven aortitis were identified for review. Median age at surgery was 69 years (range 15-88) and 67% were female. At the time of surgery, 129 (65.8%) patients met criteria for FIA, 42 (21.4%) for GCA, 14 (7.1%) for TAK and 11 (5.6%) for Other. A minimum of 6 months of clinical follow-up was available for 73 FIA patients. During follow-up (median 45 months, range months), 14/73 (19.2%) FIA patients developed symptoms of systemic disease, 17/40 (42.5%) developed elevated inflammatory markers, 29/65 (44.6%) developed new vascular lesions on imaging, 30/73 (41.1%) required a second vascular surgery, 7(9.6%) dissected and 9 died (12.3%.) Ultimately 23 of 73 (31.5%) with FIA progressed to have features of a systemic disease: 21 GCA, 1 TAK and 1 Other. When compared to patients with known systemic disease at surgery, patients with FIA were less likely to develop symptoms (p=0.01) but no different with respect to development of elevated inflammatory markers (p=0.19), new vascular lesions by imaging (p=0.92), need for further vascular surgery (p=0.84), dissection (p=0.40) or death (p=0.76) over time. Only 12 patients with FIA at surgery received immunosuppressive therapy post-operatively. Over time, 0/11 treated FIA patients with follow-up imaging developed aneurysms, but 2 (18.2%) developed new stenoses. Among the 54 untreated FIA patients with imaging available, 27 (50%) developed new lesions (23 aneurysms and 5 stenoses.) Additional tissue obtained after subsequent surgery in 2 untreated FIA patients revealed persistent inflammation in the distal aorta. Conclusion: Over time, nearly one third of patients classified as FIA at the time of surgery progressed to have features of a systemic autoimmune disease. Patients with FIA are less likely to develop overt symptoms, but equally likely to develop elevated inflammatory markers or new vascular lesions on imaging when compared to GCA, TAK and Others. These patients require regular clinical follow-up and serial imaging to assess for progression. Disclosures: A. Clifford, None. ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at Program Book * Sessions denoted with an asterisk were sold out as of August 30.

121 scientific sessions Westin Paine (Lobby) Antiphospholipid Syndrome (071) Speaker: Doruk Erkan, MD review the spectrum of antiphospholipid syndrome explain the diagnostic utility of antiphospholipid antibody tests discuss the management of persistently antiphospholipid antibody-positive patients with different antiphospholipid antibody-related clinical manifestation Westin Otis (Lobby) *Challenging Cases in Osteoporosis Management (072) Speaker: Kenneth G. Saag, MD, MSc recognize bisphosphonate drug holidays discuss timing of use of various anti-osteoporosis therapies in postmenopausal osteoporosis recognize current treatment approaches to steroid-induced osteoporosis identify other forms of metabolic bone disease that present to rheumatologists as low bone mass Westin Stone (Lobby) Osteoarthritis: Update 2014 (075) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis Westin Webster (Lobby) *Psoriatic Arthritis (076) Speaker: Philip Mease, MD discuss advances in understanding of the pathogenesis of psoriatic arthritis and implications for diagnosis and treatment learn the value of and how to accomplish a treat-to-target approach to psoriatic arthritis in daily practice appraise the data on current and emerging treatments for psoriatic arthritis, including ustekinumab, apremilast, IL-17 inhibitors and other emerging agents Westin Hancock (Lobby) Crystal: Diagnosis and Management of Gout (073) Speaker: John S. Sundy, MD, PhD discuss the pathogenesis and pathophysiology of acute and chronic gout, including the distinctive treatment modalities affecting patient outcomes appreciate the renal mechanisms underlying the hyperuricemia of most gout patients and therapeutic rationales applied to urate-lowering therapies critically assess current ACR recommendations for the treatment of acute and chronic manifestations of gout Westin Revere (Lobby) Non-Surgical Treatments for Osteoarthritis (074) Speaker: David T. Felson, MD, MPH explain how to measure the relative efficacy of treatments using effect sizes illustrate knowledge of data supporting efficacy of exercise, bracing, glucosamine, intra-articular steroids and hyaluronic acid in osteoarthritis identify pros and cons of treatments modifying knee biomechanics for knee osteoarthritis including braces, orthotics, the All Phases of Step-cycle system and others assess emerging treatments for osteoarthritis such as nerve growth factor inhibitors and where they may fit in the therapeutic armamentarium Westin Adams (Mezzanine) Spondyloarthropathy: An Update (077) Speaker: Robert D. Inman, MD identify the challenge in the early diagnosis of spondyloarthritis discuss mechanisms of disease pathogenesis describe current treatment options for spondyloarthritis Westin Alcott (Mezzanine) *Systemic Lupus Erythematosus: Lupus Nephritis (078) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis Westin Douglas (Mezzanine) Temporal Arteritis (079) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid sparing agents TUESDAY november 18, Program Book 119

122 scientific sessions describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis Westin Faneuil (Mezzanine) Vaccinations for Patients on Biologic Therapies (080) Speaker: Kevin L. Winthrop, MD, MPH recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety ACR SESSIONS 1:00 2:00 pm Ballroom East Clinical Issues Associated with the Use of Methotrexate Moderator: Mary E. Cronin, MD review the pharmacology of methotrexate discuss rational prescription of methotrexate as a solo agent or in combination therapy identify side effects and their prevention and/or treatment 1:00 pm Clinical Issues Associated with the Use of Methotrexate Joel M. Kremer, MD 253 B New Regulatory T Cells Moderators: George C. Tsokos, MD and Amit Golding, MD, PhD Speaker: Harvey Cantor, MD describe the two major T cell subsets that mediate regulatory activity summarize evidence for the contribution of Treg to selftolerance summarize evidence that defective Treg activity may contribute to autoimmune disease 210 B Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside Moderators: Tuhina Neogi, MD, PhD and Kerry Stone, MD Speaker: Helene Langevin, MD identify the different types of specialized and general connective tissues that may be of relevance for musculoskeletal pain describe the alterations in connective tissue functioning found in chronic low back pain and recognize the potential roles of inflammatory and fibrotic pathways in alterations of these connective tissues develop scientific rationale for why certain physical therapy and exercise approaches may be beneficial for chronic low back pain ARHP SESSIONS 1:00 2:00 pm TUESDAY november 18, :30 pm Clinical Issues Associated with the Use of Methotrexate Michael E. Weinblatt, MD Exhibit Hall C Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases but Not in Others Moderator: John M. Davis III, MD, MS Speaker: Peter Barnes, DM, DSc review how inflammatory genes are activated through histone acetylation appraise how corticosteroid suppress inflammation by engaging histone deacetylase-2 describe how oxidative stress induces corticosteroid resistance by inactivating HDAC2 review how this steroid resistance mechanism may be reversed, leading to new therapeutic approaches 255 Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease Moderator: Jennifer L. Trizuto, MPT Speaker: Charles E. Argoff, MD describe the various causes for neuropathy evaluate the treatment options available for treatment of neuropathy discuss neuropathic signs and symptoms in the context of various rheumatic diseases 257 A Pharmacotherapy: What s New in Rheumatology Moderator: Joan C. McTigue, PA-C, MS Speaker: Susan Bruce, PharmD critique the evidence of triple therapy vs. early aggressive biologic therapies for arthritis in light of treat-to-target guidelines Program Book

123 scientific sessions explain the mechanism of action of the new kinase inhibitors and recognize where the new oral agent tofacitinib fits in the current armamentarium of therapies examine existing and emerging treatment options for systemic lupus erythematosus ACR STUDY GROU 1:00 2:00 pm Study Groups are non-cme activities open to all attendees. 109 A ACR-EULAR Study Group: Toward a New Understanding of Myositis Through International Collaboration 1:00 pm Development of Transatlantic Registry Studies in Myositis Ingrid E. Lundberg, MD, PhD 1:30 pm New Insights into the Biology of Myositis Ann M. Reed, MD 107 B Autoantibodies in Diagnosis and Follow-Up of Rheumatic Diseases Study Group 1:15 pm Oral Health in Behçet s Disease Pathogenesis Haner Direskeneli, MD 1:30 pm Epidemiology of Behçet s Disease Alfred Mahr, MD, PhD 1:45 pm Biologics in the Treatment of Behçet s Disease: Which and When? Ina Kotter, MD, PhD 157 B Biosimilars in Rheumatology: Update Study Group 1:00 pm Introduction Morton A. Scheinberg, MD, PhD 1:10 pm Biosimilars in Asia: Where We Are Arvind Chopra, DNB, MBBS, MD 1:35 pm Biocopies and Biosimilars: Concerns and Risks Jonathan Kay, MD 1:00 pm IgG4-related Disease: Historical Background and Clinical Spectrum Hiroki Takahashi, MD 1:30 pm IgG4-related Disease: Pathophysiology and Diagnostic Challenges John H. Stone, MD, MPH 160 B Behçet s Disease Study Group assess epigenetic mechanisms and recent advances that implicate dynamic epigenetic changes during the course of Behçet s disease discuss recent data related to oral health and its effect on prognosis discuss epidemiology, genetic susceptibility factors and potential non-genetic risk determinants review the existing data of biological treatment options and management recommendations for Behçet s disease patients with severe ocular manifestations or treatment resistant symptoms 1:00 pm Epigenetics in Behçet s Disease Amr H. Sawalha, MD 151 A Closing the Gap Psoriasis to Psoriatic Arthritis Study Group 1:00 pm Review the Current Evidence of Predictors of Psoriasis Patients to Develop Psoriatic Arthritis Joseph F. Merola, MD and Vinod Chandran, MBBS, MD, DM, PhD 1:24 pm Identify Strategies to Detect Psoriatic Arthritis Earlier in Its Disease Course (Clinical Presentation, Biomarkers, or Imaging) Christopher T. Ritchlin, MD, MPH 1:36 pm Optimization of Screening Methods for Psoriatic Arthritis M. Elaine Husni, MD, MPH and Abrar A. Qureshi, MD, MPH 254 A Global Musculoskeletal Health Initiatives Study Group 1:00 pm Need for Standardized Surveillance Tools for Prevalence and Impact - Variations between International Surveys Lyn March, MBBS, MSc, PhD 1:12 pm Healthcare Quality Indicators to Enable Equity of Care Ingemar F. Petersson, MD, PhD TUESDAY november 18, Program Book 121

124 scientific sessions TUESDAY november 18, :24 pm Indicators of Equity of Care Francis Guillemin, MD, PhD 1:36 pm Measuring Musculoskeletal Disability in Developing Countries Damian Hoy, BPhysio, PhD 1:48 pm Round Table Discussion to Agree Core Questions for Health Interview and Examination Surveys Anthony D. Woolf, MBBS 259 A High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging in Arthritis Study Group 1:00 pm Radiology Perspective on the Role of Magnetic Resonance Imaging and High-Resolution Peripheral Quantitative Computed Tomography in Trials and Clinical Practice Charles G. Peterfy, MD, PhD 1:12 pm Multimodality Comparison: High-Resolution Peripheral Quantitative Computed Tomography With Magnetic Resonance Imaging and Ultrasound Xiaojuan Li, PhD 1:24 pm High-Resolution Peripheral Quantitative Computed Tomography in the Study of Psoriatic Arthritis Stephanie Boutroy, PhD 1:36 pm Reliability of High-Resolution Peripheral Quantitative Computed Tomography and Use for Longitudinal Studies Erosion Assessment Stephanie Finzel, MD 1:48 pm Reliability of High-Resolution Peripheral Quantitative Computed Tomography and Use for Longitudinal Studies Joint Space Assessment Andrew J. Burghardt, BS 156 B Juvenile Arthritis Workgroup (JAW) Study Group 1:40 pm Study Design for Treating Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis Carol A. Wallace, MD 153 B Latin American Study Group 1:00 pm Education in Rheumatology Carlo Vinicio-Caballero, MD 1:30 pm Red de Excelencia en Artritis Latinoamerica Loreto Massardo, MD 204 A Neuroendocrine Immunology Study Group 256 1:00 pm Neuroendocrine Modulation of Pain Leslie J. Crofford, MD 1:20 pm Stress and Pain John McBeth, PhD 1:40 pm Autonomic Mediators of Inflammation and Pain Gary S. Firestein, MD Pediatric Rheumatology Imaging Study Group 1:00 pm The Enthesis in Children, Normal Anatomy and Pathologic Findings Johannes Roth, MD 1:20 pm Frequency of Spinal Involvement in Children with Juvenile Idiopathic Arthritis Xenofon Baraliakos, MD 1:40 pm Magnetic Resonance Imaging vs High-resolution Peripheral Quantitative Computed Tomography for Erosions in Children with Juvenile Idiopathic Arthritis Stephanie Finzel, MD 1:00 pm Treatment of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: What We Know and What We Don t Randy Q. Cron, MD, PhD 1:20 pm A Scoring System for Evaluation of Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis Yoginder Vaid, MD 104 B Polymyalgia Rheumatica Study Group 1:00 pm Update on Polymyalgia Rheumatica Guidelines Bhaskar Dasgupta, MD Program Book

125 scientific sessions 1:20 pm Prospective Study of Overlap in Inflammatory Diseases of the Elderly Eric L. Matteson, MD, MPH 1:40 pm Glucocorticoid Receptors in Polymyalgia Rheumatica Christian Dejaco, MD, PhD 102 A Sjögren s Syndrome Study Group 1:00 pm Sjögren s Cohort in India Debashish Danda, DM 154 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T1- and T2-weighted, fat-saturated, STIR and contrast-enhanced) and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging 1:15 pm Sjögren s Cohorts in South America Juan-Manuel Anaya, MD PhD 159 Musculoskeletal Ultrasonography: Basic (238) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP 1:30 pm The United Kingdom Sjögren s Initiative Wan-Fai Ng, MA, PhD, CCT 1:45 pm Oklahoma Sjögren s Cohort Kathy Silvis, PhD ACR/ARHP WORKSHO 1:15 3:15 pm 161 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Dermatopathology of Rheumatic Diseases (236) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice 152 explain basic concepts of ultrasound physics define how to perform a proper ultrasound examination identify various tissues in an ultrasound image The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (239) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP define the importance of using disease-activity measurement tools in daily practice, the barriers which hinder routine widespread use and how these barriers can be overcome in nearly any practice setting review the practice of several of the most common and well-recognized disease activity measurement tools used in rheumatology care, including the Disease Activity Score for 28 Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for rheumatoid arthritis; the Psoriatic Arthritis Response Criteria (PsARC) for psoriatic arthritis; measurements of spine and hip flexibility as well as the Ankylosing Spondylitis Disease Activity Score (AS-DAS) for spondyloarthropathies; and the modified Rodnan skin score for systemic sclerosis TUESDAY november 18, Program Book 123

126 ACR SESSION 2:00 2:30 pm scientific sessions Ballroom West ACR Business Meeting This session is not eligible for CME credit. Moderator: Joseph Flood, MD participate in a meeting with ACR leadership recognize ACR initiatives summarize what the ACR is doing to address various practice issues and other issues College Year in Review Election of ACR Secretary Election of ACR Board of Directors Members Installation of 78 th ACR President ACR SESSIONS 2:30 4:00 pm 52 A Novel Regulatory Cell Subsets Moderator: Jennifer H. Anolik, MD, PhD review the mechanisms by which immune cell subsets regulate inflammatory responses recognize the role that mesenchymal stem cells play in downmodulating immune responses recognize the role that antigen-presenting cell subsets play in regulating immune responses 2:30 pm Regulatory Roles of Mesenchymal Stem Cells Arnold I. Caplan, PhD 3:00 pm Regulatory B Cells Claudia Mauri, PhD 3:30 pm Regulatory Macrophages James Hutchinson, MBBChir, PhD TUESDAY november 18, Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Ed Pd PrM FIT Moderators: Sharon L. Kolasinski, MD and Deana M. Lazaro, MD discuss novel approaches to curriculum development for medical students and residents in the musculoskeletal and rheumatic diseases discuss new approaches to teaching in the rheumatic and musculoskeletal diseases determine the unique and important roles of the clinician scholar educator in medical education and training 2:30 pm Development of Curricula in Metabolic Bone Disease Juliet Aizer, MD, MPH 2:50 pm Web-Based Learning Portfolios in Pediatric Rheumatology Michal Jennifer Cidon, MD 3:10 pm Development of Rheumatology Objective Structured Clinical Examination (ROSCE) Stations With Follow-up Modules Lisa G. Criscione-Schreiber, MD 3:30 pm A Dynamic, Competency Based Learning Modules Rodney Tehrani, MD 3:50 pm Question and Answer 210 B Psoriatic Arthritis: Skin, Entheses and Joints Moderators: Rennie N. G. Howard, MD and Rebecca L. Manno, MD, MHS describe the clinical manifestations of the variants of psoriasis and discuss current treatment options for psoriasis describe the concept of the synovio-entheseal complex and its role in psoriatic arthritis describe theories of the pathogenesis of psoriatic arthritis, discuss the clinical manifestations and diagnosis of psoriatic arthritis and develop a rational approach to the treatment of psoriatic arthritis 2:30 pm Psoriatic Kenneth B. Gordon, MD 3:00 pm The Synovio-Entheseal Complex Dennis McGonagle, PhD 3:30 pm Psoriatic Arthritis Christopher T. Ritchlin, MD, MPH ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm Exhibit Hall C ACR Late-Breaking Abstract Session Moderator: Chester V. Oddis, MD Program Book

127 scientific sessions Ballroom East 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Moderators: Daniel J. Wallace, MD and Maureen A. McMahon, MD 2:30 pm Introductory Talk Daniel J. Wallace, MD 2:45 pm Identification of Urinary Biomarkers for Lupus Nephritis Carolina Landolt-Martincorena, MD Carolina Landolt-Marticorena 1, Stephenie Prokopec 2, Heather Reich 3, James Scholey 4, Carmen Avila-Casado 3, Paul R. Fortin 5, Paul Boutros 2 and Joan wither 6, 1 Toronto Western Hospital, Toronto, ON, 2 Ontario Institute for Cancer Research, Toronto, ON, 3 University Health Network, Toronto, ON, 4 The Toronto Western Hospital, Toronto, ON, 5 Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, 6 University of Toronto, Toronto, ON 3:00 pm Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project Maria Dall Era 1, Kurt Snipes 2, Miriam Cisternas 3, C. Gordon 4 and Charles G. Helmick 5, 1 University of California, San Francisco, San Francisco, CA, 2 California Department of Public Health, Sacramento, CA, 3 MGC Data Services, San Diego, CA, 4 Medical School, Birmingham, United Kingdom, 5 Centers for Disease Control and Prevention, Atlanta, GA 3:15 pm Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosus Basmah Jalil 1, Wilmer Sibbitt Jr 2, Romy Cabacangun 3, Clifford Qualls 3, Arthur Bankhurst 4 and Roderick Fields 5, 1 University of New Mexico, Albuquerque, NM, 2 University of New Mexico HSC, Albuquerque, NM, 3 UNM, Albuquerque, NM, 4 University of NM Med Ctr, Albuquerque, NM, 5 University of New Mexico School of Medicine, Albuquerque, NM 3:30 pm CMR with Quantitative T2 Mapping in Patients with Active SLE Stacy P. Ardoin 1, Wael Jarjour 2, Subha V. Raman 2, Amanda Kibler 2 and Tam Tran 2, 1 Ohio State University College of Medicine, Columbus, OH, 2 Ohio State University, Columbus, OH 3:45 pm Lung Cancer in SLE Sasha Bernatsky 1, Rosalind Ramsey-Goldman 2, Michelle Petri 3, Murray B. Urowitz 4, Dafna D. Gladman 4, Edward H. Yelin 5, Christine Peschken 6, John G. Hanly 7, James E. Hansen 8, Jean-Francois Boivin 1, Lawrence Joseph 1, Patrice Chrétien Raymer 9, Mruganka Kale 10, Ann E. Clarke 11 and Systemic Lupus International Collaborating Clinics (SLICC) 12, 1 McGill University, Montreal, QC, 2 Northwestern University, Chicago, IL, 3 Johns Hopkins University School of Medicine, Baltimore, MD, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 University of California, San Francisco, San Francisco, CA, 6 University of Manitoba, Winnipeg, MB, 7 Dalhousie University and Capital Health, Halifax, NS, 8 Yale University, New Haven, CT, 9 McGill University Health Centre, Montreal, QC, 10 RI McGill Univ Health Ctr, Montreal, QC, 11 University of Calgary, Calgary, AB, 12 Systemic Lupus International Collaborating Clinics (SLICC), ON 102 A Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis Moderators: Ellen M. Gravallese, MD and Julia F. Charles, MD, PhD 2:30 pm Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a 2A Receptor (A2AR) Aranzazu Mediero 1, Tuere Wilder 1 and Bruce N. Cronstein 2, 1 NYU School of Medicine, New York, NY, 2 NYU School of Medicine, Division of Rheumatology, New York, NY 2:45 pm BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis Esmeralda Blaney Davidson 1, Arjen Blom 2, Arjan van Caam 1, Elly Vitters 2, Miranda Bennink 1, Wim van den Berg 2, Fons van de Loo 1 and Peter van der Kraan 2, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Radboud University Medical Center, Nijmegen, Netherlands 3:00 pm Deletion of the Inhibitory Receptor Motif, ITIM, on DC- STAMP Alters Osteoclast Differentiation and Function Yahui Grace Chiu 1, Edward M. Schwarz 1, Dongge Li 1, Yuexin Xu 1, Minsoo Kim 1 and Christopher T. Ritchlin 2, 1 University of Rochester, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY 3:15 pm Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Anita Boyapati 1, Jérôme Msihid 2, Emmanuelle Cousin 2, Ling Cai 3, Janet van Adelsberg 1, Jennifer D Hamilton 1, Neil Graham 1, Tanya Momtahen 4 and Stefano Fiore 4, 1 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2 Sanofi R&D, France, Chilly-Mazarin, France, 3 Sanofi R&D, China, Beijing, China, 4 Sanofi, Bridgewater, NJ 3:30 pm A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes Xian-Peng Ge, Susan Y. Ritter, Julia F. Charles, Kelly Tsang and Antonios O. Aliprantis, Brigham and Women s Hospital, Harvard Medical School, Boston, MA TUESDAY november 18, Program Book 125

128 scientific sessions TUESDAY november 18, :45 pm Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis Akilan Krishnamurthy 1, Vijay Joshua 1, Heidi Wähämaa 1, Catia Cerqueira 1, Lars Klareskog 2, Vivianne Malmström 3, Jimmy Ytterberg 1 and Anca I Catrina 1, 1 Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska Institute, Stockholm, Sweden, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden 107 B Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I Moderator: Shiva Shahrara, PhD 2:30 pm C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis Munitta Muthana 1, Sarah Hawtree 1, Holly Davies 1, Hannah Roberts 1, Sachin Khetan 1, Mohammed Akil 2, Fiona Wright 1, Barbara Ciani 1, Ursula Fearon 3, DJ Veale 4 and Anthony G. Wilson 5, 1 University of Sheffield, Sheffield, United Kingdom, 2 Rheumatology Department, Sheffield South Yorkshire, United Kingdom, 3 Translational Rheumatology Research Group, Dublin, Ireland, 4 St. Vincent s University Hospital, Dublin, Ireland, 5 University College Dublin, Dublin, Ireland 2:45 pm The Differential Impact of Obesity on the Pathogenesis of RA or Preclinical Models Is Contingent on the Disease Status Zhenlong Chen 1, Seung-jae Kim 1, Abdul Essani 1, Michael V. Volin 2, Suncica Volkov 1, William Swedler 1, Shiva Arami 1, Giamila Fantuzzi 1, Nadera J. Sweiss 1 and Shiva Shahrara 1, 1 University of Illinois at Chicago, Chicago, IL, 2 Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 3:00 pm Tofacitinib Regulates Synovial Angiogenesis in Psoriatic Arthritis through Induction of Negative Feedback Inhibitors Wei Gao, Jennifer McCormick, Carl Orr, Mary Connolly, Ursula Fearon and Douglas J. Veale, Translational Rheumatology Research Group, Dublin, Ireland Horst 2 and Sander W. Tas 1, 1 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2 Arthrogen BV, Amsterdam, Netherlands 3:45 pm Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell Based BioMAP Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes? Alison O Mahony 1, Ellen L. Berg 1, Xitong Li 1, Markus R. John 2, Kandeepan Ganeshalingam 2 and Ernest H. Choy 3, 1 BioSeek, South San Francisco, CA, 2 F. Hoffmann-La Roche, Basel, Switzerland, 3 Cardiff University, Cardiff, United Kingdom 151 A Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease Moderators: Andy Abril, MD and John D. Carter, MD 2:30 pm Rituximab in IgG4-Related Disease: A Large Single-Center Experience Zachary Wallace, Mollie Carruthers and John H. Stone, Massachusetts General Hospital, Boston, MA 2:45 pm IgG4-Related Disease: Baseline Features in 100 Patients with Biopsy-Proven Disease Zachary Wallace 1, Vikram Deshpande 1, Hamid Mattoo 2, Vinay Mahajan 2, Mollie Carruthers 1, Maria Kulikova 1, Shiv Pillai 1 and John H. Stone 1, 1 Massachusetts General Hospital, Boston, MA, 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA 3:00 pm Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren s Syndrome and Healthy Controls Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 3:15 pm IL-38: A New Factor in Rheumatoid Arthritis Shinjiro Kaieda 1, Katsuya Kanezaki 2, Naomi Yoshida 1, Yukiko Kunitake 1, Hiroaki Ida 1 and Tomoaki Hoshino 1, 1 Kurume University School of Medicine, Kurume, Japan, 2 Nagata orthopedic hospital, Omuta, Japan 3:30 pm Non-Canonical NF-Kappab Signaling Promotes Angiogenesis in a Novel 3D Spheroid Model of Rheumatoid Arthritis Synovial Inflammation Chrissta X. Maracle 1, Boy Helder 1, Ae-Ri Noort 1, Corine van der 3:15 pm Comparison of Outcomes in Septic Arthritis Caused By MRSA and MSSA Deepa Panikkath 1, Sian Yik Lim 2, Swetha Gadwala 3, Ragesh Panikkath 3 and Kenneth Nugent 2, 1 Texas Tech University of Health Sciences, Lubbock, LUBBOCK, TX, 2 Texas Tech University Health Sciences Center, Lubbock, TX, 3 Texas Tech University of Health Sciences, Lubbock, TX 3: WITHDRAWN Program Book

129 scientific sessions 3: Human Papilloma Virus and Chlamydia Trachomatis Infections in Rheumatoid Arthritis Under Anti-TNF Therapy Mariana G Waisberg 1, Ana C.M. Ribeiro 2, Wellington M. Candido 1, Poliana B. Medeiros 1, Cezar N. Matsuzaki 1, Mariana C. Beldi 1, Maricy Tacla 1, Helio H. Caiaffa-Filho 1, Eloisa Bonfá 1 and Clovis A Silva 3, 1 Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2 University of Sao Paulo, Sao Paulo, Brazil, 3 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 258 B Rheumatoid Arthritis Clinical Aspects V: Mortality and Other Outcomes Moderators: Jennifer Barton, MD and Aryeh Fischer, MD Pharma, Inc., Deerfield, IL, 5 Axio Research LLC, Seattle, WA 3:30 pm Time-to-Remission, Time-to-Relapse and Disease Severity at the Time of Relapse in RA- Results from the Ontario Best Practices Research Initiative (OBRI) Bindee Kuriya 1, Xiuying Li 2, Binu Jacob 2, Pooneh Akhavan 3, Jessica Widdifield 1, Mark Tatangelo 1, Janet E. Pope 4, Edward Keystone 5 and Claire Bombardier 6, 1 University of Toronto, Toronto, ON, 2 University Health Network, Toronto General Research Institute, Toronto, ON, 3 Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, 4 Western University, London, ON, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Institute for Work & Health, Toronto, ON 2:30 pm Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts Sam Norton 1, Elena Nikiphorou 2, Lewis Carpenter 2, David Walsh 3, Patrick Kiely 4, Josh Dixey 5 and Adam Young 6, 1 King s College London, London, United Kingdom, 2 University of Hertfordshire, Hatfield, United Kingdom, 3 University of Nottingham, Nottingham, United Kingdom, 4 St. Georges Healthcare NHS Trust, London, United Kingdom, 5 New Cross Hospital, Wolverhampton, United Kingdom, 6 ERAS, St Albans City Hospital, St Albans, United Kingdom 2:45 pm Improvements in Rheumatoid Arthritis Related Fatigue Are Driven By Reductions in Pain, Not Disease Activity Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Katie L Druce, Gareth T Jones, Gary J. Macfarlane and Neil Basu, University of Aberdeen, Aberdeen, United Kingdom 3:00 pm Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis Juha Asikainen 1, Kalevi Kaarela 2, Heidi Mäkinen 3, Hannu Kautiainen 4, Pekka Hannonen 5, Tuomas Rannio 6 and Tuulikki Sokka 7, 1 Jyvaskyla Central Hospital, Jyväskylä, Finland, 2 Jyväskylä Central Hospital, Jyväskylä, Finland, 3 Tampere University Hospital, Tampere, Finland, 4 Medcare Oy, Äänekoski, Finland, 5 Jyväskylä Central Hospital, Jyvaskyla, Finland, 6 Kuopio University Hospital, Kuopio, Finland, 7 Jyvaskyla Central Hospital, Jyvaskyla, Finland 3:15 pm Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients Vibeke Strand 1, Robert J. Holt 2, Katherine C. Saunders 3, Jeffery D. Kent 4, Ping Xu 5, Amy Y. Grahn 4, Marc Mason 3 and Carol J. Etzel 3, 1 Stanford University, Palo Alto, CA, 2 University of Illinois Chicago, Chicago, IL, 3 Corrona, LLC., Southborough, MA, 4 Horizon 3:45 pm Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy T. Martijn Kuijper 1, J.J. Luime 1, P.H.P. de Jong 1, A. H. Gerards 2, D. van Zeben 3, I. Tchetverikov 4, P.B.J. de Sonnaville 5, M. van Krugten 6, B. Grillet 7, J.M.W. Hazes 8 and A.E.a.M. Weel 9, 1 Erasmus University Medical Center, Rotterdam, Netherlands, 2 Vlietland Hospital, Schiedam, Netherlands, 3 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 4 Albert Schweitzer Hospital, Dordrecht, Netherlands, 5 Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 6 Admiraal de Ruyter Hospital, Vlissingen, Netherlands, 7 ZorgSaam Hospital, Terneuzen, Netherlands, 8 Erasmus MC, Rotterdam, Netherlands, 9 MD, PhD, Rotterdam, Netherlands 104 B Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Includes 2013 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Moderator: Miriam A. Shelef, MD, PhD and Bruce N. Cronstein, MD 2:30 pm 2013 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Bruce N. Cronstein, MD 2:45 pm Distinctive DNA Methylome Signatures in Early Rheumatoid Arthritis (RA) Synoviocytes Compared with Longstanding (RA) and Other Inflammatory Arthritides Rizi Ai 1, John W. Whitaker 2, David L. Boyle 3, Paul Peter Tak 4, Danielle M. Gerlag 5, Wei Wang 6 and Gary S. Firestein 3, 1 UC San Diego, La Jolla, CA, 2 UCSD, San Diego, CA, 3 University of California at San Diego School of Medicine, La Jolla, CA, 4 Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, 5 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6 UCSD, La Jolla, CA TUESDAY november 18, Program Book 127

130 scientific sessions TUESDAY november 18, :00 pm Histone Deacetylase One Contributes to the Auto- Aggressive Phenotype of Rheumatoid Arthritis Sarah Hawtree 1, Munitta Muthana 1, J. Mark Wilkinson 1, Anthony G. Wilson 1 and Mohammed Akil 2, 1 University of Sheffield, Sheffield, United Kingdom, 2 Rheumatology Department, Sheffield South Yorkshire, United Kingdom 3:15 pm SH2 Domain-Containing Phosphatase 2 Promotes Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes Stephanie M. Stanford 1, German R. Aleman Muench 1, Cristiano Sacchetti 1, Lifan Zeng 2, David L. Boyle 3, Gen-Sheng Feng 4, Zhong-Yin Zhang 2, Maripat Corr 3, Gary S. Firestein 3 and Nunzio Bottini 1, 1 La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2 Indiana University School of Medicine, Indianapolis, IN, 3 University of California at San Diego School of Medicine, La Jolla, CA, 4 University of California at San Diego Division of Biological Sciences, La Jolla, CA 3:30 pm The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion Beatrix Bartok, University of California, San Diego, La Jolla, CA 3:45 pm Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation Nida Meednu, Hengwei Zhang, Teresa Owen, Lianping Xing and Jennifer H. Anolik, University of Rochester, Rochester, NY 253 B Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis Late in Development Moderators: Jonathan Kay, MD and Joseph A. Markenson, MD 2:30 pm Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRá Monoclonal Antibody in Patients with Rheumatoid Arthritis Gerd Burmester 1, Iain B. McInnes 2, Joel M. Kremer 3, Pedro Miranda 4, Mariusz Korkosz 5, Jiri Vencovsky 6, Andrea Rubbert- Roth 7, Eduardo Mysler 8, Sara Sandbach 9, Matthew A. Sleeman 9, Alex Godwood 9, David Close 9 and Michael Weinblatt 10, 1 Charité University Medicine Berlin, Berlin, Germany, 2 University of Glasgow, Glasgow, United Kingdom, 3 Albany Medical College and the Center for Rheumatology, Albany, NY, 4 Centro de Estudios Reumatologicos, Santiago, Chile, 5 Malopolskie Centrum Medyczne, Krakow, Poland, 6 Charles University Institute of Rheumatology, Praha, Czech Republic, 7 University of Cologne, Koln, Germany, 8 OMI, Buenos Aires, Argentina, 9 MedImmune Ltd, Cambridge, United Kingdom, 10 Brigham & Women s Hospital, Harvard Medical School, Boston, MA 2014 Program Book 2:45 pm Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis Edward C. Keystone 1, Peter C. Taylor 2, Mark C Genovese 3, Douglas E. Schlichting 4, Inmaculada De La Torre 5, Scott D. Beattie 4 and Terence Rooney 4, 1 Mount Sinai Hospital, Toronto, ON, 2 University of Oxford, Oxford, United Kingdom, 3 Stanford University Medical Center, Palo Alto, CA, 4 Eli Lilly and Company, Indianapolis, IN, 5 Eli Lilly and Company, Alcobendas, Spain 3:00 pm Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Roy Fleischmann 1, Dennis L. Decktor 2, Chunpeng Fan 3, Hubert Van Hoogstraten 3 and Mark C Genovese 4, 1 Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3 Sanofi, Bridgewater, NJ, 4 Stanford University Medical Center, Palo Alto, CA 3:15 pm A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Arthur Kavanaugh 1, Dennis L. Decktor 2, Chunpeng Fan 3, Janet van Adelsberg 2, Renata Martincova 4 and Mark C. Genovese 5, 1 University of California San Diego, La Jolla, CA, 2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3 Sanofi, Bridgewater, NJ, 4 Sanofi Czech Republic, Prague, Czech Republic, 5 Stanford University Medical Center, Palo Alto, CA 3:30 pm A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel ), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA) Sang-Cheol Bae 1, Jinseok Kim 2, Jung-Yoon Choe 3, Won Park 4, So-Ra Lee 5, Yongho Ahn 6 and Yunjeong Seo 5, 1 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2 Jeju National University, Jeju, Korea, South Korea, 3 Catholic University of Daegu School of Medicine, Daegu, South Korea, 4 Inha University Hospital, Incheon, South Korea, 5 Hanwha Chemical, Seoul, South Korea, 6 Hanwha Chemical, Daejeon, South Korea 3:45 pm A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate Mark C. Genovese 1, Maria Greenwald 2, Christine Codding 3, Mario H. Cardiel 4, Anna Zubrzycka-Sienkiewicz 5, Alan J. Kivitz 6,

131 scientific sessions Steve Wisseh 7, Kathyjo Shay 8 and Jay P. Garg 8, 1 Stanford University Medical Center, Palo Alto, CA, 2 Desert Medical Advances, PALM DESERT, CA, 3 Health Research of Oklahoma, Oklahoma City, OK, 4 Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 5 ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, 6 Altoona Center for Clinical Research, Duncansville, PA, 7 Biocis, Chicago, IL, 8 Astellas Pharma Global Development, Northbrook, IL Ballroom West Spondyloarthropathies and Psoriatic Arthritis IV Clinical Aspects Axial Spondyloarthritis Moderators: John D. Reveille, MD and Nigil Haroon, MD, PhD, DM 2:30 pm Cervical Spine Fracture and Mortality in Ankylosing Spondylitis Katherine D. Wysham, Sara G. Murray, Nancy K. Hills, Edward H. Yelin and Lianne S. Gensler, University of California, San Francisco, San Francisco, CA 2:45 pm A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis Sofia Ramiro 1, A.M. van Tubergen 2, Robert Landewé 3, Annelies Boonen 2, Carmen Stolwijk 2, Maxime Dougados 4, Filip Van den Bosch 5 and Desiree van der Heijde 6, 1 Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, 2 Maastricht University Medical Center, Maastricht, Netherlands, 3 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 Université Paris René Descartes and Hôpital Cochin, Paris, France, 5 Ghent University Hospital, Ghent, Belgium, 6 Leiden University Medical Center, Leiden, Netherlands 3:00 pm Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality Nigil Haroon 1, Nisha Nigil Haroon 2, Ping Li 3, Michael Paterson 3 and Robert D. Inman 4, 1 Toronto Western Research Institute, Toronto, ON, 2 University of Toronto, Toronto, ON, 3 Institute of Clinical Evaluative Sciences, Toronto, ON, 4 University of Toronto and Toronto Western Hospital, Toronto, ON 3:15 pm Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis Deepak R. Jadon 1, Gavin Shaddick 2, Amelia Jobling 2, Athimalaipet V Ramanan 3 and Raj Sengupta 1, 1 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2 University of Bath, Bath, United Kingdom, 3 University of Bristol Hospital Trust, Bristol, United Kingdom 3:30 pm Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort Fiona Maas 1, Anneke Spoorenberg 1, Elisabeth Brouwer 2, Reinhard Bos 3, Rizwana N. Chaudhry 1, Freke Wink 3, Hendrika Bootsma 4, Eveline van der Veer 1 and Suzanne Arends 4, 1 University Medical Center Groningen, Groningen, Netherlands, 2 University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3 Medical Center Leeuwarden, Leeuwarden, Netherlands, 4 University Medical Center Groningen, University of Groningen, Groningen, Netherlands 3:45 pm The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study Elisabeth Lie 1, Lars Erik Kristensen 2, Helena Forsblad-d Elia 3, Johan Askling 4 and Lennart T. Jacobsson 3, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Lund University, Malmö, Sweden, 3 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 4 Karolinska Institutet, Stockholm, Sweden 205 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Moderators: Megan E. B. Clowse, MD, MPH and Kenneth C. Kalunian, MD 2:30 pm SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study Sascha Tillmanns 1, Claudia Kolligs 1, David P. D Cruz 2, Andrea Doria 3, Eric Hachulla 4, Reinhard E. Voll 5, Michael Tansey 1 and Klaus Schollmeier 1, 1 SuppreMol GmbH, Martinsried, Germany, 2 Louise Coote Lupus Unit, Guy s and St Thomas Hospital, London, United Kingdom, 3 University of Padova, Padova, Italy, 4 Lille University, Lille, France, 5 University Hospital Freiburg, Freiburg, Germany 2:45 pm Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open- Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus Richard A. Furie 1, Michelle A. Petri 2, Caroline Gordon 3, Vibeke Strand 4, Catrinel Galateanu 5, Sabine Bongardt 6, Willem Koetse 7 and Daniel J. Wallace 8, 1 North Shore Long Island Jewish Health System, Great Neck, NY, 2 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 4 Biopharmaceutical TUESDAY november 18, Program Book 129

132 scientific sessions TUESDAY november 18, 2014 Consultant, Portola Valley, CA, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, Monheim, Germany, 7 UCB Pharma, Raleigh, NC, 8 Cedars-Sinai Medical Center, Los Angeles, CA 3:00 pm A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis Cynthia Aranow 1, R. van Vollenhoven 2, Brad H. Rovin 3, Carrie Wagner 4, Bei Zhou 4, Robert Gordon 4 and Benjamin Hsu 4, 1 The Feinstein Institute, Manhasset, NY, 2 The Karolinska Institute, Stockholm, Sweden, 3 Ohio State University Medical Center, Columbus, OH, 4 Janssen Research & Development, LLC., Spring House, PA 3:15 pm Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus Michelle Petri 1, Renee S. Martin 2, Colin Hislop 2, Morton A. Scheinberg 3 and Richard Furie 4, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 Anthera Pharmaceuticals Inc, Hayward, CA, 3 Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, 4 North Shore Long Island Jewish Health System, Great Neck, NY 3:30 pm Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE Jens Y. Humrich 1, Caroline von Spee-Mayer 1, Elise Siegert 1, Angelika Rose 1, Tobias Alexander 1, Falk Hiepe 1, Andreas Radbruch 2, Gerd Burmester 3 and Gabriela Riemekasten 1, 1 Charité University Hospital, Berlin, Germany, 2 German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 3 Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany 3:45 pm Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus David Wofsy 1, Caroline Gordon 2, Yong Li 3, Stephen D. Wax 4 and David Isenberg 5, 1 Division of Rheumatology, University of California, San Francisco, CA, 2 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 3 R&D Global BioStatistics, EMD Serono, Billerica, MA, 4 Global Clinical Development Center Immunology, EMD Serono Inc, Rockland, MA, 5 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom 156 B Systemic Lupus Erythematosus Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Moderators: Gary S. Gilkeson, MD and Susan A. Boackle, MD 2:30 pm BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation Kichul Ko 1, Denisse Yanez 1, Natalya Kaverina 1, Vladimir M. Liarski 1, Yahui Peng 2, Li Lan 1, Stuart Perper 3, Annette Schwartz 3, Liz O connor 3, Andrew Souers 4, Steven Elmore 4, Lisa Olson 3, Maryellen L. Giger 1, Li Chun Wang 3 and Marcus R. Clark 1, 1 University of Chicago, Chicago, IL, 2 Beijing Jiaotong University, Beijing, China, 3 AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4 AbbVie Inc, North Chicago, IL 2:45 pm Targeting the RhoA-Rock Pathway to Reverse T Cell Dysfunction in SLE Cristina T. Rozo, Laura Leuenberger, Kyriakos A. Kirou, Margaret Robotham, Sanjay Gupta, Reena Khianey, Alessandra B. Pernis and Jane E. Salmon, Hospital for Special Surgery, New York, NY 3:00 pm Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide Belinda A. Waltman 1, Kimberly E. Taylor 1, Julio Molineros 2, Sarah French 1, Joanne Nitiham 1, Jennifer Kelly 2, Adam Adler 2, Judith A. James 2, Swapan Nath 2, Marta Alarcon-Riquelme 2 and Lindsey A. Criswell 1, 1 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 3:15 pm An Anti CD123 Monoclonal Antibody (CSL362) Depletes Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated IFNα Production and IFNα-Inducible Gene Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus Shereen Oon 1, Nicholas Wilson 1 and Ian Wicks 2, 1 The University of Melbourne, Melbourne, Australia, 2 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 3:30 pm SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity Yaya Wang, David Ewart, Ami Yamamoto, Emily C. Baechler, Parastoo Fazeli and Erik J. Peterson, University of Minnesota, Minneapolis, MN Program Book

133 scientific sessions 3:45 pm Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes Lucrezia Colonna 1, Christian Lood 1, YuFeng Peng 1, Xizhang Sun 1, Lena Tanaka 1, Sandip Panicker 2 and Keith B. Elkon 1, 1 University of Washington, Seattle, WA, 2 True North Therapeutics, South San Francisco, CA 109 A T Cell Biology and Targets in Autoimmune Disease Moderators: Insoo Kang, MD and Andras Perl, MD, PhD 2:30 pm Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt, Hendrik Schulze-Koops and Alla Skapenko, University of Munich, Munich, Germany 2:45 pm CaMK4 Inhibition Ameliorates the Development of Th17 Driven Inflammatory Diseases By Preventing Recruitment of IL- 17 Producing Cells to Target Organs Tomohiro Koga 1, Kotaro Otomo 2, Masayuki Mizui 2, Nobuya Yoshida 2, José C. Crispin 2, Atsushi Kawakami 1 and George C. Tsokos 3, 1 Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3 Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 3:00 pm Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis Maria Bokarewa 1, Karin Andersson 2, Malin Erlandsson 2, Mattias Svensson 2, Nicola Cavallini 3 and Mikael Brisslert 2, 1 University of Goteborg, Goteborg, Sweden, 2 University of Gothenburg, Gothenburg, Sweden, 3 University of Göteborg, Göteborg, Sweden 3:15 pm T-Cell Signaling Defects Can be Corrected By Manipulating TCR Signal Fine-Tuning Molecules That Are Altered Due to Increased Ubiquitination in Systemic Autoimmune Disease Julia Pinkhasov and Ram Raj Singh, UCLA, Los Angeles, CA 3:30 pm Involvement of CD8 + T Cells in the Pathogenesis of Giant Cell Arteritis and Polymyalgia Rheumatica Maxime Samson 1, Sylvain Audia 1, Malika Trad 2, Marion Ciudad 2, Hervé Devilliers 3, Alexandrine Gautheron 2, Valérie Quipourt 4, Francois Maurier 5, Nadine Meaux Ruault 6, Patrick Manckoundia 4, Paul Ornetti 7, Jean-Francis Maillefert 8, Jean-François Besancenot 3, Christophe Ferrand 9, Philippe Saas 9, Laurent Martin 10, Nona Janikashvili 2 and Bernard Bonnotte 1, 1 INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, 2 INSERM UMR 1098, Besançon, Dijon, France, 3 Department of internal medicine and systemic diseases, Dijon, France, 4 Department of Geriatric Internal Medicine, Dijon, France, 5 Department of Internal Medicine, Metz, France, 6 Department of Internal Medicine, Besançon, France, 7 Department of Rheumatology, Dijon, France, 8 University Hospital Dijon, Dijon, France, 9 INSERM UMR1098, Besançon, France, 10 INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Pathology, Dijon, France 3:45 pm MiR-125a Is Critical Regulator for Controlling Autoimmunity in Multiple Autoimmune Diseases through Stabilizing Treg Mediated Immune Homeostasis Wan Pan 1, Shu Zhu 1, Dai Dai 1, John Harley 2 and Nan Shen 1, 1 Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 2 The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH 157 B Vasculitis III Moderators: Tanaz A. Kermani, MD and Alfred Mahr, MD, PhD 2:30 pm The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis Christopher Mecoli 1, Fan Wang 2, Christopher Pappas 3, Peter C. Grayson 4, David Cuthbertson 5, Simon Carette 6, Christian Pagnoux 6, Gary S. Hoffman 7, Nader A. Khalidi 8, Curry L. Koening 9, Carol A. Langford 10, Carol McAlear 11, Paul A. Monach 12, Larry W. Moreland 13, Philip Seo 14, Ulrich Specks 15, Steven R. Ytterberg 15, Rui Feng 1, Gregory Hageman 3 and Peter A. Merkel 11, 1 University of Pennsylvania, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, OK, 3 University of Utah School of Medicine, Salt Lake City, UT, 4 National Institutes of Health, Bethesda, MD, 5 University of South Florida, Tampa, FL, 6 University of Toronto, Toronto, ON, 7 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8 St. Joseph s Hospital, McMaster University, Hamilton, ON, 9 University of Utah, Salt Lake City, UT, 10 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 11 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 12 Vasculitis Center, Boston University School of Medicine, Boston, MA, 13 University of Pittsburgh, Pittsburgh, PA, 14 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 15 Mayo Clinic, Rochester, MN 2:45 pm Evaluation of KIR3DL1/KIR3DS1 Association with Behçet s Disease in Turkish Individuals Burak Erer 1, Elaine F. Remmers 1, Masaki Takeuchi 1, Colleen Satorius 1, Duran Ustek 2, Ilknur Tugal-tutkun 3, Emire Seyahi 4, Yilmaz Ozyazgan 5, Ahmet Gul 3, Daniel L. Kastner 6 and Michael J. TUESDAY november 18, Program Book 131

134 scientific sessions TUESDAY november 18, 2014 Ombrello 7, 1 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2 Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 3 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 4 Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 5 Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey, 6 National Human Genome Research Institute, Bethesda, MD, 7 National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 3:00 pm Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet s Disease. Multicenter Study of 125 Cases Leyre Riancho-Zarrabeitia 1, Vanesa Calvo-Río 1, Ricardo Blanco 1, Paz Rodríguez-Cundín 1, Emma Beltrán 2, Juan Sánchez Bursón Sr. 3, Marina Mesquida 4, Alfredo Adan 4, M. Victoria Hernández 5, Marisa Hernandez Grafella 6, Elia Valls Pascual 7, Lucía Martinez- Costa 8, Agusti Sellas-Fernandez 9, Miguel Cordero-Coma 10, Manuel Díaz-Llopis 11, Roberto Gallego 11, Jose Luis García Serrano 12, Norberto Ortego-Centeno 13, Jose M Herreras 14, Alejandro Fonollosa 15, Angel M. Garcia-Aparicio 16, Olga Maiz Alonso 17, Ana Blanco 18, Ignacio Torre Salaberri 19, Cruz Fernández- Espartero 20, Vega Jovani 21, Diana Peiteado 22, Esperanza Pato 23, Juan Cruz 24, Carlos Férnandez Cid 25, Elena Aurrecoechea 26, Miriam García-Arias 27, Miguel Angel Caracuel-Ruiz 28, Carlos Alberto Montilla Morales 29, Antonio Atanes-Sandoval 30, Félix Francisco 31, Santos Insua 32, Senen González-Suárez 33, Maria Amalia Sanchez Andrade 34, Fernando Gamero 35, Luis Francisco Linares Ferrando 36, Fredeswinda Romero 37, A. Javier García- González 38, Raquel Almodóvar González 39, Enrique Minguez 40, Carmen Carrasco Cubero 41, Alejandro Olive 42, Julio Vázquez 43, Oscar Ruiz Moreno 44, Fernando Jiménez-Zorzo 44, Javier Manero 44, Santiago MuÑoz Fernandez 45, Javier Rueda-Gotor 1, Trinitario Pina 1, Montserrat Santos-Gómez 1 and Miguel A. González-Gay 1, 1 Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2 Hospital General Universitario de Valencia. Spain, Valencia, Spain, 3 Rheumatology. Hospital de Valme., Sevilla, Spain, 4 Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5 Hospital Clinic, Barcelona, Barcelona, Spain, 6 Ophthalmology. Hospital General universitario de Valencia, Spain, 24 Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, 25 Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, 26 Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 27 Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 28 H. Reina Sofia, Cordoba, Spain, 29 Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 30 Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, 31 Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 32 Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, 33 Rheumatology. Hospital Cabueñes, Gijón, Spain, 34 Hosp. Lucus Augusti, Lugo, Spain, 35 Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, 36 Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 37 Jiménez Díaz Foundation University Hospital, Madrid, Spain, 38 Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 39 Hospital Universitario Fundación Alcorcón, Madrid, Spain, 40 Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, 41 Hospital de Merida, Mérida, Spain, 42 Germans Trias Pujol Hospital, Barcelona, Spain, 43 Rheumatology. Hospital de Ferrol, A Coruña, Spain, 44 Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, 45 Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain 3: Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet s Syndrome Gulen Hatemi 1, Melike Melikoglu 1, Recep Tunc 2, Cengiz Korkmaz 3, Banu Turgut Ozturk 4, Cem Mat 5, Peter A. Merkel 6, Kenneth Calamia 7, Lilia Pineda 8, Ziqi Liu 8, Randall M. Stevens 8, Hasan Yazici 1 and Yusuf Yazici 9, 1 Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2 Necmettin Erbakan University, Meram Medical Faculty, Division of Rheumatology, Konya, Turkey, 3 EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, 4 Selçuk University, Konya, Turkey, 5 Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, 6 Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 7 Mayo Clinic Health System in Waycross, Waycross, GA, 8 Celgene Corporation, Warren, NJ, 9 New York University School of Medicine, New York, NY Valencia, Spain, 7 Rheumatology. Hospital Peset, Valencia, Spain, 8 Ophthalmology. Hospital Peset, Valencia, Spain, 9 H. Vall d Hebron, Barcelona, Spain, 10 Hospital de León. Spain, León, Spain, 11 Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 12 Ophthalmology. Hospital San Cecilio, Granada, Spain, 13 Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 14 Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, 15 Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 16 Virgen de la Salud Hospital, Toledo, Spain, 17 Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, 18 Ophthalmology. Hospital Donosti, San Sebastián, Spain, 19 Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 20 Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, 21 Rheumatology. Hospital General de Alicante, Alicante, Spain, 22 Hospital La Paz IdiPaz, Madrid, Spain, 23 Rheumatology. Hospital Clínico San Carlos, Madrid, 3:30 pm Efficacy and Safety of Rituximab Retreatment Regimen at Clinical Relapse in Severe Cryoglobulinemic Vasculitis Luca Quartuccio 1, Francesca Zuliani 2, Patrizia Scaini 3, Marco Lenzi 4, Antonio Tavoni 5, Marco Sebastiani 6, Teresa Urraro 7, Francesco Saccardo 8, Costanza Sbreglia 9, Pietro Pioltelli 10, Paolo Fraticelli 11, Davide Filippini 12, Salvatore Scarpato 13, Oreste Perrella 9, Armando Gabrielli 14, Dario Roccatello 15, Anna Linda Zignego 7, Clodoveo Ferri 16, Stefano Bombardieri 17, Maurizio Pietrogrande 18, Massimo Galli 19, Giuseppe Monti 8 and Salvatore De Vita 1, 1 DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 2 Rheumatology Clinic, University Hospital of Udine, Udine, Italy, 3 Nephrology, Spedali Civili di Brescia, Brescia, Italy, 4 University of Bologna, Bologna, Italy, 5 Rheumatology Clinic, University of Pisa, Pisa, Italy, Program Book

135 scientific sessions 6 Rheumatology Clinic, University of Modena and Reggio Emilia, Modena, Italy, 7 Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 8 Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, 9 Rheumatology Unit, AO Cotugno, Naples, Italy, 10 Hematology, S.Gerardo Hospital, Monza, Italy, 11 Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 12 Rheumatology Unit, Ospedale Niguarda Ca Granda, Milan, Italy, 13 Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, 14 Università Politecnica delle Marche, Ancona, Italy, 15 UNIVERSITY OF TURIN (ITALY), TURIN, Italy, 16 Univ Modena Reggio Emilia, Modena, Italy, 17 Rheumatology Unit, University of Pisa, Pisa, Italy, 18 Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, 19 Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy 3:45 pm Update on Long-Term Outcomes after Reversible Cerebral Vasoconstriction Syndrome (RCVS) Seby John 1, Aneesh Singhal 2, Leonard H. Calabrese 1, Ken Uchino 1, Tariq Hammad 1, Stewart Tepper 1, Mark Stillman 1 and Rula A Hajj- Ali 1, 1 Cleveland Clinic Foundation, Cleveland, OH, 2 Massachusetts General Hospital, Boston, MA ACR/ARHP COMBINED ABSTRACT SESSION 2:30 4: B ACR/ARHP Combined Abstract Session: Rehabilitation Moderators: Nancy A. Baker, MPH and Daniel K. White, PT, ScD, MSc 2:30 pm Restricting Back Pain Is Strongly Associated with Disability in Community-Living Older Persons over the Course of 13 Years Una Makris 1, Liana Fraenkel 2, Ling Han 3, Linda Leo-Summers 3 and Thomas M. Gill 4, 1 Dallas VA Medical Ctr, Dallas, TX, 2 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3 Department of Medicine, New Haven, CT, 4 Yale University, New Haven, CT 2:45 pm Education Effects on Outcome Expectations for Exercise in Adults with Knee Osteoarthritis Tressa Gamache, Lori Lyn Price, Jeffrey B. Driban, William F. Harvey and Chenchen Wang, Tufts Medical Center, Boston, MA 3:00 pm Randomized Controlled Trial of Postoperative Care Navigation in Total Knee Arthroplasty Patients: Does One Size Fit All? Elena Losina, Jamie E. Collins, John Wright, Meghan E. Daigle, Laurel Donnell-Fink, Doris Strnad, Vladislav Lerner, Stanley Abrams and Jeffrey N. Katz, Brigham and Women s Hospital, Boston, MA 3:15 pm Randomised Comparison of the Effectiveness of a Non- Pharmacological Multidisciplinary Face-to-Face Group-Based Treatment Program Vs. a Telephone-Delivered Treatment Program on Daily Function in Patients with Generalized Osteoarthritis Nienke Cuperus 1, Thomas Hoogeboom 2, Clarinda Kersten 1, Leonie Rietveld 1, Alfons den Broeder 1, Thea Vliet Vlieland 3 and Cornelia H.M. van den Ende 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands, 3 Leiden University Medical Center, Leiden, Netherlands 3:30 pm Changes in Knee Kinematics from a 6-Week Hip and Trunk Strengthening Program for Persons with Patellofemoral Osteoarthritis Lisa Hoglund 1, Laura Pontiggia 1, John Kelly IV 2, Mark Arnott 1, Olumide Babalola 1, Andrew Gushen 1 and James Carey 2, 1 University of the Sciences, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, PA 3:45 pm Satisfaction Following Total Knee Replacement: Journey or Destination? Jeffrey N. Katz 1, Yan Dong 1, Jamie E. Collins 1, John Wright 1, David Dalury 2, Kirk Kindsfater 3 and Elena Losina 1, 1 Brigham and Women s Hospital, Boston, MA, 2 Townson Orthopedics, Maryland, Baltimore, MD, 3 Orthopedic Center for the Rockies, Ft. Collins, CO ARHP SESSIONS 2:30 4:00 pm 204 A Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self- Management and Improve Outcomes Moderator: Christine A. Stamatos, DNP, ANP-C TUESDAY november 18, 2014 Ed Pd PrM FIT explain how clinicians can efficiently, effectively engage their patients for enhanced self-management of chronic illness and improved outcomes describe the eight core competencies of Brief Action Planning (BAP) and the four elements of the Spirit of Motivational Interviewing (MI) 2014 Program Book 133

136 scientific sessions apply the principles and practices of BAP and MI in routine clinical work for enhanced patient self-management and improved outcomes 2:30 pm Brief Action Planning: Eight Core Competencies and the Spirit of Motivational Interviewing Steven Cole, MD 3:15 pm How to Apply Brief Action Planning in Your Routine Clinical Practice Joseph Weiner, MD, PhD 256 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological Moderator: Karen Huisinga, MN, ARNP integrate new pharmacological treatment regiments for osteoporosis evaluate current evidence supporting new treatment paradigms for osteoporosis formulate rehabilitation recommendations for the treatment of osteoporosis for those with rheumatic diseases 3:15 pm Coping for Caregivers: Strength-Based Coping Strategies for Family, Friends and Partners of Patients Living with Neuropsychiatric Lupus Liz Morasso, LCSW 153 B Treatment Considerations in Chronic Pain Moderator: Afton L. Hassett, PsyD describe the pathophysiologic mechanisms that occur when acute pain becomes chronic pain discuss the latest research in treatment options for chronic pain describe at least one new technique that may revolutionize our management of persistent pain 2:30 pm Recent Advances in the Diagnosis and Management of Chronic Pain Daniel J. Clauw, MD 3:15 pm Treatment Considerations in Chronic Pain Sean Mackey, MD, PhD TUESDAY november 18, :30 pm Emerging Medicines for the Treatment of Osteoporosis Barry Gruber, MD 3:15 pm Rehabilitation Techniques for the Treatment of Osteoporosis Jennifer L. Trizuto, MPT 257 A The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Moderator: Shawn Rose, MD, PhD identify the psychosocial quality of life indicators that are frequently impacted by nervous system involvement in lupus patients and to follow-through with a referral to a mental health professional, where appropriate summarize the pharmacological and non-pharmacological approaches currently in place to treat nervous system lupus recognize the psychological impact and lifestyle adjustments experienced by family members, friends and partners of patients with neuropsychiatric symptoms apply strength-based strategies to assist the caregivers of patients with neuropsychiatric symptoms ACR WORKSHO 4:00 6:00 pm 154 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August 30. Getting Electronic Health Records Right (240) Speaker: Salahuddin Kazi, MD describe the basic structure and capability of an electronic health record explain the principles and design of rheumatology-specific templates and order sets identify the key elements in current clinical processes and workflow to help optimize the utilization of an electronic health record 2:30 pm Neuropsychiatric Lupus: Health-Related Quality of Life and Treatment Options John G. Hanly, MD Program Book

137 scientific sessions 152 Systemic Sclerosis: How to Perform Skin Scores (241) Speaker: Daniel Furst, MD, MPH review the usefulness and reasons to do a modified Rodman skin score explain how to do a modified Rodman skin score demonstrate modified Rodman skin score under the supervision of experts 159 *Ultrasound Injection Guidance (242) Speaker: Gurjit S. Kaeley, MBBS, MRCP summarize the evidence for improved outcomes with ultrasound guidance of joint injections describe methods to optimize needle visualization review best practices for maintaining aseptic technique and probe positioning explain the anatomic approach for sonographically guided injection of major joints ACR SESSIONS 4:30 6:00 pm 160 B Autophagy in Rheumatic Diseases Moderator: Wael N. Jarjour, MD review the concept autophagy examine the role of autophagy in autoimmune diseases consider whether autophagy pathways are potential therapeutic targets 4:30 pm Autophagy-Inflammation-Cell Death Axis Jenny Ting, PhD 5:00 pm Autophagy and Autoimmune Diseases Cornelia M. Weyand, MD, PhD 5:30 pm Autophagy Pathways as Therapeutic Targets Andras Perl, MD, PhD 210 B Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Moderators: Shreyasee Amin, MD CM, MPH and David T. Felson, MD, MPH discuss the potential role for different nutrients in osteoarthritis management describe the current evidence for specific vitamins in managing osteoarthritis recommend specific exercise prescriptions for knee and hip osteoarthritis may can be implemented in clinical practice 4:30 pm What Should I Eat to Help My Osteoarthritis? Shivani Sahni, PhD 5:00 pm Is There Evidence that Vitamins Can Help Osteoarthritis? Timothy E. McAlindon, MD, MPH, MRCP 5:30 pm Exercise for Osteoarthritis Management: Science in Action! Ewa M. Roos, PT, PhD 52 A Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Ed Pd PrM FIT Moderators: Michael H. Weisman, MD and Arthur Kavanaugh, MD identify important safety issues in the drug treatment of rheumatic diseases integrate knowledge of new safety issues into their treatment strategies review how to more fully advise patients about the safety issues related to treatments for rheumatic diseases recognize evolutions at the FDA that will affect drug safety monitoring and reporting 4:30 pm Rheumatological Drugs in Pregnancy: Update on Fetal Safety Gideon Koren, MD 4:50 pm Update and Safety Issues of Recently Approved Agents for Rheumatic Diseases Nikolay P. Nikolov, MD 5:15 pm The Year in Review Update on Safety Issues at the FDA for the Last 12 Months Janet W. Maynard, MD, MHS ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm 104 B Antiphospholipid Syndrome Moderators: Roger A. Levy, MD and Joyce Rauch, PhD 2014 Program Book 135 TUESDAY november 18, 2014

138 scientific sessions TUESDAY november 18, :30 pm IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study Charis Pericleous 1, Valerie Taylor 2, Lauren Bourke 3, Daniel Stuckey 2, Jed Wingrove 4, Mark Lythgoe 2, Silvia S. Pierangeli 5, Anisur Rahman 4, Ian Giles 1 and Yiannis Ioannou 6, 1 Centre for Rheumatology, University College London, London, United Kingdom, 2 Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 3 Centre for Rheumatology Research, University College London, London, United Kingdom, 4 University College London, London, United Kingdom, 5 University of Texas Medical Branch, Galveston, TX, 6 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom 4:45 pm Markers of Thrombotic Events in Autoimmune Diseases: Comparison of Antiphospholipid Score (apl-s) and Global Anti- Phospholipid Syndrome Score (GAS) Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Hokkaido University Graduate School of Medicine, Sapporo, Japan 5:00 pm The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin Bahar Artim-Esen 1, Natalia Smoktunowicz 2, Vera M. Ripoll 3, Charis Pericleous 3, Rachel Chambers 2, Ian Mackie 4, David Isenberg 5, Anisur Rahman 6, Yiannis Ioannou 5 and Ian Giles 3, 1 Rheumatology Division, Department of Internal Medicine, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey, 2 Respiratory Research Unit, University College London, London, United Kingdom, 3 Centre for Rheumatology, University College London, London, United Kingdom, 4 Haemostasis Research Unit, University College London, London, United Kingdom, 5 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom, 6 University College London, London, United Kingdom 3 Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d interface, Nancy, F-54000, France, Nancy, France, 4 CHU Nancy, Vandoeuvre, France, 5 Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, 6 INOVA Diagnostics, San Diego, CA, 7 Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, 8 University of Lorraine, Nancy, France, 9 Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 10 Bensançon University Hospital, Besançon, France, 11 Nouvel Hospital Civil, Strasbourg Cedex, France, 12 Lille University Hospital, Lille, France, 13 Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 14 Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 15 INSERM, Centre d Investigation Clinique Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 16 Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France 5:30 pm Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome Srilakshmi Yalavarthi 1, Levi F. Mazza 1, Alexandra E. Morris 1, Carlos Núñez-Álvarez 2, Diego Hernández 2, Paula L. Bockenstedt 1, Antonio R. Cabral 2 and Jason S. Knight 1, 1 University of Michigan, Ann Arbor, MI, 2 Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico 5:45 pm Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (A ACTION) Clinical Database and Repository Initial Analysis Doruk Erkan 1, Danieli Andrade 2, Maria Tektonidou 3, Amaia Ugarte 4, Alessandra Banzato 5, Angela Tincani 6, Pier-Luigi Meroni 7, Ricard Cervera 8, Paul R. Fortin 9, Roger A. Levy 10 and On Behalf of A Action 11, 1 Hospital for Special Surgery, New York, NY, 2 University of São Paulo, São Paulo, Brazil, 3 First Department 5:15 pm External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß 2 -Glycoprotein I. a Prospective Multicentre Cohort Study Stephane Zuily 1, Bas De Laat 2, Veronique Regnault 3, Pierre Kaminsky 4, Hilde Kelchtermans 5, Zakera Shums 6, Roger Albesa 6, Gary L Norman 6, Philip de Groot 7, Anne-Christine Rat 8, Jacques Ninet 9, Nadine Magy-Bertrand 10, Jean-Louis Pasquali 11, Marc Lambert 12, Bernard Lorcerie 13, Thomas Lecompte 14, Francis Guillemin 15 and Denis Wahl 16, 1 CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 2 Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4 Hospital Universitario Cruces, Bizkaia, Spain, 5 Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, 6 Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 7 University of Milan, Milano, Italy, 8 Hospital Clinic, Barcelona, Spain, 9 Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, 10 Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11 A ACTION, New York, NY Program Book

139 scientific sessions 109 A B Cell Biology and Targets in Autoimmune Disease Moderators: Jennifer H. Anolik, MD, PhD and Shaun Jackson, MD PhD 4:30 pm TLR7 Influences Autoreactive B Cell Selection in the Germinal Center Weiqing Huang 1, Megan Woods 1, Alexis Boneparth 2, Ramalingam Bethunaickan 1, Ranjit Sahu 1 and Anne Davidson 1, 1 Feinstein Institute for Medical Research, Manhasset, NY, 2 Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ 4:45 pm B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus Shaun W. Jackson, Nicole Scharping, Socheath Khim and David Rawlings, Seattle Children s Research Institute, Seattle, WA 5:00 pm Break of Anergy in Human Autoreactive B Cells By T Helper Signals Restores B Cell Receptor Signaling Capacity and Is Dependent on Upregulation of CD45 Phosphatase Activity-a Possible Novel Mechanism of Breech of B Cell Tolerance in Rheumatic Diseases Peter Szodoray 1, Stephanie M. Stanford 2, Nunzio Bottini 2 and Britt Nakken 1, 1 Institute of immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway, 2 La Jolla Institute for Allergy and Immunology, La Jolla, CA 5:15 pm B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snrnp Reactive B Cells in BXD2 Mice Jennie Hamilton 1, Jun Li 1, Qi Wu 1, PingAr Yang 1, Bao Luo 1, Hao Li 1, Troy Randall 1, John Edwin Bradley 1, Justin J. Taylor 2, John D. Mountz 3 and Hui-Chen Hsu 1, 1 University of Alabama at Birmingham, Birmingham, AL, 2 Fred Hutchinson Cancer Research Center, Seattle, WA, 3 Birmingham VA Medical Center, Birmingham, AL 5:30 pm Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling Alison Maloney 1, Drew Hotson 2, Stephen Rapecki 1, Gianluca Fossati 1, Simon Lumb 1, David Rosen 2, Santosh Putta 2, Nikil Wale 2, David Spellmeyer 2, Alessandra Cesano 2, Rachael Hawtin 2 and Anthony Shock 1, 1 UCB Pharma, Slough, United Kingdom, 2 Nodality Inc., South San Francisco, CA 5:45 pm Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity Khaled Amara 1, Lorraine Yeo 2, Natalie Sippl 1, Philip Titcombe 1, Andrew Filer 3, Karim Raza 3, Dagmar Scheel-Toellner 2 and Vivianne Malmström 4, 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE Solna, Stockholm, Sweden., Stockholm, Sweden, 2 Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, 3 Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 4 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden 107 B Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis II Moderators: George D. Kalliolias, MD, PhD and Dana E. Orange, MD, MS 4:30 pm Macrophage Expression of Hypoxia-Inducible Factor-2 Alpha Promotes Rheumatoid Arthritis Progression Munitta Muthana 1, William Jacob Hardy 1, Sarah Hawtree 1, Fiona Wright 1, Ursula Fearon 2, DJ Veale 3, Mauro Perretti 4 and Anthony G. Wilson 5, 1 University of Sheffield, Sheffield, United Kingdom, 2 Translational Rheumatology Research Group, Dublin, Ireland, 3 St. Vincent s University Hospital, Dublin, Ireland, 4 Barts and the London School of Medicine, London, United Kingdom, 5 University College Dublin, Dublin, Ireland 4:45 pm Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice Lehn K. Weaver 1 and Edward M. Behrens 2, 1 Children s Hospital of Philadelphia, Philadelphia, PA, 2 Childrens Hospital of Philadelphia, Philadelphia, PA 5:00 pm Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses Misato Hashizume 1, Jun Kikuchi 2, Keiko Yoshimoto 2 and Tsutomu Takeuchi 2, 1 Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2 Keio University School of Medicine, Tokyo, Japan 5:15 pm G Protein Signaling Modulator 3 (GM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans Teresa K. Tarrant 1, D. Stephen Serafin 1, Elizabeth Sugg 1, Roman Timoshchenko 1, Matthew J. Billard 1, David P. Siderovski 2 and Kristy Richards 3, 1 Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 West Virginia University School of Medicine, Morgantown, WV, 3 Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 5:30 pm Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β Program Book 137 TUESDAY november 18, 2014

140 scientific sessions Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts Anil Singh 1, Sharayah Riegsecker 2, Sadiq Umar 1 and Salahuddin Ahmed 1, 1 Washington State University, Spokane, WA, 2 University of Toledo, Toledo, OH 5:45 pm Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients Melissa E. Munroe 1, Kendra A. Young 2, Jennifer Fessler 1, Dustin Fife 1, Diane L. Kamen 3, Joel M. Guthridge 1, Timothy B. Niewold 4, Michael H. Weisman 5, Mariko L. Ishimori 5, Daniel J. Wallace 5, David R. Karp 6, John B. Harley 7, Gary S. Gilkeson 3, Jill M. Norris 2 and Judith A. James 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Colorado School of Public Health, Aurora, CO, 3 Medical University of South Carolina, Charleston, SC, 4 Mayo Clinic, Rochester, MN, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 UT Southwestern Medical Center, Dallas, TX, 7 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH 5:15 pm Training the Rheumatologists of Tomorrow: The Canadian Experience Alfred Cividino 1, Volodko Bakowsky 2, Susan Barr 3, Louis Bessette 4, Nader Khalidi 5, Christian A. Pineau 6, Janet E. Pope 7, David Robinson 8, Kam Shojania 9, Elaine Yacyshyn 10, Lynne Lohfeld 1 and Diane Crawshaw 1, 1 McMaster University, Hamilton, ON, 2 Dalhousie University, Halifax, NS, 3 Heritage Medical Research Bldg, Calgary, AB, 4 Laval University, Québec, QC, 5 Division of Rheumatology, McMaster University, Hamilton, ON, 6 McGill University Health Center, Montreal, QC, 7 St Joseph Health Care, London, ON, 8 University of Manitoba, Winnipeg, MB, 9 University of British Columbia, Vancouver, BC, 10 University of Alberta, Edmonton, AB 5:30 pm Clinical Training Opportunities in Two Innovative Ambulatory Resources: The Primary Care Musculoskeletal Clinic and Center of Excellence Multidisciplinary Clinic Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter Beck, Jeffery Berdan, Phillip Lawrence and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT TUESDAY november 18, B Education Ed Pd PrM FIT Moderators: Kenneth S. O Rourke, MD and Deana M. Lazaro, MD 4:30 pm The Center of Excellence in Musculoskeletal Care and Education: A Sustainable Interprofessional, Multidisciplinary Programmatic Innovation Developed with the Department of Veterans Affairs Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter Beck, Jeffery Berdan, Caroline Milne, JoAnn Rolando and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT 4:45 pm Using Decision-Based Learning to Highlight Rheumatic Disease for Third-Year Medical Students Karen Law 1, J Richard Pittman 1 and Chad Miller 2, 1 Emory University School of Medicine, Atlanta, GA, 2 Tulane University Health Sciences Center School of Medicine, New Orleans, LA 5:00 pm Rheumatology-Specific Milestones for a Musculoskeletal Radiology Curriculum Michelle Newkirk 1, Liem Mansfield 1, Jay B. Higgs 2 and Daniel Battafarano 1, 1 San Antonio Military Medical Center, JBSA Ft Sam Houston, TX, 2 San Antonio Military Medical Center, JBSA Fort Sam Houston, TX 5:45 pm Assessing Rheumatology Fellows Teaching Skills Using the Objective Structured Teaching Exercise (OSTE) Eli M. Miloslavsky 1, Marcy B. Bolster 1, Kenneth S. O Rourke 2 and Lisa G. Criscione-Schreiber 3, 1 Massachusetts General Hospital, Boston, MA, 2 Wake Forest School of Medicine, Winston-Salem, NC, 3 Duke University Health System, Durham, NC 258 B Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Moderators: Cheryl Barnabe, MD, MSc and Yvonne C. Lee, MD, MMSc 4: Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses Health Study Camilla Bengtsson 1, Susan Malspeis 2, Jeffrey A. Sparks 2, Karen H. Costenbader 2 and Elizabeth W. Karlson 2, 1 Karolinska Institutet, Stockholm, Sweden, 2 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 4:45 pm Amount of Smoking, Duration of Smoking Cessation and Their Interaction with Silica Exposure in the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study Xia Jiang 1, Camilla Bengtsson 1, Henrik Källberg 1, Lars Klareskog 2 and Lars Alfredsson 3, 1 Karolinska Institutet, Stockholm, Sweden, 2 Karolinska University Hospital, Stockholm, Sweden, 3 The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden Program Book

141 scientific sessions 5:00 pm The Association Between Changes in Inflammation and High Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis K P Liao 1, Martin Playford 2, Michelle A. Frits 1, Christine K. Iannaccone 1, Jonathan S. Coblyn 1, Michael E. Weinblatt 1, Nancy A. Shadick 3 and Nehal N. Mehta 4, 1 Brigham and Women s Hospital, Boston, MA, 2 National Heart, Blood and Lung Institute, Bethesda, MD, 3 Brigham and Women s Hospital/ Harvard University, Cambridge, MA, 4 University of Pennsylvania, Philadelphia, PA 5:15 pm Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA? Thomas Frisell 1, Saedis Saevarsdottir 2 and Johan Askling 3, 1 Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3 Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden 4:30 pm Genome-Wide Association Study of Osteoarthritis Progression: Results from the Osteoarthritis Initiative Michelle S. Yau 1, Laura M. Yerges-Armstrong 1, Youfang Liu 2, David J. Duggan 3, Joanne M. Jordan 2, Braxton D. Mitchell 1, Rebecca D. Jackson 4 and Marc C. Hochberg 1, 1 University of Maryland School of Medicine, Baltimore, MD, 2 University of North Carolina, Chapel Hill, NC, 3 Translational Genomics Research Institute, Phoenix, AZ, 4 The Ohio State University, Columbus, OH 4:45 pm Relationship of Dermal Advanced Glycation End Products and Hand OA Charles Eaton 1, Jeffrey Driban 2, Bing Lu 3, Mary Roberts 4 and Timothy E. McAlindon 2, 1 Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, 2 Tufts Medical Center, Boston, MA, 3 Brigham and Women s Hospital, Foxboro, MA, 4 Center for Primary Care and Prevention, Pawtucket, RI 5:30 pm Inflammatory Genes Are Associated with Autoantibodies in Rheumatoid Arthritis-Free Individuals Who Are at-risk for Future Disease Ryan W. Gan 1, Kendra A. Young 1, M. Kristen Demoruelle 2, Michael H. Weisman 3, Jane H. Buckner 4, P. K. Gregersen 5, Ted R. Mikuls 6, James R. O Dell 6, Richard M. Keating 7, Elizabeth W. Karlson 8, Kevin D. Deane 2, V. Michael Holers 2 and Jill M. Norris 1, 1 Colorado School of Public Health, Aurora, CO, 2 University of Colorado School of Medicine, Aurora, CO, 3 Cedars-Sinai Medical Center, Los Angeles, CA, 4 Benaroya Research Institute at Virginia Mason, Seattle, WA, 5 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 6 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 7 Scripps Clinic, La Jolla, CA, 8 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 5:45 pm The Relative Risk of Incident NON-Ischemic Heart Failure in Prevalent Rheumatoid Arthritis Ängla Mantel 1, Marie Holmqvist 2, Johan Askling 3, Lars Lund 4 and Daniel Andersson 5, 1 Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, 2 Unit of Clinical Epidemiology, Department of Medicine, Stockholm, Sweden, 3 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Unit of Cardiology section for Heart Failure. Department of Medicine, Stockholm, Sweden, 5 Unit of Cardiology Section for Heart Failure. Department of Medicine, Stockholm, Sweden 153 B Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Moderators: Philip G. Conaghan, MD, PhD and Margreet Kloppenburg, MD, PhD 5:00 pm Habitual Running Any Time in Life Is Not Detrimental and May be Protective of Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative Grace H. Lo 1, Jeffrey B. Driban 2, Andrea Kriska 3, Kristi Storti 3, Timothy E. McAlindon 2, Richard Souza 4, Charles B. Eaton 5, Nancy J. Petersen 6 and Maria E. Suarez-Almazor 7, 1 Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 2 Tufts Medical Center, Boston, MA, 3 University of Pittsburgh, Pittsburgh, PA, 4 University of California, San Francisco, San Francisco, CA, 5 Memorial Hospital of Rhode Island, Pawtucket, RI, 6 Baylor College of Medicine, Houston, TX, 7 The University of Texas, MD Anderson Cancer Center, Houston, TX 5:15 pm A Multi-Center Double-Blind, Randomized, Controlled Trial (db-rct) to Evaluate the Effectiveness and Safety of Co- Administered Traumeel (Tr14) and Zeel (Ze14) Intra articular (IA) Injections Versus IA Placebo in Patients with Moderate-to- Severe Pain Associated with OA of the Knee Carlos Lozada 1, Eve del Rio 2, Donald Reitberg 3, Robert Smith 3, Charles Kahn 4 and Roland W. Moskowitz 5, 1 University of Miami Miller School of Medicine, Miami, FL, Miami, FL, 2 Rio Pharmaceutical Services, LLC, Bridgewater, Afghanistan, 3 Rio Pharmaceutical Services, LLC, Bridgewater, NJ, 4 South Florida Rheumatology, Hollywood, FL, 5 University Hospitals Case Medical Center, Cleveland, OH 5:30 pm Exercise Therapy and/or Manual Therapy for Hip or Knee Osteoarthritis: 2-Year Follow-up of a Randomized Controlled Trial J. Haxby Abbott 1, Cathy Chapple 1, Daniel Pinto 2, Alexis Wright 3 and Jean-Claude Theis 1, 1 University of Otago, Dunedin, New Zealand, 2 Northwestern University, Chicago, IL, 3 High Point University, High Point, NC TUESDAY november 18, Program Book 139

142 scientific sessions TUESDAY november 18, :45 pm New Insights into the Primary Care Osteoarthritis Consultation with Implications for Practice Zoe Paskins, Tom Sanders, Peter Croft and Andrew Hassell, Keele University, Keele, United Kingdom 205 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Ed Pd PrM FIT Moderators: Andreas Reiff, MD and Lisa F. Imundo, MD 4:30 pm High Dose Aspirin for Treating Kawasaki Disease Outdated Myth or Effective Aid? Gil Amarilyo 1, Yael Koren 2, Dafna Brik Simon 1, Maskit Bar-Meir 3, Hilla Bahat 4, Mona Hanna Helou 5, Amir Mendelson 6, Yackov Berkun 7, Eli Eisenstein 7, Yonatan butbul Aviel 5, Galia Barkai 8, Yoav Bolkier 8, Shai Padeh 8, Philip J. Hashkes 3, Riva Brik 5, Liora Harel 1 and Yosef Uziel 6, 1 Schneider Children s Medical Center of Israel, Petach Tikvah, Israel, 2 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3 Shaare-Zedek Medical Center, Jerusalem, Israel, 4 Assaf Harofeh Medical Center, Zerifin, Israel, 5 Rambam Medical Center, Haifa, Israel, 6 Meir Medical Center, Kfar Saba, Israel, 7 Hadassah Hebrew University Medical Center, Jerusalem, Israel, 8 Sheba Medical Center, Tel-Hashomer, Israel 4:45 pm Clinically Inactive Disease in Juvenile Dermatomyositis a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria Beverley Almeida 1, Raquel Campanilho-Marques 2, Katie Arnold 2, Lucy R. Wedderburn 3, Clarissa A Pilkington 1 and Kiran Nistala 4, 1 Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 2 UCL Institute for Child Health, London, United Kingdom, 3 UCL, UCLH, GOSH NHS Trust, London, United Kingdom, 4 University College London, London, United Kingdom 5:00 pm Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis Gabriele Simonini 1, Claudia Bracaglia 2, Marco Cattalini 3, Andrea Taddio 4, Alice Brambilla 1, Cinzia DeLibero 5, Denise Pires Marafon 6, Roberto Caputo 5 and Rolando Cimaz 1, 1 Anna Meyer Children s Hospital-University of Firenze, Florence, Italy, 2 Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3 Pediatric Immunology and Rheumatology Unit, Brescia, Italy, 4 Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, 5 Anna Meyer Children s Hospital, Florence, Italy, 6 Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy 5:15 pm The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care Kirsten Minden 1, Jens Klotsche 2, Martina Niewerth 2, Angela Zink 3 and Gerd Horneff 4, 1 Charité University Medicine, Berlin, Germany, 2 German Rheumatism Research Center, Berlin, Germany, 3 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 4 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany 5:30 pm Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV) Kimberly Morishita 1, Susanne Benseler 2, Rae S.M. Yeung 3, Thomas Mason II 4, Dawn Wahezi 5, Kenneth N. Schikler 6, Erica F. Lawson 7, Susan Nielsen 8, Sirirat Charuvanij 9, Paul Dancey 10, Susan Shenoi 11, Linda Wagner-Weiner 12, Angelyne Sarmiento 1, David A. Cabral 1 and For the PedVas Initiative 1, 1 BC Children s Hospital and University of British Columbia, Vancouver, BC, 2 Department of Pediatrics/University of Calgary, Calgary, AB, 3 The Hospital for Sick Children and University of Toronto, Toronto, ON, 4 Mayo Clinic, Rochester, MN, 5 Children s Hospital at Montefiore, Bronx, NY, 6 Univ of Louisville Schl of Med, Louisville, KY, 7 University of California, San Francisco, San Francisco, CA, 8 Rigshospitalet, Copenhagen, Denmark, 9 Siriraj Hospital, Bangkok, Thailand, 10 Janeway Children s Hospital, St. John s, NL, 11 Seattle Childrens Hospital, Seattle, WA, 12 University of Chicago Hospital, Chicago, IL 5:45 pm Clinical and Radiological Features of Down s Arthropathy Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland 151 A Rheumatoid Arthritis Animal Models II Moderators: Harris R. Perlman, PhD and Thomas Pap, MD 4:30 pm The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice Jennifer L. Auger, Brianna J. Engelson, Yaya Wang, Erik J. Peterson and Bryce A. Binstadt, University of Minnesota, Minneapolis, MN 4:45 pm Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis Shuang Liu 1, Takeshi Kiyoi 2, Shohei Watanabe 3 and Kazutaka Maeyama 1, 1 Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, 2 Integrated Center for Sciences, Ehime University, Ehime, Japan, 3 Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan Program Book

143 scientific sessions 5:00 pm Loss of microrna-146a Exacerbates Inflammatory Arthritis Victoria Saferding 1, Antonia Puchner 1, Eliana Goncalvesalves 1, Birgit Niederreiter 1, Silvia Hayer 1, Gernot Schabbauer 2, Marije Koenders 3, Josef S. Smolen 1, Kurt Redlich 1 and Stephan Blueml 1, 1 Medical University of Vienna, Vienna, Austria, 2 Medical University Vienna, Vienna, Austria, 3 Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 5:15 pm Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4 + t Cells Qiquan Huang 1, Harris R. Perlman 1, Robert Birkett 1, Renee E. Doyle 1, Deyu Fang 1, G Kenneth.Haines 2, William H. Robinson 3, Syamal K. Datta 1, Hyewon Phee 1 and Richard M. Pope 4, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Mount Sinai Hospital School of Medicine, New York, New York, NY, 3 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4 Northwestern University Feinberg school of Medicine, Chicago, IL 5:30 pm Tolerogenic Splenic IDO+ Dendritic Cells from the Mice Treated with Induced-Treg Cells Could Suppress Collagen- Induced Arthritis Jie Yang 1, Huahua Fan 2 and Hejian Zou 1, 1 Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai , China, Shanghai, China, 2 Blood Engineering Laboratory, Shanghai Blood Center, Shanghai , China, Shanghai, China 5:45 pm Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice Keisuke Nishimura, Jun Saegusa, Fumichika Matsuki, Kengo Akashi, Goichi Kageyama and Akio Morinobu, Kobe University Graduate School of Medicine, Kobe, Japan Ballroom East Rheumatoid Arthritis Clinical Aspects VI: Impact of Treatment and Other Interventions Moderators: Clifton O. Bingham, III, MD and Nancy A. Shadick, MD, MPH 4:30 pm Clinical Outcomes of Early RA after 7 Years Does T2T Approach Overcome Delay of Therapy? Tuulikki Sokka 1, Hannu Kautiainen 2, Tuomas Rannio 3, Juha Asikainen 1 and Pekka Hannonen 1, 1 Jyvaskyla Central Hospital, Jyväskylä, Finland, 2 Medcare Oy, Äänekoski, Finland, 3 Kuopio University Hospital, Kuopio, Finland 4:45 pm Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program WP Maksymowych 1, M. Østergaard 2, O Elkayam 3, R Landewé 4, J Homik 5, C Thorne 6, M Backhaus 7, S Shaikh 8, G Boire 9, M Larche 10, B Combe 11, T Schaeverbeke 12, A Saraux 13, G Ferraccioli 14, M Dougados 15, C Barnabe 16, M Govoni 17, PP Tak 18, D. van Schaardenburg 19, D van der Heijde 20, R Dadashova 1, E Hutchings 1, J Paschke 1 and Oliver FitzGerald 21, 1 CaRE Arthritis, Edmonton, AB, 2 Copenhagen Center for Arthritis Research, Glostrup, Denmark, 3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4 Amsterdam Rheumatology Center, Amsterdam, Netherlands, 5 University of Alberta, Edmonton, AB, 6 Southlake Regional Health Centre, Newmarket, ON, 7 Charite University Hospital, Berlin, Germany, 8 Niagara Peninsula Arthritis Centre, Hamilton, ON, 9 CHUS-Sherbrooke University, Sherbrooke, QC, 10 St Joseph s Healthcare Hamilton, Hamilton, ON, 11 Hôpital Lapeyronie, Montpellier, France, 12 Bordeaux University Hospital, Bordeaux, France, 13 CHU Brest and EA 2216, UBO, Brest, France, 14 Catholic University of The Sacred Heart, Rome, Italy, 15 Hopital Cochin, Paris, France, 16 University of Calgary, Calgary, AB, 17 Universita di Ferrara, Ferrara, Italy, 18 Academic Medical Center, Amsterdam, Netherlands, 19 Jan van Breemen Research Institute, Amsterdam, Netherlands, 20 Leiden University Medical Center, Leiden, Netherlands, 21 St. Vincent s University Hospital, Dublin, Ireland 5:00 pm Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort Ruediger Mueller 1, Nazim Reshiti 2, Toni Kaegi 1, Axel Finckh 3, Hendrik Schulze-Koops 4, Michael H. Schiff 5 and Johannes von Kempis 6, 1 Kantonsspital St. Gallen, St. Gallen, Switzerland, 2 Division of Rheumatology, St. Gallen, Switzerland, 3 Geneva University Hospital, Geneva, Switzerland, 4 University of Munich, Munich, Germany, 5 University of Colorado, Denver, CO, 6 St. Gallen Hospital, CH St. Gallen, Switzerland 5:15 pm The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort Ruediger Mueller 1, Toni Kaegi 1, Sarah Haile 2 and Johannes von Kempis 3, 1 Kantonsspital St. Gallen, St. Gallen, Switzerland, 2 University of Zurich, Switzerland, Zurich, Switzerland, 3 St. Gallen Hospital, CH St.Gallen, Switzerland 5:30 pm Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-depth Analysis of a Prospective Observational Study with Adalimumab Marc Schmalzing 1, Frank Behrens 2, Eva C. Scharbatke 1, Michaela Koehm 3, Bianca Wittig 4, Gerd Greger 5, Harald Burkhardt 2 and Hans-Peter Tony 1, 1 University of Würzburg, Würzburg, Germany, 2 Goethe-University Frankfurt, Frankfurt, Germany, 3 Fraunhofer TUESDAY november 18, Program Book 141

144 scientific sessions TUESDAY november 18, 2014 Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, 4 Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 5 AbbVie GmbH & Co KG, Wiesbaden, Germany 5:45 pm Effects of Exercise on Body Composition, Cardiovascular Fitness, Muscle Strength and Cognition in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial of a Patient-Specific Exercise Programme Maha Azeez 1, Ciara Clancy 2, Tom O Dwyer 2, Fiona Wilson 2 and Gaye Cunnane 1, 1 St James s Hospital and Trinity College Dublin, Dublin, Ireland, 2 Trinity College Dublin, Dublin, Ireland 157 B Rheumatoid Arthritis Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Moderators: Erik J. Peterson, MD and Jeremy Sokolove, MD 4:30 pm Inhibition of PAD4 Activity and the Formation of Neutrophil Extracellular Traps Via PTPN22, but Not Its Rheumatoid Arthritis-Prone W620 Variant I-Cheng Ho 1, Hui-Hsin Chang 1, Nishant Dwivedi 1, Hsiao-Wei Tsao 1 and Anthony Nicholas 2, 1 Brigham and Women s Hospital, Boston, MA, 2 University of Alabama at Birmingham, Birmingham, AL 4:45 pm Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations Yukinori Okada 1, Kwangwoo Kim 2, Buhm Han 3, Nisha E. Pillai 4, Rick T-H. Ong 4, Woei-Yuh Saw 4, Ma Luo 5, Lei Jiang 6, Jian Yin 6, So- Young Bang 7, Hye-Soon Lee 7, Matthew A. Brown 8, Sang-Cheol Bae 9, Huji Xu 10, Yik-Ying Teo 4, Paul IW. de Bakker 11 and Soumya Raychaudhuri 3, 1 Tokyo Medical and Dental University, Tokyo, Japan, 2 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 National University of Singapore, Singapore, Singapore, 5 University of Manitoba, Winnipeg, MB, 6 The Second Military Medical University, Shanghai, China, 7 Hanyang University Guri Hospital, Guri, South Korea, 8 University of Queensland Diamantina Institute, Brisbane, Australia, 9 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10 Shanghai Changzheng Hospital, Shanghai, China, 11 University Medical Center Utrecht, Utrecht, Netherlands 5:00 pm The Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Is Regulated By TGFß and PDGF and Modulates Cell Growth in Fibroblast-like Synoviocytes Anna-Karin Ekwall 1, Deepa Hammaker 2, John W. Whitaker 3, William Bugbee 4, Wei Wang 5 and Gary S. Firestein 6, 1 UC San Diego, La Jolla, CA, 2 University of California San Diego, La Jolla, CA, 3 UCSD, San Diego, CA, 4 Scripps Clinic, La Jolla, CA, 5 UCSD, La Jolla, CA, 6 University of California at San Diego School of Medicine, La Jolla, CA 5: WITHDRAWN 5: Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis Sonia Khatter 1, Mark C. Parish 1, Marie L. Feser 1, Jason R. Kolfenbach 1, Ryan W. Gan 2, Michael H. Weisman 3, James R. O Dell 4, Ted R. Mikuls 5, Richard M. Keating 6, Peter K. Gregersen 7, Jane H. Buckner 8, V. Michael Holers 1, Kevin D. Deane 1, Jill M. Norris 2 and M. Kristen Demoruelle 1, 1 University of Colorado School of Medicine, Aurora, CO, 2 Colorado School of Public Health, Aurora, CO, 3 Cedars-Sinai Medical Center, Los Angeles, CA, 4 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 5 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 6 Scripps Clinic, La Jolla, CA, 7 Feinstein Institute for Medical Research, Manhasset, NY, 8 Benaroya Research Institute at Virginia Mason, Seattle, WA 5:45 pm Association of Single Nucleotide Polymorphisms of PADI4 Gene with Susceptibility to Rheumatoid Arthritis-Related Lung Disease Seong-Wook Kang, Seung-Taek Song, Song Soo Kim, Ji Young Kim, So Young Lee, Su-Jin Yoo, In-Seol Yoo, Jinhyun Kim and Seung- Cheol Shim, Chungnam National University School of Medicine, Daejeon, South Korea 253 B Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Moderators: Stanley B. Cohen, MD and Duncan Porter, MD 4:30 pm Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis A Obry 1, P Cosette 1, T Lequerré 2, Maria-Antonietta d Agostino 3, C Gaillez 4, M Le Bars 5 and O Vittecoq 2, 1 UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, 2 Rouen University Hospital, Rouen, France, 3 AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, 4 Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, 5 Bristol-Myers Squibb, Rueil-Malmaison, France Program Book

145 scientific sessions 4:45 pm Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis Meghna Jani 1, Hector Chinoy 1, Richard B. Warren 2, Christopher E.M Griffiths 2, Ann W. Morgan 3, Anthony G. Wilson 4, Kimme L. Hyrich 1, John Isaacs 5, Darren Plant 1 and Anne Barton 6, 1 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 2 Dermatology Centre, University of Manchester, Manchester, United Kingdom, 3 University of Leeds, Leeds, United Kingdom, 4 University College Dublin, Dublin, Ireland, 5 Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, 6 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom 5:00 pm Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy Kazuko Shiozawa 1, Takashi Yamane 1, Miki Murata 1, Chihiro Tanaka 1, Noriaki Yo 1, Ryosuke Yoshihara 1, Yasushi Tanaka 1, Ken Tsumiyama 2 and Shunichi Shiozawa 2, 1 Kohnan Kakogawa Hospital, Kakogawa, Japan, 2 Kyushu University Beppu Hospital, Beppu, Japan 5:15 pm Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy Jose Inciarte-Mundo 1, M. Victoria Hernández 1, Sonia Cabrera- Villalba 1, Julio Ramirez 1, Andrea Cuervo 1, Virginia Ruiz-Esquide 1, Azucena González Navarro 1, Jordi Yagüe 2, Juan D. Cañete 1 and Raimon Sanmarti 1, 1 Hospital Clínic of Barcelona, Barcelona, Spain, 2 Hospital Clinic Barcelona, Barcelona, Spain 5:30 pm Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis Priyanka Vashisht 1, Jessica M. Dorschner 2, Mark A. Jensen 2, Beverly Chrabot 3, Theresa Wampler Muskardin 2, Marlena Kern 4, Tetrad Investigators 5, ABCoN Consortium 6, S. Louis Bridges Jr. 7, P.K. Gregersen 8 and Timothy B. Niewold 2, 1 University of Nebraska Medical Center, Omaha, NE, 2 Mayo Clinic, Rochester, MN, 3 University of Chicago, Chicago, IL, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 AL, 6 NY, 7 University of Alabama at Birmingham, Birmingham, AL, 8 The Feinstein Institute for Medical Research, Manhasset, NY 5:45 pm Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial Jérémie Sellam 1, Houria Chavez 2, Stéphanie Rouanet 3, Nathalie Vernet 3, Bineta Ly 4, Sandrine Marion-Thore 5, Bernard Combe 6, Jean Sibilia 7, Jacques Tebib 8, Gilles Chiocchia 9, Maxime Dougados 10, Yassine Taoufik 2 and Xavier Mariette 11, 1 AP-HP, Saint- Antoine Hospital, Rheumatology Department and DHU i2b, Paris, France, 2 Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 3 Roche France, Boulogne-Billancourt, France, 4 Universite Paris-Sud, Kremlin Bicetre, France, 5 Université Versailles Saint-Quentin, Montigny le Bretonneux, France, 6 Hôpital Lapeyronie, Montpellier, France, 7 University Hospital of Strasbourg, Strasbourg, France, 8 University Hospital Lyon, Lyon, France, 9 Université Versailles-Saint Quentin, Montigny le Bretonneux, France, 10 INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 11 Université Paris-Sud, Le Kremlin Bicêtre, France 102 A Sjögren s Syndrome I: Clinical Perspectives Moderators: Arthur A. M. Bookman, MD and Stefano Bombardieri, MD 4:30 pm Molecular Diagnostics for Patient Subsetting in Sjögren s Syndrome John C. Hall 1, Alan N. Baer 1, Mi Y. Lam 2, Lindsey A. Criswell 3, Antony Rosen 1 and Livia Casciola Rosen 1, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of California San Francisco, San Francisco, CA, 3 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA 4:45 pm Precisely Quantified Fibrosis in Labial Salivary Glands Predicts Sjögren s Syndrome Classification in a Multiple Regression Model Kerry M. Leehan 1, Michael Brown 2, Courtney Montgomery 2, Astrid Rasmussen 2, David M. Lewis 1, Lida Radfar 1, Donald U. Stone 1, Stephen Young 1, R. Hal Scofield 1, Kathy L. Sivils 2 and A. Darise Farris 2, 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 5:00 pm Longitudinal Examination with Salivary Gland Ultrasonography (SGUS) of Patients with Primary Sjögren s Syndrome: A Single Center Experience Chiara Baldini 1, Nicoletta Luciano 1, Francesca Sernissi 1, Daniela Martini 1, Francesco Ferro 1, Marta Mosca 2 and Stefano Bombardieri 2, 1 Rheumatology Unit, Pisa, Italy, 2 Rheumatology Unit, University of Pisa, Pisa, Italy 5:15 pm Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren s Syndrome: A General Population-Based Cohort Study Marko Yurkovich 1, Hyon K Choi 2, Eric C. Sayre 3, Kamran Shojania 1 and J. Antonio Avina-Zubieta 3, 1 University of British Columbia, Vancouver, BC, 2 Boston University School of Medicine, Boston, MA, 3 Arthritis Research Centre of Canada, Richmond, BC 2014 Program Book 143 TUESDAY november 18, 2014

146 scientific sessions 5:30 pm Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren s Syndrome Kristopherson Lustosa Augusto 1, Eloisa Bonfá 2, Rosa M. R. Pereira 1, Cleonice Bueno 1, Vilma S. T. Viana 3 and Sandra G. Pasoto 1, 1 Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2 University of Sao Paulo, Sao Paulo, Brazil, 3 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil Descartes University, Paris, France, 4 University of Alberta, Alberta, AK, 5 Merck & Co., Inc., Whitehouse Station, NJ 5:30 pm Increased Diagnosis of Spondyloarthritis in Female Patients Started in the Early Biologic Era Nisha Nigil Haroon 1, Ping Li 2, Michael Paterson 2 and Nigil Haroon 3, 1 Department of Medicine, University of Toronto, Toronto, ON, 2 Institute of Clinical Evaluative Sciences, Toronto, ON, 3 Toronto Western Research Institute, Toronto, ON TUESDAY november 18, :45 pm Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren s Syndrome Gwenny Verstappen 1, Wayel H. Abdulahad 2, Petra M. Meiners 1, Suzanne Arends 1, Silvia Beijer-Liefers 1, Arjan Vissink 1, Frans G.M. Kroese 1 and Hendrika Bootsma 1, 1 University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2 University Medical Center Groningen, Groningen, Netherlands Ballroom West Spondyloarthropathies and Psoriatic Arthritis V Clinical Aspects and Treatment Moderators: Filip Van den Bosch, MD, PhD and Robert B. M. Landewé, MD, PhD 4:30 pm Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis Barry J. Sheane, Arane Thavaneswaran, Dafna D. Gladman and Vinod Chandran, University of Toronto, Toronto Western Hospital, Toronto, ON 4:45 pm Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases and How Does These Risks Compare to Those in Rheumatoid Arthritis? Johan Askling 1, Lennart Jacobsson 2 and Jonas Eriksson 1, 1 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2 Sahlrenska Academy, Gothenburg, Sweden 5:45 pm Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? a Prospective Study Including Magnetic Resonance Imaging Xenofon Baraliakos 1, Uta Kiltz 1, Frank Heldmann 1, Heiner Appel 2, Friedrich Dybowski 3, Manfred Igelmann 4, Ludwig Kalthoff 5, Dietmar Krause 6, Hans-Jürgen Menne 7, Ertan Saracbasi 8, Elmar Schmitz-Bortz 9 and Jürgen Braun 1, 1 Rheumazentrum Ruhrgebiet, Herne, Germany, 2 Rheumatology and Nephrology Practice, Hamm, Germany, 3 Rheumatology Practice, Herne, Germany, 4 Rheumatology Practice, Bochum, Germany, 5 Rheumatology practice, Herne, Germany, 6 Rheumatology practice, Gladbeck, Germany, 7 Rheumatology practice, Dortmund, Germany, 8 Rheumatology practice, Oberhausen, Germany, 9 Rheumatology practice, Hattingen, Germany ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at * Sessions denoted with an asterisk were sold out as of August :00 pm Evaluation of Referral Models for Axial Spondyloarthritis in Primary Care in the Spondyloarthritis Caught Early Cohort Ozair Abawi, Rosaline van den Berg, Désirée van der Heijde and Floris van Gaalen, Leiden University Medical Center, Leiden, Netherlands 5:15 pm A Randomized, Double-Blind, Placebo-Controlled, 16- Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis J Sieper 1, D van der Heijde 2, M Dougados 3, W Maksymowych 4, J Boice 5, G Bergman 5, S Curtis 5, A Tzontcheva 5, S Huyck 5 and HH Weng 5, 1 University Clinic Benjamin Franklin, Berlin, Germany, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Paris Program Book Westin Paine (Lobby) Adult Inflammatory Myopathy (081) Speaker: Robert L. Wortmann, MD, MACR review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies

147 scientific sessions Westin Otis (Lobby) Behçet s Syndrome (082) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome Westin Hancock (Lobby) Calcium Crystal Arthritis (083) Speaker: Ann K. Rosenthal, MD describe the common clinical pictures of calcium pyrophosphate disease and basic calcium phosphate arthritis as well as appreciate unusual presentations describe currently available and emerging diagnostic modalities to confirm suspected calcium crystal arthritis, including ultrasound and novel techniques for BCP crystal identification describe currently available therapies and understand the rationale behind some promising new therapies for these diseases Westin Revere (Lobby) Juvenile Dermatomyositis (084) Speaker: Susan Kim, MD, MMSc Ed Pd PrM FIT discuss what is known about the pathogenesis and epidemiology of juvenile dermatomyositis discuss the approach to the evaluation of a patient referred with possible juvenile dermatomyositis discuss different therapeutic approaches to the treatment of juvenile dermatomyositis, ranging from mild to severe Westin Stone (Lobby) Myopathy: Issues in Diagnosis and Treatment (085) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies describe the importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease Westin Webster (Lobby) Pregnancy and Rheumatic Diseases (086) Speaker: Eliza Chakravarty, MD, MS describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes. discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy Westin Adams (Mezzanine) Pulmonary Manifestations of Rheumatic Disease (087) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease Westin Alcott (Mezzanine) Raynaud s and Digital Ischemia (088) Speaker: Fredrick M. Wigley, MD discuss the current understanding of the pathogenesis of Raynaud s phenomenon classify type of Raynaud s phenomenon and differentiate it from mimics describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of an autoimmune rheumatic disease discuss current options and evidence for treatment of Raynaud s phenomenon, threatened digital ischemia and digital ulcers Westin Douglas (Mezzanine) Rheumatoid Arthritis: Challenging Cases (089) Speaker: Stephen A. Paget, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Faneuil (Mezzanine) Temporal Arteritis (090) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid-sparing agents TUESDAY november 18, Program Book 145

148 scientific sessions describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis 5:00 pm Patient Advocacy, Patient Reported Outcomes and Social Media Seth Ginsberg TUESDAY november 18, 2014 ARHP SESSIONS 4:30 6:00 pm Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Ed Pd PrM FIT Moderator: Michael Blakley, MD review how to perform the cursory history and physical exam that may lead to the diagnosis of juvenile idiopathic arthritis facilitate and initiate the multidisciplinary management of a child with juvenile idiopathic arthritis employ techniques to trouble shoot difficult juvenile idiopathic arthritis cases 4:30 pm Review of Seven Subtypes of Juvenile Idiopathic Arthritis Peter Chira, MD, MS 4:55 pm Nursing Management of the Juvenile Idiopathic Arthritis Patient Karla Jones, RN 5:20 pm Physical and Occupational Therapy Management of the Juvenile Idiopathic Arthritis Patient Speaker to be determined 5:45 pm Questions and Answers Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care Moderator: Jonathan Krant, MD, MPH review patient reported outcomes (PRO) review comparative effectiveness research (CER) recognize the differences between print and social media as regards messaging and data capture translate PRO and CER into policy regarding quality metrics and assessment of physician performance 4:30 pm Introduction of Speakers and Overview of Rheumatology Practice Management for Complex Diagnoses Jonathan Krant, MD, MPH 5:30 pm Comparative Effectiveness Research and Optimization of Patient Outcomes Jeffrey R. Curtis, MD, MPH, MS 257 A State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Moderators: David G. Borenstein, MD and Kimberly F. Kimpton, PT evaluate the current evidence for the use of transcutaneous electrical nerve stimulation for chronic low back pain discuss the benefits of physical therapy for chronic low back pain review existing evidence for the efficacy of epidural steroid injections and other interventional procedures for chronic low back pain and spinal stenosis and delineate appropriate patient selection identify clinical characteristics of chronic low back pain and spinal stenosis that warrant referral for surgical evaluation, as well as treatment to include standard and minimally invasive surgical options 4:30 pm Physical Therapy for Chronic Low Back Pain Adam Goode, DPT, PT 5:00 pm Interventional Pain Management for Chronic Low Back Pain Chad M. Brummett, MD 5:30 pm Surgical Considerations for Lumbar Stenosis and Chronic Low Back Pain Barton L. Sachs, MD, MBA 204 A Successful Aging in Rheumatic Disease Moderator: Patricia P. Katz, PhD recognize the traits that contribute to successful aging recommend interventions that can help patients successfully age explain how rheumatic disease affects the aging process 4:30 pm Successful Aging: What Does the Research Say? Marian R. Stuart, PhD 5:15 pm Successful Aging in Rheumatic Disease Kim M. Huffman, MD, PhD Program Book

149 ARHP CONCURRENT ABSTRACT SESSION 2:30 4:00 pm 254 A Epidemiology/Public Health Moderators: Kelli D. Allen, PhD and Uyen Sa D.T. Nguyen, DSc, MPH 4:30 pm Physical Function Is Independently Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project Rebecca Cleveland 1, Todd Schwartz 1, Jordan B. Renner 2, Joanne M. Jordan 3 and Leigh F. Callahan 4, 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 University of North Carolina Department of Radiology, Chapel Hill, NC, 3 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC 4:45 pm A Longitudinal Population-Based Study of Age, Period and Cohort Effects in the Prevalence of Arthritis: The Effect of Improving Socioeconomic Status and Increasing Obesity over Time Elizabeth M. Badley 1, Mayilee Canizares 2, Anthony V. Perruccio 2, Sheilah. Hogg-Johnson 2 and Monique A.M. Gignac 2, 1 Toronto Western Research Institute, Toronto, ON, 2 University of Toronto, Toronto, ON 5:00 pm Severity of Foot Pain Is Linked to the Prevalence of Depressive Symptoms: The Framingham Foot Study Arunima Awale 1, Alyssa B. Dufour 2, Patricia P. Katz 3, Virginia A. Casey 1 and Marian T. Hannan 4, 1 Hebrew SeniorLife, Boston, MA, 2 Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, 3 University of California, San Francisco, CA, 4 Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 5:15 pm Sedentary Time Is an Independent Risk Factor for Disability Onset Among Adults at Elevated Risk: Prospective Cohort Study Jungwha Lee 1, Jing Song 1, Barbara Ainsworth 2, Rowland W. Chang 1, Linda S. Ehrlich-Jones 3, Christine Pellegrini 1, Pamela Semanik 4, Dorothy D. Dunlop 1 and Leena Sharma 5, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Arizona State University, Phoenix, AZ, 3 Rehabilitation Institute of Chicago, Chicago, IL, 4 Rush University, Chicago, IL, 5 Northwestern University, Chicago, IL 5:30 pm Foot Structure and Function Show Associations with Lower Extremity Physical Function Yvonne M. Golightly 1, Marian T. Hannan 2, Patricia P. Katz 3, Howard J. Hillstrom 4, Alyssa B. Dufour 5 and Joanne M. Jordan 1, 1 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 2 Institute for Aging Research, Hebrew SeniorLife, Dept. scientific sessions of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3 University of California, San Francisco, San Francisco, CA, 4 Hospital Special Surgery (HSS), New York, NY, 5 Hebrew SeniorLife & Boston Univ, Boston, MA 5:45 pm The Association Between Accelerometer Monitored Sedentary Behavior and Observed Physical Function Loss Pamela Semanik 1, Rowland W. Chang 2, Jing Song 2, Jungwha Lee 2 and Dorothy D. Dunlop 2, 1 Rush University College of Nursing, Chicago, IL, 2 Northwestern University Feinberg School of Medicine, Chicago, IL INDUSTRY-SUPPORTED SYMPOSIA 6:30 9:30 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. ACR SESSIONS 7:30 8:30 am WEDNESDAY, NOVEMBER 19, A Co-Stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases Moderators: Gregg J. Silverman, MD and Adam Mor, MD, PhD Speaker: Vassiliki A. Boussiotis, MD, PhD examine the roles of co-receptor-mediated inhibitory pathways for the immunosurveillance of cancer and the development of autoimmune diseases, including rheumatoid arthritis and lupus appraise the relative contributions of the CD28, CTLA4, PD-1, ICOS and VISTA systems to immunoregulation review emerging data from therapeutic trials for the potential utility of manipulating these signaling pathways Ballroom East Rheumatology Roundup: Highlights from the 2014 Annual Meeting Moderator: Chester V. Oddis, MD Speakers: John J. Cush, MD and Arthur Kavanaugh, MD list research highlights from the scientific presentations discuss the clinical impact of selected research reports presented at the ACR meeting evaluate the therapeutic potential of selected clinical trials presented at the meeting 2014 Program Book 147 WEDNESDAY november 19, 2014

150 ARHP SESSIONS 7:30 8:30 am 255 scientific sessions Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Ed Pd PrM FIT Moderator: Sandra Mintz, BSN review the unique therapy needs of the juvenile dermatomyositis population at all stages of the disease process evaluate a patient with juvenile dermatomyositis formulate appropriate treatment plans for patients with juvenile dermatomyositis review the molecular and cellular pathways that link complement activation to systemic autoimmunity 9:00 am Effector Pathways Linking Complement Activation to Systemic Lupus Erythematosus Susan A. Boackle, MD 9:15 am Immune-Mediated Membranolytic Pathways: Key to Rheumatoid Arthritis Felipe Andrade, MD, PhD 9:30 am The Role of Complement in CD4+ T Cell Homeostasis and Effector Function Claudia Kemper, PhD WEDNESDAY november 19, :30 am Juvenile Dermatomyositis Stages, Physical Therapy Evaluation and Treatment Jill R. Blitz, PT, DPT 8:00 am Occupational Therapy Evaluation and Treatment for Juvenile Dermatomyositis Talitha Cox, MA, OTR/L Rheumatic Manifestations of Malignancy Moderator: Kori A. Dewing, DNP, ARNP review how patients can have a rheumatic disease as the presenting feature of a hidden malignancy explain the clinical features of paraneoplastic rheumatic disorders describe the evaluation and management of paraneoplastic rheumatic disorders 7:30 am Rheumatic Disease as a Manifestation of Malignancy David I. Daikh, MD, PhD 8:00 am Vasculitis as a Manifestation of Malignancy John H. Stone, MD, MPH ACR SESSIONS 9:00 10:30 am 253 B Complement in Rheumatic Disease Moderators: Susan A. Boackle, MD and Leendert A. Trouw, PhD review current evidence that supports a key role for complement and its receptors in regulating T-cell function review the repertoire of complement-mediated effector responses in autoimmunity 2014 Program Book Ballroom East Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Moderators: Shreyasee Amin, MD CM, MPH and Swamy Venuturupalli, MD describe major subsets of lupus patients defined by cytokine, autoantibody and genetic profiles recognize how this information may influence therapeutic strategies and responses describe emerging biomarkers that may help with disease monitoring and treatment decisions 9:00 am Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy Timothy B. Niewold, MD 9:30 am Influence of Biomarkers, Race and Ethnicity on Disease Severity and Treatment Response in Systemic Lupus Erythematosus David A. Isenberg, MD 10:00 am Improving Return on Investment: Molecular Analysis of the Kidney Biopsy for Lupus Nephritis Brad H. Rovin, MD Ballroom West Primary Angiitis of the Central Nervous System and Its Mimics Moderators: Elana J. Bernstein, MD, MSc and Rula Hajj-Ali, MD formulate a diagnostic approach to primary angiitis of the central nervous system and describe best practices in the management of primary angiitis of the central nervous system discuss the pathophysiology, clinical manifestations, diagnosis and treatment of the reversible cerebrovascular

151 scientific sessions vasoconstriction syndromes describe non-atherosclerotic cerebral vasculopathies that can mimic primary angiitis of the central nervous systems 9:00 am Primary Angiitis of the Central Nervous System Leonard H. Calabrese, DO 9:30 am Reversible Cerebrovascular Vasoconstriction Syndromes Aneesh Singhal, MD 10:00 am Non-Atherosclerotic Central Nervous System Vasculopathies Cenk Ayata, MD ACR CONCURRENT ABSTRACT SESSIONS 9:00 10:30 am 160 B Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Moderators: Anne-Marie Malfait, MD, PhD and Antonios O. Aliprantis, MD, PhD 9:00 am Adenosine a 2A Receptor As a Potential New Therapeutic Target for the Prevention/Treatment of Osteoarthritis Carmen Corciulo 1, Aranzazu Mediero 1, Tuere Wilder 1 and Bruce N. Cronstein 2, 1 NYU School of Medicine, New York, NY, 2 NYU School of Medicine, Division of Rheumatology, New York, NY 9:15 am S100 Proteins Induce Canonical Wnt Signaling, Which Causes Increased Expression of MMPs in the Synovium Martijn H. van den Bosch 1, Arjen B. Blom 1, R. Pelle Hoek 1, Rik F. Schelbergen 1, Sylvia W. Suen 1, Anke E. van Erp 1, Wim B. van den Berg 1, Peter M. van der Kraan 1 and Peter L. van Lent 2, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Experimental Rheumatology, Radboud University, Nijmegen, Netherlands 9:30 am Activation of AMP-Activated Protein Kinase (AMPK) By Berberine Limits Both Surgical Knee Instability-Induced and Aging-Related Osteoarthritis in Mice Ru Bryan 1, Xianling Zhao 2, Yun Wang 3, Han Sol Lee 2, Hyunje Kim 4, Alifah Akasdi 2 and Robert Terkeltaub 5, 1 VA Medical Center/ University of California San Diego, San Diego, CA, 2 VAMC, San Diego, CA, 3 VA Medical Ctr/UCSD, San Diego, CA, 4 Yeungnam University, Daegu, South Korea, 5 VA Medical Ctr/University of California San Diego, San Diego, CA 9:45 am Synovial Macrophages Promote TGF-β Activation after Intra-Articular Injections of Oxidized LDL in Naïve Murine Knee Joints, Preventing Production of Pro-Inflammatory Factors S100A8/9, Chemokines and Aggrecanase-Induced Neo- Epitopes Wouter de Munter, Peter M. van der Kraan, Wim B. van den Berg and Peter L. van Lent, Radboud university medical center, Nijmegen, Netherlands 10:00 am Syndecan-4 Regulates Chondrocyte Phenotype and Cartilage Homeostasis Via the WNT Signaling Pathway Charlotte Kimberley Clarke 1, Annelena Held 1, Richard Stange 2, Uwe Hansen 2, Lars Godmann 2, Jessica Bertrand 2, Thomas Pap 3, Giovanna Nalesso 4, Frank Echtermeyer 5, Francesco Dell Accio 6 and Joanna Sherwood 4, 1 Institute of Experimental Musculoskeletal Medicine (IEMM), Muenster, 48149, Germany, 2 University Hospital Münster, Münster, Germany, 3 University Hospital Muenster, Muenster, Germany, 4 Queen Mary University London, London, United Kingdom, 5 University Hospital Hannover, Hanover, Germany, 6 William Harvey Research Institute, Barts and the London Queen Mary s School of Medicine and Dentistry, Centre for Experimental Medicine and Rheumatology, London, United Kingdom 10:15 am S100A9 Inhibitor Paquinimod (ABR ) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium Peter L. van Lent 1, Rik Schelbergen 1, Arjen B. Blom 1, Tomas Leanderson 2, Helena Eriksson 3 and Wim B. van den Berg 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Lund University, Lund, Sweden, 3 Active Biotech AB, Lund, Sweden 153 B Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Moderators: Lindsey A. Criswell, MD, MPH and Patrick Gaffney, MD 9:00 am International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor Simon Rothwell 1, Robert G. Cooper 2, Ingrid E. Lundberg 3, Frederick W. Miller 4, Peter K. Gregersen 5, Jiri Vencovsky 6, Katalin Danko 7, Lucy R Wedderburn 8, Vidya Limaye 9, Albert Selva O Callaghan 10, Michael G. Hanna 11, Pedro Machado 11, Lauren M. Pachman 12, Ann M. Reed 13, Lisa G. Rider 4, Joanna Cobb 1, Hazel Platt 14, Øyvind Molberg 15, Olivier Benveniste 16, Pernille Mathiesen 17, Timothy Radstake 18, Andrea Doria 19, Jan De Bleecker 20, Boel De Paepe 20, Britta Maurer 21, William E. Ollier 14, WEDNESDAY november 19, Program Book 149

152 scientific sessions WEDNESDAY november 19, 2014 Leonid Padyukov 3, Terrance P. O Hanlon 4, Annette Lee 22, Hector Chinoy 1 and Janine Lamb 14, 1 Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester, United Kingdom, 2 University of Liverpool, Liverpool, United Kingdom, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4 Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5 The Feinstein Institute for Medical Research, Manhasset, NY, 6 Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7 University of Debrecen, Debrecan, Hungary, 8 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 9 Royal Adelaide Hospital, Adelaide, Australia, 10 Vall d Hebron General Hospital, Barcelona, Spain, 11 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, 12 Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, 13 Mayo Clinic, Rochester, MN, 14 Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, 15 Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 16 Pitié-Salpêtrière Hospital, APHP, Paris, France, 17 Paediatric Department, Holbaek University Hospital, Holbaek, Denmark, 18 University Medical Center Utrecht, Utrecht, Netherlands, 19 University of Padova, Padova, Italy, 20 University of Ghent, Ghent, Belgium, 21 Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 22 Feinstein Institute Med Rsch, Manhasset, NY 9:15 am The Amino Acid Positions 11, 13 and 26 of HLA- DR Beta Chain 1 Explain the Majority of the Association Between Systemic Lupus Erythematosus and the Major Histocompatibility Complex Locus Kwangwoo Kim 1, So-Young Bang 2, Hye-Soon Lee 2, Yukinori Okada 3, Woei-Yuh Saw 4, Paul IW. de Bakker 5, Yik-Ying Teo 6, Soumya Raychaudhuri 7 and Sang-Cheol Bae 2, 1 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 2 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3 Broad Institute, Cambridge, MA, 4 National University of Singapore, Singapore, Singapore, 5 University Medical Center Utrecht, Utrecht, Netherlands, 6 Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, 7 Broad Institute of MIT and Harvard, Cambridge, MA 9:30 am The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis Sarah French 1, Kimberly E. Taylor 1, Sharon A. Chung 1, Joanne Nitiham 1, Michelle Petri 2, Peter K. Gregersen 3, Ward Ortmann 4, Annette T. Lee 3, Timothy W. Behrens 4, Susan Manzi 5, F. Yesim Demirci 6, M. Ilyas Kamboh 6, Robert R. Graham 4, Michael F. Seldin 7 and Lindsey A. Criswell 1, 1 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 2 Johns Hopkins University School of Medicine, Baltimore, MD, 3 Feinstein Institute for Medical Research, Manhasset, NY, 4 Genentech, Inc., South San Francisco, CA, 5 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6 University of Pittsburgh, Pittsburgh, PA, 7 University of California, Davis, Davis, CA 9:45 am Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina Paula S. Ramos 1, Satria Sajuthi 2, Jasmin Divers 2, Yiqi Huang 3, Uma Nayak 3, Wei-Min Chen 3, Kelly J. Hunt 1, Diane L. Kamen 1, Gary S. Gilkeson 1, Jyotika K. Fernandes 1, Ida J. Spruill 1, W. Timothy Garvey 4, Michèle M. Sale 3 and Carl D. Langefeld 2, 1 Medical University of South Carolina, Charleston, SC, 2 Wake Forest School of Medicine, Winston-Salem, NC, 3 University of Virginia, Charlottesville, VA, 4 University of Alabama at Birmingham, Birmingham, AL 10:00 am The Rheumatoid Arthritis -Risk Locus CCR6 and Its SNP- Dependent Response to Estrogen: A Possible Genomic Link Between Sex Hormones and the IL-17 Inflammatory Pathway Ming-Fen Ho, Richard M. Weinshilboum, Liewei Wang and Tim Bongartz, Mayo Clinic, Rochester, MN 10:15 am Polygenic Analysis of Transport, Metabolism and Immune Related Genomic Compartments in Serum Urate and Gout Eli A. Stahl 1, Tony R. Merriman 2, Amanda Dobbyn 3, David B. Mount 4, Peter Kraft 5 and Hyon Choi 6, 1 Mt Sinai School of Medicine, New York City, NY, 2 University of Otago, Dunedin, New Zealand, 3 Icahn School of Medicine at Mount Sinai, New York, NY, 4 Brigham and Women s Hospital, Boston, MA, 5 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 6 Harvard Medical School, Boston, MA 104 B Metabolic and Crystal Arthropathies II: Mechanisms of Disease Moderators: Nicola Dalbeth, MBChB, MD and Alexander So, MD 9:00 am Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout Tony R. Merriman 1, Marilyn E. Merriman 1, Ruth Topless 1, Sara Altaf 1, Grant Montgomery 2, Christopher Franklin 3, Gregory T. Jones 1, Andre M. van Rij 1, Douglas HN White 4, Lisa K. Stamp 5, Program Book

153 scientific sessions Nicola Dalbeth 3 and Amanda Phipps-Green 1, 1 University of Otago, Dunedin, New Zealand, 2 Queensland Institute of Medical Research, Brisbane, Australia, 3 University of Auckland, Auckland, New Zealand, 4 Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 5 University of Otago, Christchurch, New Zealand 9:15 am Urate Genetic Loci and the Risk of Incident Cases of Confirmed Gout in Two Prospective Cohort Studies Hyon K Choi 1, Gary Curhan 2, Ying Bao 3, Eli A. Stahl 4, Peter Kraft 5, Robert M. Plenge 3, Yuqing Zhang 1 and Tony R. Merriman 6, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Brigham and Women s Hospital, Boston, MA, 4 Mt Sinai School of Medicine, New York City, NY, 5 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 6 University of Otago, Dunedin, New Zealand 9:30 am Conditional Analysis of 30 Serum Urate Loci Identifies 25 Additional Independent Effects Eli Stahl 1, Hyon Choi 2, Murray Cadzow 3, Tanya Flynn 3, Ruth Topless 3 and Tony R. Merriman 3, 1 Mt Sinai School of Medicine, New York City, NY, 2 Harvard Medical School, Boston, MA, 3 University of Otago, Dunedin, New Zealand 9:45 am Association of the Toll-like Receptor 4 (TLR4) Gene with Gout Humaira Rasheed 1, Ruth Topless 1, Richard Day 2, Diluk Kannangara 3, Kenneth Williams 3, Linda Bradbury 4, Matthew Brown 5, Catherine Hill 6, Susan Lester 7, Maureen Rischmueller 8, Malcolm Smith 6, Mariano Andrés 9, Thomas Bardin 10, Michael Doherty 11, Matthijs Janssen 12, Tim Jansen 13, Leo Joosten 13, Fernando Perez-Ruiz 14, Timothy Radstake 15, Philip L. Riches 16, Ed Roddy 17, Anne-Kathrin Tausche 18, Lisa K. Stamp 19, Nicola Dalbeth 20, Frederic Lioté 21, Alex So 22, Cushla McKinney 1 and Tony R. Merriman 1, 1 University of Otago, Dunedin, New Zealand, 2 St. Vincent s Hospital, Sydney, Australia, 3 University of New South Wales, Sydney, Australia, 4 The University of Queensland, Brisbane, Australia, 5 University of Queensland Diamantina Institute, Brisbane, Australia, 6 Queen Elizabeth Hospital, Adelaide, Australia, 7 Queen Elizabeth Hospital, Woodville South, Australia, 8 The Queen Elizabeth Hospital, SA, Australia, 9 Hospital General Universitario de Alicante, Alicante, Spain, 10 Hôpital Lariboisière, Paris, France, 11 City Hospital, Nottingham, United Kingdom, 12 Rijnstate Hospital, Arnhem, Netherlands, 13 Radboud University Medical Center, Nijmegen, Netherlands, 14 Hospital De Cruces, Baracaldo, Spain, 15 University Medical Center Utrecht, Utrecht, Netherlands, 16 University of Edinburgh, Edinburgh, United Kingdom, 17 Keele University, Staffordshire, United Kingdom, 18 Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 19 University of Otago, Christchurch, New Zealand, 20 University of Auckland, Auckland, New Zealand, 21 Université Paris Diderot, Paris, France, 22 CHUV, Lausanne, Switzerland 10:00 am The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA 10:15 am Association Analysis of Apolipoprotein B and Very Low- Density Lipoprotein with Hyperuricemia and Gout Humaira Rasheed 1, Angela Hsu 1, Nicola Dalbeth 2, Lisa K. Stamp 3, Sally McCormick 1 and Tony R. Merriman 1, 1 University of Otago, Dunedin, New Zealand, 2 University of Auckland, Auckland, New Zealand, 3 University of Otago, Christchurch, New Zealand 107 B Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Moderators: Yvonne C. Lee, MD, MMSc and M. Elaine Husni, MD, MPH 9:00 am Effects of Anti-NGF Strategies in Two Animal Models of Osteoarthritis (OA) Lilian Ngozi Nwosu 1, Paul Mapp 1, Karyn Bouhana 2, Steven Andrews 2, Victoria Chapman 1 and David Walsh 1, 1 Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, 2 Array BioPharma, Boulder, CO 9:15 am Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors Marieke J.H. Coenen 1, Maša Umicevic-Mirkov 1, Sophine B. Krintel 2, Julia Johansen 3, Corinne Miceli-Richard 4, Henrik Kallberg 5, Hans Scheffer 1, Wietske Kievit 1, Mart A. van de Laar 6, Piet L.C.M. van Riel 1, X. Mariette 7, Saedis Saevarsdottir 8, Merete Lund Hetland 9, Sita Vermeulen 1 and Cornelis A. Albers 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3 University of Copenhagen, Frederiksberg, Denmark, 4 Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, 5 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 6 University Twente & Medisch Spectrum Twente, Enschede, Netherlands, 7 Paris-Sud University, Paris, France, 8 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 9 DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark WEDNESDAY november 19, Program Book 151

154 scientific sessions 9:30 am Patient Reported Pain By the Paindetect Questionnaire Reveals Multimodal Elements to Pain Perception in Rheumatoid Arthritis Saqa Ahmed 1, Tejal Magan 1, Mario Vargas 1, Abiola Harrison 1 and Nidhi Sofat 2, 1 St George s, University of London, London, United Kingdom, 2 St. George s University of London, London, United Kingdom 9:15 am Elevations of Certain Memory-Effector T Cell and Inflammatory Monocyte Subpopulations in Rheumatoid Arthritis Are Associated with the Presence of Subclinical Coronary Artery Atherosclerosis Robert Winchester 1, Jon T. Giles 1, Simona Nativ 2, Hui-Zhu Zhang 1, Kendall Downer 1 and Joan Bathon 1, 1 Columbia University, New York, NY, 2 Morristown Medical Center, Morristown, NJ WEDNESDAY november 19, :45 am Improvement Following Total Knee Replacement (TKR) Surgery: Exploring Preoperative Symptoms and Change in Preoperative Symptoms Ernest R. Vina 1, Michael J. Hannon 2 and C. Kent Kwoh 3, 1 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 2 University of Pittsburgh School of Medicine, Pittsburgh, PA, 3 University of Arizona, Tucson, AZ 10:00 am Mortality after Knee Replacement Surgery for Osteoarthritis in a Population-Based Propensity-Score Matched Cohort Devyani Misra 1, Tuhina Neogi 1, Na Lu 1, David T. Felson 1, Thomas Einhorn 1, Hyon Choi 2, Jessica Maxwell 3 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Boston University, Boston, MA 10:15 am Psoriatic Arthritis is Associated with Heterotopic Ossification after Total Hip Arthroplasty Mario Cedillo 1, Arielle Fein 2, Susan M. Goodman 2, Rebecca Zhu 2, Mark P. Figgie 2, Michael Alexiades 2, Jayme C. Burket 2 and Lisa A. Mandl 2, 1 Weill Cornell Medical College, New York, NY, 2 Hospital for Special Surgery, New York, NY 258 B Rheumatoid Arthritis Clinical Aspects VII: New Aspects of Monitoring Disease Moderators: Merete Lund Hetland, DMSc, MD, PhD and Barbara Goldstein, MD, MMSc 9:00 am Patient s Self-Monitoring Via Smartphone: The Compass Study Correlation Between Patient Self-Assessment of Rheumatoid Arthritis Disease Activity Via Smartphone Technology and Physicians Validated Scores Ruediger Mueller 1, Ulrich Walker 2, Diego Kyburz 3, Robert Theiler 4, Adrian Forster 5, Fabiana Ganz 6 and Patrick Dufner 6, 1 Kantonspital St. Gallen, St. Gallen, Switzerland, 2 Department of Rheumatology, Basel University, Basel, Switzerland, 3 University Hospital, Basel, Switzerland, 4 Triemli spital, Zurich, Switzerland, 5 Spital Thurgau AG, Diessenhofen, Switzerland, 6 Abbvie AG, Baar, Switzerland 9:30 am The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis Eric H. Sasso 1, George Wu 1, CC Hwang 1, Michael E. Weinblatt 2, Nancy A. Shadick 2, Claire Alexander 1 and Oscar Segurado 1, 1 Crescendo Bioscience Inc., South San Francisco, CA, 2 Brigham and Women s Hospital, Boston, MA 9:45 am Multi-Biomarker Disease Activity Score Is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State Margaret H. Ma 1, Toby Garrood 2, Wanying Li 3, Nadine A. Defranoux 3, Gabrielle H. Kingsley 4, Andrew P. Cope 5 and David L. Scott 6, 1 King s College Hospital, London, United Kingdom, 2 Guy s and St. Thomas Foundation Hospital NHS Trust, London, United Kingdom, 3 Crescendo Bioscience Inc., South San Francisco, CA, 4 Kings College London, London, United Kingdom, 5 King s College London, London, United Kingdom, 6 King s College London, Department of Rheumatology, London, United Kingdom 10:00 am Residual Large Joint Synovitis By Power Doppler Ultrasonography Is Associated with Higher Disease Activity and Significant Impact of Disease in Multi-Ethnic Asian Patients with Established Rheumatoid Arthritis Yu Xiao Guo 1, Manjari Lahiri 2 and Peter Cheung 2, 1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 2 Division of Rheumatology, National University Hospital, Singapore, Singapore 10:15 am Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice Marco Antivalle, Michel Chevallard, Michele Battellino, MariaChiara Ditto, Valentina Varisco, Federica Rigamonti, Alessandra Mutti, Fabiola Atzeni, Alberto Batticciotto and Piercarlo Sarzi-Puttini, L. Sacco University Hospital, Milano, Italy Program Book

155 scientific sessions 157 B Sjögren s Syndrome II: Insights Into Pathophysiology Moderators: Alan N. Baer, MD and Kathy L. Sivils, PhD 9:00 am Distinct Serum Protein Signature and Novel Biomarkers of primary Sjögren s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis Ayumi Nishikawa 1, Katsuya Suzuki 1, Yoshiaki Kassai 2, Yuumi Gotou 3, Takahiro Miyazaki 2, Maiko Takiguchi 4, Masaru Takeshita 1, Atsuko Murota 1, Rimpei Morita 5, Akihiko Yoshimura 5 and Tsutomu Takeuchi 1, 1 Keio University School of Medicine, Tokyo, Japan, 2 Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 3 Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, 4 Takeda Pharmaceutical Company Limited, Tokyo, Japan, 5 Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan 9:15 am Characterization of the Sjögren s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1) John A. Ice 1, He Li 1, Indra Adrianto 1, Mikhail G. Dozmorov 1, Astrid Rasmussen 1, Graham B. Wiley 1, Jennifer A. Kelly 1, Kimberly S. Hefner 2, Donald U. Stone 3, Raj Gopalakrishnan 4, David M. Lewis 3, Stephen Young 3, Michael D. Rohrer 4, Juan-Manuel Anaya 5, Swamy Venuturupalli 6, Barbara M. Segal 7, Nelson L. Rhodus 4, Lida Radfar 3, Michael H. Weisman 8, Judith A. James 1, Courtney G. Montgomery 1, R. Hal Scofield 9, Patrick M. Gaffney 1, Linda F. Thompson 1, A. Darise Farris 10, Susan Kovats 1, Jonathan D. Wren 1, Kathy L. Sivils 3 and Christopher J. Lessard 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Hefner Eye Care and Optical Center, Oklahoma City, OK, 3 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4 University of Minnesota, Minneapolis, MN, 5 Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 6 Cedars-Sinai Medical Center, West Hollywood, CA, 7 Hennepin County Medical Center, Minneapolis, MN, 8 Cedars-Sinai Medical Center, Los Angeles, CA, 9 US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 10 Oklahoma Medical Research Foun, Oklahoma City, OK 9:30 am Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjögren s Syndrome Naomi I Maria 1, Cornelia G. van Helden-Meeuwsen 1, Eline C. Steenwijk 1, Arne S. IJpma 2, Wouter Beumer 1, Zana Brkic 1, Virgil A. Dalm 1, Paul L. van Daele 1, P. Martin van Hagen 1, Peter J. van der Spek 2, Hemmo A. Drexhage 1 and Marjan A. Versnel 1, 1 Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2 Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands 9:45 am Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren s Syndrome Gunnel Nordmark 1, Juliana Imgenberg-Kreuz 2, Jonas Carlsson Almlöf 2, Jessica Nordlund 2, Roald Omdal 3, Katrine B. Norheim 3, Maija-Leena Eloranta 4, Lars Rönnblom 4 and Johanna K. Sandling 2, 1 Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2 Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 3 Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 4 Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden 10:00 am Prognostic Value of the Complex P2X7 Receptor- Inflammasome in Patients with Primary Sjögren s Syndrome at Lymphoma Risk Chiara Baldini 1, Eleonora Santini 2, Chiara Rossi 2, Francesca Sernissi 1, Daniela Martini 1, Alessia Gallo 3, Valentina Donati 2, Nicoletta Luciano 1, Francesco Ferro 1, Illias Alevizos 3, Anna Solini 2 and Stefano Bombardieri 2, 1 Rheumatology Unit, Pisa, Italy, 2 Rheumatology Unit, University of Pisa, Pisa, Italy, 3 NIDCR, Bethesda, MD 10:15 am Identification of Whole Blood Gene Expression Signature in Primary Sjögren s Syndrome Associated Lymphoma Shereen Al-Ali 1, Simon Cockell 2, Andrew Skelton 3, Katherine James 2, Jessica Tarn 2, David Young 3, Bridget Griffiths 4, Simon Bowman 5, James Locke 2 and Wan-Fai Ng 2, 1 University of Basrah, Basrah, Iraq, 2 Newcastle University, Newcastle upon Tyne, United Kingdom, 3 Newcastle University, Newcastle Upon Tyne, United Kingdom, 4 Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 5 University Hospital Birmingham, Birmingham, United Kingdom 205 B Spondyloarthropathies and Psoriatic Arthritis VI Imaging and Biomarkers Moderators: Robert Inman, MD and Juergen Braun, MD 9:00 am Infliximab Added to Naproxen Does Not Increase Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints and of the Spine As Compared to Naproxen Alone in Early Axial Spondyloarthritis Denis Poddubnyy and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany WEDNESDAY november 19, Program Book 153

156 scientific sessions WEDNESDAY november 19, :15 am Degenerative Changes of the Spine on MRI in Patients with Inflammatory Back Pain F. de Bruin 1, Marc Olivier Treyvaud 2, Antoine Feydy 2, Maxime Dougados 3, Laure Gossec 4, J.L Bloem 1, Désirée van der Heijde 1 and Monique Reijnierse 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France, 3 Descartes University, Cochin Hospital, Paris, France, 4 UC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France 9:30 am Autoantibodies to η Are Novel Biomarkers Associated with Inflammation and Radiographic Progression in Ankylosing Spondylitis WP Maksymowych 1, Stephanie Wichuk 1, RG Lambert 1, Mairead Murphy 2 and Anthony Marotta 2, 1 University of Alberta, Edmonton, AB, 2 Augurex Life Sciences Corp., North Vancouver, BC 9:45 am Fat Metaplasia on MRI of the Sacroiliac Joints Is a Lead Indicator of Radiographic Progression in the Spine of Patients with Ankylosing Spondylitis WP Maksymowych 1, S Wichuk 1, P Chiowchanwisawakit 2, RG Lambert 1 and Sj Pedersen 3, 1 University of Alberta, Edmonton, AB, 2 Mahidol University, Bangkok, Thailand, 3 Copenhagen Center for Arthritis Research, Copenhagen, Denmark 10:00 am Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Chronic Low Back Pain Maximiliano Bravo 1, Leandro Ferreyra Garrott 1, David A. Navarta 1, Emmanuel Bertiller 1, Ricardo Garcia-Monaco 2, Santiago Ruta 1, Javier Rosa 3 and Enrique Soriano 1, 1 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2 Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, 3 Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina 10:15 am Calgranulin Levels Are Elevated in Spondyloarthritis and Reflect the Presence of Acute Microscopic Gut Inflammation Heleen Cypers 1, Gaëlle Varkas 1, Liesbet Van Praet 1, Johannes Roth 2, Thomas Vogl 2, Claude Cuvelier 3, Dirk Föll 4, Miha Lavric 4, Filip van Den Bosch 1 and Dirk Elewaut 1, 1 Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 2 Institute of Immunology University of Muenster, Muenster, Germany, 3 Department of Pathology Ghent University Hospital, Ghent, Belgium, 4 University Children s Hospital Muenster, Muenster, Germany 52 A Systemic Lupus Erythematosus Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Moderators: Dafna D. Gladman, MD and Stacy P. Ardoin, MD, MS 9:00 am Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus David Giangreco 1, Hervé Devilliers 2, Narender Annapureddy 1, Joel A. Block 1 and Meenakshi Jolly 1, 1 Rush University Medical Center, Chicago, IL, 2 Department of internal medicine and systemic diseases, Dijon, France 9:15 am Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study Javier Merayo-Chalico 1, Elia Apodaca 2, Ana Barrera-Vargas 1, Jorge Alcocer-Varela 1 and Diana Gómez-Martín 1, 1 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2 Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico 9:30 am Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8 Hidenaga Kawasumi 1, Takahisa Gono 1, Yasushi Kawaguchi 1, Yasuhiro Katsumata 1, Hisae Ichida 1, Akiko Tochimoto 1, Masanori Hanaoka 1, Yuko Okamoto 1, Sayuri Kataoka 1 and Hisashi Yamanaka 2, 1 Tokyo Women s Medical University, Tokyo, Japan, 2 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 9:45 am Usefulness of Diagnostic Biomarker for Neuropsychiatric Systemic Lupus Erythematosus By Anti-Microtubule Associated Protein 2 Antibody in Cerebrospinal Fluid Yusuke Yamada, Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan 10:00 am MRI in Neuropsychiatric Lupus: Correlations with the 1999 ACR Case Definitions Minyoung Her 1, Dongyook Kim 1, Na young Park 1, Seong-Kyu Kim 2, Lee Sung Won 3 and Lee sang Yeob 3, 1 Inje University, Pusan Program Book

157 scientific sessions Paik Hospital, Busan, South Korea, Busan, South Korea, 2 Catholic University of Daegu, Daegu, South Korea, Daegu, South Korea, 3 Dong-A university, Busan, South Korea, Pusan, South Korea 10:15 am WITHDRAWN 151 A Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Moderators: Laura K. Hummers, MD, ScM and Sindu R. Johnson, MD, PhD 9:00 am Surrogate Measures of Extent of Interstitial Lung Disease As Measured By Quantitative Radiographic Analysis in Patients with Systemic Sclerosis Elizabeth Volkmann 1, Donald Tashkin 2, Chi-hong Tseng 1, Kim Hyun 1, Jonathan Goldin 1, Philip J. Clements 3, Daniel E. Furst 1, Dinesh Khanna 4, Eric Kleerup 1, Michael Roth 1 and Robert Elashoff 5, 1 University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2 University of California at Los Angeles, Los Angeles, CA, 3 University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 4 University of Michigan Health System, Ann Arbor, MI, 5 University of California, Los Angeles, Los Angeles, CA 9:15 am Intestinal Pseudo-Obstruction in Patients with Systemic Sclerosis: An Analysis of the Nationwide Inpatient Sample Antonia Valenzuela 1, Shufeng Li 1, Laren Becker 1, Nielsen Fernandez-Becker 1, Dinesh Khanna 2, Linda Nguyen 1 and Lorinda Chung 1, 1 Stanford University School of Medicine, Palo Alto, CA, 2 University of Michigan Health System, Ann Arbor, MI 9:30 am Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients Robyn T. Domsic 1, Svetlana I. Nihtyanova 2, Mary Lucas 1, Stephen R. Wisniewski 3, Michael J. Fine 4, C. Kent Kwoh 5, Christopher P. Denton 6 and Thomas A. Medsger Jr. 1, 1 University of Pittsburgh, Pittsburgh, PA, 2 Royal Free and University College Medical School, London, United Kingdom, 3 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4 University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 5 The University of Arizona Arthritis Center, Tucson, AZ, 6 Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom 9:45 am Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices a Prospective Study Thomas Frauenfelder 1, Anna Winklehner 1, Thi Dan Linh Nguyen 1, Rucsandra Dobrota 2, Stephan Baumüller 1, Britta Maurer 3 and Oliver Distler 3, 1 Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, 2 Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 3 Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland 10:00 am Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis the Combined Response Index in Systemic Sclerosis Dinesh Khanna 1, Veronica Berrocal 2, Edward Giannini 3, Maureen Mayes 4, Peter A. Merkel 5, Jeffrey Siegel 6, James R. Seibold 7, Murray Baron 8, Philip J. Clements 9, Yannick Allanore 10, Virginia D. Steen 11, Christopher P. Denton 12, Oliver Distler 13, Sindhu R. Johnson 14, Marco Matucci-Cerinic 15, Lazlo Czirjak 16, Janet E. Pope 17, Susanna Proudman 18, Weng Kee Wong 19, Athol U. Wells 20 and Daniel E. Furst 9, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 University of Michigan, Ann Arbor, MI, 3 Childrens Hosp Med Ctr, Cincinnati, OH, 4 University of TX Health Science Center -Houston, Houston, TX, 5 Boston University School of Medicine, Boston, MA, 6 Genentech, South San Francisco, CA, 7 Scleroderma Research Consultants LLC, Avon, CT, 8 Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, 9 University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 10 Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, 11 Georgetown University Medical Center, Washington, DC, 12 UCL Medical School Royal Free Campus, London, United Kingdom, 13 University Hospital Zurich, Zurich, Switzerland, 14 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, 15 University of Florence, Florence, Italy, 16 University of Pécs, Pécs, Hungary, 17 Western University, London, ON, 18 Royal Adelaide Hospital, Adelaide, Australia, 19 UCLA Fielding School of Public Health, Los Angeles, CA, 20 Department of Radiology, London, United Kingdom 10:15 am Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity Hebah Alhajeri 1, Marie Hudson 1, Canadian Scleroderma Research Group CSRG 1 and Murray Baron 2, 1 McGill University, Montreal, QC, 2 Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC WEDNESDAY november 19, Program Book 155

158 scientific sessions 156 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics II Moderators: Sandeep K. Agarwal, MD, PhD and Romy Christmann, MD, PhD 9:00 am Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis Jerome Avouac 1, Lucille Desallais 2, Maxime Fréchet 3, Muriel Elhai 3, Jean François Zagury 2 and Yannick Allanore 1, 1 Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, 2 Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, 3 INSERM U1016, Cochin Institute, Paris, France 9:15 am Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis Yuichiro Shirai 1, Ilia Atanelishvili 2, Tanjina Akter 1, Richard Silver 3 and Galina Bogatkevich 1, 1 Medical University of South Carolina, Charleston, SC, 2 Medical University of South Carolina, Charleston,USA, Charleston, SC, 3 Medical University of South Carolina, Charleston, SC 9:30 am Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells and Immune Cells Tetsuo Toyama 1, Yoshihide Asano 1, Takehiro Takahashi 1, Ryosuke Saigusa 1, Yohei Ichimura 1, Takashi Taniguchi 1, Shinji Noda 1, Kaname Akamata 1, Shinichi Sato 1, Takafumi Kadono 1 and Koichi Shudo 2, 1 University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2 Reseach Foundation ITSUU Laboratory, Tokyo, Japan 10:15 am Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma Pei-Suen Tsou 1, George Zakhem 2, Beatrix Balogh 2, M. Asif Amin 3, Phillip Campbell 3, Gautam Edhayan 3, Ray A. Ohara 3, Elena Schiopu 3, Dinesh Khanna 1, Alisa E. Koch 4 and David A. Fox 3, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 University of Michigan Medical School, Ann Arbor, MI, 3 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4 Department of Veteran s Affairs and University of Michigan, Ann Arbor, MI ARHP SESSIONS 9:00 10:30 am 256 Exercise Adherence in Arthritis: The Role of Technology Moderator: Jennifer M. Hootman, PhD identify established barriers to/risk factors of poor exercise adherence discuss the prevalence of aerobic and strength exercise in arthritis review the measurement of activity adherence and challenges and opportunities in the field describe the innovative use of technology to promote adherence and the evidence to support it 9:00 am Barriers to Exercise Adherence: Challenges and Opportunities to Foster Adherence Julie J. Keysor, PhD, PT WEDNESDAY november 19, :45 am Autoantibody-Mediated Raynaud s Phenomenon: Animal Model and Human Disease Dana P. Ascherman 1, Yunjuan Zang 2, Laisel Martinez 1, Judith Pignac-Kobinger 2, Irina Fernandez 2 and Eric L. Greidinger 2, 1 Miami VAMC, Miami, FL, 2 University of Miami, Miami, FL 10:00 am Essential Role for Alternately Spliced Tenascin C and TLR4 Signaling in Persistent Organ Fibrosis Swati Bhattacharyya 1, Wenxia Wang 1, Luisa Morales-Nebreda 1, Katja Lakota 1, Robert Lafyatis 2, Monique E. Hinchcliff 1, GR Scott Budinger 1, Zenshiro Tamaki 1 and John Varga 3, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Boston University School of Medicine, Boston, MA, 3 Northwestern University Feinberg School of Medicine, Chicago, IL 9:30 am Exercise Adherence in Arthritis: Can We Improve It with Technology? Kristin Baker, PhD 10:00 am Environmental Barriers to Physical Activity in Arthritis Molly Vaughn, PhD Program Book

159 scientific sessions 255 Nothing About Us without Us: Engaging Patients in Rheumatology Research Moderator: Janet L. Poole, OTR, PhD evaluate and apply best practices for engaging patients in the research process, from the investigator perspective, including specific examples of successes and challenges describe the patient experience as a member of the research team review the funding agency perspective regarding expectations and best practices for patient engagement on the research team 9:00 am Patient Engagement from the Researcher Perspective Monique A. Gignac, PhD 9:25 am The Patient Experience: A Research Team Member Amye L. Leong, MBA 9:50 am Funding Agency Perspective on Patient Engagement Suzanne Schrandt, JD 10:15 am Panel Discussion ARHP CONCURRENT ABSTRACT SESSIONS 9:00 10:30 AM 257 A Clinical Practice/Patient Care Moderator: Marian T. Hannan, DSc, MPH 9:00 am Can Knee Pain be Prevented through Diet and Exercise Among Those at High Risk? Daniel White 1, Tuhina Neogi 2, W. Jack Rejeski 3, Michael Walkup 3, Cora E. Lewis 4, Michael Nevitt 5, Capri Foy 3 and David T. Felson 2, 1 Boston Univ School of Med, Boston, MA, 2 Boston University School of Medicine, Boston, MA, 3 Wake Forest University, Winston-Salem, NC, 4 The University of Alabama at Birmingham, Birmingham, AL, 5 UCSF, San Francisco, CA 9:15 am High Prevalence of Subclinical Ultrasonographic Enthesopathy and Synovitis in Patients with Inflammatory Bowel Disease without Clinical Signs or Symptoms of Spondyloarthritis Esther Vicente 1, Silvia Pérez-Esteban 2, María Chaparro 1, Francisco Rodríguez-Salvanés 1, Lorena Vega 1, Santos Castañeda 1 and Javier P Gisbert 3, 1 Hospital Universitario de La Princesa, IISP, Madrid, Spain, 2 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3 Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain 9:30 AM Stem Cell Augmentation for Cardiovascular Risk in Rheumatoid Arthritis Nidhi Garg 1, Ashit Syngle 2 and Pawan Krishan 1, 1 Punjabi University Patiala, India, Patiala, India, 2 Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India 9:45 am The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate Hayley McBain 1, Michael Shipley 2, Abigail Olaleye 2, Samantha Moore 3, Shashi Hirani 4 and Stanton Newman 4, 1 East London Foundation Trust, London, United Kingdom, 2 University College Hospital London, London, United Kingdom, 3 University College London, London, United Kingdom, 4 City University London, London, United Kingdom 10:00 am Ambulatory Gait Analysis in Clinical Practice: Single or Dual Task Conditions? Bernard Auvinet 1, Claude Touzard 2 and Vincent Goëb 3, 1 Polyclinic, LAVAL, France, 2 Hospital of Laval, LAVAL, France, 3 Amiens University Hospital, Amiens, France 10:15 am Needs Assessment Survey Evaluation of Sexual Dysfunction Among Patients at a Tertiary Rheumatology Clinic Sharon Nesher Peleg 1, Ori Elkayam 2, Bruria Yahini 1 and Jacob N. Ablin 1, 1 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 259 A Innovations in Rheumatologic Care Moderators: Carol M. Greco, PhD and Elizabeth M. Badley, PhD Ed Pd PrM FIT 9:00 am The Reserve Capacity Model in Patients with Rheumatoid Arthritis: Understanding the Relationship of Socioeconomic Status, Psychosocial Resources, Mood and Pain Desiree Azizoddin 1, Taylor Draper 1, Sarah Ormseth 1, Perry M. Nicassio 1, Michael R. Irwin 1, Michael Weisman 2 and Hilary Wilson 1, 1 University of California, Los Angeles, Los Angeles, CA, 2 Cedars-Sinai Medical Center, Los Angeles, CA WEDNESDAY november 19, Program Book 157

160 scientific sessions WEDNESDAY november 19, :15 am Does the Order or Amount of Risk-Benefit Information Presented Influence patients Perceived Value of a Proposed New Medication? Liana Fraenkel 1, Richard Street 2, Harjinder Chowdhary 3, Sarah Swift 3 and Ellen Peters 4, 1 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2 Texas A&M University, College Station, TX, 3 Yale University, New Haven, CT, 4 Ohio State University, Columbus, OH 9:30 am Evaluation of the effuc Educational Needs Assessment Tool (ENAT) Focused Patient Education on Health Outcomes in Patients with Rheumatoid Arthritis a Randomised Controlled Trial Adewale O. Adebajo 1, Dawn Johnson 2, Hardware Bernadette 3, Claire Hale 4 and Mwidimi Ndosi 4, 1 University of Sheffield, Sheffield, United Kingdom, 2 Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom, 3 Barnsley Hospital NHS Foundation Trust, Baarnsley, United Kingdom, 4 University of Leeds, Leeds, United Kingdom 9:45 am Measuring the Impact of an Early RA Support and Education Program Using a Program Evaluation with Patient Identified Outcomes Adena Batterman 1, Kathryn Klingenstein 1, Roberta Horton 1, Linda Leff 1, Theodore R. Fields 2 and Vivian P. Bykerk 1, 1 Hospital for Special Surgery, New York, NY, 2 Hospital for Special Surgery Weill Cornell Medical College, New York, NY 10:00 am Program Evaluation of the Joint Clinic : An Innovative Clinical Service for Patients with Hip or Knee Osteoarthritis J. Haxby Abbott 1, Helen Harcombe 1, Chris Crane 2, Liam Hutton 2, Kirsten Stout 2, Cathy Chapple 1 and David Gwynne-Jones 1, 1 University of Otago, Dunedin, New Zealand, 2 Southern District Health Board, Dunedin, New Zealand 10:15 am Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis. Wilfred FH Peter 1, Mick Loos 1, Henrica de Vet 1, Maarten Boers 1, Jaap Harlaar 1, Leo D. Roorda 2, Rudolf Poolman 3, Vanessa Scholtes 3, Jan Bogaard 1, Hilda Buitelaar 1, Martijn P.M. Steultjens 4, Ewa M. Roos 5, Anne-Christine Rat 6, Francis Guillemin 7, Maria Grazia Benedetti 8, Antonio Escobar Martinez 9, Nina Østerås 10 and Caroline Terwee 1, 1 VU University Medical Center, Amsterdam, Netherlands, 2 Amsterdam Rehabilitation Research Center Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 3 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, 4 Glasgow Caledonian University, Glasgow, Scotland, 5 University of Southern Denmark, Odense, Denmark, 6 University of Lorraine, Nancy, France, 7 INSERM, Centre d Investigation Clinique Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 8 Istituto Ortopedico Rizzoli, Bologna, Italy, 9 Basurto University Hospital, Bilbao, Spain, 10 Diakonhjemmet Hospital, Oslo, Norway ACR SESSION 11:00 am Noon Exhibit Hall C Inflammation and Atherothrombosis Moderators: Swamy Venuturupalli, MD and Anne Bass, MD Speaker: Paul M. Ridker, MD, MPH discuss the immune mechanisms responsible for atherothrombosis explain the use of statins to prevent venous thromboembolic events review the recent AHA/ACC guidelines for statin ACR SESSIONS 11:00 am 12:30 pm 52 A Advances in Molecular Profiling and Relevance to Autoimmune Disease Moderator: Dana P. Ascherman, MD review the role of proteomics-based profiling in rheumatic disease with respect to biomarker development, delineation of pathogenesis describe metabolomics and its relationship to human autoimmune/rheumatic disease acknowledge differences between metabolomics and proteomics demonstrate the utility versus limitations of molecular profiling 11:00 am Proteomics Composite Signaling Molecule Profiles William H. Robinson, MD, PhD 11:30 am Proteomics 2 Assessment of Post-Translationally Modified Target Molecules Paul Eggleton, PhD Program Book

161 scientific sessions Noon Metabolomics Relevance to Autoimmune Disease Stephen Young, BSc, PhD Ballroom East Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Moderators: Alan N. Baer, MD and Grant H. Louie, MD, MHS 11:00 am Accommodations Work: Evidence for People with Arthritis Linda C. Batiste, JD 11:30 am Overview of Arthritis-Attributable Work Limitation in U.S. Adults Kristina A. Theis, MPH describe the concept of non-radiographic axial spondyloarthritis explain the natural history of non-radiographic axial spondyloarthritis discuss differential treatment response in non-radiographic axial spondyloarthritis and ankylosing spondylitis 11:00 am Non-Radiographic Axial Spondyloarthritis: A Primer Michael M. Ward, MD 11:30 am Does Non-Radiographic Axial Spondyloarthritis Represent Pre- Radiographic Axial Spondyloarthritis? Maxime Dougados, MD, PhD Noon The Meaning and Importance of Work Nancy A. Baker, MPH, OTR, OTR/L INDUSTRY-SUPPORTED POST MEETING SYMPOSIA 1:00 4:00 pm For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. Noon Are Treatment Responses in Non-Radiographic Axial Spondyloarthritis Similar Axial Spondyloarthritis? Jürgen Braun, MD ARHP SESSION 11:00 am 12:30 pm 255 Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Moderator: Julie J. Keysor, PhD, PT describe the prevalence and impact of arthritis-attributable work limitations in U.S. adults discuss justification for the importance of working for people with arthritis health and well-being share information with participants on the Job Accommodation Network and how this resource can be used to facilitate workers remaining in the workforce explain necessary steps for disclosing and/or requesting legally protected accommodations WEDNESDAY november 19, Program Book 159

162 ACR POSTER INDICES SUNDAY, NOVEMBER 16, 2014 Poster Hall (Exhibit Hall B) Antiphospholipid Syndrome 1. Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome 2. Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis 3. Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients? 4. Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples 5. Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus 6. Performance Evaluation and Clinical Associations of the Aphl ELISA Compared to Criteria Antiphospholipid Immunoassays in Lupus Patients 7. Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients 8. Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome 9. A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation 10. Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients 11. Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome 12. Non-Criteria Antiphospholipid Antibodies in Obstetrical seronegative Anti-Phospholipid syndrome 13. Eculizumab in Antiphospholipid Antibody Syndrome 14. Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists 15. Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples 16. Differential Assay Reactivity of IgA Anti-B2glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing 17. Antiphospholipid Syndrome Following Infection: A Systematic Review of Case Reports 18. The Effect of Clinically Significant Antiphospholipid Antibody Positivity on Organ Damage in Systemic Lupus Erythematosus Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling 19. Adenosine Receptors Stimulate Bone Regeneration 20. High Systemic LDL Cholesterol Levels during Experimental Osteoarthritis Lead to Increased Synovial Activation and Ectopic Bone Formation at End-Stage Osteoarthritis, While Excessive Levels Accelerate Development of Joint Pathology Already at Early-Stage O 21. Mendelian Randomization Analysis to Examine for Causal Relationships Between Serum Urate Levels and Bone Mineral Density 22. Adenosine a2a Receptor (A2AR) Stimulation Inhibits Osteoclast Differentiation and Promotes Osteoblast Formation By Regulation of Axon Guidance Proteins 23. Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements 24. Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis 25. DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair 26. Functional Osteoclasts Differentiate Spontaneously from the Rheumatoid Joint 27. CD115+ Osteoclast Precursors Arise before Clinical Onset of Arthritis and Are Regulated By Proinflammatory Cytokines 28. Evidence for Receptor Activator of NF-Kb (RANK)- Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis 29. Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis - Anti-Inflammatory Therapy As Confounder 30. Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14+VE Monocultures Reduces Osteoclast Differentiation Program Book

163 ACR POSTER INDICES 31. Interaction of FGF-8 and TNF-a in the Regulation of BMP- Induced Osteoblast Differentiation 32. Regulation of Senescence and Inflammatory Mediators By N- and C-Terminal Parathyroid Hormone-Related Protein in Osteoarthritic Human Osteoblasts 33. Stimulation of the Adenosine a2a receptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction 34. Pro-Nerve Growth Factor (ProNGF) Stimulates Bone Growth By Stimulating Osteoblasts and Inhibiting Osteoclast Differentiation, an Explanation for Anti-NGF- Mediated Osteonecrosis; Prongf Is a Novel Therapeutic Target for Treatment of Osteonecrosis and Charc 35. Hydrogen Sulfide Inhibits Human Osteoclast Differentiation in Vitro By Triggering Sustained Antioxidant Response and Inhibiting the RANKL/OPG Ratio 36. The Use of Three-Dimensionally Printed β-tricalcium Phosphate/Hydroxyapatite to Further Understand the Regulation of Adenosine Receptors in Osteoclast Formation and Promotion in Bone Regeneration 37. Regulation of Osteoclast and T Cell Differentiation By DC- STAMP and TRAF3 38. Angiopoietin-like 4 Is over-expressed in Rheumatoid Arthritis: A Potential Role in Pathological Bone Resorption 39. Human CD14+ Monocytes Stimulated with a Combination of TNFα and IL-6 Differentiate into Osteoclast-like Cells with Bone-Resorption Activity Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More 40. Prevalence of Spondyloarthritis (ASAS Criteria) in First- Degree Relatives of Patients with Ankylosing Spondylitis 41. The Impact of Ankylosing Spondylitis on Work Impairment: Data from the Scotland Registry for Ankylosing Spondylitis 42. The Prevalence of Ankylosing Spondylitis in Sweden a Nationwide Register Study 43. Deaths Associated with Ankylosing Spondylitis in France from 1969 to Physical Function, Hyperuricemia and Gout in Older Adults 45. Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men 46. Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout 47. The Risk of Aplastic Anemia and Pancytopenia with Colchicine: A Retrospective Study of Integrated Health System Database 48. Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study 49. Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women US and Canadian Perspective 50. Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study 51. High Incidence of Non-Vertebral Osteoporotic Fracture and Hip Fracture in Brazilian Low-Income Community- Dwelling Elderly: A Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study 52. Visceral Fat Measured By Dual-Energy X-Ray Absorptiometry Is Associated with Increased Risk of Non-Spine Fractures in Nonobese Elderly Women: a Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study 53. Spine-Hip Diagnostic Discordance in the United Arab Emirates 54. Concordance with the National Osteoporosis Foundation Treatment Guidelines After DXA Result Notification 55. Validation of the Diagnosis of Avascular Necrosis of Bone in Administrative Data 56. High Prevalence of Cervical Malignant and Premalignant Lesions Among Women with Rheumatoid and Psoriatic Arthritis 57. Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort 58. What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis 59. Assessing Dietary Habits in a Large Cohort of Rheumatoid Arthritis and Psoriatic Arthritis Patients: Results of the Spanish Imid Consortium 60. Epidemiology of Polymyalgia Rheumatica in Korea 61. Advocating for Pediatric Rheumatology Care in the Mid-Canadian Provinces: Large Geographic Area, Large Pediatric Population, Low Number of Pediatric Rheumatologists and Allied Health Workers Identified As Unique Challenges 2014 Program Book 161

164 ACR POSTER INDICES 62. Severe Spine Osteoarthritis in Older Men Is Associated with the Risk of Incident Fragility Fracture 63. Spine Osteoarthritis Is Associated with All Cause Mortality in Older Men 64. Effect of Family Support on Short-and Intermediate Term Pain and Function Outcomes after Knee or Hip Replacement 65. Impact of Dropout and Total Knee Replacement on Joint Space Narrowing Estimation: Data from Osteoarthritis Initiaive 66. Association of Knee Osteoarthritis and Limitations in Physical Function in a Rural Chinese Population: The Wuchuan OA Study 67. Effects of Exercise on Depressive Symptoms in Adults with Arthritis: A Systematic Review with Meta-Analysis 68. Physical Inactivity to Activity Associated with Less Decline in Physical Function 69. Assessment of Exercise Status in Routine Care Using Patient Reported Outcomes: Initiating Exercise Is Associated with Better Outcomes Than No Exercise 70. The Odds of Work Disability, Unemployment and Depending on Living Allowances Are More Influenced By the Number of Morbidities Than By the Presence of a Musculoskeletal Disease 71. Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank 72. The Association Between Doctor-Diagnosed Arthritis and Falls and Fall Injuries Among Middle-Aged and Older Adults 73. Frequency and Risk Factors for Recurrent Falls in Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study Genetics, Genomics and Proteomics I 74. Influence of the Polymorphism IL1ß (-511 A/C) and IL6 (- 174 G/C) on the Activity, Radiographic Damage and Clinical Forms of Patients with Psoriatic Arthritis (A) 75. Robust Identification of Anti-TNF Non-Responders in RA from Blood 76. Identification of Synovial Genes and Pathways Associated with Disease Progression in a Cohort of Early Symptomatic Osteoarthritis Patients Using a Transcriptomic Approach 77. Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils 78. a HPLC-SRM-MS Based Method for the Detection and Quantification of Methotrexate Used at Doses in Clinical Practice for Patients with Rheumatological Disease in Urine 79. PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events? 80. Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry 81. Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts 82. HLA-DPB1*04:01 Confers Risk for PR3-ANCA Positive ANCA-Associated Vasculitis (AAV), but Protects Against MPO-ANCA Positive AAV, in a Japanese Population 83. Whole Exome Sequencing Analysis Performed on a Patient with Fibroblastic Rheumatism 84. Amerindian Ancestry Influences Polyautoimmunity 85. Protective Association of HLA-DRB1*13:02 Against MPO- ANCA Positive ANCA-Associated Vasculitis in a Japanese Population 86. Association of Leukocyte Immunoglobulin-like Receptor A3 (LILRA3) with Systemic Sclerosis 87. Association of TRIM21 (RO52) Polymorphisms with Systemic Lupus Erythematosus in a Japanese Population 88. Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms 89. Global mirna Expression Profiling in Peripheral Blood and Synovial Fluid Mononuclear Cells of Patients with Enthesitis Related Arthritis 90. Genetic Variants in IL-6, IL-10, C5-TRAF1 and FCRL3 and Progression of Joint Damage in Rheumatoid Arthritis; A Study on Six Cohorts 91. Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis 92. Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis Program Book

165 ACR POSTER INDICES 93. Protein Profiling of Secretome Human Cartilage to Identify Potential EARLY Specific Biomarkers in Osteoarthritis Health Services Research 94. Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA 95. Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept 96. Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients 97. Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data 98. Costs of Musculoskeletal Diseases in the United States, : Population Growth, Population Aging, Health Care Utilization, or Prices? 99. Impact of Comorbidities on Health Resource Utilization in Patients with Spa 100. Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database 101. Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA) 102. Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom 103. Rheumatology e-consult Services: a Rheumatology Workforce Management Model 104. Reasons for Leaving an Academic Career in Research Among Rheumatologists in the United States 105. Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the National Health and Wellness Survey 106. Patient Reported Outcomes Following Upper Extremity Arthroplasties in RA -a Report from the Swedish National Register of Rheuma Surgery (RAKIR) 107. Use of Internet in Adolescents and Young Adults with JIA 108. Patient Reported Outcomes Following Total Knee Arthroplasty in Rheumatoid Arthritis and Osteoarthritis 109. Knee Arthroscopy in an International Training Centre: An Audit of Safety and Impact on Work Days 110. Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation- Wide Pilot Study 111. Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy 112. Relationship Between Rheumatology Physician Supply and Travel Distances to Rheumatologists for Medicare Beneficiaries in the United States 113. Dermatologic Rheumatism: Our Experience with a Multidisciplinary Dermatology/Rheumatology Clinic 114. Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists 115. Biologic Dmards Modify the Association Between Patient Expectations and Outcomes of Total Knee Replacement in Rheumatoid Arthritis Patients 116. Is Socioeconomic Status at Diagnosis Associated with Long-Term Direct Medical Costs in Systemic Sclerosis? a General Population-Based Cohort Study 117. Predictors of Gout Flares in a US Managed Care Setting 118. Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis Imaging of Rheumatic Diseases: Ultrasound 119. Sonographic Evaluation of the Fifth Metatarsophalangeal Joint Erosion in Rheumatoid Arthritis 120. Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication? 121. Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission 122. The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission 123. Combination with Joint Power Doppler Signals with Anti- Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis 2014 Program Book 163

166 ACR POSTER INDICES 124. Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis 125. PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World 126. Asymptomatic Versus Symptomatic Ankle Joints in Rheumatoid Arthritis: A High Resolution B-Mode and Power Doppler Ultrasound Study 127. Metacarpophalangeal Cartilage Loss in Rheumatoid Arthritis. a Simple and Fast Ultrasonographic Assessment Comparing Patients and Healthy Controls 128. A Rapid 4- Joint Ultrasonographic Score to Daily Monitoring Disease Activity in Patients with Rheumatoid Arthritis: Validity and Sensitivity to Change 129. Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice 130. Inter-Rater Reliability of the US-7 Score in a Population of Volunteers: Is a Post-Hoc Analysis of Still Images Comparable to the Dynamic Analysis? Results from the German Rheuma-Truck Cohort 131. Detection of Synovitis and Erosions with an Automated Ultrasound System: Data from a Prospective Cohort with Early and Established RA 132. Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA) 133. On-Demand Ultrasonography Assessment in the Most Affected Joint Is Efficient for Management of RA Patients in Daily Practice 134. Histopathological Correlation of Ultrasound-Defined Active Synovitis in Patients with Rheumatoid Arthritis in Clinical Remission. Preliminary Results 135. Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents 136. Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis 138. Can Ultrasonography of Peripheral Entheses Play a Role in the Diagnosis and Understanding of Diffuse Idiopathic Skeletal Hyperostosis (DISH)? 139. Ultrasound Enthesitis in Primary Care Psoriasis Patients with Musculoskeletal Complaints 140. Are Entheses Ultrasound Findings Similar in Axial Spa Patients and in Athletes? 141. Prevalence of Subclinical Enthesopathy in Asymptomatic First Degree Relatives of Patients with Spondyloarthritis 142. Prevalence of Subclinical Entheseal Involvement in Patients with Paediatric Inflammatory Bowel Disease: An Ultrasonographic Study 143. Detailed Anatomical Distribution of Synovial Inflammation Revealed By Ultrasound in Patients with Blau Syndrome 144. Sonographic Differentiation of Heel Pain: Focal Degenerative Versus Systemic Inflammatory Enthesitis 145. A Cut-Off Value Analysis By Ultrasound for the Diagnosis of Giant Cell Arteritis (GCA) 146. Ultrasonographic Evaluation of Joint and Tendon Involvement in Patients with Early Systemic Lupus Erythematosus (SLE) in Comparison with Early Rheumatoid Arthritis (RA) 147. US Lung Examination in SSc Patients: A Comparison of Two Different Scoring Systems 148. Value of Ultrasonography Parotid Glands in Patients with Suspected Primary Sjögren s Syndrome 149. Automated Digital Analysis of Major Salivary Gland Ultrasound Images 150. Ultrasonographic Evaluation of Major Salivary Glands in Primary Sjögren s Syndrome: Comparison of Two Scoring Systems and Diagnostic Value of Sonoelastography 151. Sonographic Measurements Can be Misleading for Diagnosing Carpal Tunel Syndrome in Patients with Rheumatoid Arthritis 152. Subclinical Synovial Inflammation in Gout 153. Musculoskeletal Ultrasound of Finger and Foot Joints in a Population of Volunteers: Is Osteoarthritis an Underestimated Problem? Results from the German Rheuma-Truck Cohort 154. Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes 137. Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging Program Book

167 ACR POSTER INDICES Metabolic and Crystal Arthropathies: Clinical Aspects 155. Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency in Korea 156. Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study 157. Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis 158. Performance of Joint Ultrasonography in the Diagnosis of Suspected Acute Crystal Arthritis : Results of a Prospective Study of 112 Patients 159. Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up 160. All Men with Gout Should be Screened for Erectile Dysfunction 161. Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients 162. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises 163. Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat 164. Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat 165. Prevalence of Gout in the Adult Population of France in Risk Factors for Gout Attack Recurrence during Urate- Lowering Allopurinol Treatment 167. Target Serum Urate: Do Patients Know Their Goal? 168. Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares 169. Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? 170. Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases 171. High-Protein Diet (Atkins Diet) and Uric Acid Response 172. Sleep Apnea and Risk of Incident Gout: A Population- Based Body-Mass Index Matched Cohort Study 173. Self-Management Education for Patients with Gout: A Review of Existing Resources 174. Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study 175. Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12- Week Data 176. Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both 177. Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine- Oxido-Reductase 178. The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes 179. Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis 180. Analytical Comparison Between Point of Care Uric Acid Testing Meters 181. Adherence to Treatment Recommendations of Gout: A Patient Survey in China 182. Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients 183. Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients 184. Ultrasound Versus X-Rays Versus Synovial Fluid Analysis for the Diagnosis of Calcium Pyrophosphate Dihydrate Deposition Disease: Is It CPPD? Ask US! 185. Distribution of Haemochromatosis Arthropathy. High Ankle and Mid Foot Prevalence; A Diagnostic Clue? Orthopedics, Low Back Pain and Rehabilitation 186. The Association Between Low Back Pain and Radiographic Features: A Systematic Review with Meta-Analysis 187. Revision Arthroplasty in Rheumatoid and Osteoarthritis: Does Methotrexate Decrease Radiographic Lucency in RA Patients? 2014 Program Book 165

168 ACR POSTER INDICES Time Trends in Total Ankle Arthroplasty in the U.S.: A Study of the Nationwide Inpatient Sample 189. Sex Differences in Characteristics, Utilization and Outcomes of Patient Undergoing Total Elbow Arthroplasty: A Study of the U.S. Nationwide Inpatient Sample 190. Hospital Volume Predicts Outcomes and Complications after Total Shoulder Arthroplasty 191. Utilization and Outcomes Following Total Shoulder Arthroplasty in Elderly and Non-Elderly Patients 192. Title: Use of Non-Traditional Modalities for Pain Management after Knee or Hip Joint Replacement 193. Pre-Operative Pain and Function: Profiles of Patients Selected for Total Knee Replacement Among Surgeons in the United States 194. Differences in Total Knee Replacement Outcomes Based on Age 195. Dependence on Walking Aids and Patient-Reported Outcomes after Total Knee Arthroplasty 196. Dependence on Walking Aids Is Associated with Pain and Mobility Limitation after Total Hip Arthroplasty 197. Differences in Total Hip Replacement Outcomes Based on Age 198. Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA 199. Increasing Complexity of Patients Undergoing Primary Total Hip Arthroplasty in the U.S Osteoarthritis - Clinical Aspects: Imaging and Biomechanics 200. Leg Length Inequality and Hip Osteoarthritis 201. Measures of Hip Morphology Are Related to Development of Incident Radiographic Hip Osteoarthritis over 6 to 13 Year Follow-up: The Johnston County Osteoarthritis Project 202. Is Schuss View Alone Enough for the Diagnosis of Femorotibial Osteoarthritis? the Khoala Cohort Study 203. Predictors of Radiographic Progression of Interphalangeal Finger Joints in Erosive Osteoarthritis: A Prospective Study 204. Ultrasonographic Predictors for Clinical and Radiological Progression in Knee Osteoarthritis after 2 Years Follow up 205. Natural History and Clinical Significance of Meniscal Tears over 8 Years in a Largely Non-Osteoarthritic Cohort 2014 Program Book 206. Risk Factors for Increased Extrusion of the Meniscus Body in Subjects Free of Radiographic Knee Osteoarthritis: 6-Year MRI Data from the Osteoarthritis Initiative 207. Changes in Knee Compartment Distriubtion of Cartilage Loss and Bone Marrow Lesions over 7 Years: The MOST Study 208. Correlates of Knee Bone Marrow Lesions in Younger Adults 209. Physical Performance and Obesity Measures Are Associated with Tibial Cartilage Volume and Explains the Sex Difference in Cartilage Volume 210. Preliminary Assessment of Predictive Validity of Cartilage Thickness MRI Biomarkers in Knee OA - the Fnih OA Biomarkers Consortium 211. Association Between Baseline External Knee Adduction and Flexion Moments during Gait and Medial Tibiofemoral Cartilage Thickness Loss over Two Years in Persons with Knee Osteoarthritis (OA) 212. Relation of Shoe Stability to Risk of Knee Cartilage Damage: The Multicenter Osteoarthritis Study 213. Foot Center of Pressure in Knee Osteoarthritis (OA) and Its Association with Knee Load Reduction with Barefoot Walking 214. Knee Instability and Advanced Function Decline in Persons with Knee Osteoarthritis 215. External Hip Adduction Moment and Progression of Medial Tibiofemoral Cartilage Damage and Bone Marrow Lesions in Persons with Knee Osteoarthritis 216. Hip Adiposity, Not Local Knee Adiposity, Is Associated with Knee Pain Independent of Radiographic Osteoarthritis Severity 217. The Relationship of Quadriceps and Hamstrings Intramuscular Fat and Lean Muscle with Power in Women with Knee Osteoarthritis 218. Surface Area and Fatty Infiltration of Vastus Medialis Measured By Magnetic Resonance Imaging Are Risk Factors for the Progression of Knee Osteoarthritis and Discriminate Two Osteoarthritis Phenotypes 219. DXA Body Composition, Sarcopenia and Knee and Hip Osteoarthritis: Results from the Khoala Cohort 220. Lower Extremity Presarcopenia Is Associated with the Severity of Knee Pain 221. An Analysis of Age-Related Loss of Skeletal Muscle Mass and Its Significance on Osteoarthritis in a Korean Population

169 ACR POSTER INDICES 222. OA Phenotypes Rather Than Disease Stage Drive Structural Progression Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis 223. Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study 224. Is the Protective Effect of Obesity Against Hip Fracture Due to Changes of Proximal Femur Shape? 225. Association Between Lean Mass and Hip Bone Mineral Density 226. Improved Prediction of Hip Fracture Using the Health Assessment Questionnaire-Disability Index and FRAX in Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Study 227. Increasing Fat-Mass May Reverse Bone Loss As Detected By DXA Scan 228. Is Adult Hypophosphatasia a Cardiovascular Risk Factor? 229. Correlates of Heel Bone Mass in Young Adults: The Role of Cholesterol over 20 Years from Childhood to Early Adulthood 230. Risk Factors That Predict Poor Bone Health in Those Aged over 75 Years - a Cross Sectional Study 231. Factors Predicting Fracture in the over-75s: An Observational Case-Control Study 232. Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis 233. Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study 234. The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence 235. Lower P1NP Serum Levels: a Predictive Marker of Bone Loss after One-Year Follow-up in premenopausal SLE Patients 236. Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic Fibrosis 237. Analysis of Vitamin D Receptor Gene Polymorphisms and Bone Mineral Density in a Population of Women with Rheumatoid Arthritis in Use of Steroid 238. RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus 239. Does Adjusting BMI for Lean Mass Deficits Affect Calculated Fracture Risk Using FRAX in Rheumatoid Arthritis? 240. An Observational Study on the Influence of Glucocorticoid Exposure on Bone Pain: Basic and Clinical Aspects 241. Reduced Estimated Glomerular Filtration Rate Was Improved after Cessation of NSAID and Switching to Tramadol Hydrochloride/Acetaminophen Tablets (UltracetTM) in Patients with Chronic Musculoskeletal Pain 242. WOMAC Pain Score Reflects Preceding Daily Pain Ratings in Knee Osteoarthritis Interventional Randomized Clinical Trials 243. Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study 244. Onset, Magnitude, and Durability of Pain Relief in Patients with Knee OA Receiving a Fixed-Dose Combination Tablet of Enteric-Coated (EC) Naproxen Plus Immediate-Release (IR) Esomeprazole Magnesium Versus Celecoxib and Placebo: Pooled Results from Two Ran 245. WITHDRAWN 246. Neuropathic PAIN in Patients with Ankylosing Spondylitis 247. Cognitive Task Related Hypoperfusion of Frontal Gyrus in Patients with Chronic Fatigue 248. Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF? 249. A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes 250. Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment 251. Chronic Fatigue Is Associated with Hypoperfusion of Parahippocampal Gyrus 252. Preliminary Validation of the Michigan Body Map 253. Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome 2014 Program Book 167

170 ACR POSTER INDICES The Effect of Milnacipran on Pain in Rheumatoid Arthritis Patients with Widespread Pain: a Randomized Blinded Crossover Trial 255. Pain As Predictor of Organ Involvement in Fabry Disease 256. Characteristics of Pain in Fabry Disease 257. Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia 258. Pain Characteristics Among Patients with Rheumatoid Arthritis in the Context of Patient-Physician Discordance in Disease Activity Assessments 259. Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System 260. Validation of the Dutch-Flemish Promis Physical Functioning Item Bank in Patients with Chronic Pain 261. Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain 262. Longitudinal Assessment of Promis Pediatric Item Banks in Children with Chronic Musculoskeletal Pain 263. Nutraceutical Products and Pain or Non-Pain Medications Use in Patients with Knee Osteoarthritis 264. Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials 265. Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study 266. An Examination of the Interaction of Opioid Use, Pain, and Depression 267. Selective and Peripheral-Specific Trk Inhibitor Shows Potent Analgesic Effect Comparable to Morphine in Rat Osteoarthritis Model without CNS Toxicity 268. The Effect of Treatment with Resiniferatoxin and Capsaicin on Dynamic Weight Bearing Measures and Evoked Pain Responses in a Chronic Inflammatory Arthritis Murine Model Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis 269. Discontinuation of Concomitant Medication for Enthesitis- Related Arthritis during 52 Weeks of Treatment with Adalimumab 270. Disease Burden Is Comparable in Children with Enthesitis- Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis 2014 Program Book 271. Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) 272. Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers 273. Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis 274. Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study 275. Environmental Risk Factors and Development of Juvenile Idiopathic Arthritis 276. Growth during Tocilizumab Therapy for Polyarticular- Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial 277. Nearly 20% of Children ARE NOT Correctly Classified According to Current ILAR Classification in a Printo Dataset of More THAN 12,000 Juvenile Idiopathic Arthritis Patients 278. Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis? 279. Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care 280. Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry 281. Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections 282. Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries 283. Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis 284. Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE) Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis 285. Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX

171 ACR POSTER INDICES 286. Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study 287. Role of Joint Status in Decreased Accelerometer-Assessed Daily Physical Activity in Juvenile Idiopathic Arthritis 288. Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis 289. Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab 290. Patterns of Active Joint Involvement in JIA 291. Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis 292. Flares in Children with JIA: Results from the Reacch-out Cohort 293. Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register 294. Long-Term Pharmacokinetics of Body Surface Area- Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis 295. Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study 296. Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect 297. S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis 298. Long-Term Impact of Juvenile Idiopathic Arthritis in the Greek adults Psychosocial Life 299. A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis 300. Patient-Reported Joint Count in Juvenile Idiopathic Arthritis: The Reliability of a Mannequin Format 301. Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate Results from a Biologic Register 302. Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis 303. Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study 304. Juvenile Rheumatoid Arthritis and Future Risk for Cardiovascular Disease; A Multicenter Population-Based Study Pediatric Rheumatology - Pathogenesis and Genetics 305. Understanding the Molecular Pathogenesis of and Response to Canakinumab Treatment in TNF Receptor- Associated Periodic Syndrome By Gene Expression Profiling of Whole Blood from Patients 306. Association of Kawasaki Disease with Tropospheric Winds in Central Chile: Is Wind-Borne Desert Dust a Risk Factor? 307. Sibling Exposure and Risk of Juvenile Idiopathic Arthritis 308. Tenascin-C, a TLR4 Ligand Levels in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis: Cross- Sectional and Longitudinal Study 309. Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis 310. Differential Expression of microrna in Monocytes from Children with Systemic Juvenile Idiopathic Arthritis: Implications for Polarized Phenotype 311. Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome 312. Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis 313. Elevated Cardiovascular Disease Burden and Inflammatory Biomarker Levels in Adults with Juvenile Idiopathic Arthritis 314. Next Generation Sequencing Reveals Restriction of the Treg Cell Repertoire and an Abundance of Shared Synovial Treg Clonotypes in JIA 315. NLRC4-Related Macrophage Activation Syndrome (NLRC4- MAS): A Novel Primary Autoinflammatory Syndrome Caused By Activating Mutations in NLRC Cytokines in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Tipping the Balance Between Interleukin-18 and Interferon-Gamma 317. Myeloid Related Proteins 8 and 14 (MRP 8/14) - Potential Biomarkers of Disease Activity of Arthritis in Children with Trisomy Program Book 169

172 ACR POSTER INDICES 318. HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis 319. Systemic Juvenile Idiopathic Arthritis and Exposure to Fine Particulate Air Pollution 320. Autoantibodies in Juvenile Systemic Sclerosis 321. Mutations of Familial Hemophagocytic Lymphohistiocytosis (FHL) Related Genes and Abnormalities of Cytotoxicity function tests in Patients with Macrophage Activation Syndrome (MAS) Occurring in Systemic Juvenile Idiopathic Arthritis (sjia) Rheumatoid Arthritis - Animal Models 322. Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis 323. Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation 324. Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail 325. Tadalafil Decreases Joint Inflammation in TNF-Tg Mice By Restoring Passive Lymphatic Transport 326. IL-1 Receptor Antagonis (IL-1Ra)-Fc Ameliorate Autoimmune Arthritis By Regulation of the Th17 Cells/ Treg Balance and Arthrogenic Cytokine Activation 327. AMPK Activation in Inflammatory Arthritis 328. Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono- Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis 329. A Novel, Small Molecule Cyclin-Dependent Kinase 4/6 Inhibitor As the New Option for Treatment of Rheumatoid Arthritis 330. Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis 331. WITHDRAWN 332. Improvement of the Stability of RNA Aptamers Against Interleukin-17A 333. Deletion of the Prolactin Receptor Aggravates the Course of Antigen-Induced Arthritis 334. Inflammatory Arthritis in K/BxN Mice Is Associated with Abnormal HDL Function 335. Interleukin-33 Suppresses Experimental Arthritis through Promoting Foxp3+ Regulatory T-Cells and Type-2 Immune Responses in Mice 336. The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit 337. Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis 338. Bombina Variegate peptide8/prokineticin 2: A Novel Arthritis-Inducible Chemokine 339. Toll-like Receptor Dependent Autoantigens and Vesicles from P.Gingivalis in Animal Models of RA to Modulate Collagen and Collagen Antibody Induced Arthritis 340. Role of Beta-Catenin Signaling to Control Dendritic Cell Function in Collagen-Induced Arthritis 341. Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis 342. Vascular Permeability As an Imaging Biomarker for Chronic Inflammatory Arthritis: A Dynamic Contrast Enhanced Magnetic Resonance Imaging Study 343. The Caspase 8/RIPK3 Signaling Axis Has Opposing Roles in Myeloid and Dendritic Cells during Progression of a Murine Model of Acute Inflammatory Arthritis 344. Reduced Macrophages in the Synovium Contribute to the Effective Treatment of Spontanneous Arthritis Observeded in Human TNF-Transgenic Mice 345. A Low Salt Diet Ameliorates Clinical Manifestations in Collagen-Induced Arthritis 346. Treatment of Collagen Induced Artritis with Human Embrionic Stem Cell-Derived Multipotent Mesenchymal Stromal Cells (hesc-msc) 347. Salt Aggravates Arthritis By Th17 Polarization Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity 348. Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation? 349. Galectin-3 in the Systemic Circulation Is Increased in Newly Diagnosed Rheumatoid Arthritis and Is Associated with Anti-CCP and Bone Marrow Edema Program Book

173 ACR POSTER INDICES 350. Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies 351. Doctor, Will My Fatigue be Better If I m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient- Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission 352. Remaining Pain in Spite of Suppressed Inflammation in Early Rheumatoid Arthritis Long-Term Strongly Increased Risk for Widespread Pain and Fatigue 353. Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE 354. Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG- PET/CT Scan 355. Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Mag 356. The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis 357. Development and Validation of a Diagnostic Bead- Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect Seronegative Rheumatoid Arthritis 358. Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers? % of Recent Onset Polyarthritis Patients Are Positive for η Markers and η Auto-Antibodies Inform a Favourable Prognosis 361. Citrullinated η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA η Early RA Biomarkers: Does Seronegative RA Exist? 363. Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis 364. In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression 365. Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada 366. Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis 367. In Early Rheumatoid Arthritis Patients with Non- Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy 368. Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis 369. Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP) in Canadian Patients with Rheumatoid Arthritis 370. Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis 371. The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort 372. Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain 373. Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis 374. IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study 375. Evaluation of RAPID3 with Minimal Joint Count and ACR/ EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab 376. Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment 377. Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents 378. The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate 2014 Program Book 171

174 ACR POSTER INDICES 379. What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months? 380. In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA 381. Distribution and Clinical Significance of Anti-Heterogenic Nuclear Ribonucleoprotein A2 Antibody in Connective Tissue Diseases 382. What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months? 383. How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry 384. Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID) 385. Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial 386. Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis 387. Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA 388. Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis 389. High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis 390. Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis 391. Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer 392. Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis Do Free Fatty Acids Play a Role? 393. Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis 394. Very Low or High Body Mass Index Negatively Affects patients Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort 395. Could Osteoprotegerin and TNF-Related Apoptosis- Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort 396. Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis 397. Th9 Lymphocytes in Rheumatoid Arthritis 398. Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA) 399. Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis 400. Clinical Utility of η in the Evaluation of Inflammatory Arthritis 401. Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis 402. Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis? 403. Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis 404. The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis η: A Mechanistic Biomarker That Supports the Concept of Uncoupling of Inflammation and Joint Damage 406. The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis 407. Serum η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA 409. Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels 410. Vascular Endothelial Function Changes during Treatment in Patients with Rheumatoid Arthritis 411. ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis 412. Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK Program Book

175 ACR POSTER INDICES 413. Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis 414. Relationship Between Range of Motion of Joints in Upper Limbs and Physical Function in Patients with Long- Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function 415. a Dual-Center, Double Blind Randomized Study for a New Scientific Approach in Assessment of Tender Joints in Inflammatory Arthritis Using the Smart Joint Assessor Glove Device (Smart JAG Device) 416. Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score Normal Scores of 0 (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities Walk 2 Miles or 3 Kilometers, 418. Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients 419. Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA 420. Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population 421. Prediction of Remission By Patients and Physicians: Does the Doctor Know Best? 422. Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA 423. Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease- Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis 424. The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis 425. Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis 426. Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registr 427. Multimedia Patient Education Tool for Patients with Rheumatoid Arthritis 428. Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis 429. Investigation of MRI Bone Changes in Early-Stage RA Patients Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort 430. Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis 431. Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy 432. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression Rheumatoid Arthritis - Human Etiology and Pathogenesis 433. Bronchiectasis: A Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis 434. Characterization of Lung Inflammation in the Lungs of Early Rheumatoid Arthritis 435. Smoking Functions As a Negative Regulator of IGF-1 Levels and Adipokine Network in Patients with Rheumatoid Arthritis 436. Increasing Cartilage Turnover in Smokers Developing Rheumatoid Arthritis Is Associated with High Disease Activity in Early Disease 437. Anti-Citrullinated Heat Shock Protein 90 Antibodies Identified in Bronchoalveolar Lavage Fluid Are a Marker of Lung-Specific Immune Responses 438. Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease 439. The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis 2014 Program Book 173

176 ACR POSTER INDICES 440. Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (egfr) in Patients with Rheumatoid Arthritis (RA) 441. Arthritis Associated Autoantibodies in Non-Rheumatoid Arthritis Patients with Mucosal Inflammation 442. Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels 443. Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis 444. Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis 445. Differing Specificities of Anticitrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: A Case-Control Study 446. Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-risk for Future Rheumatoid Arthritis 447. Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis 448. Citrulline-Specific Autoimmunity Resides in Quiescent Circulating Memory B Cells in Rheumatoid Arthritis 449. Citrullinated-Vimentin-Specific Regulatory T-Cell Responses Associate with ACPA Positive Individuals with Non-Specific Musculoskeletal Symptoms 450. The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis 451. The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with disease Severity in African-Americans with RA 452. The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis 453. In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA 454. The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis 455. Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis 456. AAA-Atpase p97 Regulates Autophagy-Associated Cell Death in Arthritis Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis 457. First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan 458. Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials 459. Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis 460. Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program 461. Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease- Modifying Antirheumatic Drugs 462. Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies 463. Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double- Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis 464. Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib 466. Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery? 467. Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort 468. Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients 469. Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study 470. Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate- Related Lymphoproliferative Disorder Program Book

177 ACR POSTER INDICES 471. Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan 472. Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease 473. Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids 474. Assessment of 12-Month Efficacy and Safety of 168 Certolizumabpegol Rheumatoid Arthritis Treated Patients from a Multicenter Retrospective National Study in Spain 475. Risk Analysis of a First Adverse Event and Recurrent Infections during Biological Therapy in Chronic Inflammatory Arthritis 476. Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials 477. Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials 478. Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study 479. Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years 480. Serious Infection Risk By Treatments and Types in Patients with RA 481. Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old 482. Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents 483. Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience 484. Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy 485. Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment a Two-Year Prospective Study in an Interdisciplinary Patient Cohort 486. Tofacitinib Improves Arterial Stiffness Despite up- Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study 487. Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months 488. Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis 489. Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases 490. A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis an Interim Analysis 491. Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections? 492. Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept 493. Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD 494. Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis 495. Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status 496. Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study 497. Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs 498. Patient Experience with Initiation of SQ and Oral MTX 499. Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic 500. Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement 501. Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics Results from the National Swedish Rheumatology Quality Register 2014 Program Book 175

178 ACR POSTER INDICES Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab 503. Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial 504. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries 505. A Structured Approach for Comparative Benefit- Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis 506. Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis 507. Efficacy and Safety of Adalimumab Therapy in Japanese Patients with Rheumatoid Arthritis 508. Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 509. Etanercept Have Better Drug Survival Than Monoclonal Antibodies in Rheumatoid Arthritis: Results of Single Center Hur-BIO Registry 510. Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept - Results from the National Swedish Rheumatology Quality Register 511. First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis 512. Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards 513. Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics 514. Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis 515. Dosing of Intravenous Tocilizumab in a Real-World Setting Analyses from a US RA Registry 516. The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study 517. Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results 2014 Program Book 518. Risk of Infection Associated with Subsequent Biologic Use Following Rituximab Results from a National RA Patient Registry 519. Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study Sjögren s Syndrome: Pathophysiology 520. Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren s Syndrome Patients (pss) 521. CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren s Syndrome Patients 522. Whole Blood microrna Signature for Primary Sjögren s Syndrome-Related Lymphoma 523. Serum CXCL4 Is Increased in Patients with Primary Sjögren s Syndrome and Is Associated with Features of Microvascular Impairment 524. Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren s Syndrome Disease Status 525. The Genetic Basis of Sjögren s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort 526. A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren s Syndrome Patients Using RNA-Seq 527. Salivary Expression of S100A7/Psoriasin and Oral Damage in Primary Sjögren s Syndrome and Overlapping Disorders 528. Calcium-Calcineurin-NFAT Signaling Pathway Regulates AQP5 Expression in Primary Salivary Gland Acinar Cells 529. IP3R3 Deficit Underlies the Loss of Fluid Secretion in Salivary Glands from Sjögren s Syndrome Patients 530. Downregulation of Microrna-183 in Sjögren s Syndrome Minor Salivary Glands. Implications in Control of Ezrin Expression and Salivary Gland Function 531. Expression of Indoleamine 2,3 Dioxygenase-1 and -2 in Focal Sialoadenitis of Patients with Sjögren s Syndrome 532. Adipose Tissue Is Prominent in Salivary Glands of Sjögren s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs 533. Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren s Syndrome

179 ACR POSTER INDICES 534. Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block 535. WITHDRAWN Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I 536. Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing 537. Secukinumab, a Human Anti Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial 538. Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subc 539. Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double- Blind, Placebo-Controlled Study 540. Two Years Sacroiliac Radiographic Progression Rate and Influence of Baseline Markers of Inflammation in Recent Onset Spondyloarthritis 541. Collagen II Neo-Epitopes in Spondyloarthritis Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis a Cohort Study 543. Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol 544. Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis 545. Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure 546. Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression 547. Comparison of Clinical and Imaging Characteristics of Axial Psoriatic Arthritis and Axial Spondyloarthritis 548. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials 549. Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis 550. Secukinumab, an Anti Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial 551. Predictors Associated with Rheumatologist Referral Time in Patients with Ankylosing Spondylitis 552. Sustained Improvement in Physical Function, Health- Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis 553. Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis 554. Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain 555. Urinary Excretion of Type II Collagen C-Telopeptide and Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers in Early Spondyloarthritis 556. Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations 557. Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages 558. Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index 559. Ultra Sonographic Evaluation of the Anterior Chest Wall in Spondyloarthritis. a Prospective Study 560. High Sensitivity of the ASAS Classification Criteria in Patients with HLA-B27 Positive Undifferentiated Spondyloarthritis with Onset of Disease after Age A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis 562. Clinical Response and Remission in Patients with Non- Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy 2014 Program Book 177

180 ACR POSTER INDICES Evaluation of Clinical Parameters and Quality of Life in Smokers with Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis 564. Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis 565. Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis 566. Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis 567. Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab 568. Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years 569. Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors 570. Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity 571. Unraveling the Familial Tendency for Ankylosing Spondylitis in Korea 572. Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests 573. Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF- Inhibitors 574. Do Extra-Articular Manifestations Influence Outcome in Ankylosing Spondylitis? a 12 Year Follow-up Study 575. Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort 576. Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axspa) Are Related to Disease Duration 577. A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort 578. Female Patients but Not Male Patients with Ankylosing Spondylitis Are at Increased Risk of Developing Ischemic Heart Disease: A Population-Based Cohort Study 2014 Program Book 579. Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the then Test in Patients Treated with TNF-Inhibitors 580. MRI Is Often Negative in Clinically Suspected Non- Radiographic Axial Spondyloarthritis 581. Evaluation of the Nonsteroidal Anti-Inflammatory Drug- Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 582. Non-Steroidal Anti-Inflammatory Drugs in Axial Spondyloarthritis: A Cochrane Review 583. What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction 584. Flare in Spondyloarthritis: Proposal of a Meaningful Change in Symptomatic Outcome Measures in Axial Spondyloarthritis 585. Optimism Levels Are Moderate and Similar in Patients with Axial Spondyloarthritis and Chronic Low Back Pain, and Are Related to Mental Quality of Life but Not Physical Quality of Life. a Cross Sectional Study of 277 Patients 586. Helplessness in Coping Is Associated with Worse Patient Reported Outcomes Among Patients with Ankylosing Spondylitis: A Longitudinal Multi-Country Cohort Study 587. Clinical Characteristics of Nonradiographic Axial Spondyloarthritis in Korea: A Comparison with Ankylosing Spondylitis 588. Blacks with As Have Greater Disease Severity Than Whites 589. Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa 590. Factors Associated with a Poor Functional Prognosis in Early Inflammatory Back Pain: Results from the DESIR Cohort 591. The Fat Spondyloarthritis Spine Score (FASSS) Independently Predicts Radiographic Progression in Patients with Ankylosing Spondylitis 592. Clinical and Psychological Correlates of Sleep Difficulties in Patients with Spondyloarthropathies Compared to Patients with Rheumatoid Arthritis 593. The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers 594. Do Bone Marrow Edema Lesions in the Sacroiliac Joint Change into Fatty Lesions over a 1-Year Period in Patients with Axial Spondyloarthritis or Possible Spondyloarthritis

181 ACR POSTER INDICES 595. Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort 596. Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis 597. Inflammatory Burden in Recent-Onset Axial Spondyloarthritis 598. Anti-Drug Antibodies As a Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis 599. Is There Any Gender Specific Difference in the Cut Off Values of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Axial Spondyloarthritis? 600. Differing Patterns of Axial Spondyloarthritis in Females and Males 601. Combined Hip Abduction Angle Measured By Using Iphone Compass Application; A Novel Measurement Tool to Asses Hip Mobility 602. A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology 603. Periostin May Have a Role in Ankylosing Spondylitis and It Is Associated with Wnt Signalling Pathway Regulators 604. Characterisation of Mucosal-Associated Invariant T (MAIT) Cells in Ankylosing Spondylitis Patients 605. Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers 606. The Immunological Basis of the Sex-Bias in Ankylosing Spondylitis: Th17 Expansion Is Restricted to Male Patients and Correlates with Sex-Related Alteration in Vitamin D Metabolism 607. The HLA-B27 Peptidome in Vivo in Transgenic Rats 608. Identification of Novel Autoantibodies in Patients with Ankylosing Spondylitis Using Human Protein Microarray 609. Induced Pluripotent Stem Cells (ics) As a Tool for Unraveling the Role of Different Cell Types in the Disease Process of Spondyloarthritis Pathogenesis 610. Functional Implications of the Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) Association with Ankylosing Spondylitis and Crohn s Disease: Impact on the Unfolded Protein Response 611. Autophagy and Unfolded Protein Response: A Fine Balance That Can Influence the Pathogenesis of Ankylosing Spondylitis and Inflammatory Bowel Disease 612. Association of Platelet Endothelial Cell Adhesion Molecule-1 and beta1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis 613. The Amount of Free Heavy Chain and β2-microglobulin in the Cytoplasm of B*2705 Ankylosing Spondylitis Patients Compared to B*2705 and B*2709 Healthy Subjects Does Not Support the UPR Theory. Influence of ERAP1 Polymorphisms 614. The Association of P1A with Inflammasome Activation in Ankylosing Spondylitis 615. Analysis of the Gut Transcriptome in HLA-B27 Transgenic Rats By RNA-Seq Reveals Prominent Interferon and IL-23/ IL-17 Axis Signatures 616. In Situ Analysis of Mechanisms of New Bone Formation in Zygapophyseal Joints from Patients with Ankylosing Spondylitis 617. Shared HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis Among Three Ethnic Groups 618. A Gender Bias in Gut Microbiota of SKG Mice Colonized with a Limited Bacterial Consortium Associated with Severity of Spondyloarthritis and Ileitis Triggered By Beta- Glucan 619. Effect of ERAP1 Knockdown on Conformation of HLA-B27 and Other HLA Class I Molecules in Human Monocytic Cells 620. Innate Immune Stimulation Triggers Altered IL-1a/b Gene Expression and Experimental Spondyloarthritis in HLA-B27/huβ2m Transgenic Rats 621. ERAP1 Knockdown Affects HLA-B27 Misfolding and Endoplasmic Reticulum Stress in HLA-B27 Transgenic Rat Macrophages 622. Gut Microbiota Variations Correlate with Disease Activity in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA) 623. Epigenetic Studies in Maternally Versus Paternally Transmitted Psoriatic Disease 624. Genome-Wide Methylome Investigation Reveals New Candidate Genes Associated with Arthritis Mutilans 625. Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes 2014 Program Book 179

182 ACR POSTER INDICES The Impact of the Interaction Between Human Leukocyte Antigen Alleles and Obesity on Psoriatic Arthritis Risk 627. HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease 628. The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease 629. Biomarkers of Chondrocyte Activity Are Increased in Psoriasis Arthritis and Spondyloarthritis 630. Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis 631. Joint and Bone Related Pathways Discriminate Psoriatic Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin 632. IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy 633. Immunological and Clinical Relationships of Synovial IL- 17+ T Cells in Psoriatic Arthritis Systemic Lupus Erythematosus - Animal Models 634. Characterization of CD4+ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL) 635. Mir-663 Impairs the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on MRL/Lpr Mice 636. Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE 637. Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival 638. Commensal Microbiota Influence Systemic Autoimmune Responses 639. Lack of Response Gene to Complement-32 Impairs Th17 Differentiation and Attenuates Lupus-like Chronic Graft Versus Host Disease 640. A Peptide Mimic Inhibits the Cross Reaction of Anti-DNA Antibodies with Glomerular Antigens 641. Peptidylarginine Deiminase Inhibition Mitigates NET Formation and Protects Against Kidney, Skin, and Vascular Disease in Lupus-Prone MRL/Lpr Mice 642. Treatment with a Glycolipid Ameliorates Lupus Dermatitis and Expands Skin ãä T Cells That Promote the Migration of Langerhans Dendritic Cells 643. The Effect of TNF Inhibition on the Autoreactive B Cell Repertoire in SLE Prone Mice 2014 Program Book 644. HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis and Extends Life Spans in Lupus Prone MRL/Lpr Mice 645. The Combination of Metformin and 2-Deoxy-D-Glucose Normalizes CD4 T Cell Metabolism and Functions, and Reverse Disease in Murine Models of Lupus 646. ONO a Highly Potent and Dual Oral Inhibitor of Bruton s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies mediated SLE in Mice 647. Helminthes Derivative for Treating Lupus and Colitis in Mice Models 648. Influenza A (H1N1) Virus Infection Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice Following Viral Clearance 649. Enhance Translatability Using Multi-Modality Disease Evaluation Approach in Lupus Model 650. Decreased Severity of Pristane Induced Lupus in mir155 Deficient Mice 651. Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus 652. Identification of Eat-2 As a Lupus Susceptibility Gene in New Zealand Black (NZB) Mice That Regulates Dendritic Cell Function 653. Dermal Injury Promotes Nephritis Flare in Lupus-Prone NZM2328 Mice 654. Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice 655. Hydroxycholorquine Is Cardioprotective in an In Vivo Rat Model of Myocardial Ischaemic Reperfusion Injury 656. Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice 657. Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis 659. Breakdown of Tolerance at the Tissue Level in Systemic Autoimmunity: Role of Tissue-Resident Dendritic Cells 660. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis

183 ACR POSTER INDICES 661. Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis 662. Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus 663. STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice 664. The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies 665. Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus 666. Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings 668. Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings 669. Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients 670. Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus 671. Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting 672. Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus 673. A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus 674. A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE) 675. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience 676. Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register 677. Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus 678. The Effectiveness of Tacrolimus for Minor Flares of the Patients with Systemic Lupus Erythematosus 679. Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort 680. Influence of Antimalarial doesn t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus 681. Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus 682. Impact of Patient s Priorities on the Management of Systemic Lupus Erythematosus 683. Impact of Lupus on Work Productivity in Patients and Caregivers: Findings from a Cross-Sectional Online Survey in the United States 684. Effects of Current Therapies for Lupus on Disease Activity and Renal Flares 685. Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors 686. Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey 687. Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus the Hopkins Lupus Cohort 688. Corticosteroids in Early Treatment Pathways in SLE 689. Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE) 690. Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course - a Phenotypic Description 691. Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE) 692. Circulating Anti-Ro/SSA Antibodies Are Associated with the Presence of Severe Mitral Regurgitation in Systemic Lupus Erythematosus 693. Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea 694. Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics 695. Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome 2014 Program Book 181

184 ACR POSTER INDICES 696. Clinical Characteristics and Outcome of Intestinal Pseudo-Obstruction in Patients with Systemic Lupus Erythematosus 697. Venous and Arterial Thrombosis in SLE: Differences in Natural History 698. Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus 699. Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes 700. Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease 701. How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study 702. Protein Losing Enteropathy in Systemic Lupus Erythematosus 703. Autoimmune Hepatitis in Systemic Lupus Erythematosus 704. Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort 705. Lupus Chest Pain in the Emergency Department: a Common Diagnostic Dilemma 706. Humoral Immunodeficiency in Patients Presenting with Clinical Features of Systemic Lupus Erythematosus 707. Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody 708. Determining Risk Factors That Increase Hospitalizations in Patients with Systemic Lupus Erythematosis 709. Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (QI)in Female with Systemic Lupus Ertyhematosus (SLE) Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis 711. Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare? 712. Mapping the Disease-Specific Lupusqol to the SF-6D 713. Lupuspro Is Responsive to Changes in Disease Activity over Time 714. The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study 715. The REAL Life with Lupus Study: Developing a Patient Reported Outcome Measure for Use in Clinical Trials and Clinical Care 716. Simple Disease Assessment for People with Lupus Erythematosus 717. Comparison of Responsiveness of Lupus Impact Tracker with Lupus Quality of Life to Selena Responder Index 718. Safety of Gardasil Vaccine in Systemic Lupus Erythematosu, Trial Update 719. Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes 720. Measures of Disease Status in Systemic Sclerosis: Systematic Review 721. Muscle Disease in Systemic Sclerosis Is Associated with an Increased Risk for Cardiac Involvement 722. Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis 723. Early Mortality in Australian, Canadian and Spanish Scleroderma Patients: Rationale for Establishing a Multi- National Inception Cohort of Patients with Systemic Sclerosis 724. Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients 725. Reduced Diffusing Capacity of Carbon Monoxide Is Independently Associated with Worse Subclinical Left Ventricular Function on Speckle-Tracking Echocardiography in Systemic Sclerosis 726. Risk of Ischemic Stroke in Patients with Systemic Sclerosis: A Systematic Review and Meta-Analysis 727. International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) a Necessary Map to Health Care Provision in the Era of ICD Program Book

185 ACR POSTER INDICES 728. Prediction and Impact of Attacks of Raynaud s Phenomenon, As Judged By Patient perception 729. A Dilated Esophagus Is an Independent Risk Factor for Interstitial Lung Disease in SSc 730. Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies 731. Performance of the Old ACR and the New ACR-EULAR Systemic Sclerosis Classification Criteria in Patients with Limited Cutaneous Disease: Effect on the Ascertainment of Severe Pulmonary Arterial Hypertension 732. Predictors of Inpatient Mortality in Patients with Systemic Sclerosis: A Case Control Study 733. Impact of Geographic Variation on the Risk of Digital Ulcers Development in Systemic Sclerosis: A Brazilian Multicenter Registry 734. Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort 735. Sarcopenia in Systemic Sclerosis: Prevalence and Association with Functional Parameters and Quality of Life 736. Serum Galectin-3 Levels in Early Diffuse Systemic Sclerosis and the Relationship to Skin Score and Skin Score Change 737. Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy 738. Troponin T as a Diagnostic and Prognostic Biomarker of Primary Cardiac Involvement in Systemic Sclerosis 739. Lack of Association Between Esophageal Symptoms and Abnormal Findings in High-Resolution Manometry in a Mexican Mestizo Cohort with Systemic Sclerosis (SSc) 740. Right Ventricular Diastolic Impairment Is Common in Systemic Sclerosis and Is a Marker of Several Organ-Target Damage of the Disease 741. Abnormal Right Ventricular Longitudinal Strain Detected in Systemic Sclerosis Patients Prior to Abnormalities in Conventional Measures of Right Ventricular Size and Function 742. Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer 743. Outcome of Patients with Systemic Sclerosis Admitted to the Intensive Care Unit Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics 744. Integrin Inhibitor Modulates Pulmonary Fibrosis in the Reactive Oxygen Species Murine Model of Systemic Sclerosis 745. Genetic Susceptibility Loci of Idiopathic Interstitial Pneumonitis Do Not Represent Risk for Systemic Sclerosis 746. Elevated Pentraxin 3 in Patients with Systemic Sclerosis: Associations with Vascular Manifestations and Defective Vasculogenesis 747. Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms 748. Increased Expression of Chemerin in Endothelial Cells Due to Fli1 Deficiency May Contribute to the Development of Digital Ulcers in Systemic Sclerosis 749. Progranulin Overproduction Due to Fli1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor a in Systemic Sclerosis 750. Molecular Characterization of Systemic Sclerosis Esophageal Pathology Identifies Inflammatory and Proliferative Signatures with Few Fibrotic Markers 751. Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis 752. Potential Roles of Toll-like Receptor 4 in the Murine Models of Systemic Sclerosis 753. Identification of IL12RB1 As a Novel Systemic Sclerosis Susceptibility Locus 754. The Global mirna Whole Blood Profile in Systemic Sclerosis and Its Correlation with Serum Cytokine Levels 755. Increased Degradation of BMPR2 in a TGFβ Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension 756. Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells 757. Distinctive Patterns of Telomere Shortening and Apoptosis in Limited and Diffuse cutaneous Systemic Sclerosis 758. Assessment of mrna Gene Expression Based on Forearm Skin Score in Systemic Sclerosis Patients 759. The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By Urokinase 2014 Program Book 183

186 ACR POSTER INDICES 760. Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis 761. Specific Autoantibody Profiles and Disease Subgroups Correlate with Circulating Micro-RNA in Systemic Sclerosis 762. IQGAP1 Enhances Contractility of Scleroderma Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fibrosis 763. Caveolin-1 and Peroxisome Proliferator-Activated Receptor Gamma Co-Regulate the Differentiation of Monocytes to Adipocytes and Myofibroblasts in Vivo and in Vitro 764. ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications 765. Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc) 766. Endothelial Fli1 Deficiency Delays Wound Healing Due to Impaired Anastomosis of Newly Formed Vessels a Possible Mechanism of Refractory Skin Ulcers in Systemic Sclerosis 767. The Impact of Plasmacytoid Dendiritc Cells (pdcs) on Fibrosis in bleomycin induced Murine Model of Systemic Sclerosis (SSc) 768. Transforming Growth Factor Beta Induces anti Angio and Vasculo-Genesis Phenotype in Dermal Fibroblasts through Secretion of Pigment Epithelium Derived Factor 769. Anti-Fibrotic Effects of an Investigational Drug: Bis- Oxetanyl Sulfoxide 770. Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays 771. Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1- Induced Endothelial-to-Mesen 772. RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression 773. Functional Autoantibodies from Patients with Systemic Sclerosis Reactive to Angiotensin II Type 1 and Endothelin-1 Type a Receptor Induce Inflammatory Lymphocyte Infiltration into Lungs of Mice 774. Endothelin-1 Synergistically Increases TGF-β-Induced Hif1α Expression Under Normoxic Conditions during Endothelial-to-Mesenchymal Transition in Murine Endothelial Cells. a Novel Mechanism for the Fibrogenic Effects of Endothelin Vasculitis 775. HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis: Literature Review and Meta-Analysis 776. A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA 777. Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility 778. PTPN22 rs and Susceptibility to Biopsy Proven Giant Cell Arteritis (GCA) in an Australian Sample 779. Toll-like Receptor 2 Agonism Induces Inflammation, Angiogenesis and Cell Migration in Giant Cell Arteritis 780. Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis 781. Rho Kinase (ROCK) Activity in Aortitis: Comparison of Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and Isolated Aortitis (IA) 782. Temporal Artery Microbiome in Giant Cell Arteritis 783. Increased Migration and Proliferation Potential Characterize Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis 784. Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy 786. The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported 787. Cardiovascular Risk Factors and Incident Giant Cell Arteritis 788. Fast-Track Diagnostic Procedure for Giant Cell Arteritis 789. Association Between Histological Features and Clinical Features of Patients with Biopsy Positive Giant Cell Arteritis 790. Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis 791. Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis 792. Is Temporal Artery Biopsy the Gold Standard for the Diagnosis of Giant Cell Arteritis? 793. Preliminary Analysis of Histological Findings in Diagnosis of Giant Cell Arteritis Biopsy Positive Patients Program Book

187 ACR POSTER INDICES 794. Color Doppler Ultrasonography Findings in Giant Cell Arteritis and Their Relationship with Clinical Manifestations 795. High Interobserver Agreement on Ultrasonographic Findings in Patients with Large Vessel Vasculitis 796. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis 797. PET/CT for the Diagnosis of Giant Cell Arteritis: A Prospective Study 798. Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis 799. Peripheral Arterial Disease in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis 800. Hospitalization Rates and Utilization Among Patients with Giant Cell Arteritis: A Population-Based Study from 1987 to Venothromboembolism in Large Vessel Vasculitis 802. Inpatient Complications in Patients with Giant Cell Arteritis: Increased Risk of Thromboembolism, Delirium and Adrenal Insufficiency 803. Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis 804. Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature 805. Takayasu Arteritis and Ulcerative Colitis High Concurrence Ratio and Genetic Overlap 806. Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis 807. Serum Cytokine Profiles in Takayasu s Arteritis: A Search for a Biomarker 808. Biomarkers of Disease Activity in Vasculitis 809. Risk Factors for Severe Ischemic Complications in Takayasu Arteritis: A French Multicenter Retrospective Cohort of 182 Patients 810. Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS) 811. Biologics in Takayasu Arteritis: Preliminary Data from the French Registry 812. Prognosis of Clinically Inactive Takayasu s Arteritis 813. Long-Term Outcomes of Takayasu s Arteritis Patients with Renal Artery Involvement 814. Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients MONDAY, NOVEMBER 17, 2014 Poster Hall (Exhibit Hall B) B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases 982. Identification of Potential SERUM Autoantibody Biomarkers in Rheumatic Diseases Using a New Generation of Protein Arrays 983. Identification of Annexin A2 As an Autoantigen in Rheumatoid Arthritis and in Lyme Arthritis 984. Apolipoprotein B Is a Target of T and B Cell Responses in a Subgroup of Patients with Lyme Disease 985. Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren s Patients 986. Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjögren s Syndrome Pathogenesis 987. Novel Auto-Antigen in Aortic Aneurysms of Large Vessel Vasculitis 988. Serum CXCL13 As a Biomarker of Disease Activity and Severity in Rheumatoid Arthritis: Comparison with Acute Phase Reactants and the Autoantibody Profile 989. Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-cd20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro 990. WITHDRAWN 991. The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis 992. Differential Antigen-Presenting B-Cell Phenotype from Synovial Microenvironment of Rheumatoid Arthritis and Psoriatic Arthritis Patients 993. Anti-Citrullinated Proteins Antibodies Promote Synovial Fibroblast Migration in Rheumatoid Arthritis 2014 Program Book 185

188 ACR POSTER INDICES IL-7 Modulates B Cell Immunoglobulin Isotype Production and Increases B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Synovial Fibroblasts from Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients 995. Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood 996. Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis 997. Explore Translational Pharmacokinetics/ Pharmacodynamics Response/Efficacy Relationship of a Novel Bruton s Tyrosine Kinase Inhibitor in Rat Collagen- Induced Arthritis Model 998. β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL Microrna-155 As an Epigenetic Regulator of B-Cell Activation in Rheumatoid Arthritis: In Vivo and in Vitro Evidences Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression Proteomic Analysis of Connexin 43 Reveals Novel Interactors Related to Osteoarthritis Elevated Levels of BMP2 Compensate for Loss of TGF-Beta in Articular Cartilage during Experimental Osteoarthritis Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases Markedly Increased Mesenchymal Stem Cell Activity in MRI Bone Marrow Lesions Compared with Non-Involved Bone in Osteoarthritic Hips Autophagy Activation Protects from Mitochondrial Dysfunction in Human Chondrocytes Regeneration of Articular Cartilage in Situ with Bone Marrow-Derived Mesenchymal Stem Cells 2014 Program Book Catecholaminergic-to-Cholinergic Transition of Sympathetic Nerve Fibers in Arthritis and in a Co-Culture System of Sympathetic Ganglia in Vitro Fibroblast Growth Factor-2 and Its Receptor Antagonists in Osteoarthritis Role of High Glucose Environment on Chondrocyte Activation and Characterization of Diabetic Osteoarthritic Cartilage: Toward Pathophysiological Delineation of Diabetes Mellitus-Related Osteoarthritis Mitochondrial Function Is Impaired in Human Knee Osteoarthritic (OA) Chondrocytes and Improved By Pharmacologic AMPK Activation Via SIRT1 and PGC-1α Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes Reduced Expression of Circadian Rhythm Genes in Human Osteoarthritis Cartilage: NR1D1 Suppression Alters Chondrocyte Response to IL-1β Stimulation BMP9-Induced psmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ Monolayer Culture Induced the Expression of Zyxin- Related Protein 1 (ZRP-1), αvβ3 integrin Complex and Leptin in Human Articular Chondrocytes Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP Changes in Peripheral Blood Immune Cell Composition in Osteoarthritis Transthyretin and Amyloid in Cartilage Aging and Osteoarthritis Fibroblast-like Synovial Cells and Monocytes Team up in the Organization and the Dynamic Modelling of the Synovial Tissue Chronic PTHrP Treatment Promotes Hypertrophic Differentiation and Inflammatory Gene Expression in Chondrocytes Racial Differences in Biochemical Knee Cartilage Composition Between African American and Caucasian American Women with MR-Based T2 Relaxation Time Measurements Data from the Osteoarthritis Initiative Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein

189 ACR POSTER INDICES Monosodium Urate Monohydrate Crystals Induces the Expression of Ihh and MMP-13 in ATDC5 Cells: Implications in Osteoarthritis (OA) Development. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Hematopoietic Cell Kinase (HCK) As a Novel Regulator of Fibroblast-like Synoviocyte Function in RA ADAM-10 Plays Monocyte Migration and Adhesion in Rheumatoid Arthritis Synovial Fibroblasts Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels ABT-122, a Novel Dual Variable Domain (DVD)-IgTM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects Induction of Pro-Apoptotic Noxa Expression By Ursolic Acid Sensitizes Rheumatoid Arthritis Synovial Fibroblasts to Apoptosis: A Role of Mir-181a Neutralization of IL-17 Ameliorated Kidney Pathology Associated with Immune-Complex Mediated Autoimmune Glomerulonephritis Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling Therapeutic Potential of Targeting Sialic Acid Modified Receptors in Osteoarthritis TNF-á Modulates the Expression of Circadian Clock Genes Via Calcium Signaling in Rheumatoid Synovial Cells Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared IFN Signature Macrophage-Fibroblast Crosstalk Pathways Amplify RA Joint Pathology Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention Imaging the Role of Chemoattractants in Inflammatory Arthritis IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts Identification of Putative Biomarkers and Molecular Mechanisms Associated with Adverse Tissue Reactions to Metal-on-Metal and Modular Neck Hip Implants Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis Tertiary Lymphoid Organ Developmental Program: Diversgent Paradigm of Lymphoid Organogenesis Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients Type I and II Interferon Signatures in Sjögren s Syndrome: Contributions in Distinct Clinical Phenotypes and Sjögren s Related Lymphomagenesis Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells Bioactive TGF-β Is Present on Bovine Milk-Derived Exosomes: Consequences for Patients? A Role for Purinergic Receptor Signalling in Basic Calcium Phosphate Crystal-Induced Inflammation Epidemiology and Public Health: Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta- Analysis Time Trends in Comorbidities Among Patients with Rheumatoid Arthritis Compared to the General Population Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis Identifying Flare in Rheumatoid Arthritis (RA): Performance of the Flare-Assessment in RA (FLARE) Questionnaire in a US Population Factors Associated with Impairment on Quality of Life in Early or Established RA Patients Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis 2014 Program Book 187

190 ACR POSTER INDICES Levels of Fatigue Are Dependent on Country of Residence in Rheumatoid Arthritis: An Analysis Among 3920 Patients from 17 Countries Patients with RA from Wealthier Countries Perform Better on Clinical Disease Activity Measures, but Tend to Show Worse Person Reported Outcomes Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study How Does Rheumatoid Arthritis Disease Activity Affect Development of Upper Cervical Lesions? a Retrospective Study of Cervical Spine X-Rays Combined with a Cohort Study in Rheumatoid Arthritis Patients Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control Characteristics of Rheumatoid Arthritis Patients with and without Cardiovascular Diseases - Data from the Ontario Best Practice Research Initiative (OBRI) Factors Associated with Recording of Rheumatoid Arthritis on Death Certificate Mortality Trends in Rheumatoid Arthritis during the Biologic Era, 1998 to Smoking-Related Mortality in Rheumatoid Arthritis: A Retrospective Cohort Study Using Electronic Medical Records Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non Hodgkin s Lymphoma What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer? Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus on Immunosuppressive Drugs U.S. Geographic Trends in the Distribution and Treatment Practices of Juvenile Systemic Lupus Erythematosus: An Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry A Real-World Characterization of US Patients with Moderate-to-Severe Systemic Lupus Erythematosus Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus Stroke Risks Among U.S. Medicaid Recipients with Systemic Lupus Erythematosus, : Racial and Ethnic Variation Prediction of Mortality Risk Related to Cerebrovascular Accidents in Patients with Systemic Lupus Erythematosus (SLE) vs Anti-Phospho-Lipid-Antibody (apl) syndrome Risk of Intra Cranial Hemorrhage among Patients with Anti-Phospho-Lipid-Antibody (apl) syndrome vs Systemic Lupus Erythematosus (SLE) in Stroke Population: A Nationwide Analysis Epidemiology and Public Health (ARHP) The Relation of Step Length to MRI Features of Osteoarthritis in the Patellofemoral Joint: The MOST Study Obesity Is a Risk Factor for Depression in Systemic Lupus Erythematosus (SLE) Trajectories and Predictors of Physical Activity over Two Years in Rheumatoid Arthritis The Effect of Foot Pain on Mobility Disability in Older Adults: The Framingham Foot Study The Prevalence of Knee Arthritis and Associated Self- Reported Limitation of Activity in Chinese Populations Socioeconomic Disparities in Health Outcomes Among Individuals with, or at Risk for, Osteoarthritis from the United States: Data from the Osteoarthritis Initiative Trajectories of Disability over Time Among Patients with Systemic Sclerosis Association of Objectively Measured Physical Activity and Metabolic Syndrome Among Adults with Osteoarthritis in the United States Program Book

191 ACR POSTER INDICES Skeletal Muscle Fat and Its Association with Physical Function and Physical Activity in Adults with Rheumatoid Arthritis Does Arthritis Status Predict Starting or Stopping Work over a 2-Year Period? Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus Female Sexual Function in Fibromyalgia Work Productivity and Healthcare Utilization in Patients with Fibromyalgia and Comorbid Depression Taking Antidepressant Medication Treatment of Fibromyalgia with Neurostimulation: A Randomized, Double-Blinded, Sham-Controlled Trial Fibromyalgia Patients Who Have More Symptoms at Their Initial Office Visit Tend to Have a Worse Clinical Course Can We Help Identify Learning Disabilities in Fibromyalgia Patients? Clinical Efficacy of the High-Concentration Capsaicin Patch for the Treatment of Carpal Tunnel Syndrome Which Stresses Bother Fibromyalgia Patients Most? System Review: The Most Common Symptoms of Fibromyalgia Patients Other Than Pain, Fatigue, Insomnia, and Cognitive Dysfunction Numbness and Tingling: Neurological Symptoms in Fibromyalgia Anxiety in Fibromyalgia Patients Analgesic and Anti-Hyperalgesic Effects of Deep Dry Needling Therapy in Fibromyalgia Patients Utility of the 2010 ACR Diagnostic Criteria for Fibromyalgia for Pediatric Patients with Juvenile Fibromyalgia The Effectiveness of Mirror Therapy in Patients with Adhesive Capsulitis Most Patients Diagnosed with Fibromyalgia By Physicians Do Not Have Fibromyalgia: The 2012 National Health Interview Survey Fibromyalgia Study A Strong Association Between Memory Loss and Word Finding Difficulties in Fibromyalgia Understanding Baseline Clinical Characteristics May be of Use in Considering the Response to Pregabalin in FM Patients with Comorbid Depression Impact of Age on Symptom Severity and Disease Management at Fibromyalgia Diagnosis The Comparative Efficacy of Kinesio Taping and Local Injection Therapy in Patients with Subacromial Impingement Syndrome The Effect of High Intensity Laser Therapy in the Management of Myofascial Pain Syndrome of the Trapezius: A Double Blind, Placebo-Controlled Study Cognitive Symptoms in Fibromyalgia Patients Compared with Rheumatoid Arthritis Patients Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study Clinical Effectiveness of Exercise and Corticosteroid Injection for Subacromial Impingement Syndrome: A Randomised Controlled Trial The Effects of Mulligan s Mobilization with Movement Techniques in Patients with Lateral Epicondylitis Mindfulness Is Associated with Sleep Quality Among Patients with Fibromyalgia Fibromyalgia Patients Taking Opioids Have Low Self- Efficacy and High Pain Catastrophizing but No Reduction in Pain or Improvement in Activity Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections Comparison High Intensity Laser Therapy and Wrist Splint in the Treatment of Lateral Epicondylitis The Relationship Between Tender Points and Disease Severity in Patients with Fibromyalgia Genetics, Genomics and Proteomics II The mtdna Haplogroups Influence the DNA Methylome of Articular Chondrocytes Transmitocondrial Cybrids: A Tool to Study the Role of mtdna Haplogroups in OA Pathogenesis Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis Genome-Wide Profiling of DNA from Cartilage Reveals Regions Differently Methylated in Osteoarthritis Patients The Mitochondrial Genome Influences the Risk of Incident Knee OA. DATA from the Osteoarthritis Initiative 2014 Program Book 189

192 ACR POSTER INDICES Quantitative Proteomics (itraq) Reveals Putative Biomarkers in Pre-Radiological Osteoarthritis Mass Spectrometry Imaging Revealed Potential Lipid Chondrogenic Biomarkers for Cell-Based Therapy in Cartilage Regulation of PIWIL4 By Histone Modifications in Rheumatoid Arthritis FCGR2A Polymorphism and Response to Anti-TNF Treatment in Rheumatoid Arthritis IRF8 Gene Contributes to Disease Susceptibility and Interacts with NF-KB By Modulating Interferon Signature in Patients with Systemic Sclerosis Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis A Novel Epigenetic Mark, Histone H1 Fucosylation, Orchestrates Macrophage Differentiation and Plasticity By Remodeling the Enhancer Landscape in Rheumatoid Arthritis Genetic Variants Influencing Joint Damage in Mexican Americans and European Americans with Rheumatoid Arthritis Role of NOD2 Pathway in Sarcoidosis Cases with Characteristics of Blau Syndrome Genes Involved in Cartilage Synthesis and Risk to Knee Osteoarthritis Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter Multiway Transcriptomic Analysis of Monocyte-Derived Dendritic Cells Discriminates Effects of Disease and of HLA-B27 in Spondyloarthritis Vasoactive Intestinal Peptide (VIP) Genetic Variants Determine VIP Serum Levels and Could be Used As a Prognosis Biomarker TACR1 rs Single Nucleotide Polymorphism Is a Genetic Risk Factor for Sicca Syndrome in Fibromyalgia Patients Association of Polymorphisms on OPG, RANK and RANKL with ACPA Presence and Erosions: Results of a Meta- Analysis on 1570 Rheumatoid Arthritis Patients from 3 French Cohorts Health Services Research (ACR) Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post- Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA) Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors Area of Residence and Socio-Economic Factors Significantly Affect Access to Biological Therapy for Rheumatoid Arthritis Patients in Romania Increasing Discrepancies Between Physician Assessment of Disease Activity and Patient Global Health in Germany Between 2000 and Economic Impact of Frequent Gout Flares in a Managed Care Setting Satisfaction with Rural Rheumatology Telehealth Service Delay in Diagnosis from Onset of Symptoms By More Than One Year in 31% of Patients with Different Rheumatic Diseases in Australia Program Book

193 ACR POSTER INDICES A Patient Survey Study of Zoledronic Acid Utilization and Factors Associated with Persistence Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic Annual Real-Practice Costs of Biologics for 200 Cases with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated By Tight Control and Treat to Target Strategy Permitting Dose Reduction The Price of a Positive Test: Is It Worth the Cost? Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway) Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany Health Services Research (ARHP) Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany A Description and Comparison of Treatments for Low Back Pain in the United States Usng an Advanced Clinician Practitioner in Arthritis Care Trained Physiotherapist and a Standardized Electronic Medical Record Triage Assessment Tool to Detect Inflammatory Arthritis and Initiate Dmards Earlier in a Community Rheumatology Office Setting Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI) Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren s Syndrome Neurological Complications during Anti-TNF Therapy: A Prospective Imaging and Electrophysiological Study Diffusion weighted Magnetic Resonance Imaging (MRI) of Wrist and Hands in Patients with Rheumatoid arthritis reproducibility and Correlation with Conventional MRI Assessing the Validity and Reliability of a Novel MRI Semi- Automated Algorithm for Quantifying Bone Loss in the Hand Magnetic Resonance Imaging of Inflammatory Severity and Cartilage Damage of Finger Joints in Rheumatoid Arthritis Evaluating MRI-Detected Tenosynovitis of the Hand and Wrist in Early Arthritis Association of Hand MRI Findings with the Level of Plasma Cytokines in Patients with Newly Diagnosed Rheumatoid Arthritis Feasibility and Clinical Implication of Radiocarpal Cartilage T1ρ MR Imaging in Rheumatoid Arthritis Evaluation of a Simplified Version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Comprising 5 Joints (RAMRIS5) Novel Quantification of MRI Provides a More Sensitive Outcome Measure Than Ramris Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging Dynamic Magnetic Resonance Imaging in the Assessment of the Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Results from a Phase IIIb Randomized Study Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naïve Patients with Early Active Rheumatoid Arthritis (Duration 2 Years): Results of an Exploratory Phase 2 MRI Study Do Patients with Active RA Also Have Inflamed Atherosclerotic Plaques on PET-MRI? Validation of the Omeract Psoriatic Arthritis Magnetic Resonance Imaging Score for the Hand and Foot in a Randomized Placebo-Controlled Trial Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging Feature of Fatty Deposition in Sacroiliac Joints in Ankylosing Spondylitis Patients Seen By MRI Prevalence of MRI Spinal Lesions Typical for Axial Spondyloarthritis in Patients with Inflammatory Back Pain Scoring of Spinal Lesions Compatible with Axial Spondyloarthritis on MRI in Clinical Practice By Local Radiologist or Rheumatologist in Desir; Comparison with Central Reading 2014 Program Book 191

194 ACR POSTER INDICES Reproducibility of Magnetic Resonance Imaging Diffusion Weighted Imaging in Axial Spondyloarthritis Patients and Healthy Subjects Conventional Magnetic Resonance Imaging (MR) and Hybrid 18F-Fluoride Positron Emission Tomography MRI (18F-F- PET/MRI) of the Spine and the Sacroiliac Joints a Detailed Description of Pathologic Signals in Patients with Active Ankylosing Spondylitis Osteoarthritis-like Changes Are Present in the Tibia and Femur 1 Year Following ACL Reconstruction The Kimriss Bone Marrow Lesion Score in Patients with Osteoarthritis of the Knee Correlates with WOMAC Pain Status Using Target-Lesion Based Scoring Methodology; Data from the Osteoarthritis Initiative Erosions Detected By Magnet Resonance Imaging in Patients with Juvenile Idiopathic Arthritis (JIA) Are True Erosions As Visualized By Computed Tomography Diagnostic value of Contrast-Enhanced MR-Angiography in diagnosing large Vessel Vasculitis Innate Immunity and Rheumatic Disease: Signaling Mechanisms Cofilin-1 Is a ROS Sensor in Regulating the NLRP3 Inflammasome Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis Febuxostat Inhibits Monosodium Urate Crystal-Induced IL- 1beta Secretion and Cell Death Via ROS- and Intracellular ATP-Dependent Pathways Prolactin Is Locally Produced in the Synovium of Patients with Inflammatory Arthritic Diseases and Promotes Macrophage Activation Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort Plasma Levels of Pattern Recognition Molecules of the Lectin Pathway Are Altered in SLE Patients Hypoxia Modulates Peptidyl Arginine Deiminase 4 Activity and Neutrophil Extracellular Trap Formation Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE NK/NKT Cells from Early and Definite Systemic Sclerosis Patients Show Different Immunological Responses after IL-2 Stimulation Oral Administration of Nano-Emulsion Curcumin in Mice Suppresses Inflammatory-Induced NFkB Signaling and Macrophage Migration Expression of Lectin-like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis Low Dose Colchicine Anti-Inflammatory Effects Are Transduced By AMP-Activated Protein Kinase (AMPK) Novel Role of Liver X Receptor Alpha (LXRα) in the Attenuation of TLR Signalling: Implications in Congenital Heart Block Cholesterol Loading Induces Neutrophil Extracellular Traps, and Atorvastatin Attenuates This Effect Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton s Tyrosine Kinase The Role of the Transcription Factor camp Responsive Element Binding Protein 1 in Lipopolysaccharide-Induced Tolerance Gene Expression Profile in Muscle Tissue before and after Immunosuppressive Treatment in Patients with Myositis Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator Absence of Hormone Responsive Estrogen Receptor Alpha Reduces the Activation of Plasmacytoid Dendritic Cells in Lupus Prone Mice Metabolic and Crystal Arthropathies: Mechanisms of Disease Oxidative Stress from Use of Allopurinol - Is There a Reason for Patients with Gout to Take Vitamin C? Circulating Mediators of Bone Remodeling in Patients with Tophaceous Gout The Relationship Between Serum Homocysteine, Uric Acid and Renal Function in Chronic Gouty Patients: 2 Year Follow-up Results The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients The Reduction of Serum Uric Acid Level Might Prevent Atherosclerosis in Mice Program Book

195 ACR POSTER INDICES Lack of Gene-Diuretic Interactions on Risk of Incident Gout: The Nurses Health Study and Health Professionals Follow-up Study Higher Inflammatory Response in Elderly Patients during Gout Attack Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent Suppressive Effect of Butyrate on Monosodium Urate (MSU) Crystal-Induced IL-1beta Production Is Mediated Via Inhibition of Class I Histone Deacetylases Enhancement of Proinflammatory Cytokine Production By Uric Acid in Human Cells Via Down Regulation of IL-1Ra Pegloticase for Tophus Debulking: Comparison of Dual Energy Computerized Tomography (DECT), Musculoskeletal Ultrasound (MSK-US) and Topographic Caliper Measurement for Assessing Debulking Rate Miscellaneous Rheumatic and Inflammatory Diseases Clinical Presentation and Cytokine Production Abnormalities in a Cohort of Patients Carrying NLRP12 GENE Variants Studying Patients with Autoinflammatory Diseases: The Past, Present, and a Perspective for the Future Cryopyrinopathy with a Myeloid-Specific NLRP3 Mutation Involvement of the IFN-Õ Pathway in a Patient with Candle Syndrome Carrying a Novel Variant of MB8 Gene Is NOD2-Associated Autoinflammatory Disease Remotely Related to Familial Mediterranean Fever or Continuum of It? Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients Evidence Based Recommendations for Genetic Diagnosis of Familial Mediterranean Fever Canakinumab Therapy in Patients with Familial Mediterranean Fever Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever Periodic Fever Syndromes in an Academic Medical Center Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases Retroperitoneal Fibrosis and IgG4 Disease: Response to Immunosuppressive Therapy - a Single Centre Retrospective Study Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease Is Lymphocytic Sialadenitis IgG4-Related? Efficacy of Anakinra in Refractory Adult-Onset Still s Disease: Multicenter Study of 41 Patients Efficacy of Tocilizumab Therapy in Korean Patients with Adults Onset Still s Disease: Multicenter Retrospective Study of 20 Cases Switching Biologic Agents in Refractory Adult-Onset Still s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center Macrophage Activation Syndrome Complicating Adult Onset Still s Disease - Single Center Experience and Literature Review The Prevalence of Malignancy in Adult-Onset Still s Disease Long Term Outcome of Infliximab in Severe and Refractory Systemic Sarcoidosis: Report of 16 Cases Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population The Prevalence of Sacroiliitis and Spondyloarthritis in Patients with Sarcoidosis Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases Efficacy of Tocilizumab in Patients with Uveitis Refractory to Other Biologic Drugs: A Multicenter Study on 31 Cases Golimumab As an Alternative Therapy in Patients with Uveitis Refractory to Other Anti-TNFα Drugs. Multicenter Study of 29 Cases Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study Anakinra a Promising New Therapy for Idiopathic Recurrent Pericarditis 2014 Program Book 193

196 ACR POSTER INDICES Anakinra for the Management of Resistant Idiopathic Recurrent Pericarditis in Adults Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype Pathogenic Role of Tyrosyl Transfer RNA Synthetase in Anti-Synthetase Syndrome Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study A New Multianalyte Assay for Detection of Dermatomyositis-Specific Autoantibodies Undetectable By Commercially Available Immunoassays Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis- Associated Interstitial Lung Disease with Anti- Synthetase Antibodies Pulmonary Arterial Hypertension in Patients with Anti- -Scl Antibody Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto- Antibodies Evidence for the Involvement of NK Cells in Antisynthetase Syndrome Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis Are Anti-SRP Auto-Antibodies Specific for Myositis? 2014 Program Book Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique Distinctive Muscle Histopathological Features of Anti- Synthetase Syndrome Myocarditis in Antisynthetase Syndrome Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome Osteoarthritis - Clinical Aspects: Epidemiology and Pathogenesis Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway Association Between Cardiometabolic Disorders and Hand Osteoarthritis Severity: A Cross-Sectional and Longitudinal Study Hyperglycemia and Risk of Osteoarthritis Retinal Arteriolar Narrowing and Incidence of Knee Replacement for Osteoarthritis: A Prospective Cohort Study Association of Low Birth Weight and Preterm Birth with the Incidence of Knee and Hip Arthroplasty for Osteoarthritis Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients Relationship of Buckling and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-Based Case- Crossover Stud Knee Pain and a Prior Injury Are Associated with Increased Risk of a New Knee Injury: Data from the Osteoarthritis Initiative Systemic Pain Modulation Is Related to Body Perception in People with Knee Osteoarthritis WITHDRAWN Sensitivity to Change of Patient Preference Outcome Measures for Pain in Trials of Patients with Knee Osteoarthritis

197 ACR POSTER INDICES Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment Results of a Large Non-Intervention Study The Natural Course of Physical Function in People with Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative Patient Perspective of the Main Health Concerns and Needs of Living with Hand Osteoarthritis Older Adults with Osteoarthritis Do Not Have an Increased Risk of Cognitive Impairment Classification of Osteoarthritis Phenotypes By Metabolomics Analysis Knee Osteoarthritis Progression Is Predictable By Genetic Polymorphisms. Results from a Multicenter Association Study Relationships Between Inflammation, Disease Severity and Synovial Fluid Calcium Crystals Detected By Scanning Electronic Microscopy in Early Osteoarthritis Synovitis Characteristics and Associated Intra- Articular Pathology in a Cohort of Patients Undergoing Meniscectomy for Meniscal Tear Identification of an Inflammation-Driven Phenotype of Osteoarthritis By Quantification of Synovial Inflammation Ex Vivo and in Serum from Patients Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis Gender Differences in the Lupus Nephritis Biomarkers in Children Childhood-Onset Systemic Lupus Erythematosus: Short- Term Treatment Response Rates in Proliferative Lupus Nephritis Pulse- Pediatric Update on Lupus in South Africa: Epidemiology and Management Safety and Efficacy of Rituximab in Pediatric Lupus and Other Rheumatic Diseases Macrophage Activation Macrophage Activation Syndrome: A Severe and Frequent Manifestation of Acute Pancreatitis in Childhood-Onset Compared to Adult Systemic Lupus Erythematosus Patients A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers Subclinical Right Ventricle Systolic Dysfunction By Two- Dimensional Speckle-Tracking Echocardiography in Childhood-Onset Systemic Lupus Erythematosus Patients Trabecular Bone Impairment Assessed By HR-pQCT in Juvenile-Onset Systemic Lupus Erythematous with Vertebral Fractures The Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus Outcome of Lupus Nephritis in Children Less Than 12 Years Old from North-India Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood Onset Systemic Lupus Erythematosus? Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis Lupus Nephritis in Mexican Children Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry 2014 Program Book 195

198 ACR POSTER INDICES A Hybrid Conjoint Analysis Model Is Proposed As the Definition of Minimal, Moderate and Major Clinical Improvement in Juvenile Dermatomyositis Clinical Trials Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups Safety of Rituximab in Treating Pediatric Rheumatic disease Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies Cardiopulmonary Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation Gastrointestinal Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation Predictors of Disease Relapse in Juvenile Localized Scleroderma Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE): Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Localized Scleroderma and Juvenile Systemic Sclerosis Transition of Care and Long-Term Outcomes of Juvenile Systemic Sclerosis during Adulthood: Results from a French Single-Center Case-Control Study Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis Modulation of Natural IgM-Autoantibodies to Oxidative Stress-Related Neo-Epitopes on Apoptotic Cells in Newborns of Mothers with Anti-Ro Autoimmunity Comparison of Clinical and Serological Features of Childhood Sjögren Syndrome Based on the Presence or Absence of Parotitis 2014 Program Book Pediatrics (ARHP) The Efficacy of a Multidisciplinary Intervention Strategy for the Treatment of Benign Joint Hypermobility Syndrome (BJHS) in Childhood: A Randomized, Single Center Parallel Group Trial Factors Associated with Pain in Children with Hypermobility - a Pilot Study Psychology/Social Sciences (ARHP) From Social Support to Information Sharing, How Are Persons with Rheumatoid Arthritis Using Disease-Specific Facebook Communities? a Content Analysis Bridging the Social Support Needs Gap for African American Women with Systemic Lupus Erythematosus through the Chronic Disease Self-Management Program Social Support and Suicidal Ideation in Systemic Lupus Erythematosus: Georgians Organized Against Lupus Cohort Early Birds Versus Night Owls: Morning/Evening Preference and Its Association with Sleep Problems, Fatigue, and Emotional Well-Being Among RA Patients Associations of Physical and Mental Factors with Outcome Expectations for Exercise in a Clinical Trial Mindfulness Is Associated with Symptom Severity and Pain Impact in Patients with Fibromyalgia Correlates of Body Image Dissatisfaction in Patients with Limited and Diffuse Systemic Sclerosis Is Psychological Status Related to Symptom Experience in Behçet s Syndrome? Quality Measures and Quality of Care Choosing Subserologies Wisely: An Opportunity for Rheumatologic Healthcare Resource Savings Choosing Not so Wisely: The Tale of Antinuclear Antibody Testing Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus A Quality Improvement Initiative to Improve Pneumococcal Vaccination Rates in Immunosuppressed Patients Electronic Medical Record-Based Best Practice Alert Used By Clinical Staff Improved Pneumococcal Vaccination and Documentation Among Immunosuppressed Rheumatoid Arthritis Patients

199 ACR POSTER INDICES Improving Pneumococcal Immunization Rates for Patients on Immunosuppressant Medications at an Academic Rheumatology Clinic Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis Understanding Vaccination Rates Among Patients with Rheumatoid Arthritis Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record A Decision Support Tool to Improve Herpes Zoster Vaccination Rates Among Patients Starting Biologic Medications Practice What You Preach? Suboptimal Guideline Adherence By Rheumatologists in Patients with Rheumatoid Arthritis Assessment of ACR Endorsed Quality Indicators in Rheumatoid Arthritis Patients a Quality Improvement Initiative Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care Improving the Measurement of Disease Activity for Patients with Rheumatoid Arthritis: Validation of an Electronic Version of the Routine Assessment of Patient Index Data (RAPID 3) Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care Improving Compliance for Tuberculosis Screening for Patients on Biologics in Rheumatology Clinics A Systematic Analysis of the Safety of Prescribing Anti- Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women Care of Women with Rheumatological Conditions during Family Planning and Pregnancy Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience Rheumatologists Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center Rheumatoid Arthritis - Clinical Aspects: Comorbidities, Treatment Outcomes and Mortality Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes Psychosocial Comorbidities Are Independently Associated with Subclinical Atherosclerosis in Rheumatoid Arthritis Accelerated Diastolic Dysfunction in Premenopausal Women with Rheumatoid Arthritis ARE Erosions a Disappearing Feature in Rheumatoid Arthritis (RA)?Joint Damage in Patients with EARLY RA at 10 YEARS after Diagnosis Outcomes of Interstitial Lung Disease Associated with Rheumatoid Arthritis in High Volume Referral Centers Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis? Predictors of Deterioration in Subjective Cognition: Results from a Rheumatoid Arthritis (RA) Observational Cohort Study The Association of Body Mass Index (BMI) and Radiographic Progression of Joint Disease in Rheumatoid Arthritis (RA) Impact of Metabolic Syndrome (MetS) on Rheumatoid Arthritis Disease Activity Prevalence of Cardiovascular Disease in US Veterans with Rheumatoid Arthritis and Hepatitis C Infection Physical Function of Patients with RA Varies Importantly Across Countries, and These Differences Are Not Attributed to GDP: Results from Multi-National Study with 17 Countries A Comparison of the Risk for Cardiovascular Event in Patients with Rheumatoid Arthritis Treated with Biologic Disease Modifiers and Patients Treated with Methotrexate Only Educational Level and Not Ethnicity an Important Determinant of Disease Progression in Patients with Rheumatoid Arthritis 2014 Program Book 197

200 ACR POSTER INDICES Angiographic Pattern Among Rheumatoid Arthritis Patients Who Are Hospitalized Due to Acute Coronary Syndrome Anti-Citrullinated Peptide Antibody Titers and the Prevalence of Interstitial Lung Disease in Patients with and without Rheumatoid Arthritis The Impact of Rheumatoid Arthritis Activity and Medications on Pregnancy Outcomes Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis Patient Global Impression of Change for Patient Reported Outcomes in Rheumatoid Arthritis: Impact of Comorbidities Subaxial Cervical Spine Involvement in Symptomatic Rheumatoid Arthritis Patients: Comparison with Cervical Spondylosis The Longitudinal Course of Fatigue in Rheumatoid Arthritis Results from the Norfolk Arthritis Register Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability Radiographic Progression Differs Between Trajectory Clusters Defined By DAS28 Scores in Early Rheumatoid Arthritis Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis Osteophytes Increase the Ambiguity of Clinical Evaluation of Joint Swelling in Rheumatoid Arthritis Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries - Implications for CV Risk Assessment Weight Loss and Risk of Death in Rheumatoid Arthritis Predictors of Long-Term Changes in Body Mass Index in Rheumatoid Arthritis 2014 Program Book Periodontal Disease and Its Impact on Structural Joint Damage in a Rheumatoid Arthritis Peruvian Population Low Vitamin D Level Is Not Associated with Increased Risk of Cardiovascular Disease in Rheumatoid Arthritis Patients Disease Activity Is Associated with Insulin Resistance in Early Rheumatoid Arthritis Assessment of Pulmonary Function in Rheumatoid Arthritis Patients Attending Rheumatology Clinics in Nairobi,Kenya Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal Proteinase K-like Serine Protease PCSK9 Influence on the Dyslipidemia and Endothelial Dysfunction Observed in Rheumatoid Arthritis Patients Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies Higher-Order Neuropsychological Deficits Are Frequent and Occur Early in RA and SLE: The Impact of Basic Processing Abilities on Psychological Well-Being Parameters of Periodontitis Correlate with Anti- Citrullinated Protein Antibodies and P. Gingivalis Antibody Titers in Patients with Early or Chronic Rheumatoid Arthritis Psychosocial Impact of Rheumatoid Arthritis Patients on Their Family Members Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis Five-Year Changes in Myocardial Structure and Function in Patients with Rheumatoid Arthritis Comorbidity in Rheumatoid Arthritis. It Is Feasible to Record Concomitant Medical Conditions and Multi- Morbidity in Observational Research Studies. Can This be Extended to Routine Clinical Settings? Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF- Alpha Treatment Inflammatory Biomarkers, Sleep Quantity and Sleep Quality in Rheumatoid Arthritis

201 ACR POSTER INDICES Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies? Psychological Distress over Time in Early Rheumatoid Arthritis: Results from a Longitudinal Study in an Early Arthritis Cohort Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis Investigation of the Association Between Gastroesophageal Reflux Disease and Clinical Factors in Patients with Rheumatoid Arthritis Differential Gender Impact in the Quality of Life of Patients with Rheumatoid Arthritis. Comprehensive Study Including Clinical, Comorbidity and Psicho-Social Variables Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis Red Cell Distribution Width: A Measure for Cardiovascular Risk in Rheumatoid Arthritis Patients? Prevalence of Vitamin D Deficiency in Rheumatoid Arthritis Rituximab Use in Patients with Rheumatoid Arthritis- Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR Preclinical Interstitial Lung Disease in Early Rheumatoid Arthritis Demographic Differences in Health Related Information Technology Use Among Patients with Rheumatic Diseases Cardiovascular Risk Estimation in Rheumatoid Arthritis: What Is Missing in Traditional Risk Estimators? Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-Ray Erosion Detection Screening Behavior and Prevalence of Hepatitis C Virus in Mexico Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients Low Prevalence of Sarcopenic Obesity in Rheumatoid Arthritis Patients with Moderate Clinical Activity Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis Systemic Inflammation in Alzheimer s Disease: Relevance to Patients with Rheumatoid Arthritis IMPACT of Initiative to Control Cardiovascular Risk Factors in Collaboration with LOCAL Doctors in Patients with Rheumatoid Arthritis Influence of Radiographic Joint Damage in Mortality Risk in a Cohort of Rheumatoid Arthritis Patients: A 20 Years Survival Study Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease The Longitudinal Association Between Inflammation and Blood Pressure in Rheumatoid Arthritis Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil Cholesterol Efflux Capacity of HDL and Coronary Atherosclerosis in Rheumatoid Arthritis Association Between Chronic Inflammatory Conditions and Anti Cyclic Citrullinated Peptide Antibodies in Patients with Early Rheumatoid Arthritis Miscarriage in Rheumatoid Arthritis Association with Disease Characteristics and Medication Use Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function The 2013 ACC/AHA Cardiovascular Risk Prediction Model and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis 2014 Program Book 199

202 ACR POSTER INDICES Increased Occurence of Carotid and Femoral Plaques, but Not Increased Arterial Stiffness of Hypertrophy, in Classical Risk Factor-Free Patients with Rheumatoid Arthritis Clinical Practice/Patient Care (ARHP) The Vocational Experiences of Young People with Juvenile Idiopathic Arthritis and the Role of the Multidisciplinary Team Supporting Positive Employment Outcomes Improving Osteoarthritis Outcomes Utilizing a Multidisciplinary Model of Care; Experience in a Diverse Multicultural Urban Teaching Hospital Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness Implementing American College of Rheumatology (ACR) Quality Indicators for Rheumatoid Arthritis (RA) in the United Arab Emirates (UAE) A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis WITHDRAWN Spironolactone As a Novel DMARD in Rheumatoid Arthritis Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort Timing of Decisions to Adjust Disease Modifying Anti- Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting Gastrointestinal Risk Factors and Treatment Patterns of Rheumatoid Arthritis Versus Osteoarthritis Patients in Korea Rheumatoid Arthritis - Human Etiology and Pathogenesis Quantitative and Qualitative Tracking of Expanded CD4+ T Cell Clones in Rheumatoid Arthritis Patients Ex Vivo-Expanded, but Not in Vitro-Induced, Human Regulatory T Cells Are Suitable for Cell Therapy in Rheumatological Autoimmune Diseases Thanks to Stable FOXP3 Demethylation Foxp3+ Regulatory T Cells in Peripheral Blood and Synovial Fluid of Patients with RA: A Comparative Phenotypic Analysis Stem Cell Growth Factor Expression in Rheumatoid Arthritis Functional Phenotype of Synovial Monocytes Modulating Inflammatory T-Cell Response in Rheumatoid Arthritis IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT Midkine, a Growth Factor, May Play a Pathophysiological Role in Patients with Rheumatoid Arthritis Quantitave Analysis of Cadherin-11 and Beta-Catenin Signaling during Proliferation of Rheumatoid Arthritis- Derived Synovial Fibroblast Cells Cadherin-11 mrna Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis Numbers of Circulating CD4 Positive CD28null T Cells Are Increased in Patients with Rheumatoid Arthritis and Are Associated with Rheumatoid Factor Positivity but Not Subclinical Cardiovascular Disease Follicular Helper T Cells Control Autoimmunity through IL- 21/IL-21 Receptor Interaction in RA Patients Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells Do G-CSF and Neutrophils Contribute to the Pathophysiology of Rheumatoid Arthritis? Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti- Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes Program Book

203 ACR POSTER INDICES Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls Anti-Peptidyl Arginine Deiminase 4 Antibodies in African- Americans with Rheumatoid Arthritis and Radiographic Scores Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis a Dose Response Relationship Between Shared Epitope and ACPA Level: But Not All SE Alleles Are Created Equal Overweight and Obesity Are Associated with Reduced Risk of Rheumatoid Arthritis in Men, but Not in Women Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel Therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX- 0061: Post-Hoc Analysis of Phase I/II Data Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug- Drug Interactions Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed- Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA) Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase Discovery of ARN a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~ Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis a Multicenter Registry Study Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases Safety and Tolerability of NNC , an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-csf1r) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis- Specific Blood Gene Signature to Healthy State Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain- Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout Efficacy and Safety of Iguratimod for Rheumatoid Arthritis ALX-0061, an Anti-IL-6R Nanobody for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain- Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models 2014 Program Book 201

204 ACR POSTER INDICES Immunogenicity Assessment of PF , a Potential Biosimilar to Infliximab, in Healthy Volunteers A Phase I Trial Comparing PF (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects The Biosimilar Landscape: A Systematic Review of Its Current Status Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge An Analysis of in-vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically- Meaningful Concentrations The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis 2014 Program Book Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis Disentangling the Effects of Tocilizumab on Neutrophil Survival and Function Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI- TNF Drugs Gene Expression Analyses of Abatacept- and Adalimumab- Treated Patients from the Ample Trial Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 - Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Follow-up Data on the Rheumatoid Arthritis Comparison of Active Therapies Trial: Observational Cohort Rituximab Done! What s Next in RA? Cumulative Clinical Response in Rheumatoid Arthritis Patients with Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year Data Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry Efficacy of the Subcutaneous Formulation of Abatacept/ Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience

205 ACR POSTER INDICES Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata Clinical Database and registry Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata Clinical Database and Registry Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for All Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population Distinct Regulation of T Helper Cell Differentiation By Biologic DMARD Therapy in Rheumatoid Arthritis Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD- Naive Patients: Results from a Phase 3, Randomized, Controlled Trial Economic and Comorbidity Burden Among Moderate-to- Severe Psoriasis Patients Comorbid with Psoriatic Arthritis Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients Endocrine Co-Morbidities in Patients with Psoriatic Arthritis: A Population-Based Study Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial The Swedish Early Psoriatic Arhtritis (SWEA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis 2014 Program Book 203

206 ACR POSTER INDICES Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients with Psoriasis Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients University Students with Psoriatic Nail Changes Have a Greater Number of Tender Enthesial Points Than Those with Normal Nails The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis Reversal of Damage in Psoriatic Arthritis Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis - Preliminary Analysis from a Single Centre, Placebo- Controlled, Crossover Study Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies Cumulative Inflammatory Burden Is Independently Associated with Increased Arterial Stiffness in Patients with Psoriatic Arthritis Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers The Economic Impact of Psoriatic Arthritis in Toronto, Ontario Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis Program Book

207 ACR POSTER INDICES Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondyl Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities? Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis? Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies IFN-γ (Th1), IL4 (Th2), and IL5 (Th2) Are Elevated in Pre- Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease New Autoantigens Associated with Lupus Nephritis Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients Deficient Repair of DNA Double-Strand Breaks and Increased Apoptosis in Patients with Lupus Nephritis Circulating micrornas As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease- Associated Dysfunctional Signaling Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE) A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE 2014 Program Book 205

208 ACR POSTER INDICES Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies The Global Antiphospholipid Syndrome Score (GAS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus A Novel NMR Biomarker of Inflammation (GlycA) Is Elevated in Systemic Lupus Erythematosus Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus? Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients Thrombophilia Associated with DFS70 Antibodies Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus LACK of Association of ANTI CCP and Arthritis in SLE Anti-Dense Fine Speckled 70 Antibodies: Long-Term Followup Study of Clinical Associations in a US Laboratory Patient Population Serum Anti-Müllerian Hormone Levels in SLE Patients. the Disease Severity and Cyclophosphamide Reduce the Ovarian Reserve Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus 2014 Program Book Baseline Factors That Predict High BLyS Levels in Patients with Systemic Lupus Erythematosus (SLE) and High Disease Activit A Prospective Study of Vitamin D Effects on T Cells Phenotype in Patients with Systemic Lupus Erythematosus Treated with Different Regimens of Supplementation for Two Years Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated? Mycophenolic Acid and Ribavirin Induces Cytoplasmic Autoimmunogenic Rods and Rings Structures in Vivo Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-ifnγ) Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus Serum Cystatin C As a Biomarker for Clinical Practice in Patients with Lupus Nephritis Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies Rate of Histological Transformation to Higher Grade Nephritis in Class II Mesangial Proliferative Lupus Glomerulonephritis Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?

209 ACR POSTER INDICES Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares A Systematic Review and Network Meta-Analysis of Cyclophosphamide and Mycophenolate Mofetil in Lupus Nephritis Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares? Lupus Nephritis Patients Who Stopped Maintenance Immunosuppressive Therapy without Relapse Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a sleeping beauty? Efficacy Versus Safety of Prednisone in Lupus Nephritis Since The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus Probability of 3 and 6 Month Complete Response in Lupus Nephritis Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus Renal Relapses Are Common in Lupus Nephritis Facilitating the Medication Decision-Making process What Do Patients with Lupus Nephritis Say? Disease Specific Quality of Life in Patients with Lupus Nephritis Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects Long-Term Efficacy of Rituximab in Systemic Sclerosis Regional Implantation of Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients with Systemic Sclerosis Physical Therapy for Systemic Sclerosis: Systematic Review and Meta-Analysis Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Sclero A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma An Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud s Phenomenon Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis DUAL Energy Computed Tomography for the Evaluation of Calcinosis in Systemic Sclerosis Key Role of Cardiac Biomarkers in the Assessment of Systemic Sclerosis: Contribution of High Sensitivity Cardiac Troponin Early Detection of Left Ventricular Morphological, Functional Abnormalities and Myocardial Characteristics in Systemic Sclerosis without Cardiac Symptoms Using Cardiac Magnetic Resonance Imaging: A Preliminary Report Microhaemorrages and Giant Capillaries in Nailfold Videocapillariscopies Are Able to Accurately Predict Disease Activity Level in Systemic Sclerosis Improvement of Digital Ulcerative Disease in Patients with Systemic Sclerosis Is Associated with Better Functional Prognosis 2014 Program Book 207

210 ACR POSTER INDICES Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement Progressive Disease in Systemic Sclerosis after One Year of Follow-up; Results of a Standardized Multidisciplinary Health Care Program A Feasibility Study of Subjective and Objective Assessment of Sublingual Abnormalities in Systemic Sclerosis Validation of Vesmeter As a Diagnostic Tool of Scleroderma Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis High Frequency Skin Ultrasound Detects Subclinical Diffuse Dermal Involvement in Patients with Limited Cutaneous Systemic Sclerosis Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud s Phenomenon Laser Speckle Contrast Analysis in the Follow-up of Digital Ulcers in Systemic Sclerosis Patients Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance? An Association of Anti-/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition The Lectin Pathway of Complement a Potential Role in the Pathogenesis and Disease Manifestations of Systemic Sclerosis Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan High Oxidative Stress in Fibrotic and Non-Fibrotic Skin of Patients with Systemic Sclerosis The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease WITHDRAWN Endothelin-1 Is a Downstream Mediator of Profibrotic Effects by Transforming Growth Factor-β1 in Systemic Sclerosis Skin Fibroblasts The Relationship Between Vascular Biomarkers and Disease Characteristics in Systemic Sclerosis: Elevated MCP-1 Is Associated with Predominantly Fibrotic Manifestations Monocytic Angiotensin and Endothelin Receptor Imbalance Determines Secretion of the Profibrotic Chemokine Ligand CCL Increased Number of CD206+cells in Peripheral Blood and Skin of Systemic Sclerosis Patients IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma Serum Levels of CD163/Tweak Predict Risk of Digital Ulcers in Patients with Systemic Sclerosis MHC Class I and Class II Genes Influence Systemic Sclerosis Susceptibility, Clinical Presentation and Autoantibody Profile in a Mexican Admixed Population Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis Periostin May Promote Productin of Extracellular Matrix By Modulating TGF-β Signaling in Human Skin Fibroblasts GATA6 Deficiency Activates UPR Pathways in Endothelial Cells during the Development of Pulmonary Arterial Hypertension Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis Program Book

211 ACR POSTER INDICES TLR4 and TLR7 Are Required for Gadolinium Based Contrast Agent Induction of Dermal and Pulmonary Fibrosis in an Adenine-Induced Model of Chronic Renal Failure Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies Loss of IRF5 Ameliorates Tissue Fibrosis in a Murine Model of Systemic Sclerosis The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse Murine Hypochlorite-Induced Systemic Sclerosis Poly(ADP-ribose) Polymerase-1 (PARP-1) Suppresses the Profibrotic Effects of Transforming Growth Factor â in Systemic Sclerosis Bromodomain Inhibitor JQ1 Modulates Collagen Processing and Ameliorates Bleomycin Induced Dermal Fibrosis in Mice Adenosine A2A Receptor (A2AR) Promotes Collagen Type 3 Expression Via β-catenin Activation Identification of Novel Scleroderma associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation Translocation of IGFBP-5 to the Nucleus and Its Interaction with Nucleolin Do Not Dictate Its Fibrotic Effects Attenuation of Sclerodermatous Graft Versus Host Disease (sclgvhd) in IL4RA Receptor-Deficient Mice T cell Biology in Rheumatoid Arthritis and Other Arthritis Immunomodulatory Effects of Dietary Non-Digestible Oligosaccharides in T Cell-Mediated Autoimmune Arthritis IL-22 Plays a Significant Role in the Initiation and Augmentation of Th17-Dependent Experimental Arthritis T cell Tolerance Induction By the Glycosylated Type II Collagen Peptide-Based Vaccination in Murine Arthritis Immune Related Adverse Events Associated with Anti- CTLA-4 Antibodies: Systematic Review and Meta-Analysis Altered Phenotype and Function of Senescent Regulatory T Cells in Rheumatoid Arthritis Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA Immunomodulatory Properties of CD271+ and CD271- Synovial Mesenchymal Cells Predicting the Evolution of Inflammatory Arthritis in ACPA-Positive Individuals: Can T-Cell Subsets Model Help? Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation Depletion of Reactive Oxygen Species Biases T Cells to Proinflammatory Cytokine Production in Rheumatoid Arthritis Antigen-Specificity Regulates Peripheral Homeostasis of Regulatory T Cells CD4+ T Cell Subpopulations in Blood and Synovial Fluid Defined By Differential Expression of Integrins Memory Stem T Cells Are Selectively Enriched in Patients with Rheumatoid Arthritis, Contract upon Anti-TNF Treatment, and May Provide a Long-Term Reservoir of Arthritogenic Lymphocytes Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis WITHDRAWN CCR6+CD4+ Cells Are Counterparts of Follicular T-Cells Supporting Autoantibody Production in Rheumatoid Arthritis Molecular Mechanisms Underlying 1,25(OH)2D3- Mediated Suppression of Th17 Cell Activity The Effect of a Pro-Inflammatory Milieu on Tregalizumab (BT-061)-Induced Regulatory T-Cell Activity CD4 Aptamer-RORγt shrna Chimera Inhibits IL-17 Synthesis By Human CD4+ T cells CD30 As a Target of Aptamers and Delivery Portal for Aptamer-shRNA to Block Th17 Cells Human T-Cells Express RANKL in Response to Combination of ZAP-70, Calcineurin and Voltage-Gated K+-Channel Signaling Following Co-Ligation of the Adhesion Molecule CD2 and the T-Cell Receptor Complex Vasculitis Peripheral CD5+ b-cells in ANCA-Associated Vasculitis Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation 2014 Program Book 209

212 ACR POSTER INDICES Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases An Analysis of the Incidence and Characteristics of ANCA Positive Vasculitis before and after the Christchurch Earthquake Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis United Kingdom & Ireland Vasculitis Registry Cross- Sectional Data on the First 1085 Patients Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application The Muscle Biopsy Is a Useful and Noninvasive Procedure in Diagnosing Systemic Vasculitis Affecting Small-to- Medium-Sized Vessels: A Prospective Evaluation Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase Comparison of Clinicopathologically- and Serologically- Based Classification Systems for ANCA-Associated Vasculitis Granulomatosis with Polyangiitis (Wegener s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome Cardiac Involvement in Granulomatosis with Polyangiitis: A Magnetic Resonance Imaging Study of 31 Consecutive Patients Abdominal Visceral Adipose Tissue Measured By DXA As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study Arterial Thrombotic Events in Systemic Vasculitis Venous Thromboembolic Events in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 2014 Program Book Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO- ANCA Associated Vasculitis Granulomatosis with Polyangiitis (Wegener s): Endoscopic Management of Tracheobronchial Stenosis - Results from a Multicenter Experience in 47 Patients Predicting Relapse in Patients with Granulomatosis with Polyangiitis - the Potential Use of Monitoring in Vitro ANCA Production Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA- Associated Vasculitis Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis Survival of Microscopic Polyangiitis (MPA) Patients with and without Pulmonary Fibrosis (PF) Vasculitis As Underlying Cause of Death in the United States: HLA-DRB1*01 Is Associated with Henoch- Schönlein Purpura in the Spanish Population Association of HLA-B*41 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status Are EULAR/Printo/PRES Classification Criteria Appropriate for Classification of IgA Vasculitis in Adults?

213 ACR POSTER INDICES Follow up of an Unselected IgA Vasculitis (Henoch- Schönlein Purpura) Population at Single Rheumatology Center Applicability of the 2006 European League Against Rheumatism (EULAR) Criteria for the Classification of Henoch-Schönlein Purpura. an Analysis Based on 766 Patients with Cutaneous Vasculitis Clinical-Biological and Pathological Spectrum and Outcome of IgA Vasculitis in Adults: A French Study Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study TUESDAY, NOVEMBER 18, 2014 Poster Hall (Exhibit Hall B) B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases Effects of Mesenchymal Stem Cells on Human B Cell Proliferation Development of Cell Based Enzyme Linked Immunosorbent Assay for the Quantification of Anti M type phospholipase a receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Nephropathy A Novel Murine Model of B Cell-Mediated Glomerular Injury Is Mediated By Cytokines Neuropsychiatric Lupus Is Substantially Unaffected By B-Cell Deficiency Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus CD22 Is Required for Formation of Memory B Cell Precursors within Germinal Centers Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice A Dual Role for IFN-γ in Development of Peripheral B Cells in Lupus-Prone MRL/Lpr Mice Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus Circulating CD19+CD38+CD43+ B Cell Subset in SLE Patients Have More Cell Cycle Related Genes Than Healthy Controls A Novel CD27(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE Elucidation of Molecular Mechanisms of Breg Induction in Autoimmune Diseases Circulating Plasmablasts from Patients with Systemic Lupus Erythematosus Produce Autoantibodies Reactive to Epstein-Barr Virus Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Dysregulation of CC Chemokines at Microvascular Endothelial Cells of Blood and Lymphatic Vessels Under Inflammatory Conditions Pyrrolopyrimidine Derivatives That Inhibit Binding of BAFF to Its Receptor, BR3, Are Drug Candidates for Primary Sjögren s Syndrome Interaction of PDE4 and β-arrestin Reverses Anti- Inflammatory Effects of Catecholamine-Producing Cells in Chronic Arthritis Via Adrenoceptor Switching from Gαs to GαI Signalling NF-κB-Inducing Kinase (NIK) Is Expressed in Synovial Endothelial Cells in Early Arthritis Patients and Correlates with Local Disease Activity and Systemic Markers of Inflammation Chemokine-like Receptor 1 (CMKLR1) is Expressed on Synoviocytes and Proinflammatory Monocytes in Arthritis and is Predominantly Regulated By β arrestin 2 and G Protein Coupled Receptor Kinase (GRK) Inflammatory Properties of Inhibitor of DNA Binding 1 As a Unique Fibroblast Derived Nuclear Protein 2014 Program Book 211

214 ACR POSTER INDICES Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis Changes in Soluble CD18 Reflect Latency in the Immune System and Predict Radiographic Progression in Early Rheumatoid Arthritis Characterization of the Thyroid Hormone System in Rheumatoid Arthritis CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells Transforming Growth Factor Beta Is a Major Regulator of Micro-RNA Synthesis in Rheumatoid Arthritis Synovial Fibroblasts Highly activated IL-23/Th17 axis and JAK2/STAT3 signal pathway in PBMC of active AS patients involve in pathogenesis of AS Neurotrophin Receptor p75 (CD271) Defines a Distinct Synovial Fibroblast Subset in Rheumatoid and Osteoarthritic Synovial Tissues with Enhanced Proinflammatory Potential TH17 Inflammatory Responses Occur in a Subset of Patients with Erythema Migrans or Lyme Arthritis, but Are Not Predominant Responses in Joints The Role of the Proinflammatory Mediator High-Mobility Group Box Protein 1 (HMGB1) in Anti-Collagen-Antibody- Induced Arthritis Is Dependent on Vascular Endothelial Growth Factor (VEGF) Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects Ectopic Lymphoid Neogenesis Is Strongly Associated with Activation of the IL-23/IL-17 Pathway in Rheumatoid Synovitis Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts Profiling η in Human Primary Cell Based BioMAP Disease Models Reveals a Unique Pro-Inflammatory Phenotypic Signature Consistent with RA-Inflammation Biology Elevation and Functional Activity of Interferon Omega in Human Systemic Lupus Erythematosus The Proangiogenic Function of the Epigenetic Regulator EZH2 in Synovial Tissue Is Mediated By Fibroblasts in Rheumatoid Arthritis 2014 Program Book Role of Monocytes Subsets in the Pathology of Rheumatoid Arthritis: Involvement in Endothelial Dysfunction and Proinflammatory Profile Pseudostarvation By AMPK Activator Therapy Is Associated with Reduced Disease Activity and Downregulation of Pro-Inflammatory Responses in Rheumatoid Arthritis (RA) Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels Education (ACR) A Qualitative Analysis of Methotrexate Injection Videos on Youtube Final Year Medical Students Prefer E-Reading Content to Interactive Case-Based Quizzes in a Pediatric Rheumatology E-Learning Module Improving Resident Confidence with the Musculoskeletal Exam through a Rheumatology-Dedicated Musculoskeletal Workshop Implementation and Performance of an Objective Structured Clinical Examination (OSCE) in a National Certification Process of Trainees in Rheumatology. Two Years of Experience Rheumatology Learning Management System Ambulatory Rheumatology Curriculum: Effect of Multimodal Curriculum Enhancement Simulation in Continuing Education: Improving Evidence- Based Decisions for Rheumatoid Arthritis Management Process Outcomes and Community-Wide Efficacy of the Amigo Inter-Institutional Mentoring Initiative within Pediatric Rheumatology Application of an Experiential Learning Framework for Clinician Scholar Educator Training in a Rheumatology Fellowship Pilot Musculoskeletal Workshop for Internal Medicine Residents Integration of Nailfold Capillary Microscopy and Dermoscopy into the Rheumatology Fellows Curriculum Resident s Guide to Rheumatology Mobile Application: An International Needs Assessment Does Psychological Safety Impact Learning Environments Among Rheumatology Fellows: Findings from Veterans Affairs Learners Perception Survey

215 ACR POSTER INDICES Incorporation of Musculoskeletal Ultrasound Curriculum and 6-Month Assessment of Knowledge Retention into the 2nd Year of Medical Student Training Design and Implementation of a Clinical Teaching Tool for Approach to Children with Suspected New Rheumatologic Diagnosis Improvement in Basic Bone Health Knowledge Among VA Primary Care Practitioners during a Focused Musculoskeletal Mini-Residency Structured Integrative Rheumatology Modules (SIRM) pgals Training Increases Kenyan Pediatric Residents Confidence in Performing a Musculoskeletal Exam Internal Medicine Resident Confidence in Rheumatologic and Musculoskeletal Diseases: A Needs Assessment Survey The Effect of a Rheumatology Ambulatory Rotation for Medical Residents on Documentation of Musculoskeletal Complaints The Musculoskeletal Mini-Residency Collaborative Network: A National Department of Veterans Affairs Interdisciplinary and Interprofessional Educational Innovation for Primary Care Providers Implementation of a Collaborative Rheumatology and Physiatry Musculoskeletal Ultrasound Training Program Pilot Study of a Web-Based Module on Gout Osteoporosis Screening and Fracture Risk Assessment Tool Usage Among House Staff Multimedia Patient Education Tool for Patients with Osteoporosis Education (ARHP): Education/Community Programs Multiple Joint Osteoarthritis: Patient Preferences for a Generic Exercise and Self-Management Programme Using Photovoice Techniques to Empower Lupus Patients and Create Public Awareness: A Program Evaluation Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives Development of Multimedia Patient Education Tools (MM-PtET) for Osteoarthritis (OA), Osteoporosis (OP) and Rheumatoid Arthritis Patients (RA) Reaching out to Physical Therapists: Results of a Survey on Physical Therapists Preferences for Learning about Evidence-Based Community Programs What Do State Legislators Think about Arthritis? Results of Focus Groups with State Legislators Moving Social Media Beyond Health Education and into Patient Engagement Quality Appraisal of Educational Websites on Osteoporosis and Bone Health Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment Performance of Self-Reported Measures for Periodontitis in Rheumatoid Arthritis and Osteoarthritis Fine Particulate Air Pollution and Systemic Autoimmune Rheumatic Disease in Two Canadian Provinces Occupation and Risk of Developing Rheumatoid Arthritis Fish Consumption and Risk of Rheumatoid Arthritis Among Women in Large Prospective Cohorts Do Mediterranean or Vegetarian Diets Influence Risk of Rheumatoid Arthritis? Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen Are Associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis Circulating Carotenoids and Subsequent Risk of Rheumatoid Arthritis The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults First Nations Persons Have an Increased Risk of Developing Rheumatoid Arthritis with an Early Onset Age but Are Seen Less Frequently By Rheumatologists: A Population Based Study Prevalence of Inflammatory Arthritis Conditions in the First Nations Population of Alberta Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study Factors Associated with Time to Diagnosis from Symptom Onset in Early Rheumatoid Arthritis Patients Treatment Delays and Worse Outcomes Associated with Lower Socioeconomic Status in Rheumatoid Arthritis Higher Educational Level Correlates with Retarded Onset and Less Severe Disease in Rheumatoid Arthritis Patients 2014 Program Book 213

216 ACR POSTER INDICES Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes Patient Factors Associated with Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA) Joint Distribution and Outcome in 350 Patients with Monoarthritis of Less Than 16 Weeks Duration: Data from a Multicenter Longitudinal Observational Study in Eastern Norway Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sil-2rá): Results of a 21-Year Community-Based Cohort Survival Analysis Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi- Years before Clinical Onset (Pre-RA) Than in Non Opportunistic Infections in Patients Treated with Biologic Drug Therapy Performance of a Two-Step Latent Tuberculosis Screening Algorithm in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis Prior to Treatment with Tumor Necrosis Alpha Inhibitors: Prospective Observational Data from the Biorx.S Tuberculin Conversion in Patients with Autoimmune Arthropathies Receiving Biologic Therapy How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists? Systematic Review of the Effect of Anti-Rheumatic Therapies upon Vaccine Immunogenicity Epidemiology and Public Health (ARHP) Interaction Effects Between Genes and Blood Lead Level on a Composite Score of Multiple Joint Symptoms: The Johnston County Osteoarthritis Project Perceived Discrimination in Individuals with Radiographic Knee and Hip Osteoarthritis No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort Disability in Discretionary Valued Life Activities and Self- Efficacy Explain a Significant Portion of RA Patients Global Assessments Fatigue Is a Risk Factor for Subsequent Functional Decline in SLE Knee Arthritis Is Positively Associated with Physical Impairment: Conclusion Based on Physical Examinations from a Cross-Sectional Study of Chinese Residents Modification of Effects of Household Income and Homeownership By Block Group Poverty on Health Outcomes in a Cohort of African Americans with Rheumatoid Arthritis Foot and Ankle Characteristics Associated with Falls in Adults with Rheumatoid Arthritis Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Followup Period: The Role of Specific Comorbidities Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus Are There Immunological Abnormalities in Fibromyalgia Patients: Flow Cytometry Analysis Program Book

217 ACR POSTER INDICES Fibromyalgia Symptoms Beyond the Pain and Its Impact on the Patient Electrophysiological Evaluation of Autonomic Nervous System and Cutaneous Silent Period in Patients with Fibromyalgia Syndrome The Impact of Environmental Stress on Pain in Fibromyalgia Patients Muscle Tension Is Increased in Fibromyalgia Do Fibromyalgia Patients Have a Distinct Sleep Signature? Unexpectedly High Prevalence of Immunoglobulin Deficiency in Fibromyalgia WITHDRAWN Analysis of the Fibromyalgia Rapid Screening Tool Spanish Version to Detect Fibromyalgia in Primary Health Care Centers Assessment of the Spanish Version of the American College Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia A Cross-Sectional Analysis of Psychological Symptoms, Sleep Quality, and Functional Balance in Fibromyalgia Ultra Orthodox Religious Orientation Associated with Reduced Rates of Pain, Anxiety and Fatigue in a Population Based Study Understanding the Factors Influencing Time to Diagnosis in Fibromyalgia Joint Hypermobility Syndrome and Postural Orthostatic Tachycardia Syndrome (HyPOTS) Investigation of the Effects of Physical Exercise on the Control Mechanisms of Cutaneous Circulation in Patients with Fibromyalgia Syndrome Elevated Serum Leptin Concentrations in a Subset of Fibromyalgia Patients with High Inflammatory Markers Chronic Widespread Pain Versus Multi-Site Pain: Does the Distribution Matter? Ultrasound Assessment of Both Hands in Fibromyalgia Patients: What Could We Detect? Is Susceptibility to Fibromyalgia a Trait? Hypervigilance and FMS The Lumbar Spine in Fibromyalgia Predictive Modeling of a Fibromyalgia Diagnosis: Increasing the Accuracy Using Real World Data A New Tender Point on the Plantar Arch in Primary Juvenile Fibromyalgia: A Potential Point to be Considered A Proposed Simple 3-Variable Index for Identification of Fibromyalgia, Analogous to Classification Criteria for RA and SLE The Association Between Straight Neck and Fibromyalgia Carryover Effects in Crossover Design Studies in Fibromyalgia and Other Pain Conditions Ehlers-Danlos Hypermobile (EDS-HT) Patients and Postural Instability : Another Clue to Explain Pain and Fatigue? Presence of Acrocyanosis in Patients with Joint Hypermobility Evaporative Dry-Eye Disease and Aqueous Deficient Dry- Eye Disease Associated with Fibromyalgia Genetics, Genomics and Proteomics Are Genetic Markers Associated with Myocardial Infarction in Patients with Early Rheumatoid Arthritis? Association of Circulating Mirnas with Spinal Involvement in Patients with Axial Spondyloarthritis Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis Defective Regulation of L1 Endogenous Retroelements in Primary Sjögren s Syndrome and Systemic Lupus Erythematosus: Role of Methylating Enzymes Association of TNFAIP3 Gene Polymorphisms with the Risk for RA and Prediction of Therapy Outcome of TNFα- Blocker Treatment The APOL1 Gene Is Not Associated with Lupus Nephritis in Individuals with Enriched Amerindian Ancestry Contribution of MTHFR Gene Polymorphisms in Sjögren s Syndrome Related Lymphomagenesis Plasma Microparticle Protein Features Distinctively Classify Systemic Lupus Erythematosus and Systemic Sclerosis and Their Clinical Phenotype Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone- Related Suppression of Type I Interferon Response Gene Expression 2014 Program Book 215

218 ACR POSTER INDICES Deep Sequencing Reveals Differential RNA Expression during Malignant Transformation in Major Salivary Glands in a Mouse Model of Sjögren s Syndrome Two Novel Serum Urate Levels Associated Genetic Loci Identified By GWAS in European Were Confirmed in Chinese Han Population Assessment of RA Heterogeneity in Two Independent Cohorts of Patients Identification of Diagnostic and Activity Metabolomic Urine Biomarkers in Six Immune-Mediated Inflammatory Diseases Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset Activation of NFkβ Pathways in Sjögren s Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a Putative Cis-Regulator, Bridging Genetics and Disease Health Services Research Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence Anxiety in Caregivers of Patients with Chronic Rheumatic Conditions WITHDRAWN Overcoming Barriers to Acute Patient Access: Is There a Need for Urgent Care Clinics in Rheumatology Practices? Patterns of Medication Use Before, During, and After Pregnancy Among Women with Systematic Lupus Erythematosus: A Population-Based Study The Number of Morbidities Drives the Health Care Expenditures and Presence of a Musculoskeletal Condition Is Additionally Accountable for Higher Costs Comorbidity Characteristics of Patients Starting First- Line Acute Gout Agents - Colchicine, NSAID, and Corticosteroids Inflammatory Arthritis Treatment Outcomes at a First Nations Reserve Rheumatology Specialty Clinic Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to Association Between Depression and High Utilization of Emergency Department in Patients with Systemic Lupus Erythematosus from the Southeastern United States: The Goal Cohort Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population- Based Cohort Study Off Work Days Decreased RATE in Muskuloeskeletal Disease Patients: Usefulness of the EARLY Intervention Program Societal Preferences for Rheumatoid Arthritis Treatments. Evidence from a Discrete Choice Experiment Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease Variation in the Prescribing Practices of Biologic Dmards Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study Are Patient Ratings of Providers and Health Plans Associated with Technical Quality of Care in SLE? Program Book

219 ACR POSTER INDICES Imaging of Rheumatic Diseases: Various Imaging Techniques The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission Effectiveness of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgialike Illness Sensitivity and Specificity of the Green Nail Sign in Fluorescence Optical Imaging in Psoriatic Arthritis Bone Microstructure in Patients with Cutaneous Psoriasis and No History of Psoriatic Arthritis Shows Bone Anabolic Changes at a Greater Extent Than in Healthy Controls The Impact of Patient-Reported Flares on Radiographic Progression in Rheumatoid Arthritis Patients with Low- Disease Activity: Secondary Analyses from a Randomized Trial What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity? Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy Rheumatoid Arthritis Erosion Detection and Measurement in Longitudinal Datasets Using High-Resolution Peripheral Quantitative Computed Tomography Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis Radiological Outcomes after Two Years of Remission Steered Treatment in Early Arthritis Patients Predictors of Radiologic Disease Progression during the Rheumatoid Arthritis Comparison of Active Therapies Trial Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis Sensitivity to Change of Joint Space Width Measurements in Hand Osteoarthritis in a Two Year Follow-up Study Sensitivity and Precision of Automated Osteophyte Volumetric Measurement in Knee Osteoarthritis over Four Years Cortical Breaks and Bone Erosions in the Hand Joints: A Cadaver Study Comparing Conventional Radiography with High-Resolution and Micro-Computed Tomography Cuantification of Hand Bone Mineral Density By Radiogrammetry and Dual X-Ray Absorptiometry in Early Arthritis Patients Diagnostic Performance and Disease Activity Assessment By FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis Optimal Hand Position for Reliable Volumetric Joint Space Width Measurements Using High-Resolution Peripheral Quantitative Computed Tomography Automatically Extracted Quantitative Biomarkers for Assessing Connective Tissue Disease Using Nailfold Capillaroscopy Dual Energy CT Scanning: Variable Sensitivity for Gout in Non-Tophaceous and Tophaceous Disease and in Individual Erosions Relationship Between the Magnitude of Bone Formation in the Anterior Vertebral Corners, As Assessed through 18F-Fluoride Uptake, and Lumbar Spine Bone Mineral Density in Patients with Ankylosing Spondylitis The Craniocervical Junction in Ankylosing Spondylitis: A Computed Tomography Based Study Infections, Infection-related Biomarkers and Impact of Biologic Therapies Abatacept Related Infections: No Association with Gammaglobulin Reduction Frequency of Postoperative Deep Infection in Patients with Rheumatoid Arthritis Clinical Characteristics and Outcomes in Synovial Fluid Culture Negative Septic Arthritis Risk for Developing Adult T-Cell Leukemia in Patients with Human T Lymphotropic Virus Type-I Carrier Receiving Immunosuppressive Therapy Chikungunya Fever in Patients Under Biologics Persistent Arthralgia Following Chikungunya Fever 2014 Program Book 217

220 ACR POSTER INDICES Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases Severe Neutropenia in Patients with Rheumatic Diseases at a Tertiary Care Hospital in South Korea Human T-Lymphotropic Virus Type 1 Biomarkers in Patients with Rheumatoid Arthritis WITHDRAWN Interest of Systematic Lyme Serology in Context of Recent Onset Arthritis Immunological Abnormalities in Adult Patients with Parvovirus B19 Infection : A study of 23 Cases Genetic Variants of TNFAIP3 in Patients with HCV Related Lymphoma Are Associated with the Presence of Rheumatoid Factor (RF) Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of antiinflammatory Myeloid-Derived Suppressor Cells (MDSC) Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe? Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization Snapin Is Critical for Cathepsin D Activation and the Normal Lysosomal Function Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation Targeting ITGAM+ Cells Successfully Treats a Model of Anti-RNP-Associated Pulmonary Hypertension Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor Are Optimal for Regulatory T Cell Induction-a Comparative Study Polymorphisms in the FCN1 Gene Coding for M-Ficolin Are Associated with Disease Activity, Radiographic Damage and Are the Strongest Predictors of DAS28 Remission in 180 DMARD naïve Early Rheumatoid Arthritis Patients PTPN22 Promotes TLR-Induced Amelioration of Arthritis Role of Natural Killer Cells and Gamma Delta T Cells in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis 2014 Program Book MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren s Syndrome Macrophages from the Synovium of Active Rheumatoid Arthritis Exhibit an Activin a- Dependent Pro- Inflammatory Profile Macrophages-Mediated Response to Uric Acid Crystals Is Modulated By Their Functional Polarization Class a Scavenger Receptor SR-a Exacerbated Synovial Fibroblasts-Mediated Inflammation in Rheumatoid Arthritis Extensive Natural Killer Cell Receptor Phenotyping on NK and T Cells Discloses Differences in RA and Psa, Potentially Mirroring Diverse Immunoregulatory Functions The Monocyte-Phagocyte System in Gout: Enhanced Inflammasome Activity and Expansion of CD14++CD16+ Monocytes in Patients with Gout Macrophage Depletion Ameliorates Nephritis Induced By Pathogenic Antibodies Investigating Myeloid and Plasmacytoid Dendritic Cell Activation within the Synovium and Peripheral Blood of Rheumatoid Arthritis Patients Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases Release of Enzymatically Active Peptidyl Arginine Deiminases (PADs) By Neutrophils Allows Generation of Citrullinated Extracellular Autoantigens in the Synovial Fluid of Patients with Rheumatoid Arthritis Selective Consumption of C2 Component in HCV Patients Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2 Miscellaneous Rheumatic and Inflammatory Diseases Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies Revisiting RS3PE after Twenty Five Years: A Systematic Review of 250 Cases Incidence and Mortality of Relapsing Polychondritis in the United Kingdom: A Population-Based Cohort Study Multicentric Reticulohistiocytosis- Case Series from a Tertiary Care Center Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort

221 ACR POSTER INDICES Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease Successful Therapy with Intravenous Sodium Thiosulfate for Adult Dermatomyositis Associated Calcinosis Prevalence of Raynaud s Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry s Disease: A Cross- Sectional Study Blue Digit Syndrome: The Rheumatologist s Perspective Eculizumab Treatment of Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): World Experience to Date Treprostinil Use in Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): Review of Worldwide Experience to Date Malignant Atrophic Papulosis (MAP) Complicating Connective Tissue Diseases (CTDs) The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing? Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients Elevated Serum Ferritin Levels in Adult Inpatients As a Predictor of in-hospital Mortality and Association with Macrophage Activation Syndrome Haematological Complications in Rheumatic Diseases: Not Only Lymphomas Pilot Study of Tocilizumab in Patients with Erdheim- Chester Disease Adalimumab Therapy Improves Insulin Sensitivity in Non- Diabetic Psoriatic Patients: A 6-Month Prospective Study New Onset Vitiligo Under Biological Agents: A Case Series Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease The Incidence of Zoster in Patients with Cutaneous Lupus Erythematosus and Dermatomyositis Is Increased Compared to the Average U.S. Population Decreased Bone Mineral Density in Patients with Ehler- Danlos Syndrome Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet s Disease and Spondyloarthritis Impact on Anti-Muellerian Hormone Levels Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy Redefining Dermatomyositis: Description of New Diagnostic Criteria That Differentiate Pure Dermatomyositis from Overlap Myositis with Dermatomyositis Features Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome Gene Expression Profiling of T Helper Subsets in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with Juvenile and Adult Dermatomyositis Power Doppler Ultrasonography for Detection of Abnormal Fascial Vascularity: A Potential Early Diagnostic Tool in Fasciitis of Dermatomyositis Clinical Characteristics and Prognosis of Malignancies Associated with Active Myositis Muscle Type I Interferon Gene Expression May Predict Therapeutic Responses to Rituximab in Myositis Patients Ultrasonography Analysis of Carotid Parameters in Patients with Idiopathic Inflammatory Myopaties: Correlation with Demographic Profile and Disease Activity Endoplasmic Reticulum (ER) Stress-Induced Mitochondrial Dysfunction and Atrophy Can be Prevented By Pharmacological Upregulation of Heat Shock Protein 70 (HSP) in Cultured Murine Myotubes Contribution of Tripartite Motif Proteins Modulating Membrane Repair to the Pathogenesis of Autoimmune- Mediated Myositis Overexpression of Ankyrin Repeat Domain Containing Protein 1 Gene (ANKRD1) in Polymyositis Muscle Biopsies Is Correlated to Hypoxia Reduction of Ovarian Reserve in Adult Patients with Dermatomyositis Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry 2014 Program Book 219

222 ACR POSTER INDICES High Prevalence of Hepatitis C Virus Infection in a Japanese Inclusion Body Myositis Cohort Increased Immune Complex Levels in Children with Juvenile Dermatomyositis Are Not Associated with Levels of Von Willebrand Factor Antigen, C4, Duration of Illness, Disease Activity Score, or the Absolute NK Count Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies? Systemic Treatment for Clinically Amyopathic Dermatomyositis Physical Impairment in Patients with Idiopathic Inflammatory Myopathies Is Predicted By the American College of Rheumatology Functional Status Measure Has MRI an Added Value over Serum Creatine Kinase Measurement in Myositis? How Often Are Clinically Amyopathic Dermatomyositis Patients Truly Amyopathic? Osteoarthritis - Clinical Aspects: Therapeutics Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis. a Prospective Randomized Double-Blinded Study Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities Plant Derived Products Are Effective for Treatment of OA Pain and Safer Than Other Active Therapies Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients Exploratory Six Month Phase IIa Study of a Potential Disease Modifying Drug in Patients with OA of the Knee Efficacy of Ketoprofen Lysine Salt in Reducing Inflammation and Pain in Primary Osteoarthritis of the Hand: Preliminary Results of a Retrospective and Prospective Clinical Trial An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee Intermittent Analgesic Use and Risk of Pain Exacerbation in Knee Osteoarthritis: A Web Based Case-Crossover Study Effects of Intraarticular (IA) Corticosteroid Injections on Bone Markers and Endogenous Cortisol in Patients with Knee Osteoarthritis (OA): A Randomized, Double-Blind, Placebo Controlled Trial Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough? Multimedia Patient Education Tool for Patients with Osteoarthritis Characteristics of Conventional Footwear and Their Association with Reductions in Knee Loading with a Flexible Footwear Intervention Reduction of Knee Osteoarthritis Symptoms in a Cohort of Bariatric Surgery Patients Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis Criteria for Clinically Important Worsening in Knee and Hip Osteoarthritis The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort Kneeling Disability Associated with the Treatment of Osteoarthritis: Analysis of a Copcord Study in Mexico Autoimmune Thyroid Disease Is Associated with a Higher Frequency of Spinal Degenerative Disc Disease Program Book

223 ACR POSTER INDICES Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study How Does Non-Compliance to Prolia (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients? WITHDRAWN Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases Continued Zoledronic Acid Use in a Large Healthcare System Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients Changes in Cerebral Blood Flow Velocity in Patients with Familial Mediterranean Fever Symptom and Treatment Characteristics of Juvenile Primary Fibromyalgia Syndrome: Are Males and Females Created Equal? Assessment of Transition Readiness in Adolescents and Young Adults with Rheumatic and Other Chronic Health Conditions Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? : A Preliminary Assessment of a Single Center Experience TNF Inhibitors Provide Long-Term Clinical Benefits in 6 Patients with Early-Onset Sarcoidosis Immunization Status and Barriers in Childhood Rheumatic Diseases Consensus Statement on the Transition Process from Pediatric Care to Adult Care in Patients with Chronic Inflammatory Rheumatic Diseases with Childhood-Onset Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRA) Evidence Based Recommendations for the Management of Cryopyrin Associated Periodic Syndromes (CA) Dissecting the Heterogeneity of Macrophage Activation Syndrome Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD) Steroid-Sparing Effect of Anakinra (Kineret ) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome 2014 Program Book 221

224 ACR POSTER INDICES Joint Involvement in Pediatric Crohn s Disease Is Related to Higher Disease Activity and Worse Quality of Life Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis Cartilage Thickness and Bone Health in Children with Juvenile Idiopathic Arthritis The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis Accuracy of the Use of Administrative Diagnostic Codes to Identify Pediatric in-patient Musculoskeletal Conditions in an African Tertiary Hospital Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis Canakinumab in Biologic-naïve Versus Previously Biologic- Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria - an Analysis of 12-Week Pooled Data Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience The New Proposal Classification Criteria for Juvenile Spondyloarthropaties Classification of Juvenile Spondyloarthropathies According to ASAS Criteria Clinical Observation on Ankylosing Spondylitis Patients with Different Phenotypes Positive HLA-B27 in Juvenile Spondyloarthritis Is Associated to Early Sacroiliitis and Progression to Ankylosing Spondylitis Quality Measures and Quality of Care Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines Cardiovascular Disease Prevention in Rheumatic disease: Assessing Screening in a Primary Care Setting Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines A Novel Approach to Assess Wait-Times to Rheumatologists Improving Access to Health Care in Rheumatology Practices through Initiation of an Outpatient Urgent Care Clinic, a Paradigm Shift Tele-Rheumatology: Despite Improved Access Could There be a Potential Delay in Care without a Skilled Presenter? Use of Physician Extenders to Improve Quality and Efficiency of Clinical Visits Best Practices for Best Practice Alerts: Evaluation of a Best Practice Alert to Detect Chronic Glucocorticoid Use Dexa Testing in Long-Term Steroid Use Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting Adherence to Denosumab in a Large Healthcare System Towards Reliable Implementation and Optimal Use of Medication Decision Aid Cards for Shared Decision Making in Juvenile Idiopathic Arthritis Program Book

225 ACR POSTER INDICES Increasing Rates of Remission in Juvenile Idiopathic Arthritis through a Quality Improvement Learning Network the Pediatric Rheumatology Care and Outcomes Improvement Network Standardizing and Documenting Patient Education and Disease Indices in Childhood-Onset Systemic Lupus Erythematosus Initial Benchmarking of the Quality of Medical Care of Childhood-Onset Systemic Lupus Erythematosus Quality Improvement in the Identification of Crystals from Synovial Fluid: Hospital Laboratory Versus Rheumatology Department Evaluation Aim for Better Gout Control: A Retrospective Analysis of Preventable Hospital Admissions for Gout WITHDRAWN Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It Rehabilitation Sciences (ARHP) A Systematic Review of the Educational Approach of Occupational Therapy for Rheumatoid Arthritis Investigation of Parameters Used to Test Quadriceps Muscle Power Using Isokinetic Dynamometer in Arthritis Delivering ESCAPE-Pain (Enabling Self-Management and Coping of Arthritic Pain through Exercise ) - an Online Guide for Healthcare Professionals The Physical and Psychosocial Effects of Exercise on Chronic Hip and Knee Pain: A Cochrane Review with Meta- Analysis Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry Construct Validity of the Adult Myopathy Assessment Tool in Individuals with Inclusion Body Myositis People s Views, Beliefs and Experiences of Exercise for Chronic Hip and Knee Pain: Cochrane Review with Qualitative Synthesis Use of Wrist Hand Orthoses during Hand Function Skills and Functional Tasks By Adults with and without Rheumatoid Arthritis The Natural Use of Activity Pacing in Daily Life Does Not Result in Lower Symptoms in Osteoarthritis Understanding the Experiences of Rural Community- Dwelling Older Adults in Using a New DVD-Delivered Otago Exercise Programme Research Methodology (ARHP) Reliability and Validity of the Arthritis Helplessness Index in Systemic Sclerosis Evaluating the Use of Video-Stimulated Recall to Research the Osteoarthritis Consultation in Primary Care: Reaching Parts Other Methods don t Reach The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis Cost-Effectiveness and Yield of Different Recruitment Strategies Utilized in an Exercise Trial of Fibromyalgia Patients Rheumatoid Arthritis - Animal Models Detecting Inflammation in Vivo Using Activatable Fluorescence Contrast Agents in Inflammatory Arthritis Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL- 2Rγnull Mice The Combination Therapy of Cell Cycle Regulation Therapy Combined and TNF Blockade Ameliorated the Established Arthritis Redox Regulation of a New Autoimmune Mouse Model, Glucose-6-Phosphate Isomerase Peptide Induced Arthritis in Mice Therapeutic Effects of Mesenchymal Stem Cells, Anti- Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis Amelioration of Collagen-Induced Arthritis By Water- Soluble Fullerene C60(OH)36 Nanoparticles through the Inhibition of Angiogenesis Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis Specific Overexpression of FPR2 (FPRL-1) on Th1 Cells in GPI-Induced Arthritis and Patients with Rheumatoid Arthritis Therapeutic Effect of a Novel Histone Deacetylase 6 Inhibitor, CKD-L, on Collagen Induced Arthritis and Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis 2014 Program Book 223

226 ACR POSTER INDICES Activatory Fc Gamma Receptor IV Plays a Crucial Role in Pathogenesis of Experimental Immune Complex Mediated Chronic Arthritis Early Sympathectomy Inhibits Egress of Lymphocytes in Control and Arthritic Animals and Ameliorates Arthritic Disease A Humanized Monoclonal Antibody Raised Against a Heat Shock Protein Epitope Suppresses Autoimmune Inflammatory Diseases By Skewing the Immune System Selectively Towards an Anti-Inflammatory Response Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen- Induced Arthritis Via P38 MAPK and STAT3 Pathway RORγt Expressing Foxp3+ Regulatory T Cells Regulates the Development of Autoimmune Arthritis in Mice The Nitric Oxide Receptor Soluble Guanylyl Cyclase Is Found in Lymphatic Vessels of Arthritic Mice and Inhibition Alters Lymphatic Pulse Efficacy of a Novel Orally Bioavailable JAK1 Selective Compound in a Preclinical Rat Collagen-Induced Arthritis Model Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes Vascular Adhesion Molecule-1 Overexpression in Collagen-Induced Arthritis: Modeling Vascular Dysfunction in Rheumatoid Arthritis The Role of Dendritic Cells during Inflammatory Arthritis CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146+ Cells for Experimental Arthritis Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model 2014 Program Book Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis PET-CT Imaging of Joints: A Quantitative Tool for Developing Novel Anti-Inflammatory Drugs Rheumatoid Arthritis - Clinical Aspects: Impact of Various Interventions and Therapeutic Approaches Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry Impact of Physicians Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients Should Physician Reduce patients Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics? Safety of Rapid Rituximab Infusion in Rheumatoid Arthritis in a Single Community Practice A Pilot Randomized Controlled Trial of a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 Months Despite Infrequent Use of Biologic Therapies

227 ACR POSTER INDICES Minimal Radiographic Progression in RA Patients Receiving Routine Care in the Espoir Early Arthritis Cohort: Similar Prognosis According to 6 Different Remission Criteria Durability of First Biologic Is Not Influenced By Initial/ Early DAS Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice? Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database Reasons for Non-Vaccination in Rheumatoid Arthritis and Spondyloarthritis Patients Patients Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis Determinants and Impact of Early Initiation of Disease- Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice Anti-Carbamylated Antibodies (anti-carpa) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR) Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor Understanding Patient Preferences Associated with the Use of Therapies for Rheumatoid Arthritis: Results of a Conjoint Analysis Treat to Target in Routine Clinical Practice Improvement of Fatigue in Patients with Rheumatoid Arthritis Treated with Biologics: Relationship with Sleep Disorders, Depression and Clinical Efficacy. a Prospective, Multicenter Study Continued Participation in a 10-Year Tight Control Treatto-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing Their BeSt? Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy? Evaluation of Perceived Self-Efficacy, Learned Helplessness and Functional Capacity in Patients with Rheumatoid Arthritis From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI- Remission during Drug-Free Follow-up RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long- Term Response When Switched to SC MTX Monotherapy Quality of Patient- Clinician Communication in a Diverse Cohort of Adults with Rheumatoid Arthritis Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort 2014 Program Book 225

228 ACR POSTER INDICES Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting Regime of Use of Rituximab in Patients with Rheumatoid Arthritis in Daily Clinical Practice Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non- Interventional Study Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice Is Remission Really Achievable in EARLY Rheumatoid Arthritis? Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review Patient Treatment Goals in Rheumatoid Arthritis: Results of Focus Groups Among Rheumatologists, English and Spanish-Speaking Patients A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration Comparison of Medication Use in Rheumatoid Arthritis Patients Between University and Private Settings Results from Ontario Best Practice Research Initiative Rheumatoid Arthritis Stable Follow up Visits 3 Month Versus 6 Month Intervals Comparison of Patient Self-Reported and Physician Reported Rheumatoid Arthritis Medication Use - Results from the Ontario Best Practices Research Initiative Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database Seasonal Changes May Influence Activity of Rheumatoid Arthritis Clinical Practice/Patent Care (ARHP) Serological and Clinical Characteristics of a Large Collection of Incomplete Lupus Erythematosus Patients Tai Chi and Yoga Are Effective for Improving Physical Function in Adults with Rheumatoid Arthritis- a Meta- Analysis Nutritional Assessment in Patients with Systemic Lupus Erythematosus and Systemic Sclerosis Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Gait Instability in the Elderly: A New Dedicated out- Patients Consultation It s like the Worst Toothache You ve Ever Had How Persons with Rheumatoid Arthritis Describe and Manage Pain in Daily Life Analytical and Clinical Evaluation of an Immunoassay for Estimating Immunogenicity of Infliximab and Etanercept in Indian Population Why Doesn t Participation in Activity Increase Following Hip or Knee Replacement? A Multi-Centre Survey of Tolerability Problems for Patients on Regular Methotrexate Knee Joint Pathology in Patients with Rheumatoid Arthritis and Osteoarthritis Using a Validated Ultrasound Scoring System: A Cross Sectional Study Factors Influencing Health Related Quality of Life (HR- QOL) for Korean Patients with Rheumatoid Arthritis Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians Program Book

229 ACR POSTER INDICES A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis Pharmacist-Developed Letters May Enhance Success in Obtaining Insurer Approval for Off-Label Use of Biologics Rheumatoid Arthritis - Human Etiology and Pathogenesis A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro DNA Methylation Profiles That Distinguish Rheumatoid Arthritis from Osteoarthritis in Fibroblast-like Synoviocytes Can be Detected in Immune Cells from Peripheral Blood The Role of TET3-Mediated DNA Demethylation By Pro- Inflammatory Cytokines in Rheumatoid Arthritis DNA Methylation Analysis of Lymph Node Stromal Cells of Rheumatoid Arthritis Patients Microrna-346 Regulation of Follicular Helper T Cells Is Involved in the Pathogenesis of rheumatoid Arthritis Disease Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis Protective Effect of the IL33 rs Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis High-Density Genotyping of Risk Loci in African Americans with RA Genetic Influences on Rheumatoid Arthritis in African- Americans IL-6 Proximal Promoter SNP rs Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4+ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway Cyclic Phosphatidic Acid (cpa) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α Increased Risk of Rheumatoid Arthritis (RA) Among Shared Epitope-Negative (SE-) Mothers with Shared Epitope-Positive (SE+) Children Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis Effectiveness and Safety of Tocilizumab in Biologics Naïve RA Patients - Interim Analysis of S for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naïve RA Patients Study Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area 2014 Program Book 227

230 ACR POSTER INDICES Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study WITHDRAWN Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDs in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working- Aged Early Rheumatoid Arthritis Patients Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis Relationship Between Different Clinical Measurements and Patient-Reported Outcomes Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR) Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real- World Study Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada Correlation Between Time to Switch and Clinical Response Amplitude to Rituximab in Second Line Treatment in Rheumatoid Arthritis Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate Program Book

231 ACR POSTER INDICES Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret )? Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA) Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview Serum Survivin in Early Rheumatoid Arthritis Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors? Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF? Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis Results from an International European Collaboration Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components Evolution over Time The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors 2014 Program Book 229

232 ACR POSTER INDICES Sjögren s Syndrome: Clinical Science Risk of Venous Thromboembolism in Patients with Sjögren s Syndrome: A Systematic Review and Meta- Analysis Characteristics of Primary Sjögren Syndrome in the Black Population of Martinique Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting Ocular Surface Temperature in Early Sjögren s Syndrome and Established Disease Performance of the Ocular Staining Score (OSS) Vs. the Van Bijsterveld Score in the Assessment of Sjögren s Syndrome-Related Keratoconjunctivitis Sicca The Sjögren s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjögren s Syndrome Patients: A Meta- Analysis Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren s Syndrome Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis Sjö, an Advanced Diagnostic Panel for Detection of Sjögren s Syndrome Autoantibodies Autoantibodies in Pediatric Sjögren s Patients La Positive, Ro60 Negative Subset of Primary Sjögren s Syndrome Is a Reality Anti-Ro/SSA Positive Incomplete Sjögren s Syndrome How Does a Younger Age at the Onset of Sjögren s Syndrome (pss) Influence the Clinical Presentation and the Clinical Course of the Disease? Risk of Cervical Root and Incisal Caries in Patients with Sjögren s Syndrome Metabolic Disorders Causing Fatigue in Sjögren s Syndrome The Impact of Primary Sjögren s Syndrome on Female Sexual Function Primary Sjögren s Syndrome Is Associated with Significant Cognitive Dysfunction Renal Involvement in Primary Sjögren s Syndrome: A Multicenter French Study of 95 Biopsy Proven Cases Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren s Syndrome Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjögren s Syndrome Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren s Syndrome (pss) with Articular Involvement Results of a Pilot Study Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort The Effect of Co-Medication with Conventional Synthetic (cs)dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS) Analysis from the Czech Biologics Registry At Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician s Diagnosic Confidence? Results from the DESIR Cohort Are We over-treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis Program Book

233 ACR POSTER INDICES The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of TNF-α- Blockade Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index Recognition of Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling Do Patients with Axial Spondyloarthritis (AxSpA) Perform Enough Physical Activity? a Cross-Sectional Study of 207 Patients Validation of the RAPID-3 Questionnaire in a Cohort of Patients with Axial Spondyloarthritis Diffusing Weight Magnetic Resonance Imaging May Suggest the Treatment Strategy in Ankylosing Spondylitis The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? an Analysis in the DESIR Cohort A Comparison of Baseline Characteristics and Real-Life Effectiveness of Anti-TNF Therapy in Non-Radiographic Axial Spondyloarthritis Versus Ankylosing Spondylitis a Single Center Cohort Study Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint Serum Levels of Bone Morphogenetic Protein-7 and Sclerostin Are Elevated in Ankylosing Spondylitis, but Not Linked with Structural Damage Unexpected High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of Sacroiliitis on Magnetic Resonance Imaging (MRI)? Results from the Esperanza Cohort Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of HLA-B27? Results from the Esperanza Cohort EULAR Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice Comparison of Radiographic Damage Score in Ankylosing Spondylitis According to Tumor Necrosis Factor Inhibitor: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) Data Effects of Self-Management Model on the Disease-Related Knowledge, Joint Function and Quality of Life in Patients with Ankylosing Spondylitis 2014 Program Book 231

234 ACR POSTER INDICES Assessment of Spondyloarthritis International Society Endorsed Recommendations for Early Referral of Patients Suspected for Axial Spondyloarthritis Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment Using Iphone Compass Application for the Assessment of Cervical Rotation in Patients with Ankylosing Spondylitis Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort Impact of Repeating Imaging of the Sacro-Iliac Joints over One Year on the Classification According the ASAS Axial Spa Criteria of Patients Disease Characteristics Associated with the Presence of Dactylitis in Patients with EARLY Spondyloarthritis: Results from Esperenza Cohort Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab Prevalence of Subclinical Atherosclerosis in Patients with Spondyloarthritis without Clinically Evident Cardiovascular Disease Using Carotid Intima-Media Thickness Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort Profiling Ankylosing Spondylitis Patients Likely to Respond to NSAID Treatment How to Classify Spondyloarthritis after a Two Year Follow up? Results from the French Recent onset spondyloarthritis Cohort Fatigue in Ankylosing Spondylitis: A Multivariable Analysis Implicates Inflammation As the Key Determinant of Disability Do You Assess Gastro-Intestinal Auto-Antibodies and Symptoms in Patients with Spondyloarthritis? Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents The Role of IL-20 in the Pathogenesis of Ankylosing Spondylitis with Peripheral Joint Involvement Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry Different Performance of the Major Disease Activity Measures ASDAS and Basdai in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti- Inflammatory Agents Results from a Prospective Study Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis Reliability of Electronic Patient Self-Assessment of Swollen and Tender Joints in Psoriatic Arthritis: A Comparison Study with B-Mode Ultrasonography, Physician and Nurse Assessments Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis Comparison of Characteristics of Ankylosing Spondylitis in Association with Familial Mediterranean Fever with Those of Typical Ankylosing Spondylitis No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women s Health, Cardiovascular and CNS Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Program Book

235 ACR POSTER INDICES Systemic LUPUS Erythematosus in Spanish Males Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features Relationship of Socio-Demographic and Disease Factors with Loss-to-Follow-up and Appointment Noncompliance in Indigent Patients with Systemic Lupus Erythematosus Comparison of Disease Characteristics and Organ Damage in Patients with Juvenile and Adult-Onset Systemic Lupus Erythematosus in Large Cohort from Turkey Risk of Cancer Is Not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study Childhood-Onset and Adult-Onset Systemic Lupus Erythematosus: Distinctions in an Underserved Ethnic Minority Cohort An Evaluation of Quality of Life of Patients with Systemic Lupus Erythematosus Attending Rheumatology Clinic in Kenyatta National Hospital, Nairobi, Kenya Overall Cause and Cause-Specific Mortality in a Multinational Inception Cohort of SLE The Cornerstone to Reasonable Allocation of Health Resource: Valuation of Health Utility in Systemic Lupus Erythematosus Factors Associated with Damage Accrual and Survival in Chinese Patients with Systemic Lupus Erythematosus (SLE): A Prospective Cohort Analysis of 747 Patients A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months Noncalcified Plaque Progression in Systemic Lupus Erythematosus Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE) Assessment of Plaque Thickness and Area in Patients with SLE As Measures of Atherosclerosis - Associations with Disease Activity The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients Cardiac Magnetic Resonance Imaging in Systemic Lupus Erythematosus Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case- Control Study Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience Mood Disorders in Systemic Lupus Erythematousus (SLE): Results from an International, Inception Cohort Study Predictors of Incident Seizure in Systemic Lupus Erythematosus Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus Point of Care Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NLE) Cognitive Impairment in SLE and Non-Criterion Anti- Phospholipid Antibodies Predictors of Therapeutic Outcomes in Patients with Neuropsychiatric Systemic Lupus Erythematosus Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies Clinical Features in Patients with Anti-Triosephosphate Isomerase Antibody-Positive Neuropsychiatric Systemic Lupus Erythematosus Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study Cerebral Small Vessel Disease in Systemic Lupus Erythematosus: Histopathological Study The Burden of Neuropsychiatric Symptoms in Systemic Lupus Erythematosus: Physician s and Patient s Perspectives 2014 Program Book 233

236 ACR POSTER INDICES Brain Gray and White Matter Volume Losses and Their Associations with Glucocorticoid Use in Patients with Newly Diagnosed Systemic Lupus Erythematosus (SLE) a Prospective MR Study Cognitive Symptoms and Associated Disease and Non- Disease Related Factors in Patients with Systemic Lupus Erythematosus : A Longitudinal Study Neurofilament H Is Associated with White Matter Lesions in Childhood-Onset Systemic Lupus Erythematosus Metabolic Syndrome Features Can Influenciate Cognitive Functions and Brain Lesions in Childhood-Onset Systemic Lupus Erythematosus Serum Neuronal Biomarkers and Brain Atrophy in Childhood-Onset Systemic Lupus Erythematosus Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus Increased Risk of Hematological Malignancies in Children Born to Women with SLE Risk of Hydrocephalus and/or Macrocephaly in Children Born to Mothers with SLE Causes of Stillbirths in Women with SLE First-Trimester Disease Activity Does Not Predict Pre- Eclampsia in SLE Pregnancy Maternal Clinical Characteristics of SLE and Pregnancy: Hopkins Lupus Pregnancy Cohort Systemic Lupus Erythematosus and Lactation: Factors Affecting Infant Feeding Choices in Women with SLE Premature Delivery in Patients with Systemic Lupus Erythematosus Impact of Glucocorticoid Dose on Maternal and Fetal Outcomes in Lupus Pregnancies Characteristics of the Reproductive System in Systemic Lupus Erythematosus: A Cross-Sectional Survey with Pair- Matched Controls Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants High-Throughput Sequencing of 219 Candidate Genes for Identification of SLE-Associated Risk Variants 2014 Program Book The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4+ T Cells from SLE The Selective Loss of SLAMF4+ CD8+ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27kip1 in Patients with Systemic Lupus Erythematosus Decreased Levels of SRSF1 (Serin/Arginine-Rich Splicing Factor1) Induced Lower Levels of RasGRP1 in T Cells from Patients with Systemic Lupus Erythematosus UC-MSCs Inhibit T Cell Autophagy and Apoptosis in Patients with Systemic Lupus Erythematosus through Mitochondrial Transfer Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus DNA Hydroxymethylation Changes in CD4+T Cells from Patients with Systemic Lupus Erythematosus Activated SLE-T Cells Enhance the Interferon-Alpha Production By Plasmacytoid Dendritic Cells Stimulated By RNA-IC Serine Arginine-Rich Splicing Factor 1 (SRSF1) Regulates Transcriptional Activation of the T Cell Receptor CD3 Zeta Chain in Human T Cells The Discovery of Novel Splicing Variants of Neurogranin and Their Role in the Pathogenesis of Systemic Lupus Erythematosus Association of Adam33 Polymorphisms with Systemic Lupus Erythematosus Ten-Eleven Translocation 2 Protein Down-Regulates DNA Methylation of Interleukin-17A Promoter and Induces Its Expression in CD4+t Cells of Patients with Systemic Lupus Erythematosus Gene Array Analysis Reveals Unique Estrogen Signature in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus Estrogen-Mediated STAT1 Activation By Estrogen Receptor a Induces TLR8 Expression: A Novel Pathogenic Mechanism in Systemic Lupus Erythematosus Comparison of Systemic Lupus Erythematosus and Healthy Anti-Nuclear Antibody Positive African-Americans Reveals Distinct Differences in T Cell and Progenitor Populations The CUL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus

237 ACR POSTER INDICES Autoregulatory Function of IL-10 Producing Pre-Naïve B Cells Is Defective in Systemic Lupus Erythematosus A Novel CD123-CD11c- Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus Up-Regulated Expression of CXCR4 on Circulating B Cells in Patients with Systemic Lupus Erythematosus Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients B Lymphocyte Stimulator (BLyS) Promotes Dysregulated Monocyte Function in Systemic Lupus Erythematosus(SLE) Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab Relationship Between Soluble scd23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts Clinical Phenotype of Systemic Sclerosis Patients with Anti-RNA Polymerase III Antibodies: A New French Cohort, Systematic Review and Meta-Analysis Relevance of the 6-Minute Walking Test in Assessing the Severity and Outcome of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Extensive Interstitial Lung Disease Key Roles for Mir-155 and Mir-21 in Progressive Lung Fibrosis Associated with Systemic Sclerosis (SSc-ILD) Elevated Serum Levels of Endostatin in Mixed Connective Tissue Disease - Association with Pulmonary Fibrosis and Digital Ulcers Fatigue in Systemic Sclerosis Reduction of Cerebral and Corpus Callosum Volume in Systemic Sclerosis. a Volumetric Magnetic Resonance Imaging Study Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn Post-Occlusive Reactive Hyperemia (PORH) Test Mirrors Vascular Changes in Systemic Sclerosis (SSc):a Laser Speckle Contrast (LASCA) Study Could a Fibroblast-Free Environment Protect the Microcirculation in Systemic Sclerosis? Evidence from Retinal Vascular Imaging Research The New ACR-EULAR 2013 Systemic Sclerosis Classification Criteria Show Good Performance in a Capillaroscopy Clinic Joint and Tendon Involvement Predict Severe Disease Progression in Systemic Sclerosis: A Prospective Study Nailfold Videocapillaroscopy in Healthy Children and Adolescents: Description of Patterns of Normality The Relationship of Patient Reported Skin Symptoms to the Scleroderma HAQ, the Modified Rodnan Skin Score and Skin Pathology Application of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis in Korean Patients with Raynaud Phenomenon Reliability and Validity of the Duruöz Hand Index in an Argentinian Population with Scleroderma Development of a Renal Crisis Prevention Card As an Educational Tool Aimed at Improving Outcomes in High- Risk Patients with Systemic Sclerosis Comparison of PROMIS survey Between Scleroderma Patients in an Academic Center and Patient-Based Scleroderma Foundations The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis Performance of the New ACR Criteria in Systemic Sclerosis: A Multicenter Study Prevalence and Features of Metabolic Syndrome in Systemic Sclerosis Patients Perspective of Skin Involvement in Systemic Sclerosis T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity Rapamycin Corrects GATA-3 Deficiency in Lupus Treg Programmed Death 1 Inhibits T-Cell Adhesion By Regulating Rap Ulnar and Radial Stenosis in Systemic Sclerosis 2014 Program Book 235

238 ACR POSTER INDICES Deficiency of Ro52/TRIM21 in Different Subsets of Peripheral Blood Mononuclear Cells from Patients with Inflammatory Myopathies Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren s Syndrome Patients CD28null T Cells from Polymyositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Via Perforin- Dependent Mechanisms T Cells Trigger Interstitial Pneumonia in Polymyositis Reduction of MAIT Cell Frequency Associated with Reduced Cell Proliferation and Enhanced Cell Death in Systemic Lupus Erythematosus To Live or Let Die... the Battle Between PD-1 and OX40 on SLE T Cells FcγRIIIa Ligation in Human Peripheral CD4+ T-Cells Generate TH17 like Population Th1 and Th17 Cytokines Drive Takayasu Arteritis Inflammation Massive Ex Vivo Expansion of Functionally Stable Behcet s Patient-Derived Regulatory T Cell Clones Decreased CXCR3+CCR4-CCR6+ CD4+ Effector Memory T Cells in Patients with Granulomatosis with Polyangiitis B55β Regulates T Cell Survival through the Modulation of AKT during Cytokine Deprivation Association of a-kinase Anchoring Protein-79 (AKAP79) to PKC Mediates Inhibition of IL2 Transcription and Erk Activation in T Cells Female Specific Increase in T Cell Glycosylation in Lupus Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis SHP-1 Regulates the Activation Threshold of inkt Cells Microbiota Modulate Intraepithelial Lymphocyte Presence and Function The Role of Fli1 in Lupus T Cell Function and Nephritis Polymorphisms in the Slam Family of Molecules Play a Role in the Development and Function of Invariant Natural Killer T Cells in New Zealand Black Mice Vasculitis Mi-RNA Profile of Active Vascular BEHÇET S Patients Plasma of Patients with Active Behçet s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors The Importance of the Serum Visfatin Levels in Behcet s Disease Patients Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis Microparticles May Play a Role in Causing Thrombosis in Behçet s Syndrome and Act As a Biomarker for Risk Management The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet s Syndrome Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet s Disease with Vascular Involvement F-FDG PET/CT in Vascular Disease Due to Behçet s Syndrome Budd-Chiari Syndrome Due to Behçet s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome Reduced Heart Rate Variability in Patients with Behcet s Disease Predictors of Quality of Life in Behçet s Syndrome Disease Activity and Quality of Life in BEHÇET S Disease: The Role of Patients Reportedoutcomes Treatment of Mucocutaneous Manifestations in Behçet s Disease with Anakinra: A Pilot Open-Label Study Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet s Disease Anti-TNF Treatment for Refractory Vascular Involvement of Behçet s Syndrome Interferon Alfa-Associated Depression in Patients with Behçet s Syndrome Increased Risk of Parenchymal Neurological Involvement in Behcet s Syndrome Patients with Panuveitis CD27 Is a Key Regulator of T Cell Responses 2014 Program Book

239 ACR POSTER INDICES Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet s Disease Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet s Disease S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (R) Using Omeract Filter Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study Polymyalgia Rheumatica Relapse and Silence Large Vessel Vasculitis. Is There Any Association? PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta- Analysis Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica Why Leg Ulcers Do Not Heal? a Prospective Study Showing High Proportion of Small Vessel Vasculitis Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome Systemic Inflammatory and Autoimmune Manifestations Associated with Myelodysplastic Syndrome: A French Multicenter Retrospective Study Effectiveness of a Sequential Treatment with Intravenous Prostaglandins Followed By Bosentan in Patients with Buerger Disease and Severe Ischemic Lesions: A Case Series 2014 Program Book 237

240 INNOVATION THEATER These non-cme accredited presentations have been planned and will be implemented with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A Each of the following Innovation Theater presentations will be held in Exhibit Hall A (Booth #139). 10:30-11:15 am Sunday, NOVEMBER 16, 2014 Transforming Infusion Therapy in the U.S. Healthcare System Presented by Janssen Biotech, Inc. 12:30-1:15 pm First in a New Class of JAK Inhibitors for the Treatment of Moderate to Severe Rheumatoid Arthritis Presented by Pfizer, Inc. 2:30-3:15 pm Otezla (apremilast) for the Treatment of Adults With Active Psoriatic Arthritis Presented by Celgene Corporation Innovation Theater B Each of the following Innovation Theater presentations will be held in Exhibit Hall A (Booth #1401). Sunday, NOVEMBER 16, :30 am - 12:15 pm The Role of IL-6 in Rheumatoid Arthritis: What Have We Learned So far? Presented by Regeneron Pharmaceuticals 1:30-2:15 pm When Is the Right Time for ORENCIA (abatacept)? Presented by Bristol-Myers Squibb 3:30-4:15 pm 2014 Update: Examining the Treatment Paradigm in RA Presented by Medac Pharma, Inc. Monday, NOVEMBER 17, :30-11:15 am Rituxan (rituximab) for the Treatment of Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) with Updated Data for GPA/MPA Presented by Genentech, a Member of the Roche Group 12:30-1:15 pm Serious Infections in Moderately to Severely Active Rheumatoid Arthritis: Hepatitis B Reactivation Presented by Amgen, Inc. 2:30-3:15 pm The Uric Acid Journey: From Purine to Crystal Presented by AstraZeneca Monday, NOVEMBER 17, :30 am - 12:15 pm Vectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis? Presented by Crescendo Bioscience, Inc. 1:30-2:15 pm Rheumatologists Perspectives on the Diagnosis and Treatment of CA and SJIA Presented by Novartis Pharmaceuticals 3:30-4:15 pm The New Era of Biologic Therapy in Rheumatology Presented by Celltrion Healthcare Co., LTD. Tuesday, NOVEMBER 18, :30-11:15 am Understanding the Role of the IL-17 Receptor and Cytokines in Psoriatic Arthritis Presented by Amgen, Inc. 12:15-1:00 pm Demystifying Biosimilars in Rheumatology Presented by Pfizer, Inc. Tuesday, NOVEMBER 18, :30-12:15 am Serum η: Novel Mechanistic Biomarker Enables a More Accurate and Earlier Diagnosis of RA Presented by Quest Diagnostics 1:30-2:15 pm Advancing the Science of Analgensia With SoluMatrix NSAIDs SoluMatrix is a trademark of iceutica Pty Ltd and is licensed to Iroko. Presented by Iroko Pharmaceuticals, LLC Program Book

241 INDUSTRY-SUPPORTED SYMPOSIA Sunday, NOVEMBER 16, :30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Practical Considerations for Treating Patients With XELJANZ (tofacitinib citrate) Developed and offered by Pfizer, Inc. Seaport Hotel, Plaza Ballroom Learning Objectives Upon completion of this activity, participants should be able to: Provide practical guidance regarding the use of XELJANZ in clinical practice through a series of case-based presentations and panel discussion among rheumatologists 6:30 pm 6:35 pm Introduction and Welcome Andrew Koenig, DO, FACR, Immunology Lead, US Medical Affairs, Pfizer, Inc. 6:35 pm 7:35 pm Case Presentations Case Study 1 MTX-IR Patient, XELJANZ Monotherapy Alvin Wells, MD, PhD, Rheumatology & Immunotherapy Center, Oak Creek, WI Case Study 2 MTX-IR Patient, XELJANZ Combination Therapy R. Elaine Lambert, MD, Stanford University School of Medicine, Stanford, CA 7:35 pm 7:40 pm Summary and Wrap Up Andrew Koenig, DO, FACR, Immunology Lead, US Medical Affairs, Pfizer, Inc. 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. The IL-17 Receptor and Cytokine Axis: New Insights Into the Pathogenesis of Psoriatic Arthritis Developed and offered by Amgen, Inc. Renaissance Boston Waterfront, Pacific Grand Ballroom Learning Objectives Upon completion of this activity, participants should be able to: Understand the impact of psoriatic arthritis, including a review of the disease and related comorbidities Examine the unmet medical need for patients who may not meet the therapeutic goals with current treatment options Discuss new research highlighting the role of the IL-17 pathway in the pathogenesis of psoriatic arthritis 6:30 7:00 pm Registration and Dinner 7:00 7:10 pm Chairman s Welcome Iain B. McInnes, PhD, FRCP, FRSE, Institute of Infection, Immunity, and Inflammation, University of Glasgow Biomedical Research Centre, Glasgow, Scotland 7:10 7:30 pm The Systemic Impact of Psoriatic Arthritis Alice B. Gottlieb, MD, PhD, Tufts Medical Center Boston, Massachusetts 7:30 7:50 pm The Current Unmet Medical Need Among Psoriatic Arthritis Patients Arthur F. Kavanaugh, MD, University of California, San Diego School of Medicine, San Diego, California 7:50 8:15 pm The Importance of the IL-17 Receptor and Cytokine Pathway in the Pathogenesis of Psoriatic Arthritis Christopher T. Ritchlin, MD, MPH, University of Rochester Medical Center Rochester, New York 8:15 8:30 pm Question and Answer All Faculty 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Otezla (apremilast): Redefining Management of Psoriatic Arthritis Developed and offered by Celgene Corporation Westin Waterfront, Harbor Ballroom 1 3 Learning Objectives Upon completion of this activity, participants should be able to: Understand the pathophysiology and mechanism of the disease of psoriatic arthritis Review the efficacy and safety for a new oral treatment option for adults with active psoriatic arthritis Understand the patient types appropriate for treatment with Otezla (apremilast) 6:30 7:00 pm Registration and Dinner 7:00 7:05 pm Introduction and Program Objectives Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 7:05 7:15 pm Unmet Needs in Psoriatic Arthritis Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 2014 Program Book 239

242 INDUSTRY-SUPPORTED SYMPOSIA 240 7:15 8:00 pm Overview of Otezla Martin Bergman, MD, Arthritis and Rheumatology, Ridley Park, PA 8:00 8:10 pm Case Study Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 8:10 8:30 pm Question and Answer Session Martin Bergman, MD, Arthritis and Rheumatology, Ridley Park, PA Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. The Future of Spondyloarthritis: Understanding a Challenging Group of Diseases Developed and offered by AbbVie, Inc. Westin Waterfront, Grand Ballroom A E Needs Assessment Statement There have been numerous advances in the field of psoriatic arthritis including updated criteria, characterization of the burden of disease, new treatment options and more. This will provide the US rheumatologist with a consolidated update on the latest evidence in these areas. Learning Objectives Upon completion of this activity, participants should be able to: Evaluate Treat to Target in the Management of Spondyloarthritis Assess the True Prevalence of Spondyloarthritis Address the Complexity of Managing Psoriatic Arthritis-Treating the skin vs treating the Joints 6:30 7:15 pm Registration and Dinner 7:15 7:20 pm Welcome and Introductions John J. Cush, MD, Baylor University Medical Center, Dallas, TX 7:20 7:40 pm Topic 1: In PsA: What Takes Priority, the Skin or the Joints? Eric M. Ruderman, MD, Feinberg School of Medicine, Chicago, IL Ken Gordon, MD, Feinberg School of Medicine, Chicago, IL 7:40 7:55 pm Panel Discussion All Faculty 7:55 8:05 pm Topic 2: Targeting Spondyloarthritis Sergio Schwartzman, MD, Weill Medical College of Cornell University, New York, NY 8:05 8:20 pm Panel Discussion All Faculty 2014 Program Book 8:20 8:30 pm Topic 3: The Prevalence of Spondyloarthritis Atul A. Deodhar, MD, MRCP, FACP, FACR, Oregon Health & Science University, Portland, OR 8:30 8:45 pm Panel Discussion All Faculty 8:45 8:50 pm Postprogram Evaluation 8:50 9:15 pm Dessert Reception Tuesday, NOVEMBER 18, :30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Chronic Rheumatologic Disorders in the Age of Treat-to-Target (T2T) Strategies: Why? How? Developed and offered by Eli Lilly & Company Westin Waterfront, Harbor Ballroom 1 3 Needs Assessment Statement The T2T approach has gained recognition as an indispensable strategy for the prevention of several ubiquitous, prevalent diseases associated with very significant morbidity and mortality: diabetes, arterial hypertension and coronary heart disease. While heterogeneity of therapeutic aims and patient expectations characterize daily practice in the treatment of chronic rheumatologic disorders, a growing body of evidence supports the benefits of treating these disorders strategically. This strategic approach entails treating according to defined outcome targets by adopting therapeutic changes within distinct timeframes, and ideally following therapeutic algorithms. Learning Objectives Discuss the rationale for the T2T approach: Evidence from other chronic diseases Assess the clinical issues and barriers in the practical implementation of T2T in RA Examine the emerging T2T paradigm in SLE and critically assess similarities and differences between the RA and SLE algorithms Explore the pros and cons of personalized T2T in RA and SLE 6:30 7:00 pm Registration and Dinner 7:00 7:10 pm Welcome and Introductions Susan Manzi, MD, MPH, Lupus Center of Excellence, Pittsburgh, PA 7:10 7:30 pm Treat-to-Target: What It Is and Why It Is a Good Idea Joanne M. Foody, MD, Brigham and Women s Hospital, Boston, MA

243 INDUSTRY-SUPPORTED SYMPOSIA 7:30 7:50 pm Treat-to-Target for RA: Outcomes-based Treatment Approach Edward C. Keystone, MD, FRCP(C), University of Toronto, Canada 7:50 8:10 pm Treat-to-Target for SLE: The Emerging Paradigm Professor Ronald van Vollenhoven, Sweden 8:10 8:30 pm Treat-to-Target for RA/SLE: Charting the Road Ahead All faculty 8:30 8:40 pm Question and Answer All faculty 8:40 8:45 pm Concluding Remarks Susan Manzi, MD, MPH, Lupus Center of Excellence, Pittsburgh, PA 6:30 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. The Master Clinician s Approach: Diagnosis and Management of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Supported by an educational grant from UCB, Inc. Sponsored by Cleveland Clinic Westin Waterfront, Grand Ballroom A & B Physician (ACCME) Accreditation Statement The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit. Needs Assessment Statement In the United States, rheumatic diseases are one of the most prevalent chronic conditions, diagnosed in more than 1% of adults (1.3 million).1 Research into the pathogenesis, diagnosis, and management of rheumatic diseases, specifically rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondyloarthritis (AS), has produced important findings in terms of therapeutic outcomes. Given the health care impact of these diseases, education that highlights clinical standards for screening, diagnosis, and management, engages clinicians, and improves the disease identification and treatment has the potential to improve outcomes in this patient population. Learning Objectives Describe the impact of revised guidelines for early recognition and treatment on outcomes in patients with RA, PsA, and AS Recognize psoriatic skin involvement, describe skin scoring systems, and define best practices for dermatology-rheumatology collaborations Summarize the expanding spectrum of AS, including inflammatory back pain and nonradiographic axial spondyloarthropathy Identify the extra-articular variants of AS, especially occult IBD and ocular effects Institute recent evidence-based recommendations on the therapeutic role of biologics, especially emerging data on TNF inhibitors and their use in early and aggressive therapy Critically appraise emerging data on the potential impact of therapies on patient outcomes, and list the patient characteristics that best predict response to therapy 6:30 7:30 pm Registration and Dinner 7:30 7:40 pm Welcome Leonard Calabrese, DO, Cleveland Clinic, Ohio 7:40 8:00 pm Rheumatoid Arthritis New Guidelines for Diagnosis and Management: How Early and Aggressive Should Management Be? Paul Emery, MD, University of Leeds, Leeds, United Kingdom 8:00 pm 8:20 pm Psoriatic Arthritis in the Clinic: Treating to Target and Working with Dermatologists for Patient Centered Care Philip Mease, MD, University of Washington School of Medicine, Seattle, Washington 8:20 8:40 pm Spondyloarthropathy in Practice: From Inflammatory Back Pain to Ankylosing Spondylitis Michael Weisman, MD, Cedars-Sinai Medical Center, Los Angeles, CA 8:40 9:30 pm Challenge the Master Clinicians: Interactive Case-based Panel in RA, PsA, and SpA Moderators: Leonard Calabrese, DO, and M. Elaine Husni, MD, MPH, Cleveland Clinic Faculty: Paul Emery, MD; Philip Mease, MD; and Michael Weisman, MD Virtual Consultants: Brian Feagan, MD; Douglas A. Jabs, MD, MBA; Abrar Qureshi, MD, MPH; and Michael Roizen, MD 6:30 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. So You Think You Know Gout: Fresh Perspectives on Hyperuricemia for Today s Complicated Patients Supported by an educational grant from AstraZeneca. Sponsored by Creative Educational Concepts Renaissance Boston Waterfront Pacific Grand Ballroom A H Physician (ACCME) Accreditation Statement In support of improving patient care, Creative Educational Concepts, Inc. (CECI) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team. Credit Designation Statement CECI designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement With such a long history, it is surprising that gout is often inappropriately managed. It is a more complex disease state than many believe, often presenting in patients with serious comorbidities with the possibility for multiple drug-drug interactions. Adding to these complications is the fact that gout is not a priority in training programs for the majority of healthcare professionals, including rheumatologists. Education outreach programs can bridge this knowledge gap, giving clinicians the knowledge to improve patient outcomes. Clinicians must understand the new insights into gout biology, new treatment options, complicating comorbidities, as well as new recommendation and guidelines, in order to resist the comfort of relying on long-standing therapies, thus bringing gout treatment from ancient history into the new millennium Program Book 241

244 INDUSTRY-SUPPORTED SYMPOSIA 242 Learning Objectives Upon completion of this activity, participants should be able to: Review inadequacies in the traditional treatment of gout while examining how new understandings of the disease process have led to improvements in treatment, especially when dealing with resistance hyperuricemia. Analyze current and emerging pharmacologic treatment options for gout, answering questions about recent changes to traditional therapies and highlighting the potential role for newer agents. Consider the effect of comorbidities on the treatment of gout from the standpoint of drug selection, drug-drug interactions, and contraindications while assessing the impact of hyperuricemia in other disease states, and the necessity of screening gout patients. Discuss the challenges of treating gout patients with renal insufficiency, addressing pharmacologic choices, patient screening, and the role or uric acid in renal disease progression. 6:30 pm 7:00 pm Registration and Buffet Dinner 7:00 pm 7:10 pm Welcome and Introductions/Pre-test Brian F. Mandell, MD, PhD, FACR, MACP (Activity Chair) 7:10 pm 7:30 pm Case 1: I Want To Go Home! Brian F. Mandell, MD, PhD, FACR, MACP 7:30 pm- 8:05 pm Case 2: My Big Toe is Killing Me, but Won t Diabetes or a Heart Attack Really Kill Me? Robert T. Keenan, MD, MPH 8:05 pm- 8:45 pm Case 3: What Does the Gout Pain in My Hands Have To Do With My Kidneys? N. Lawrence Edwards, MD 8:45 pm- 9:00 pm Conversations with the Experts and Q&A/Post-test All Faculty; Moderated by Brian F. Mandell, MD, PhD, FACR, MACP 2014 Program Book Wednesday, November 19, :00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Rheums With Views Workshop: Challenging Conventional Wisdom on Psoriatic Arthritis Care Supported by an educational grant from Celgene Corporation Sponsored by Albert Einstein College of Medicine Westin Waterfront, Commonwealth Ballroom A C Physician (ACCME) Accreditation Statement Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians Credit Designation Statement Albert Einstein College of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits. Each course participant should only claim credits commensurate with the extent of their participation in the activity. Needs Assessment Statement Physicians are not necessarily screening for comorbidities that have related etiologies with psoriatic arthritis (PsA); therefore, patients are not being optimally treated and outcomes often remain poor. This assessment process is compromised by the fact that clinicians do not fully understand the etiologic interrelationship of inflammatory processes of comorbid conditions associated with PsA, nor the inflammatory cascade of events that drive PsA and its severity. Moreover, despite available guidelines to diagnose PsA, many patients are not diagnosed early in the course of the disease and many go undiagnosed. Moreover, the diagnosis of PsA often is missed, partly because patients may present with inflammatory spinal pain, tendonitis, enthesitis, or dactylitis rather than a true arthritis. If PsA is not identified early and managed appropriately, progressive joint damage with deformities and disability may result. Clinicians are also not knowledgeable of nor competent to administer all treatment options available for PsA. Learning Objectives Discuss the spectrum of PsA disease based on clinical presentation, patient reported outcomes and clinical assessment tools Recognize the need for early intervention and implementation of aggressive treatment strategies based on dominant PsA clinical features and classification domains Identify and treat the most common comorbid conditions associated with PsA to ensure optimal patient outcomes Outline the currently approved and emerging treatments for psoriasis and PsA in regards to mechanism of action, safety and efficacy Utilize biologic therapy when appropriate with the goals of minimizing disease progression and improving quality of life 1:00 1:30 pm Buffet Lunch 1:30 1:35 pm Welcome and Introductions Stanley Cohen, MD, Rheumatology Associates, Dallas, TX 1:35 1:50 pm Brief Overview of Psoriatic Arthritis Epidemiology, Including Relation to Plaque Psoriasis, Diagnosis and Classification Criteria Elaine Husni, MD, Cleveland Clinic, Cleveland, OH 1:50 2:05 pm Review of PsA Pathophysiology and Inflammatory Cascade Stanley Cohen, MD, Rheumatology Associates, Dallas, TX 2:05 3:05 pm Case Discussions Case 1: Newly Diagnosed Patient With PsA Case 2: Loss of Response With TNF inhibition Case 3: Worsening Disease With Comorbidities Stanley Cohen, MD, Rheumatology Associates, Dallas, TX Elaine Husni, MD, Cleveland Clinic, Cleveland, OH 3:05 3:15 pm Closing Remarks All Faculty 3:15 3:30 pm Audience Question and Answer All faculty 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Prevention and Management of Infections With Biologic Therapy: Do s, Don ts, and Maybe Supported by an educational grant from Oxford Immunotec Sponsored by CME Outfitters, LLC Westin Waterfront, Harbor Ballroom 1

245 INDUSTRY-SUPPORTED SYMPOSIA Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC, and Jespersen & Associates, LLC. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement CME Outfitters, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement A recent review of international recommendations on the management of latent tuberculosis infection determined that there is a general consensus that evaluation of the global risk of TB infection is a crucial point and that patients with LTBI must receive chemoprophylaxis prior to biologic therapy. 1 The study also concluded the critical point is implementing dissemination and awareness of the recommendations among rheumatologists to improve adherence in real life. 1 Rheumatologists and other healthcare professionals treating patients with rheumatic diseases undergoing biologic therapy need to be educated on the best screening methods for detecting LTBI in rheumatic patients and how to keep their patients safe from developing TB and other infections while receiving biologic therapy. 1. Iannone F, Cantini F, Lapadula G. J Rheumatol Suppl. 2014;91: Learning Objectives Describe the most important opportunistic infections in the setting of biologic and synthetic disease modifying antirheumatic drug (DMARD) therapy. Assess the utility of various screening and prevention algorithms for TB, HBV, and other infections in the setting of biologic therapy. Describe appropriate vaccination strategies and timing for patients using DMARD therapy. Discuss the appropriate clinical management in cases of patients who develop infections during therapy. 1:00 1:15 pm Registration and Lunch Buffet 1:15 1:45 pm Screening and Risk of Opportunistic Infections With Emphasis on HBV and TB Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 1:45 2:15 pm Vaccination To Do or Not To Do, and When Kevin Winthrop, MD, Oregon Health & Science University, Portland, OR 2:15 2:45 pm Co-management of Infections and DMARD Therapies Clinical Conundrums Daniel Furst, MD, David Geffen School of Medicine at UCLA, Westwood, CA 2:45 3:00 pm Panel Discussion All Faculty 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. SPARTAN-GRAPPA-ASAS Educational Symposium on Axial Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) Supported by an educational grant from AbbVie, Inc. Sponsored by Ohio State University Westin Waterfront, Grand Ballroom C, D, E Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Oregon Health & Science University School of Medicine and NW Arthritis & Osteoporosis Institute. The OHSU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Needs Assessment Statement There have been numerous new developments in our understanding of the pathogenesis and approach to management of spondyloarthritides within the last few years. The role of microbiome in the etiopathology of Spondyloarthritis continues to evolve. Basic mechanisms of osteoproliferation and pharmacotherapy to prevent them continue to evolve. New strategy trials on treat to target are being conducted in Spondyloarthritis. These topics need to be informed to attendees. Learning Objectives Discuss the classification criteria for axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) Describe the new understanding in the pathogenesis of axial spondyloarthritis and psoriatic arthritis Develop an evidence based treatment plan for the management of axial spondyloarthritis and psoriatic arthritis 1:00 pm Registration and Lunch 1:00 1:05 pm Welcome and Introductions Philip Mease, MD, Swedish Medical Center/University of Washington 1:05 1:20 pm Pre-test (Quiz using audience response system) Speaker to be Determined 1:20 1:45 pm Role of Gut Microbiome in SpA Pathogenesis Dirk Elewaut, MD, University of Ghent, Belgium 1:45 2:10 pm Year-in-Review in Spondyloarthritis John Reveille, MD, University of Texas Health Science Center Atul Deodhar, MD, Oregon Health & Science University 2:10 2:35 pm Treat-to-target Concept for SpA Philip Helliwell, MD, University of Leeds, UK 2:35 3:00 pm Osteoporosis and Osteoproliferation in AxSpA: Pathology, Prevention and Treatment Lianne Gensler, University of San Francisco 3:00 3:15 pm Post-Test (Quiz using audience response system) Speaker to be Determined 3:15 4:00 pm Break-out Session Hands-On Assessment of Axial SpA and PsA: Axial SpA and PsA Physical Exam: Spine, Enthesitis, Skin & Nails Speakers to be Determined 2014 Program Book 243

246 INDUSTRY-SUPPORTED SYMPOSIA 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Multicenter Osteoarthritis Intervention Study With Sysadoa (MOVES): An International, Double-blind, Randomized Trial Comparing Combined Chondroitin Sulfate and Glucosamine Versus Celecoxib Supported by an educational grant from Bioiberica, S.A. Sponsored by Medical Education Resources Westin Waterfront, Burroughs Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement MER designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the educational activity. Needs Assessment Statement Knee osteoarthritis (OA) is a major cause of pain and functional restriction in older adults. Effective treatment of OA must focus on addressing all aspects of pathophysiology, including identification, prevention and treatment of joint cartilage, synovial membrane and subchondral bone injuries. Current data suggest the use of combined chondroitin sulfate and glucosamine may provide disease-modifying benefits and an option that may prevent knee OA progression. Combined chondroitin sulfate and glucosamine may result in improved quality of life for patients with OA, as well as significantly reduced costs of this disease to society. This program will investigate the mechanism of action of combined chondroitin sulfate and glucosamine, as well as current data and outcomes from the MOVES [multicenter OA intervention study with symptomatic slow acting drugs for OA (SYSADOA)] clinical trial. Learning Objectives Evaluate the synergistic mechanism of action of combined chondroitin sulfate and glucosamine Appraise current clinical data and outcomes concerning combined chondroitin sulfate and glucosamine in osteoarthritis Assess safety considerations from relevant clinical trials Examine the relationship between meniscal extrusion, knee cartilage, and subchondral bone 1:20 1:25 pm Welcome and Introduction Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD, United States 1:25 1:40 pm Mechanisms of Action and Synergic Activity of Combined Chondroitin Sulfate and Glucosamine Patrick du Souich, MD, PhD, University of Montreal, Montreal, Quebec, Canada 1:40 1:55 pm MOVES Rationale, Protocol and Study Design Allen Sawitzke, MD, University of Utah School of Medicine, Salt Lake City, UT 1:55 2:10 pm Effects of Combined Chondroitin Sulfate and Glucosamine vs Celecoxib in Patients With Moderate-to-Severe Knee OA Pain Jean-Pierre Pelletier, MD, University of Montreal, Montreal, Quebec, Canada 2:10 2:25 pm Post-hoc Analyses and Safety Considerations From MOVES Trial Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD 2:25 2:40 pm Impact of Meniscal Extrusion on the Progression of Knee OA Structural Changes: Data From the Osteoarthritis Initiative Progression Cohort. Johanne Martel-Pelletier, PhD, University of Montreal, Montreal, Quebec, Canada 2:40 2:55 pm Question and Answer Session All Faculty 2:55 3:00 pm Concluding Remarks Marc C. Hochberg, MD, MP, University of Maryland School of Medicine, Baltimore, MD 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Psoriasis and Psoriatic Arthritis: Emerging Paradigms and Treatment Options Supported by an educational grant from Celgene Corporation Sponsored by North American Center for Continuing Medical Education, an HMP Communications Holding Company and National Psoriasis Foundation Westin Waterfront, Harbor Ballroom 2 Accreditation North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Credit Designation Statement CME NACCME designates this live activity for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity CNE This continuing nursing education activity awards 2.0 contact hours. Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.0 contact hours. Needs Assessment Statement While rheumatologists rarely treat psoriasis alone, understanding the inflammation cascade is important in determining a treatment plan that aggressively pursues remission goals. Collaboration among dermatologists and rheumatologists is critical to optimize management of psoriasis and psoriatic arthritis. Studies show patients are more likely to receive a systemic medication or biologic agent through a multidisciplinary collaborative care approach. This multidisciplinary care approach may facilitate the earlier diagnosis of joint disease and is shown to offer a more comprehensive treatment approach for patients with both psoriasis and psoriatic arthritis (PsA). Learning Objectives Implement routine assessment of disease status, progression and comorbid conditions using clinical and patient-reported measurement tools Utilize patient engagement and education to improve adherence and develop patient-centric care approaches Program Book

247 INDUSTRY-SUPPORTED SYMPOSIA Develop early intervention, treat-to-remission strategies based on an improved understanding of disease pathophysiology, epidemiology, inflammatory cascade, clinical features, and classification Implement processes to improve co-management and decisionmaking with other providers who care for patients with PsA, psoriasis and other immune mediated inflammatory diseases 1:00 1:30 pm Registration and Lunch 1:30 2:15 pm Implementing Routine Assessment of Disease Status, Progression and Comorbid Conditions Using Clinical and Patient-Reported Measurement Tools Utilizing Patient Engagement and Education to Improve Adherence and Develop Patient-Centric Care Approaches Speaker to be Determined 2:15 3:00 pm Developing Early Intervention, Treat-to-Remission Strategies base on Disease Pathophysiology, Epidemiology, Inflammatory Cascade, Clinical Features, and Classification Processes for Improved Co-Management and Decision-Making with Other Providers Who Care for Patients with PsA, Psoriasis and Other Immune-Mediated Inflammatory Diseases Speaker to be Determined 3:00 3:30 pm Question and Answer Session Luis R. Espinoza, MD, Louisiana State University School of Medicine, New Orleans, LA Joseph F. Merola, MD, MMSc, Brigham and Women s Hospital, Boston, MA 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Sequential Therapy for Established Rheumatoid Arthritis: New Targeted Therapies as Part of an Individualized Approach to Care Supported by an educational grant from Lilly USA, LLC Sponsored by Med Learning Group Westin Waterfront, Harbor Ballroom 3 Learning Objectives Review and interpret the ACR new classification criteria, and updated ACR and EULAR treatment guidelines and the new remission criteria for RA Evaluate different biologic DMARDs-based regimens and small molecule kinase inhibitors for their efficacy and safety in the contest of individual patient treatment plan across several lines of therapy Explain how frequent assessment of disease progression, response monitoring and treatment switching can optimize RA management 1:00 1:30 pm Registration and Buffet Lunch 1:30 1:40 pm Welcome and Introductions Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Birmingham, AL Gregg J. Silverman, MD, NYU School of Medicine, New York, NY 1:40 2:05 pm Rheumatoid Arthritis: Overarching Concepts Treat to Target: Evidence Supporting the Principle Composite Measures of Disease Activity and Assessment New ACR/EULAR Classification Criteria: Review and Implementation in Clinical Ppractice New Definition of Remission Gregg J. Silverman, MD, NYU School of Medicine, New York, NY 2:05 2:30 pm Role of DMARDs-based Regimens in Established Disease Treatment Options After Inadequate Response to Methotrexate (MTX-IR) Superiority Trials and Head-to-Head for Comparing Biologic Agents, and the First Approved TKI 2012 ACR and 2013 EULAR Treatment Guidelines Case Study Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Birmingham, AL 2:30 2:45 pm Conclusions All Faculty 2:45 3:00 pm Questions and Answers All Faculty Physician (ACCME) Accreditation Statement Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity. Needs Assessment Statement In 2010, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) issued new clinical classification criteria for RA with the goal of codifying a strategy to identify patients with early RA and to get them into treatment before joint damage progresses (Aletaha 2010). Several factors were identified that best discriminate patients with a new presentation of undifferentiated inflammatory synovitis who are at high risk of developing persistent and/or erosive disease from those who are not at high risk. The resulting classification of definite RA is based on the (Aletaha 2010). In addition, indices used for monitoring disease activity in clinical trials (e. g. PAS, PASII and DAS28) have been validated and proposed for wider use in clinical practice. They characterize RA according to whether there is low disease activity, moderate disease activity, high disease activity or remission (Singh 2012) Program Book 245

248 CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: The ACR designates this live educational activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. International Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s) must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers and address. The information will be used to verify your meeting attendance. The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit to EACCME credit should contact the UEMS. Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category 1 Credit(s). For non-cme sessions, attendees may also request a certificate of participation. EVALUATIONS, CME CREDIT AND CERTIFICATES Your evaluation of the meeting is very important. The ACR/ ARHP Annual Meeting Planning Committee uses feedback from attendees to assist in the development of future educational activities; therefore, we encourage you to complete your session evaluations. Overall meeting and session evaluations can be completed online at You will be able to and print your CME certificate or certificate of participation. At the on-site Technology Center located in Level 1: North Lobby, computers are available for you to complete overall meeting and session evaluations and claim your hours for a CME Certificate or Certificate of Participation. International physicians requiring a Certificate of Attendance, can find one enclosed in your meeting bag.please complete the session evaluations and CME application online at or at the on-site Technology Center located in Level 1: North Lobby. CLAIMING CME CREDIT You may claim your CME credit at the Technology Center, located on Level 1 in the North Lobby, during or at the end of the meeting for all sessions attended. You may also claim your credit online during and after the meeting at ACRannualmeegting.org. How Do I Claim Credit? It is an AMA requirement that you claim only the EXACT amount of time spent in each educational session. This accurately reflects the extent of your participation in the activity. You may attend sessions for LESS than their entirety and claim partial credit to the nearest quarter hour. Note that you may NOT claim credit hours for attending two full sessions at a given time in their entirety. Therefore, if you inaccurately record your credit hours and exceed the meeting maximum of AMA/PRA Category 1 Credits TM, you will need to correct your claim in order to receive your certificate. Example: You attend half of a 1-hour session and half of another in the same time slot. You must report that you spent.5 hours in the first session and.5 in the second session. If you attempt to claim full credit (1hr) for each of the two sessions, the claim system may over-calculate your CME credit and you may exceed the maximum number of credit hours allowed. In this case you would not be able to receive your certificate. How Do I Claim Credit for Poster Sessions? You may only be awarded CME credit for viewing posters during the 9:00-11:00 AM time slot. It is an AMA requirement that poster presenters must be available to engage learners. You must therefore claim ONLY the credit commensurate with the extent for your participation in the activity during this time slot. You may claim partial credit Program Book

249 CERTIFICATES OF CME CREDIT OR PARTICIPATION CONFLICT OF INTEREST AND DISCLOSURE As an educational provider accredited by the Accreditation Council for Continuing Medical Education, the American College of Rheumatology must ensure balance, independence, objectivity and scientific rigor in all its educational activities. Therefore, all those in a position to control content (e.g., speakers and moderators) participating in an ACR-sponsored activity are required to disclose to the planning committee and audience any financial or other relationships including, but not limited to: None: Nothing to disclose 1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan 2. Research grants 3. Employment (full or part time) 4. Ownership or partnership 5. Consulting fees or other remuneration (payment) 6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson 7. Receipt of royalties 8. Speakers bureau 9. Other Disclosures for invited speakers are listed in the indices by presenters last name. Abstract author disclosures are published online and in a supplement to the October issue of Arthritis & Rheumatology. Disclosures for the late-breaking abstracts are published online and in the December issue of Arthritis & Rheumatology. Any individual who refuses to disclose relevant financial relationships is ineligible to serve as a planning committee member, presenter or author of an ACR CME activity, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. Disclosure Policy It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that all individuals in a position to control content disclose all relevant financial relationships with any commercial interest if the relationship is financial and occurred within the past 12 months. This includes the relationships of spouse/partners. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content. Sunshine Act Compliance at the Annual Meeting The Sunshine Act Under the Physician Payment Sunshine Act (Section 6002 of the Patient Protection and Affordable Care Act), medical device, biologic and drug companies are required to track all payments and transfers of value (TOV) to U.S. physicians. Companies must report any payment or TOV with a minimum value of $10/ payment or cumulatively $100/year or more to the Department of Health & Human Services (HHS) which publicly discloses the information on their Web site. As defined by the Sunshine Act, TOV include, but are not limited to, gifts, food and beverages of a certain nature, entertainment, consulting fees and honoraria. At the Annual Meeting this means companies will be required to track certain items handed out at their exhibit booths at meetings and conventions. As an accredited provider honoraria are exempt from reporting. National Provider Identification Number The National Provider Identifier (NPI) number, a unique identification number assigned to you if you have received payments from the federal government for services you provided to a patient, will be used to record and track these transactions. The ACR requested that you voluntarily provide your NPI number during the registration process. If you do not know your NPI number a searchable registry is available at cms.hhs.gov/nppesregistry/npiregistryhome.do. This number will be transferred to exhibiting companies when your badge is scanned in the exhibit hall or at an industry supported session Program Book 247

250 2014 ACR/ARHP ANNUAL MEETING LEADERSHIP Thank You! The ACR/ARHP Board of Directors extends its gratitude to the ACR/ARHP Annual Meeting Planning Subcommittee, ACR Abstract Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels and ARHP Clinical Focus Task Force members for their leadership and volunteering their services to plan the 2014 Annual Meeting. Their significant contributions and expertise make the Annual Meeting the premier event for specialists in the field of rheumatology. ACR/ARHP Annual Meeting Planning Subcommittee Chester V. Oddis, MD, Chair Richard F. Loeser, MD, Chair Elect Mary Cronin, MD, Clinical Sub-chair Jasvinder Singh, MD, MPH, MTP/Workshop/ Study Group Sub-chair John Varga, MD, Basic Science Sub-chair Mary K. Peggy Crow, MD, Abstract Selection Co-Chair (Basic Science) Eric Matteson, MD, Abstract Selection Co-Chair (Clinical) Afton Hassett, PsyD, ARHP Chair Hazel L. Breland, PhD, OTR/L, ARHP Chair Elect Robert R. McLean, DSc, MPH, ARHP Abstract Selection Chair Shreyasee Amin, MDCM, MP Stacy Ardoin, MD Dana Ascherman, MD Alan N. Baer, MD Thuy T. Beam, RN Elana Bernstein, MD Susan Boackle, MD, Committee on Research Representative Hermine Brunner, MD, MSc, MBA Dominic O. Co, MD, PhD Andrew P. Cope, MD, PhD Betty Diamond, MD N. Lawrence Edwards, MD Judy Fozworth, PhD, PT Mark F. Gourley, MD Rula Hajj-Ali, MD Marian T. Hannan, DSc, MPH, Committee on Journal Publications Representative Jonathan Hausmann, MD, Fellows Subcommittee Representative Simon Helfgott, MD Rennie Howard, MD Laurie Hughell, PA-C, MPH Wael Jarjour, MD Meenakshi Jolly, MD, MS Mariana J. Kaplan, MD Dinesh Khanna, MD, MSc Sharon Kolasinski, MD, Committee on Government Affairs Representative Kristine M. Lohr, MD, MS, Committee on Rheuamtology Training and Workforce Issues Representative Rebecca L. Manno, MD William McClatchey, MD, Committee on Registries and Health Information Technology Representative Sandra J. Mintz, RN, BSN, ARHP Executive Committee Representative Kenneth S. O Rourke, MD Egla Rabinovich, MD, MPH Leonard H. Sigal, MD Gregg J. Silverman, MD, Committee on Research Representative Nora Singer, MD, Committee on Research Representative Chokkalingam Chuck Siva, MD, MS Christine Stamatos, ANP-C George Stojan, MD Kerry Stone, MD Greg Taylor, MSW Rodney Tehrani, MD George C. Tsokos, MD Swamy R. Venuturupalli, MD Douglas W. White, MD, PhD, Committee on Rheumatologic Care Representative Margaret R. Wilkes, MD Ex Officio Members Joel A. Block, MD, Chair, Committee on Education Joseph Flood, MD, ACR President ACR Abstract Oversight Committee Steven R. Ytterberg, MD, Chair C. Ronald MacKenzie, MD Shreyasee Amin, MD Kathleen M. O Neil, MD Emily C. Somers, PhD, ARHP Representative ARHP Clinical Focus Task Force Karen Huisinga, MN, ARNP, Chair Aleksander Feoktistov, MD Scott M. Hasson, EdD, PT Michael J. Jennings, RT, CBDT Amanda F. Sells, PA-C ACR and ARHP Abstract Selection Committees (including category chairs, reviewers and ad hoc reviewers) Mary K. Peggy Crow, MD, Abstract Selection Co-Chair (Basic Science) Eric Matteson, MD, Abstract Selection Co-Chair (Clinical) Jennifer H. Anolik, MD, PhD Alan N. Baer, MD Dominique L. Baeten, MD, PhD Thomas Bardin, MD Cheryl Barnabe, MD Jennifer Barton, MD Michael J. Battistone, MD Thuy T. Beam, BSN, RN Clifton O. Bingham III, MD Bryce A. Binstadt, MD, PhD Arthur A. M. Bookman, MD Chad Boomershine, MD, PhD Hazel L. Breland, PhD Lin A. Brown, MD Hermine Brunner, MD Rachelle Buchbinder, PhD Lenore M. Buckley, MD Gerd Burmester, MD Jill P. Buyon, MD Vivian P. Bykerk, MD Megan E. B. Clowse, MD Philip L. Cohen, MD Philip G. Conaghan, MD, PhD Mary E. Cronin, MD Nicola Dalbeth, MD Maria Dall era, MD Kathryn H. Dao, MD Anne Davidson, MBBS John M. Davis III, MD, MS Atul A. Deodhar, MD N. Lawrence Edwards, MD Keith B. Elkon, MD Polly J. Ferguson, MD Aryeh Fischer, MD John FitzGerald, MD, PhD Oliver FitzGerald, MD Judy Foxworth, PhD Patrick M. Gaffney, MD Gary S. Gilkeson, MD Dafna D. Gladman, MD Mary B. Goldring, PhD Jessica K. Gordon, MD Paulette C. Hahn, MD William F. Harvey, MD Afton L. Hassett, PsyD Merete Lund Hetland, MD, PhD Jay B. Higgs, MD Laurie A. Hughell, PA-C Laura K. Hummers, MD M. Elaine Husni, MD Lisa F. Imundo, MD Robert D. Inman, MD Sindhu R. Johnson, MD, PhD George D. Kalliolias, MD, PhD Diane L. Kamen, MD Insoo Kang, MD Jeffrey N. Katz, MD Arthur Kavanaugh, MD Jonathan Kay, MD Salahuddin Kazi, MD Program Book

251 2014 ACR/ARHP ANNUAL MEETING LEADERSHIP Robert Lafyatis, MD Andrew J. Laster, MD Yvonne C. Lee, MD Roger A. Levy, MD S. Sam Lim, MD Grace H. Lo, MD Richard F. Loeser, MD Grant H. Louie, MD Anne-Marie Malfait, MD, PhD Joseph A. Markenson, MD Ann Marshak-Rothstein, PhD Mehrdad Maz, MD Iain B. McInnes, PhD Philip Mease, MD Kaleb Michaud, PhD Timothy B. Niewold, MD Peter A. Nigrovic, MD Nancy J. Olsen, MD Lauren M. Pachman, MD Stephen A. Paget, MD Harris R. Perlman, PhD Alessandra B. Pernis, MD David S. Pisetsky, MD, PhD Joyce Rauch, PhD Ann M. Reed, MD John D. Reveille, MD Carla R. Scanzello, MD, PhD Gabriela Schmajuk, MD Wolfgang A. Schmidt, MD Thomas J. Schnitzer, MD, PhD Shiva Shahrara, PhD Victoria K. Shanmugam, MBBS, MRCP Nora G. Singer, MD Ram P. Singh, PhD Chokkalingam Siva, MD Robert F. Spiera, MD Christine A. Stamatos, DNP Lisa Suter, MD Gregory Taylor, MSW Filip van Den Bosch, MD, PhD Kenneth J. Warrington, MD Jinoos Yazdany, MD Andrew Zeft, MD Angela Zink, PhD Andy Abril, MD Paul M. Adam, MSW Rohit Aggarwal, MD Daniel Aletaha, MD Yannick Allanore, MD, PhD Kelli D. Allen, PhD Cynthia Aranow, MD Dana P. Ascherman, MD Anca Askanase, MD Shervin Assassi, MD Catherine L. Backman, PhD Nancy A. Baker, ScD Kamil E. Barbour, PhD April Barnado, MD Franck Barrat, PhD Christie M. Bartels, MD Susan J. Bartlett, PhD Mara L Becker, MD Edward M. Behrens, MD Jessica Berman, MD Maria Laura Bertolaccini, MD, PhD Timothy Beukelman, MD Neal S. Birnbaum, MD Susan J. Blalock, PhD Susan A. Boackle, MD Maarten Boers, MD, PhD Francesco Boin, MD Stefano Bombardieri, MD Laurence A. Bradley, PhD Juergen Braun, MD S. Louis Bridges Jr., MD, PhD Mary Brothers, MSN Ewa Cairns, PhD Leigh F. Callahan, PhD Liron Caplan, MD, PhD Roberto Caricchio, MD John D. Carter, MD Flavia V. Castelino, MD Isabel Castrejón, MD, PhD Eliza Chakravarty, MD Vinod Chandran, MD, PhD Julia F. Charles, MD, PhD W. Winn Chatham, MD Di Chen, MD, PhD Hyon Choi, MD, PhD Mary E. Christenson, PhD Cecilia P. Chung, MD Maria C. Cid, MD. PhD Michal Cidon, MD Marcus R. Clark, MD Daniel O. Clegg, MD Dominic Co, MD, PhD Stanley B. Cohen, MD Maripat Corr, MD Mary-Beth Coty, PhD, RN Talitha Cox, OTR/L Joseph E. Craft, MD Lindsey A. Criswell, MD Bruce N. Cronstein, MD Mary K. Crow, MD Cynthia Crowson, MS J. R. Curtis, MD Aileen M. Davis, PhD Kurt L. de Vlam, MD Kevin D. Deane, MD, PhD Kristen Demoruelle, MD Christopher P. Denton, MD, PhD Kori A. Dewing, DNP, ARNP William G. Dixon, PhD Robyn T. Domsic, MD Robin K. Dore, MD Leonard L. Dragone, MD, PhD Alyssa B. Dufour, PhD Dorothy D. Dunlop, PhD Linda S. Ehrlich-Jones, PhD, RN Dirk Elewaut, MD, PhD Helen M. Emery, MD Doruk Erkan, MD Agustin Escalante, MD John M. Esdaile, MD, Luis R. Espinoza, MD Carol A. Feghali-Bostwick, PhD Candace H. Feldman, MD Theodore R. Fields, MD Nadine M. Fisher, EdD Roy Fleischmann, MD David A. Fox, MD Cem Gabay, MD, PhD Angelo L. Gaffo, MD Harry K. Genant, MD, PhD MC Genovese, MD Lianne S. Gensler, MD Piet Geusens, MD, PhD Allan Gibofsky, MD Jon T. Giles, MD John A. Goldman, MD Steven R. Goldring, MD Barbara L. Goldstein, MD Yvonne M. Golightly, PhD Adam P. Goode, DPT, PhD Susan M. Goodman, MD Carol M. Greco, PhD K. Douglas Gross, DPT, ScD Andrew A. Guccione, PhD Loic Guillevin, MD Nigil Haroon, MD, PhD Philip S. Helliwell, PhD Catherine L. Hill, MD K. Hobbs, MD Haochu Huang, PhD Marie Hudson, MD David Hunter, PhD Kimme Hyrich, MD, PhD Maura D. Iversen, DPT Binu Jacob, MSc, PhD Karla Jones, RN Roland Jonsson, DDS, PhD Gurjit S. Kaeley, MBBS, MRCP Kenneth Kalunian, MD Mariana J. Kaplan, MD Lisa M. Kastanek, RN Robert S. Katz, MD Robert T. Keenan, MD Tanaz A. Kermani, MD Susan Kim, MD Wan-Uk Kim, MD, PhD Kyriakos A. Kirou, MD Eugene Y. Kissin, MD Marisa S. Klein-Gitelman, MD Margreet Kloppenburg, MD, PhD Isabelle Koné-Paut, MD Dwight H. Kono, MD Bindee Kuriya, MD 2014 Program Book 249

252 2014 ACR/ARHP ANNUAL MEETING LEADERSHIP C. Kent Kwoh, MD Vasileios C. Kyttaris, MD Robert Landewé, MD, PhD Marissa N. Lassere, MD, PhD Terri M. Laufer, MD Michael P. Lavalley, PhD Edward S. Leib, MD Alana B. Levine, MD Gerald D. Levy, MD Linda C. Li, PhD Katherine P. Liao, MD Stamatis Nick Liossis, MD Rik J. Lories, MD, PhD Martin K. Lotz, MD Steven K. Magid, MD Alfred Mahr, MD, PhD Una E. Makris, MD Brian F. Mandell, MD, PhD Lisa A. Mandl, MD Wendy Marder, MD Richard Martin, MD Thomas Mason II, MD Alan K. Matsumoto, MD Eric L. Matteson, MD Robert R. McLean, DSc Maureen A. McMahon, MD Ted R. Mikuls, MD Shikha Mittoo, MD Chandra Mohan, MD, PhD Laurence Morel, PhD Kathy Moser Sivils, PhD Iris Navarro-Millan, MD Oscar Neira, MD Tuhina Neogi, MD, PhD Uyen Sa D.T. Nguyen, DSc Chester V. Oddis, MD James O Dell, MD Terry H. Oh, MD Catalina Orozco, MD Nicole M. Orzechowski, DO Thomas Osborn, MD Mikkel Ostergaard, MD, PhD Thomas Pap, MD Christopher T. Parker, DO Murray H. Passo, MD Andras Perl, MD, PhD Christine A. Peschken, MD Charles G. Peterfy, MD, PhD Erik J. Peterson, MD Kristine Phillips, MD, PhD Michael H. Pillinger, MD Janet L. Poole, PhD Duncan Porter, MD Sampath Prahalad, MD Chaim Putterman, MD Kate T. Queen, MD Andreas Radbruch, PhD Anisur Rahman, MD, PhD Soumya Raychaudhuri, MD, PhD Andreas Reiff, MD Christopher T. Ritchlin, MD Jillian A Rose, LMSW Shawn Rose, MD, PhD Ann K. Rosenthal, MD Robert Roubey, MD Kelly A. Rouster-Stevens, MD Eric Ruderman, MD Shivani Sahni, PhD Elizabeth G. Salt, PhD Amr H. Sawalha, MD Jose U. Scher, MD Elizabeth A. Schlenk, PhD, RN Kara M. Schmidt, MD Hendrik Schulze-Koops, MD, PhD Sergio Schwartzman, MD Nancy A. Shadick, MD Leena Sharma, MD Miriam A. Shelef, MD, PhD Lisa Shelton, RN Caroline H. Shiboski, PhD Gregg J. Silverman, MD Robert W. Simms, MD Karen L. Smarr, PhD Alexander So, MD Jeremy Sokolove, MD Jason Jungsik Song, MD Enrique Soriano, MD William St.Clair, MD Lisa K. Stamp, PhD Anne M. Stevens, MD, PhD Camilla Svensson, PhD Deborah P. Symmons, MD, PhD Zoltan Szekanecz, MD, PhD Clement E. Tagoe, MD, PhD S. Bobo Tanner, MD Laura L. Tarter, MD Janalee Taylor, CPNP Nora R. Taylor, MD Peter C. Taylor, MD, PhD Regina Taylor-Gjevre, MD Akaluck Thatayatikom, MD Ralf G. Thiele, MD Derrick J. Todd, MD, PhD Kathryn S. Torok, MD Sebastian Unizony, MD Paul J. Utz, MD, PhD Rafael R. Valle, MD John Varga, MD Peter van der Kraan, PhD Yvonne JL van Eijk-Hustings, RN Piet van Riel, MD, PhD Ronald van Vollenhoven, MD, PhD Barbara J Vilen, PhD Ernest R. Vina, MD Evelyne Vinet, MD David Walsh, PhD Michael H. Weisman, MD David A. Williams, PhD Barton L. Wise, MD Joan E. Wither, MD, PhD Edward H. Yelin, PhD John H Yost, DO Brandi Young, DNP Muhammad B. Yunus, MD JoAnn Zell, MD Carol M. Ziminski, MD Program Book

253 2014 Fellows Education Fund Through the Fellows Education Fund, the ACR is accelerating the education and training of the next generation of rheumatologists. The ACR Fellows Education Fund has a proven track record of successfully providing rheumatology fellows-in-training with outstanding educational opportunities to advance their knowledge and skills to treat an ever-changing patient population. The ACR thanks the following organizations for their support of the 2014 Fellows Education Fund: Bristol-Myers Squibb Janssen Biotech, Inc. The ACR thanks the following companies for providing educational grant support for the 2014 ACR Fellows-in-Training Scholarship Program: Celgene Corporation Takeda Pharmaceuticals International, Inc., US Region

254 EXHIBITORS 4S DAWN Clinical Software Office Software/Equipment Booth#: com A Trans-Atlantic Cardiovascular risk Calculator for Rheumatoid Arthritis (ATACC-RA) Booth#: 329 AbbVie Pharmaceuticals Booth#: 211, Actelion Pharmaceuticals Pharmaceuticals, Therapeutic/ Patient Aid Products Booth#: 1218 Alexion Pharmaceuticals Booth#: AmbiMedInc Medical Device Booth#: American Board of Internal Medicine Booth#: 3 American College of Physicians/ Annals of Internal Medicine Nonprofit Organization, Publisher Booth#: 11 Amgen, Inc. Biotech Booth#: 943, Antares Pharma Medical Device, Pharmaceuticals Booth#: APLAR Nonprofit Organization Booth#: 6 Apricus Biosciences Booth#: Arthritis Foundation Nonprofit Organization Booth#: ARTHROS (Annual Rheumatology & Therapeutics Review for Organizations & Societies) Booth#: AstraZeneca Biotech, Pharmaceuticals Booth#: Autoimmune Diseases Association Booth#: Bayer Healthcare Pharmaceuticals Booth#: Besse Medical Distributor, Pharmaceuticals Booth#: Bioxydyn Contract Research Booth#: bmj/ard/rheumatology Booth#: 224 Bristol-Myers Squibb Pharmaceuticals Booth#: British Society for Rheumatology Nonprofit Organization Booth#: Celgene Corporation Pharmaceuticals Booth#: Celltrion Healthcare Co., LTD Pharmaceuticals, Therapeutic/ Patient Aid Products Booth#: CESAS Medical Nonprofit Organization Booth#: Chugai Pharmaceutical Co., Ltd Pharmaceuticals Booth#: 447 Cleveland Clinic Contract Research, Educational Materials for Patients, Registry Booth#: 325 Clinical and Experimental Rheumatology Publisher Booth#: ContextMedia:Health Digital Media, Educational Materials for Patients Booth#: Corrona, LLC Biotech Booth#: Crealta Pharmaceuticals Booth#: Crescendo Bioscience, Inc. Diagnostic Products Booth#: Diplomat Specialty Pharmacy Booth#: Edan Diagnostic Products, Medical Device Booth#: Elsevier Publisher Booth#: EMD Serono, Inc. Pharmaceuticals Booth#: Enovative Technologies Medical Device Booth#: Esaote North America Diagnostic Equipment/Products Booth#: ESCEO asbl Nonprofit Organization Booth#: 327 European Journal of Rheumatology Digital Media, Nonprofit Organization Booth#: 4 European League Against Rheumatism (EULAR) Nonprofit Organization Booth#: Everidis Health Sciences Nutritional Products Booth#: Exagen Diagnostics, Inc Diagnostic Products Booth#: Federation of Clinical Immunology Socieites (FOCIS) Nonprofit Organization Booth#: Ferring Pharmaceuticals Inc. Medical Device Booth#: Fidia Pharma USA Inc. Biotech, Medical Device Booth#: Find-A-Code Booth#: Fresenius Kabi Booth#: Program Book

255 EXHIBITORS FUJIFILM SonoSite, Inc. Diagnostic Equipment/Products, Medical Device Booth#: GE Healthcare Diagnostic Equipment/Products, Medical Device Booth#: 846 Genentech, A Member of the Roche Group Pharmaceuticals Booth#: Genzyme, a Sanofi company Biotech Booth#: 842 GlaxoSmithKline Pharmaceuticals Booth#: 1339, 1548 Hawaiian Moon Sunblock/Skincare Booth#: 311 Horizon Pharma, Inc. Pharmaceuticals Booth#: Hospira Pharmaceuticals Booth#: Image Analysis Medical Device, Pharmaceuticals Booth#: Immco Diagnostics, A Trinity Biotech Company Booth#: Inova Diagnostics, Inc. Diagnostic Products, Laboratory Equipment/Products Booth#: inpractice Resources LLC. Booth#: International Foundation for Autoimmune Arthritis Booth#: 8 Investigator Databank Booth#: Iroko Pharmaceuticals, LLC Pharmaceuticals Booth#: Janssen Biotech, Inc. Pharmaceuticals Booth#: Johns Hopkins Rheumatology Medical Conference, Nonprofit Organization Booth#: Journal of Rheumatology, The Publisher Booth#: La Lettre Du Rhumatologue - EDIMARK SANTE Publisher Booth#: LabCorp Booth#: 826 Letter to Editor Rheumatology Digital Media, Publisher Booth#: Lilly USA, LLC. Pharmaceuticals Booth#: 1310, LipoScience Diagnostic Products, Medical Device Booth#: MBL International Biotech, Diagnostic Products Booth#: Mallinckrodt Autoimmune & Rare Diseases (formerly Questcor) Pharmaceuticals Booth#: 457, McKesson Specialty Health Distributor, Pharmaceuticals Booth#: mckessonspecialtyhealth.com MD Conference Express Booth#: Medac Pharma, Inc. Pharmaceuticals Booth#: MediNatura Pharmaceuticals Booth#: METEOR Nonprofit Organization Booth#: 9 Metro Medical Distributor Booth#: Mission Pharmacal Company Booth#: Mitek Sports Medicine Booth#: Modernizing Medicine Office Software/Equipment Booth#: MotherToBaby Pregnancy Studies conducted by Organization of Teratology Information Specialists Nonprofit Organization Booth#: 2 Multispecialty Physician Partners Booth#: com mycme Digital Media, Educational Materials for Patients Booth#: www. haymarketmedicaleducation. com National Data Bank for Rheumatic Diseases Nonprofit Organization Booth#: National Institute of Arthritis and Musculoskeletal and Skin Diseases Educational Materials for Patients, Government Agency Booth#: National Jewish Health Booth#: National Library of Medicine Educational Materials for Patients, Government Agency Booth#: 1 National Scleroderma Core Centers Contract Research, Nonprofit Organization Booth#: Neovacs Biotech Booth#: Novartis Pharmaceuticals Corporation Pharmaceuticals Booth#: 1328, 1328A,1329, NYU Langone Medical Center - NYU Hospital for Joint Diseases Nonprofit Organization Booth#: rheumatology 2014 Program Book 253

256 EXHIBITORS Ossur Americas Medical Device Booth#: Otto Trading Inc Booth#: Oxford Immunotec Diagnostic Products Booth#: Oxford University Press Publisher Booth#: PAIGE1 Booth#: 1402 PANLAR Nonprofit Organization Booth#: Patient Access Network Foundation Nonprofit Organization Booth#: 10 PatientPoint Digital Media, Educational Materials for Patients Booth#: Pfizer, Inc. Pharmaceuticals Booth#: QIAGEN Biotech, Diagnostic Products Booth#: Quest Diagnostics Diagnostic Products Booth#: 513 Quintiles Booth#: R. J. Fasenmyer Center for Clinical Immunology Nonprofit Organization Booth#: 323 Raintree Systems, Inc. Booth#: RDL Reference Laboratory Diagnostic Products Booth#: Regeneron Pharmaceuticals, Inc. Pharmaceuticals Booth#: RheumaKnowledgy Digital Media, Publisher Booth#: Rheumatology News Publisher Booth#: Rottapharm Ltd Nutritional Products, Pharmaceuticals Booth#: Scandinavian Journal of Rheumatology Nonprofit Organization Booth#: Scleroderma Foundation Educational Materials for Patients, Nonprofit Organization Booth#: Scleroderma Research Foundation Booth#: 13 SI-BONE Medical Device Booth#: Sjögren s Syndrome Foundation Nonprofit Organization Booth#: 432 Sobi, Inc Biotech, Pharmaceuticals Booth#: Spondylitis Association of America Educational Materials for Patients, Nonprofit Organization Booth#: Springer Publisher Booth#: Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals Booth#: The Gout & Uric Acid Education Society Educational Materials for Patients, Nonprofit Organization Booth#: The Myositis Association Nonprofit Organization Booth#: 7 The RAConnection Booth#: TheraTest Laboratories, Inc. Diagnostic Equipment/Products, Diagnostic Products Booth#: 612 Tonix Pharmaceuticals Booth#: 1517 TSI Healthcare Office Software/Equipment Booth#: UCB, Inc. Pharmaceuticals Booth#: University of Alabama at Birmingham Booth#: 222 US Rheumatology Booth#: 201 Value-Based Care in Rheumatology Publisher Booth#: com Vasculitis Foundation Educational Materials for Patients, Nonprofit Organization Booth#: 5 Wiley Publisher Booth#: Wolters Kluwer Health Booth#: Zimmer Booth#: Program Book

257 Corporate Roundtable The Rheumatology Research Foundation is making great strides in its mission to advance research and training to improve the health of people with rheumatic diseases. The Foundation is increasing its funding for research and training thanks in large part to the generosity of its Corporate Roundtable donors. Participation in the Corporate Roundtable is a direct investment in the Foundation s efforts to develop the next generation of rheumatology professionals who will provide high quality care for patients, as well as accelerate research that will lead to advances in treatments and, one day, cures. Donations from the Corporate Roundtable support the Foundation through Journey to Cure: The Campaign to Advance Patient Care and Accelerate Discoveries. The Foundation thanks the Corporate Roundtable donors for their exemplary support. Leadership ($7,500,000+) Principal ($2,500,000+) Partner ($1,000,000+) Follow us on social media: Corporate Roundtable members as of September 30, 2014

258 AcKNOWLEDGMENTS The ACR and the ARHP wish to thank the following organizations for providing support for the 2014 ACR/ARHP Annual Meeting AbbVie Networking Lounges Exhibit Hall Stair Clings Digital Media Tower Video Wall and Plasma Network North Lobby Banner Amgen, Inc. North Lobby Area Column Clings Scientific Program Book Session Tracker ARHP Morning Forum Bristol-Myers Squibb Company Hanging Aisle Signs Wi-Fi Way Celgene Corporation Exhibit Hall Floor Decals North Lobby Banner Genentech, a Member of the Roche Group Hotel Key Cards Pfizer, Inc. North Lobby Window Clings Shuttle Buses Regeneron Digital Media Tower Program Book

259 AcKNOWLEDGMENTS In addition to the support provided for the 2014 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for activities and programs throughout the year. AbbVie Corporate Roundtable, Leadership Level Fellows Education Fund State-of-the-Art Clinical Symposium Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Membership Directory Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium Amgen, Inc. Corporate Roundtable, Leadership Level Fellows Education Fund Amgen Fellowship Training Award Pediatric Visiting Professorship Award Pediatric Research Award ARHP Morning Forum Annual Meeting Corporate Roundtable Symposium AstraZeneca Corporate Roundtable, Principal Level Annual Meeting Corporate Roundtable Symposium Bioiberica, S.A. Annual Meeting Industry-Supported Post-Conference Symposium Bristol-Myers Squibb Company Corporate Roundtable, Partner Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Celgene Corporation Corporate Roundtable, Principal Level Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Annual Meeting FIT Scholarship Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium Eli Lilly and Company Corporate Roundtable, Principal Level Winter Rheumatology Symposium Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium GE Healthcare Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop - Intermediate Genentech, a Member of the Roche Group Corporate Roundtable, Principal Level Janssen Biotech, Inc. Corporate Roundtable, Partner Level Fellows Education Fund Scientist Development Award Oxford Immunotec Annual Meeting Industry-Supported Post-Conference Symposium Pfizer, Inc. Corporate Roundtable, Leadership Level State-of-the-Art Clinical Symposium Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Image Bank Annual Meeting Corporate Roundtable Symposium Takeda Pharmaceuticals Annual Meeting FIT Scholarship UCB, Inc. Corporate Roundtable, Principal Level Annual Meeting Corporate Roundtable Symposium 2014 Program Book 257

260 Annual Meeting Planning Committee (AMPC) Disclosures The AMPC provides oversight and guidance on all educational activities related to the ACR/ARHP Annual Scientific Meeting. Because it is not always clear what content or topic will be discussed, committee members are asked to disclose all financial relationships. Recusal is the primary mechanism for resolution. However by the nature of committee work, the peer process also plays a role in ensuring balance. Amin, Shreyasee, MDCM, MP Disclosure: Tissue Gene, Inc., 5 Ardoin, Stacy, MD Disclosure: Johnson & Johnson, 5 Ascherman, Dana, MD Disclosure: Intermune, 2 Baer, Alan N., MD Disclosure: Nothing to disclose Beam, Thuy T., RN Disclosure: Nothing to disclose Bernstein, Elana, MD Disclosure: Nothing to disclose Block, Joel A., MD Disclosure: Ferring, Inc., 5; PLx Pharma, Inc., 9; Agios, Inc., 7; Daiichi-Sankyo, 7; Glaxo-SmithKline, 7; Elsevier, Inc. - other (Editor); Gilead, Inc., 1 Boackle, Susan, MD Disclosure: National institute of Health, 2; University of Colorado Denver, 3; National Institutes of Health, 5; American College of Rheumatology, Arthritis Foundation, 6 Breland, Hazel L., PhD, OTR/L Disclosure: Nothing to disclose Brunner, Hermine, MD, MSc, MBA Disclosure: Novartis, 5; Novartis, 8; Roche, 5; UCB, 5; Janssen, 5; Pfizer, 5; Medimmune, 5; Merck/Serono, 5; Celgene, 5; Abbvie, 5 Co, Dominic O., MD, PhD Disclosure: Orasure Technologies, 1 Cope, Andrew P., MD, PhD Disclosure: Roche, 5; Roche, 8; BMS, 5; Cellgene, 5 Cronin, Mary, MD Disclosure: Nothing to disclose Crow, Mary K. Peggy, MD Disclosure: Johnson & Johnson, 1; Pfizer, 1; Pregeneron, 1; Biogen Idec, 1; Amgen, 1; Merck, 1; Novo Nordisk, 2; Bristol Myers Squibb, 5; GlaxoSmithKline, 5; Takeda, 5; UCB, 5; EMD Merck Serono, 5; Roche Genentech, 5; Eisai, 5; Lilly, 5 Diamond, Betty, MD Disclosure: Nothing to disclose Edwards, N. Lawrence, MD Disclosure: Cymabay Pharmaceutical, 5; Novartis Pharmaceutical, 5; Quarteer Pharmaceutical, 5 Flood, Joseph, MD Disclosure: Nothing to disclose Foxworth, Judy, PhD, PT Disclosure: Nothing to disclose Gourley, Mark F., MD Disclosure: Nothing to disclose Hajj-Ali, Rula, MD Disclosure: Intuitive Surgical, 5; Endocave, 5; Ethicon, 5; Roche, 8; Up to date, 7 Hannan, Marian T., DSc, MPH Disclosure: Nothing to disclose Hassett, Afton, PsyD Disclosure: Bristol-Myers Squibb, 2; Pfizer, Inc., 2 Hausmann, Jonathan, MD Disclosure: Nothing to disclose Helfgott, Simon, MD Disclosure: Abbvie, 5; Genetech, 5; Best Doctors, 5; Up To Date, 7 Howard, Rennie, MD Disclosure: Nothing to disclose Hughell, Laurie, PA-C, MPH Disclosure: Nothing to disclose Jarjour, Wael, MD Disclosure: Naridea Biopharmaceutical, 2; Naridea Biopharmaceutical, 5 Jolly, Meenakshi, MD, MS Disclosure: GSK, 5; Medlmmune, 5; LupusPro, 7 Kaplan, Mariana J., MD Disclosure: Nothing to disclose Khanna, Dinesh, MD, MSc Disclosure: NIH/NAIMS, 2; Scleroderma Foundation, 2; Pulmonary Hypertension Association, 2; Astra Zeneca, 2; BMS, 2; Savient, 2; The University of Michigan, 3; Actelion, 5; Astra Zeneca, 5; Bayer, 5; BMS, 5; Celgene, 5; DIGNA, 5; InterMune, 5; Merck, 5; Roche, 5; Sanofi-Aventis, 5; Takeda, 5 Kolasinski, Sharon, MD Disclosure: Nothing to disclose Loeser, Richard F., MD Disclosure: Nothing to disclose Lohr, Kristine M., MD, MS Disclosure: MEDISYS, 1; Baxter, 1; Merck, 1; Pfizer, 1; St Jude Medical, 1; Walgreen s, 1; Colgate, 1; Palmolive, 1; Sanofi, 1; Takeda Clinical Trail, 2; Site PI, 2; American College of Rheumatology, 2; Rheumatology Research Foundaition 2 Manno, Rebecca L., MD Disclosure: Nothing to disclose Program Book See page 247 for the list of disclosure relationships.

261 Annual Meeting Planning Committee (AMPC) Disclosures Matteson, Eric, MD Disclosure: Mesoblast, 2; Pfizer, 2; UCB Pharma, 2; Novartis, 2; Johnson & Johnson, 2; Janssen, 2; Celgene, 2; Roche/ Genetech, 2; Ardea Biosciences In Practice, 2; Medscape, 7; Up to Date, 7 McClatchey, William, MD Disclosure: Nothing to disclose McLean, Robert R., DSc, MPH Disclosure: Nothing to disclose Mintz, Sandra J., RN, BSN Disclosure: Nothing to disclose Oddis, Chester V., MD Disclosure: Questcor, 2; Questcor, 5; atyr Pharma (advisory board), 5 O Rourke, Kenneth S., MD Disclosure: Genetech (multicenter clinical trials), 2; Human Genome Sciences (multicenter clinical trials), 2 Rabinovich, Egla, MD, MPH Disclosure: Janssen Research & Develop, 2; UCB Pharma, 2; Abbvie, 2; Hoffman- LaRoche, 2 Sigal, Leonard H., MD Disclosure: BMS, 1; Novo Nordisk, 1; I work for a Clinical Research Organization and have been involved in trials for many companies, yet in no case do I benefit from that relationship or success of the study Silverman, Gregg J., MD Disclosure: Nothing to disclose Singer, Nora, MD Disclosure: Nothing to disclose Singh, Jasvinder, MD, MPH Disclosure: Takeda research grants; Savien, 2; Taked, 5; Savient, 5; Allergan, 5; Novartis Regeneron, 5; Market Research Companies (<$500 one time interviews), 5 Siva, Chokkalingam Chuck, MD, MS Disclosure: Nothing to disclose Stamatos, Christine, ANP-C Disclosure: Nothing to disclose Stojan, George, MD Disclosure: Nothing to disclose Stone, Kerry, MD Disclosure: Merck & Company (Husband), 3 Taylor, Greg, MSW Disclosure: Nothing to disclose Rodney Tehrani, MD Disclosure: Nothing to disclose Tsokos, George C., MD Disclosure: GSK, 5; Biogen (DMC) Member), 5; Elsevier Consulting (editor), 5 Varga, John, MD Disclosure: JBT, 1; Baxter, 2; Takeda, 2; Actelion, 2; Roche, 2; Bioline, 5; Biogen, 5; Sprige, 7 Venuturupalli, Swamy R., MD Disclosure: Nothing to disclose White, Douglas W., MD, PhD Disclosure: Crescendo Bioscience, 5 Wilkes, Margaret R., MD Disclosure: Nothing to disclose 2014 Program Book 259

262 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures ACR/ARHP Abstract CATEGORY Chairs A Anolik, Jennifer H., MD, PhD Disclosure: Karyopharm Therapeutics, Inc., 2; Medimmune, 2 B Baer, Alan N., MD Baeten, Dominique L., MD, PhD Bardin, Thomas, MD Disclosure: Manarini, Savient, Astra Zeneca, Novartis, Sobi, 5 Barnabe, Cheryl, MD, MSc Barton, Jennifer, MD Disclosure: Investigator-initiated research grant from Pfizer; ending 10/2014, 2 Battistone, Michael J., MD Beam, Thuy T., BSN, RN Bingham III, Clifton O., MD Disclosure: Abbvie, 9; BMS, Pfizer, Janssen, 2; Lilly, NovoNordisk, UCB, Janssen, BMS, Abbvie, Genentech/Roche, Pfizer, 5; OMERACT, 6; PCORI, NIH, 2; UpToDate, 7 Binstadt, Bryce A., MD, PhD Bookman, Arthur A. M., MD Disclosure: Journal of Rheumatology, 6 Boomershine, Chad, MD, PhD Disclosure: Pfizer Inc, 8; Takeda, 8 Breland, Hazel L., PhD, OTR/L Brown, Lin A., MD Brunner, Hermine, MD Buchbinder, Rachelle, MBBS, MSc, PhD Buckley, Lenore M., MD, MPH Burmester, Gerd, MD Disclosure: AbbVie, BMS, Medmune, MSD, Novartis, Pfizer, Roche, UCB, 5; AbbVie, BMS, MSD, Pfizer, Roche, UCB, 8; AbbVie, BMS, Pfizer, Roche, UCB, 2 Buyon, Jill P., MD Bykerk, Vivian P., MD Disclosure: Amgen, 9; Antares Pharma Inc, 9; Becton Dickinson, 9; Bristol-Myers Squibb, 9; Genentech/Roche Inc, 9; Medac Inc, 9; Merck Pharmaceuticals, 9; Novartis Pharmaceutical Corporation, 1; Pfizer Inc, 9; UCB Pharmaceuticals, 9 Clowse, Megan E. B., MD, MPH Disclosure: UCB, 9 Cohen, Philip L., MD Disclosure: Janssen Pharmaceutica Product, L.P., 2 Conaghan, Philip G., MD, PhD Disclosure: Abbvie, 8; Bioiberica, 8; Bristol- Myers Squibb, 5; Janssen Pharmaceutica Product, L.P., 5; Merck Pharmaceuticals, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8; UCB, 8 Dalbeth, Nicola, MBChB, MD Disclosure: Ardea, 2; AstraZeneca, 5; Fonterra, 5; Menorini, 8; Takeda, 5 C D Dall era, Maria, MD Dao, Kathryn H., MD Disclosure: Merck Human Health, 5; Pfizer, Celgene, UCB, Novartis, 2 Davidson, Anne, MBBS Disclosure: Eisai, 5; Eli Lilly and Company, 5; GSK, 8 Davis III, John M., MD, MS Deodhar, Atul A., MD Disclosure: Abbvie, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 E Edwards, N. Lawrence, MD Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5 Elkon, Keith B., MD Ferguson, Polly J., MD Fischer, Aryeh, MD FitzGerald, John, MD, PhD FitzGerald, Oliver, MD Disclosure: Cellgene, UCB, Janssen, 8; Janssen, UCB, 5; Pfizer Inc, BMS, Abbott, MSD, 2 Foxworth, Judy, PhD, PT F G Gaffney, Patrick M., MD Gilkeson, Gary S., MD Disclosure: Alexion Pharmaceuticals, Inc., 7; Berg, 2; Dynavax, 2; GlaxoSmithKline, 2 Gladman, Dafna D., MD Disclosure: BMS, 2, 5 Goldring, Mary B., PhD Disclosure: Abbott Laboratories; Biogen-IDEC, 2; Endocyte, 5 Gordon, Jessica K., MD, MSc H Hahn, Paulette C., MD Harvey, William F., MD, MSc Disclosure: Vindico Medical Education, 5 Hassett, Afton L., PsyD Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5; Pfizer Inc, Program Book See page 247 for the list of disclosure relationships.

263 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Hetland, Merete Lund, DMSc, MD, PhD Higgs, Jay B., MD Hughell, Laurie A., PA-C, MPH Hummers, Laura K., MD, ScM Disclosure: Actelion Pharmaceuticals US, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 2; Roche Pharmaceuticals, 2 Husni, M. Elaine, MD, MPH Disclosure: Genzyme Corporation, 2 Imundo, Lisa F., MD Inman, Robert D., MD Disclosure: Abbvie, Amgen, Janssen, Pfizer, UCB, 5 Johnson, Sindhu R., MD, PhD Kalliolias, George D., MD, PhD Kamen, Diane L., MD, MS Kang, Insoo, MD Katz, Jeffrey N., MD, MSc I J K Kavanaugh, Arthur, MD Disclosure: Abbvie, 2; Amgen, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; UCB, 2 Kay, Jonathan, MD Disclosure: AbbVie Inc., 2, 5; Amgen, 5; Ardea Biosciences, Inc., 2; AstraZeneca, 5; Bristol- Myers Squibb, 5; Crescendo Bioscience, Inc., 5; Eli Lilly and Company, 2, 5; Epirus Biopharmaceuticals, Inc., 5; Genentech Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, 5; Roche Laboratories, Inc., 2, 5 Kazi, Salahuddin, MD L Lafyatis, Robert, MD Disclosure: Biogen Idec, 5; BMS, 5; Bristol- Myers Squibb, 5; Celgene, 5; Genentech, 2; Human Genome Sciences, Inc., 2; Intermune, 5; Medimmune, 5; Precision Dermatology, 5; PRISM Pharma Co. Ltd., 5; Regeneron, 2; Shire, 2, 5; UCB, 2 Laster, Andrew J., MD Disclosure: Amgen; Genentech; Eli Lilly, 8; Genentech and Biogen IDEC Inc.; Eli Lilly, 5; ISCD, 6; MediMaps, 9 Lee, Yvonne C., MD, MMSc Disclosure: Cubist Pharmaceuticals, 1; Express Scripts Holding Co, 1; Forest Research Institute, 2; Merck and Co, 1; Perrigo Co, 1 Levy, Roger A., MD Lim, S. Sam, MD, MPH Disclosure: Accordant, 5; Bristol-Myers Squibb, 9; Eli Lilly and Company, 9; Exagen, 5; Genentech and Biogen IDEC Inc., 9; GSK, 2; MedImmune, 5, 9; Pfizer Inc, 9; Questcor, 5 Lo, Grace H., MD, MSc Disclosure: ACR, 9; NIH/NIAMS, 2 Louie, Grant H., MD, MHS Disclosure: AbbVie, 5 M Malfait, Anne-Marie, MD, PhD Disclosure: Ferring, 5 Markenson, Joseph A., MD Disclosure: Abbvie, 8; Amgen, 5; Anteres, 8; BMS, 8; Celgene, 8; Iroko, 8; Jansen, 8; Lilly, 5 Marshak-Rothstein, Ann, PhD Maz, Mehrdad, MD McInnes, Iain B., PhD Disclosure: Astra Zeneca, 2, 5; Janssen Pharmaceutica Product, L.P., 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2, 5; UCB, 2 Mease, Philip J., MD Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; Covagen, 5; Crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5, 8; Vertex, 2, 5 Michaud, Kaleb, PhD N Niewold, Timothy B., MD Nigrovic, Peter A., MD Disclosure: Alkermes, Inc., 5; Baxter, 2; Momenta, Inc., 5; Novartis Pharmaceutical Corporation, 5 O Olsen, Nancy J., MD Pachman, Lauren M., MD Paget, Stephen A., MD Disclosure: Crescendo Bioscience and Medscape, 5 Perlman, Harris R., PhD Pernis, Alessandra B., MD Pisetsky, David S., MD, PhD P R Rauch, Joyce, PhD Reed, Ann M., MD Reveille, John D., MD Disclosure: Abbvie, UCB, BMS, Program Book 261

264 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures S Scanzello, Carla R., MD, PhD Schmajuk, Gabriela, MD, MS Schmidt, Wolfgang A., MD Disclosure: Abbvie, 2, 5, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 5, 8; Esaote, 2; General Electric, 2; Medac, 8; Merck Pharmaceuticals, 2, 8; Mundipharma, 2, 8; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 2, 5, 8; Savient, 2; Siemens, 2; UCB, 8 Schnitzer, Thomas J., MD, PhD Disclosure: Allergan, 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, 2; McNeil Consumer & Specialty Pharmaceuticals, 5; Nuvo, 2 Shahrara, Shiva, PhD Shanmugam, Victoria K., MBBS, MRCP Disclosure: Multiple, 9 Singer, Nora G., MD Disclosure: abbvie, 5; Clinical site- contract wtih MetroHealth, 9; Merck Pharmaceuticals, 2 Singh, Ram P., PhD Siva, Chokkalingam, MD Spiera, Robert F., MD Disclosure: Actelion Pharmaceuticals US, 2; GlaxoSmithKline, 2; Intermmune, 2; Novartis Pharmaceutical Corporation, 2; Roche- Genetech, 2 Stamatos, Christine A., DNP, ANP-C Suter, Lisa, MD Taylor, Gregory, MSW T V van Den Bosch, Filip, MD, PhD W Warrington, Kenneth J., MD Yazdany, Jinoos, MD, MPH Y Z Zeft, Andrew, MD, MPH Disclosure: Merck Human Health, 1; Novartis Pharmaceutical Corporation, 5; OPKO, 1 Zink, Angela, PhD ACR/ARHP Abstract Reviewers A Abril, Andy, MD Adam, Paul M, MSW Aggarwal, Rohit, MD, MS Aletaha, Daniel, MD, MSc Allanore, Yannick, MD, PhD Disclosure: Actelion Pharmaceuticals US, 5; Pfizer Inc., 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5 Allen, Kelli D., PhD Aranow, Cynthia, MD Ascherman, Dana P., MD Askanase, Anca, MD, MPH Disclosure: GSK. Centocor, 5 Assassi, Shervin, MD, MS B Backman, Catherine L., PhD Baker, Nancy A., MPH, OTR, OTR/L Barbour, Kamil E., PhD Barnado, April, MD Barrat, Franck, PhD Disclosure: Biogen Idec, 5 Bartels, Christie M., MD, MS Bartlett, Susan J., PhD Becker, Mara L, MD, MSCE Behrens, Edward M., MD Berman, Jessica, MD Bertolaccini, Maria Laura, MD, PhD Beukelman, Timothy, MD, MSCE Disclosure: Crescendo Bioscience, 5; Genentech and Biogen IDEC Inc., 5; McKesson Health Solutions, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2; UCB, 5 Blalock, Susan J., PhD Boackle, Susan A., MD Boers, Maarten, MD, MSc, PhD Disclosure: BMS, 5; GSK, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5 Boin, Francesco, MD Program Book See page 247 for the list of disclosure relationships.

265 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Bombardieri, Stefano, MD Bradley, Laurence A., PhD Disclosure: UpToDate Rheumatology, 7 Braun, Juergen, MD Bridges Jr., S. Louis, MD, PhD Brothers, Mary C., ARNP, CPNP Cairns, Ewa, PhD Callahan, Leigh F., PhD Caplan, Liron, MD, PhD Caricchio, Roberto, MD Carter, John D., MD Castelino, Flavia V., MD Castrejón, Isabel, MD, PhD Chakravarty, Eliza, MD, MS Chandran, Vinod, MBBS, MD, DM, PhD Disclosure: Abbvie, 2; Abbvie, Amgen, Celgene, Janssen, UCB, 5; Oxford University Press, 7 Charles, Julia F., MD, PhD Chatham, W. Winn, MD Chen, Di, MD, PhD Choi, Hyon K., MD, DrPH Christenson, Mary E., PhD, PT C Chung, Cecilia P., MD, MPH Cid, Maria C., MD. PhD Cidon, Michal, MD Clark, Marcus R., MD Clegg, Daniel O., MD Disclosure: Abbvie, 5 Co, Dominic, MD, PhD Disclosure: Orasure Technologies, 1 Cohen, Stanley B., MD Disclosure: Abbvie, 2; Amgen, 5; Amplimmune, 2; BMS, 5; Corrona, 6; Flexion, 2; Lilly, 2; Merck Human Health, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2 Corr, Maripat, MD Coty, Mary-Beth, PhD, RN Cox, Talitha, MA, OTR/L Craft, Joseph E., MD Disclosure: AbbVie, Pfizer, Novo Nordisk, 5; L2 Diagnostics, 1; UV Therapeutics, 1 Criswell, Lindsey A., MD, MPH Disclosure: Medimmune, 5 Cronstein, Bruce N., MD Disclosure: AstraZeneca, 2; Bristol-Myers Squibb, 5; Canfite Pharma, 1; Celgene, 2; Eli Lilly & Co., 5; Gilead, 2; Numerous patents, 9; Takeda, 2 Crow, Mary K., MD Disclosure: Johnson & Johnson, 1 Crowson, Cynthia, MS Disclosure: Roche Pharmaceuticals, 2 Curtis, J. R., MD, MPH, MS Disclosure: Abbvie, 2, 5; Amgen, 2, 5; BMS, 2, 5; Celgene, 5; Corrona, 2, 5; Janssen Pharmaceutica Product, L.P., 2, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 2, 5 D Davis, Aileen M., PhD de Vlam, Kurt L., MD Disclosure: Abbott Laboratories, UCB, Janssen, MSD, Pfizer, 5; Pfizer, Janssen, 8 Deane, Kevin D., MD, PhD Demoruelle, Kristen, MD Denton, Christopher P., MD, PhD Disclosure: Actelion GSK, CSL Behring, Sanofi Aventis, Merck-Serono, Genentech-Roche, 5; Actelion Pharmaceuticals US, 2 Dewing, Kori A., DNP, ARNP Dixon, William G., MRCP, PhD Domsic, Robyn T., MD, MPH Disclosure: Actelion, 5 Dore, Robin K., MD Disclosure: Amgen, Eli Lilly, 2, 5, 8; UCB, 8 Dragone, Leonard L., MD, PhD Dufour, Alyssa B., PhD Dunlop, Dorothy D., PhD Ehrlich-Jones, Linda S., PhD, RN Elewaut, Dirk, MD, PhD Emery, Helen M., MD E Erkan, Doruk, MD Disclosure: Alexion Pharmaceuticals, Inc., 5; A ACTION Executive Committee Chair, 6; Eli Lilly and Company, 2; GlaxoSmithKline, 8; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Escalante, Agustin, MD 2014 Program Book 263

266 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Espinoza, Luis R., MD Feghali-Bostwick, Carol A., PhD Feldman, Candace H., MD, MPH Disclosure: Pfizer Inc, 2 F Fields, Theodore R., MD Disclosure: AstraZenica Pharmaceutics, 5; Crealta Pharmaceuticals, 5; Pfizer Pharmaceuticals, 8; Takeda Pharmaceuticals, 5, 8 Fisher, Nadine M., EdD Fleischmann, Roy, MD Disclosure: AbbVie, Amgen, Pfizer, Janssen, UCB, BMS, Genentech, Roche, Lilly, Novartis, Vertex, Merck, Sanofi-Aventis, Regneron,, 2; AbbVie, Amgen, Pfizer, UCB, BMS, Lilly, Vertex, Sanofi-Aventis, Regeneron, 5 Fox, David A., MD Disclosure: Janssen Pharmaceutica Product, L.P., 2 Gabay, Cem, MD, PhD Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 2, 5 G Gaffo, Angelo L., MD, MSPH Disclosure: Cymabay Inc, 5 Genant, Harry K., MD, PhD Disclosure: Amgen, Lilly, Merck, Pfizer, Janssen, Roche, Servier, Daiichi, Synarc, 5 Genovese, Mark C., MD Disclosure: Abbvie, 2, 5; Amgen, 2, 5; Lilly, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5; Sanofi- Aventis Pharmaceutical, 2, 5; Vertex, 2, 5 Gensler, Lianne S., MD Disclosure: AbbVie, 5; OptumRx, 5; UCB, 5 Gibofsky, Allan, JD, MD Disclosure: Abbott Immunology Pharmaceuticals, 1, 5, 8; Amgen, 1, 5, 8; Antares Pharma, 5; Bristol-Myers Squibb, 1; Celgene, 5; FDA, 6; GlaxoSmithKline, 1; Horizon Pharma, 5; Iroko Pharma, 5; Johnson & Johnson, 1; Pfizer Inc, 1, 5, 8; UCB, 8 Giles, Jon T., MD, MPH Disclosure: Genentech and Biogen IDEC Inc., 5; Pfizer Inc, 2 Goldman, John A., MD Disclosure: Amgen, BMS, 1; Celgene, Pfizer, Amgen, 8 Goldring, Steven R., MD Goldstein, Barbara L., MD, MMSc Golightly, Yvonne M., PT, MS, PhD Goode, Adam P., DPT, PhD Goodman, Susan M., MD Greco, Carol M., PhD Guccione, Andrew A., PhD, DPT Guillevin, Loic, MD Disclosure: LECTURE FEES, 9 Haroon, Nigil, MD, PhD, DM Disclosure: Abbvie, Amgen, Pfizer, Celgene, UCB, Janssen, 5 Helliwell, Philip S., MA, PhD Disclosure: Janssen, Abbvie, BMS, Celgene, Amgen Eli Lilly, 5 H Hill, Catherine L., MBBS, MD Hobbs, Kathryn, MD Disclosure: Amgen., 5; UCB, 9 Huang, Haochu, PhD Hudson, Marie, MD, MPH Hunter, David J., MBBS, PhD Hyrich, Kimme, MD, PhD Disclosure: Pfizer Inc, 5 Iversen, Maura D., BSc, DPT, SD, MPH Jacob, Binu, MSc, PhD Jones, Karla, RN Jonsson, Roland, DDS, PhD Kaeley, Gurjit S., MBBS, MRCP Disclosure: Abbott Immunology Pharmaceuticals, 5; Esaote, 9; Sonosite, 9 Kalunian, Kenneth, MD Kaplan, Mariana J., MD Kastanek, Lisa M., RN, CCRC Katz, Robert S., MD Keenan, Robert T., MD, MPH Disclosure: AstraZeneca, 5; Takeda, 5 Kermani, Tanaz A., MD Kim, Susan S., MD Kim, Wan-Uk, MD, PhD Kirou, Kyriakos A., MD Kissin, Eugene Y., MD Disclosure: SonoSite inc, 9; USSONAR Secretary, 6 Klein-Gitelman, Marisa S., MD, MPH Disclosure: UCB, Abbott, BMS, Hoffman- LaRoche, 2 Kloppenburg, Margreet, MD, PhD Disclosure: Abbvie, 9; Arthritis and Rheumatology, 6; Dutch Arthritis Foundation, Pfizer, TI Pharma, 2; Leiden University Medical Center, 3; Pfizer Inc, 8 I J K Program Book See page 247 for the list of disclosure relationships.

267 2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Koné-Paut, Isabelle, MD Disclosure: Novartis Pharmaceutical Corporation, Swedish orphan biovitrum, CHUGAI, PFIZER, 5 Kono, Dwight H., MD Kuriya, Bindee, MD, MS Kwoh, C. Kent, MD Disclosure: Abbott Immunology Pharmaceuticals, 2; Express Scripts, 5; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9 Kyttaris, Vasileios C., MD Disclosure: Vertex Pharmaceuticals, 5 Landewé, Robert, MD, PhD Lassere, Marissa N., MD, PhD Laufer, Terri M., MD Lavalley, Michael P., PhD Leib, Edward S., MD Disclosure: Medi-Imaps, 5 Levine, Alana B., MD Levy, Gerald D., MBA, MD Li, Linda C., PhD, PT Liao, Katherine P., MD, MPH Liossis, Stamatis Nick, MD Lories, Rik J., MD, PhD Disclosure: Abbvie, 5; Boehringer Ingelheim, 2; Celgene, 2; Pfizer Inc, 5 Lotz, Martin K., MD L M Mahr, Alfred, MD, PhD Disclosure: Chemocentryx, 5; CSK Behring, 2; Laboratoires Français de Biotechnologies, 9; MSD, 9 Makris, Una E., MD Mandl, Lisa A., MD, MPH Marder, Wendy, MD Martin, Richard, MD Disclosure: Amgen, 9; Boehringer Ingelheim, 9; Eli Lilly and Company, 9; Resolve Therapeutics, 9 Matsumoto, Alan K., MD Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Amgen, 2, 5; Ardea Biosciences, 2; Astellas, 2; AstraZeneca, 5; Auxillium Pharmaceuticals, 2; Boehringer Ingelheim, 2; Bristol-Myers Squibb, 2; Celgene, 2, 5; Centocor, Inc., 2; Corrona, 2; Eli Lilly and Company, 2; Forest Laboratories, 2; Genentech and Biogen IDEC Inc., 2, 5; Hoffmann-La Roche, Inc., 2; Human Genome Sciences, Inc., 2; Janssen Pharmaceutica Product, L.P., 2; Novartis Pharmaceutical Corporation, 2; Paragon Scientific Corp, 2; Pfizer Inc, 2; Q Med AB, 2; Regeneron, 2; Sanofi-Aventis Pharmaceutical, 2; Seikagaku, 2; Takeda, 2; Xoma Corporation, 2 Matteson, Eric L., MD, MPH McLean, Robert R., DSc, MPH McMahon, Maureen A., MD Disclosure: GSK, 8; Questcor, 5 Mikuls, Ted R., MD, MSPH Disclosure: Roche/Genentech, 2 Mittoo, Shikha, MD, MHS Disclosure: Abbott Immunology Pharmaceuticals, 2; Abvie, 5; Celgene, 5; UCB, 5; UCB Pharmaceuticals, 2 Mohan, Chandra, MD, PhD Morel, Laurence, PhD Moser Sivils, Kathy, PhD N Navarro-Millan, Iris, MD Neogi, Tuhina, MD, PhD Nguyen, Uyen Sa D.T., DSc, MPH O O Dell, James R., MD Disclosure: Abbvie and Lilly, 5 Oh, Terry H., MD Orozco, Catalina, MD Orzechowski, Nicole M., DO Osborn, Thomas, MD Ostergaard, Mikkel, DMSc, MD, PhD Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough,, 2 Pap, Thomas, MD P Passo, Murray H., MD Disclosure: Pfizer Inc, 5 Perl, Andras, MD, PhD Disclosure: Pfizer Inc, 2 Peschken, Christine A., MD, MSc Peterfy, Charles G., MD, PhD Disclosure: Amgen, 8; Spire Sciences, Inc., 4 Peterson, Erik J., MD 2014 Program Book 265

268 Phillips, Kristine, MD, PhD Pillinger, Michael H., MD Disclosure: Takeda Inc, 9; Takeda Inc; Savient Inc, 2 Poole, Janet L., OTR, PhD Porter, Duncan, MD Disclosure: Medimmune, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5 Prahalad, Sampath, MD, MSc Putterman, Chaim, MD Q Queen, Kate T., MD R Radbruch, Andreas, PhD Rahman, Anisur, MD, PhD Ruderman, Eric, MD Disclosure: AbbVie, 5; Amgen, 5; Celgene, 5; Corrona, 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, 5; Medac, 5; Pfizer Inc, 2, 9; UCB, 5; Vertex, 5 S Sahni, Shivani, PhD Disclosure: General Mills Bell Institute of Health and Nutrition, 2 Salt, Elizabeth G., PhD Disclosure: ACR Scientist development award, 2; I received honorarium for speaking for the Insion Nursing society, 9; I serve on Pfizer medical education grant Reew Group, 5; NIH co-investigator, 2; Smithkline Beecham, 1 Sawalha, Amr H., MD Scher, Jose U., MD Schlenk, Elizabeth A., PhD, RN Schmidt, Kara M., MD Schulze-Koops, Hendrik, MD, PhD Smarr, Karen L., PhD So, Alexander, MD Disclosure: Astra-Zeneca, 5; Menarini, 5 Sokolove, Jeremy, MD Song, Jason Jungsik, MD Soriano, Enrique, MD Disclosure: Abbvie, Bristol-Myers Squibb, Janssen, Roche, UCB, 2; Abbvie, UCB, Roche, 5; Bristol-Myers Squibb, Pfizer, Abbvie, UCB, Janssen, Roche, 8 St.Clair, William, MD Disclosure: Biogen Idec, 2; Bristol-Myers Squibb, 9; Merck Pharmaceuticals, 9 Stevens, Anne M., MD, PhD Svensson, Camilla, PhD Szekanecz, Zoltan, MD, PhD Raychaudhuri, Soumya, MD, PhD Reiff, Andreas, MD Ritchlin, Christopher T., MD, MPH Disclosure: Abbott Laboratories, 5; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P., 2, 5; Novartis Pharmaceutical Corporation, 5; Regeneron, 5 Rose, Jillian A, LMSW Rose, Shawn, MD, PhD Rosenthal, Ann K., MD Roubey, Robert, MD Rouster-Stevens, Kelly A., MD, MS Schwartzman, Sergio, MD Disclosure: Abbvie, 5, 8; Genentech and Biogen IDEC Inc., 5, 8; Janssen Pharmaceutica Product, L.P., 5, 8; Pfizer Inc, 1, 5, 8; UCB, 5, 8 Shadick, Nancy A., MD, MPH Disclosure: ABBVIE, 2; Amgen, 2; BMS, 9; Crescendo Biosciences, 2; Genentech and Biogen IDEC Inc., 2; UCB, 2 Sharma, Leena, MD Shelef, Miriam A., MD, PhD Shelton, Lisa, B.Sc., BSN, RN Shiboski, Caroline H., DDS, MPH, PhD Silverman, Gregg J., MD Disclosure: Genentech, Pfizer, Lilly, Onyx, 5 Simms, Robert W., MD Disclosure: Actelion Pharmaceuticals USte, 2; Gilead, 8; Medimmune, 2 Tagoe, Clement E., MD, PhD Tanner, S. Bobo, MD Disclosure: Anteres, AMGEN, UCB, 5; BMS, Pfizer, Anteres, 8; GSK, Genentech, Lilly, UCB, Astra Zeneca, Novartis, Pfizer, Merck, Centocor, 2 Tarter, Laura L., MD Taylor, Janalee, CNS, CPNP, MSN Taylor, Nora R., MD T Taylor, Peter C., MD, PhD Disclosure: I have received research grants from AstraZeneca and from UCB Pharma, 2; I have served as a consultant to NovoNordisk, AstraZeneca, Lilly, Merck, Pfizer, UCB, Celgene, FujiBiologics, Program Book See page 247 for the list of disclosure relationships.

269 Taylor-Gjevre, Regina, MD Thatayatikom, Akaluck, MD Thiele, Ralf G., MD Torok, Kathryn S., MD U Unizony, Sebastian, MD Utz, Paul J., MD V Valle, Rafael R., MD van der Kraan, Peter, PhD van Eijk-Hustings, Yvonne JL, MSc, RN van Riel, Piet, MD, PhD van Vollenhoven, Ronald, MD, PhD Disclosure: AbbVie, Biotest, BMS, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex, 5; AbbVie, BMS, GSK, Pfizer, Roche, UCB, 2 Vilen, Barbara J., PhD Vina, Ernest R., MD, MSc Vinet, Evelyne, MD W Walsh, David, PhD Disclosure: Pfizer Inc, 2 Weisman, Michael H., MD Disclosure: Abbvie, 5; Amgen, 2; Astellas Pharma Global Development, 5; Celgene, 5; Centocor, Inc., 2; Cephalon, 2; Crescendo Bioscience, 5; Dynavax, 2; Genentech and Biogen IDEC Inc., 2; GSK, 2; Lilly, 2, 5; Pfizer Inc, 2; Rigel Pharma, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; Teva Pharmaceuticals, 2; UCB Pharma, 5 Williams, David A., PhD Disclosure: Pfizer Inc, 2 Wise, Barton L., MD Disclosure: Pfizer, Inc, 9 Wither, Joan E., MD, PhD Yelin, Edward H., PhD Yost, John H, DO Young, Brandi, DNP, FNP-C Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., 8 Yunus, Muhammad B., MD Zell, JoAnn, MD Ziminski, Carol M., MD Y Z 2014 Program Book 267

270 Invited Speaker /Moderator Index 268 A Abril, Andy, MD ACR-EULAR Rheumatica Guidelines Acuna, Jose Carlos Crispin, MD Autoimmunity in Immunodeficiency...45 Adelowo, Olufemi, MD Patient Access to Biologics Across the Globe..108 Aggarwal, Rohit, MD, MS Myopathy: Issues in Diagnosis and Treatment (055) Disclosure: Questcor, 2, 5 Myopathy: Issues in Diagnosis and Treatment (085) Disclosure: Questcor, 2, 5 Aizer, Juliet, MD, MPH Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Disclosure: Hospital for Special Surgery Rheumatology Academy of Medical Educators, 2; Rheumatology Research Foundation, 2 Albayda, Jemima, MD Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (231) Alder, Jonathan, PhD Telomeres, Telomerase and the Aging Immune System...83 Allanore, Yannick, MD, PhD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion Pharmaceuticals US, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Sanofi- Aventis Pharmaceutical, 5 Allen, Kelli D., PhD Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Aluri, Vijay, MD ACR Knowledge Bowl: Preliminary Round...42 ACR Knowledge Bowl: Final Round...74 Amato, Anthony A., MD Myositis Mimics: Clinical and Molecular Diagnosis Program Book Amin, Shreyasee, MD CM, MPH Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Disclosure: TissueGene, Inc, 9 Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Disclosure: TissueGene, Inc, 9 Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Disclosure: TissueGene, Inc, 9 Anderson, Lee, BSN Practical Practice Management Session One: Improve Quality and Efficiency...53 Andrade, Felipe, MD PhD Complement in Rheumatic Disease Disclosure: Medimmune, 2; Padlock, 5 Anolik, Jennifer H., MD, PhD Novel Regulatory Cell Subsets Antonelli, Maria, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Aranow, Cynthia, MD Systemic Lupus Erythematosus: Central Nervous System (048)...63 Ardoin, Stacy P., MD, MS Protecting Bone Health in Pediatric Rheumatic Diseases Argoff, Charles E., MD Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease Arroyo, Ramon, MD ACR Knowledge Bowl: Final Round...76 Disclosure: Genentech and Biogen IDEC Inc., 8 ACR Knowledge Bowl: Preliminary Round...42 Disclosure: Genentech and Biogen IDEC Inc., 8 Ascherman, Dana P., MD Advances in Molecular Profiling and Relevance to Autoimmune Disease Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases Astourian, Patrick, MPAS, PA-C ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions Outline the Value of Ultrasound...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions Ultrasound Case Presentations...30 Atkinson, John, MD Basic Immunology for Clinical Rheumatologists (001)...32 Disclosure: 9 R01 GM99111 (Atkinson, John P.) 2 P30 AR48335 (Yokoyama, Wayne) 5 T32 AR (Atkinson, John P.) Edward N. and Della L. Thome Memorial Foundation (Atkinson, John P.) U54 HL (Sadler, Evan) Alexion Pharmaceutic, 2; Compliment Corporation; Scientific Advisory Board, 2010 present., 1; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Con, 5; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Kyp, 3 Basic Immunology for Clinical Rheumatologists (032)...70 Disclosure: 9 R01 GM99111 (Atkinson, John P.) 2 P30 AR48335 (Yokoyama, Wayne) 5 T32 AR (Atkinson, John P.) Edward N. and Della L. Thome Memorial Foundation (Atkinson, John P.) U54 HL (Sadler, Evan) Alexion Pharmaceutic, 2; Compliment Corporation; Scientific Advisory Board, 2010 present., 1; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Con, 5; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Kyp, 3 Avery, Michael Thomas, DO Thieves Market Posters - ACR/ARHP Poster Session C Ayata, Cenk, MD Primary Angiitis of the Central Nervous System and Its Mimics B Backman, Catherine L., PhD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Baer, Alan N., MD ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 Disclosure: UptoDate, 7 Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Disclosure: UptoDate, 7 Gout Management in Disclosure: UptoDate, 7 See page 247 for the list of disclosure relationships.

271 Myositis Mimics: Clinical and Molecular Diagnosis Disclosure: UptoDate, 7 Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Disclosure: UptoDate, 7 Bailey, L. Charles, MD, PhD ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...24 Baker, Kristin, PhD Exercise Adherence in Arthritis: The Role of Technology Baker, Nancy A., MPH, OTR, OTR/L Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Bannuru, Raveendhara R., MD New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Barbour, Kamil E., PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross- Sectional Studies Barnes, Betsy, PhD Therapeutic Targeting of the Innate Immune System...55 Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others Baron, Roland, DDS, PhD Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges Disclosure: Merck Pharmaceuticals, Chugai, 2; Merck, Amgen, Lilly, Radius Health, Bone Therapeutics, Ashi Kasei, Daiichi Sankyo, Pfizer, 5 Barron, Karyl, MD Macrophages Gone Wild Bartlett, Susan J., PhD Role of Nutrition in Rheumatic Diseases Barton, Anne, MD, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Basharat, Pari, MD Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (231) Bass, Anne, MD Inflammation and Atherothrombosis Disclosure: Pfizer Inc, 9; Weill Cornell Medical College Clinical Translational Science Center, 2 Bathon, Joan M., MD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 Batiste, Linda C., JD Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Battafarano, Daniel F., DO Affordable Care Act...38 Battistone, Michael J., MD Educator: Medical Education: The Year in Review...45 Beam, Thuy T., BSN, RN Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Behrens, Edward M., MD Macrophages Gone Wild Belkaid, Yasmine, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Bernstein, Elana J., MD, MSc Hepatitis C in Neonatal Lupus: From Bench to Bedside...83 Primary Angiitis of the Central Nervous System and Its Mimics Sarcoidosis in The Butterfly Effect: Lupus Rashes and Their Mimics...45 The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 Bhusal, Santosh, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Bianco, Paolo, MD Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases Bingham III, Clifton O., MD ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: OMERACT, 6; PCORI, 2 Birnbaum, Julius, MD, MHS Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Blackwell, Timothy, MD Insight into Lung Fibrosis...84 Disclosure: Boerhringer Ingelheim, 5; Intermune, 9 Blakley, Michael, MD Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Blitz, Jill R., PT, DPT Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Boackle, Susan A., MD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Complement in Rheumatic Disease Bockenstedt, Linda, MD Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 Disclosure: L2 Diagnostics, 2 Bolster, Marcy B., MD Career Opportunities in Rheumatology: Making a Choice...94 Borenstein, David G., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: Clinical Care Options, 9; Patient Access Network Foundation, 6; Sucampo, 5 State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Disclosure: Back In Control Inc, 1; Clinical Care Options, 9; Patient Access Network Foundation, 6; Sucampo, 5 Boussiotis, Vassiliki A., MD, PhD Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases..147 Invited Speaker /Moderator Index 2014 Program Book 269

272 Invited Speaker/Moderator Index Brasington, Richard D., MD Biomarkers in Rheumatic Care... Disclosure: Clinical Trials for GSK, 2; Pfizer Inc, 8 Braun, Jonathan, MD, PhD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Braun, Jürgen, MD Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Disclosure: Abbott Immunology Pharmaceuticals, 5; MSD, 5; Pfizer Inc, 5; UCB, 5 Breeden, Elizabeth A., PharmD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Breland, Hazel L., PhD, OTR/L Thriving With Rheumatic Disease: Cultivating Resilience...93 Brenner, Michael B., MD Rheumatology Research Foundation: Disease Targeted Research Special Session Disclosure: Adheron Therapeutics, 1, 5 Bridges Jr., S. Louis, MD, PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Year in Review...32 Bucala, Richard J., MD, PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Burke, Allen, MD Histopathology of Rheumatic Lung Disease (206)...38 Histopathology of Vasculitis (218)...76 Burnham, Jon M., MD, MSCE Protecting Bone Health in Pediatric Rheumatic Diseases Disclosure: National Institutes of Health, 2 Buyon, Jill P., MD Neonatal Lupus: From Bench to Bedside...83 C Cacoub, Patrice, MD Curbside Consults Ask the Experts...95 Disclosure: Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier, Vifor., 5 Calabrese, Leonard H., DO Primary Angiitis of the Central Nervous System and Its Mimics What is Not Central Nervous Angiitis: Making the Right Diagnosis (020)...44 Cantor, Harvey, MD New Regulatory T Cells Cao, Xu, PhD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Castelino, Flavia V., MD Insight into Lung Fibrosis...84 Strategies for Academic Success: The Roadmap From Mentee to Mentor...73 Chakravarty, Eliza, MD, MS Pregnancy and Rheumatic Diseases (036)...71 Disclosure: UCB, 5 Pregnancy and Rheumatic Diseases (086) Disclosure: UCB, 5 Chandel, Navdeep S., PhD Bioenergetics and Energy Regulation Chang, Anthony, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221)...76 Disclosure: Amirsys Publishing, Inc, 7; Questcor Pharmaceuticals, Inc, 5; Roche Organ Transplantation Research Foundation, 2 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234) Disclosure: Amirsys Publishing, Inc, 7; Questcor Pharmaceuticals, Inc, 5; Roche Organ Transplantation Research Foundation, 2 Charles, Julia F., MD, PhD Rheumatology Research Foundation Special Session Chatterjee, Soumya, MD, MS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Chen, Lan, MD, PhD Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Brophy, Robert, MD Meniscus Biology in Osteoarthritis...69 Caplan, Arnold I., PhD Novel Regulatory Cell Subsets Disclosure: Osiris, 7 Cheroutre, Hilde, PhD How the Gut Primes the Immune System Bruce, Susan, PharmD Pharmacotherapy: What s New in Rheumatology Brummett, Chad M., MD Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Bryan, Angela, MD Thieves Market Posters - ACR/ARHP Poster Session C Program Book Caplan, Arthur L., PhD Ethics and Rheumatology...34 Caplan, Liron, MD, PhD Axial Spondyloarthritis Guidelines...44 Carey, John J., CCD, MS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Carsons, Steven E., MD ACR-EULAR Rheumatica Guidelines Chira, Peter, MD, MS Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Disclosure: BMS, UCB, NIH, 2 Chohan, Saima, MD Crystal: Diagnosis and Management of Gout (021)...66 Choi, Hyon K., MD, DrPH Role of Nutrition in Rheumatic Diseases Disclosure: AstraZeneca, 5; Takeda, 5 Chrostowski, Susan, MS, ANP-C, RN What Are Biosimilars?...70 See page 247 for the list of disclosure relationships.

273 Chung, Antanya, CPC, CPC-I, CRHC, CCS-P ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 Chung, Raymond T., MD Hepatitis C in Disclosure: Gilead, Mass Biologic, Abbvie, 2 Cidon, Michal, MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Clark, Marcus R., MD Systems Biology of Lupus Nephritis...73 Disclosure: AbbVie, 2; Medimmune, 2 Clauw, Daniel J., MD Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain..77 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Fibromyalgia 2014: Update on Management (004)...33 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Treatment Considerations in Chronic Pain Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2; Pfizer, Lilly, Forest, Astellis, Therevance, Tonix, IMS, Wyeth, Nuvo, 5; Pfizer, Lilly, Forest, Wyeth, Cerephex, Nuvo, 2 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain? Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Clements, Philip J., MD, MPH Fibrotic Complications of Scleroderma...95 Cleveland, Rebecca J., PhD Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Clifford, Alison, MD ACR Plenary Session III: Discovery Colbert, Robert A., MD, PhD The Microbiome in Health and Disease...35 Cole, Steven, MD Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes..134 Disclosure: Comprehensive Motivational Intervions, LLC, 4 Collins, Christopher E., MD Social Media Boot Camp: Twitter Basics...37 Conaghan, Philip G., MD, PhD Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232) Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237) Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Coney, Cynthia, MEd, CAPP ARHP Keynote Address: Happiness From the Inside Out...37 Conway, Richard, BAO, BCh, MB, MRCPI ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Cook, Karon, PhD ACR Clinical Research Conference - Session I: Methodology and Development Costenbader, Karen H., MD, MPH Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Cox, Talitha, MA, OTR/L Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Crawford, Donah Z., BS, MA Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Disclosure: Abbvie, Pfizer, Lilly, Bioventus, Genentech, 9 Criscione-Schreiber, Lisa G., MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Cron, Randy Q., MD, PhD Macrophages Gone Wild Disclosure: Novartis Pharmaceutical Corporation, 5; Swedish Orphan Biovitrum, 5 Cronin, Mary E., MD ACR Plenary Session II: Discovery Clinical Issues Associated with the Use of Methotrexate Cronstein, Bruce N., MD Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Disclosure: ACR Board of Directors, Ex officio, 6; ACR Committee on Research, 6; Arthritis Foundation, 6; AstraZeneca, 2; Bristol- Myers Squibb, 5; Canfite Pharma, 1; Celgene Pharmaeuticals, 2; Eli Lilly and Company, 5; Gilead Pharmaceuticals, 2; Multiple Patents, 9; Rheumatology Research Foundation, 6 Crosby, Judy K., JD ACR Clinical Research Conference - Session V: Patient Perspective...27 Crow, Mary K., MD ACR Plenary Session III: Discovery Disclosure: Bristol-Myers Squibb, 5; Eisai, 5; GlaxoSmithKline, 5; Lilly, 5; Novo Nordisk, 2; Pfizer-CTI, 2; Takeda, 5 Cruz, Nilsa ACR Practice Management Pre-Meeting Course - Customer Service That Rocks: Boost Patient Satisfaction...27 ACR Practice Management Pre-Meeting Course - Improve Time-of-Service Collections From the Front-End...27 ACR Practice Management Pre-Meeting Course - Increase Team Performance and Productivity.. 27 ACR Practice Management Pre-Meeting Course - In s and Out s of an Effective Compliance Plan...27 ACR Practice Management Pre-Meeting Course - Managing Denials in a Complex Reimbursement Environment...27 ACR Practice Management Pre-Meeting Course - Take Your Appeals to the Next Level...27 Disclosure: UnitedHealthcare, 5 Culver, Daniel, DO Sarcoidosis in Curtis, Jeffrey R., MD, MPH, MS ACR Clinical Research Conference - Session I: Methodology and Development Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care Practical Use of Registries...73 Vaccinations for Patients on Biologic Therapies (018)...43 Invited Speaker/Moderator Index 2014 Program Book 271

274 Invited Speaker/Moderator Index Cush, John J., MD Rheumatology Roundup: Highlights from the 2014 Annual Meeting Still s Disease and Autoinflammatory Syndromes (047)...82 Cutolo, Maurizio, MD Nailfold Capillaroscopy (202)...34 Patient Access to Biologics Across the Globe D Daikh, David I., MD, PhD Rheumatic Manifestations of Malignancy Dalbeth, Nicola, MBChB, MD Classification Criteria for Gout...82 Disclosure: AstraZeneca/Ardea, 2, 5; Takeda, 5; Teijin, 8 Dall era, Maria, MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (010)...33 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (039)...71 Danska, Jayne, PhD The Microbiome in Health and Disease...35 Dao, Kathryn H., MD Infections with Biologics (022)...66 Infections with Biologics (054) Dasgupta, Bhaskar, MD ACR-EULAR Rheumatica Guidelines Disclosure: Servier, 5 Davidson, Anne, MBBS Rheumatology Research Foundation Special Session: Disease Targeted Research Systems Biology of Lupus Nephritis...73 Davis III, John M., MD, MS Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others Deane, Kevin D., MD, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Deane, Peter, MD Hereditary Angioedema Update (014)...43 Dejaco, Christian, MD, PhD ACR-EULAR Rheumatica Guidelines Disclosure: Pfizer, MSD, 2; Pfizer, MSD, Roche, UCB, BMS, AbbVie, 8 DeMarco, Paul J., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Billing, Coding and Report Generation...26 Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Auxilium Pharmaceuticals, 2; UBM Medica US, 5 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Auxilium Pharmaceuticals, 2; UBM Medica US, 5 Deodhar, Atul A., MD Axial Spondyloarthritis Guidelines...44 Disclosure: Abbvie, Amgen, Janssen, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 Joint Injection Techniques (201)...33 Joint Injection Techniques (222)...83 Deshmukh, Umesh, PhD ACR Plenary Session II: Discovery Dewing, Kori A., DNP, ARNP Providing Evidence for Mid-Level Providers in Rheumatology Practice Rheumatic Manifestations of Malignancy Distler, Oliver, MD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion, Pfizer, Ergonex, BMS, Bayer, United BioSource Corporation, Roche/ Genentech, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4D Science, Active Biotec, Sinoxa, Sanofi-Aventis, Serodapharm, GSK, Epipharm,, 5; Actelion, Pfizer, Ergonex, Sanofi-Aventis, 2 Dixit, Rajiv, MD Pain: Evaluation and Treatment of Back Pain (006)...33 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Dixon, William G., MRCP, PhD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Dodge, Carole V., OT, CHT Role of Nutrition in Rheumatic Diseases Domsic, Robyn T., MD, MPH Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049)...82 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069) Dougados, Maxime, MD, PhD Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Disclosure: Pfizer Inc; Abbvie;Novartis,Sanofi,Li lly,ucb, 2, 5 Dufour, Alyssa B., PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher (230) Disclosure: Pearson Publisher, 7 E Edwards, N. Lawrence, MD Curbside Consults Ask the Experts...94 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 Thieves Market: Show Me Your Best Cases...55 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 Eggleton, Paul, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease Erkan, Doruk, MD Antiphospholipid Syndrome (051) Disclosure: Alexion Pharmaceuticals, Inc., 2, 5; Eli Lilly and Company, 2; EMD Serono, 2; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Antiphospholipid Syndrome (071) Disclosure: Alexion Pharmaceuticals, Inc., 2, 5; Eli Lilly and Company, 2; EMD Serono, 2; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Evangelisto, Amy M., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Elbow...22 Musculoskeletal Ultrasound (220)...76 Musculoskeletal Ultrasound (233) Program Book See page 247 for the list of disclosure relationships.

275 F Farrell, Jessica, PharmD ACR Practice Management Pre-Meeting Course - Take Your Appeals to the Next Level...28 Felson, David T., MD, MPH Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Non-surgical Treatments for Osteoarthritis (074) Disclosure: Zimmer Knee Creations, 5 The Role of Bone in the Pathogenesis of Osteoarthritis...95 Disclosure: Zimmer Knee Creaions, 5 Ferguson, Polly J., MD Pediatric Rheumatology Town Hall...32 Fields, Karl, MD Sports Medicine for the Rheumatology Provider...54 Disclosure: Body Helix, 6 Fields, Theodore R., MD Crystal: Diagnosis and Management of Gout (002)...32 Disclosure: AstraZeneca Pharmaceuticals, 5; AstraZenica Pharmaceutics, 5; Crealta Pharmaceuticals, 5; Pfizer Pharmaceuticals, 8; Takeda Pharmaceuticals, 5, 8 Finan, Patrick, PhD Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Fine, Derek M., MD Forefronts in Lupus Nephritis...84 Fischer, Aryeh, MD ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Pulmonary Manifestations of Rheumatic Disease (056) Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Pulmonary Manifestations of Rheumatic Disease (087) Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Fitzcharles, Mary-Ann, MBChB, MD The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond FitzGerald, John, MD, PhD The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: RAND, 5 Flemming, Donald J., MD X-Ray Challenges in Rheumatic Diseases (235) Disclosure: American Board of Radiology, 6; Elsevier, 7 Flood, Joseph, MD ACR Business Meeting ACR Plenary Session I: Discovery Patient Access to Biologics Across the Globe Foxworth, Judy, PhD, PT Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation Sports Medicine for the Rheumatology Provider...53 Fraenkel, Liana, MD, MPH ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Franzosa, Eric, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Friday, Robert P., MD, PhD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Fu, Shu Man, MD, PhD Systems Biology of Lupus Nephritis...73 Furst, Daniel, MD, MPH Rheumatoid Arthritis: Challenging Cases (009)...33 Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 Rheumatoid Arthritis: Challenging Cases (038)...71 Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 Systemic Sclerosis: How to Perform Skin Scores (241) Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 G Gabriel, Sherine E., MD, MSc ACR Clinical Research Conference - Session I: Methodology and Development ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 ACR Clinical Research Conference - Session V: Patient Perspective...27 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases Ganguli, Arijit X., MBA, PhD ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Disclosure: AbbVie, Inc, 1, 3 Ganti, Niharika, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Gardiner, Philip, MD Social Media Boot Camp: Blogging for Beginners...75 Gatla, Nandita, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 GC, Yathish, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Thieves Market Posters - ACR/ARHP Poster Session B...74 Gensler, Lianne S., MD Ankylosing Spondylitis: 2014 Update (011)...43 Disclosure: AbbVie, 5; Celgene Corporation, 9; UCB, 5 Ankylosing Spondylitis: 2014 Update (031)...70 Disclosure: AbbVie, 5; Celgene Corporation, 9; UCB, 5 Gewirtz, Andrew, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Invited Speaker/Moderator Index Ghetie, Daniela, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round Program Book 273

276 Invited Speaker/Moderator Index Gignac, Monique A., PhD ARHP Distinguished Lecturer: Maintaining Health and Well-Being Despite Living With a Rheumatic Disease Nothing About Us Without Us: Engaging Patients in Rheumatology Research Gilbert, Jack, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Giles, Jon T., MD, MPH Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything Ginsberg, Seth Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care Gladman, Dafna D., MD Psoriatic Arthritis (007)...33 Disclosure: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB, 5; Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, UCB, 2; Abbvie, Amgen, Celgene, Janssen, Pfizer, UCB, 2 Psoriatic Arthritis (043)...81 Disclosure: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB, 5; Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, UCB, 2; Abbvie, Amgen, Celgene, Janssen, Pfizer, UCB, 2 Glimcher, Laurie H., MD Bone Biology...38 Disclosure: Bristol-Myers Squibb, 4, 5; Waters Corporation, 4, 5 Goddard, David, MD Legislative Update: Chat with Congress...75 Disclosure: Pizer Inc, Amgen, Eli Lilly, Takeda, Astra Zeneca, 8 Goglin, Sarah, MD Thieves Market: Show Me Your Best Cases..56 Golden, Angela K., DNP Affordable Care Act...38 Goldenberg, Don L., MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Disclosure: Pfizer Inc, 5 Golding, Amit, MD, PhD New Regulatory T Cells Goldring, Steven R., MD Bone Biology...38 Goldschneider, Kenneth, MD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...36 Goldszmid, Romina, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Golightly, Yvonne M., PT, MS, PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies Goode, Adam, DPT, PT State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Goodman, Susan M., MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Gordon, Kenneth B., MD Psoriatic Arthritis: Skin, Entheses and Joints Gossec, Laure, MD, PhD ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 Disclosure: AbbVie, Janssen, Novartis, Pfizer, Roche, UCB, 5 Goyal, Janak R., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance Musculoskeletal Ultrasonography: Basic (228) Musculoskeletal Ultrasonography: Basic (238) Graf, Jonathan D., MD Rheumatology on the Street...83 Gravallese, Ellen M., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: AbbVie, 2; Eli Lilly and Company, 2 Greenberg, Jeffrey D., MD, MPH Update on Findings From Large Registries: Emphasis on Health Disparities in Rheumatic Arthritis...70 Grembiale, Rosa Daniela ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Grice, Elizabeth A., PhD The Microbiome in Health and Disease...35 Disclosure: Amway, 5; GoJo, 5; Janssen Research and Development, LLC, 2; Stiefel, 5 Grom, Alexei A., MD ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Disclosure: Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Macrophage Activation Syndrome (005)...33 Disclosure: Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Gruber, Barry, MD Osteoporosis: Emerging Treatments Both Pharmacological and Non- Pharmacological Disclosure: Amgen, 8; Genentech and Biogen IDEC Inc., 8; GlaxoSmithKline, 8; Janssen Pharmaceutica Product, L.P., 8; Questcor, 8 Guccione, Andrew A., PhD, DPT RheumCha...113t Gultekin, Sakir Humayun, MD Muscle Involvement in Rheumatic Diseases (211)...55 Gwilliam, Evan, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P Practice Issues: Practice Success in an Environment of Transition...73 Disclosure: Findacode, 3 Practice Issues: The Road to I Disclosure: Findacode, 3 H Hahn, Bevra H., MD The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 Disclosure: Astellas, 5; Eisai, 5; Lilly, 5; Merck Human Health, 5 Hajj-Ali, Rula, MD Curbside Consults Ask the Experts...94 Primary Angiitis of the Central Nervous System and Its Mimics Thieves Market: Show Me Your Best Cases Hanly, John G., MD The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Program Book See page 247 for the list of disclosure relationships.

277 Hannan, Marian T., DSc, MPH Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 RheumCha...113t Hansen, Karen E., MD, MS Osteoporosis: Current Concepts for the Clinician...35 Hant, Faye N., DO, MSCR Scleroderma Mimics (046)...82 Harrington, J. Timothy, MD Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066) Disclosure: Joiner Associates LLC, Crescendo Bioscience, 5; Pfizer Inc, 5 Harris, Helena E., BSc, PhD Therapeutic Targeting of the Innate Immune System...55 Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain? Disclosure: Pfizer Inc, 2, 5 Harvey, William F., MD, MSc Advocacy: Meet the Expert - A Senator s Perspective on Advocacy Best Practices...36 Legislative Update: Chat with Congress...75 Practice Issues: The Road to I Hassan, Sobia, BM BS, MRCP ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Hassett, Afton L., PsyD ARHP Distinguished Lectuer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease...75 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 ARHP Keynote Address: Happiness From the Inside Out...37 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 RheumChat Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 Treatment Considerations in Chronic Pain Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 Hasson, Scott, Pt, PhD Update on Findings From Large Registries: Emphasis on Health Disparities in Rheumatic Arthritis...70 Helfgott, Simon M., MD ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 Disclosure: Abbvie, 5 ACR Review Course - Genomics for the Clinician...29 Disclosure: Abbvie, 5 ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review...28 Disclosure: Abbvie, 5 ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 Disclosure: Abbvie, 5 ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 Disclosure: Abbvie, 5 ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 Disclosure: Abbvie, 5 ACR Review Course - Rheumatoid Arthritis Therapy After Diagnosis of Malignancy...29 Disclosure: Abbvie, 5 ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Disclosure: Abbvie, 5 Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Disclosure: Abbvie, 5 Henderson Sumpter, Anita, MBA, MHA, CPC, CMOM ACR Practice Management Pre-Meeting Course - In s and Out s of an Effective Compliance Plan...28 Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 Her, Minyoung, MD Thieves Market Posters - ACR/ARHP Poster Session C Higgs, Jay B., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Principles of Musculoskeletal Ultrasound for Rheumatologists...25 Advanced Musculoskeletal Ultrasound (208).. 45 Advanced Musculoskeletal Ultrasound (214).. 71 Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229) Hillstrom, Howard J., PhD Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Hochberg, Marc C., MD, MPH New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Disclosure: Bioiberica S.A., 5; Carbylan, 9; EMD Serono Inc., 5; Iroko Pharmaceuticals, 5; Moebius Medical Ltd., 5; Novartis Pharma AG, 5; Pfizer Inc, 5; Strategic Science and Technology, 5; Theralogix LLC, 1 Hoellein, Andrew R., MD Educator: Medical Education: The Year in Review...45 Hoffman, Gary S., MD Vasculitis - Factors That Influence Disease Patterns (060) Disclosure: Roche Pharmaceuticals, 9 Vasculitis - Factors That Influence Disease Patterns (070) Disclosure: Roche Pharmaceuticals, 9 Hood, Leroy, MD, PhD ACR/ARHP Opening Lecture and Awards...31 Hootman, Jennifer M., PhD Exercise Adherence in Arthritis: The Role of Technology Horonjeff, Jennifer R., MS Young Adults with Rheumatic Disease: The Patient Perspective...54 Hotamisligil, Gökhan S., PhD, MD Metainflammation Disclosure: Servier Pharmceuticals, UCB Pharmaceuticals, 2 Howard, Rennie N. G., MD Neonatal Lupus: From Bench to Bedside...83 Psoriatic Arthritis: Skin, Entheses and Joints Huber, Adam M., MD MSc Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...73 Huffman, Kim M., MD, PhD Successful Aging in Rheumatic Disease Hughes, Laura B., MD, MSPH ACR Knowledge Bowl: Final Round...76 Disclosure: Janssen Pharmaceutica Product, L.P., 5 ACR Knowledge Bowl: Preliminary Round...42 Disclosure: Janssen Pharmaceutica Product, L.P., 5 Huisinga, Karen, MN, ARNP ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Introduction...30 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological Disclosure: Pfizer Inc, 5 Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 Invited Speaker/Moderator Index Hutchinson, James, MBBChir, PhD Novel Regulatory Cell Subsets Program Book 275

278 Invited Speaker/Moderator Index 276 Hutchinson, Tim, The Honorable Advocacy: Meet the Expert - A Senator s Perspective on Advocacy Best Practices...36 Huttenlocher, Anna, MD Pediatric Rheumatology Town Hall...32 I Inman, Robert D., MD Spondylarthropathy: An Update (077) Disclosure: Abbvie, Amgen, Janssen, Pfizer, UCB, 5; Amgen, Janssen, UCB, Abbvie, Pfizer, 5 Iobst, William, MD Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required Irrgang, James J., ATC, PhD, PT Sports Medicine for the Rheumatology Provider...54 Isenberg, David A., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus Iversen, Maura D., BSc, DPT, SD, MPH Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Google Minefield: Empowering Patients to Evaluate Online Resources...58 J Jansen, Tim L., MD, PhD Classification Criteria for Gout...82 Disclosure: research grant for POET-US =additional study to nationwide TNFi stop study) from Abbvie, 2 Janssen, Erin, MD, PhD Autoimmunity in Immunodeficiency...45 Jansson, Janet, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Jarjour, Wael N., MD Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Disclosure: Navidea Pharmaceutical, 5 Autophagy in Rheumatic Diseases Disclosure: Navidea Pharmaceutical, 5 How the Gut Primes the Immune System...44 Disclosure: Navidea Pharmaceutical, Program Book Johnson, Kiana, PhD Young Adults with Rheumatic Disease: The Patient Perspective...54 Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Jolly, Meenakshi, MD, MS The Butterfly Effect: Lupus Rashes and Their Mimics...45 Jones, Karla, RN Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Jordan, Joanne M., MD, MPH Osteoarthritis: Update 2014 (035)...71 Disclosure: Algynomics, 5; ClearView Healthcare Partners, 5; Flexion, 5; Samumed, 5; Trinity Partners, LLC, 5 Osteoarthritis: Update 2014 (075) Disclosure: Algynomics, 5; ClearView Healthcare Partners, 5; Flexion, 5; Samumed, 5; Trinity Partners, LLC, 5 Joshi, Piyush, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Jurisson, Mary L., MD Tai Chi in Rheumatic Disease (203) K Kaeley, Gurjit S., MBBS, MRCP ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Shoulder...23 Disclosure: AbbVie, 5; Esaote, 9 Musculoskeletal Ultrasonography: Basic (228).. 94 Disclosure: AbbVie, 5; Esaote, 9 Musculoskeletal Ultrasonography: Basic (238) Disclosure: AbbVie, 5; Esaote, 9 Ultrasound Injection Guidance (242) Disclosure: AbbVie, 5; Esaote, 9 Kalish, Robert A., MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Kang, Jane, MD Ethics and Rheumatology...34 Kaplan, Mariana J., MD From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Karp, David R., MD, PhD Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Geneenvironment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 Kashikar-Zuck, Susmita, PhD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Kastner, Daniel L., MD, PhD Pediatrics: Periodic Fevers in Children (065)..109 Katz, Jeffrey N., MD, MSc New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Katz, Patricia P., PhD Successful Aging in Rheumatic Disease Thriving With Rheumatic Disease: Cultivating Resilience...93 Kaur, Primal P., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: Amgen, 1, 3 Kavanagh, Ronan, MD, MRCP Social Media Boot Camp: Blogging for Beginners...75 Disclosure: Vidscrip / Clear.MD, 1; Viscrip / Clear. MD, 1 Social Media Boot Camp: Twitter Basics...37 Disclosure: Vidscrip / Clear.MD, 1; Viscrip / Clear. MD, 1 Kavanaugh, Arthur, MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Disclosure: AbbVie, 2; Amgen, 2; Astellas, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; UCB, 2 Rheumatology Roundup: Highlights from the 2014 Annual Meeting Disclosure: AbbVie, 2; Amgen, 2; Astellas, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; UCB, 2 Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Disclosure: Abbvie, 2; Amgen, 2; bms, 2; Janssen Pharmaceutica Product, L.P., 2; ucb, 2 Kay, Jonathan, MD Practice Issues: The Road to I Kazi, Salahuddin, MD Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Getting Electronic Health Records Right (240) Practical Use of Registries...73 See page 247 for the list of disclosure relationships.

279 Keenan, Robert T., MD, MPH The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: AstraZeneca, 5; Crealta, 5; Takeda, 5 Kelly-Hall, Leslie ACR Clinical Research Conference - Session I: Methodology and Development Disclosure: Healthwise, 3 Kemper, Claudia, PhD Complement in Rheumatic Disease Keysor, Julie J., PhD, PT Exercise Adherence in Arthritis: The Role of Technology Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Keystone, Edward C., MD Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213)...55 Rheumatoid Arthritis: Biological Agents (016)...43 Disclosure: Abbott Laboratories, 2, 5, 8; Amgen, 8; Amgen Canada, 2; AstraZeneca, 5, 8; Astrazeneca Pharmaceuticals LP, 2; Biotest, 5; Bristo-Myers Squibb, 2; Bristol-Myers Squibb, 5, 8; Eli Lilly and Company, 2, 5; F. Hoffman La-Roche Inc., 2, 8; F. Hoffman-La Roche Inc., 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5, 8; Sanofi-Aventis Pharmaceutical, 2; UCB, 8 Rheumatoid Arthritis: Biological Agents (044).. 82 Disclosure: Abbott Laboratories, 2, 5, 8; Amgen, 8; Amgen Canada, 2; AstraZeneca, 5, 8; Astrazeneca Pharmaceuticals LP, 2; Biotest, 5; Bristo-Myers Squibb, 2; Bristol-Myers Squibb, 5, 8; Eli Lilly and Company, 2, 5; F. Hoffman La-Roche Inc., 2, 8; F. Hoffman-La Roche Inc., 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5, 8; Sanofi-Aventis Pharmaceutical, 2; UCB, 8 Khan, Mehwish, MBBS, MD Thieves Market: Show Me Your Best Cases...56 ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Khanna, Dinesh, MD, MSc ACR Clinical Research Conference - Session III: Research Perspective...27 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 Current Understanding of Malignancies in Connective Tissue Diseases...34 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 Fibrotic Complications of Scleroderma...95 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Astra-Zeneca, Takeda, Savient, 5; NIH, Scleroderma Fdn, 2 Kim, Susan, MD, MMSc Juvenile Dermatomyositis (084) Kimel, Alexandru F., MD Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (028)...66 Kimpton, Kimberly F., PT State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Kissin, Eugene Y., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Hand and Wrist...23 Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Opening Remarks...25 Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists Introduction...22 Disclosure: SonoSite Inc, 9 Musculoskeletal Ultrasound (220)...76 Disclosure: SonoSite Inc, 9 Musculoskeletal Ultrasound (233) Disclosure: SonoSite Inc, 9 Kitsis, Elizabeth A., MD, MBE Ethics and Rheumatology...34 Kiyono, Hiroshi, DDS, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Klareskog, Lars, MD, PhD Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Geneenvironment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 Knight, Rob, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Kohler, Minna J., MD Beyond Musculoskeletal Ultrasound for Rheumatologists (204)...37 Kolasinski, Sharon L., MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Kong, Heidi H., MD, MHSc ACR Basic Research Conference - Session I: Overview of General Principles...24 ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Koren, Gideon, MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Kotton, Darrell, MD Insight into Lung Fibrosis...84 Krant, Jonathan, MD, MPH Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care Krause, Megan L., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Kremer, Joel M., MD Clinical Issues Associated with the Use of Methotrexate Krishnan, Eswar, MD From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Disclosure: Ardea, 2, 5; Takeda, 5; UCB, 2 Krohn, Kelly D., MD Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Disclosure: Eli Lilly and Company, 3 Kumar, Bharat, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Kunkel, Gary A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Knee...22 Invited Speaker/Moderator Index 2014 Program Book 277

280 Invited Speaker/Moderator Index 278 Kyttaris, Vasileios C., MD Systems Biology of Lupus Nephritis...73 Disclosure: Vertex Pharmaceuticals, 5 L La Cava, Antonio, MD, PhD Bioenergetics and Energy Regulation Lane, Nancy E., MD Vitamin D and Bone Health (030)...67 Lang, Jason, MD Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation Disclosure: Smith & Nephew, Inc., 5 Langevin, Helene, MD Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside Langford, Carol A., MD ACR/ABIM MOC Learning Session - Session I: Questions from 2014 Update...25 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session One of Three...34 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session Three of Three Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session Two of Three...72 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 Curbside Consults Ask the Experts...95 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 Lavalley, Michael P., PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Disclosure: Athritis Care & Research, 3 Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Disclosure: Athritis Care & Research, 3 Laxer, Ronald, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Lazaro, Deana M., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Educator: Medical Education: The Year in Review Program Book Leder, Benjamin Z., MD Osteoporosis: Current Concepts for the Clinician...35 Disclosure: Amgen, 2; Lilly, 2; Merck Human Health, 5; Radius, 5 Lee, Jungwha, PhD, MPH Basic Statistical Concepts for the Medical Researcher (230) Lehman, Thomas J. A., MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (024)...66 Disclosure: Abbott Immunology Pharmaceuticals, 8; Genentech and Biogen IDEC Inc., 8; Novartis Pharmaceutical Corporation, 8 Leong, Amye L., MBA Nothing About Us Without Us: Engaging Patients in Rheumatology Research Levine, Alana B., MD Antiphospholipid Syndrome (061) Li, Linda C., PhD, PT Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Lightstone, Liz, MD, PhD Forefronts in Lupus Nephritis...84 Disclosure: Anthera, EMD Serono, GSK, Medimmune, Merck, UCB, 5; Roche Pharmaceuticals, 2; UCB, GSK, 8 Systemic Lupus Erythematosus: Novel Treatments (029)...67 Disclosure: Anthera, EMD Serono, GSK, Medimmune, Merck, UCB, 5; Roche Pharmaceuticals, 2; UCB, GSK, 8 Lin, Clara, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Introduction to typical sonographic findings & Tissue Characteristics in Rheumatology...23 Lin, Jenny, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Littmann, Dan, MD, PhD ACR Basic Research Conference - Keynote Lecture: Microbiome and Host Immune Defenses...24 Loeser, Richard F., MD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Lohr, Kristine M., MD, MS ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 ACR Review Course - Genomics for the Clinician...29 ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review...28 ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 ACR Review Course - Rheumatoid Arthritis Therapy after Diagnosis of Malignancy...29 ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Career Opportunities in Rheumatology: Making a Choice...94 Rheumatology on the Street...83 Lories, Rik, MD, PhD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Louie, Grant H., MD, MHS Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Disclosure: AbbVie, 5 Lovell, Daniel, MD, MPH Pediatric Rheumatology for Adult Rheumatologists (042)...81 Disclosure: Bristol-Myers Squibb, 5; Celgene, 5; Forest Laboratories, 9; Genetech, 5, 8; Johnson & Johnson, 5; Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Lundberg, Ingrid E., MD, PhD Classification Criteria for Myositis...83 Luqmani, Raashid A., DM Vasculitis: Update (019)...44 Disclosure: GSK, 5 Vasculitis: Update (040)...71 Disclosure: GSK, 5 Lynch, Susan, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Disclosure: Janssen Pharmaceuticals, 2 M MacKenzie, C. Ronald, MD Ethics and Rheumatology...34 See page 247 for the list of disclosure relationships.

281 Mackey, Meggan, MD, MS Systemic Lupus Erythematosus: Central Nervous System (068) Mackey, Sean, MD, PhD RheumChat Treatment Considerations in Chronic Pain Mackool, Bonnie T., MD, MSPH The Butterfly Effect: Lupus Rashes and Their Mimics...45 Magid, Steven K., MD Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Majka, Darcy S., MD Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Maksymowych, Walter P., MD Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210)...55 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223)...83 Malcarne, Vanessa L., PhD Multidisciplinary Management of Scleroderma...68 Mammen, Andrew L., MD, PhD Myositis Mimics: Clinical and Molecular Diagnosis Mandelin II, Arthur M., MD, PhD The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (217)...72 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (239) Mandell, Brian F., MD, PhD Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Mandl, Kenneth D., MD, MPH ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Manno, Rebecca L., MD, MHS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Curbside Consults Ask the Experts...94 Psoriatic Arthritis: Skin, Entheses and Joints Thieves Market: Show Me Your Best Cases...55 Manzi, Susan, MD, MPH Systemic Lupus Erythematosus: Novel Treatments (017)...43 Disclosure: Eli Lilly and Company, 5; Exagen, 5, 7; GlaxoSmithKline, 2, 5 Marcus, Donald M., MD Complementary and Alternative Therapies in Rheumatic Disease (215)...71 Maricic, Michael J., MD Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges Marri, Reshma, BS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Marston, Bethany A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Pediatrics...23 Martinez, Joseph, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Matteson, Eric L., MD, MPH ACR-EULAR Rheumatica Guidelines Disclosure: Novartis Pharmaceutical Corporation, 2 Mauri, Claudia, PhD Novel Regulatory Cell Subsets Maynard, Janet W., MD, MHS Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond McAlindon, Timothy E., MD, MPH, MRCP Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Disclosure: ACR, 2; OARSI, 2; Sanofi-Aventis Pharmaceutical, 5 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: ACR, 2; OARSI, 2; Sanofi-Aventis Pharmaceutical, 5 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 McCarthy, Geraldine M., MD ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 McCloskey, Deborah, RN, BSN Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Multidisciplinary Management of Scleroderma...68 McCormick, David, MB, BaO, BCh, MRCP Thieves Market: Show Me Your Best Cases..55 McGaha, Tracy, PhD Therapeutic Targeting of the Innate Immune System...55 McGonagle, Dennis, PhD Psoriatic Arthritis: Skin, Entheses and Joints McInnes, Iain B., PhD ACR Review Course - Rheumatoid Arthritis Therapy After Diagnosis of Malignancy...29 Disclosure: Abbvie, 5; Astra Zeneca, 5; BMS, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc, 2, 5; UCB, 2, 5 McLean, Robert R., DSc, MPH Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 McTigue, Joan C., PA-C, MS Pharmacotherapy: What s New in Rheumatology Mease, Philip J., MD Psoriatic Arthritis (076) Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; covagen, 5; crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5 Meffre Sr., Eric, PhD Autoimmunity in Immunodeficiency...45 Mehraban, Navid, MD ACR Knowledge Bowl: Final Round Invited Speaker/Moderator Index 2014 Program Book 279

282 Invited Speaker/Moderator Index 280 Menezes, Rikitha, MD Thieves Market Posters - ACR/ARHP Poster Session C Merkel, Peter A., MD, MPH ACR Clinical Research Conference - Session III: Research Perspective...26 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Biomarkers in Rheumatic Care...93 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Vasculitis Mimics (050)...82 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Messier, Stephen P., PhD New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Meysami, Alireza, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Mikuls, Ted R., MD, MSPH ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Miller, Daniel, MD Dermatopathology of Rheumatic Diseases (225)...93 Dermatopathology of Rheumatic Diseases (236) Miller, Frederick W., MD, PhD Classification Criteria for Myositis...83 Current Understanding of Malignancies in Connective Tissue Diseases...34 Mills, David A., MS, PHD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: Evolve Biosystems Inc., 4; Mars Inc., 5; Matatu Inc., 5; MicroTrek Inc., 4 Mintz, Sandra, BSN Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Young Adults with Rheumatic Disease: The Patient Perspective Program Book Mohan, Chandra, MD, PhD Systems Biology of Lupus Nephritis...73 Monrad, Seetha U., MD ACR/ABIM MOC Learning Session - Session II: Questions from 2014 Update...25 Moore, Suzanne, MD Practice Issues: Practice Success in an Environment of Transition...73 Mor, Adam, MD PhD Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases..147 Morasso, Liz, LCSW The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Morgan DeWitt, Esi M., MD, MSCE ACR Clinical Research Conference - Session I: Methodology and Development ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Mulvagh, Sharon, MD Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases Murthy, Vijaya, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 N Najem, Catherine E., MD Thieves Market: Show Me Your Best Cases Nakanishi, Kensuke, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Napadow, Vitaly, PhD What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain? Naty, Saverio, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Negoescu, Andra, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Neogi, Tuhina, MD, PhD Classification Criteria for Gout...82 Gout Management in Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside Nguyen, Uyen Sa D.T., DSc, MPH Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Ni Mhuircheartaigh, Orla, BAO, BCh, MB, MRCPI ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Niewold, Timothy B., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Disclosure: Biogen Idec, EMD Serono, 5; Janssen Pharmaceutica Product, L.P., EMD Serono, 2 Nikiphorou, Elena, MRCP, MD(Res), PGCME ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Nikolov, Nikolay P., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Nishio, Midori Jane, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Hip...26 Nussenzweig, Michel C., MD, PhD Therapeutic Targeting of the Innate Immune System...55 O O Dell, James R., MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 See page 247 for the list of disclosure relationships.

283 O Rourke, Kenneth S., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: American Board of Internal Medicine, 9; Genentech and Biogen IDEC Inc., 2; InPractice Rheumatology, 9 Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required Joint Injection Techniques (201)...33 Disclosure: American Board of Internal Medicine, 9; inpractice Rheumatology, 9 Joint Injection Techniques (222)...83 Disclosure: American Board of Internal Medicine, 9; inpractice Rheumatology, 9 Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Oberle, Edward J., MD Thieves Market Posters - ACR/ARHP Poster Session C Painter, Mark ACR Practice Management Pre-Meeting Course - Improve Time-of-Service Collections From the Front-End...27 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 ACR Practice Management Pre-Meeting Course - Increase Team Performance and Productivity...28 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 ACR Practice Management Pre-Meeting Course - Managing Denials in a Complex Reimbursement Environment...28 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 Parr, Tim Practical Use of Registries...73 Disclosure: FiGMD, Inc., 3 Patel, Nirupa J., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Poddar, Piyush, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Poole, Janet L., OTR, PhD Multidisciplinary Management of Scleroderma...68 Nothing About Us Without Us: Engaging Patients in Rheumatology Research Proudman, Susanna, MBBS, PhD Role of Nutrition in Rheumatic Diseases Punaro, Marilynn G., MD Pediatric Rheumatology Town Hall...32 Putterman, Chaim, MD Biomarkers in Rheumatic Care...93 Disclosure: Biogen Idec, 2; Exagen, 5; Immunarray, 5 Invited Speaker/Moderator Index Oddis, Chester V., MD Classification Criteria for Myositis...83 Disclosure: ATyr, 5; Questcor, 5 Rheumatology Roundup: Highlights from the 2014 Annual Meeting Disclosure: ATyr, 5; Questcor, 5 Year in Review...32 Disclosure: ATyr, 5; Questcor, 5 Ostergaard, Mikkel, DMSc, MD, PhD Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice ( Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough, 2 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237) Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough, 2 Östör, Andrew, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 P Paget, Stephen A., MD Rheumatoid Arthritis: Challenging Cases (045)...82 Disclosure: Crescendo bioscience, 5 Rheumatoid Arthritis: Challenging Cases (089) Disclosure: Crescendo bioscience, 5 Peacock Jr., James E., MD Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Disclosure: Pfizer Pharmaceuticals, 1 Pennathur, Subramaniam, MD Rheumatology Research Foundation: Disease Targeted Research Special Session Perl, Andras, MD, PhD Autophagy in Rheumatic Diseases Disclosure: Pfizer Inc, 2 Petri, Michelle, MD, MPH Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders Forefronts in Lupus Nephritis...84 Pile, Kevin, MD Patient Access to Biologics Across the Globe Pincus, Theodore, MD MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, Toward Better Clinical Decisions and Outcomes (227)...94 Disclosure: Abbvie, Celgene, 2; Pfizer, Abbvie, Merck, Health Report Services, 7 Pineda, Carlos, PhD Patient Access to Biologics Across the Globe Piva, Sara R., PhD, PT Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation R Rabinovich, C. Egla, MD, MPH Pediatric Rheumatology Town Hall...32 Raman, Vidya, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Ramessar, Nina, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Ravelli, Angelo, MD ACR Clinical Research Conference - Session III: Research Perspective...27 Macrophages Gone Wild Ray, Laura E., MA, MLS Google Minefield: Empowering Patients to Evaluate Online Resources...53 Raychaudhuri, Soumya, MD, PhD ACR Review Course - Genomics for the Clinician...29 Reed, Ann M., MD Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Reid, Gregor, MD, PhD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome Program Book 281

284 Invited Speaker/Moderator Index Reveille, John D., MD Axial Spondyloarthritis Guidelines...44 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Reactive Arthritis: An Update (008)...33 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Reactive Arthritis: An Update (037)...71 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Richardson-Nassif, Karen, PhD AAMC Medical Education Research Certificate (MERC) Workshop: Formulating Research Questions and Designing Studies...31 AAMC Medical Education Research Certificate (MERC) Workshop: Measuring Educational Outcomes With Reliability and Validity...31 Richmond, Susan, MS, PA-C Mycobacterium Infections in Immunocompromised Patients Rider, Lisa G., MD Classification Criteria for Myositis...83 Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...73 Ridker, Paul M., MD, MPH Inflammation and Atherothrombosis Disclosure: AstraZeneca, Novartis, Pfizer, Amgen, 2; ISIS, Vascular Biogenics, BostonHeart, 5; Seimens, 7 Ritchlin, Christopher T., MD, MPH ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Disclosure: Amgen, 2; UCB, 2 Psoriatic Arthritis: Skin, Entheses and Joints Disclosure: Amgen, 2; UCB, 2 Robinson, Angela, MD, MPH Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Robinson, William H., MD, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease Disclosure: Atreca, Inc., 5 Roos, Ewa M., PT, PhD Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Rose, Jillian A., LCSW The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Rose, Shawn, MD, PhD Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders Rosen, Antony, MD Current Understanding of Malignancies in Connective Tissue Diseases...34 Rosenbaum, James T., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Rosenthal, Ann K., MD Calcium Crystal Arthritis (083) Ross, Michael D., PT, DHSc, OCS ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Diagnostic Imaging a Tool for Differential Diagnosis...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Outlining the Value of Plain Film...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Plain Film Case Presentation...30 Roth, Johannes, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Pediatrics...23 Roubey, Robert, MD Curbside Consults Ask the Experts...95 Round, June L., PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Rouster-Stevens, Kelly A., MD, MS Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Pediatric Systemic Lupus Erythematosus (015)...43 Protecting Bone Health in Pediatric Rheumatic Diseases Rovin, Brad H., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Systemic Lupus Erythematosus: Lupus Nephritis (059) Disclosure: aurina, 5; Centocor, Inc., 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 5; Lilly, 5; Medimmune, 5; Questcor, 2 Systemic Lupus Erythematosus: Lupus Nephritis (078) Disclosure: aurina, 5; Centocor, Inc., 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 5; Lilly, 5; Medimmune, 5; Questcor, 2 Rudrangi, Rajani, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Russell, Linda, MD Osteoporosis: Novel Treatments (064) Russell, P. W. James, MA (Cantab), MB BChir Thieves Market: Show Me Your Best Cases...56 Ryan, Sean, PhD Glycosylation and Glycan Binding Proteins in Immune Function S Saag, Kenneth G., MD, MSc ACR Clinical Research Conference - Session III: Research Perspective...26 Disclosure: Abbott Immunology Pharmaceuticals, 5; AbbVie, 5; BMS, 5; Crescendo, 5; Iroko, 5; Lilly, 5; Merck Pharmaceuticals, 5; Roche Pharmaceuticals, 5 Challenging Cases in Osteoporosis Management (072) Disclosure: Amgen, 2, 5; Lilly, 2, 5; Merck Pharmaceuticals, 2, 5 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: Abbott Immunology Pharmaceuticals, 5; AbbVie, 5; BMS, 5; Crescendo, 5; Iroko, 5; Lilly, 5; Merck Pharmaceuticals, 5; Roche Pharmaceuticals, 5 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Ardea, 2; Takeda, 2 Sachs, Barton L., MD, MBA State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Disclosure: Globus Medical, 2, 7; United Health Care, 9 Sadowsky, Mike, PhD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: CIPAC, LLC, 5 Sahni, Shivani, PhD Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Role of Nutrition in Rheumatic Diseases Program Book See page 247 for the list of disclosure relationships.

285 Salmon, Jane E., MD Career Opportunities in Rheumatology: Making a Choice...94 Samant, Rohini, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Sammaritano, Lisa R., MD ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 Schanberg, Laura E., MD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Disclosure: Arthritis Foundation, 2; Eli Lilly and Company, 5; NIAMS-NIH, 2; Novartis Pharmaceutical Corporation, 2; UCB, 5 Scher, Jose U., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 The Microbiome in Health and Disease...35 Schikler, Kenneth N., MD Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain...77 When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Schneider, Rayfel, MBBCh Macrophages Gone Wild Schoenfeld, Sara, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Schrandt, Suzanne, JD Nothing About Us Without Us: Engaging Patients in Rheumatology Research Schwartz, Todd A., DrPH Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Schwartzman, Sergio, MD Inflammatory Eye Disease/Uveitis (023)...66 Disclosure: Abbott Immunology Pharmaceuticals, 5, 8; Amgen, 8; antares, 8; Genentech and Biogen IDEC Inc., 5, 8; Janssen Pharmaceutica Product, L.P., 5, 8; Paizer, 8; Pfizer Inc, 5; ucb, 5, 8 Scott, Joshua, DO, MS, BS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Seibold, James R., MD Pulmonary Hypertension in the Rheumatic Diseases (026)...66 Disclosure: Aries, 5; Bayer, 5; Boehringer Ingelheim, 5; EMD Serono, 5; Gilead, 5; InterMune, 5; Sigma Tau, 5; United Therapeutics, 5, 8 Selby, Joe V., MD, MPH ACR Clinical Research Conference - Session I: Methodology and Development Semb, Anne Grete, MD, PhD Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases Sethi, Manpreet, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Thieves Market Posters - ACR/ARHP Poster Session B...74 Seton, Margaret, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Shah, Ami A., MD, MHS Current Understanding of Malignancies in Connective Tissue Diseases...34 Shah, Jigar, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Shakoor, Najia, MD, MS Footwear in Orthoarthritis (063) Disclosure: DJO and Dr. Comfort, 7 Shane, Elizabeth J., MD Osteoporosis: Current Concepts for the Clinician...35 Disclosure: Amgen, 2; Eli Lilly and Company, 2 Sharma, Leena, MD Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Shelton, Lisa, B.Sc., BSN, RN Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Mycobacterium Infections in Immunocompromised Patients Sherry, David D., MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management Shmerling, Robert H., MD Ethics and Rheumatology...34 Sibille, Kim, PhD Thriving With Rheumatic Disease: Cultivating Resilience...93 Sibley, Cailin H., MD ACR Knowledge Bowl: Final Round...76 Siegrist, Richard, Jr., MBA, MS, CPA ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification (012)...43 Disclosure: Abbott Immunology Pharmaceuticals, Pfizer, Merck, 2 Sigal, Leonard H., MD ACR Immunology Update: Innate Lymphoid Cells...76 Glycosylation and Glycan Binding Proteins in Immune Function Telomeres, Telomerase and the Aging Immune System...83 Silverman, Gregg J., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Disclosure: Genentech, Pfizer, Lilly, Onyx, 5 ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases Silverman, Stuart, MD Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212)...55 Disclosure: Pfizer, Amgen, Lilly, Roche, 5 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216)...72 Disclosure: Pfizer, Amgen, Lilly, Roche, 5 Invited Speaker/Moderator Index Simon, Lee S., MD Safety of Drugs Used to Treat Rheumatoid Arthritis (058) Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, 2014 Program Book 283

286 Invited Speaker/Moderator Index Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi Safety of Drugs Used to Treat Rheumatoid Arthritis (067) Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi What Are Biosimilars?...70 Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi Singer, Nora G., MD ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Autoimmunity in Immunodeficiency...45 Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Singh, Abha G., MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Singh, Jasvinder A., MD, MPH Classification Criteria for Gout...82 Disclosure: I am on the steering committee of the OMERACT, an organization that receives arms-length funding from 36 pharmaceutical companies, 9; Takeda, Savient, 2; Takeda, Savient, Regeneron, Allergan, 5 From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Gout Management in Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Singh, Namrata, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Thieves Market Posters - ACR/ARHP Poster Session B...74 Singhal, Aneesh, MD Primary Angiitis of the Central Nervous System and Its Mimics Disclosure: Medicolegal Firms, 9 Siva, Chokkalingam, MD Biomarkers in Rheumatic Care...93 Skeff, Kelley M., MD, PhD Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Slusher, Barbara A., PA-C, MSW Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions Smith, Benjamin J, PA-C Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Providing Evidence for Mid-Level Providers in Rheumatology Practice Smith, Stacy, MD ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - MRI Case Presentations...31 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Outlining the Value of MRI...31 Smolen, Josef, MD Rheumatoid Arthritis: Biological Agents (027)...66 Disclosure: Abbvie, Astra, BMS, Celgene, Glaxo, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer, Samsung, UCB, 5; Abbvie, BMS, MSD, Pfizer, Roche, 2 Solomon, Daniel H., MD, MPH Providing Evidence for Mid-Level Providers in Rheumatology Practice Spencer, Jo, PhD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Spiegel, Brennan, MD, MSHS, AGAF ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: Amgen, 2; Ironwood, 2; Nestle Health Sciences, 2; Shire, 2; Takeda, 2 Spiera, Robert F., MD Temporal Arteritis (079) Disclosure: Roche Genetch, 2; Roche-Genetech, 2 Temporal Arteritis (090) Disclosure: Roche Genetch, 2; Rroche-Genetech, 2 Spits, Hergen, MD, PhD ACR Immunology Update: Innate Lymphoid Cells...76 Sreih, Antoine G., MD Polymyalgia Rheumatica (025)...66 Disclosure: Genentech and Biogen IDEC Inc., 5; Roche Pharmaceuticals, 5 Stamatos, Christine A., DNP, ANP-C Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes Stamp, Lisa K., PhD Gout Management in Disclosure: Abbvie, 9; Astra Zenec, 5; PHARMAC, 6 Ste-Marie, Peter A., BA, LLB The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond Steen, Virginia D., MD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion Pharmaceuticals US, 8; Bayer, 5; CSL Berhing, 2; Gilead Science, 8; Intermune, 2; Roche Pharmaceuticals, 2; Sanofi- Aventis Pharmaceutical, 2; United Therapeutics, 5 Multidisciplinary Management of Scleroderma Disclosure: Actelion Pharmaceuticals US, 8; Bayer, 5; CSL Berhing, 2; Gilead Science, 8; Intermune, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Stojan, George, MD Forefronts in Lupus Nephritis...84 Stone, John H., MD, MPH Rheumatic Manifestations of Malignancy Stone, Kerry, MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside Strand, Vibeke, MD What Are Biosimilars?...70 Disclosure: Abbvie, 5; Amgen, 5; Anthera, 5; AstraZeneca/medimmune, 5; BiogenIdec, 5; BioMarin, 5; BMS, 5; Celltrion, 5; Genentech/ Roche, 5; GSK, 5; Hospira, 5; Incyte, 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, Program Book See page 247 for the list of disclosure relationships.

287 5; MerckSerono, 5; Novartis Pharmaceutical Corporation, 5; Novo Nordisk, 5; Pfizer Inc, 5; Regeneron, 5; Royalty, 5; Sanofi - Genzyme, 5; Takeda, 5; UCB, 5; Vertex, 5 Stuart, Marian R., PhD Successful Aging in Rheumatic Disease Sufka, Paul, MD Social Media Boot Camp: Blogging for Beginners...75 Social Media Boot Camp: Twitter Basics...37 Sundy, John S., MD, PhD Crystal: Diagnosis and Management of Gout (073) Disclosure: Ardea/Astra Zeneca, 2, 5; General Electric, 1; Gilead Sciences, 3; Novartis Pharmaceutical Corporation, 5; PAR Pharma, 5; Pfizer Inc, 5; Pharmos, 2 Sweiss, Nadera J., MD Sarcoidosis in T Tavora, Fabio, MD, PhD Histopathology of Rheumatic Lung Disease (206)...38 Histopathology of Vasculitis (218)...76 Taylor, William, PhD, MBChB Classification Criteria for Gout...82 Disclosure: AstraZeneca, 5 Tehrani, Rodney, MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Disclosure: Rheumatology Research Foundation, 9 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Theis, Kristina A., MPH Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Thiele, Ralf G., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Foot and Ankle...26 Disclosure: Bioclinica, Virtual Scopics, Cresendo Biosience, 5; Amgen, Abbvie, 8; Sonosite, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance Disclosure: Bioclinica, Virtual Scopics, Cresendo Biosience, 5; Amgen, Abbvie, 8; Sonosite, 9 Thomas, Ranjeny, MBBS, MD Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy...75 Disclosure: Johnson & Johnson, 9 Tillman, Melesia, CPC, CPC-I, CRHC, CHA ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 Ting, Jenny, PhD Autophagy in Rheumatic Diseases Tinkle, Brad, MD, PhD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Disclosure: Various, 5 Todd, Derrick J., MD, PhD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Toledo-Garcia, Aixa, MD Thieves Market Posters - ACR/ARHP Poster Session C Toppin, Bruce, JD Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 RheumChat Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Torr, James, PharmD Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Townsend, Anne F., MA, PhD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Trizuto, Jennifer L., MPT Biomarkers in Rheumatic Care...93 Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological Trouw, Leendert A., PhD Complement in Rheumatic Disease Tsokos, George C., MD Bone Biology...38 New Regulatory T Cells Tucker, Lori B., MD The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond U Ursini, Francesco, MD, PhD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Invited Speaker/Moderator Index Terkeltaub, Robert, MD Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 Disclosure: Astar Zeneca, Takeda, Relburn, Abbvie, BioMarin, Quest, 5 Theander, Elke, MD, PhD Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Theis, David, DO, BA ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Torgerson, Troy R., MD, PhD Immunodeficiency Syndromes (053) Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 V Van Dyke, Kenneth, DO ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Varga, John, MD Insight into Lung Fibrosis...84 Vashisht, Priyanka, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round Program Book 285

288 Invited Speaker/Moderator Index Vaughan, Molly, PhD Exercise Adherence in Arthritis: The Role of Technology Venuturupalli, Swamy, MD Inflammation and Atherothrombosis Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Villasenor Ovies, Pablo, MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Vinino, Frederick, MD Controversies in Sjögren s Syndrome (033)...70 Disclosure: Biogen-Idec, 5; Nicox, Inc., 5; Novartis, Inc., 9; Takeda, Inc., 5 Controversies in Sjögren s Syndrome (062) Disclosure: Biogen-Idec, 5; Nicox, Inc., 5; Novartis, Inc., 9; Takeda, Inc., 5 Vleugels, Ruth Ann, MD, MPH Cutaneous Vasculitis (003)...33 Dermatological Manifestations of Rheumatic Diseases (013)...43 Dermatological Manifestations of Rheumatic Diseases (034)...70 Ward, Michael M., MD Axial Spondyloarthritis Guidelines...44 Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Warren, Robert, MD, PhD, MPH Practical Practice Management Session One: Improve Quality and Efficiency...53 Practice Issues: Practice Success in an Environment of Transition Warrington, Kenneth J., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 Wei, Kevin, MD PhD Thieves Market: Show Me Your Best Cases...55 Weinblatt, Michael E., MD Clinical Issues Associated with the Use of Methotrexate Disclosure: Antares, 5 Weiner, Joseph, MD, PhD Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes Weissman, Barbara, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Wells, Alvin F., MD, PhD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance Wells, Courtney, MPH, MSW Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Weyand, Cornelia M., MD, PhD Autophagy in Rheumatic Diseases From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Year in Review White, Douglas, MD, PhD Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 Practice Issues: The Road to I Whittier, Xena, MD, MS, BA ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 W Wallace, Zachary, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Ward, Ian, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Weinstock, Joel, MD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: Coronado Biosciences, 5 Weisman, Michael H., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Disclosure: Abbvie, 5; Amgen, 2; Astellas Pharma Global Development, 5; Celgene, 5; Centocor, Inc., 2; Cephalon, 2; Crescendo Bioscience, 5; Dynavax, 2; Genentech and Biogen IDEC Inc., 2; GSK, 2; Lilly, 2, 5; Pfizer Inc, 2; Rigel Pharma, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; Teva Pharmaceuticals, 2; UCB Pharma, 5 Wigley, Fredrick M., MD Raynaud s and Digital Ischemia (057) Disclosure: CSL Behring, 2; Kinemed, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 5; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Raynaud s and Digital Ischemia (088) Disclosure: CSL Behring, 2; Kinemed, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 5; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Wilkes, Margaret R., MD Osteoporosis: Current Concepts for the Clinician Program Book See page 247 for the list of disclosure relationships.

289 Winthrop, Kevin L., MD, MPH Mycobacterium Infections in Immunocompromised Patients Disclosure: Abbvie, 5; Insmed, 2, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 5; UCB, 5 Vaccinations for Patients on Biologic Therapies (080) Disclosure: Abbvie, 5; Insmed, 2, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 5; UCB, 5 Witter, James P., MD, PhD ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Wortmann, Robert L., MD, MACR Adult Inflammatory Myopathy (041)...81 Adult Inflammatory Myopathy (081) Young, Kelly, BA ACR Clinical Research Conference - Session V: Patient Perspective Young, Stephen, BSc, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease Z Zautra, Alex, PhD Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Thriving with Rheumatic Disease: Cultivating Resilience...93 Invited Speaker/Moderator Index Wu, Kim M., MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Zupko, Karen, BS Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 Wynn, Thomas, PhD Insight into Lung Fibrosis...84 Y Yazdany, Jinoos, MD, MPH Practical Practice Management Session One: Improve Quality and Efficiency...53 Yazici, Yusuf, MD Behçet s Syndrome (052) Disclosure: Celgen, BMS, Genentech, 2 Behçet s Syndrome (082) Disclosure: Celgen, BMS, Genentech, 2 Young, Brandi, DNP, FNP-C ACR Practice Management Pre-Meeting Course - Customer Service That Rocks: Boost Patient Satisfaction...27 Disclosure: Abbott Immunology Pharmaceuticals, 8; Genentech and Biogen IDEC Inc., 8 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., 8 Practical Practice Management Session One: Improve Quality and Efficiency...53 Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., Program Book 287

290 abstract author Index 288 A A Pilkington, C..1314, 1316, 1322, 1323, 2900 Aalokken, TM , 2703 Aaron, L Aati, O , 1215 Abad, M Abad, S Abasolo, L , 1431 Abawi, O Abbas, S Abbott, JH...889, 2897, 3017 Abbott, J , 712 abd El Baky, N Abdala, M , 1438, 2381 Abdel-Fattah, YH Abdel-Wahab, N... 17, 970, 2013 Abdelhaleem, M Abdi, D Abdollahi-Roodsaz, S , 1734, 1816 Abdul, W Abdulahad, WH. 1775, 1956, 2733, 2738, 2934 Abdullah, A Abdullah, H , 611 Abe, A Abecasis, GR Aberle, T Abignano, G Abji, F...626, 627, 628, 630, 2099 Ablin, JN , 3012 Abou Zahr, Z Abou-Ghantous, J Aboulhosn, J Aboutaam, M Abraham, D , 1721, 1728 Abraham, DJ , 1706 Abraham, TP Abrahamowicz, M , 2308 Abrahams, V Abram, F , 2250 Abrams, K Abrams, K , 931 Abrams, K Abrams, RI Abrams, S Abramson, SB... 81, 2246 Abria, C , 1963 Absher, D Abud-Mendoza, C. 933, 1649, 1650 Abujam, B Abulaban, K , 1303, 1304, 1826 Accortt, N Acevedo-Vásquez, EM Acharya, S Achenbach, SJ , 2116 Achkar, JP Program Book Acikel, C Ackermann, F Ackermann, G Acosta, A Sr Acosta Felquer, ML Acosta-Hernandez, RI Adachi, J Adachi, JD...48, 217, 1172, 1424, 1566, 2257 Adam, P...384, 416, 2442 Adami, S Adami, S , 2268 Adamidi, S Adamopoulos, IE Adan, A , 1250, 1251, 2853 Adan, N , 333 Addimanda, O , 2757 Adebajo, AO , 602, 1543, 1561, 1564, 1572, 1579, 1590, 2438, 3015 Ades, L Adhikarakunnathu, S Adibnia, Y Adinolfi, A , 908 Adler, A Adler, B Adler, RA Adler, S Adluri, RS Admiraglio, E Admon, A Adnan, E , 2170 Adriaans, A Adrianto, I , 2978 Adu, J Aegerter, P Aelion, JA...602, 1543, 1572 af Klint, E Affandi, AJ Affentranger, U Aga, AB , 905 Agard, C Agarwal, A Agarwal, SK Agarwal, V , 1679, 2603 Agca, R Agewall, S Aggarwal, A...89, 308, 318, 928, 1272, 2173 Aggarwal, R Aggarwal, R. 912, 914, 1266, 1316, 1344, 1348, 1410 Agha, A Agnihotry, S Agrawal, R Aguado, P Aguero, S Aguiar, C...1 Aguiar, R Aguilar-Salinas, CA Aguirre, A , 2117 Aguirre, MA , 2622 Aguirre Zamorano,... 7, 1978 Ahadieh, S Ahearn, J Ahlstrand, I Ahluwalia, V. 517, 714, 1168, 1833, 2309, 2424 Ahmad, J Ahmad, Y Ahmadi, N Ahmed, S , 2879 Ahmed, S Ahmed Abdi, B , 1721 Ahn, JK Ahn, SM. 614, 702, 703, 812, 847, 2564 Ahn, Y Ai, R Aigner, S Aihara, M Aikawa, NE Ailioaie, C Aimer, P Ainsworth, B Ainsworth, H Aire-MB, G , 1531 Airo, P , 1256 Aissopou, EK Aitken, D Aiyer, A Aizaki, Y...39 Aizer, J Ajmone Marsan, N Ajmone Marsan, N Ak, F Akagi, M Akagi, R , 1885 Akahoshi, M , 1952 Akaike, H , 2274 Akamata, K...748, 749, 752, 3003 Akar, S...603, 1230, 2157, 2616 Akasaki, Y Akasdi, A Akashi, K Akashi, K , 1952 Akdemir, G , 2502 Akdeniz Leblebicier, M Akdogan, A...509, 1432, 2616 Akerkar, S Akhavan, P , 2814 Akikusa, J , 2281 Akil, M...676, 711, 2798, 2817 Akilesh, S Akita, K Akiyama, M Akiyama, Y , 1765 Akiyama, Y Akiyama, Y...39 Akkoc, FN Akkoc, N Akkoc, N.. 601, 1230, 1584, 2562, 2595, 2611, 2616 Akkurt, E Aksentijevich, I...816, 1227, 1817 Aksu, K , 2616 Aktay Ayaz, N Akter, T , 3002 Akyuz, G , 2057 Al, M... 96, 1141 Al adba, B Al Ghanim, N , 2101 Al Maini, M...53 AL Osaimi, N , 416 Al Sawah, S...683, 687, 2623 Al-Ali, S , 2982 Al-Khalili, L Al-Suwairi, W Ala-Korpela, M Alabiad, C Alade, R Alam, J Álamo, M Alarcón, G Alarcon, GS...6, 961, 1080, 1415, 2089, 2646 Alarcon Riquelme, ME Alarcon-Riquelme, M Alarcón-Riquelme, ME Alasthi, F Alasti, F Alavi, A Alba, P Albani, S Albarrán Hernández, F Albers, CA Albert, D Albert, DA Albert, D Albert, G.. 691, 1655, 1656, 1659, 2194, 2620 Albesa, R , 2866 Albrecht, K Alcañiz, C Alcaraz, MJ...32 Alcid, D Alcocer-Varela, J. 1658, 1664, 2676, 2724, 2990 Aldag, J Aldag, JC Alderaan, K , 2667 Aldigeri, R Aledrissy, M Alegre, C Alegre, JJ , 2622 Alegre de Miguel, C

291 Alegre Sancho, JJ Alekseeva, E Alemán-Sánchez, N Alemany, FX Alemao, E.96, 841, 898, 1060, 1141, 2103, 2486 Alemao, E , 1362 Alemo Munters, L Alenius, GM Alessandro, R , 611 Aletaha, D. 906, 1054, 1389, 1407, 2387 Alevizos, I , 529, 530 Alevizos, I , 2981 Alexander, C Alexander, K Alexander, T , 2837 Alexander, Y , 1464, 1699, 1923, 2636 Alexandersen, P , 2230 Alexanderson, H Alexeeva, E , 2296 Alexiades, M , 2970 Alfaguter, I Alfaiate, T Alfaro-Lozano, JL Alfredsson, L.352, 358, 2016, 2018, 2888 Alhajeri, H Ali, Y Ali, Z Alia, P Alibaz-Oner, F , 2750 Aliferis, CF...81 Aliprantis, AO...28, 1732, 2796 Alivernini, S Alkatan, H , 1756 Allaart, CF.. 361, 817, 1386, 2138, 2398, 2502 Allaart, C Allanore, Y.473, 476, 722, 730, 740, 743, 747, 876, 1130, 1140, 1687, 1926, 2559, 2711, 2999, 3001 Allegra, M Allegri, F...4, 15 Allen, IE Allen, J Allen, KD , 977 Allen, R Allenbach, Y , 1262, 1263, 1270 Allevi, E Allison, J.. 64, 192, 194, 197, 1279 Allison, P , 1141 Alloush, J Ally, MM Alm, G Almaghlouth, I , 604 Almagor, O.211, 214, 215, 729, 750, 2698 Almayouf, S Almeida, B , 2900 Almeida, GJ Almeida de Jesus, A...315, 1812, 1896, 1898, 2285 Almodóvar González, R.2586, 2598, 2853 Almutairi, A Alonso, A Alonso, A.59, 475, 2097, 2391, 2526 Alonso Blanco-Morales, E Alonso-Castro, S Alosco, S Aloush, V Alperi-López, M... 59, 2445 Alraqi, S Alsuwaidi, M Altaf, S Altan, A , 1155 Altavilla, D Altawil, R Altemus, J Alten, R , 2492 Alten, R...159, 940, 1482 Altenburg, J Altman, R , 249 Alunno, A Alvarellos, A Alvarellos, AJ , 2040 Alvarellos, T Alvarenga Rezende, R Alvarez, A , 1438, 2381 Alvarez, A , 2625 Alvarez, AP Alvarez, AM Álvarez, L , 2775 Álvarez de Mon, M Alvarez-Garcia, O.1016, 1021, 1885 Alvarez-Vega, JL...40 Álvaro-Gracia, J Alves, CH Alves, M Alvey, C Amano, H...87 Amano, K Amano, K Amano, K Amara, K Amarilyo, G Amarnani, A...91 Amato, AA Amato, MD, AA Amatruda, J. 370, 1375, 2378, 2413 Ambrose, N Ambrozic, A Ambrus, J. 2094, 2540, 2541, 2546 Ambudkar, I , 529 Amengual, O...2, 5, 1179, 1628, 2638, 2677, 2864 Amezcua-Guerra, LM , 1984 Amici, S Amigo, E , 2459 Amin, MA...444, 937, 1962, 3006 Amin, S Aminoff, AR Amiri, N , 1865 Amital, H Amital, H Amiya, E Ammitzbøll, CG Amoruso, MC Amoura, Z. 811, 1263, 1634, 1792, 1925, 2778, 2779 Ampel, NM Amundsen, L An, J , 898 An, J Anandarajah, AP Ananieva, LP Anavekar, N Anaya, JM... 84, 2978 Ancuta, C. 1525, 1526, 1538, 2497 Ancuta, I.. 823, 1153, 1525, 1526, 1538, 2497, 2524 Andersen, F Andersen, GN... 80, 1516 Andersen, J Andersen, M... 80, 1516 Andersen, Andersen, T...366, 1741, 2737 Andersen, V Anderson, AE , 2460 Anderson, D , 1470 Anderson, E Anderson, JK...269, 270, 551, 553, 558, 562, 2581 Anderson, J Anderson, J Anderson, JR Anderson, K Anderson, M Anderson, N , 2631 Anderson, R Anderson, R Andersson, D Andersson, K Andersson, KM Andersson, M Ando, K , 1698 Andrade, D , 2868 Andrade, JL Andrade, LEC , 2184, 2745 Andrade Medeiros Freire, E Andrade-Ortega, L , 1984 Andreassen, K Andreoli, L...4, 15, 671, 1642 Andrés, M... 99, 829, 2962 Andreu, JL , 1670 Andrews, A Andrews, J Andrews, JS Andrews, S Aneja, R...53 Anema, J Angel, T Angeles-Han, S , 1151 Angeles-Han, ST Angelini, F Angerer, P , 1078 Aniel-Quiroga, MA Anink, J , 300, 932 Anis, AH , 2781 Anisfeld, A , 849 Ankri, A... 8, 1634 Annaloro, C Annan, A Annapureddy, N...353, 713, 717, 1990, 2111, 2207, 2315, 2989 Annunziata, K Anolik, JH , 2820 Anthanari, S Anthony, M Antivalle, M , 2976 Antoch, G Antoch, PDG , 1177 Anton, A , 606, 2553, 2605, 2607 Anton, J. 277, 282, 284, 930, 1231, 1325, 1900, 2279, 2282 Antonatou, K Antonelli, M Antoniol, MN Antonioli, A Anway, S Aoyagi, K , 2389 Aozasa, N Aparicio, L Apaz, M Apkarian, AV Apodaca, E Apostolidis, S Apostolidis, SA Appel, H...616, 2612, 2940 Appenzeller, S , 1622, 1636, 2320, 2659, 2660, 2661, 2662, 2663, 2705, 2720 Apras, S Apras Bilgen, S , 1432 A Action, OBO Aqrawi, LA Aquavella, J Aquino-Beaton, C Arabshahi, B Aractingi, S Arad, U Aradi-Vegh, B , 2450 Arafat, A abstract author Index 2014 Program Book 289

292 abstract author Index Arami, S , 2799 Arana-Guajardo, A Aranishi, T Aranow, C...684, 961, 2646, 2835 Arato, A Araújo, AC...675, 2409, 2656 Arbab, A Arbab, AS Arbillaga, H Arce, CA Arce Gonzalez, N Arce-Franco, MT Arden, N Arden, NK , 2231 Ardern, R , 2101 Ardoin, S Ardoin, SP. 304, 1303, 1304, 1320, 1826, 2272, 2318, 2320, 2641, 2790 Ardouin, E Aref-Eshghi, E , 1289 Arena, V Arenas-Osuna, J Arends, S , 2831, 2934 Arendse, R...365, 382, 383, 943, 1550, 1551, 2416, 2496, 2518 Arendt-Nielsen, L , 2783 Arfi, S , 1767, 2024, 2155, 2532 Argyropoulou, M Arico, M Sr Arida, AI , 2617 Arima, K...429, 1719, 2389, 2651 Aringer, M Arinobu, Y , 1952 Arinuma, Y Arismendi, M Ariza, Y Ariza-Ariza, R... 40, 576 Arkachaisri, T , 1309, 1618 Arkema, EV...825, 1072, 1877 Ärlestig, L , 2098 Armaka, M Armas-Gonzalez, E Armengol, E.691, 1657, 1659, 2194, 2620, 2780 Armesto, S , 2775, 2776 Armon, K Armstrong, A Arnett, DK , 2454 Arnett, FC , 765 Arnold, G Arnold, K , 2900 Arnott, M Arntz, OJ Arold, G Arron, S Arroyo-Villa, I Arstila, L Arthur, J Artieda, M Artim-Esen, B , 2865 ARTIS and DANBIO study groups,. 853 Arturi, V , 2670 Arvikar, S Arvikar, SL , 1402 Arya, R Aryal, M Asai, N Asai, S Asako, K , 2762 Asami, Y Asano, T Asano, Y. 748, 749, 752, 756, 766, 1724, 3003 Asare, A , 1862 Ascherio, A Ascherman, DP...437, 911, 3004 Asfahani, L Ashcroft, M Ashkenazi, RI Asikainen, J , 2812, 2911 Askanase, A..672, 715, 961, 1307, 2269, 2646 Askanase, A Askari, A Askari, A Asker-Hagelberg, C Askling, J. 42, 825, 846, 853, 1071, 1072, 1376, 1804, 1837, 1838, 2018, 2832, 2890, 2892, 2936 Aslam, A Aslanov, R... 56, 714, 1374 Asli, B Asmawidjaja, P Asmawidjaja, Asquith, M , 1919 Assassi, S. 588, 745, 747, 751, 753, 754, 765, 1677 Assimes, TL Assirelli, E Astudillo, L Atagunduz, P , 2769 Atak Yucel, A Atanelishvili, I , 3002 Atanes, A Atanes-Sandoval, A , 2853 Aten, A Aterido, A Athanasou, N...38 Atilla, N Atisha-Fregoso, Y.. 411, 694, 1779 Atkinson, ML Atsumi, T...2, 5, 456, 805, 1179, 1628, 2467, 2472, 2638, 2677, 2864 Attur, M... 81, 2246 Atzeni, F , 2443 Atzeni, F.. 397, 2433, 2512, 2514, 2550, 2976 Aubin, A Auboire, L Auclair, M Audemard, A Audia, S Audisio, M Audo, R Auger, JL Augustin, M Augusto, KL Aulie, H Aumaître, O , 1778, 1925 Aurrecoechea, E.. 814, 1415, 2853 Auvinet, B , 3011 Avau, A Avci, AB Avcin, T Avenano, C Avila, G...475, 1129, 2391, 2526 Avila, G...59 Avila-Casado, C , 2787 Avina, M Avina-Zubieta, JA..379, 915, 2306, 2308 Avina-Zubieta, JA...116, 382, 426, 1770, 1865, 2112, 2118, 2416, 2518, 2932 Avouac, J...476, 730, 740, 1130, 1687, 1926, 2711, 3001 Awale, A , 2943 Awosogba, JA Axelsen, M Axelsen, MB Axelsson, M Ayala Gutierrez, MDM Ayanoglu, G Aydin, SZ , 2769 Ayearst, R Ayeroff, JR Ayers, D...194, 197, 1279 Ayers, DC Aylward, H Ayoub, WT Ayral, X Ayvaz, S Azadi, P Azeez, M Azeni, F Azizoddin, D Aznar, JJ Aznar Sánchez, JJ , 2190 Azukizawa, M B Babai, I Babalola, O Babaoglu, H , 1432 Babbe, H Bachiller Corral, J Backhaus, M Backhaus, M...130, 153, 2129 Backman, C , 2442 Bacon, H Baddley, J... 57, 820, 1589 Badea, T Bader, RA Bader-Meunier, B , 1326 Badley, EM , 2942 Badsha, H Bae, D Bae, EK Bae, SC.946, 961, 1056, 2025, 2158, 2646, 2825, 2918, 2954 Bae, SH.. 614, 703, 812, 847, 2564 Bae, SH Bae, YS Baechler, E Baechler, EC Baecklund, E Baek, IW Baena, S Baer, AN.44, 525, 1872, 2148, 2538, 2539, 2929 Baer, P , 365, 379, 382, 383, 426, 943, 2416, 2496, 2518 Baeriswyl, L Baerlecken, NT Baerwald, CG Baeten, DL.536, 538, 561, 562, 620, 819, 850, 1916, 1973 Baffari, E Bagaria, BR Bagavant, H...648, 1798, 2542 Bagchi, S Bagheri, H Baglaenko, Y , 2742 Bagnasco, M , 2443 Bagnato, G Bagnato, G Bagny, K Baguley, E Bahat, H Baik, YA Baildam, E...272, 274, 295, 303, 1322, 1323, 1325 Bailey, L , 2106 Baillet, A Baillet, N Bailly, F Bain, G Bajaj, P Bajocchi, G , 1256 Bak, R Baker, AM Baker, D Program Book

293 Baker, DW , 1347 Baker, J. 236, 732, 840, 1063, 1391, 1392, 1891, 2140, 2545 Baker, JF , 1372 Baker, K Baker, M.365, 421, 583, 1551, 1601, 2496 Baker, N...97 Baker, NA Bakker, A Bakker, P...594, 2589, 2597 Bakowsky, V Bakshi, R Balanescu, A..58, 351, 1525, 1526, 1538, 1539, 2497 Balasubramanian, A Balasubramanyam, A Balblanc, JC Balci, MA Baldassari, AA , 2051 Baldin, B Baldini, C.. 527, 1772, 2201, 2544, 2755, 2931, 2981 Baldini, M Baldissera, E , 1745 Baldwin, C , 2112 Baldwin, N Bale, P Baliki, M Balint, P Balkarli, A. 2157, 2523, 2750, 2769 Ball, J Ballanti, E Ballas, ZK Ballina, FJ Ballina, J Ballina-García, J Ballou, SP , 1997 Balogh, B Balsa, A , 2400, 2459, 2513, 2522 Baltus, G Bananis, E Bananis, E Bandeira, M Bandyopadhyay, S Banerjee, S. 385, 952, 1141, 1362, 2103 Bang, D Bang, SY , 2918, 2954 Bangs, A Bank, S Bankhurst, A , 2789 Baños, M Bansal, P Bansback, N , 2120, 2781 Banydeen, R Banzato, A Bao, G.959, 1334, 1811, 2117, 2626 Bao, Y...551, 586, 1147 Bao, Y , 2960 Bar-Meir, M Bar-On, Y Baracat, EC Baraf, HSB Baraliakos, X...536, 538, 579, 819, 1189, 2563, 2566, 2567, 2581, 2589, 2601, 2612, 2940 Baranda, L Barash, J Baratham, A Barausse, G Barbarossa, S Barbarroja, N... 7, 1978 Barber, DF Barber, X , 1531 Barber-Vallés, X Barbey, F Barbhaiya, M...55, 1080, 1876 Barbo, A...427, 2005, 2009, 2244 Barbosa, J , 1424 Barbosa, R , 2662 Barbour, KE...72 Barcellos, LF...524, 2446, 2466 Barchechath-Flaisler, F Bardin, N Bardin, T. 159, 163, 164, 165, 2962 Barenholz, Y Barham, B Barham, T Barile-Fabris, LA Barilla-LaBarca, ML Barinas-Mitchell, E Barini, A Barini, A Barkai, G Barken, D. 1608, 1631, 1921, 1924 Barker, AM , 2881, 2885 Barkmann, R Barnabe, C Barnabe, C.1387, 2015, 2023, 2115, 2136, 2146, 2410 Barnea, E Barnes, K Barnetche, T. 393, 466, 1490, 1736, 2483 Barnett, K...259, 262, 288, 1104 Baron, M...720, 723, 745, 1089, 2707, 2999, 3000 Barone, F , 1045 Barone, P Barr, S Barra, L Barre, E , 2485 Barreira, JC. 887, 2040, 2441, 2706 Barrera-Vargas, A.1658, 1664, 2676, 2724, 2990 Barrett, J Barrett, JH Barron, K.. 816, 1231, 2279, 2280, 2282 Barron, N Barros, DL Barros Kahwage, C Barrowman, N Barshack, I Barsotti, S , 2217 Bartels, CM Barthe, Y Bartlett, SJ , 425 Bartok, B , 2819 Bartolome, N Bartoloni-Bocci, E , 2544 Barton, A... 78, 1884, 2392, 2460, 2924 Barton, D Barton, J.. 698, 1084, 2048, 2049, 2405, 2421 Barut, K , 2627 Bas, S Basharat, P Bashi, T Bashir, M Baskaya, MC Bass, A , 1500 Bass, AR Bassani-Sternberg, M Bassett, S Basu, N , 1760, 2811 Bateman, B Bathon, J , 2972 Bathon, JM Batley, M Batman, B Battafarano, D...103, 1066, 1133, 2026, 2374, 2883 Battagliotti, C Battellino, M Batterman, A Batteux, F Batticciotto, A...142, 908, 2976 Battistone, M Battistone, MJ , 2881, 2885 Batur, HZ Baum, R , 1813 Baumgarten, M Baumgartner, R Baumüller, S Bautista - Molano, W Bautista-Caro, MB Bautista-Molano, W Bava, C Bay Laurberg, T Bayındır, Bay-jensen, AC. 222, 368, 541, 629, 1019, 1293, 2209, 2230 Bayan, N Bayard, M Bayat, N...912, 1316, 2211, 2222 Bayer, M Baz, S Bazan Bardales, MC Bazelier, M Bazzichi, L...527, 2399, 2499 Beal, J Beall, D Beamer, M Bean, KM Bearden, A Beasley, M...71, 975, 1880, 2071 Beaton, D Beattie, K , 1424 Beattie, KA Beattie, SD , 2822 Beatty, M Beaudart, C Beaulieu, A , 2493 Beaumont, J Bebris, L Becciolini, A Beck, JP Beck, P , 2885 Becker, JCP Becker, L abstract author Index Becker, ML Becker, M Becker, MO Bedaiwi, M , 2607 Bedenbaugh, AV Beermann, H Behin, A Behrens, EM.279, 1899, 2168, 2876 Behrens, F , 2915 Behrens, TW Beiderwellen, K Beijer-Liefers, S Bejerano, C Bekker, P Belasco, J Belchis, D Beldi, MC Belenguer, R , 2064 Belisle, L , 214, 215 Belisle, P , 2015 Bell, E Bell, G Bell, M Bellance, R Bellini, B Bellis, E Bello, JM Belmont, HM Beltrán, E. 1252, 1928, 2586, 2853 Beltrán-Catalán, E Ben-Ami Shor, D Benaglio, F , 2403 Benarous, L , 1763 Benavent, E Program Book 291

294 abstract author Index 292 Bendele, A Bendele, P Bendlin, KA Benedek, G Benedetti, MG Bengtsson, AA Bengtsson, C...358, 2016, 2018, 2887, 2888 Benham, H Benham, H , 632 Benhamou, C Benissan-Messan, D Benjamin, K Bennell, K , 2241 Bennet, B Bennett, M.1294, 1303, 1304, 1826 Bennink, M , 1036, 2793 Benoit, S , 1616 Benseler, S...61, 315, 2275, 2280, 2903 Benseler, SM Bensen, R , 2257 Bensen, W Bensen, W...421, 426, 943, 2491, 2492 Bensen, W...248, 383, 583, 956, 1507, 1550, 1566, 1601, 2411, 2424, 2496 Bensen, WG Bensen, WG , 1397, 1424, 2257 Bensen, W Benson, J , 2743 Bentayou, D Bentin, J Benveniste, O , 1262, 1263, 1270, 1271, 2778, 2953 Benzaquen, N Bérard, A Berardi, G Berdan, J , 2885 Berenbaum, F...581, 1012, 1275, 2028, 2231 Berendsen, A Beresford, MW , 676 Bereswill, M , 289 Beretta, L. 747, 753, 776, 777, 880, 1203, 1675 Berezne, A. 743, 1326, 1690, 1759, 1769, 2778 Berg, EL , 1975, 2803 Berg, IJ , 2571 Bergamini, A Berger, A...913, 941, 1395 Berggren, O Berglin, E...90 Bergman, G Bergman, MJ. 375, 417, 896, 1106 Bergström, M Bergström, U , 1477 Berke, Z Program Book Berks, M , 2147 Berktold, J Berkun, Y Berland, Y Berman, A Berman, A. 1388, 1438, 2077, 2381 Berman, H. 1388, 1438, 2077, 2381 Berman, J Berman, N Bermas, BL Bermudez, LM , 2269 Bermudez-Santiago, LM Bernadette, H Bernal, JA Bernard, L Bernard-Brunel, M Bernard-Medina, A Bernardi, L Bernatsky, S , 1833, 1866, 1998, 2015, 2023, 2289, 2309, 2619, 2664, 2665, 2666, 2791 Berner, R Berner Hammer, H Bernero, E Bernhard, J Bernstein, EJ , 1797 Berrocal, V , 2999 Bert, J Berthelot, JM , 2536 Berthier, S Berti, A Bertiller, E Bertiller, E , 2987 Bertolaccini, ML Bertoldi, I Bertoli, AM , 681, 716 Bertrand, A Bertrand, J Bertschinger, J , 1511 Bertsias, G , 2645 Berzi, A Berzin, E Besancenot, JF Bessette, L...118, 396, 502, 567, 1535, 1536, 2125, 2569, 2884 Bessis, N Besson, C Betelli, M Bethel, M , 2106 Bethge, J Bethunaickan, R Bettano, K Bettendorf, B Bettio, S Betts, K , 1555 Beukelman, T...302, 1297, 2293, 2294 Beumer, W Beussink-Nelson, L , 1929 Bevers, K Beyer, C , 1322 Beyer, MK , 2652 Bhadra Brown, P , 1108 Bhalla, S , 1935 Bhalla, V Bhamra, K Bharat, A...498, 1422, 2367 Bharucha, KN Bhatia, G Bhatia, J Bhattacharyya, I Bhattacharyya, S.. 750, 965, 3005 Bhavsar, SV Bhuyan, Z Biale, L Bianchi, G Bianchini, E Bianchino, L Biancotto, A Biard, L Biavasco, R Bica, B Bichile, T , 1665 Bielecki, M Bielfeld, P Bienkowska, J Bienvenu, B.....8, 255, 256, 1782, 1792, 2193 Biggioggero, M Biggs, C Bihlet, A , 2230 Bijkerk, C Bijlsma, JWJ Bijlsma, JWJ. 500, 1180, 1843, 2249 Bijlsma, JW Bijzet, J , 1626 Bilezikian, J Bilgin, E Bili, A...913, 1394, 1395, 1830 Billard, MJ , 2878 Billig, E Binda, E , 2403 Bingham, CA Bingham, CO III...479, 608, 1537 Biniecka, M Binkley, N Binstadt, BA BIOBADASER 2.0 study group, OBO Biologics for Children with Rheumatic Diseases (BCRD) study, T Biomdo, I Birbara, CA...548, 1561, 1579 Bird, P...461, 1178, 1183 Bird, P.602, 1543, 1565, 1572, 2419 Birkett, R...344, 2167, 2908 Birlik, M , 1584, 2595, 2611 Birmingham, J Birnbaum, J Birring, S Bisagni, A Biscetti, F Bischoff, S Bishwal, S Biswas, P Bitik, B , 2761 Bitman, B Biton, J Bitterman, H Bitto, A Bitton, A Björk, M Björnsson, J Bjørneboe, O Blaauw, M Black, RJ Blackman, B Blackstone, E Blagojevic-Bucknall, M Blair, C Blaison, G Blakley, M , 1323 Blanchais, A Blanchard, F Blanchard-Delaunay, C. 1776, 1778 Blanco, A , 1251, 1252, 2853 Blanco, F...59, 1129, 2097 Blanco, FJ Blanco, FJ , 2231 Blanco, FJ , 1034 Blanco, I Blanco, LP Blanco, P Blanco, R.776, 777, 814, 880, 1240, 1249, 1250, 1251, 1252, 1787, 1788, 1791, 1845, 2203, 2452, 2459, 2461, 2775, 2776, 2853 Blanco Alonso, R Blanco Garcia, FJ...93, 982, 1121, 1122, 1125, 1126, 1127, 2602 Blanco-Favela, F Blaney Davidson, E , 1017, 2793 Blangero, J Blank, M Blauer-Peterson, C Blazer, A Blazevic, I , 716 Bleck, E Bledsoe, C Bleil, J Blevins, D Bliddal, H , 2439 Bligh, M Blijdorp, IC , 1973 Blinn, J...322

295 Blits, M Blizzard, L , 208, 209 Bloch, M Block, J Block, JA , 1990 Block, JA.213, 713, 716, 2111, 2207, 2245, 2310, 2315, 2989 Blockmans, D Bloem, JL , 2984 Blokland, SLM Blom, A , 2348, 2793 Blom, AB...76, 1199, 2948, 2952 Blueml, S Bluett, J... 78, 2032 Blumen, H Blüml, S... 27, 650, 2358 Boackle, SA Boas, R Bobba, R , 1424 Bobba, S Boccassini, L Bockenstedt, PL Bodaghi, B Bodemer, C Boedigheimer, M Boehm, M Boekhorst, J Boellaard, R Boeltz, S Boers, M Boers, M. 240, 260, 261, 361, 362, 2767, 3018 Boettner, F Boffa, JJ Bogaard, J Bogatkevich, G Bogatkevich, GS Bohdanowicz, M Bohgaki, T. 2, 5, 1179, 1628, 2638, 2677, 2864 Bohnsack, J Bohnsack, JF Bohórquez Heras, C Boiardi, L. 777, 785, 790, 791, 798, 882 Boice, J Boice, J , 1500, 1528 Boin, F Boire, G Boire, G.. 360, 361, 371, 394, 442, 1387, 2410 Boissier, MC. 335, 938, 1196, 2357 Boivin, JF Bojanowski, CM Bojinca, M. 823, 1525, 1526, 1538, 2497 Bojinca, V Bokarewa, M...435, 1748, 2515, 2847 Bolce, RJ , 367 Bolce, RJ Bolge, SC Bolkier, Y Bolland, M...21 Bolognese, M...916, 2254, 2255 Bolster, M Bolster, MB , 2002, 2886 Bolt, I Bombardier, C , 1833, 2309, 2380, 2424, 2426, 2814 Bombardieri, M Bombardieri, S , 527, 1772, 2201, 2217, 2432, 2499, 2544, 2656, 2708, 2755, 2855, 2931, 2981 Bond, G Bond, H , 2055, 2073 Bone, HG Bone, H , 2254 Bonegio, R Bonel, H Boneparth, A , 2869 Bonfa, AC Bonfa, AC Bonfa, E...235, 238, 863, 957, 1298, 1300, 1301, 1824, 2151, 2221, 2809, 2933 Bongardt, S , 2834 Bongartz, T...258, 390, 428, 2957 Bongiorni, D Bonilla, E Bonilla, G , 2622 Bonilla, MG , 2513, 2522 Bonilla, N Bonini, C Bonner, M Bonnotte, B , 2849 Bonomi, F Bony, C Book, C Boom, V Boonacker, C Boonen, A...70, 101, 557, 578, 579, 586, 1058, 1059, 1164, 1373, 2113, 2573, 2828 Boot, C Booton, R Boots, AMH , 1956 Bootsma, H.2547, 2551, 2831, 2934 Borah, A Borangiu, A Borba, EF Borba, EF Borderie, D Borekci, S Borges, C Borghi, MO Borgia, RE , 1312 Borie, D Borjas García, JA Borman, P , 1110 Born, T Borofsky, MA Boros, C Borrego, ME Borrell, H.. 695, 1381, 1655, 1657, 1659, 2194, 2620, 2780 Bortoluzzi, A Borzutzky, A Bos, R Bosello, SL Boshuizen, HC , 2054 Bossini-Castillo, L , 880 Bosworth, HB , 977 Botsios, C , 2408 Bottaro, A , 934 Bottini, N , 2871 Botto, M Boudaoud, S Bouée, S Bouhana, K Boulenger, J Boulman, N Bouman, C Boumier, P Boumpas, D Bourgeois, P Bourhis, F... 96, 1060 Bourji, KI Bourke, L , 2863 Bournia, VK , 2709 Bourré-Tessier, J...681, 716, 2210 Bourret, J , 2406 Bourrienne, MC...12 Bouta, EM...325, 934, 2353 Boutet, MA Boutin, D Boutros, P Boutroy, S Boveda, MD Bovis, F...277, 282, 2281 Bowcock, AM Bowes, MA Bowman, J Bowman, S , 2982 Boyapati, A Boyce, B...25, 37 Boyd, SK Boyer, O Boyesen, P Boyle, B Boyle, DL , 2816, 2818 Bozcan, S Bozsaki, G Brabosa, R Bracaglia, C. 311, 321, 1225, 1228, 1901, 2901 Bracciolini, G Bradburn, M Bradbury, L , 2962 Braddock, M Bradley, JD Bradley, JE Bradley, LA Brady, B , 1832 Brady, TJ , 2011 Braesch, C Brambilla, A Bramwit, M Branco, JC Brand, A Brandl*, C Brasier, A...6 Bratus, A Braun, J...557, 819, 2560, 2573 Braun, J Braun, J... 58, 463, 536, 538, 565, 566, 852, 1189, 2563, 2566, 2567, 2593, 2601, 2612, 2940 Braun, N , 777 Braun, T Bravi, E Bravo, B Bravo, M , 2987 Bray, S Breban, M , 1137 Breban, MA Breda, L , 2281 Breda, S Bremander, A Bremander, ABI Brennan, C Brennan, D Brennan, GP Brenner, D Brenner, M Brenner, MB Brensinger, C Brenton-Rule, A Brescia, AC Bretton, E Breuillard, P Brezin, A Brick, M , 2011 Bridges, SL Jr..363, 451, 1132, 1474, 2051, 2453, 2454, 2927 Brik, R Brik Simon, D Brink, M Brinkman, WB Brinkmann, GH , 2035 Brinks, DR Brinks, R...357, 701, 1057, 1078 Brion, R Briot, K...234, 257, 1769 Brisse, E Brisslert, M abstract author Index 2014 Program Book 293

296 abstract author Index Brithmer, L Brito, A Brito, M Brizzolara, R , 1966 Brkic, Z , 2979 Brock, M Brocq, O Broder, MS Brodmerkel, C Brodsky, J Broen, J Broeren, MGA Brogan, P. 1231, 2279, 2280, 2282 Brohawn, P Bromley, L Brooks, E Brooks, EB Brooks, L Brooks, S , 1898 Brooks, S...615, 1812, 1896 Brooks, S Brophy, M.. 462, 2139, 2373, 2781 Broussard, C Brouwer, E Brouwer, E Brouwer, E. 441, 1205, 1956, 2831 Brouwer, J Brouwers-Haspels, I Brown, B Brown, EE , 2454 Brown, E Brown, JP , 175 Brown, JP Brown, J Brown, J , 1795 Brown, J Brown, L Brown, LA Brown, M , 2962 Brown, MA...569, 617, 778, 1886, 2918 Brown, M , 2930 Brown, P Brown, RD Jr Brown, R Brown, T , 1347 Browne, L Broyde, A Brubaker, J Bruce, I...686, 711, 961, 2646 Bruce, IN , 712, 1182, 1464, 1923, 2636 Bruchfeld, A Bruet, A Bruijnen, STG Brummett, C Brummett, CM Brun, JG Brundidge, AD Brundige, A Bruni, C Brunier, L , 2155 Brunier-Agot, L , 2532 Brunner, HI Brunner, HI Brunner, HI , 2298 Brunner, H...273, 1294, 1825 Brunner, HH Brunner, HI...83, 276, 930, 933, 1302, 1303, 1304, 1826, 1988, 2211, 2222, 2320 Bruss, M...911, 1204, 2687 Bruyere, O Bryan, R , 1206, 2949 Brys, R Brzosko, M , 1715 BSPAR Etanercept Cohort Study, OBOT , 272 BSRBR Control Centre Consortium, 467, 1909 Bucala, R Buchbender, DC. 1173, 1177, 1189 Buchbinder, R Buchdaul, AL Buckeridge, D Buckinx, F Buckley, C.. 389, 1045, 2183, 2463 Buckley, LM...10 Buckner, JH. 446, 453, 1904, 2891, 2921 Buckner, TR...16 Budde, P Budinger, GS , 3005 Budoff, M Bueno, C Bugatti, S , 2403 Bugbee, W Buitelaar, H Bukhari, M.224, 227, 230, 231, 240 Bukowski, J...855, 1893, 2577 Bukowski, J Bukowski, J Bulbin, D Bundy, N Buoncompagni, A Burbridge, C Burd, C Burghardt, AJ , 2136 Burgos-Vargas, R Burgos-Vargas, R , 557, 928 Burke, B , 1872 Burket, JC , 2970 Burkhardt, H , 2915 Burkly, L , 1920 Burmester, G...29, 339, 357, 378, 493, 497, 735, 773, 1485, 1486, 1515, 1518, 1521, 1845, 2468, 2485, 2486, 2491, 2492, 2530, 2552, 2693, 2821, 2837 Burnell, J Burns, S , 2106 Burr, DB Burrell, S Burrill, R Burska, A...137, 1020, 1740 Burtey, S Burtner, P Busch, M Busch, VJJF Busfield, S Bush, H Bushmakin, AG Busman, E Bussey, M Bussey, MR , 1327, 1377 Busso, N Bussone, G Bustabad, S Bustabad-Reyes, S Bustos Rivera Bahena, C butbul Aviel, Y Butera, P Butt, D , 2309 Butter, C Butterwick, M Buttgereit, F. 29, 1006, 1482, 1518 Buttner, P Button, P Buxbaum, J Buyon, JP...534, 672, 684, 871, 961, 1207, 1328, 1605, 1608, 1631, 1635, 1829, 1924, 2646 Buysman, E , 1155 Byford, A Bykerk, VP...187, 350, 361, 371, 394, 464, 1387, 1515, 1521, 2369, 2370, 2410, 2468, 2485, 2486, 3016 Byram, K Byrjalsen, I...222, 368, 2230 Byrne, R Büsch, K Bytautas, J Bzarova, T Bäcklund, J Bäuml, M Börsbo, B Bøyesen, P C Caamano, J Cabacangun, R Cabane, J Cabral, AR...11, 1654, 2867 Cabral, DA , 2903 Cabral, F Cabrera, J Cabrera, S , 2478 Cabrera-Villalba, S. 134, 445, 2508, 2926 Cacoub, P. 8, 809, 811, 1245, 1792, 1925, 2163, 2731, 2757 Cadelis, G Cadet, C Cadet, M Cadzow, M... 21, 168, 2961 Caeiro, F.. 959, 1388, 1438, 2040, 2381 Cagatay, Y , 2750, 2769 Caglar, E Cagnoni, M Cagnotto, G Cai, A Cai, CH Cai, L Cai, Y Cai, Z Caiaffa-Filho, HH Caiello, I...311, 1228, 1901 Caini, S Cakir, N , 2719 Cakmak, A Calabrese, LH...837, 2764, 2765, 2856 Calabro, S. 1562, 1563, 1569, 1851 Calamia, K Calamia, V... 93, 982, 1127 Calandra, S Calcagni, M Calderillo, ML Caldwell, T Calero, I...74 Calero Munoz, S Calise, SJ Callaghan, MJ Callahan, LF.978, 1088, 2046, 2051, 2941 Callejas, JL Callhoff, J Callon, KE Calvet, J Calvo, I Calvo, K Calvo-Alen, J.668, 814, 1415, 1670, 2622 calvo-gutierrez, J Calvo-Penedes, MI Calvo-Río, V.814, 1249, 1250, 1251, 1252, 1787, 1788, 1791, 2775, 2776, 2853 Cam, O Camacho, C Camacho, M Cambon-Thomsen, A Cambridge, G. 452, 989, 995, 1955, Program Book

297 Camellino, D Cameron, V Caminal-Montero, L Caminis, J Camp, H Campanilho-Marques, R.1314, 2900 Campbel, M Campbell, D Campbell, G Campbell, P Campbell, PL...444, 937, 1962 Campbell, S Campbell, TM Campochiaro, C , 2202 Campos, J Campos, LMA , 1300 Can, G Can, G Can, M , 2769 Cañal Villanueva, J , 1252 Canavan, M Candido, WM Cañellas, J Canestrari, G Canestri, S...403, 999, 1639 Cañete, JD...58, 59, 134, 445, 469, 947, 992, 1129, 1739, 1969, 1973, 2097, 2478, 2508, 2926 Canhao, H. 504, 1524, 1837, 1838, 2428, 2524 Canioni, D Canizares, M Canna, S Cannavale, T Cannella, A Cannon, GW..348, 494, 840, 1372, 1391, 1392, 1540, 1993, 1996, 2001, 2494, 2881, 2885 Cano, C , 1531, 2423 Cantagrel, AG...466, 1140, 2028, 2483 Cantarini, L.1231, 2279, 2280, 2282 Canzoni, M Cao, J Cao, X Cao, Y Cao, ZM Cao, Z...66, 1803, 2050 Caorsi, R Caparbo, V.50, 51, 52, 73, 235, 238, 1301 Capdevila, O.695, 1655, 1659, 2620 Capeau, J Capelozzi, VL Caplan, L.. 840, 1372, 1391, 1392, 2386, 2570 Caporali, R...483, 519, 988, 1256, 2403, 2512, 2514, 2609 Cappelleri, J Cappelleri, JC Capri, J...91 Caprioli, M Capuccio, A Caputo, R Caracuel-Ruiz, MA Caramaschi, P , 2711 Carames, B Carandang, K Carbillon, L...12 Carbone, L , 2106 Carbonella, A Cardenas-de La Garza, A Cardiel, M Cardiel, MH Cardoso, A Carette, S. 801, 804, 808, 880, 883, 1861, 2851 Carey, H Carey, J Carey, JJ Carey, V Caricchio, R Cariou, A Carita, P Carle, A , 262, 288 Carlesso, L Carletto, A Carli, L...147, 2432, 2656 Carlsen, AL Carlsson Almlöf, J Carmona, FD Carmona, L...99, 723, 731, 2710 Carmona-Fernandes, D Carmona-Rivera, C Carns, MA , 1929 Caro, X Carpenter, L , 2135, 2810 Carpenter, S Carpentier, P , 1928 Carpintero-Fernández, P , 1034 CARRA Registry Investigators, T , 2271, 2292 Carranco, T...74 Carrara, G Carrasco, R...274, 295, 303, 2294 Carrasco, S Carrasco Cubero, C , 2853 Carrat, F Carreira, P...723, 747, 753, 1240, 2097, 2459, 2622 Carreira, PE.. 680, 731, 2710, 2711 Carretero, R Carrier, N , 442 Carriero, A Carrillo, I Carrillo Vazquez, S Carrillo-Palacios, RA Carrino, JA Carro-Esteban, SR Carroll, K Carron, P Carron, PL Carruthers, E , 416, 915 Carruthers, M , 2804, 2805 Carter, A Carter, D , 1844 Carter, D Carter, JD Carter, R Carter, S Cartwright, A Carubbi, F Caruso, A Carvalho, AF Carvalho, C Casado, G , 2040 Casali, B Casals, JL Casanueva, B , 2063, 2064 Casas, I Casciola Rosen, L Casciola-Rosen, L , 2539 Casella, CB Casellas, J Casey, VA Caspi, D , 700, 971 Castañeda, S...776, 777, 880, 1240, 1367, 1787, 1788, 2412, 2452, 2459, 3008 Castañeda-Sanz, S. 814, 1256, 2144 Castelino, FV...104, 1151, 1796 Castellani, RJ Castelli, C Castellvi, I.. 753, 1670, 1674, 2622 Castellvi Barranco, I Castiblanco, J...84 Castillo, D Castillo, JR Castillo, R Castillo-Gallego, C. 595, 605, 2596 Castonguay, M Castrejón, I...69, 353, 417, 1157, 2111, 2310, 2379, 2568 Castro, MC Catalán Pellet, A , 1438 Catanoso, MG Catanoso, M , 2417 Catay, E Catelani, MB Cathebras, P Catoggio, C Catoggio, LJ Catrina, AI...434, 993, 2797 Catrina, SB Cats, H...76 Cattalini, M Cauli, A Cavagna, L Cavalli, G , 2202 Cavallini, N , 2847 Cavatorta, F Cavazza, A. 785, 790, 791, 798, 882 Cavazzana, I , 1532 Cavill, C Cavillion, E Cawston, H... 96, 1060 Cawston, H Cayetti, LA , 2575 Cazenave, T...127, 128, 141, 410 Cazzato, M Ceccarelli, F Ceccato, F Ceccatto, F...406, 1388, 2381 Cecchetti, S Cedeno, C Cedillo, M Cefle, A , 2750 Celik, S Celis, R , 1973 Cella, D , 261 Cellucci, T Cenac, S , 2707 Cendes, F , 2659, 2661 Centeville, M Cerda, O , 1438 Cerda, OL Cerf-Payrastre, I Ceroti, M Cerqueira, C Cervera, R , 2868 Cervinski, M Cesana, L Cesano, A , 1616, 2873 Cesta, A Cetica, V Cetin, A Cetin, P , 1230, 1584, 2562, 2595, 2611, 2616 Cetinkaya, F Cha, HS.. 60, 182, 587, 598, 1056, 1221, 1241, 2464 Cha, S Chaabo, K Chacon, R Chadha-Boreham, H Chae, JJ , 1817 Chaer, FGG Chafey, P Chaganti, RK Chagnaud, C Chaichian, Y Chaitow, J Chakravarthy, K...328, 997, 2354 Chakravarti, R... 88, 987 Chakravarty, E abstract author Index 2014 Program Book 295

298 abstract author Index 296 Chalan, P Chales, G , 1368 Chales, GH Challacombe, S Challener, GJ Chalmers, S Chalmeta, I Chalom, E Chambers, CD Chambers, R Chambers, R Chamizo Carmona, E , 2190 Chan, B...57, 1546, 1589, 1849 Chan, E Chan, EKL Chan, KL Chance, K Chandra, D Chandran, AK...419, 838, 1366 Chandran, V...542, 623, 624, 625, 626, 627, 628, 630, 1568, 1575, 1576, 1586, 1587, 1592, 1593, 1850, 2099, 2935 Chandy, KG Chang, AH , 214, 215 Chang, BH Chang, CCH Chang, DM Chang, EJ Chang, E Chang, H Chang, HH Chang, JT Chang, L Chang, NH , 2742 Chang, RW...68, 729, 750, 1800, 2698, 2944, 2946 Chang, S , 1336 Chang, SC...818, 1876, 2017 Chang, SH Chang, SK Chang, S , 2501 Chang, WI Chang, Y Chanroux, L Chaparro, M Chaparro, R Chaparro del Moral, R. 1388, 1438, 2381 Chapelle, DC...315, 1896, 1898 Chapelle Neal, DC Chapelon, C Chaplais, E Chapman, A Chapman, PT...173, 1214, 1757, 1758 Chapman, V Chapnick, J Chappell, C Chapple, C , Program Book Chapple, I Chapurlat, R... 62, 63, 920 Charby, G Charles, JF... 28, 2796 Charles, J Charles, P Charles-Schoeman, C.334, 487, 493 Charlier, E , 1025 Charlton, J Charpentier, J Chartier, M , 2492 Chartier, S Chartrand, S Charuel, JL Charuvanij, S Chary-Valckenaere, I Chary-Valkenaere, I Chase, M Chasnyk, V Chastek, BJ Chatelais, M Chatelus, E , 1707 Chatfield, S Chatham, WW...706, 1668, 1672, 1924, 1953, 2200 Chatterjee, S , 1927 Chatzidionysiou, K , 2524 Chaudhari, A Chaudhry, A Chaudhry, N Chaudhry, RN Chauhan, AK , 2730 Chaussabel, D Chauvin, N Chavda, R Chavez, H Chavez-Rueda, K Chávez-Sánchez, L Ché, H , 2324 Cheah, P Chebane, L Checchi Gibilaro, J Checchio, T Cheeseman, C Cheetham, TC , 898 Chehab, G Chen, A Chen, C Chen, CI Chen, CH Chen, D Chen, H Chen, H Chen, JS Chen, J Chen, L.. 57, 498, 820, 842, 1148, 1422, 1546, 1589, 1839, 1849, 1910, 2367, 2375, 2388 Chen, M Chen, N Chen, P , 1968 Chen, SY , 2344 Chen, SY , 2621 Chen, S , 2581 Chen, V Chen, WV Chen, WM Chen, WH Chen, W , 2118 Chen, X Chen, Y...460, 465, 1908 Chen, YW Chen, YH Chen, YS Chen, YF Chen, Y Jr Chen, Y Chen, Z , 2799 Cheng, D Cheng, LI Cheng, Q Cheng, S CHENG, Y Jr Cheon, YH...220, 2262, 2356 Cherkas, Y , 2096 Chernitskiy, V , 1353 Chernoff, D , 367 Chervinsky, L Cheung, A Cheung, P , 2975 Cheungpasitporn, W...726, 799, 2531 Chevalier, P Chevalier, X Chevallard, M Chevli, P Chevreau, M Chew, DW Chhana, A Chiba, A , 2728 Chiba, N...87 Chiche, JD Chiche, L.. 809, 1611, 2536, 2549, 2731 Chicoine, A Chieng, A , 295, 303 ChiesaFuxench, Z Chighizola, CB Childhood Arthritis Prospective Study (CA), OBO Childs, J Chimenti, MS Chinchilla, SP Chines, A Chino, K Chinoy, H...912, 2924, 2953 Chioccha, G Chiocchia, G...622, 1137, 2928 Chiowchanwisawakit, P.2613, 2986 Chiowchanwisawakit, P.. 557, 591 Chistyakova, E Chitkara, P Chitu, V Chiu, CS Chiu, YG... 25, 37, 2794 Chiu, Y Chiuzzi, E Chmiel, JS , 214, 215 Cho, CS , 1364 Cho, ML , 1048 Cho, SK , 1805, 2025, 2158 Cho, YN Chodick, G Chodosh, J Choe, HR Choe, JY. 1056, 1508, 2025, 2078, 2825 Choi, B Choi, CB...946, 1056, 1857, 2025 Choi, D , 1756 Choi, H.. 171, 172, 822, 827, 901, 923, 1874, 1875, 2958, 2961, 2969 Choi, HK , 974, 1136, 1155, 1219, 1400, 2114, 2932, 2960 Choi, IYK , 2463 Choi, J Choi, S Choi, ST , 1217, 1241 Choi, SC Choi, YI Choi, YJ Choi, YH chollet Martin, S...12 Chong, C Chopra, R , 2689 Choquette, D...365, 379, 382, 383, 396, 426, 499, 502, 567, 943, 956, 1535, 1536, 1550, 1551, 1601, 2569 Chorus, AM... 70, 2113 Chou, YK , 1751, 1752 Choudat, D Chow, A.379, 421, 583, 1550, 1551, 1601, 2411 Chow, V Chowalloor, P Chowdhary, H Chowdhary, V , 2628, 2642 Choy, EH... 30, 2803 Chrabot, B Chrétien Raymer, P Christensen, A Christensen, AF.349, 541, 629, 1905 Christensen, B Christensen, R , 2131 Christiansen, C...222, 368, 2230 Christiansen, S Christiansen, T

299 Christianson, TJH Christmann, R , 2721 Christodoulou, E Christoffersen, C Christoph, E Christopher-Stine, L Christopoulos, PF Christos, P , 2370 Chrobak, I Chrysidis, S Chu, CQ , 1751, 1752 Chu, D Chua, RM Chuang, PC Chugh, S Chukkapalli, S Chung, C , 844 Chung, CP. 1117, 1442, 1630, 1902, 1986 Chung, J Chung, L.721, 734, 878, 2698, 2996 Chung, M , 2065 Chung, SW Chung, SE Chung, SA Chung, WT Churchill, M Cialic, R Ciambotti, B Ciani, B Ciccia, F , 611 Ciceri, F Cicmil, M...328, 649, 2354 Cicutinni, F , 208, 209 Cicuttini, F...218, 926, 1277, 1278 Cid, MC , 777, 880 Ciechanowski, K Cieri, N Cieza, A Cieza-Borrela, C...74 Cifaldi, L Cigolotti, A Cillero-Pastor, B Cimaz, R Cimaz, R , 2901 Cimino, L , 882 Cimmino, MA...776, 880, 1966 Cimmino, MA , 2771 Cinar, M Cinar, S Cioffi, E , 2201 Ciofu, C Cipriani, P Cisternas, M , 2788 Cisternas, MG...98, 888, 963, 980 Citera, G...127, 128, 141, 406, 410, 887, 1285, 1388, 1438, 2040, 2042, 2381, 2402, 2441, 2575, 2706 Ciudad, M Ciurea, A , 2565 Ciurea, P , 1526, 1538, 2497 Cividino, A. 1172, 1424, 1566, 2884 Civino, A Clabbers, A Clair, A , 1108, 1879, 2076, 2080 Clair, AG Clancy, C Clancy, M Clancy, R Clancy, RM...387, 534, 871, 1207, 1328, 1605 Clancy, Z Clapp, C , 333 Clark, E Clark, EA Clark, JD , 1616 Clark, K Clark, KEN Clark, MR Clarke, A Clarke, AE...681, 716, 961, 1673, 2015, 2646, 2664, 2665, 2666, 2791 Clarke, CK Clary, G Claudepierre, P...540, 1186, 1187, 1894 Clausen, BE Clauw, DJ , 924 Clavel, G , 2357 Clayton, E Cleary, L Clegg, D Clegg, DO Cleland, LG Clements, PJ , 2335, 2697, 2995, 2999 Clements-Baker, M Cleophas, M , 1223 Clerson, P...163, 164, 165, 1690, 2701 Cleveland, R...978, 2051, 2941 Cleveland, RJ , 2046 Clifford, A... 88, 797, 2786 Clifford*, A Close, D , 1486, 1496, 2821 Clowse, MEB...679, 1359, 1378, 1409, 1599, 2669 Cluzel, P , 2731 Co, C Co, DO , 2319 Coates, LC Cobankara, V , 2523, 2750, 2769 Cobb, I Cobb, J Coblyn, JS. 1335, 1369, 1370, 1408, 2122, 2889 Cobraiville, G Coburn, B Coburn, BW , 250 Coca, A Coca, M Cockell, S , 2982 Codding, C Codner, D Codreanu, C , 1525, 1526, 1538, 2497 Coelho Horimoto, AM Coenen, MJH Coeytaux, R Coffman, C , 977 Coggeshall, M Cohen, AD Cohen, F Cohen, H Cohen, JD Cohen, M Cohen, P.. 811, 1759, 1763, 1767, 1769, 1776, 1778, 1782, 1864 Cohen, S Cohen, SB Cohen, S Cohen-Aubart, F Cohen-Bittan, J , 1925 Cohen-Hallaleh, V Cohn, D Coindreau, J Coit, P...77 Coit, Coladonato, L Colaone, F Colbert, RA...283, 607, 609, 615, 619, 621, 1815, 1919 Cole, M , 2446 Coles, M Colgan, SP Colin, E Colin, L Coll, J Coll, RC Collaborative Group, AR Collaborative Group, CP Collado, A Collado, MV , 2441 Collado, S Collantes- Estevez, E...40 Collantes-Estevez, E.. 7, 596, 1978, 2588, 2596 Collier, D , 1853, 2498 Collier, D Collier, DS , 2425 Collins, CE Collins, E Collins, FL...30 Collins, JE.65, 210, 900, 2235, 2859, 2862 Collins, K Collins, M Collinson, N Colmegna, I , 1998, 2289 Colombo, C Colombres, F , 1438, 2381 Colonna, L Colunga-Pedraza, IJ Comarmond, C Comarmond, C , 2731 Combe, B. 395, 2477, 2485, 2486, 2493, 2912 Combe, BG , 1521, 2468 Combe, B...121, 393, 581, 590, 1384, 1411, 1490, 2379, 2385, 2397, 2587, 2928 Comte, D Conaghan, PG , 954, 1007, 1020, 1178, 1181, 1183, 1521, 1891, 2231, 2589 Conde-Jaldón, M , 1788 Condino-Neto, A Conigliaro, P Coniglio, ML Conklin, J , 1631, 1921, 1924 Conlon, D Conn, DL Connelly, MA , 1902 Connelly, M Connolly, K , 2717 Connolly, M , 1195, 2800 Connolly, SE Connolly, S Conrad, K Conroy, A , 1616 Cons Molina, F Consolaro, A , 2298 Consolaro, A...277, 278, 282, 299, 928, 2281 Consortium, A Constantin, A...466, 1140, 2028, 2483 Constantin, T...284, 1322, 1323, 1325 Contini, P , 1966 Contreras-Yañez, I , 1371 Conway, R Cook, J Cook, K...259, 260, 261, 288 Cook, RJ...542, 1576, 1592, 1850 Cooney, M Cooper, A Cooper, C Cooper, H Cooper, M Cooper, MA Cooper, P Cooper, RG , 2953 Cooper, MD, FRCP, RG Cope, AP abstract author Index 2014 Program Book 297

300 abstract author Index 298 Cope, F Corbí, L Corciulo, C Cordel, N Cordero, M Cordero-Coma, M Cordier, JF Cordingley, L...303, 2031, 2032 Cordtz, R , 848 Coresh, J... 44, 1872 Cormier, C Cormier, H Cornec, D , 2536, 2606 Cornish, J Corominas, H Corominas, H... 59, 474, 1129 Corona, F Coronell, C Corr, EM Corr, M Corr, M Corrales, A. 228, 2452, 2459, 2461 Correa, MDLA Correia, C Correig, X Corteguera, M...40 Cortelezzi, A Cortes, J Cortés-Pereira, E. 1121, 1122, 1125 Cortis, E Cosatti, MA Cosette, P Cosman, F Cossette, P Cossio Jimenez, PJ Cossu, M , 2178 Costa, JA Costallat, L , 2663 Costallat, LT Costantino, F Costanza, D Coste, J Costedoat-Chalumeau, N.. 8, 835, 1245, 1759, 1925, 2549, 2779 Costello, CE , 984 Costenbader, KH. 55, 818, 867, 903, 1080, 1876, 2017, 2020, 2887 Costi, AC , 2670 Cote, J , 1395, 1830 Cotrim, AP , 529 Cottreel, E Couderc, M Sr , 1448 Coudert, M Coughlan, RJ Coulson, E Coupal, L.396, 499, 502, 567, 1535, 1536, 2569 Courties, A , 1275 Cousin, E Program Book Couto, S Covelli, M Cowan, P Cowburn, D Cox, E Cox, V Cozic, C Cozmuta, R Cozzi, F Crabol, Y Crackower, M Cragg, M , 1955 Craggs, J , 251, 897 Cram, P...54 Crane, C Craven, A Crawshaw, D Créange, A Creese, A Cremer, I Crespo, G Crespo, G Crespo, ME. 406, 1388, 1438, 2381 Cretu, D Criado, G , 660, 1739, 1969, 2175, 2735 Criales-Vera, S Crichlow, G Crins, M , 261 Crisan, T , 1223 Criscione-Schreiber, LG...3, 1983, 2886 Crispin, JC , 2734, 2846 Cristanacce, P Criswell, LA...520, 524, 525, 2446, 2466, 2841, 2929, 2955 Crittenden, D Crittenden, DB , 1224 Crittenden, D Crittenden, S Croca, S Croci, S Crofford, LJ , 2227 Croft, P , 2898 Croitoru, S Croker, B Cron, RQ , 2281 Cronin, ME Cronstein, BN...19, 22, 23, 24, 33, 34, 36, 156, 187, 1729, 2355, 2792, 2947 Cross, M , 209 Crow, C Crow, MK. 872, 1047, 1607, 2087, 2090 Crowe, S Crowley, JT Crowson, CS...258, 304, 390, 419, 428, 800, 838, 914, 1052, 1055, 1366, 1405, 1852, 2116, 2213, 2628, 2642 Cruickshank, S , 367 Crump, G Cruz, G Cruz, J Cruz Lagunas, A Cruz-Domínguez, P Cryer, B , 249 Cseh, A CSRG, CSRG Csuka, ME Cuadrado, MJ...7 Cubino, N...74 Cuchacovich, R , 1643 Cucho-Venegas, JM Cucnik, S Cuda, CM , 969 Cudrici, C Cuende Quintana, E Cuervo, A...134, 445, 469, 2478, 2926 Cuff, C , 1030 Cui, J , 1369, 1370, 1408 Cui, K Culpo, R Cumming, J , 2331 Cummings, S Cunnane, G , 2916 Cunningham, CC Cunningham, J Cunningham, MA , 1213 Cunningham, N Cunnington, J Cuomo, G , 2711 Cuperus, N , 2860 Cure, S Curhan, G...171, 1219, 2960 Curran, JE Curran, M Curran, V Curtis, JR , 465 Curtis, JR...49, 57, 114, 169, 378, 468, 498, 515, 820, 842, 919, 1148, 1387, 1422, 1474, 1546, 1589, 1839, 1844, 1849, 1910, 2367, 2375, 2388 Curtis, S Curtis, S Cush, JJ , 1409 Cusi, D Cuthbertson, D. 801, 804, 808, 880, 1861, 2851 Cutolo, M , 737, 1561, 1565, 1697, 1700, 1713, 1928, 1966, 1991 Cuttica, M Cuttica, R Cuttica, RJ Cuvelier, C Cypers, H Czerwinski, E Czirják, L , 2711 Czirjak, L Czyz, C , 1756 D D Elkhalifa, A d Agostino, MA...132, 1368, 1517, 2589, 2923 D Angelo, S , 2758 D Ario, G D Artois, J d Ascanio, A , 2432, 2708, 2755 D Cruz, D D Cruz, DP. 676, 1237, 2188, 2695, 2833 D Lima, D D Orazio, A , 2441 da Rocha, G Da Ros, M da Silva, MA Dadashova, R Dadhania, D...9 Dadoun, S.. 585, 2527, 2574, 2599 Daele, PLV , 1863, 2979 Dagfinrud, H , 577 Dagfinrud, H , 2571 Dagna, L , 2202 Daha, N Dahlqvist, J Dai, D Dai, G Dai, X Daien, C , 1490 Daien, CI Daigle, ME Dailey, D Dailey, R , 1756 Daizadeh, NS Daizadeh, NS Daizadeh, N , 2254 Dakin, P Dal Pra, F...406, 1438, 2381 Dalakas, M Dalal, D Dalbeth, N. 21, 162, 168, 826, 828, 1215, 2052, 2959, 2962, 2964 Dalkilic, E Dall Ara, F Dall era, M.3, 667, 963, 1668, 1672, 2788 Dalm, VA , 2979 Dalprà, S Dalury, D Daly, RP Daly, RP , 2012 Daly, T...987

301 Damian, LO Damm, T Damman, W Dampier, C , 262 Dancey, P Danda, D , 2542 Dandinoglu, T Daniels, T Danielsen, M Danila, MI.. 451, 1474, 2453, 2454 Dankers, W Danko, K...910, 912, 2953 Danoff, SK Danré, A Dantas, AT Danve, A Daoud, J Dare, J Darghosian, L Daridon, C , 1951, 2693 Darne, B Darnige, L...8 Darrah, E Darrieutort-Laffite, C Daruwalla, V , 1929 Das, L , 1309 Dasgupta, B...775, 793, 796, 880, 885, 909, 2493, 2772 DaSilva, CA Dastmalchi, M , 1211 Datta, P Datta, S , 977 Datta, SK Datta Mitra, A , 1963 Dauchet, L Daugas, E Daures, JP , 2161 Dave, A Dave, AJ Davelaar, N , 1749 Davenport, T Davi, F Davì, S...299, 1901, 2281 Davidson, A , 2869 Davidson, J , 295, 303 Davidson, K Davidson, M Davidsone, Z Davies, H Davies, O. 543, 544, 565, 566, 1553 Davies, R , 272, 274 Davies, S Davin, S Davis, A Davis, HM , 1529 Davis, JM III...258, 390, 428, 1052, 1405 Davis, LA...840, 1372, 2386, 2570 Davis, M , 2628, 2642 Davis, M Davis, TE Davis, WE Davison, MJ Dawood, H Day, R Dayanand, S de Almeida, MA de Alvarellos, T De Avila, J De Avila, MD de Bakker, PIW de Bakker, PI. 625, 880, 2918, 2954 De Bandt, M , 2155 De Benedetti, F Sr...276, 299, 311, 321, 1225, 1228, 1901 de Bie, R... 70, 2113 De Bleecker, J de Boer, B , 1930 de Bruin, F De Bruin, ML de Bruin, SE de Brum-Fernandes, AJ.. 360, 442 De Bruyn, S De Ceulaer, K...6 De Cunto, C De Cuyper, D De Dios, JR De Fusco, C de Graaf, D...75 De Graaf, K de Gregório, LH de Groot, P de Hair, MJH , 2463 de Hair, MJH de Hooge, M , 577 de Hooge, M...594, 1186, 1187, 1894, 2597 De Inocencio, J , 2281 de Jager, J de Jesus, NR de Jong, J , 2143 de Jong, PHP , 2815 de Jong, TD de la Barrera, MI de la Morena Barrio, I De La Sota, M De La Torre, I de la Vega, MC De Laat, B de Lama, E , 1655 de Lautour, H de Leeuw, K de Longueville, M , 468 de los Riscos, M De Lott, LB De Luca, G De Lucia, O De Menis, E de Mesy-Bentley, K de Miguel, E..595, 605, 777, 2578, 2586, 2596, 2598, 2604 de Min, C , 1901 De Moreuil, C de Munter, W...20, 1199, 2950 De Nard, F , 2609 De Paepe, B de Seny, D , 1025 De Smet, K De Smit, E de Smit, MJ De Somer, L de Sonnaville, PBJ , 2815 de Souza, AWS de Souza, FHC de Souza, MC de Souza Muller, C De Sozya, A De Swert, K De Toro, J De Vera, M , 2112 de Vera-Gonzalez, AM de Vet, H...260, 261, 3018 de Villiers, T de Visser, M De Vita, S , 2855 de Vlam, K De Vos, F de Vries, A de Vries, D de Vries, F de Vries, M de Vries-Bouwstra, JK. 1692, 1930 De Vries-Bouwstra, JK.. 753, 1693 de Wazières, B de Wit, M... 58, 351 Deal, CL , 2263, 2316 Deamude, M , 1507 Dean, LE... 41, 563 Dean, M Deane, KD. 446, 1904, 2019, 2891, 2921 DeBandt, M , 2532 Debelius, J DeBerardine, M Decaris, M Decaux, O , 1778, 2779 Dechaisemartin, L...12 Dechartres, A Decker, P...335, 938, 1196 Decktor, DL , 2824 Dedeoglu, F. 314, 319, 1226, 1321 Deehan, R...75 Deering, D Defrance, T Defranoux, NA , 2974 Dehghan, N , 1865 Dehlinger, V , 2024, 2155, 2532 Deibjerg, L Dejaco, C Dejonckheere, F , 2501 Dekker, J. 260, 261, 572, 573, 1451, 2053, 2054 del Blanco, J Del Galdo, F , 968 Del Papa, N.. 531, 879, 1675, 1689 Del Pino, M Del Pino-Montes, J...74 Del Rey, MJ , 1969 del Rincon, I , 2026, 2374 del Rio, AP , 2720 del Rio, E del Río-Martínez, P Delaval, P Delayen, A Deleuran, B...26, 366, 409, 1200, 1741, 1964, 2729, 2737 Delgado, C Delgado, M Delgado-Frias, E DeLibero, C Deligny, C. 1269, 1271, 1767, 2024, 2155, 2532 Dell Accio, F Dell Acqua, D Della Rossa, A , 2708 Dellaripa, P Dellaripa, PF Delle Sedie, A Dellyes, A Delorme, P DelVecchio, B Demary, W Demattei, C Demirci, FY Demirkaya, E Demirovic, D Demirtas, S Demmelmaier, I Demmer, RT Demoruelle, MK.. 446, 1904, 2891, 2921 Demougeot, C , 2360 den Boer, E den Broeder, A , 2860 den Broeder, AA...204, 500, 1843, 2249 den Uyl, D Denayer, T Deng, H Deng, W Deng, Z...315, 1812, 1898 Denio, AE , 1830 abstract author Index Denis, G Program Book 299

302 abstract author Index 300 Denisova, R Deniz, G Denton, C...753, 1717, 1721 Denton, CP.. 755, 968, 1703, 1706 Denton, CP...760, 768, 874, 876, 1714, 2711, 2997, 2999 Denys, A Deodhar, AA...536, 538, 543, 544, 545, 547, 551, 819, 852, 1557, 2601 Depresseux, G Deprez, X DeQuattro, K Derambure, C Derambure, C Dereli, E Derfalvi, B Derk, CT Dernis Labous, E.. 473, 1385, 1413, 2324 Deroux, A , 2757, 2777 Derrett-Smith, EC...755, 768, 968, 1703, 1706 Dertkigil, S Dervieux, T.1608, 1631, 1921, 1924 Desai, K Desai, R , 1434, 1911 Desai, SP Desallais, L Desbois, AC Deschamps, M Deshayes, S Deshmukh, S Deshmukh, U...985, 1798, 2542 Deshpande, B Deshpande, GA Deshpande, V Desjardin, C Desjardins, O Desmurs-Clavel, H Desmurs-Clavel, H Dessein, PH Dessole, G , 2559 Detert, J Devanarayan, V Devarajan, P , 1303, 1304, 1826 Devauchelle, V...521, 1368, 2161, 2606 Devauchelle-Pensec, V Devenport, J Devilliers, H...713, 717, 811, 1263, 1782, 2849, 2989 DeVito, A Dewey, CM Dey, P Dhar, JP Dhar, R Dhillon, N Dhillon, N Program Book Dhindsa, N , 2401 Dhir, V Dhote, R Di, Y Di Bello, S Di Bernardo, A Di Ceglie, I Di Lascio, N Di Luca, G Di Mario, C , 999 Di Sabatino, V , 908 Diamandis, E Diamantopoulos, A Diamantopoulos, AP.776, 786, 793, 795, 796, 880, 909, 1573, 2770 Dianongco, ML Diatchenko, L Diaz, C , 2526 Diaz, C Diaz, D Diaz, J Diaz, MP Diaz Alvarez, A...74 Díaz-Cordovés, G Diaz-Gonzalez, F.. 992, 1367, 1399 Díaz-Llopis, M , 2853 Diaz-Martin, A Diaz-Torne, C Dibatake, A Diboll, J DiCarlo, EF DiCarlo, JC DiCicco, M Dickinson, A Dickson, K , 2331 Diderichsen, P Diego, S Diekman, LA Dieude, P...520, 521, 747, 1130, 1140 Dieval, C Diez Alvarez, E...668, 814, 1670, 2622 Diez Lizuain, ML Diez-Perez, A Dijkmans, BAC Dijkmans, BAC , 572 Dijkstra, M , 300 Dikranian, A , 2489 Dileepan, K Dilillo, D Dimattia, M Dimitraki, G Dimitrov, EA Dimon, M Dimonaco, S Dimopoulou, D Dinarello, C Dinc, A Dincer, F Dinçer, Ding, C...205, 208, 209, 229, 926 Ding, J Ding, L Dinis, V Dinsdale, G , 2147 Dion, C Dion, J Diot, E , 1690 Direskeneli, H.119, 807, 1423, 2157, 2750, 2769 Dirven, L...817, 1386, 2398, 2502 Dissanayake, T Distler, JHW Distler, JH , 753 Distler, O...727, 876, 967, 1928, 2998, 2999 Distler on behalf of the EUSTAR investigators and co-authors, O Ditto, M Divakaruni, A Divekar, A Divers, J Dixey, J , 2135, 2810 Dixit, S...714, 1397, 2496 Dixon, W , 1838 Dixon, WG , 2033 do Rosário e Souza, EJ Dobbyn, A Dobrota, R...722, 823, 2998 Docampo Martinez, E Docherty, P Dodeja, A Doerffel, Y Doerner, J , 664 Dogra, P Doheny, K Doherty, M...165, 179, 2962 Doi, T Doleckyj, S Dolev, Y Dolezal, T Dolezalova, P...277, 284, 1325 Dolhain, RJ...107, 1439, 1871 Doll, H Dolman, KM Dolman, P , 1756 Dolstra, H Domènech, E Domiciano, DS...52 Domiciano, DS... 50, 51, 73 Domingues, V...9 Dominguez-Luis, MJ Dominguez-Quintana, M Domont, F Domsic, RT. 736, 1677, 1678, 1694, 2997 Donath, E Donati, V Donato, A Dong, D Dong, LL Dong, Y... 55, 2862 Dong, Y Donica, M Donlin, LT Donmez, S... 79, 2523 Donnell-Fink, L Donnelly, S , 2694 Donohue, JM Donovan, E Dooley, M Dooley, MA...684, 961, 2646 Doornbos-van der Meer, B Dorais, M , 2250 Doran, M Dore, R Dorfleutner, A Doria, A...671, 2408, 2833, 2953 Doria Medina, R Dorman, CW Dorr, A Dorris, ML , 620 Dorschner, JM , 2927 Dorton, B dos Santos, FC Doucette, S Doucette-Preville, D Dougados, M , 2912, 2938 Dougados, M...101, 351, 536, 538, 540, 574, 581, 584, 590, 819, 852, 1058, 1059, 1186, 1187, 1368, 1373, 1413, 1418, 1428, 1894, 2029, 2161, 2324, 2379, 2554, 2556, 2557, 2568, 2599, 2600, 2606, 2828, 2928, 2984 Douillard, C , 256 Dowell, S...370, 1375, 2378, 2413 Downer, K Dowty, ME Doyle, A , 1215 Doyle, RE Doyle, T , 1273 Dozmorov, MG Draghessi, A Draibe, JB Drake, R Draper, T Draves, K Dregan, A Drenkard, C , 2117, 2626 Drenkard, CM.899, 959, 1333, 1334 Drennan, M Drescher, E Drews-Botsch, C Drexhage, HA , 2979 Dreyer, L...848, 853, 1837, 1838

303 Driban, J , 1818, 2894 Driban, JB. 216, 1281, 1337, 2065, 2337, 2858, 2895 Drier, A Driest, KD Drokman, I Drosos, AA , 1170 Drossaert, CHC Drouin, EE...983, 984, 1970 Drubin, D... 75, 1619 Druce, KL , 2811 Drynda, S , 2088 du Souich, P Duan, J Duan, L Duarte, V Dubanchet, A Dubinsky, D Dubost, JJ...520, 521, 1448, 2536 Dubovy, S Dubreuil, F Dubreuil, M...144, 172, 554, 822, 827, 1875 Dubucquoi, S , 2700 Duchesne, J Ducreux, J , 1623 Dudek, A Dudley, L Duerr, RH Dueymes, M Duffy, C Duffy, C Duffy, CM Duffy, S Dufner, P Dufour, AB. 1085, 1086, 2943, 2945 Dufrenot, D Duggan, DJ Duggirala, R Dumancas, G Dumortier, T Dumusc, A , 158 Duncan, JA Dundar, U Dunham, JS Dunkel, J Dunlop, DD.. 68, 1800, 2944, 2946 Dunlop-Thomas, CM , 1334 Dunne, A Dunogué, B , 1763, 1767, 1769, 2199 Duny, Y Dupin, N Dupont, S Durán Santa Cruz, J Durandin-Truffinet, M Durden, E Durez, P Durukan, E Duruoz, MT Duryea, J Duryee, M Duryee, MJ , 1475, 2782 Dusad, A , 1475 Dussol, B , 1611 Dutasta, F...8 Dutoit-Lefèvre, V Duval Modeste, AB Duymaz, J...79 Dvorkina, O...3 Dwivedi, N Dwyer, T , 209, 229 Dybowski, F , 2940 Dyer, A Dyer, J Dzangue Tchoupou, G Dzhambazov, B Dälken, B Dörner, T , 996, 1944, 1951, 2693 E E. Harper, P , 1289 Earley, K Eastman, Easton, V Eathakkattu Antony, BS.. 208, 209, 229 Eaton, C , 1281, 1818, 2894 Eaton, CB , 2895 Ebbo, M Ebeling, P Eberhard, BA , 1304, 1826 Echtermeyer, F Eckman, J Eckstein, F...210, 211, 1280 Edberg, JC Eddings, W Edelman, D Eder, L.. 542, 626, 627, 628, 1575, 1850 Eder, V Ederveen, T , 1816 Edhayan, G.. 444, 937, 1962, 3006 Edison, JD Edmonds, S...54 Edwan, JH...619, 816, 1815 Edward, D , 1756 Edwards, C.. 548, 676, 1566, 1579 Edwards, CJ. 372, 602, 1543, 1561, 1565, 1572 Edwards, L Edwards, RR Edworthy, SM Eeg, I Effat, D Eggebeen, AT Eggleton, P Egsgaard, LL Egsmose, EL Eguchi, K , 2472 Egurbide, MV Ehrenstein, BP Ehrlich-Jones, LS , 2944 Ehrmann Feldman, D Eichenfield, A Eichenfield, AH , 2269 Eijkel, G Eimon, A Einarsson, HB...26 Einarsson, JT Einhorn, T Eisen, D Eisenstein, E Eivaz Mohammadi, S Ejbjerg, BJ Ejstrup, L , 629 Ekberg, S Ekpenyong, A Ekwall, AK , 2919 El-Gabalawy, H..1476, 1855, 2115, 2401 El-Gabalawy, HS El-Hallak, M El-Sawy, NA El-Zorkany, B El-Zorkany, B Elagib, E Elalouf, O Elashoff, D...91 Elashoff, R Elassaiss-Schaap, J Elbagir, S Elberg Godskesen, L Elder, JT Elefante, E , 2755 Elewaut, D.. 203, 638, 2134, 2988 Elford, K Elfving, P Elhai, M Elias, B Elías-López, D Elkayam, O Elkayam, O...443, 700, 971, 3012 Elkon, KB.657, 861, 873, 1814, 2844 Ellegaard, K Ellinghaus, E Ellingsen, T. 349, 1441, 2030, 2171 Ellis, J Ellis, M , 1500 Ellsworth, J...61 Elmesmari, A Elmore, S , 2839 Elner, VM Eloranta, ML , 2681, 2980 Elshafie, A Elting, L...111, 1069, 1070 Elwood, F Embi, PJ , 1422 Emery, P.. 385, 1362, 1515, 1521, 2468, 2485, 2486 Emery, P , 137, 380, 449, 536, 538, 768, 819, 968, 1020, 1178, 1740, 1891, 2495, 2503, 2773 Emil, NS Emir, B , 1879, 2076, 2080 Emond, PD , 1424 Emoto, K Emson, C Encinas, L Encinas, L Enciso, S Enck, R Endo, N Enecik, ME Eng, C... 88, 782 Eng, H...404, 886, 1410 Eng, SWM Engelke, K Engelson, BJ England, BR Englbrecht, M.351, 940, 1184, 2130 Engler, A Englund, M Enriquez Merayo, E Epailly, E Epis, OM Eraña, F Erausquin, C Erb, N Erba, G Ercalik, C Erden, A , 1432 Erer, B Erer, B Erfani, T , 2241 Erguven, M Erhard-Ramírez, A Erickson, A Erickson, AR Eriksson, A , 659 Eriksson, H Eriksson, J... 42, 2936 Eriksson, JK Erkan, D... 1, 3, 9, 18, 2868 Erken, E Erlandsson, M...435, 1748, 2515, 2847 Erman, B , 1316 Ermini, I Ernestam, S Ernst, M Ernste, FC , 1852 abstract author Index 2014 Program Book 301

304 abstract author Index 302 Erny, F Erondu, N , 1557 Erra, A... 59, 1129 Ertenli, I.. 509, 1432, 2157, 2562, 2611 Eryilmaz, E Esbrit, P...32 Escalante, A , 1133, 2026, 2374 Escobar Martinez, A Escolano, E Escorpizo, R Escribano, P Escudero-Contreras, A Esdaile, J , 2023 Esdaile, JM , 2306, 2308 Esen, E Eskehave, T Esmaili, N Espesen, J Espinosa, G Espinosa, R Espinosa Cuervo, G Espinosa-Morales, R Espinoza, F Sr Espinoza, LR.370, 1375, 1600, 1643, 2378, 2413 Espiritu, B Esquivel-Valerio, J , 1427 Essani, A , 2799 Essenmacher, L Essers, I.. 557, 574, 578, 579, 2600 Esteban, MM Estis, J Estivill, X Estrach, C Estrada, P.. 695, 1655, 1656, 1659 Estrada-Capetillo, L Estublier, C...62, 63 Etchepare, F Etcheto, A... 58, 257, 2324 Etomi, O Etzel, CJ...418, 1594, 2813 Eudaly, JG , 1213 Eudy, A Euller Ziegler, L Eun, JS Evans-Young, G Evensen, E , 1616 Ewart, D , 2843 Exarchou, S... 42, 1804 Exeni, IE Eymard, B Ezaki, Y Ezzeddine, R Program Book F Fabre, S , 2574 Fabreguet, I , 158 Facchini, A... 35, 1292 Fagerli, KM , 1848 Fahrleitner-Pammer, A Fain, O Fain, O.8, 12, 811, 2145, 2757, 2779 Faiq, A , 2222 Fairley, J Fakharzadeh, S..1562, 1563, 1569, 1851 Falgarone, G Falk, R Falkmer, T Fall, N Fallarino, F Faltus, R...328, 649, 2354 Faltys, M Fan, C...48 Fan, C Fan, C , 2824 Fan, H Fan, J Fan, Q Fan, R Fanelli, P Fang, D Fang, F Fang, H...6 Fang, L Fang, MA Fang, W Fang (Lin), C Fangxiang, M Fanouriakis, A , 2645 Fantana, J Fantuzzi, G Faraawi, R.. 421, 583, 1397, 2376, 2411, 2496 Farbstein, M Fardellone, P Faré, R...134, 1739, 1969 Farewell, V , 2646 Farias, F Farina, I Farkasch, A Farnetti, E Farook, VS Farraro, R Farrell, J , 262 Farrell, JF. 2195, 2196, 2197, 2444, 2716 Farris, AD.. 985, 2543, 2930, 2978 Fassina, A Fasth, AER Fauchais, AL...520, 521, 2549 Faugier, E Faustini, F. 1184, 1892, 2130, 2233 Faustino, A Fautrel, B. 58, 202, 351, 585, 1055, 1385, 1413, 2028, 2132, 2379, 2483, 2527, 2574, 2599 Favalli, EG , 2512, 2514 Faveeuw, C Favero, M Fayet, F Fazeli, P Fazio, S , 1437 Fearon, U , 884, 1044, 1195, 1977, 1979, 2181, 2798, 2800, 2875 Feaver, R Feced, C Fechtenbaum, J Fedele, AL Federici, C Feghali-Bostwick, C.759, 769, 1720, 1731 Feghali-Bostwick, CA...757, 770, 1887, 1897 Fein, A...187, 1854, 2970 Feinberg, B Feist, E , 2552 Feitosa de Oliveira, SK. 1316, 1900 Feldhamer, I Feldman, B.1231, 1310, 1321, 2279, 2280, 2282 Feldman, BM , 1316 Feldman, CH , 1075 Feldman, S , 2036 Feldman, SR Feldon, M MD...83 Felea, I Feller, L Felson, DT...200, 207, 212, 822, 973, 974, 1083, 1276, 1284, 1286, 1384, 1820, 1821, 1874, 2721, 2969, 3007 Feltrop, D Femia, A Fenaux, P Feng, CW Feng, GS Feng, J , 1557 Feng, J , 1410 Feng, R , 2851 Feng, X Feng, X Feng, X. 635, 654, 960, 2343, 2678 Ferdowsi, N Ferguson, PJ , 1988 Ferlin, W Fernandes, JK Fernandes, PT Fernandez, I , 3004 Fernandez, JL Fernández, M Fernández Berrizbeitia, O Férnandez Cid, C Fernández Dapica, MP Fernández de Castro, M Fernandez Gutierrez, B.. 59, 1129, 2459 Fernandez Moreno, M. 1121, 1122, 1125 fernandez Nacul, S Fernandez Nebro, A.59, 1129, 1670, 2097, 2622 Fernández- Espartero, C.1250, 2853 Fernandez-Becker, N Fernández-Carballido, C.2578, 2604 Fernández-Costa, C. 93, 982, 1127 Fernández-Gutiérrez, B.. 90, 1139, 1431 Fernández-Gutiérrez, B Fernandez-Llaca, H Fernandez-Lopez, C. 93, 982, 1121, 1122, 1125, 1126, 2602 Fernandez-Nebro, A Fernández-Puente, P.93, 982, 1003, 1126, 1127 Fernández-Tajes, J.982, 1121, 1122, 1125 Ferraccioli, G Ferraccioli, G..403, 738, 999, 1639, 1971 Ferrand, C , 2849 Ferrándiz, C Ferrandiz, M Ferrara, N Ferrari, C Ferrari, G Ferrari, M Ferrari, S Ferrari, S Ferrarini, M Ferraz, ML Ferraz-Amaro, I , 2461 Ferreira, A , 2125 Ferreira, WG Ferreiro-Iglesias, A Ferreti Silveira, L Ferreyra Garrott, L Ferreyra-Garrot, L Ferri, C , 2855 Ferrigno, C Ferrigno, C Ferro, F , 2201, 2931, 2981 Fert Bober, J Ferucci, E Ferucci, ED Feser, ML , 2921 Fessler, B Fessler, BJ , 2646 Fessler, J Fessler, J Fetisova, A Fève, B Feydy, A , 1186, 1187, 1894, 1926, 2984

305 Ficjan, AC Fiehn, C Fields, R , 2789 Fields, TR Fife, D , 2880 Figgie, MP...115, 187, 198, 1854, 2970 Figueiredo, CP... 51, 52, 73 Filer, A...389, 2183, 2463, 2874 Filipescu, I Filippi, N Filippini, D Filippou, G , 908 Filippucci, E , 2589 Filková, M , 2085, 2450 Fillatreau, S Filocamo, G Fina-Aviles, F Finckh, A.. 504, 1837, 1838, 2565, 2913 Fine, A , 1408 Fine, MJ Finkelstein, E Finklestein, J Finlay, K , 1424 Finzel, S...940, 1192, 2130, 2136 Fiore, S Fiorentino, D.721, 912, 1563, 1851, 2539 Fireman, E , 700 Firestein, GS.935, 1027, 1889, 2339, 2816, 2818, 2919 Fisch, KM , 1885 Fischer, A...836, 1419, 1931 Fischer, K Fischer, N , 312 Fischer-Betz, R , 701 Fisher, K , 2641 Fisher, MC Fisher, M , 1512 Fisher, N , 2001 Fisher, P Fishman, E Fishman, P Fishman, S Fisk, N Fiter, J Fitilev, S Fitzcharles, MA...264, 265, 1109 Fitzgerald, GK Fitzgerald, KA , 1813 FitzGerald, O , 2614, 2912 Flageul, B Flanagan, R Flato, B Flato, B Flecher, E Fleck, M , 940 Fleet, L Fleischer, S Fleischer, SJ , 2693 Fleischer, V , 2693 Fleischmann, R. 463, 465, 493, 545, 1520, 1553, 2488, 2495, 2823 Fleisher, T Fletcher, T Flewelling, C Flex, A Fligelstone, K...727, 2699, 2707, 2716 Flint, J Flipo, RM.163, 164, 165, 511, 1411, 2481 FloraCruz, S Florence, N Florentinus, S Flores, A Flores, D Flores, NM Flores-Alvarado, D , 1425 Flores-Fernández, R Flores-Suarez, LF Florestano, MC Flynn, JA Flynn, T... 21, 168, 2961 Foa, E Focherini, MC Foeldvari, I...273, 282, 285, 1322, 1323, 1325 Foerster, M Fogel, O , 521 Fogg, LF Fojtikova, M , 2555, 2594 Foley, C , 2904 Foltz, V Fong, SL Fongen, C Fonollosa, A , 2853 Fonseca, C Fonseca, E Fonseca, JE , 2428 Fontsere, O Foody, JM Forbess, LJ Ford, A Ford, J Forejtova, S. 136, 851, 2371, 2422, 2555, 2580, 2594 Forejtová, Forestier, A Forgues, M Forrester-Barker, W Forsberg, S Forsblad, H Forsblad-d Elia, H.. 42, 1804, 2832 Forslind, K , 367, 376 Forster, A Fort, J Fortin, I...365, 396, 421, 502, 567, 682, 1535, 1536, 1550, 1551, 1601, 2416, 2569 Fortin, P , 2646 Fortin, PR. 682, 2015, 2619, 2787, 2868 Fossati, G , 2873 Foster, HE Foster, H...274, 284, 295, 1998 Foster, HE...272, 303, 1444 Foster, J... 47, 49, 170 Foster, JM Foster, J , 1756 Foster, N Foster, S Foster, SA , 2623 Fourcaudot, MJ Fourret, P Fowler, J , 231 Fowler, R...95 Fox, C Fox, DA...444, 937, 1962, 3006 Fox, RS , 1338, 2335 Foxworth, J Foy, C Fradin, J Fraenkel, L.1422, 1809, 1934, 1935, 1936, 2857, 3014 Fragkiadaki, K , 1462 Fragkioudaki, S Fragoso-Loyo, H , 694 Fraison, JB Frallonardo, P , 1291 Frampton, C , 1758, 2377 França, CMP Francès, C , 1925 Franceschini, F , 1532 Franchini, S Francisco, F , 1252, 2853 Francisco, M Francois, H Frane, J Franek, E Frank Bertoncelj, M... 92, 2785 Franke, A , 880 Franklin, C , 2959 Franklin, J Franklin, PD.64, 192, 193, 194, 197, 1279 Fransen, J Fraser, N Frassi, M Fraticelli, P , 2855 Frauenfelder, T Frazier, D Frech, T...745, 1927, 2699, 2707 Frech, TM , 1694 Fréchet, M Fredberg, U Frederiksen, KS Frediani, B Freed, G Freeston, JE , 2773 Freilich, B Freire, M , 2622 French, J French, S , 2955 French Vasculitis Study Group (FVSG), T Frenkel, J , 2279, 2280, 2282 Fréret, M Freshwater, T , 1500 Fresko, I Frey-Law, L Freyhult, E Friday, SC Fridkin, M Friedman, A...378, 1555, 1577 Friedman, D Frielinghausen, J Frisell, T Frits, M , 2103 Frits, MA , 1408, 2889 Fritschy, D Frittoli, R Fritz, J Fritzler, M , 1476, 2115 Fritzler, MJ...320, 745, 2210 Frizelle, S Frobell, R Froeschlin, J Frugoni, F Fryburg, D...75 Fu, B Fu, B , 2392 Fu, Q Fuegener, S...29 Fuentes, M Fuhlbrigge, RC , 1321 Fuhrer, O Fujii, H Fujii, T Fujiki, Y Fujimoto, M...86, 1258, 1259 Fujimoto, M Fujio, K , 1454 Fujio, N...232, 233, 1460, 2259 Fujisawa, Y Fujisawa, Y Fujita, Y Fujiwara, S Fukuba, E Fukuda, K Fukui, N Fukui, S...429, 2389, 2651 Fukui, T...2, 5, 1179, 2638 Fukuma, Y abstract author Index 2014 Program Book 303

306 abstract author Index Fukushima, Y Fuld, M Fulla, Y Fulladosa, X , 1656, 1659 Fuller, H Funahashi, K. 471, 512, 2504, 2516 Funchain*, P... 88, 782 Funkenbusch, SC Furet, JP Furey, A , 1289 Furie, R. 13, 672, 1608, 1631, 1924, 2836 Furie, RA , 2834 Furst, DE.. 844, 1515, 1521, 2468, 2485, 2486, 2718 Furst, DE. 740, 745, 751, 767, 1338, 1678, 2335, 2697, 2995, 2999 Furst on behalf of FaSScinate Clinical Trial in Patients With SS, DE Furukawa, H.. 82, 85, 86, 87, 2457 Furuya, H Furuya, K Furuya, T , 226 Fusaro, E , 2512, 2514 Föll, D...932, 1900, 2988 Förger, F Førre, T G G. van Helden-Meeuwsen, C. 1799, 2979 Gabay, C , 2524, 2565 Gabba, A Gaber, T , 1006, 1518 Gabler, NB Gabriel, SE...258, 390, 428, 1052, 1055, 1405 Gabrielli, A , 2855 Gaches, F , 256 Gadina, M , 816 Gadwala, S Gaffen, SL Gaffney, Gaffo, AL Gago-Fuentes, R , 1034 Gaillez, C...132, 1517, 2291, 2923 Gaillez, C...931, 2297, 2298 Gaillez, C Galan, P Galarza-Delgado, D Galarza-Delgado, DA Galateanu, C , 1945, 2834 Galaverna, S Galeazzi, M...132, 2491, 2492 Galeazzi, M , 885 Galeotti, C. 1231, 2279, 2280, 2282 Galicier, L Galien, R Program Book Galimberti, S Galindez-Agirregoikoa, E , 1787, 1788 Galindo, M...346, 660, 2735 Galindo Izquierdo, M , 1670 Galindo-Feria, AS Galindo-Izquierdo, M Gallagher, L Gallagher, P. 109, 1578, 2312, 2614 Gallardo, MDLA Gallardo-Perez, E Gallego, R , 2853 Gallego Flores, A , 2190 Galli, M Gallizzi, R Gallo, A...526, 530, 2981 Gallo, J Gallo, MC Galloway, J , 2044 Galo, J Galvani, S Gamache, T Gamba, MJ Gambari, L...35 Gamble, G , 1215 Gamboa, J Gamboa-Cardenas, RV Gamero, F Gamir, ML Gamir Gamir, ML Gammaitoni, A Gamonet, C Gan, RW.. 446, 1904, 2019, 2891, 2921 Gancheva, R Gandhi, K Gandjbakhch, F , 2132 Ganeshalingam, K Gangidi, S Ganguli, A Ganguly, R Ganser, G , 285 Gansky, S...98 Gantes, M , 2622 Ganz, F Gao, N Gao, W , 2800 Gao, Y , 2658 Garchon, HJ , 1137 García, A Garcia, D Garcia, F Garcia, MV García, M. 406, 1388, 1438, 2040, 2381 García, MA , 2670 Garcia, S García, V García de la Peña, P , 2622 Garcia de Yebenes, MJ.. 731, 2710 García de Yebenes, MJ Garcia Kutzbach, A Garcia Montero, A...59 García Serrano, JL García Serrano, JL García Yébenes, MJ Garcia-Aparicio, AM...668, 1250, 2853 García-Arias, M García-Bermúdez, M , 2459 Garcia-Carazo, S García-Carrasco, M Garcia-De La Torre, I Garcia-Fructuoso, F García-González, AJ García-Hernández, FJ García-Herrero, C Garcia-Martos, A Garcia-Melchor, E , 2179 Garcia-Monaco, R , 2987 Garcia-Pompermayer, M Garcia-Rodriguez, F García-Trejo, P García-Unzueta, MT Garcia-Vadillo, A Garcia-Valladares, I...370, 1268, 1375, 2378, 2413 Garcia-Vicuña, R. 1138, 2144, 2412 Garcia-Villanueva, MJ Gardin, C Gardner, D Gardner, M Garen, T , 2703 Garesse, R Garg, JP , 2826 Garg, N Garg, N Garg, S Garg, V...289, 1147, 2232, 2393 Garnery, B Garofalo, F Garrido, M Garrood, T Garssen, J , 1816 Garvey, WT Garvin, K Garyfallos, A Garyfallos, G Garza-Elizondo, M.739, 1420, 1427, 2251 Garza-Elizondo, MA Gasparini, S Gaspersic, N Gates, DF Gathany, TA Gatmaitan, M Gattamelata, A Gatterova, J Gattinara, M Gatto, M Gattorno, M Gattorno, M.299, 1231, 1900, 2279, 2280, 2282 Gaubitz, M Gaud-Listrat, V Gaudin, P , 1517 Gaudin, P...351, 1368, 1385 Gaudric, J , 2731 Gauer, L Gaujoux Viala, C Gaujoux-Viala, C , 1413 Gauna, A Gauna, M Gaur, N Gaur, P , 2173 Gautheron, A Gaweco, A , 1512 Gay, C Gay, R... 92, 2450 Gay, RE.456, 967, 1128, 1210, 1967, 2448, 2785 Gay, S...92, 456, 967, 1128, 1210, 1967, 1977, 2085, 2448, 2450, 2785 Gaydukova, I Gayed, M Gaylis, NB Gazeau, P Gazitt, T Ge, C Ge, XP Geborek, P...364, 367, 376, 2394, 2525 Gebretsadik, T Gedalia, A Geffray, L...8 Géher, P Geier, J...458, 460, 1908 Geier, J Geiger, J Geijer, M Gelber, AC...45 Gelfand, J Gelpi, M Genant, HK Gendi, N Gendreau, J , 1878 Gendreau, RM , 1878 Genest, G Geng, L , 654 Genovese, MC...488, 1522, 1557, 2495, 2822, 2823 Genovese, MC...549, 2824, 2826 Genre, F , 2063, 2064 Genre, F. 1787, 1788, 2203, 2452, 2459, 2461 Gensler, LS...420, 569, 588, 617, 1856, 2827

307 Gent, YYJ Genta, M...94 Genty, M Geny, B George, A George, C George, D George, E George, J George, LM georgin Lavialle, S Geraldes, R Gerards, AH , 2815 Gerber, N Gerber, R...100, 1145, 2406, 2487 Gerenli, O Gergely, P Gergiannaki, I Geri, G Gerin, M Gerlag, DM Gerlag, DM. 392, 1198, 1960, 2816 Gerlag, DM , 2463 Gerli, R Gerloni, V...276, 299, 1225 Germanò, G , 791 Gerou, S Gerschman, T... 61, 2275 Gerstein, M , 1312 Gervais, F , 1495 Gessl, I , 650 Getu, L , 1328 Geusens, P Gherardi, R Gherghe, AM , 2387 Ghia, C Ghillani-Dalbin, P Ghimbovschi, S Ghimire, S Gholizadeh, S , 1338, 2335 Ghomrawi, H Ghosh, S Giacomelli, C , 2499 Giacomelli, R Giancane, G Giangreco, D...353, 713, 2989 Giannelou, A Giannini, C Giannini, E Giannini, EH , 2222 Gianturco, L Gibbon, M Gibney, SM Gibofsky, A , 249 Gibson, KA , 1157 Gibson, S Giesecke, C Giezek, H Gigante, MR , 1639 Giger, ML Gignac, MAM Giguere, G Gil, A Gil Latorre, F Gilbane, A , 1728 Gilbane, AJ , 1706 Gilbert, A...68 Gilbert, M...10 Gilboe, IM Gilchrist, DG Gilchrist, N Giles, BM Giles, I , 1358, 2863, 2865 Giles, J , 1395 Giles, JT Giles, K Gilhar, A Gilio, M , 2758 Gilkeson, GS.637, 1213, 1938, 1948, 2880, 2956 Gill, E Gill, T , 1919 Gill, TM Gillespie, C Gillespie, J , 968 Gillet, P Gillies, H Gilliland, WR Gillispie, L Gillooly, AR Gilman, S Gilson, B Gilson, M Giltiay, NV Ginsberg, S , 1422 Ginzler, EM...322, 684, 961, 1512, 2646 Giordano, R Giraldo, CL , 2706 Girard, C Girard, JP Giraud, B Giraud, M Giri, S Gisbert, JP Gisbert, JP Gisi, K Gissel, C Gladman, DD...542, 545, 548, 623, 624, 625, 626, 627, 628, 630, 685, 690, 699, 865, 961, 1552, 1561, 1564, 1565, 1568, 1575, 1576, 1577, 1579, 1586, 1587, 1590, 1592, 1593, 1850, 1858, 1859, 2099, 2631, 2634, 2640, 2646, 2791, 2935 Glass, J Glaysher, B Glazov, E Glerup, H Glintborg, B , 853 Gloetzner, M Glushko, T Glüer, C Gnann, H Gobbi, C Gobeaux, C Gobert, P , 1778 Gochuico, B Godeau, B Godfrin-Valnet, M , 559 Godmann, L Godmer, P. 1767, 1776, 1778, 2777 Godoy, A...370, 1375, 2378, 2413 Godwood, A , 1486, 1496, 2821 Goeb, V.520, 521, 2434, 2536, 3011 Goekoop-Ruiterman, YP Goel, N Goel, R Goemaere, S , 2255 Goeminne, C Goesling, J , 266 Goess, C Goettl, KH Goffin, L Goglin, S Gogus, F Gohr, C Goker, B , 716, 1673, 2548, 2761 Goksu, H Gokun, Y Gold, D Gold, DT Goldbach-Mansky, R...315, 1812, 1815, 1896, 1898, 2285 Goldbach-Mansky, RT Goldberg, A Goldberg, B , 2222 Goldberg, G Goldberg, GS Goldeinstein-Schainberg, C...957, 2304 Golden, W Goldfien, R Goldin, J Golding, A , 1151 Goldman, B Goldring, MB Goldring, SR...24, 1043, 1292 Goldschneider, K , 262 Goldsmith, CH , 416 Goldsmith, DP Goldsmith, JV Goldstein, M Goldstein, N Golembesky, A Golightly, YM , 2945 Golinski, ML Goltzman, D...48 Gomara, MJ Gomariz, RP Gombert, B Gomes Ferraz, ML Gomez, A Gomez, E Gómez, G , 2040 Gómez, G...887, 2040, 2441 Gomez Arango, C Gomez Vaquero, C.695, 1381, 1430, 1657, 2194, 2780 Gómez-Centeno, A Gómez-Gerique, J Gomez-Gomez, A Gómez-Martín, D.1658, 1664, 2676, 2724, 2990 Gomez-Puerta, JA , 2511 Gomez-Reino, J Gomez-Reino, J , 1579, 2086 Gomez-Reino, JJ Gomez-Reino, JJ..455, 1561, 1564, 1590, 2524 Gómez-Vaquero, C , 2459 Gon, Y Gonçalves, CR , 2304 Goncalves-Alves, E... 27, 2358 Goncalvesalves, E Gondaira, F Gondouin, B Góngora-Rivera, F Gono, T , 1255, 1264, 1640, 1710, 1939, 2991 Gonuguntla, S...53 Gonzalez, A , 2086 Gonzalez, CM...59 Gonzalez, E... 6, 1357 Gonzalez, EB González, JA Gonzalez, P Gonzalez, R...74 González Escribano, F. 1787, 1788 Gonzalez Fernandez, C González Navarro, A González Ortega, S González-Alvaro, I. 59, 1129, 1138, 2144, 2175, 2412, 2459, 2480 Gonzalez-Bello, Y González-Gay, M.1103, 1787, 1788, 2063, 2064, 2203, 2461 González-Gay, MA.747, 1240, 1249, 1252, 1256, 2452, 2459 González-Gay, MA...776, 777, 814, 880, 1250, 1251, 1367, 1399, 1791, 2775, 2776, 2853 Gonzalez-Ibarra, F abstract author Index González-Juanatey, C , 2452, 2459, Program Book 305

308 abstract author Index 306 González-López, MA , 2203, 2775 Gonzalez-Navarro, A Gonzalez-Navarro, EA Gonzalez-Puig, L Gonzalez-Reyes, JA Gonzalez-Rivero, AF González-Rodríguez, C González-Suárez, S Gonzalez-Vela, C.. 814, 1791, 2775, 2776 Gonzalez-Vela, MDC González-Zúñiga, A Gonzalo-Gil, E , 660 Gooberman-Hill, R Good, R , 1728 Goode, AP Gooderham, M Goodman, A...1 Goodman, SM. 115, 187, 198, 350, 394, 1854, 2369, 2370, 2970 Goodpaster, B Goodsitt, M Goodson, N , 1062 Gopalakrishnan, R , 2978 Gordon, C Gordon, C...676, 711, 961, 1358, 2624, 2646, 2834, 2838 Gordon, C , 1424 Gordon, D Gordon, JK. 734, 878, 1677, 1691, 1991, 2699, 2707 Gordon, M Gordon, P Gordon, R Gorelik, G , 2736 Gorla, R , 2514 Gorlova, O Gorlova, OY Goronzy, JJ , 1742 Gorter, S , 2572 Goss, S Gossec, L...58, 351, 557, 584, 585, 1058, 1059, 1385, 1413, 1428, 2132, 2554, 2556, 2557, 2574, 2599, 2984 Goto, H Gotou, Y Gottenberg, J. 504, 520, 521, 1681, 2536 Gottenberg, JE , 1837, 1838 Gottlieb, AB Gottlieb, AB. 537, 539, 1548, 1554, 1556, 1559 Gottlieb, BS , 2318 Gottwald, M Gough, A , 880 Goulet, JR Goulet, L Gouni, S Goupille, Program Book Gourh, P Gourlay, ML , 2316 Gouya, H Govoni, M , 2493, 2912 Govoni, M Govoni, M Sr Goyal, J Goyal, K , 1563, 1569, 1851 Grabulovski, D , 1511 Gracey, E , 606 Grader-Beck, T Grady-Benson, J Graeber, A , 1965 Graessel, S Graf, J Graf, N Graff, C , 1499 Graft, J Graham, N , 2795 Graham, RR Graham, TB Grahn, AY.. 244, 418, 1482, 2415, 2813 Grainge, MJ Grammatikos, AP Grammer, A Gran, JT Graña, G Graña, J Granados, J Granados Afonso de Faria, A Granel, A...887, 2040, 2042, 2441 Granger, B. 2132, 2554, 2556, 2557 Graninger, WB Grant, E Grant, R , 2331 Grasland, A Grassi, F...35 Gratacós, J... 59, 2097 Gratacos-Masmitja, J Grateau, G. 1231, 2279, 2280, 2282 Grau, E Grauer, A Gravallese, EM , 1813, 1914 Gravani, F Graves, S , 1278 Gray, D Grayson, PC. 794, 801, 1862, 2756, 2851 Grazio, S Grbic, JT Greco, R Green, A Green, B Green, K Green, M , 880 Green, RC Green, R , 1289 Greenberg, JD...156, 387, 448, 515, 518, 1148, 1537, 1853, 2367, 2375, 2415 Greenberg-Dotan, S Greenfield, M Greenspan, JS Greenwald, M , 2826 Greenwald, MW Greer, J Greger, G Gregersen, PK Gregersen, PK...90, 1379, 2927 Gregersen, PK , 625, 1904, 2019, 2453, 2454, 2921, 2953, 2955 Greidinger, EL , 3004 Greiner, J Greisen, S... 26, 409, 2729 Greloni, G Gremese, E.. 403, 999, 1639, 1971 Gressin, V Greth, W Greve, OJ , 2652 Grewal, HK Greysen, H Griffin, M Griffin, N , 2318 Griffin, R...3 Griffin, T Griffing, WL Griffith, J , 2393 Griffiths, B...522, 676, 2982 Griffiths, CEM Griffiths, G Griffiths, H Grigg, JB Grignano, E Grigoriou, A Grillet, B Grillo, E Grimaldi, A Grimaldi, D Grimm, C Grisius, M Grodzicky, T Grogan, S Groh, M Grom, A Grom, A...310, 319, 1900, 1901 Grom, AA Grootenboer, S...12 Gross, AJ , 1353 Gross, D Gross, KD...212, 923, 973, 1083, 2245 Grossman, JM Grossniklaus, H Grosso, G Grosso, V...483, 2512, 2514, 2609 Grotle, M Grotzke, M , 2881, 2885 Grotzke, MP Grouard-Vogel, G Gruben, D.. 100, 1145, 2406, 2487 Gruber-Baldini, A Grundahl, K Grunke, M Grünke, M Grönwall, C...387, 448, 1328 Grøvle, L Gu, J...557, 1185, 2303, 2591 Gu, NY Guan, H...867, 903, 1080 Guay, H Gudjonsson, J Gudman, NS Gudmann, NS Gudnason, V Guellec, D Guenther, J , 1712 Guenther, L Guerau, M Guerette, B...378, 1577, 2517 Guerin, M Guermazi, A...200, 207, 210, 215, 1083, 1821, 2142 Guerra, SG Guerra Vázquez, JL Guerrier, T Guest, C Guggino, G , 611 Guh, D Gui, Y...360, 405, 1903, 1975 Guiducci, C Guilhot, F Guillard, G Guillaume Czitrom, S Guillemin, F.202, 1055, 2379, 2866, 3018 Guillén, MI...32 Guillevin, L...783, 811, 958, 1326, 1768, 1777, 1778, 1782, 2199, 2549, 2701 Guillevin for the French Vasculitis Study Group, L..1759, 1763, 1767, 1769, 1774, 1776, 1792, 1864, 2777, 2778 Guillot, X... 43, 559 Guillou, C Guilpain, P Guimarães, I Gujar, B Gul, A , 2852 Gulati, G Gulati, N Gulgielmi, B Gulinello, M , 1941 Gull, E Gulliford, MC

309 Guma, M , 935, 2176, 2179, 2339 Gumbiner, B Gunn, J Gunnarsson, I Gunnarsson, R Guo, C Guo, J , 1500 Guo, J Guo, R Guo, X Guo, YX Gupta, A Gupta, K Gupta, N Gupta, S , 2840 Gupta, S Gupta, V Gurkan, H...79 Gurman- Balbir, A Gushen, A Guthridge, JM , 1922, 2430, 2688, 2880 Gutierrez, M , 908 Gutierrez, MA Gutierrez-Rubio, AK , 2156 Gutierrez-Ureña, SR Guzman, J , 2288 Gúzman, R Guzman, R Gvozdenovic, E Gwynne-Jones, D Gyftopoulos, S Gül, A Gülfe, A , 1152 Györi, N Gärtner, M Götz, G Gøransson, LG , 2652 H Ha, CM , 1962 Ha, N Ha, YJ , 2714 Haacke, EA Haake, R Haas, JP Haas, JP , 312 Haavardsholm, EA , 905 Habers, GEA Hachiya, Y...86 Hachulla, E...255, 256, 520, 521, 1130, 1690, 2536, 2700, 2701, 2711, 2757, 2833 Hacioglu, A , 1233, 2043 Hack, CE Hackman, J Haddad, A...624, 1576, 1850 Haddon, DJ Hade, EM Hadji, P Hadziyannis, E Haga, N Hagan, J Hagberg, N Hageman, G Hagemann, A Hahn, BH Hahne, M Haibel, H Haidar, R Haider, S Haile, S , 2914 Haimovich, Y Haines, GK III Haji, Y , 2727 Hajj-Ali, R Hajj-Ali, RA , 2856 Hakky, M Hakl, M Halder, R Hale, C Hall, A Hall, JC Hall, S , 1590 Hallac, M Hallén, B Halliday, A Halpern, M Halpern, R Halushka, M , 1207 Haluskas, B Halvorsen, B Hama, M , 125, 133 Hamalainen, M Hamann, D Hamann, J Hambardzumyan, K. 364, 367, 376 Hambleton, J Hamblin, M Hamidou, M.811, 1778, 1782, 1864, 2779 Hamilton, BJ Hamilton, B Hamilton, J Hamilton, JD Hamilton, S , 2101 Hammad, T , 2856 Hammaker, D , 1889, 2919 Hammenfors, DS Hammer, A Hammer, HB Hammer, HB...905, 1274, 1913 Hammer, RE Hammond, A Hammond, A Hammond, C Hamuryudan, V. 1233, 2043, 2749, 2752, 2759 Han, BK Han, B...625, 1900, 2918 Han, C , 2495 Han, KH , 2502 Han, L Han, M , 1805 Han, R , 1720 Han, SW Han, X Hanafusa, T Hanaoka, B Hanaoka, H Hanaoka, M.877, 1255, 1264, 1640, 1710, 1939, 2991 Hands, R Hanley, D Hanly, JG...688, 797, 2791 Hanly for the Systemic Lupus International Collaborating Clinics, JG , 2646 Hanna, MG Hanna Helou, M Hannagan, K...462, 1523, 2139 Hannan, J Hannan, MT , 2047, 2943, 2945 Hannon, MJ Hannonen, P , 2812, 2911 Hanova, P , 136 Hanrahan, LM Hanrotel-Saliou, C Hansen, I Hansen, JE Hansen, R Hansen, U Hanson, E Hanson, H Hansson, M Hant, FN Hao, Y Happe, J Haqqi, T , 1015 Haque, S Hara, M Harada, ND Haraoui, B.371, 379, 383, 386, 394, 396, 421, 464, 468, 492, 502, 517, 519, 567, 943, 1387, 1397, 1535, 1536, 2410, 2496, 2569 Harbers, JB Harboe, E , 2652 Harcombe, H Hardie, DL Hardy, D Hardy, R Hardy, WJ Harel, L Hargreaves, B Hargrove, J Harigae, H Harigai, M... 82, 85, 2467 Harkin, A Harlaar, J Harle, JR Harley, J Harley, JB...83, 1604, 2454, 2880 Harlow, L Harmon, D Harnett, J...100, 1145, 2406 Harniman, E Haro, I Haroldsen, C Haroon, M , 2614 Haroon, N...600, 610, 611, 2605, 2607, 2829, 2939 Harpaz, Z Harper, J Harper, L Harrington, C , 1756 Harrington, JT , 1355 Harrington, TM...913, 1395, 1830, 2322 Harris, EN...6 Harris, G , 1756 Harris, J Harris, J Harris, JG Harris, T Harris-Love, M Harrison, A Harrison, A Harrison, DG Harrison, DJ , 1540 Harrison, H Harrison, M , 2120 Harrold, L...193, 194, 197, 1279 Harrold, LR Harry, R Harsha Strong, E Hart, D Hart, L , 1424 Hart, R Hartgring, SAY Hartman, C Hartman, D Hartmann, N Hartog, A Hartono, C...9 Hartung, W Haruta, K Harvey, AK...30 Harvey, BP Harvey, J Harvey, P Harvey, WF. 200, 1336, 1337, 2065, 2337, 2338, 2858 abstract author Index 2014 Program Book 307

310 abstract author Index 308 Hasan Al Faruque, M Haschka, J.. 940, 1184, 1892, 2130 Hase, N Hasebe, N...82, 85 Haseeb, A , 1015 Hasegawa, H , 2170 Hasegawa, M...86 Hashiguchi, A Hashimoto, H... 82, 85, 87 Hashimoto, J Hashimoto, N Hashimoto, T Hashiramoto, A Hashizume, M , 2877 Hashkes, P Hashkes, PJ Haskard, DO Hasler-Nguyen, N Hasni, S Hassan, S , 1997 Hassebroek, A Hassell, A , 2898 Hassett, AL , 266 Hassuna, D Hasturk, H Hasunuma, T. 232, 233, 1460, 2259 Hatemi, G. 1232, 2043, 2157, 2704, 2754, 2759, 2854 Hatron, PY , 2536, 2700 Hatta, K Hattori, H Hattori, Y Hauari, H , 2331 Hauge, E Hauge, EM...26, 1524, 1964 Hauge, EM Haugeberg, G , 1573 Haugen, AJ , 2035 Haugen, IK , 1822 Hausmann, JS Hauspie, C Hawkes, W Hawkins, PN Hawtin, R , 1616, 2873 Hawtree, S , 2817, 2875 Hay, E Hayashi, E , 2728 Hayashi, M Hayashi, N , 424 Hayashi, S Hayashi, YK Haye Salinas, M. 1388, 1438, 2040, 2381 Hayem, G , 2536 Hayer, S... 27, 2907 Hayes, KW , 214, 215 Hayes, S Haynes, K Program Book Haynes, K , 1839 Hayward, K Hazan, L Hazel, E Hazen, MM , 2318 Hazen, S Hazes, JMW. 120, 139, 1571, 1583, 2382, 2815 Hazes, JMW Hazes, JM , 1738 Haznedaroglu, S , 2761 Hazra, A , 1478 Hazra, N He, D He, J He, J , 665 He, Q He, T , 1540 He, W He, X He, Y Head, AJ Hearth-Holmes, M , 1953 Heath, J Heathcote, G Hecht, I Hecker, R Hedemann-Andersen, A Hedges, W Hedrich, C Heegaard, N Heegaard, NHH.. 761, 2091, 2500 Heeren, RM Heeringa, P , 1775, 2733 Hefelfinger, J , 2011 Heffernan, EJ Hefner, K Hefner, KS , 2543, 2978 Heggeness, M , 2106 Heiberg, T... 58, 351 Heijda, TF Heilmeier, U , 1176 Heimans, L Hein, MS , 2213 Heine, G , 2693 Hejduk, K.. 280, 2371, 2555, 2580 Hekmatjou, H Helal, A Held, A Helder, B Heldmann, F...579, 2612, 2940 Hellerstein, M Hellgren, K , 1837 Helling, CA Helliwell,...58 Helliwell, T Helmick, C Helmick, CG.. 72, 980, 2624, 2788 Helsen, MM , 1733, 1734 Hembree, E Hemmelgarn, B Hempfing, A Hempstead, B...34 Henaux, S Henderson, LA Hendrickson, B Hendrickson, RC Hendrikx, T Henes, JC Henes, M Hennon, T Henriksen, K Henriksen, M Henriksson, K Henrotin, Y Henry, M Hensor, E...137, 380, 1178 Hensor, EMA , 1740 Hensvold, AH , 993 Hentgen, V.1231, 2279, 2280, 2282 Hentzen, KS Heo, M Her, M Herbelin, A Heredia, S.. 691, 695, 1657, 1659, 2194, 2620, 2780 Heretiu, L Herlin, T.277, 287, 928, 1867, 2287, 2299 Herlitz, L Herlyn, K Hermann, KG Hermann, KGA..2563, 2566, 2567, 2601 Hermann, S Hermida-Gómez, T Hermine, O Hernan, M Hernández, A Hernández, D Hernandez, JL Hernandez, J Hernandez, JL Hernández, JL...814, 1791, 2775, 2776 Hernández, MV...445, 469, 504, 1240, 1250, 2478, 2508, 2511, 2853, 2926 Hernández, MV , 1249 Hernández, M , 1252 Hernandez, V Hernández, V , 1838 Hernández Beiraín, J , 2622 Hernandez Gañan, J , 1381 Hernandez Grafella, M Hernandez Quintela, E Hernández Vásquez, R Hernández-Cáceres, A Hernández-Cruz, B , 2622 Hernandez-diaz, S Hernández-González, R Hernández-Hernández, C Hernandez-Hernandez, V Hernandez-Molina, G...11, 1654, 2533 Hernández-Rodríguez,...40 Hernández-Rodríguez, J.. 776, 777, 880 Hernández-Sanz, A , 2604 Herrem, C Herrera, F Herrera, S Herrera Van Oostdam, D Herrera-Garcia, A Herreras, JM Herrero, M Herrero-Beites, AM Herrick, A...728, 737, 753, 1928, 2147 Herrick, AL Herrinton, L Herson, S , 1262 Herve, R Herve, R Hervier, B. 1037, 1245, 1263, 1270, 1271 Heschel, B Heslinga, SC Heslop, Hesselstrand, R , 753, 761 Hetland, ML...349, 366, 409, 504, 848, 942, 1171, 1524, 1831, 1837, 1838, 2171, 2500, 2524, 2966 Heuck, C Heusch, P Heuser, R Hewitt, A Heyl, D Heymann, D Hickman, K Hicks, A Hidaka, M...82, 87 Hidaka, T Hidalgo-Calleja, C...74 Hider, S Hié, M Hiepe, F , 2693, 2837 Hifinger, M , 1059 Higashi, R Higgins, GC , 2272 Higgs, BW Higgs, JB , 2883 Higuchi, T. 877, 1255, 1640, 1710, 1939 Higuchi, T Higuera, V Hildebrand, B Jr Hildreth, E III

311 Hiligsmann, M Hilkens, C Hill, C , 2962 Hill, CL...778, 789, 2772 Hill, D Hillen, MR , 2725 Hilliard, P Hills, NK Hillstrom, HJ , 2945 Hiltesperger, M Hinchcliff, M..725, 745, 750, 1677, 1929, 2698 Hinchcliff, ME...729, 966, 3005 Hindman, H Hines, D Hinojosa-Azaola, A Hinsch Gylvin, L Hirabara, S...516, 1488, 1489 Hirai, K Hirai, Y Hiraki, LT , 1312 Hiramatsu, K Hiramoto, S Hirani, S Hirano, I Hirano, Y...471, 512, 516, 1488, 1489, 2504, 2516 Hirao, K Hirata, A , 424 Hirata, S Hirayama, Y Hirohata, S. 87, 1696, 2652, 2762, 2763 Hirokawa, T Hiromura, K Hiron, M Hirosaki, Y , 1952 Hirose, T Hirota, Y Hirsh, JM Hisada, R... 2, 2638, 2864 Hisdal, J...489, 1913, 2571 Hishitani, Y Hislop, C Hissem, T Hitchon, C. 394, 1387, 1998, 2289, 2410 Hitchon, CA.371, 1855, 2022, 2401, 2619 Hjeltnes, G Hjuler, ST Hla, T Hmamouchi, I...101, 1058, 1059, 1373, 2029 Ho, IC Ho, LY...854, 2264, 2633 Ho, M Ho, MF Ho, PR Ho, P Ho, RC Ho, V Hočevar, A...788, 1789, 1790 Hoagland, K Hoang, S Hobeldin, I...53 Hocevar, A Hochberg, M Hochberg, M , 2231 Hochberg, MC. 81, 243, 979, 1288, 2893 Hochfeld, M Hockings, P Hodge, M , 1616 Hodgin, J Hodgin, JB , 653 Hodgson, RJ , 2773 Hodkinson, B Hoeck, HC Hoek, RP Hoekstra, OS Hoenig, H Hoepken, B , 852 Hoerslev-Petersen, K.349, 366, 409, 1905, 2329 Hofer, M Hofer, M , 2279, 2280, 2282 Hoff, P... 29, 1518 Hoffart, C , 2271 Hoffman, E Hoffman, GS...782, 801, 804, 808, 880, 987, 1754, 1766, 1861, 2786, 2851 Hoffman, HM Hoffman, S Hoffman, V...97 Hoffman*, GS...88 Hoffmann, P , 1817 Hoffmann-Vold, AM , 2703 Hoffmeyer, P Hogan, SL Hogg-Johnson, S Hoglund, L Hoh, SF , 1309 Hojnik, M Hokken-Koelega, ACS Holers, VM. 446, 1904, 2019, 2182, 2891, 2921 Holgado, S , 1267 Holingue, C Holinka, J Hollan, I Holle, J Holliday, K Hollidt, J Hollins, A Holm, C Holmdahl, R , 2342 Holme, I , 1913 Holmes, AM.755, 1706, 1717, 1728 Holmqvist, M , 2892 Holochwost, D Holt, R , 1482 Holt, RJ...418, 2415, 2813 Holt, S Holzinger, D Homey, B Homik, J Hong, EC Hong, F Hong, J Hong, J Hong, J Hong, MJ Hong, SD Hong, S.. 614, 702, 703, 812, 847, 2564 Hong, SJ , 2025 Hong, S , 621 Hong, W Hong, W Hong, YH Hood, DB Hoogeboom, T , 2860 Hook, P Hootman, J...67, 72 Hope, H , 2032 Hopkins, A Hoppenreijs, EPA , 932 Horai, Y...429, 2159, 2389, 2651 Horcada, ML , 2622 Hordon, L , 880 Hordyk, J Horie, K Horikoshi, H , 2128 Horita, T...2, 5, 805, 1179, 1628, 2638, 2677, 2864 Horiuchi, H Horlyck, A Horn, EM Horn, HC Hornberger, L Horne, A Horne, A , 1215 Horne, L , 1143 Horneff, G...269, 273, 282, 284, 285, 289, 301, 834, 932, 933, 2281, 2902 Horowitz, D...13 Horslev-Petersen, K Horst, G , 1956 Horton, DB Horton, R Hose, M Hoshi, D Hoshino, T Hoshioka, A Hosono, Y Hosoya, T Hospach, T Hossain, A...962, 1051, 1660 Hossain, MS Hota, K Hotson, D , 1616, 2873 Hou, Y Hou, Z Houard, X Hough, Y Houghton, D Hourseau, M House, M Houshyar, H , 1500 Houssiau, FA...958, 1609, 1623 Houvenagel, E Howard, D , 2694 Howard, R Howell, K Hoyer, BF Hoyos-Bachiloglu, R Hrachovec, J Hrdy, MM Hrycaj, P Hrycaj, P Hsia, EC...463, 479, 2495 Hsieh, CM Hsu, A Hsu, B.463, 2563, 2566, 2567, 2601, 2835 Hsu, HC , 1209, 2872 Hsu, V Hu, C. 548, 602, 1543, 1561, 1572, 1579, 1590 Hu, D Hu, F , 2165, 2177 Hu, L Hu, Y Hu, Z Hu, Z Hua, C Hua, M Hua, SY Huang, A Huang, B Huang, C Huang, CC , 2224 Huang, C Huang, C Huang, J , 2169 Huang, L Huang, QQ , 2167 Huang, Q Huang, SY Huang, WT , 1691 Huang, W , 2869 Huang, X , 2648 Huang, Y...315, 1896, 1898, 2285 abstract author Index 2014 Program Book 309

312 abstract author Index 310 Huang, Y Huber, A Huber, AM. 912, 1316, 1317, 1825 Huber, LH Hudry, C...585, 2324, 2574 Hudson, M...720, 723, 745, 1089, 2015, 2619, 3000 Hueber, AJ. 940, 1184, 1892, 2130, 2233 Hufnagl, P , 1262 Huggins, JL...83, 1302, 2320 Hughes, G Hughes, GC Hughes, L Hughes, M Hughes, R Hughes-Austin, JM Hugle, B , 312 Hugo, C Hugunin, M Hui-Yuen, J , 2269 Hui-Yuen, JS Huisman, J Huitema, MG Huizinga, TWJ , 1521, 2468, 2485, 2486 Huizinga, TWJ , 1692, 2138 Huizinga, TWJ..90, 594, 817, 1386, 1693, 1930, 2398, 2502, 2597 Huizinga, T , 2102 Huizinga, TWJ Hulejova, H , 1039 Hulot, J Hulscher, M Human, A Humbert, M Humbría, A Humby, F , 904 Hummel, A Hummers, LK , 745 Humphrey, MB Humphreys, JH Humrich, JY Hunder, GG Hung, HC Hunt, B...14 Hunt, KJ Hunt, L...124, 380, 449, 1740 Hunter, AG Hunter, DJ.. 210, 1280, 2235, 2241 Hunter, J... 41, 563 Hunzelmann, N , 753, 1730 Huppertz, H Huppler, A Hur, JW Hurley, BL...16 Hurley, MV Hurley, , 2331 Hurnakova, J , Program Book Hurrel, A Huscher, D Husic, R Husmark, T , 1549 Husni, ME , 1591, 2247 Hussain, SM , 1278 Huston, J III Huston, KK Hutchings, A.. 793, 796, 909, 2772 Hutchings, E Hutchinson, D Hutchinson, K Huttenlocher, A Hutton, L Huybrechts, K Huyck, S , 2493, 2938 Huynh, DH Hvid, M.. 26, 366, 409, 1741, 1964 Hwang, C , 2973 Hwang, IY Hwang, J.. 60, 182, 587, 598, 2464 Hwang, M Hwang, YG , 886 Hübbe, C Hyland, D Hyphantis, T Hyrich, K , 467, 1837, 1838, 2031, 2032 Hyrich, KL. 271, 272, 274, 282, 295, 1542, 1848, 1909, 2294, 2924 Hyun, K Hähnlein, J Hämäläinen, M Häuser, W , 893 Höller, E Hørslev-Petersen, K , 2131 I Iaccarino, L Iacobellis, C Iacono, D Iadonato, SP Iagnocco, A Iagnocco, A Iannaccone, C , 2103 Iannaccone, CK..1335, 1369, 1370, 1408, 2889 Iannone, F. 504, 1701, 1837, 1838, 2228 Iannuzzi, MC Ibanez, D.685, 690, 699, 865, 1858, 1859, 2631, 2634, 2640 Ibanez Barcelo, M , 2622 Ibañez Ruán, J Ibarra, C Ibarra, MF , 2293 Ibrahim, F Ibrahim, N...53 Ibrahim, S Ice, JA Ichida, H , 2991 Ichimura, Y...748, 749, 752, 756, 1724, 3003 Ichinose, K...429, 2389, 2651 Iczkovitz, S Ida, H Idier, I Idler, K Idolazzi, L Idrees, J Iervolino, S Igel, A Igelmann, M , 2940 Iglarz, M Iglesias, G Iglesias-Gamarra, AA Igoe, A Ihata, A Iikuni, N Iizuka, M Ijdo, JW IJpma, AS Ikari, K...223, 1061, 1123 Ikdahl, E , 1913 Ikeda, K Ikeuchi, H Ikic, A Iking-Konert, C Ikle, D Ikuma, D Ikumi, N...355, 1688, 1906, 2340 Ilar, A İlhan, B , 838 Ilikci, R Iliopoulos, A Ilizaliturri-Guerra, O Illei, G Illei, GG , 530 Ilowite, N Ilowite, NT , 2293 Imadome, K Imamura, M Imanaka, H , 2274 Imasogie, O , 249 Imbert, B , 2193 Imboden, JB Imgenberg-Kreuz, J Imran, M , 2242 Imundo, LF. 672, 1303, 1304, 1307, 1826, 2269 Imura, Y , 1260 Inagaki, K Inagaki, K...31 Inanc, M.. 961, 1711, 1928, 2627, 2646 Inanc, N...119, 1423, 2769 Ince, A...370, 1375, 2378, 2413 Ince, O Inciarte-Mundo, J...134, 445, 469, 2478, 2508, 2926 Ingham, M Ingham, MP Ingleshwar, A...427, 2005, 2009, 2244 Ingolia, GM Initiative, FTP Inmaculada, DR Inman, RD...600, 604, 606, 2553, 2601, 2605, 2607, 2829 Innala, L Inomata, H. 355, 1688, 1906, 2340 Inoue, A Inoue, E.. 223, 226, 430, 495, 1061 Inoue, M Inoue, N Inoue, Y Inoue, Y Insalaco, A.. 299, 321, 1225, 1228 Insua, S Investigation Group, M Investigators, C...363, 451, 2453 Investigators, P Investigators, RO Investigators, R Investigators, T Investigators, T Ioan-Fascinay, A Ioannidis, C Ioannidis, G. 883, 1172, 1424, 2257 Ioannou, Y...274, 295, 655, 2863, 2865 Ionescu, R.1153, 1525, 1526, 1538, 1539, 2497 Ioseliani, M Irace, R Irazoque-Palazuelos, F Irazoque-Palazuelos, F Irigoyen, P Irrera, N Irwin, MR , 3013 Isaacs, J Isaacs, J Isaacs, JD , 2460 Isayeva, K Isenberg, D. 675, 912, 2637, 2838, 2865 Isenberg, DA..676, 961, 989, 1955, 2646, 2696 Isgro, J , 2269 Ishack, S...36 Ishida, K Ishida, O...223, 226, 1061 Ishida, T Ishigaki, K Ishigatsubo, Y...125, 133, 2763 Ishiguro, N...380, 414, 471, 512, 516, 1488, 1489, 1890, 2427, 2467, 2472, 2504, 2516

313 Ishihara, M Ishihara, S Ishii, K Ishii, S Ishii, T , 1950 Ishii, Y Ishikawa, H , 414 Ishikawa, S Ishimori, ML.705, 1079, 1287, 2880 Ishioka, E Ishiwata, H Ishizaki, J , 2170 Ismael, R Isobe, M Isojima, S Isozaki, T , 1962, 2509 Issa, SF , 1905 Issac, RJA Itadani, S Itert, L , 2222 Ito, H Ito, H Ito, H , 424 Ito, H Ito, K Ito, S... 87, 481, 1416 Ito, T Itoh, K , 2128 Itou, T Ivanov, A Ivanova, M Ivashkiv, LB Ivers, N , 2309 Iversen, LV Iversen, MD Ivorra, J , 2119 Ivorra-Cortes, J... 90, 1431 Iwai, H Iwaki, K Iwamoto, N.. 429, 967, 2389, 2651 Iwamoto, Y Iwanaga, M Iwasaki, Y Iwata, M , 2340 Ix, JH Izmirly,. 534, 679, 1605, 1635, 1829 Izquierdo, E Izuhara, K Izumi, K J Jaakkimainen, RL , 2309 Jabbarzadeh-Tabrizi, S. 1000, 1952 Jachiet, M Jacklin, A Jackson, BS Jackson, MJ Jackson, RD , 2893 Jackson, R...117, 1155, 2114 Jackson, SW Jackson, S Jacob, B , 2380, 2424, 2426, 2814 Jacob, CO Jacobs, J Jacobsen, S...961, 2091, 2646 Jacobsson, L. 436, 853, 1477, 1596, 2936 Jacobsson, LT...42, 1804, 2832 Jacobsson, LTH Jacobsson, LT Jadon, DR , 2830 Jadoul, M Jaeger, VK , 2699 Jaeggi, E Jafri, K Jagerschmidt, A Jahan-Tigh, R Jahreis, A , 874 Jaimes-Piñón, GT Jain, R , 2310, 2315 Jain, S Jain, S Jakez-Ocampo, J , 694 Jakstadt, M...29 Jalil, B Jalilian, B Jallouli, M Jalota, L Jamal, S...394, 517, 2410 Jamalyaria, F James, J James, J , 2430 James, JA...648, 707, 866, 985, 1002, 1604, 1922, 2688, 2841, 2880, 2978 James, K , 2982 James, S Janech, M Jang, JA Jang, SI , 528, 529 Jani, M Janigro, D Janikashvili, N Janot, A Janow, GL Jansen, A , 2222 Jansen, G Jansen, T.. 826, 1222, 1223, 2178, 2962 Janssen, E Janssen, KMJ Janssen, M Jara, LJ Jara, LJ , 2671 Jaremko, J Jarjour, W Jarjour, WN. 708, 911, 1204, 1473, 1888, 2219, 2686, 2687 Jarosova, K.. 280, 851, 2371, 2422 Jaroszynska, A , 2518 Jarraya, M Jarrett, S , 880 Jarvis, J Jarvis, JN Jasek, M Jasiek, M Jasson, M Jatwani, K Jatwani, S Jaussaud, R...255, 2081, 2193 Javaid, MK Jayakumar, K Jayne, D...676, 813, 1760, 1863 Jean, YH Jean Baptiste, G , 2532 Jean-Baptiste, G , 2155 Jeanmaire, C Jefferies, C , 2694 Jeffreys, A Jeffries, MA Jego, P Jeka, S Jenei-Lanzl, Z Jeng, M Jenkins, K Jenkins, K Jenkins, M Jenkinson, CP Jennings, F Jensen, DV Jensen, MA , 2927 Jensen, MP Jensen, MD Jensen, P Jensen, S Jensenius, JC , 2171, 2299 Jeon, HJ Jeon, JY Jeon, MG Jeong, H...60, 1221, 2464 Jeong, HJ Jeong, H , 587, 598 Jerabek, S Jerman, E Jernberg, T Jessome, M , 1424 Jeyaratnam, J Ji, RC Jiang, K , 2094 Jiang, L Jiang, X Jiang, Y , 2140 Jibaja-Weiss, M..427, 2005, 2009, 2244 Jibatake, A , 2506 Jimenez, SA...771, 774, 1722 Jiménez Gómez, Y... 7, 1978 Jimenez Lopez-Guarch, C Jiménez-Moleón, I Jiménez-Zorzo, F Jin, D Jin, HM Jin, JO Jin, X Jin, Y Jin, Z Jinzaki, M Jobling, A Joe, G Jog, N Joh, K Johansen, J Johansson, A Johansson, K Johansson, M John, A , 515, 518 John, ML , 2583 John, MR John, S , 2765, 2856 Johnson, A , 2222, 2320 Johnson, D Johnson, DL Johnson, D Johnson, H Johnson, J Johnson, KJ Johnson, M Johnson, N... 61, 2275 Johnson, SR Johnston, D... 88, 987 Johnston, M Johnston, S... 95, 1142 Johnstone, DA Jolly, M.. 353, 681, 713, 716, 717, 1673, 2310, 2989 Jonas, BL Jones, A Jones, CA Jones, C , 1932 Jones, E Jones, GT , 2811 Jones, GT... 41, 71, 563 Jones, G. 205, 208, 209, 229, 778, 926, 2236 Jones, GT Jones, H , 1558, 1893, 2577 Jones, H , 1847, 2498 Jones, J Jones, JD Jones, JT Jones, K Jones, KB abstract author Index 2014 Program Book 311

314 abstract author Index 312 Jones, KL Jones, K Jones, N...383, 421, 745, 1601 Jones, PBB Jones, SA...30 Jones, T Jones, V Jonsson, MV Jonsson, R , 532 Jonuleit, H Joo, K Joo, KB Joo, S...385, 1141, 1362, 2103 Joo, SH Joo, YB Joos, R Joosten, L , 1223, 2962 Jordan, A Jordan, J Jordan, J...81 Jordan, JM...201, 978, 979, 1088, 2045, 2046, 2235, 2893, 2941, 2945 Jordan, LA...30 Jordan, N Jordan, R Jordana, M Jorgensen, C...276, 391, 1726 Jorgenson, B Jorquera, H Joseph, GB Joseph, G , 1522 Joseph, L , 2015, 2791 Joseph, R Joseph, RM Joshi, AD , 552, 586 Joshi-Barr, S Joshua, V...434, 993, 2797 Josse, R Jou, IM Jouneau, S Joung, J Jourde-Chiche, N , 1792 Jousse-Joulin, S. 1368, 2161, 2536, 2606 Jovaisas, A.. 248, 383, 1397, 2411, 2416 Jovani, V Joven, BE Joven, BE , 2710 Jover, JA...482, 1139, 1431 Joyal, E Joyal, F Ju, JH , 347, 484 Ju, Y Juan, M , 2179 Juanola, X.40, 596, 691, 1655, 2578, 2620 Juárez, RV.. 406, 887, 1388, 2381, Program Book Juarez, V Juarranz, Y Juba, B Judge, A Judo, M Juengel, A , 2450 Julia, A Julia, T... 59, 2097 Juliao, H Julie, D Jullien, D Jun, JB , 2025, 2158 June, R June, RR Jung, B Jung, HJ Jung, J Jung, KH Jung, LK , 1304, 1826 Jung, SM , 347, 484 Jung, YO , 1056 Jungmann, Junker, K , 1905 Junker, P. 349, 366, 409, 541, 629, 1905, 1964, 2171 Jurado, T , 2513, 2522 Jurcic, V Jurik, AG Jurriaans, E , 1424 Jussif, J Just, S Juverdeanu, R Jüngel, A , 2085 Jørgensen, H K Kaarela, K , 2812 Kaburaki, M. 232, 233, 1460, 2259 Kachaochana, A Kado, R Kadono, T , 3003 Kadono, Y , 2260 Kaegi, T , 2914 Kaeley, GS...122, 378, 2393 Kafaja, S...767, 1338, 2335, 2718 Kageyama, G , 2910 Kahan, A , 740, 1687, 1768, 1926, 2559 Kahlenberg, JM...104, 653, 1151 Kahn, C Kahn, JE , 2779 Kahn, JE...809, 811, 1774, 2778 Kahr, A Kaieda, S Kaine, J Kaine, J Kaipiainen-Seppanen, O Kairalla, RA Kaiser, K Kaji, H Kajiyama, H , 1666 Kalabic, J. 122, 269, 270, 273, 289, 2393 Kalani, A Kalb, R Kale, M Kalia, SS Kalil, A Kalinowski, M Kallankara, S Kallberg, H Kallenberg, C , 1766 Kallinich, T Kallinich, T. 1231, 2279, 2280, 2282 Kalstad, S Kalthoff, L , 2940 Kaltsonoudis, E Kalunian, K , 1631, 1924 Kalunian, KC...684, 961, 2646 Kaly, L Kalyoncu, U...58, 509, 1432, 2523, 2562, 2611, 2750 Kamali, S , 2627 Kamath, S Kambe, N Kamboh, MI , 2955 Kamboj, MK Kameda, H , 424 Kamen, DL , 679, 961, 2646, 2880, 2956 Kamenicky,, P Kaminsky, P , 2866 Kamishima, T Kamiyama, R , 133 Kamogawa, Y Kamp, S...866, 1605, 1921 Kan, H , 2117 Kanamono, T Kanayama, Y..471, 512, 516, 1488, 1489, 2504, 2516 Kanazawa, N Kanazawa, T Kandel, L Kane, D Kaneko, A.. 471, 516, 1488, 1489, 2516 Kaneko, H Kaneko, K...232, 233, 1460, 2259 Kaneko, S Kaneko, T Kaneko, Y.. 470, 1175, 1398, 2479 Kaneshiro, K Kaneshita, S Kanezaki, K Kang, A Kang, EH , 2215 Kang, JH Kang, JY , 484 Kang, SW...612, 1458, 2684, 2922 Kang, YM , 593 Kangas, A Kannan, L Kannangara, D Kantarci, A Kantarci, F Kao, AH , 2621 Kapetanovic, MC Kaplan, MJ...77, 641, 872, 1862 Kaplanski, G Kaplonek, P Kapovic, AM Kapp, L Kapsimali, V Kapsogeorgou, EK Kapur, S , 2411 Karaaslan, Y...422, 2746, 2761 Karaca, G Karaca, N Karaca, T Karadag, O. 509, 1432, 2562, 2611, 2750 Karadag, YS Karademas, E Karadeniz, A Karadeniz, M Karageorgas, T Karagoz, A Karampetsou, M Karasawa, H Karasawa, R Karasik, A Karatsourakis, TP Karis, E Kariv, I Karki, C...515, 518, 1853 Karlson, EW.818, 1876, 2008, 2017, 2020, 2036, 2887, 2891 Karlsson, A Karlsson, JA Karlsson, JA , 1152 Karlsson, N Karmacharya, P Karonitsch, T Karouzakis, E , 2448, 2785 Karp, DR , 2880 Karpouzas, GA Karpus, ON Karr, R Karras, A , 1778, 2549 Karreman, MC...139, 1571, 1583 Karsdal, M Karsdal, MA , 1293 Karsdal, MA. 222, 368, 1019, 2230, 2237 Karumanchi, SA...872

315 Karyekar, CS , 1521, 2468, 2485, 2486 Kasama, T , 2509 Kasapcopur, O , 2301, 2627 Kasapoglu Gunal, E Kashikar-Zuck, S...259, 262, 1104, 1302 Kashner, TM Kashyap, S Kasifoglu, T , 2750 Kaso, A Kassai, Y...986, 1040, 1238, 2977 Kastbom, A Kastner, DL. 816, 1194, 1227, 1817, 1900, 2852 Kataoka, S , 2991 Katayama, M...87 Kato, H Kato, M Katsahian, S Katsiari, C Katsicas, MM Katsumata, S Katsumata, Y...877, 1255, 1264, 1640, 1710, 1939, 2991 Katsuyama, E Katsuyama, T... 31, 678 Katz, A Katz, JD Katz, JN. 55, 210, 900, 1809, 2036, 2235, 2859, 2862 Katz, PP...420, 698, 890, 1084, 1086, 2048, 2049, 2405, 2421, 2943, 2945 Katz, RS...892, 893, 896, 1096, 1097, 1099, 1100, 1101, 1102, 1106, 1107, 1112, 1662, 1881, 2055, 2058, 2059, 2060, 2073, 2074, 2075 Katz, SJ Katzavian, G Kaufman, I , 700, 971 Kaufman, KM... 83, 1900 Kaufman, P Kaufmann, J Kaur, A , 2390 Kaur, J Kaur, M Kaur, P Kaur, PP Kautiainen, H...399, 1365, 2368, 2484, 2812, 2911 Kavanaugh, A..463, 464, 537, 539, 548, 550, 953, 1131, 1537, 1548, 1552, 1554, 1556, 1559, 1561, 1564, 1565, 1573, 1577, 1579, 1590, 1594, 2517, 2560, 2824 Kaverina, N Kavian, N Kawabata, H...841, 898, 2103 Kawabata, K Kawabata, T Kawabata, T Kawabe, A Kawaguchi, H Kawaguchi, Y.805, 877, 1255, 1264, 1640, 1710, 1939, 2991 Kawahata, K Kawai, S...232, 233, 1460, 2259 Kawai, VK Kawakami, A...429, 1258, 1259, 2159, 2389, 2651, 2846 Kawamoto, M , 1640, 1939 Kawana, K Kawano, M Kawano, S Kawasaki, A... 82, 85, 86, 87 Kawasaki, Y Kawashiri, SY , 2651 Kawashiri, S Kawasumi, H...877, 1255, 1264, 1640, 1710, 1939, 2991 Kawazoe, M. 232, 233, 1460, 2259 Kawut, SM , 2701 Kay, J , 1845 Kay, S Kaygisiz, F Kaymakcalan, Z Kayo, T Kayser, C...733, 1130, 2712 Kazerooni, E Kazi, S Kazim, M , 1756 Kazmi, S Ke, Y... 66, 1803 Kearns, GM , 2694 Kearsley-Fleet, L , 272 Keating, RM.446, 1904, 2891, 2921 Kecebas, HD Kedor, C Kee, SJ Keen, HI Keen, KJ Keenan, RT , 1224 Kehrl, J Keir, PJ Keith, MP Kekow, J , 2088 Kelchtermans, H Keller, KK Kelley, GA...67 Kelley, KS...67 Kellner, H , 2233 Kelly, A Kelly, C Kelly, J Kelly, JA Kelly, J IV Kelly, K Kelly, S Kelly, S , 904 Kelman, A Kelsall, J , 943, 1397, 1551, 1601, 2411, 2416, 2496 Kelsey, C , 1897 Kelsey, S Keltsev, V Kemiche, F Kenar, G , 2595 Kendler, D Keniston, A Kenna, T Kennedy, A Kennedy, C Kennedy, C Kennedy, WP Kenneth.Haines, G Kent, J Kent, JD...418, 2415, 2813 Keppeke, GD Sr Kerdel, F Keren, A Keren, R Kern, DM , 1143 Kern, M Kerr, A Kerr, G Kerr, GS.348, 370, 840, 1372, 1375, 2378, 2413 Kerr, J Kerr, S Kersten, C Kerstens, PJSM...817, 1386, 2398, 2502 Kesavalu, L Keser, G Keser, M Keshavamurthy, C Keskin, G Keskin, G , 2610 Keskin, H Keskin, Y Kessabi, S , 2125 Keszei, A.70, 101, 1058, 1059, 1164, 1373, 2113 Kettle, A Keystone, E...361, 375, 379, 386, 421, 426, 943, 1523, 2139, 2373, 2410, 2426, 2814 Keystone, EC , 382, 383, 394, 462, 463, 479, 488, 492, 1387, 2475, 2495, 2518, 2781, 2822 Khadka, P khaleghparast Athari, S Khalidi, N Khalidi, NA.745, 801, 804, 808, 880, 883, 1861, 2851 Khalilova, I Khalique, S Khamashta, M , 1359 Khamashta, MA. 7, 676, 961, 1627, 2646 Khan, E Khan, H Khan, HI Khan, K , 1714 Khan, M Khan, MA Khan, NA , 2390 Khan, N Khan, O Khan, S Khan, T...53 Khandekar, P Khandelwal, S , 2207 Khanna, D...740, 745, 751, 874, 876, 1338, 1677, 1962, 2335, 2717, 2995, 2996, 2999, 3006 Khanna, S Khatter, S Khau VAN Kien, A Khawaja, AA Khemis, A Khetan, S Khianey, R...350, 1989, 2840 Khifer, C Khim, S Khodadadi, L Khoja, SS , 2326 Khouatra, C , 1778, 1864 Khoury, M Khoury, V Khraishi, M.56, 517, 583, 714, 1374, 1550, 1551, 1581, 2496 Khraishi, MM Khraishi, S... 56, 714 Khubchandani, R Khurram, M Kiani, A , 1669, 2635 Kibler, A Kida, D Kiel, DP , 2268 Kiely, P...185, 1841, 2810 Kiener, HP Kievit, W Kikkawa, D , 1756 Kikly, K Kikuchi, H , 2762, 2763 Kikuchi, J Kilgallen, B Kilic, E Kilic, G Kilic, L , 2523, 2611 Kilickap, S , 1432 Kill, A , 1712 Killeen, O , 2904 Kiltz, U.. 58, 557, 2573, 2612, 2940 Kim, A...104, 1151, 1940 Kim, BS Kim, C , 1820 Kim, D , 1805, 2025 abstract author Index 2014 Program Book 313

316 abstract author Index 314 Kim, D Kim, GT , 2753 Kim, G Kim, HY Kim, HR Kim, H...315, 1896, 1898 Kim, HY , 484 Kim, HW Kim, HJ Kim, HA , 1613 Kim, HO , 2356 Kim, H... 60, 182, 587, 598, 1221, 2464 Kim, H , 2949 Kim, IJ Kim, IY... 60, 598 Kim, I , 587 Kim, J Kim, JY Kim, JM , 2158 Kim, J Kim, JJ Kim, J...612, 1458, 2684, 2922 Kim, J...587, 1056, 1221, 2825 Kim, J Kim, KJ , 1364 Kim, K , 2954 Kim, L , 933 Kim, M Kim, M Kim, M Kim, N , 1041 Kim, RB Kim, R Kim, S Kim, SH , 2158 Kim, SK , 2078, 2993 Kim, SC.46, 1073, 1075, 1434, 1911, 2036 Kim, SJ , 2799 Kim, SS Kim, S Kim, TH , 1056, 2025, 2158, 2590 Kim, TJ , 2590 Kim, TJ Kim, WU...347, 693, 1364 Kim, YS Kim, YG.. 571, 614, 702, 703, 812, 847, 2564 Kim, Y Kim, YS Kimberly, R , 2089 Kimberly, RP Kimberly on behalf of PROFILE investigators, RP Kimmel, JN Kimura, F , 2128 Kimura, T Program Book Kimura, Y , 2762 Kimura, Y. 1313, 2292, 2293, 2294 Kimura-Hayama, E Kimyon, G. 2611, 2744, 2750, 2769 Kindsfater, K King, JK Kingetsu, I Kingsbury, D Kingsbury, DJ , 289 Kingsley, GH Kinjo, M Kir Karatas, O Kiraz, S...509, 1432, 2562, 2611 Kirby, F Kirby, S Kirchner, HL Kirillova, L...913, 941, 1395, 1830 Kirino, Y...123, 125, 133, 805 Kirkham, B...537, 550, 633, 953 Kirou, KA.. 872, 1118, 1607, 1924, 2087, 2840 Kirsh, S Kirwan, J Kirwan, JR Kis-Toth, K Kisacik, B. 2157, 2523, 2562, 2611, 2616, 2744, 2750 Kise, T Kishimoto, D , 125, 133 Kishimoto, M , 2021, 2727 Kislat, A Kissin, EY Kisten, Y Kita, J Kita, Y Kitagaichi, M Kitagori, K Kitamura, N. 355, 1688, 1906, 2340 Kitas, G Kitas, GD , 2617 Kitt, M Kittelson, A Kivitz, A , 175 Kivitz, AJ Kivitz, A , 602, 1487, 1543, 1572, 1844, 2240, 2469 Kivitz, AJ...243, 948, 2826 Kiyoi, T Kjeldsen, J Kjelgaard-Petersen, CF Klag, M...45 Klappenbach, J Klareskog, L...352, 358, 434, 447, 993, 2016, 2797, 2888 Klarich, K Klassen, L Klassen, LW , 2782 Klatt, S Klatzman, D Klearman, M Kleerup, E Klein, K , 1210 Klein, M , 136 Klein-Gitelman, M , 1304, 1826, 1988 Klein-Gitelman, MS...320, 1825, 2293, 2320 Kleinert, S Kleyer, A...940, 1184, 1892, 2130 Klimes, J Klinge, LG Klingenstein, K Klink, T Klopocki, A Kloppenburg, M Kloppenburg, M Klopsch, T Klotsche, J , 2902 Kloubert, I Klukovits, A Klumb, EM Kneepkens, EL , 2400 Knemeyer, I Knevel, R...90 Knight, A Knight, JS , 2867 Knight, R Knowles, H...38 Ko, DJ Ko, HJ , 484 Ko, JY Ko, K Kobak, S Kobayashi, A Kobayashi, D , 1416 Kobayashi, H Kobayashi, H...355, 1688, 1906 Kobayashi, S...82, 85 Kobayashi, T Kobayashi, Y...355, 1688, 1906 Kocak, A Kocer, EB Koch, AE , 3006 Koch, T , 1078 Kochar, G Kochi, Y , 1454 Kocijan, R , 2130, 2136 Kodama, S , 1416 Kodera, Y Koduri, G Koehm, M , 2915 Koeleman, BPC , 753, 880 Koelsch, KA...985, 2542, 2543 Koenders, M Koenders, MI , 1733, 1734, 1816 Koenig, A...100, 1145, 2395, 2406 Koenig, AS Koenig, CJ Koenig, M Koenig, M Koening, CL , 808 Koening, CL...801, 880, 2851 Koessler, RE Koetse, W , 2834 Koga, T...429, 2389, 2651, 2846 Koh, EM. 60, 182, 587, 598, 1221, 2464 Koh, E , 2025 Koh, JH , 484 Koh, M Koh, MX Koh, WP Kohan, P , 2441 Kohler, MJ , 2002 Kohsaka, H...329, 1645, 2341 Koide, H Koike, T Kojima, M Kojima, T. 380, 414, 471, 512, 516, 1488, 1489, 2504, 2516 Kolarov, Z Kolatat, K Kolfenbach, JR...446, 1904, 2921 Kollias, G Kolligs, C Kolling, C.92, 456, 1210, 1967, 2785 Kolomeyer, A Kolset, SO Kolta, S Komai, T Komarc, M , 136 Komarla, A , 2305 Komiya, A Komori, H Komuro, I Kon, V Kondo, T Kondo, Y Kondo, Y... 87, 2352 Koné-Paut, I Kone-Paut, I. 473, 930, 1231, 2279, 2280, 2282 Kong, W Konings, TC Konitsiotis, S Kono, H...87, 1218, 2762 Kono, M...2, 5, 456, 1179, 1628, 2638, 2677 Kononoff, A Konsta, M Konstantonis, G , 2617 Konthur, Z Koo, G Koopman, FA , 1513 Koopman-Keemink, Y Koppiker, N...581

317 Kordbarlag, C Koren, E Koren, Y Korendowych, E Korenstein, D Korkmaz, C Korkopoulou, P Korkosz, M , 2821 Korn, B , 1756 Korotkova, M Korrer, S , 1155 Kortekaas, MC Korver, W , 1616 Koscielny, V , 668 Kosek, J Koskas, F , 2731 Kosloski, M Kossi, S Kostine, M , 2397 Kostis, J Kotani, K Kotani, T Kotb, A...962, 1051, 1660 Kotsis, K Kottaiyan, R Kottgen, A... 44, 1872 Kottyan, LC Kougkas, N Koumakis, E , 1130 Koumitsu, N Koutsianas, C , 1466 Koutsilieris, M Kovats, S Kowal, K Kowal-Bielecka, O Kowal-Bielecka, OM Kowalczyk, M Koyama, Y Koyanagi, T Kozaci, LD Kozakowski, N Kozera, L Koziell, A Kozlowski, J Kozma, C Kozyrev, S Krabben, A Kraft, P , 2958, 2960 Krag, A Kragstrup, T...26 Kragstrup, TW Krams, T Krasnokutsky, S Krasnokutsky Samuels, S.. 81, 156 Krasnokutsky-Samuels, S Krasowska, D Kratz, A Kraus, S , 2130, 2136 Kraus, VB... 81, 210 Krause, A , 2414 Krause, D , 2940 Krause, M Krege, JH Kreiger, P Kreis, S , 2574 Kremer, H Kremer, J Kremer, JM...488, 515, 518, 1484, 1485, 1486, 1537, 2367, 2375, 2415, 2444, 2821 Kretzschmar, M Kreuter, A , 753 Krieckaert, CLM Kriegel, M...1, 856 Krintel, SB Krishan, P , 3009 Krishnamurthy, A Krishnaswami, S...458, 508, 2489 Kriska, A Kristensen, KD Kristensen, LE...42, 1804, 2832 Kristensen, LE , 1152 Kristy, R Kritikos, L Kroegel, C Kroese, FGM , 2551, 2934 Kroesen, BJ Kroft, LJM Kroft, L Krogh, NS Krohn, KD , 2471 Kronenberg, M Kroon, F Kroop, S Krueger, GG , 1569 Krueger, JG Krug, HE Kruger, J Kruize, AA , 2725 Kruize, AA Kruse Rasmussen, T Krüger, K Ktistaki, G Kubach, J Kubo, S , 2691, 2806 Kubota, T...143, 1868, 2274 Kuchroo, VK Kucuksen, S Kudela, H Kudrin, A Kueider, A Kuemmerle-Deschner, JB Kuemmerle-Deschner, J.2279, 2280, 2282 Kuemmerle-Deschner, JB Kuester, RM Kuettel, D Kuhn, KA Kuhn, M Kuhn, S Kuijper, TM , 2815 Kujime, R , 424 Kulcsar, Z , 2261, 2311 Kulikova, M Kullenberg, T Kumagai, S Kumanogoh, A Kumar, M Kumar, P Kumar, S Kume, K Kumke, T Kumm, J Kunadian, V Kundurdjiev, A Kundurzhiev, T Kung, A Kunishita, Y , 125, 133 Kunitake, Y Kuo, CF Kupper, H...122, 273, 289, 1131, 2393 Kurano, T Kurashima, Y Kurei, S Kuriakose, K Kurien, B Kurien, BT , 2543 Kurisu, R Kurita, T.. 2, 5, 1179, 1628, 2638, 2677 Kuriya, B , 2410, 2426, 2814 Kurmashev, D Kuroki, A Kuroki, Y Kurosaka, D , 2214 Kurosaka, M Kurosawa, H Kurowska-Stolarska, M Kurozumi, A Kurreeman, F Kurth, W Kurthen, R Kurzinski, K , 1897 Kusaoi, M...87 Kushner, J Kusunoki, N. 232, 233, 1460, 2259 Kuusalo, L Kuwaba, N Kuwajima, A , 1259 Kuwana, M. 746, 805, 1175, 1257, 1258, 1259, 1266, 2692 Kuwana, M Kuzin, I , 934 Kvaløy, JT , 2652 Kvien, T Kvien, TK...58, 101, 356, 905, 907, 944, 1164, 1274, 1373, 1383, 1440, 1822, 1913, 2035, 2524, 2561, 2571 Kvien, TK Kwan, L , 1662, 2073 Kwoh, CK , 2997 Kwok, K Kwok, K.. 460, 487, 493, 849, 2489 Kwok, SK , 347, 484 Kwok, WY Kwon, HM Kwon, SH Kwon, SR Kwon, T Kyburz, D Küçükşahin, O Kühl, A Kyndt, X Küseler, A Kyttaris, VC , 1033 Källberg, H , 2888 Kästner, P L L Abbate, S La Batide Alanore, S La Cruz, L La Rocca Vieira, R Laasonen, L Labalette, M Laborde, HA Laborde-Casterot, H Labrador, E Lacaille, D...384, 416, 2306, 2308 Lacaille, DV Lacalle, M Lacbawan, F Lachenbruch, PA , 1316 Lachmann, H Lachmann, H , 2279, 2280, 2282 Lackner, A LaCount, S Ladenburg, A Lafaille, J Lafeber, FPJG Lafeber, F Lafeber, FPJG...76 Laffan, MA Lafforgue, P , 2584 Laforet, P LaFranco-Scheuch, L Lafyatis, R...757, 758, 772, 1723, 1732, 1796, 2702, 2713, 2721, 3005 Lage-Hansen, PR Lages, A abstract author Index Lahdenne, P Program Book 315

318 abstract author Index 316 Lahey, LJ...348, 452, 815, 1476 Lahiri, M Lahouti H., A Lai, JS Lai, S , 251 Laifenfeld, D...75 Laiguillon, MC Lakota, K , 3005 Lakshman, U Laliberté, MC Lallas, G Lally, L Lam, MY , 2929 Lamana, A Lamas, JR Lamaury, I Lamb, J Lamba, M , 1478 Lambert, B Lambert, C Lambert, D Lambert, M.811, 1864, 2700, 2757, 2866 Lambert, R. 855, 1191, 1893, 2577, 2613, 2985, 2986 Lambert, RG Lamberth, S , 2096 Lammi, MR. 727, 1246, 1678, 1931, 2699 LaMoreaux, B Lampa, J Lampropoulos, CE Lan, L Lanata, L , 2433, 2443 Lancioni, E Land, J Landen, J , 1108 Landewé, R , 2912 Landewé, R...361, 561, 574, 582, 953, 1164, 2137, 2579, 2592, 2600, 2828 Landewé, RBM. 544, 565, 566, 852, 954, 2387, 2475, 2586, 2588 Landi, M...406, 1388, 1438 Landis, JR Landolt-Marticorena, C Landry, T Landsittel, DP...363, 889, 1410 Landstein, D Lane, NE , 1276, 1801, 1820 Lanfranchi, H Lanfranchi, MA Lang, A... 29, 1006 Lang, D Langdahl, B , 2268 Lange, U Langefeld, CD , 2454, 2956 Langella, P Langer, HE , 2507 Langfeld, CD Program Book Langford, CA...801, 804, 808, 880, 1754, 1766, 1861, 2851 Langholff, W , 1563, 1569, 1851 Langley, R Lanni, S Lansdown, DA Lanyon, P...676, 711, 793, 1760 Lapa, AT. 1622, 2659, 2660, 2661, 2662, 2663, 2705 Lapadula, G , 2228, 2399 Lapane, K Lapey, A Lappan, C Lara, ME Lara, P Larche, M Larche, M , 1424 Lard, LR Larmann, J Larroche, C...520, 521, 2199 Larroude, M Larsen, T Larsson, PT Laska, MJ Laskin, CA Laskow, B Laslett, L Lattanzi, B , 2281 Latus, J Lau, A , 1424 Lau, AN...369, 1507, 1566, 2257 Lau, EY Laudes, M Laufer, VA Lauffenburger, JC , 2316 Launay, D. 1718, 2700, 2701, 2779 Laurant-Noel, V Laurent, F Lauridsen, UB Laurie, C Laustsen, JK Lauvsnes, MB , 2652 Lauwerys, BR , 1623 Lavalley, MP , 1818, 1874 Laven, JS Lavery, G Lavery, J Lavi, I Lavigne, C , 256, 811 Lavric, M Law, A... 44, 1872 Law, K Law, SC Lawrence, A Lawrence, P Lawrence Ford, T , 2413 Lawrence-Ford, T , 2378 Lawson, EF , 2903 Laxer, RM.. 315, 1321, 1992, 2318 Layh-Schmitt, G Lazaro, DM Lazaro, E , 2549 Lazaro, M Lazaros, G Lazo, F Lazzaro, A Le, B , 2106 Le, T... 96, 1060 Le Bars, M. 132, 1517, 2491, 2492, 2923 Le Cao, KA Le CRI, R Le Devic, P Le Goff, B Le Gouellec, N Le Goux, P Le Guenno, G , 2549 le Guern, V...520, 521, 958, 2536, 2549 LE Hoang, P Le Jeunne, C.783, 1759, 1763, 1769 Le Quellec, A Le-Guern, V Leal, GN Leal, M , 1438, 2381 Leaman, D Leanderson, T Leandro, MJ..452, 989, 995, 1955, 2696 Leatherman, S , 2781 Leavitt, F , 1107 LeBlay, P Sr Leboime, A , 1137 Lebrun, A Lebwohl, M , 1851 Leccese, E Leccese, P , 2758 Leceta, J Leclair, V Leclercq, S Lecompte, T Lecomte, P , 2125 Ledbetter, J Ledbetter, L Lederer, DJ Ledesma, C , 1438, 2381 Ledesma-Colunga, MG.. 330, 333 Lee, A Lee, AT Lee, CH Lee, CK.. 614, 702, 703, 812, 847, 2564 Lee, CK , 1056 Lee, D Lee, EB , 849 Lee, EB...166, 1220, 2347 Lee, EY , 1220, 1241, 1453, 1508, 2215, 2347 Lee, EJ Lee, EJ Lee, HS Lee, HP Lee, H Lee, HS , 1056, 2025, 2918, 2954 Lee, JH Lee, J... 60, 182, 587, 598, 1056, 1221, 2464 Lee, JJ Lee, J , 347, 484 Lee, JJ Lee, JY , 1347 Lee, J Lee, J , 2025, 2690 Lee, J Lee, J Lee, JH Lee, JH Lee, JW Lee, JW Lee, J. 729, 750, 1800, 2698, 2944, 2946 Lee, K Lee, KA Lee, K Lee, KH Lee, KE...155, 533, 2266 Lee, M , 588 Lee, MS Lee, R Lee, SH Lee, SJ , 2215 Lee, SJ Lee, SH Lee, SI...220, 2262, 2356 Lee, SW Lee, SY , 2576 Lee, SY Lee, SY Lee, S...60, 182, 587, 598, 1221 Lee, SG , 2753 Lee, S Lee, SS...155, 533, 1056, 2266 Lee, SY Lee, SR Lee, SK , 2714 Lee, SW Lee, SY Lee, SJ Lee, S Lee, TC , 2318 Lee, WS Lee, WW Lee, YH Lee, YN Lee, YC Lee, YY...334

319 Lee, YJ , 2215 Lee, YY , 1854 Lee, YC , 1335, 1408 Leehan, KM Leese, J Lefevre, G. 1271, 1687, 1718, 2700 Leff, L Leffler, M Lefkowitz, EJ Legangneux, E Léger, JM Legmann, P Legorreta-Haquet, M Leguy-Seguin, V , 256 Lehane, PB Lehman, AJ...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Lehmann, A Lehner, PJ Lehtimäki, L Leinonen, M , 2507 Leipe, J , 2845 Leirisalo-Repo, M Leirisalo-Repo, M , 2484 Leiss, H... 27, 634, 650 Leluc, O Lemay, C... 64, 192 Lembke, W , 1511 Lemeiter, D , 2357 Lemmers, H , 1223 Lems, WF. 817, 1386, 2127, 2398, 2502, 2558 Lems, WF Len, CA , 2712 Lencina, V , 2441 Lendl, U Lenert, A Leng, J , 1540 Leng, L Lenhartz, H Lenna, S Lensen, KJDF Lenzi, M Leo-Summers, L Leon, EP Leon, F Leon, L , 1431 Leonard, D , 2681 Leonardi, C , 1851 Leonardi Bertazzi, GR Leong, JY , 1309, 1618 Lepore, L Lepore, N Lepri, FR Lequerré, T , 2923 Lequerré, T Lerner, D Lerner, V Leroux, G.. 835, 1037, 1925, 2757 Lertratanakul, A LeSage, D Lescarbeau, R... 75, 1619 Leské, C Lespessailles, E...548, 1561, 1564, 1590 Lessard, C Lessard, CJ , 2543, 2978 Lester, S...778, 789, 2034, 2962 Lesuis, N Leszczynski, P Letourneau, V Letourneur, F Letzkus, M Leu, JH Leuenberger, L... 18, 2840 Leung, A Leung, YY , 1582 Leung, YT LeVan, T Levarht, EWN Levarht, N Levartovsky, D , 700, 971 Levascot, A Leverson, J Levesque, MC Levi, M Levin, AM Levine, AB Levine, DM Levine, Y Levitan, E , 2388 Levitsky, A , 2515 Levrini, G Levy, DM , 1310, 1312, 1825 Levy, RA , 2868 Levy, S Levy, Y Lew, R , 2139 Lewallen, D...195, 196, 199, 1802 Lewandowski, L Lewiecki, EM Lewis, CE , 1083 Lewis, C Lewis, CE Lewis, CE , 973, 1276, 1286, 1821, 3007 Lewis, C Lewis, DM.1798, 2535, 2543, 2930, 2978 Lewis, E Lewis, J Lewis, JD...929, 1546, 1839 Lewis, M Lewis, MJ Lexberg, S Leyland, KM Leyton-Mange, A Lheritier, K , 2291 Lheritier, K.. 175, 931, 2297, 2298 Lheritier, K , 930 Li, A Li, D... 25, 37, 2794 Li, D Li, E , 1582 Li, G Li, H Li, H , 2872 Li, H Li, H... 66, 1803 Li, J , 37 Li, J Li, J , 1209, 2872 Li, K Li, L Li, LC , 2442 Li, M Li, P , 2939 Li, Q Li, Q Li, QK Li, QZ Li, QZL Li, R Li, R... 66, 1803 Li, S Li, S , 1554, 1556, 1559 Li, S Li, S , 2782 Li, S Li, SC Li, W Li, W...193, 194, 197, 1279 Li, XQ Li, X , 1190, 2136 Li, X Li, X Li, X Li, X , 2424, 2426, 2814 Li, Y Li, Y , 2177 Li, Y , 2838 Li, Y Li, ZG Li, Z...150, 665, 1463, 2165, 2177 Li, Z , 1723 Liaaen Jensen, JC Liakouli, V Liang, G Liang, H Liang, KP , 1410 Liang, K , 2099 Liang, MH Liang, P , 442 Lianza, AC Liao, H , 2782 Liao, J Liao, KP...841, 898, 1370, 2889 Liao, K.. 96, 385, 1141, 1434, 1911 Liao, KP Liao, W Liao, Z Liarski, VM Libanati, C , 2255 Libanati, C Licheva, RN Lidove, O...255, 256, 2193, 2757 Lidtke, RH , 2245 Lie, BA Lie, E , 504, 905, 944, 1164, 1383, 1804, 2035, 2524, 2832 Lieber, SB Liebergall, M Lieberman, S Liebl, H Liedmann, A , 153 Lifermann, F Lightfoot, AP Ligozio, G Likhodii, S Lilleby, V Lim, DH.. 614, 702, 703, 812, 847, 2564 Lim, H Lim, MK , 2684 Lim, MJ Lim, MJ Lim, N , 1862 Lim, SS.899, 961, 1334, 1811, 2117, 2624, 2626, 2646 Lim, SY Lim, SK Lim, YH Lima, G , 1824 Lima, G Lima, J Limal, N , 1778, 1925 Limaye, V Limburg, PC Limone, B Limpers, A Lin, A Lin, CJF Lin, C , 2254 Lin, D , 2410 Lin, G Lin, H...427, 2005, 2244 Lin, J...183, 2226, 2246 Lin, JH... 66, 1087 Lin, J , 2050 Lin, LL Lin, N...97 Lin, P Lin, TS abstract author Index 2014 Program Book 317

320 abstract author Index 318 Lin, T , 1616 Lin, YY Lin, Z , 2303, 2591 Linares, LF Linares, LF Linares Ferrando, LF , 2853 Lind-Albrecht, G Lindblad, S...501, 510, 1596 Lindblad-Toh, K Lindegaard, HM , 1905 Lindquist, JH Lindquist, LA Lindqvist, E Lindqvist, E Lindqvist, U Lindsey, S , 2191 Lindsley, CB Lindsley, H Lindström, U...42 Lineker, S Ling, N Ling, X Linghu, B Linglart, A Link, TM , 1176 Link, TM Lintermans, LL Linton, D Linton, MF , 1437 Lioger, B Liossi, C Lioté, F Lioté, F.118, 165, 1543, 1565, 2125, 2962 Liozon, E Lippe, R Lippuner, K Lipsky, PE.. 674, 1949, 1951, 2690 Lipstein, EA Lipton, JM Lisignoli, G...35 Liss, DT , 1347 Lisse, JR Listing, J.. 491, 1837, 1838, 2027, 2618 Litinsky, I Little, MA Littlejohn, G Littlejohn, GO Litz, B Liu, B Liu, CC...178, 254, 1434 Liu, D Liu, F , 1801 Liu, H Liu, H , 1976 Liu, H Liu, J Program Book Liu, J Liu, J...46, 1075, 2036 Liu, L Liu, M Liu, MF , 2344 Liu, ML Liu, N...97 Liu, N LIU, Q...66, 1087, 1803, 2050 Liu, S Liu, SH Liu, S Liu, S Liu, S Liu, W Liu, Y. 315, 1812, 1896, 1898, 2285 Liu, Y Liu, Y...979, 2045, 2893 Liu, Y Liu, Z Liu, Z Liu-Ambrose, T Liu-Bryan, R Llinares-Tello, F , 1531, 2423 LLobet, JM Llorca, J Llorca, J Llorca, J , 1415, 1787, 1788, 2203, 2459, 2461 Llorens, V Llorente, I Llorente, L , 694 Llorente Cubas*, I Lloyd, TE Lluch Mesquida, P Lo, GH...216, 1281, 1818, 2895 Lo, MS Lo, Y , 2658 Lo, Y Lo Monaco, A Lobo, F...95 Lobosco, S Locher, M , 1511 Locht, H Locke, C Locke, J , 2982 Lodato, C Lodi, A Loeb, V Loell, IM Loeschmann, PA Loeuille, D , 540 Lofek, S Loft, AG , 629 Logeart, I Logeart, I , 584 LoGrasso, P Lohani, S Lohfeld, L Lohne, F Lok-Charles, C Lomakina, O Lombardi, A Lommerse, J Londoño, J Longo, AV Longo, D , 1616 Lood, C , 2186, 2844 Looney, RJ Loos, M Lopes, JB... 50, 51, 52, 73 Lopez, H Lopez, I...91 Lopez, JA , 2280 Lopez, LR...16 López, P López de Figueroa, P Lopez de Padilla, C , 2213 López Lasanta, M...59 Lopez Longo, F Lopez Longo, FJ Lopez-Barrera, F , 333 López-Bote, JP Lopez-Isac, E López-Lasanta, MA , 1129, 2097, 2391, 2526 López-Longo, FJ , 2459 López-López, J López-Mejías, R. 1103, 2063, 2064 López-Mejías, R. 1787, 1788, 2203, 2452, 2459, 2461 Lopez-Olivo, MA...17, 427, 970, 1676, 2005, 2009, 2013, 2244, 2420 Lopez-Pedrera, C... 7, 1978 Lopez-Robledillo, JC Lopez-Zepeda, J Lorcerie, B Loredo-Alanís, S Lorente-Betoret, ML Lorenz, HM Lorenz, HM Lorenz, H , 2492 Lorenzin, M Lorenzini, L Lorenzini, S Loricera, J. 814, 1250, 1791, 2775, 2776 Lories, R Lortholary, O Losina, E.. 55, 65, 210, 900, 1809, 2235, 2859, 2862 Lottenburger, T , 1905 Lotz, M , 1013 Lotz, MK , 1021, 1885 Louder, A Louie, GH Louie, JS Louie-Gao, Q , 1874, 1875 Louis-Joseph, L Lourido, L... 93, 982, 1127 Louw, I Lovell, DJ Lovell, DJ...931, 2297, 2298 Lovell, D. 273, 276, 277, 930, 933, 2318 Low, C Lowin, T.. 994, 1029, 1959, 1965, 1974 Loza, E...731, 2276, 2710 Lozada, C Lozano, I Lu, B. 254, 818, 1281, 1809, 1876, 2017, 2020, 2894 Lu, CC , 1540 Lu, D Lu, J Lu, J Lu, L Lu, N.171, 172, 827, 923, 974, 1875, 2969 Lu, Q , 2680, 2685 Lu, R , 1922, 2688 Lu, S Lu, X...54 Lubberts, E. 340, 1738, 1749, 1799 Luberto, F Luca, N... 61, 2275 Lucas, M Luccioli, F Lucena, J Luciano, N , 2931, 2981 Lueking, A Luggen, M Lugonja, B Luijtens, K , 1409 Luime, JJ , 139, 1571, 1583, 2815 Lukas, C.121, 395, 590, 1140, 2385, 2397, 2587 Lukert, B Lukina, G Lumb, S Lunardi, C...747, 753, 776, 880 Lund, L Lund, MB , 2703 Lund Hetland, M , 1964 Lundberg, IE. 910, 912, 1211, 2726, 2953 Lundberg, K Lunt, M...271, 467, 1909, 2033 Luo, B , 1209, 2872 Luo, C.370, 1375, 2378, 2413, 2528 Luo, F Luo, M Luo, R...111, 1069, 1070 Luo, X Luo, Y...821

321 Luong, P Luqmani, R.372, 793, 794, 796, 909, 1760, 1761 Luster, AD Lutalo, P , 1237 Lutalo, K Luther, S Luttringer, O Lux, A Lux, J Lv, Q Ly, B Ly, KH...256, 1782, 1864 Ly, KH Lübbeke, A Lyberg, T Lyddiatt, A Lyden, AK Lynch, JA , 1801 Lynch-Jordan, A Lyons, J...404, 886, 1410 Lyons-Weiler, J Lystad, L Lythgoe, M , 2863 Lyu, R Løgstrup, BB M Ma, CB Ma, C Ma, J Ma, KM Ma, MH Ma, X Ma, Y , 734 Maas, F Maas, M Mabille, C Macahilig, C Maccari, F Maccarone, M...58 MacCarter, D , 2393 Macchioni, P...785, 790, 791, 798, 908, 2417 MacDermott, EJ , 2904 MacDonald, AG... 41, 563 Maceiras Pan, F Macfarlane, GJ...41, 71, 563, 975, 1382, 1880, 2071, 2811 MacFarlane, L Macfarlane, T...71 Macgregor, AJ Machado, KL...73 Machado, LG... 50, 51, 52, 73 Machado, P , 2579, 2953 Machida, T Machiyama, T Macias, W Macias, WL Maciuca, R Mackey, A Mackey, D , 1422 Mackey, M Mackie, I Mackie, S.. 775, 880, 2767, 2772, 2773 MacLaughlin, E MacMullan, P Macoritto, M Macovei, L Madan, R Madar-Balakinski, N Madaule, S Maddess, M , 1500 Maddison, P , 2646 Maddox, J Mader, R Madhavan, R , 251, 897 Madhok, R Madhoun, H Madhoun, HM Madsen, OR , 1188 Maecker, HT Maeda, T Maeda, Y Maehlen, MT Maejima, Y Maeoka, A Maers, K Maeyama, K Magalhaes Martins, F Magallares, B Magan, T Maganti, R Magder, LS , 1667, 1920 Magder, LS...687, 689, 697, 1652, 2635, 2647, 2648, 2667 Magee, A Magee, K Maggio, MC Magliano, DJ , 1278 Magliano, M Maglione, W...879, 1675, 1689 Magner, R , 518 Magni-Manzoni, S , 2281 Magnusson, B , 284, 930 Magrey, MN , 1997 Maguin-Gaté, K , 2360 Magy-Bertrand, N Mahadevan, U Mahajan, M Mahajan, V Mahé, E Maher, A Maher, G Maheu, E , 2324 Mahgoub, EY , 2487 Mahler, EAM , 2249 Mahler, M...4, 15, 446, 1629 Mahmood, Z Mahmoud, TG Mahoney, JM Mahowald, ML Mahr, A Maiburg, B Maier, R Maier-Moore, J , 2543 Maiese, B Maijer, KI , 2463 Maillard, S Maillefert, JF , 2849 Mairon, N Maisonobe, T , 1262, 1270, 2778 Maixner, W Maíz, O , 1252 Maiz Alonso, O , 2853 Maiz-Alonso, O Majithia, V , 2570 Major, BT , 1052 Major, G Mak, A Makino, H... 31, 82, 85, 678 Makino, S Makita, N Makol, A Makovey, J , 2241 Makowka, A Makris, A Makris, U. 104, 1151, 1342, 1936, 2857 Maksimowicz-McKinnon, K Maksymowych, W Maksymowych, WP.408, 586, 2573 Maksymowych, WP. 557, 562, 565, 566, 591, 852, 1191, 1903 Maksymowych, W..359, 360, 361, 362, 405, 855, 1893, 1975, 2577, 2613, 2615, 2912, 2985, 2986 Malaise, MG , 1025 Malaise, O , 1025 Malattia, C Malcarne, VL , 1338, 2335 Maldonado, M Maldonado-Ficco, H Maldonado-Garza, H Maldonado-Velázquez, M...933, 1984 Maldonado-Velázquez, MDR Maletta, KI Malfait, AM Malik, S Mallari Moher, A Mallen, C...179, 831, 2767 Malley, K Malloy, M Malm, D Malm- Green, S Malmström, V...993, 2726, 2797, 2874 Malochet-Guinamand, S Maloney, A Maloney, KM Malouf, J Malspeis, S , 2887 Maly, MR Malyavantham, K , 2541 Malysheva, O Mamani, M , 2381 Mamani, M...148, 1438, 2715 Mamas, M Mammen, AL , 1265 Mamtani, R , 1839 Mamyrova, G , 1318 Man, A , 2721 Manapat-Reyes, BH Manchanda, T Manches, O Manckoundia, P Mandal, A Mandl, KD Mandl, L Mandl, LA.. 187, 198, 1691, 1854, 2970 Mandl, P...906, 1389, 2589 Manero, J , 2853 Mangano, K Manger, K Mangnus, L Maniaci, B Manickam, S Manicki, P Manion, K , 2742 Manka, D Mann, HF...136, 851, 2371 Manning, C Manning, J Mannion, ML Manno, A Manocha, S Manoussakis, MN Mansfield, L Mansikka, H , 1030 Mansiz Kaplan, B Manske, S Mansour, L Mantel, , 2892 Manthena, S Mantilla, R Mantilla, RD...84 Manzano, M Manzi, S , 961, 1924, 2646, 2955 Manzo, A , 2403 Mapp, P abstract author Index 2014 Program Book 319

322 abstract author Index Mara, C Maracle, CX Maradiaga-Ceceña, M Maradit Kremers, H , 2628, 2642 Marangoni, RG Maravic, M Marcantonio, G , 1500 March, L...208, 209, 1280, 2241 Marchesoni, A , 2512, 2514 Marchi, G Marciniak, S Marcos, AI , 2042, 2441 Marcos, J.. 406, 1388, 1438, 1637, 2381, 2670 Mardekian, J Marder, G...3 Marder, RL Marenco de la Fuente, J Marenco de la Fuente, JL Marengo, F Marengo, MF , 2441 Margaretten, M..698, 1084, 2048, 2049 Margolis, D Margolis, P Marhadour, T , 2606 Mari, K Maria, A Maria, NI , 2979 María Blanco-Madrigal, J , 1788 Mariampillai, K , 1262 Marian, V Maricic, M Marie, I...255, 811, 2757 Marie, SKN , 2225 Mariette, X , 2966 Mariette, X...8, 504, 520, 521, 1368, 1385, 1837, 1838, 2163, 2536, 2549, 2757, 2928 Marijnissen, R Marin, J Marini, R. 1622, 1636, 2659, 2660, 2661, 2662 Marino, G Marino, L. 406, 1388, 1438, 2381, 2715 Marion, S Marion-Thore, S Mariz, HA Markham, A Markham, AJ Marklein, B Marks, E Markt, J Markus, R Markusse, IM...817, 1386, 1692, 2398, 2502 Markusse, I Marlet, J Marmarelis, E Marotta, A.359, 360, 361, 362, 405, 408, 1903, 1975, 2985 Marotte, H Maroun, MC Marques, R Marques-Neto, JF , 2720 Márquez, A.. 776, 777, 1787, 1788 Marra, C Marra, CA , 2118 Marras, C Marras Fernández Cid, C Marras Fernández-Cid, C Marras Fernandez-Cid, C Marren, A Marrero, B , 1812 Marroquín, M Marsal, S...59, 475, 1129, 1973, 2097, 2391, 2526 Marshak-Rothstein, A. 1794, 1813 Marshall, D... 41, 563, 2438 Marshall, D Marshall, L...855, 1893, 2577 Marshall, L.1847, 2418, 2498, 2503 Marshall, T Martel-Pelletier, J...205, 218, 926, 2231, 2250 Martikainen, J Martimianakis, T Martin, A Martin, DA Martin, G Martin, G Martin, G , 1289 Martín, J. 745, 747, 753, 765, 776, 777, 880, 1787, 1788, 2452, 2459 Martin, JE , 880 Martin, KR Martin, L Martin, MA Martin, RS Martin, R Martin, R , 819 Martin, S Martin, T Martin, U Martin Lopez, M Martín-Esteve, I Martin-Hervas, C Martín-Mola, E...351, 595, 605, 1603, 2400, 2513, 2522 Martin-Toutain, I Martincova, R Martinez, A. 406, 1388, 1438, 2381 Martínez, A Martínez, A Martínez, C Martínez, C Martinez, D Martínez, H Martinez, L Martínez, O Martínez Costa, L Martinez de la Escalera, G.330, 333 Martínez Ferrer, A Martinez Rivera, JI Martínez Taboada, V , 2622 Martínez-Cácerez, E Martinez-Cordellat, I Martinez-Costa, L Martínez-Galla, D Martínez-Hernández, E Martínez-Lavín, M , 2079 Martinez-Martinez, LA.. 894, 2079 Martinez-Martinez, MU.1649, 1650 Martinez-Mora, C Martínez-Morillo, M Martínez-Taboada, V Martinez-Taboada, VM Martini, A , 2291 Martini, A...931, 2297, 2298 Martini, A. 273, 276, 277, 278, 282, 284, 299, 928, 930, 1900, 2281 Martini, D.. 527, 1772, 2931, 2981 Martins, F , 1838 Martire, MV Martire, V Martucci, E Martyanov, V Marut, W Maruyama, S Marzan, K Marzan, K Marzo-Ortega, H...544, 557, 586, 2589 Mas, L , 406 Masayuki, Y Masetto, A...360, 442, 2518 Masi, AT , 2039 Mason, M...418, 2415, 2813 Mason, T II , 2903 Mason, TG II Masotti, A Massaad, R Massarotti, E Massarotti, E Massarotti, M Masseau, A Massey, J Mastaglio, C Masteller, E Masters, E Masters, ET , 2076 Masuda, I Masui, Y Masuoka, S.. 232, 233, 1460, 2259 Mat, C Mata, C Mata, D Mata-Arnaiz, C Mateo, I Mateo, ML , 1267 Mateos, J...93, 982, 1003, 1126, 1127 Mateus, C Mathai, SC Mathers, D Mathew, S , 1830 Mathian, A Mathiesen, P Mathieu, A , 2559 Mathieu, R Mathieu, S , 1448 Mathsson-Alm, L Matsuda, F Matsudaira, R Matsue, H Matsui, K Matsui, Y Matsukawa, Y Matsuki, F , 2910 Matsukura, M Matsumoto, AK Matsumoto, I...87, 2346, 2352 Matsumoto, S Matsumoto, T , 2170 Matsumoto, Y Matsumura, T Matsuo, S... 82, 85, 1651 Matsushima, S Matsushita, M Matsushita, T...86 Matsutani, T Matsuura, M Matsuzaki, CN Mattan, Y Mattar, M Mattat, K Matteson, EL...258, 390, 419, 428, 438, 800, 838, 885, 1052, 1055, 1253, 1366, 1405, 1742, 1852, 2116, 2495, 2628, 2642 Mattey, D Matthews, K Matthys, P Mattocks, K Mattoo, H Mattox, D Matucci-Cerinic, M.351, 908, 1130, 1703, 2709, 2711, 2999 Matzko, C Maughn, K Maurer, B...722, 967, 2953, 2998 Maurer, K Maurier, F. 1776, 1778, 1792, Program Book

323 Mautalen, C Mautalen, C Mauvais, FX Maverakis, E Mavi, B Mavragani, C , 2087, 2090, 2100 Mavragani, CP Mavria, G Mawdsley, A Maxwell, J Maya, JJ Mayan, MD , 1034 Mayes, M...747, 754, 2999 Mayes, MD , 751, 765 Mayes, MD Mayman, DJ Maymo, J... 59, 1129 Maynard, JW Maz, M , 1404 Mazieres, B Mazilu, D Mazza, LF McAdams-DeMarco, M.. 44, 1872, 2148 McAlear, C...801, 804, 880, 1861, 2851 McAlindon, TE...216, 1281, 1818, 2894, 2895 McArdle, A McBain, H McCallum, R McCarthy, B McCarthy, EM , 2694 McCarthy, GM...779, 884, 1050 McChulloch, CE McClellan, W McClinton, C McClory, D McClung, M McClung, MR McClung, M McColl, E McColm, J McConnell, R... 49, 1422 McCormick, J McCormick, J...779, 884, 2800 McCormick, N , 2118 McCormick, S McCracken, C McCulloch, C McCulloch, CE McCune, WJ , 704 McCurdy, DK , 1076 McDermott, M McDonald, B McDonald, C McDonald, M McDougall, D McDougall, J Jr McDuffie, J McElhanon, K McElhone, K , 712 McElroy, B McFadden, M McGarry, T , 1195 McGeachy, MJ McGettigan, B Mcgill, R McGlynn, L McGonagle, D , 2773 McGowan, D McGregor, JAG McGuinness, D McGwin, G , 1415 McGwin, J , 684 McHugh, C McHugh, G McHugh, N McHugh, NJ , 1699 McInnes, IB...537, 539, 550, 953, 954, 1486, 1548, 1554, 1556, 1559, 1577, 2451, 2821 McKeown, T McKinney, C McMahon, MA... 3, 1647 McMorrow, D...95 McNally, E , 909 McNamee, K McNinch, N McPhillips-Tangum, C McQueen, FM , 1215 McWilliams, L Meacock, R Meadows, A Meara, A , 2641 Mease, PJ...537, 545, 548, 549, 550, 558, 561, 852, 952, 953, 954, 1183, 1528, 1545, 1552, 1553, 1557, 1561, 1564, 1565, 1577, 1579, 1590, 1594, 1853 Meaux Ruault, N Mecchella, J...113, 1354, 2311 Mech, C , 1507 Mecoli, C Medeiros, PB Medema, J Mediero, A..19, 22, 23, 24, 33, 34, 36, 2355, 2792, 2947 Medina, J Medina Bornachera, D Medina Montalvo, S Medina Peralta, M Medina-Chinchon, M Medina-Rodriguez, FG Medrano, M Medrano-Ramírez, G , 1984 Medsger, TA Jr , 736, 1887, 1897, 2997 Meednu, N Meersseman, P Mehdi, A Mehta, J Mehta, K , 1082 Mehta, NN , 2140, 2889 Mehta, N Mehta, RI Mehta, T , 1082 Mei, H Meijs, J , 1930 Meijs, J Meiners, , 2934 Meini, A Meissner, Y Mekinian, A.. 12, 811, 2145, 2779 Melguizo-Madrid, E Meli, L Melia, LA Melikoglu, M , 2749, 2751, 2752, 2759, 2854 Melikoglu, MA Melin, J Melissa, P Mellado Narciso, LM Mellemkjær, L...848, 1837, 1838 Meller, S Mellins, ED , 2292 Mello, SBVD Melo Gomes, JA Melo-Gomes, J Melton, MH...49 Melzer, M , 998 Mempel, TR Ménard, HA Mendelsohn, AM...294, 479, 539, 933, 1548, 1554, 1556, 1559 Mendelson, A Mendes, A Mendez, I Menendez, M Menéndez, P Menet, C Menezes, PR...51 Meng, T Meng, X , 1502 Mengi, A Menne, HJ , 2940 Menon, B Menon, I , 2370 Menon, S Menor Almagro, R... 40, 1670 Menter, A , 1569 Menz, HB Menza, L Meoni, L...45 Mera, A Merayo-Chalico, J , 1664, 2676, 2724, 2990 Mercado Velazquez, P Mercan, R , 2761 Mercer, L , 1838 Mercer, LK Merino, R Merino-Meléndez, L Merino-Meléndez*, L Merkel, PA , 780, 787, 794, 801, 804, 808, 875, 880, 1754, 1766, 1781, 1860, 1861, 1862, 2851, 2854, 2999 Merle, S Merola, J Meroni, PL , 2383 Meroni, PL Merrien, D Merrihew, K , 2311 Merrill, JT. 666, 684, 707, 715, 866, 961, 1605, 1921, 1922, 2469, 2646 Merriman, ME Merriman, TR...21, 168, 778, 1136, 1219, 2958, 2959, 2960, 2961, 2962, 2964 Mery-Bossard, L Merz, EL Mesbah, R Mescam-Mancini, L Meshefedjian, G Mesquida, M , 1250, 1251, 2853 Messas, E , 811 Messemaker, T Messia, V , 1228 Messina, OD Messuti, L Metcalf, B , 2241 Metcalf, R Mettler, S Metyas, S Meune, C...730, 740, 1687 Meyer, A , 1271, 1707 Meyer, MK... 80, 1516 Meyer, P Meyer, R , 1832 Meyerhoff, J Meyuhas, R Meza-Romero, R Micalizzi, C Miceli-Richard, C...520, 521, 581, 2966 Michaelson, J Michalowicz, BS Michalska-Jakubus, M Michaud, K.108, 110, 480, 840, 890, 1067, 1452, 2456, 2519 Michel, BA Michelsen, B Michet, CJ III..419, 800, 838, 1366, 2116 Michet, CJ , 390, 428 abstract author Index Michot, JM Program Book 321

324 abstract author Index Middleton, J Midtvedt, O Miese, DF , 1177 Miese, F Mieszkalski, KL Miettunen, P... 61, 2275 Miguelez, R Mihai, C , 823 Mihali, E Mihaylova, D Mihaylova, MK Mikdashi, JA Miki, K Mikkelsen, JG Mikkelsen, K , 944 Mikkers, H Mikuls, TR...108, 167, 250, 348, 446, 462, 480, 840, 1067, 1372, 1391, 1392, 1470, 1474, 1475, 1523, 1620, 1904, 2014, 2139, 2454, 2456, 2494, 2781, 2782, 2891, 2921 Miles, A Milicescu, M...823, 1538, 2497 Millán, A Millen, C Miller, A Miller, B Miller, C Miller, FW. 912, 1316, 1317, 1318, 2211, 2216, 2222, 2953 Miller, H Miller, J Miller, KL Miller, M Miller, P Miller, P Miller, RE Miller, R , 1500 Miller, RJ Miller, SD Miller Kroouze, R Mills, SD , 1338, 2335 Milne, C Milojevic, D , 2286 Miloslavsky, E Miloslavsky, EM. 1754, 1766, 2886 Milward, M Mimori, T.. 805, 806, 1258, 1259, 1260, 2467 Mims, CC Mimura, T... 39, 1666 Min, C , 2727 Min, HK , 347, 484 Mina, R Mincheva-Nilsson, L Minden, K. 270, 273, 284, 285, 289, 301, 2902 Minegishi-Takase, K. 123, 125, 133 Miner, J Miner, JN , 2963 Minguez, E Minoia, F Minor, L Minota, S , 1765 Minten, M Mintz, DN Mintz, J Miozzari, H Mira, JP Mirabelli, G Miranda, D Miranda, P , 2821 Miranda, V , 1969 Miranda-Carus, ME Miranda-Filloy, JA , 1788, 2452, 2459 Miranda-Limón, J Mirault, T , 811 Misaki, K Misharin, A , 969 Mishima, M , 1259 Mishra, A Sr Misra, D Misra, R...89, 1272, 2173 Missler-Karger, B Mistry, N Mitchell, B Mitchell, BD... 81, 2893 Mitchell, N Mitenko, E Mitera, T Mitjavila, F.1655, 1657, 1659, 2620 Mitoma, H , 1952 Mitra, A , 1963, 2364 Mitri, G Mitsugi, N Mitsuhiro, T Mitsui, H Mittal, M , 552, 586 Mittleman, B , 1616 Mitton-Fitzgerald, E Miura, Y , 2462 Miura, Y Miwa, Y , 2509 Mix, C Miyabe, C Miyabe, Y Miyahara, H Miyake, S , 2728 Miyamoto, T Miyamura, T Miyanokoshi, M Miyara, M Miyasaka, N...82, 85, 2427, 2472 Miyata, T Miyazaki, M Miyazaki, T. 986, 1040, 1238, 2977 Miyazaki, T Miyazaki, Y Mizui, M Mizuno, T Mizushima, I Mizushina, K , 424 Mjaavatten, MD , 2035 Mlakar, L , 769 Mlcoch, T Mo, X , 1983 Moallem, E , 2350 Mobley, JA Mochida, Y Moder, K Moder, KG Modesto, C Modi, A...48 Modi, M Modjinou, D Moericke, R , 175 Moericke, R , 2125 Moeser, A Moghadam-Kia, S. 736, 1266, 1348 Mogosan, C , 1525, 1526 Mogun, H Mohammad, A Mohasseb, DM Mohring, S mohsen Abdul Salam, M Moilanen, E , 1011 Moilanen, LJ Moilanen, T Moisio, K , 215 Moisio, KC Mok, CC.681, 716, 854, 1673, 2264, 2633 Mok, MY , 2658 Molad, Y Molano, I Molano-González, N...84 Molberg, O Molberg,...777, 2703, 2953 Molcard, S Moldovan, I , 716 Molenaar, THE Molina, E , 2026, 2374 Molina, J , 1531 Molina Molina, M , 1674 Molineros, J , 2841 Molitor, JA , 745, 1931 Moll Tuduri, C Moller, I Molloy, E Molloy, ES...779, 884, 2694 Molnar, M Molta, CT...667, 1641, 2117 Moltó, A.. 585, 2324, 2554, 2556, 2557, 2574 Momohara, S..223, 226, 430, 495, 1061, 1123, 2465 Momtahen, T , 2795 Monach, P , 1766, 1861 Monach, PA...780, 801, 804, 808, 880, 1786, 1862, 2851 Monfort, J , 2231 Mongelli, F Monguzzi, A , 2433, 2443 Montagna, P , 1966 Montagnier-Petrissans, C Montastruc, JL Monteagudo, I Montealegre, G Montealegre Sanchez, GA...315, 1812, 1896, 1898 Montecucco, C...483, 988, 1256, 2403, 2609 Montell, E Montes, A Montesinos, MC Montestruc, F Montgomery, C , 2930 Montgomery, CG.2535, 2543, 2978 Montgomery, G Monti, G Monti, S Montiel Hernandez, JL Montilla, C... 40, 2622 Montilla Morales, CA , 2853 Montilla-Morales, CA...74 Montilla-Morales, C. 59, 596, 2604 Moon, JY Moore, K Moore, K...24, 33 Moore, L Moore, O Moore, RA Moore, S Moore, T Moore, TL Moore, T Moore, T , 2147 Moore, T Moorthy, LN , 1988 Moosig, F , 777, 880 Moots, R Moots, R , 1339 Mor, A Mora, C Morado, IC Moraes, JCB...957, 2151, 2304 Moraes-Fontes, MF , 2656 Moragues, C , 2125 Morales, K Morales, M Morales, MA Morales-Nebreda, L , 3005 Moramarco, A Program Book

325 Moran, S Morange, S Morardet, L Morehouse, C Moreira, E Morejon, E Morel, J...121, 393, 395, 473, 520, 521, 1140, 1385, 1490, 1837, 1838, 2385, 2536, 2587 Morel, L Morel, N Moreland, L , 880 Moreland, LW..363, 404, 804, 808, 886, 1344, 1348, 1410, 2051, 2851 Morell-Dubois, S Morella, K Morelos, M Moreno, JV Moreno, J Moreno, M...40, 595, 1240, 2578, 2622 Moreno-Martinez, D Morf, H Morgan, AW Morgan, AW.. 449, 775, 880, 2924 Morgan, C Morgan, GA , 2224 Morgan, L , 1337 Morgan, M Morgan, N , 1337 Morgan, R Morgan DeWitt, EM. 259, 262, 288, 2317, 2318 Morgan-DeWitt, E Mori, S Mori, S Mori, S Morina, P Morinelli, TA Morinobu, A , 2910 Morishima, Y Morishita, K , 2903 Morita, K Morita, R...986, 1040, 1238, 2977 Moriyama, T Morlock, R...105, 901, 1165 Moroncini, G Morris, AE Morris, Q Morris, R , 2222 Morrison, M Morsley, K Mortensen, JH Moruno Cruz, H Mosca, M. 527, 1772, 2432, 2656, 2708, 2755, 2931 Moser, S , 266 Moser Sivils, K Mosher, DP Moshkovich, O Moshref, M Moskowitz, RW Mosley-WIlliams, A...370, 1375, 2378, 2413 Mosquera, A Mossell, J Mota-Mondragón, BA Motojima, S...472, 1698, 2506 Moturu, S Moulis, G...845, 2549, 2757 Moulton, V , 2682 Mount, DB , 1219, 2958 Mountian, I Mountz, JD , 1209, 2872 Moura, B Moura, RA Mouterde, G , 1418 Mouthon, L. 743, 783, 1326, 1690, 1759, 1763, 1767, 1769, 1774, 1776, 1778, 1782, 1792, 1864, 2199, 2549, 2701, 2777, 2778 Moutsopoulos, HM...478, 1047, 2087, 2090, 2100 Movahedi, M...824, 1068, 2033 Movasat, A , 1683 Moxness, M Moy, E Moy, L Moy, LY Mpofu, S. 536, 537, 538, 550, 819, 953, 954 Mroczek, A Mrowietz, U Msihid, J Mudano, A Mueller, R. 131, 2366, 2913, 2914, 2971 Mueller-Lutz, A Muellershausen, F Muench, GRA Mukherjee, M Mulero, J , 2604 Mulero- Mendoza, J...40 Mulgund, M Mulla, MJ Mullan, R Mullen, M Muller, G Muller, KE Muller, R Muller, S Muller-Ladner, U , 2711 Municio, C Muniz, L Munk, HL , 629 Munn, A Muñoz, A Muñoz, S...59 Muñoz, S MuÑoz Fernandez, S... 40, 2853 Muñoz-Calleja, C Muñoz-Elías, EJ Muñoz-Fernández, S Muñoz-Monroy, OE Munro, J Munroe, M Munroe, ME.866, 1604, 1922, 2880 Muntner, , 2388 Murakami, A , 1259 Murakawa, M Muramatsu, Y , 1885 Muraoka, S.. 232, 233, 1460, 2259 Murasawa, A...135, 481, 1416 Murat, S Murata, M Murata, M , 2925 Murata, M.S., T Muratore, F...785, 790, 791, 798, 882, 2766 Muratore, M , 2239 Muroga, Y Murooka, TT Murosaki, T , 1765 Murota, A , 2977 Murphy, A Murphy, C , 884 Murphy, E Murphy, J Murphy, L...72, 888, 980, 1092 Murphy, M.359, 360, 361, 362, 405, 408, 1903, 2985 Murphy, SL , 2333 Murray, A , 2147 Murray, M , 2312 Murray, SG , 2827 Murru, V Murtaugh, M , 1694 Murtaza, A Murthy, V Mus, AM , 1749 Muscal, E. 104, 1151, 1825, 1988, 2273 Muschter, D Musenge, E Mussano, E Mussard, J , 1196 Mustafa, A Musto, A Mutebi, A Muth, T , 1078 Muthana, M , 2817, 2875 Mutlu, G Mutti, A Myasoedova, E...419, 838, 1055 Myasoutova, L Myklebust, G , 795 Müller-Ladner, U Myoung, E Mysler, E , 2821 Myung, G , 2107 Mäkinen, H , 2812 Möller, I Möller, I Møller, HJ Møller, JM , 1188 Møller-Bisgaard, S N N. Amaral, T , 2720 Naderi, MY Nadkarni, A... 95, 1142 Naegeli, A Naga, OS , 1213 Nagaev, I Nagaeva, O Nagafuchi, H Nagahira, A Nagai, T... 87, 1696 Nagakura, T , 2274 Nagamine, M Nagamine, R Nagamoto, T Nagano, S Nagaoka, S...86, 87 Nagaraja, V Nagaraju, K , 2216 Nagasawa, Y , 2340 Nagasawa, Y Nagata, M Nagatani, K , 1765 Nagaura, T Nahin, R , 1106 Naides, SJ Nair, A , 2245 Nair, N Nair, RP Naka, T Nakachi, S Nakagawa, I.2, 5, 1179, 1628, 2638, 2864 Nakagawa, N Nakahashi, S , 424 Nakai, A Nakajima, A Nakajima, A , 495 Nakajima, H Nakajima, T , 806 Nakamura, H Nakamura, H.429, 2159, 2389, 2651 Nakamura, K Nakamura, M Nakamura, M Nakamura, T Nakamura, T Nakamura, Y Nakamura, Y abstract author Index Nakanishi, K Program Book 323

326 abstract author Index 324 Nakanishi, T , 2128 Nakano, K , 2806 Nakano, K Nakano, M Nakano, T Nakaoka, Y Nakashima, H Nakashima, R , 1260 Nakashima, Y...429, 2389, 2651 Nakashita, T...472, 1698, 2506 Nakayamada, S...805, 1541, 2691, 2806 Nakazono, K , 1416 Nakken, B Nalesso, G Nalli, C...4, 15 Nalotto, L Nam, EJ , 593 Nam, JL.. 124, 137, 380, 449, 1740 Namour, F Nan, B Nanki, T , 2762 Nantel, F...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Nantz, EP Nanus, D Napalkov, P Naparstek, Y , 2350 Narain, S Narayan, A Narazaki, M... 31, 678 Narbonne, V Naredo, E Naredo, E Narita, I...805, 1235, 1416, 1648 Narula, N Narváez, J...412, 691, 695, 776, 777, 814, 1240, 1381, 1421, 1430, 1655, 1656, 1657, 1659, 1670, 1674, 2194, 2620, 2622, 2780 Narvaez, JA , 1381 Nascimento, JJD Nash, P , 550 Nash, P...537, 953, 1682 Nasmyth-Miller, C Nasonov, EL Nasonov, E , 2524 Nasrullayeva, G Nassif, C Nataf, H Nath, A Nath, S...415, 2089, 2841 Nathan, S Nativ, S Natour, J Natter, MD , 2286 Natvig, B Nava-Zavala, A Program Book Navarra, S , 1673 Navarra, SV Navarro-Compán, V...557, 576, 595, 2387, 2578, 2579, 2586, 2588, 2589, 2596, 2598, 2604 Navarro-Millan, I Navarro-Sarabia, F , 2469 Navarro-Zarza, JE Navarta, DA , 2987 Navid, F Nayak, P , 1070, 2420 Nayak, U Nayar, S , 1045 Ndosi, M Nduaka, C...460, 487, 849, 2489 Neal, R Needell, S Neel, A Neeman, N Neerinckx, B Negrete-López, R , 2251 Negueroles, R Neidhart, M , 2448 Neilson, B Neira, O Nel, H Nel, L Nelson, AE Nelson, JL Nelson, S , 1304, 1826 Nelson, SL Nelson,...104, 1151, 2045 Nemes, D. 1525, 1526, 1538, 2497 Nemkova, D , 1323 Nennesmo, I Neogi, T.. 172, 822, 826, 827, 923, 974, 1821, 2783, 2969, 3007 Neovius, M...42, 2018, 2525 Neri, R , 2217 Neria, E Nerome, Y Nes, PG Nesher Peleg, S Netea, M , 1223 Neto, D Neuhaus, J Neumann, T Neuville, S , 1025 Neveu, S Neville, C Nevitt, M...207, 1083, 3007 Nevitt, MC , 210, 212, 973, 1024, 1276, 1286, 1288, 1820, 1821, 2783 Newkirk, M Newkirk, M Newman, ED...941, 1395, 1830 Newman, S Newmark, R Neyaz, Z Nezamzadeh, M Nezos, A , 2087, 2090, 2100 Ng, B Ng, E Ng, J , 1756 Ng, LWK Ng, M Ng, N Ng, WF...313, 522, 2982 Ngamjanyaporn, P Ngcozana, T Ngian, G Ngian, GS Nguyen, C Nguyen, L Nguyen, MHV Nguyen, M Nguyen, M Nguyen, TDL Nguyen, T Nguyen, T Nguyen, USDT...193, 974, 1874 Nguyen, V Nguyen, Y Nguyen Huu, VA Ngwiri, T Ni, J Ní Gabhann, J , 2694 Ni Mhuiri, A Nicaise-Roland, P...12 Nicassio, , 3013 Nicco, C Nicholas, A , 2917 Nicholls, D Nicolai, R , 1228 Nicolaides, A Nicolas, P Nicoli, D Niedermayer, D...58 Niederreiter, B...634, 650, 2907 Nielsen, CT Nielsen, MA Nielsen, S...277, 282, 2903 Nieminen, R Nierkens, S Nieto, C Nieuwenhuis, WP Nieuwland, S , 1623 Niewerth, M , 2902 Niewold, TB , 2880, 2927 Nigil Haroon, N , 2829, 2939 Nigon, D , 2028 Nigro, A Nigrovic, PA...314, 1744, 1988 Nihtyanova, SI Niinisalo, H Niiro, H , 1952 Nijsten, TEC...139, 1571, 1583 Niki, Y Nikiphorou, E , 1841, 2135, 2810 Nikpour, M...720, 723, 1705 Nikpour, M Nilo DeMagaldi, E Nilsdotter, A Nilsson, J Ninaber, MK Ninaber, MK Ninet, J , 2866 Nirmala, N Nirula, A , 1557 Nisar, M Nishida, K Nishikawa, A Nishikomori, R Nishimi, S Nishimoto, N Nishimoto, T Nishimura, K Nishina, N Nishino, A...429, 2389, 2651 Nishino, I Nishio, MJ , 2393 Nishioka, J Nishioka, M Nishioka, Y Nishiwaki, A , 1906 Nissen, MJ Nistala, K , 931 Nistala, K , 2900 Nitiham, J , 2955 Nititham, J Nitschke, L Nitta, H Nitta, K Niu, J.66, 200, 207, 212, 923, 1083, 1286, 1384, 1803, 1821 Niu, J Nived, O , 2646 Nivuori, M Noble, J Noble, P Nocturne, G...520, 521, 2163 Noda, K , 2214 Noda, K , 1952 Noda, S...748, 749, 752, 3003 Noel, D Noel, E Noel, N...8 Noergaard, M Nograles, K Noguchi, A...5, 1179, 1628, 2638 Noguchi, S Nojima, T Nojima, Y

327 Nolla, JM , 695, 1381, 1421, 1430, 1655, 1656, 1657, 1659, 1674, 2194, 2620, 2780 Nomura, J Nonaka, I Nonaka, Y , 2274 Noordenbos, T Noort, AR , 2802 Nordberg, LB Nordgren, B Nordin, A Nordlund, J Nordmark, G Nordsletten, L Nordström, D Nordström, DC Norheim, KB Norli, ES , 2035 Norman, G...4, 15 Norman, GL Norman, K Noroozi Farhadi, P , 2222 Norris, JM. 446, 1904, 2019, 2880, 2891, 2921 Norscini, J Northrup, A , 1500 Norton, K Norton, S , 1841, 2135, 2810 Norvang, V Noss, E Notarangelo, LD Notarnicola, A Noth, I Novakovich, E Novofastovski, I Nowak, E , 2606 Nowatzky, J Nowell, B , 1422 Nowling, TK , 2741 Nozaki, T...355, 1688, 1906, 2340 Nugent, K Nugnes, M Nuhaily, S...53 Numeric, P , 2155 Nummenmaa, E Nunes, E Nuñez, E Nunez, K Nunez Alvarez, C Núñez-Álvarez, C , 2867 Nuñez-Cornejo Piquer, C Nuño, L , 1603, 2400, 2513, 2522 Nunokawa, T , 1773 Nur, M Nurminen, T...543, 544, 565, 566, 852, 1553 Nurmohamed, MT , 2558 Nurmohamed, MT , 2093 Nurmohamed, MT. 572, 573, 2053, 2400, 2583 Nurmohamed, M , 2492 Nutz, A Nwosu, LN Nygaard, H , 2035 Nüßlein, H , 2492 Nüßlein, H O O Cuiv, P O Dell, J , 1523, 2139 O Neill, L , 2694 O Brien, SH O brien, S O Brien, WR...28 O Connell, PG , 2694 O Connor, K O Connor, L O connor, L , 2839 O Dell, AA O Dell, J...108, 1953, 2373 O Dell, JR , 462, 1904, 2781, 2782, 2891, 2921 O Doherty, C O Donnell, JL , 1757, 1758 O Donnell, M O Donoghue, J O Dwyer, T O Flynn, E O Hanlon, TP O Keefe, R O Keeffe, A O Leary, N O Mahony, A , 1975, 2803 O Malley, C , 2037 O Malley, T , 1631, 1924 O Neil, KM , 1304, 1826 O Neil, L O Neill, C O Neill, L , 884 O Neill, LA , 1979 O Neill, M O Neill, T O Neill, TW O Reilly, D , 2101 O Rielly, DD O Rourke, C , 1429, 2247 O Rourke, KS O Rourke, MA O Shea, A , 897 O Shea, JJ Oakley, S Oates, J , 1669 Oba-Shinjo, SM Ober-Blöbaum, JL Oberle, EJ Oberst, A Obici, L Obmolova, G OBrien, T Obry, A Ocal, L , 2627 Ocheltree, C Ochi, K , 226 Ochiai, M Ochoa, E Ochs, W...491, 940, 2233 Oda, K Oddis, CV.437, 910, 912, 914, 1266 Oddone, E , 977 Odegard, J Odeh, M Odhiambo, J Odoit, S Odom, E , 2011 Oelke, K Oen, K...290, 292, 2288 Oeser, A , 1442 Oeser, AM , 1630, 1902 of Their Collaborators, OB Ofer-Shiber, S Ogbonnaya, A Ogdie, A.. 104, 1063, 1151, 1361, 2140, 2305 Ogimoto, A Ogollah, R Ogorzaly, S Ogunbambi, O Ogura, T , 424 Oguro, N Oh, BR Oh, J , 1405 Oh, K Oh-Ishi, M Ohara, RA...444, 937, 1962, 3006 Ohara, Y Ohashi, S Ohata, J Ohira, H Ohira, T Ohmura, K , 5, 1179, 2638 Ohmura, K , 806, 1260 Ohno, S... 87, 123 Ohrndorf, S , 153 Oikonomopoulos, I Oikonomou, D Øiestad, BE Ojeda, AF Oka, H Oka, S Okada, A , 2389 Okada, K Okada, M. 1645, 1842, 2021, 2727 Okada, T Okada, Y...625, 2918, 2954 Okafuji, I Okamoto, A , 1218, 2762 Okamoto, A Okamoto, Y.877, 1255, 1264, 1640, 1710, 1939, 2991 Okamura, K , 2133 Okamura, T Okawa, J Okayama, A... 92, 2159 Okazaki, T Okazaki, Y...746, 1257, 2692 Oksel, F Oku, K... 2, 5, 1179, 1628, 2638, 2677, 2864 Okubo, N Okuda, A Okun, M Okura, C , 2133 Okura, T Okuyama, A Olaleye, A Olazagasti, J Oldroyd, A...224, 230, 231, 240 Olech, E Olejarova, M Olejarova, M Olenginski, TP , 1830, 2322 Olferiev, M Olivas Vergara, OM Olive, A... 59, 1129, 1240, 1670, 2622, 2853 Olivé Marqués, A , 1267 Olivecrona, H Oliveira, CS Oliveira, G Oliveira, R...51 Oliveira, RM... 50, 52, 73, 235 Oliveira, S Oliveira, S Oliver, A , 2011 Oliver, M Oliver, P Oliver, S , 2331 Oliver, SJ Olivieri, I...557, 560, 2758 Oliviero, F Olivotto, E Ollier, WE Olsen, IC...489, 905, 1274, 1913 Olsen, NJ Olsen C, I Olson, JC , 2319 Olson, L...858, 1499, 2839 Olszynski, W...248, 426, 583, 956, 1601, 2411 Omata, Y Ombrello, A , 1227 Ombrello, MJ , 2852 abstract author Index 2014 Program Book 325

328 abstract author Index 326 Omdal, R , 2652, 2980 Ometto, F Omma, A...422, 2523, 2627, 2750 Omouri, M On behalf of the BSRBR,.467, 1542, 1848 Onat, AM. 2157, 2523, 2562, 2611, 2616, 2744, 2750, 2769 Onda, A Oneata, R Onel, K , 1304, 1826, 2293 Onen, F , 1230, 1584, 2562, 2595, 2611 Ong, HL Ong, JP Ong, MS , 2286 Ong, RTH Ong, VH , 1714 Ongen, G Ongenaert, M Onida, F Onishi, S , 2170 Ono, K Onuma, K Oomura, K Oon, S Oparanov, BA Opava, CH Oppermann, B Opris, D Orabona, C Orban, I Ordas, C...40 Ordi-Ros, J Ordóñez, MC Oreiro, N...93, 1126, 2602 Oreiro-Villar, N...982, 1121, 1122, 1125 Orellana, C Oren, A Oren, S Orfanos, P Organ, JM Origasa, H , 2472 Origuchi, T.. 429, 805, 2389, 2651 Orlovsky, Y Orman, M Ormseth, M , 1902 Ormseth, MJ , 1630 Ormseth, S Ormseth, SR Ørnbjerg, LM Ornetti, P Oros-Ovalle, C Orozco, C Orozco, MC. 887, 2381, 2441, 2575 Orozco-Barocio, G Orr, C...109, 2312, 2800 Ort, T Program Book Ortega, R Ortego, N Ortego-Centeno, N.. 753, 776, 777, 1256, 1787, 1788, 2853 Ortiz, AM Ortiz, EC Ortiz Garcia, AM Ortiz Sanjuan, F. 1791, 2775, 2776 Ortiz Sanjuan, FM Ortiz-Fernández, L , 1788 Ortiz-García, AM Ortiz-Sanjuán, F..814, 1240, 1250, 1252 Ortiz-Santamaría, V Ortiz-Villalvazo, MA Ortmann, W Ortolan, A Orwoll, E Osborn, T Osorio, J , 1273 Ospelt, C.. 456, 1210, 1967, 2448, 2785 Ostendorf, PDB...130, 153, 1173, 1177, 1189 Ostenfeld, T Østerås, N , 3018 Ostergaard, M Ostergaard, M...366, 409, 1188, 2171, 2589 Østergaard, M , 2912 Østergaard, M...349, 1171, 1180, 1183, 1891, 1964 Østergaard, O Østgård, R Osthoff, M Osting, V Ostrovrsnik, J Ostrowski, M Ostrowski, RA , 1343, 1377, 1985 Oswald, M Ota, SI , 1952 Ota, T Ota, Y , 1710 Otaki, N Otani, K Otawa, S...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Oto, Y Otomo, K Otsa, K... 58, 351 Otsuka, F...31 Otsuzi, CI Otten, MH , 932 Otvos, JD Otvos, J Otvos, L Oufnac, B Overman, RA , 2263, 2316 Owen, C Owen, T , 2820 Oyake, N Oyoo, OG Ozaki, S... 82, 85, 780 Ozanich, A , 1347 Ozawa, Y Ozbalkan, Z , 2746 Ozbek, S Ozdemir, M Ozdemir, O Ozdogan, H , 1232, 1233, 2043, 2279, 2280, 2282 Ozen, G...119, 1423, 2769 Ozen, S , 1231, 1900, 2279, 2280, 2282 Ozeri, D Ozgocmen, S Özgör*, L Ozguler, Y. 2043, 2157, 2749, 2754 Özgür, MF Ozisik, L Ozkan, O Ozmen, M Ozturk, MA , 2761 Ozturk Gokbakan, D Oztuzcu, S Ozyazgan, Y , 2852 P Pablos, JL.134, 346, 660, 992, 1739, 1969, 1973, 2175, 2735 Pachas, W Pachman, LM , 2224, 2953 Packham, J , 1848 Padeh, S Padley, R , 1030 Padula, A , 2758 Padyukov, L Paek, S Paget, SA , 1991 Pagnoux, C.801, 804, 808, 880, 883, 1776, 1778, 1782, 1864, 2851 Pagovich, OE Pahau, H Sr Pain, C , 1323 Paiola, L Paira, S...406, 1388, 2040, 2381 Paira, SO Pakozdi, A , 1663, 1671 Palacios, G Palazzi, C , 2758 Paller, A Palli, D Palm, , 777, 880 Palmer, S , 1512 Palmisano, M Palmou, N Palmsten, K Paltiel, AD Pamfil, C Pamuk, G... 79, 1725 Pamuk, O Pamuk, ON. 79, 1725, 2523, 2562, 2611, 2719, 2769 Pamukcu, M Pan, A Pan, F Pan, W Pan, X Panaviene, VV , 282, 933 Panayiotidis, P Panchal, S Pandya, J Pang, D Pang, ES Pangan, AL...269, 552, 561, 562, 1545, 2581 Panicker, S Panico, B Panikkath, D Panikkath, R Panopolou, A Panopoulos, S Paolazzi, G , 2512, 2514 Paolino, S. 1697, 1700, 1713, 1966 Pap, T , 2951 Papachristos, A , 1932 Papageorgiou, A , 2100 Papaioannou, TG Papalardo, E...6 Papapoulos, S , 2254 Papapoulos, S , 2268 Papastefanakis, E Papo, T Papo, T , 1774, 1778, 1864, 2757 Papoila, AL Papon, L Papp, K Pappas, C Pappas, DA...515, 2367, 2415 Pappone, N Pappu, R Paramarta, JE , 850 Paran, D , 700, 971 Paraskos, J Parasu, N , 1424 Pardeo, M , 1228 Pardo, D Parida, J Parienti, JJ Parikh, M Parimi, N Paris, A Pariser, D Parish, MC...446, 1904, 2921

329 Parisi, F Parisi, S , 1256 Park, C Park, DJ...155, 533, 2266 Park, EH , 1217 Park, EJ Park, EK , 2753 Park, HJ Park, JL Park, JW Park, JK , 2347 Park, JS Park, JE Park, KS Park, KS...326, 347, 484, 1364 Park, NY Park, S Park, SH Park, SH Park, SH...155, 347, 484, 2440 Park, W , 1509, 2265, 2825 Park, YH , 1817 Park, YB , 2714 Park, YW Park, YJ , 1364 Parker, B...676, 686, 1699 Parker, M Parkes, MJ Parks, C , 2222 Parlak, S Parma, A , 2708 Parmar, D V Parmeggiani, M Parmer, P Parnes, M Parodis, I Parra, ER Parra-Izquierdo, V Parra-Salcedo, F Paruolo, C Parvu, M. 1153, 1525, 1526, 1538, 2497 Pascal, S Pascart, T , 511 Paschke, J Pascual, V Pascual Ramos, V Pascual-Ramos, V Pascual-Ramos, V , 1371 Pascual-Salcedo, D , 2400, 2459, 2513, 2522 Paskins, Z...831, 2336, 2898 Pasma, A Pasoto, SG Pasquale, M Pasquali, JL Passo, MH , 2317, 2318 Pasta, DJ , 980 Pastan, S Pastor-Asurza, CA Pastore, R...9 Pastula, C Patarroyo-Pinto, P...17 Patel, A Patel, DR , 939 Patel, G Patel, H Patel, J...81 Patel, M Patel, P , 1756 Patel, R Patel, R Patel, Y , 2396 Paterson, JM , 2309 Paterson, M , 2939 Pathak, R Patki, A Patnaik, A Pato, E , 2853 Patrikos, D Patsopoulos, N Patsouras, M Patterson, SL Pattier, S Pattison, J Patton, E Patzer, R Pau, D Pauer, L , 1108, 2080 Paul, A Paul, G Pauling, J Pauling, JD Paulissen, SMJ , 1799 Paulus, H Paupitz, J , 1824 Pavelka, K.. 504, 2491, 2492, 2493 Pavelka, K...129, 136, 851, 1039, 1524, 2085, 2371, 2422, 2524, 2555, 2580, 2594 Pavenski, K Pavlov, A Pavuluri, P Pawar, R Pawaria, S Pay, S , 2750 Payette, MP , 2210 Payne, AS Payne, J , 2014, 2782 Paz, Z Pazzola, G , 882 Pea, L Pearce, A Pearce, W Pearson, M Pease, CT...775, 880, 2767, 2773 Peckham, DW Pecondón Español, Pecorini, G Pectasides, D Peddi, M Peddi, P Pedersen, JK Pedersen, R Pedersen, S , 2986 Pedersen, SJ...591, 1188, 2589 Pedersen, TR , 1913 Pedersen, TK Pedoia, V , 1190 Pedro, S.. 108, 110, 480, 890, 2519 Peeters, AJ Peeva, E , 1616 Pego-Reigosa, JM Pego-Reigosa, JM Pehlivan, Y.2157, 2523, 2744, 2750 Pei, J , 2469 Peichl, P , 2492 Peiró, ME Peiteado, D. 595, 605, 1603, 2400, 2513, 2522, 2853 Peláez-Ballestas, I Peliçari, KDO Peliçari, KO , 2662, 2663 Pellecchia, L Pellegrini, C Pellegrini, V Pellerito, R , 2512, 2514 Pelletier, JP.. 396, 567, 1535, 1536 Pelletier, JP...205, 218, 502, 926, 2231, 2250, 2569 Pelletier, M Pellett, F Peloquin, C , 822 Peloso, Pelzek, A Pena, CE , 2670 Peña, J Penatti, AE Pendegraft, RS Pendl, JD Pène, F Peng, SL Peng, Y Peng, Y , 2844 Penmetsa, S Penserga, E , 2156 Pepper, RJ Pera, MA , 2670 Perales, M Peralta Ginés, C Perandones, C Perard, L Perard, L Perazzio, SF , 2745 Perdan-Pirkmajer, K Perdriger, A...520, 521, 2536 Pereira, B. 1413, 1418, 1428, 1448 Pereira, D Pereira, K Pereira, PVS Pereira, RMR..52, 235, 238, 1301, 1824 Pereira, RMR.. 50, 51, 1298, 2933 Pereira, RMR Pereira, RM...73 Pereira da Costa, I Pereira Da-Silva, J Pereira Gonçalves, M Peres, F Peres, FA , 1636, 2663, 2720 Perez, A Perez, MO Perez, M Perez, S Perez Alamino, R. 370, 1375, 1600, 1643, 2378, 2413 Pérez Gómez, A Perez Riveros, P Perez Venegas, JJ...59 Perez-Aso, M.22, 23, 33, 1729, 2355 Pérez-Barbosa, L Pérez-Esteban, S Pérez-Lorenzo, MJ , 2735 Perez-Pampin, E , 814 Perez-Ruiz, F , 2962 Perez-Sanchez, C... 7, 1978 Pérez-Vicente, S... 99, 1367 Pérez-Yagüe, S Pericelous, C Perich-Campos, RA Pericleous, C , 2863, 2865 Perka, C...29 Perl, A Perlat, A Perlman, HR...343, 969, 2908 Perna, A Pernis, AB , 2840 Perper, S , 2839 Perrella, O Perretti, M Perricone, R Perrodeau, E Perruccio, A Perruccio, AV Perry, B Perry, E Pers, JO Pers, YM Sr Pértega-Díaz, S Perthuiset, E Pertuiset, E.1782, 1864, 2162, 2574 Peruzzo, L abstract author Index 2014 Program Book 327

330 abstract author Index 328 Peschken, C , 2619, 2791 Peschken, CA...961, 1855, 2022, 2401, 2646 Pestaña, M Peter, HH , 2492 Peter, WF Peterfy, C Peterfy, CG , 1528 Peters, E Peters, M Peters, MA Petersen, KK Petersen, NJ Peterson, A Peterson, C Peterson, ER Peterson, EJ , 2213, 2843, 2905 Peterson, HJ , 1348 Peterson, L Petersson, I Petersson, IF Petersson, IF , 367 Petitpain, N Petri, C Petri, M...6, 672, 687, 689, 697, 870, 961, 1619, 1652, 1665, 1667, 1669, 1920, 2089, 2539, 2635, 2646, 2647, 2648, 2667, 2668, 2791, 2834, 2836, 2955 Petricca, L Pettersson, G... 88, 987 Peykova, L Pezic, A Pfeiffenberger, M Pfister, T Phadke, A Pham, A Pham, H Pham, M Pham, T...140, 473, 1385, 2584 Phan-Chronis, K Phee, H Phibbs, C Philips, R Philipson, R Phillips, K , 924 Phippard, DJ , 1766, 1862 Phipps-Green, A Pialat, JB , 1187, 1894 Pianta, A Piantoni, S Picco, P Picerno, V , 908 Pickrell, D Pielberg, G Pierangeli, S...6 Pierangeli, SS Pieters, BCH Pietrogrande, M Program Book Piette, JC Piette, JC... 8, 835, 1925 Piga, M , 908 Pigatto, E Pignac-Kobinger, J Pikazis, D Pike, VC Pikwer, A Pikwer, M , 1477 Pilkington, C , 1331 Pillai, J Pillai, NE Pillai, S Pillebout, E Pillinger, MH...156, 176, 1224 Pilström, B Pimentel-Santos, F Pina, T , 2853 Pina Murcia, T...814, 1240, 1250, 1256, 1787, 1788, 1791, 2203, 2452, 2459, 2775, 2776 Pinal-Fernandez, I Pincus, T. 69, 353, 417, 1157, 2078, 2111, 2310, 2379, 2568 Pineau, CA.1771, 2619, 2664, 2665, 2666, 2884 Pineda, L Pinedo-Villanueva, R Pinhata, MM Pinkhasov, J Pintilie, S Pinto, D Pinto, D Pinto-Tasende, JA Pintor-Iglesias, A Pioli, P Pioltelli, P Pioro, M , 1996, 2001 Piotto, D Piper, J , 909 Piper, M Pipitone, N...790, 791, 798, 2228 Pires Marafon, D Jr , 2901 Pirkmajer, S Pirronello, F Pisal, D Pisaneschi, E Pisetsky, DS , 679 Pisoni, CN Pispati, A Pistorio, A , 1316 Pittman, JR Pitts, KR...16 Pitzalis, C Piva, SR , 2326 Piwinski, J Pizem, J Pizzino, G Pizzo, AS Pizzorni, C. 1697, 1700, 1713, 1966 Planck, SR , 1756 Plant, D , 2924 Plantinga, L Plasencia-Rodriguez, C. 605, 1603, 2400, 2513, 2522 Plass, N , 1896 Plata, A...74 Platas, J...32 Platt, A Platt, H Platt, RW , 2665, 2666 Playford, M Plenge, RM , 2960 Pleštilová, L , 2450 Pluma-Sanjurjo, A. 475, 2391, 2526 Poddubnyy, D...558, 2592, 2593, 2618, 2983 Podlusky, S , 1929 Podojil, JR Pohle, S Poiley, J Poireaud, T Poiroux, L Pokroy-Shapira, E Polachek, A Pollock, Pollock, R...623, 625, 2099 Polokoff, MA Polomat, K , 2155 Polomat, K , 2532 Polyak, JL. 1097, 1099, 1100, 1881, 2060, 2073 Poncet, C , 2492 Ponchel, F , 1020, 1740 Pongratz, G...994, 998, 1974 Pons, A , 1531, 2423 Pons-Estel, B Pons-Estel, B Pons-Estel, GJ Pons-Estel on behalf of GENLES, B Ponsonby, AL Ponte, C , 796, 909 Pontiggia, L Poole, JL Poolman, R Poon, V Pope, CA Pope, E Pope, JE...371, 386, 394, 492, 673, 745, 1065, 1074, 1387, 2380, 2410, 2469, 2619, 2814, 2884, 2999 Pope, R Pope, RM , 2908 Popmihajlov, Z Popov, JM Popoviciu, H , 2497 Porru, G , 2559 Portal-Nuñez, S Portela Hernandez, M Porter, B , 538, 819 Porter, JC Porto, LC Possemato, N Postal, M. 1622, 1636, 2659, 2660, 2661, 2662, 2663 Potarca, A Potvin, J Pouchot, J Poudel, D Poulin-Costello, M , 492 Poulsen, K Poulton, CJ Pounds, J Jr Pouplin, S Pourrat, J Powell, M Powers, T Poyraz, C Pozzi, MR Pozzuoli, A Prabhakaran, S Prabu, A Pradel, V , 2584 Prado, M Pradsgaard, D Praestgaard, A Prafioriti, A Prahalad, S. 319, 1900, 2290, 2293 Praino, E Prajzlerová, K , 2085 Praprotnik, S Prasad, N Prasad, P , 215 Prasad, P Prati, C , 559 Pratsidou-Gertsi, P Pratt, AG Pratt, G Pratt, J , 2318 Predeteanu, D Pregnolato, F Preijers, F Preis, E Prencipe, G. 311, 1225, 1228, 1901 Presby, M Prescott, K Presnell, S Price, D , 251, 897 Price, LL , 1116, 1281, 1336, 1337, 1818, 2065, 2337, 2338, 2858 Pricop, L...537, 550, 953, 954 Pridgen, W Prieto-Alhambra, D Prihar, B Primdahl, J

331 Prince, F Prince Nelson, S Prior, D Prior, Y Priori, R Pritchard, C Prokopec, S Proost, P Protogerou, AD Protogerou, AD , 2617 Proudman, S.720, 723, 1682, 1705, 2034, 2520, 2999 Provan, S Provan, SA , 2571 Prowse, P Pruhs, ZM Pruijn, GJ Przebinda, A Przepiera-Bedzak, H Psaradellis, E , 1550 Psarelli, E Puar, R Puchner, A.27, 634, 650, 2358, 2907 Puéchal, X.. 520, 521, 1759, 1763, 1767, 1768, 1769, 1776, 1777, 1778, 1782, 1864, 2536, 2779 Pugliese, DM , 1830 Pugnet, G...845, 1768, 1778 Puig Sanz, L.539, 1548, 1554, 1556, 1559 Puig-Kröger, A , 2175 Pullman-Mooar, SW Punaro, MG , 1321, 1898, 2293 Punzi, L , 1291, 1292, 1707, 2408 Puolakka, K , 2484 Purcaru, O , 2560 Purdue, E... 24, 1043 Puri, S , 1082 Pushparajah, DS Put, K Put, S Putrik, P.70, 101, 1058, 1059, 1164, 1373, 2113 Putt, ME Putta, S Putterman, C. 640, 651, 664, 1608, 1631, 1924, 1941, 2180, 2649 Puvenna, V Puyraveau, M Puzas, E...25 Puzenat, E Py, G Pyatak, E Pyne, D , 1663, 1671 Pyo, T Pyrkotsch, P Pörings, AS Pødenphant, J Q Qaiyum, Z Qazi, S Qi, J , 2591 Qi, M Qin, J Qin, Y Qizilbash, N Qu, B , 1615 Qu, H , 1672 Qu, K Quach, D , 2446 Quach, HL...524, 2446, 2466 Quach, L Qualls, C Quan, A Quang, C Quarta, E Quarta, L Quartarone, G Quartey, G Quartier, P Quartier, P , 2298 Quartier, P.270, 273, 282, 284, 289, 316, 473, 1326 Quartuccio, L , 2544, 2855 Queiro, R...59 Quemeneur, T , 1778 Querci, F , 2656 Quesada, A...74 Quevedo, V , 2622 Quilès, N Quinet, R Quinn, EK , 2783 Quinn, S Quiñones, J Quinones, M.370, 1375, 2378, 2413 Quintana, R , 2381 Quintana, R Quintanar, M Quintanilla, MA Quinteros, A , 1438, 2040, 2381 Quinzanos, I , 2570 Quipourt, V Quirke, AM Quismorio, A Quismorio, FP Jr R R Bernatsky, S , 2646 Raaschou, P , 1838 Raastad, J Raber, S Rabin, B Rabinovich, CE , 1321 Rabot, S Raboud, J Rabusa, C , 723 Racaza, G , 2108 Radbruch, A Radbruch, AH Rademacher, J Radfar, L. 1798, 2535, 2543, 2930, 2978 Radner, H , 2029 Radominski, SC Radominski, S Radstake, TRDJ. 336, 747, 753, 757, 1704, 2725 Radstake, T , 1720, 2178, 2953, 2962 Radtke, D Radvanski, DC Raes, J Raffeiner, B...908, 1160, 2408 Raffray, L , 2779 Raganelli, L Ragazzi, M Raggi, P , 1442 Raghavan, S Rahbar, MH , 588 Rahimi, H , 2353 Rahman, A...676, 711, 961, 2637, 2646, 2863, 2865 Rahman, P...248, 537, 539, 550, 583, 623, 624, 625, 626, 953, 956, 1124, 1289, 1548, 1550, 1554, 1556, 1559, 2101, 2411 Rahmani, B Rai, MK Rai, R Rai, S Raimondo, S , 611 Raisch, D Raj, P Raja, R Rajakariar, R , 1663, 1671 Rajendran, S Rakel, B Rakieh, C Rakocevic, G Rakow, A...29 Ralston, P , 468 Ramachandaran, R.. 169, 188, 189, 190, 191 Ramachandran, S.. 105, 901, 1165 Ramakrishna, J Raman, I Raman, SV Ramanan, A Ramanan, AV Ramanathan, A Ramani, A Ramani, K Rambhad, G Ramentol, M Ramires de Jesus, G Ramirez, D Ramirez, J...134, 445, 469, 1973, 2478, 2508, 2926 Ramirez, M Ramírez-Fernández, M Ramiro, S...70, 101, 561, 574, 582, 1058, 1059, 1164, 1373, 2113, 2600, 2828 Ramkhelawon, B...24, 33 Ramonda, R Ramonda, R , 1291 Ramos, JG Ramos, , 2956 Ramos-Casals, M , 2646 Rampakakis, E , 365, 379, 382, 383, 421, 426, 943, 956, 1109, 1397, 1601, 2411, 2416, 2496, 2518 Ramsay, E Ramsey-Goldman, R , 1631 Ramsey-Goldman, R.672, 862, 961, 1924, 2089, 2646, 2791 Ranade, K Randall, T Randazzo, B , 1556 Randell, E Randhawa, D Rangel-Moreno, J Ranger, A Rannio, T , 2812, 2911 Rantalaiho, V , 2484 Rantapää-Dahlqvist, S...90 Rantapää-Dahlqvist, SM Rantapää-Dahlqvist, S.. 447, 2084 Rantapää-Dahlqvist, SM Rao, DA Rao, V Rao, VR Raouf, J Rapecki, S Raschi, E Rasheed, H , 2964 Rashid, A Rashkov, R Rasker, J , 893 Rasmussen, A...985, 1798, 2430, 2535, 2543, 2930, 2978 Rasmussen, S Rasmussen, TK Rastalsky, N , 1349 Rat, AC , 3018 Rat,, AC , 219 Ratanasrimetha, P. 726, 799, 2531 Ratnarajah, S Rattan, S Ratz, T Ratzlaff, C Rauch, C , 2492 Rauch, L Rauen, T abstract author Index 2014 Program Book 329

332 abstract author Index 330 Ravaud, P , 1864 RAVE-ITN Investigators, FT Raveendran, R Raveendran, V Ravelingien, I Ravelli, A , 2298 Ravelli, A. 277, 278, 284, 299, 928, 1316, 1325, 1901, 2281 Ravenell, R Ravera, F Ravindran, R Ravindran, V Rawat, A Rawlings, D Ray, DW , 2636 Ray, L Raya, E , 2622 Rayahin, J , 215 Rayavarapu, S Raychaudhuri, S. 1602, 1963, 2364 Raychaudhuri, SK.1602, 1963, 2364 Raychaudhuri, S..625, 1744, 1900, 2918, 2954 Raynauld, JP...218, 396, 502, 567, 1535, 1536, 2210, 2250, 2569 Raza, K , 2183, 2463, 2874 Razawy, W Rebello, R Rech, J , 2233 Rech, J...940, 1184, 2130 Recillas-Gispert, C Recknor, C , 2255 Reddy, D Reddy, SM Reddy, ST Reddy, V...989, 995, 1955, 2696 Redecha, Redlich, K...27, 2358, 2907 Redman, R Rednic, S , 1525, 1526, 2645 Redondo, G Reed, AM...304, 320, 914, 1316, 2213, 2953 Reed, GW...515, 518, 1537, 2375 Reed, J Reed, M Reed, TJ Reedquist, KA Reese, C Regent, A , 1769 Reggia, R , 1532 Reginato, A Reginato, AM Reginster, JY Reginster, JY , 2268 Regnault, V Rego-Pérez, I , 1122, 1125, 1126 Reguiai, Z Program Book Rehaume, L , 632 Rehman, A Rehman, AA Rehman, MI Reich, H Reid, C Reid, IR , 2268 Reiff, A Reijnierse, M , 1379 Reijnierse, M.540, 594, 1186, 1187, 1823, 1894, 2597, 2984 Reilly, P Reiman, M Reimold, A , 2494 Reimold, AM Reimundes, C Rein, C Reinhardt, A Reis, L Reis, RC Reiser, M Reiseter, S Reiss, W Reitberg, D Reitblat, T Reixach, N Rejeski, WJ Reker, D Relaño, S Relaño-Fernandez, S , 1122 Relic, B , 1025 Rell-Bakalarska, M Rémillard, MA...396, 502, 1535, 1536, 2569 Remmers, EF , 2852 Remy, P Remy Piccolo, V Ren, P Ren-Fielding, C Renaud, J Renner, B Renner, JB...201, 978, 2046, 2941 Rennie, W Repa, A Repp, H Resch, H Resche Regon, M Resche-Rigon, M Reshiti, N Resick, P Restrepo, JF , 1133, 2026, 2374 Restuccia, G...785, 790, 791, 798 Reutermann, P Reveille, JD..6, 569, 588, 617, 754, 2089 Revicki, D...259, 260, 261, 549 Reyes, MA Reyes Llerena, G Reyes-Lopez, AL , 333 Reynisdottir, G Reynolds, JA , 2636 Reynolds, K , 898 Reynolds, R...451, 1474, 2453 Reynolds, RJ Rezaei, H Rezus, E , 1526, 1538, 2497 Rharbaoui, F Rhead, B Rhéaume, M Rhee, RL...875, 1781, 2701 Rhodes, B Rhodes, C Rhodus, NL , 2543, 2978 Riancho, JA Riancho-Zarrabeitia, L , 814, 1240, 1249, 1250, 1251, 1252, 1791, 2775, 2776, 2853 Riba-Garcia, I...78 Ribeiro, ACM...957, 2151, 2809 Ribon, M , 1196 Riccardi, A Ricci, J...36 Ricci, M Riccieri, V Rice, L Rice, P Rich, E Richard, D , 175 Richard, D Richard, MA Richards, H.536, 537, 538, 550, 819, 953, 954 Richards, JS , 2570 Richards, K Richardson, A Richardson, B Richardson, BC Richardson, C Riches, PL Richette, P...164, 165, 2231 Richez, C Richi, P , 2622 Richter, A Richter, J , 701 Richter, JG , 1078 Ricse, M. 1655, 1656, 1657, 1659, 2194, 2620, 2780 Rider, LG Rider, LG.. 912, 1316, 1317, 1318, 2211, 2222, 2953 Riebschleger, M Riebschleger, MP Riecke, BF Riega-Torres, J Riegsecker, S Riemekasten, G.730, 735, 747, 753, 773, 1712, 2711, 2837 Riente, L Riese, R...458, 508, 849, 2487 Rietschel, M Rietveld, L Rifkin, I Rigamonti, F Rigante, D Rigby, W , 2198 Rigby, WFC Rigolet, A. 1037, 1262, 1270, 1271, 2778 Riis, BJ , 2230 Riisbro, R Rillo, O Rillo, OL , 1438, 2042, 2441, 2706 Rillo, OL...406, 1388, 2381 Rimar, D Rinaldi, M , 1316 Rincheval, N , 1411 Ringold, S , 2293 Riopedre, AM Sr Ripoll, VM Rischmueller, M , 2962 Riso, N , 2656 Rispens, T Rist Bouillon, S , 521 Ritchlin, CT...25, 37, 325, 539, 934, 1548, 1554, 1556, 1557, 1559, 1807, 2353, 2794 Rittberg, R Ritter, SY Riva, M Rivas, P Rivera, J Rivera, J Rivera-Kweh, M Rivero, M Riveros-Frutos, A. 568, 1240, 2622 Rivière, S Rivkin, G Riyazi, N Robbiano, C Robbie, G Roberts, C Roberts, H Roberts, J Roberts, LJ II Roberts, L , 2419 Roberts, MS Roberts, M Roberts, ME Roberts, N Roberts, VC Roberts, WN Jr Roberts, WN Robertson, AAB Robertson, JM Robinson, D Robinson, DB...745, 1476, 1855,

333 2401 Robinson, ES Robinson, G Robinson, G Robinson, M , 251, 897 Robinson, SM Robinson, WH. 348, 451, 452, 453, 815, 840, 1457, 1470, 1476, 2019, 2456, 2908 Robles, M Robles Perez, A Roblin, D...54 Roblot, P Robotham, M Robson, J , 1761 Robson, M Robustillo Villarino, M Roccatello, D , 2855 Rocchetta, PA , 2514 Rocha, B... 93, 982, 1127 Rocha Muñoz, AD Rocher, V Rockette, H , 1316 Roddy, E Roddy, E...172, 831, 1114 Roddy, J Rodere, M Rodrigues, I , 1424 Rodrigues, J..365, 382, 426, 1397, 2416, 2518 Rodriguez, ER Rodriguez, J... 59, 2097 Rodríguez, JM Rodriguez Amado, J Rodriguez Araya, TL , 2190 Rodriguez de la Serna, A Rodriguez Gil, G , 2441 Rodriguez Moreno, J Rodriguez Rodriguez, L Rodriguez Rodriguez, N.1033, 2734 Rodríguez Valls, MJ Sr Rodriguez-Almaraz, E , 1670 Rodríguez-Amado, J Rodriguez-Ariza, A...7 Rodriguez-Bellido, Z Rodríguez-Carrio, J Rodríguez-Cundín, P Rodríguez-Gómez, M Rodríguez-Gómez, M , 2622 Rodríguez-Moreno, J Rodriguez-Muguruza, S. 568, 1267 Rodriguez-Olivo, J Rodriguez-Pla, A , 1786 Rodríguez-Portales, JA Rodriguez-Reyna, TS Rodriguez-Rodriguez, L.. 90, 1139, 1431 Rodriguez-Rodriguez, L.. 482, 776, 1138, 2459 Rodríguez-Salvanés, F Roebuck-Spencer, T Roeleveld, DM , 1734 Roemer, F...207, 210, 1083, 1821 Roesch, SC , 1338 Roeterink, A , 577 Roeven, M Roga, S Roger, M Rogers, S Rogier, R , 1734, 1816 Rogovski, O Rohekar, G Rohrer, MD Roig, D...59 Roitg, I Rojas-Villarraga, A...84 Rokutanda, R , 2727 Rolando, J Rollefstad, S.489, 1274, 1440, 1913 Román Acosta, S Roman Ivorra, JA Romanini, F Rome, K Romero, F Romero, J Romero Bogado, ML Romero Sanchez, C Romero-Díaz, J...961, 2533, 2639, 2646 Romo-Tena, J Ronday, HK , 2502 Rood, J Rooney, T , 2822 Roorda, LD. 260, 261, 1451, 2053, 2054, 3018 Roos, EM Roppelt, H Rorick, MJ Rosa, J.141, 410, 1388, 1438, 1585, 2072, 2381, 2402, 2987 Rosa, J , 1761 Rosado-Canto, R Rosales, Z Rosario, MP Rosas, I , 1273 Rosas, J , 1519, 1531, 1670, 2622 Rosas Saucedo, J Rosas-Gómez de Salazar, J Rose, A Rose, CD , 2278 Rose, C Rose, K , 2222 Rose, S Roselli, E... 88, 987, 2786 Rosemffet, MG.127, 128, 141, 2402 Rosen, A , 2539, 2929 Rosen, C.626, 627, 628, 1575, 1850 Rosen, D Rosen, O Rosenbaum, J Rosenbaum, JT...544, 615, 1236, 1756 Rosenberg, AM Rosenberg, D Rosenberg, I Rosenthal, AK Rosenzwajg, M Rosenzweig, S Roset, A...691, 695, 1657 Roskos, L , 1496 Rosner, I Rosol, TJ Ross, JA Rossello-Urgell, J Rossetti, M Rossi, C Rossi, D Rossignol, J Rossini, P Rotar, Z...788, 1789, 1790, 2041 Rotar, Roth, B Roth, D , 1641 Roth, J...932, 1199, 2988 Roth, K Roth, M Roth-Wojcicki, E , 2319 Rothenbuhler, A Rothwell, S Rotman, G Rotondo, C Rottat, L Rouanet, S Roubey, R...3 Roubille, C Roujeau, JC Rousseau, M Rousseau, V Rouster-Stevens, KA , 1304, 1316, 1826, 1988, 2290 Routledge, C Roux, C. 202, 234, 257, 1769, 2268, 2579 Roverano, S Rovin, BH Rovira, J Rowell, L Rowland, CM Rowshandel, J Royant, V Rozadilla, T Rozenbaum, M Rozenberg, S Rozenblyum, EV , 1992 Rozo, C Rozo, CT Rua Elorduy, MJ Rúa-Figueroa, I , 2622 Ruaro, B , 1700 Rubbert, C Rubbert-Roth, A. 1486, 1845, 2821 Rubin, L Rubin, LA Rubinstein, T Rubio Rivas, M...691, 1655, 1656 Rubio Romero, E Rubio-Pérez, N Rucco, M Ruddy, M , 1500 Ruderman, EM , 1347 Rudrangi, R Rudwaleit, M. 543, 544, 852, 2560, 2589, 2593 Rueda-Gotor, J..1791, 2775, 2776, 2853 Ruetsch, C , 1832 Ruff, W...1, 856 Ruhlmann, V Ruivard, M , 1864 Ruiz, B , 1130 Ruiz, N Ruiz Gutiérrez, L Ruiz Moreno, O Ruiz-Cano, MJ Ruiz-Esquide, V , 445, 469, 2478, 2508, 2926 Ruiz-Irastorza, G , 2646 Ruiz-Limon, P... 7, 1978 Ruiz-Nodar, JM Ruiz-Romero, C.93, 982, 1126, 1127 Ruiz-Zorrilla, A... 40, 596 Rullo, OJ Rumba-Rozenfelde, I.277, 284, 928, 2281 Rump-Goodrich, L Ruperto, N Ruperto, N...931, 2297, 2298 Ruperto, N , 276, 930 Ruperto, N.277, 282, 284, 299, 912, 933, 1316, 2281, 2295 Rus, H Rus, V Rush, S Russell, AM Russell, CB Russo, A Russo, D Russo, G Russo, R , 2280, 2282 Russo, RAG. 284, 1325, 1900, 2302 Ruta, S , 2072, 2987 Rutgers, A , 1956, 2733 Ruth, J , 1962 Ruth, JH Ruth, NM , 1825 abstract author Index 2014 Program Book 331

334 abstract author Index Rutkowska-Sak, L Rutledge, M Rutten-van Molken, M... 96, 1141 Ruyssen Witrand, A...466, 1140, 2483 Ruyssen-Witrand, A , 2028 Ruzehaji, N Ruzek, M , 1030 Ruzickova, O Ryals, M Ryan, PC Rybak, D Rybak-Feiglin, A Rybakowska, P Rybicki, BA Rybin, D , 2139 Rönnblom, L , 2681, 2980 Rönnelid, J , 1534 Röver, H Rødevand, E S S.Akhavan, P Sa Leitao, D Saad, CGS...957, 2151, 2304 Saad-Magalhaes, C , 2281 Saadoun, D...8, 809, 811, 1245, 2731, 2757 Saag, KG. 49, 54, 64, 302, 498, 820, 842, 844, 919, 1422, 2268, 2388, 2471 Saas, P , 2849 Saavedra, MA Saavedra, MA Saavedra, MA Sabapathy, A Sabbadini, MG , 2202 Sabbatini, ARM Sabelli, M Sabnis, S Saccardo, F Sacchetti, C Sacchi, A Sackeyfio, A Sacksen, IA Sacnum, M Sacnun, MP , 1438, 2381 Sacre, K , 1925 Sada, KE... 31, 82, 85, 678 Sadatsafavi, M...116, 1770, 2118 Sadlonova, M Saegusa, J , 2910 Saeki, T Saeki, Y Saevarsdottir, S. 352, 358, 367, 376, 501, 510, 1596, 2018, 2524, 2890, 2966 Saevarsdottir*, S Saez, L Program Book Saferding, V...27, 2358, 2907 Safford, M , 2388 Sagalovskiy, I Sagar, H Sagara, Y Sagawa, A Saggar, R Saggar, R Sagliani, J Sahhar, J , 1705 Sahin, A Sahin, K , 2761 Sahin, S Sahinkaya, Y Sahl, S Sahni, S Sahu, R , 2869 Said Nahal, R , 1137 Saigusa, R...756, 1724, 3003 Saiki, O , 1533 Sailler, L Sainz de la Maza, M Saito, K...805, 1541, 2806 Saito, K Saito, M , 1885 Saito, M Saito, R Saito, S Saito, S...470, 1398, 2479 Saito, T Saito, T Saitta, A Sajuthi, S Sakai, R Sakai, Y Sakamoto, K Sakamoto, N Sakatsume, M Sakellariou, G , 2403 Sakellariou, G Saketkoo, LA...727, 1246, 1256, 1678, 1931, 2699, 2707, 2716 Sala-Icardo, L , 1788, 2412 Salama, AD , 1860 Salama, S Salas, A...406, 1388, 1438, 2381 Salas, AP , 2670 Salas-Heredia, E. 1519, 1531, 2423 Salazar, G , 754 Salcedo, M , 2441 Saldarriaga Rivera, LM Sale, J Sale, MM Saleh, L Saliba, L Salinas-Encinas, D Salli, A Salmon, J... 18, 1072 Salmon, JE.. 872, 1647, 1877, 2840 Salt, EG Saltarelli, M Salts, S Salvador, G Salvarani, C...776, 777, 785, 790, 791, 798, 880, 882, 885, 2228, 2417, 2757, 2766 Salvatierra, G , 1438, 2381 Salvi, E Salzberger, W Sambataro, D.531, 879, 1675, 1689 Sambataro, G , 1689 Sammour, M Sampaio-Barros, PD...957, 2304, 2702 Sampalis, JS...248, 265, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1109, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Sampedro, J Samson, M , 2849 Samuels, J...81, 1224, 2246 Sánchez, A Sanchez, MD...74 Sanchez Andrade, MA Sánchez Atrio, A , 2622 Sánchez Bursón, J Sr Sánchez Costa, J Sanchez Riera, L...53 Sanchez-Alonso, F Sánchez-Andrade, A Sánchez-Barrioluengo, M Sánchez-Guerrero, J.. 3, 961, 2533, 2639, 2646 Sanchez-Mateos, P , 2175 Sánchez-Menéndez, M Sanchez-Nuñez, AL Sandbach, S , 2821 Sandberg, M Sandberg, MEC Sander, DO , 153 Sanders, T , 2898 Sandhu, A Sandikci, SC Sandler, DS , 1347 Sandling, JK Sandoval Rios, M sang Yeob, L Sanges, S , 1792, 2701 Sanghi, D III Sangle, S , 1237 Sanint, J SanJose, B Sanmarti, R...134, 445, 469, 1973, 2478, 2508, 2511, 2926 Sanna, G Sansinanea, P , 2670 Santacatterina, M Santana, M Santaniello, A. 747, 753, 777, 1203, 1675 Santarelli, C Santiago, L Santimaria, R Santini, E Santora, A , 2268 Santos, L Santos, MJ , 2428 Santos-Gómez, M. 814, 1240, 1249, 1250, 1251, 1252, 1791, 2775, 2776, 2853 Santos-Ramirez, C.1519, 1531, 2423 Santos-Soler, G , 1531, 2423 Sanz, J Saporiti, G Saracbasi, E , 2940 Sarano, J Saraux, A Saraux, A , 520, 1186, 1187, 1368, 1894, 2161, 2536, 2606 Sari, I.601, 1230, 1584, 2562, 2595, 2611, 2616 Sarin, R Saritaş, F Sarkar, S Sarmiento, A Sarsour, K Saruhan-Direskeneli, G Sarver, C Sarzi-Puttini, P , 2443 Sarzi-Puttini, P...397, 1543, 2433, 2512, 2514, 2550, 2976 Sasaki, A Sasho, T , 1885 Sassano, MF Sasso, EH.364, 367, 376, 2615, 2973 Sasu, M Sato, EI , 1898 Sato, E , 495 Sato, H...232, 233, 1460, 2259 Sato, K...39 Sato, M Sato, S.86, 748, 749, 752, 756, 966, 1724, 3003 Sato, S , 1259, 1266 Sato, S Sato, T , 1765 Sato, T Satoh, M Satoh, T Satorius, C , 2852 Satumtira, N , 620 Satyanarayana, C Sauer, B , 1540 Saul, M , 1410 Saunders, KC...418, 1537, 2813 Saura, C Saurit, V , 2040 Sautet, A Sauvageau, D. 396, 502, 567, 1535, 1536, 2569

335 Savasta, C Savel, C Saverno, K Savey, L Savjani, M Savolainen, E Saw, WY , 2954 Sawada, T Sawalha, AH... 77, 881, 1002 Sawitzke, A Sawyer, L , 2501 Saxena, A...3, 534, 1605, 1829 Saxne, T Sayani, A Sayarlioglu, M , 2270, 2523, 2616, 2750 Sayegh, F Saygin, C , 2754 Sayles, H...167, 348, 840, 1067, 1470, 1475, 2014, 2456 Sayre, EC.. 915, 1770, 1865, 2112, 2306, 2308, 2932 Sbreglia, C Scaglioni, V. 792, 1388, 1783, 2381 Scaini, P Scanu, A Scarabelli, M , 2403 Scarafia, S , 2715 Scaramuzzino, S Scarcia, M Scardapane, A Scarpato, S Scarsi, M Scavone, J , 1108, 2080 Schabbauer, G Schabert, VF Schaeverbeke, T Schaeverbeke, T.. 165, 1140, 1736 Schafer, P Schafer, PH , 2689 Schaier, M Schall, TJ Schanberg, L , 1313, 2292, 2293, 2294 Schaper, F Scharbatke, EC , 2915 Scharmga, A , 2143 Scharping, N Schau, T Schauer, P Schaufelberger, C Scheel-Toellner, D. 389, 2183, 2874 Scheet, P Scheffer, H Scheinberg, MA Scheinecker, C Scheines, E Schelbergen, R , 2952 Schelbergen, RF Schenfeld, J Scher, JU , 1605 Scherer, P Scherer, S Schett, G.. 940, 1184, 1892, 2130, 2233 Schett, GA. 548, 1192, 1561, 1564, 1565, 1579, 1590, 2589 Scheuern, A , 312 Schiappapietra, B Schiel, A Schiff, M Schiff, MH Schiff, MH Schikler, K Schikler, KN , 2903 Schiopu, E.. 745, 1927, 1962, 3006 Schiødt, M Schlefman, A Schleich, DC , 1177 Schleinitz, N Schlereth, B Schlesinger, L Schlesinger, N...159, 160, 1686 Schlichting, DE...488, 1483, 2822 Schlichting, U Schmajuk, G.112, 1084, 1856, 2048, 2049, 2123, 2124 Schmalzing, M...996, 1560, 2915 Schmeling, H , 2275 Schmid, A Schmidt, MFG Schmidt, T Schmidt, TJ , 2308 Schmidt, WA...795, 796, 885, 909 Schmitz-Bortz, E , 2940 Schmunk, G Schneck, L Schneeberger, E , 2575 Schneeberger, EE Schneeweiss, S Schneider, F Schneider, M. 357, 491, 701, 1057, 1078, 1189, 2233 Schneider, PDM...130, 153, 1173, 1177, 1730 Schneider, R.319, 1988, 2292, 2300 Schnitzer, TJ , 925 Schoenfeld, S Schoindre, Y , 2757, 2779 Scholey, J Schollmeier, K Scholtes, V Scholtz, J Scholz, B Scholz, J Schouffoer, AA Schouffoer, AA , 2138 Schouffoer, A Schramm, C Schreiber, K Schreiber, S Schreiter, J Schroeder, E Schroeder, HW Jr Schroeder, J Schroeder, LL , 1830 Schröder, A Schueller-Weidekamm, C Schuldt, D Schulert, G , 1901 Schulman, E Schulman, K Schulman, S Schulte, M Schulte-Pelkum, J Schulz-Knappe, P , 1730 Schulze-Koops, H Schulze-Koops, H..131, 497, 1131, 2845, 2913 Schumacher, HR Jr , 250, 826 Schumacher, R Schwab, P Schwarting, A Schwartz, AV Schwartz, A...858, 1499, 2839 Schwartz, N Schwartz, N Schwartz, S Schwartz, T , 2941 Schwartz, TA Schwartzman, S Schwarz, C Schwarz, EM. 325, 934, 2353, 2794 Schwarz, T Schwarz, UI Schwarzecker, B , 650 Schwill, U Schüttrumpf, J Schönau, V Sciascia, S... 14, 1627 Scioscia, C , 2399 Scirè, CA , 1256 Scofield, RH.985, 1798, 2535, 2542, 2543, 2930, 2978 Scolnik, M , 1783 Sconfienza, L Scott, B Scott, BB Scott, C Scott, DL , 2974 Scott, FI , 1839 Scott, FI IV Scott, JR Scott, JL , 1213 Scott, S , 2665, 2666 Scrivo, R...58 Scuccimarri, R , 2289 Scully, M Sebastiani, M Sébastien, J Secco, A , 406, 1388, 1438, 2381, 2625, 2715 Sedhom, M Sedky Abdou, M Sedlis, SP Sedova, L , 2422 Seeger, JD...46 Seeliger, B Seelmann, D Segal, BM.. 745, 2535, 2543, 2978 Segal, NA...200, 207, 1083, 1276 Segarra-Linares, SL Segelmark, M Segurado, O , 2973 Seguro, L Seguro, LPC Sehgal, N Sehnert, B Sehra, S Sehra, ST Seibold, JR Seishima, M , 1259 Sejer Hansen, M Sekhon, S Seki, S Sekicki, V Sekine, H Sekine, H Sekiyama, J , 2712 Seldin, MF Selga, D Seligman, V Sellam, J , 1275, 2928 Sellas-Fernandez, A , 2853 Selmi, C Selva, D , 1756 Selva O Callaghan, A Semanik, P , 2946 Semanik, PA... 68, 1800 Semb, AG. 489, 1274, 1440, 1913, 2561, 2571 Semenova, O Semerano, L Semeraro, A Senabre-Gallego, JM , 1531, 2423 Sène, D...8, 520, 521, 835, 2757 Senécal, JL Senel, K Senel, S Şenel, S Sengupta, R Şeniz, BN ŠEnolt, L Senolt, L.. 136, 1039, 1128, 2085, 2371, 2450 Seo, P.. 801, 804, 808, 880, 1754, 1766, 1861, 2851 Seo, Y Sequeira, W , 716, 717 Serada, S abstract author Index 2014 Program Book 333

336 abstract author Index 334 Serafim, AS , 909 Serafin, DS , 2878 Sergeant, J Seriolo, B , 1966 Sermon, J Sernissi, F.. 527, 1772, 2931, 2981 Seror, R , 2549 Serrallonga, M Servettaz, A Seshan, SV Sesseng, S Seta, N Sethi, M Seto, Y Setoguchi, K...87 Setoguchi, S Sève, P Sever, F Sevilla, R , 997 Sevilla Pérez, B , 1788 Sewerin, DP. 130, 153, 1173, 1177 Seyahi, E. 1232, 2043, 2749, 2751, 2752, 2759, 2760, 2852 Seymour, M Sezen, M Sfikakis, PP.1443, 1462, 1612, 2617, 2709 Shaddick, G , 2830 Shadick, N , 2103 Shadick, NA , 1369, 1370, 1408, 2889, 2973 Shafaie, N , 928 Shafi, L Shah, A , 1507 Shah, A , 1151 Shah, AA...741, 745, 1677, 1927 Shah, A Shah, B Shah, H Shah, K Shah, K , 1579 Shah, M Shah, N , 1540 Shah, SJ , 1929 Shah, SN Shah, U , 1854 Shahbazian, A Shaheen, M Shahidul Makki, M Shahrara, S , 2799 Shai, I Shaik, IH Shaikh, S Shaikh, S...956, 1550, 1601 Shakil, H Shakoor, N , 2245 Shakoory, B Shalev, V Shallom, G Program Book Shamilov, R , 1512 Shanahan, EM Shanahan, E Shang, Q , 1582 Shanmugam, VK Shao, X...524, 2446, 2466 Shapiro, LS.1694, 2195, 2196, 2197, 2444, 2716 Shapiro, M Sharma, A Sharma, A Sharma, A Sharma, L...211, 214, 215, 2944 Sharma, S Sharma, S Sharma, S Sharma, T , 1830 Sharma, TS...941, 1394, 2322 Shaughnessy, L Shaw, A Shaw, AT Shaw, JE , 1278 Shaw, M Shaw, Y Shaweesh, Y Shawi, M...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2496, 2518 Shay, K , 2826 Shay-Aharoni, H Sheaff, M , 1663, 1671 Shealy, D Sheane, BJ...690, 1858, 2935 Sheen, DH Sheen, DH , 2684 Shehwaro, N Shen, B , 1229 Shen, H , 1850 Shen, J , 1582 Shen, L , 2541, 2546 Shen, M , 1229 Shen, N...310, 1202, 1615, 2850 Sheng, F Shenoi, S , 2903 Shenstone, B Sheriff, M.248, 365, 943, 956, 1397, 1550, 2411, 2416, 2496 Sherrer, Y.. 370, 1375, 2378, 2413 Sherry, DD , 262, 281 Sherwood, J Shesternya, P Sheth, H , 1348 Sheth, K , 1082 Sheth, T Shetty, A Shetty, N Shetuni, B Sheu, JH Sheu, TR...25 Shewade, A , 515, 518 Shewchuk, R , 1672 Shi, B , 2167 Shi, J Shi, K Shi, L , 2177 Shi, L Shi, L Shi, R Shi, XA Shi-Wen, X Shiao, R Shiau, AL , 2344 Shiba, H Shibanuma, N Shibasaki, Y Shibata, A Shiboski, CH Shiboski, S Shida, H...2, 5, 1179, 1628, 2638 Shidara, K Shields, AM Shields, KJ Shiels, P , 757 Shiff, NJ...61 Shigematsu, K , 1533 Shikano, K...232, 233, 1460, 2259 Shim, SC.. 612, 1056, 1458, 1508, 1509, 2684, 2922 Shima, Y Shimada, K...86, 87, 1762, 1773, 2457 Shimamura, S...2, 5, 1179, 1628, 2638 Shimbova, KM Shimizu, H Shimizu, M Shimizu, Y Shimizu, Y. 2, 5, 1179, 1628, 2638, 2677 Shimojo, N Shimonov, R SHIN, JH Shin, KC Shindo, E...232, 233, 1460, 2259 Shinjo, SK. 2212, 2220, 2221, 2225 Shintani, A Shiozawa, A...117, 1155, 2114 Shiozawa, K , 2925 Shiozawa, S , 2925 Shipley, JA Shipley, M Shir, Y...264, 265, 1109 Shirai, T Shirai, Y...746, 762, 3002 Shiraiwa, H Shiraiwa, H , 1906 Shirota, Y Shiwen, X , 1721 Shlomchik, M Shmerling, RH Sho, N Shock, A. 1942, 1943, 1944, 1945, 2873 Shoda, H , 1454 Shoda, N Shoda, T Shoenfeld, Y Shojania, K , 2884 Shojania, K , 1865, 2932 Shoji, T Sholter, D. 248, 365, 379, 383, 583, 2411, 2518 Short, L Shott, S , 2058, 2073 Shpigelman, A Shrader, J Shrestha, A , 2252 Shrestha, P Shu, GL Shu, J Shudo, K Shufflebotham, J Shukla, A , 2603 Shums, Z Shupak, R Siaton, B Sibbitt, W Jr , 2789 Sibilia, J , 811, 1140, 1681, 1707, 2204, 2536, 2757, 2928 Sibley, CH (SICCA), SSCCA Siddiqui, I Siderovski, DP , 2878 Sidiropoulos, P...298, 1401, 2645 Sieber, J , 2693 Siebuhr, AS...368, 541, 629, 1293 Siegel, DL Siegel, J , 2999 Siegel, R Siegel, S... 57, 1589 Siegert, E...735, 1712, 2837 Siegwald, E Sieni, E Sieper, J Sieper, J.. 536, 538, 544, 553, 562, 616, 819, 852, 1545, 2581, 2589, 2592, 2593, 2618, 2983 Sifuentes Giraldo, A Signorini, V Signorovitch, J , 1555 Siguenza, P Sikara, M Sikes, D Sikora, K Sikora, KA...83 Silacci, M

337 Silva, CA , 1300, 2151, 2809 Silva, CA , 2320 Silva, CAA Silva, DR Silva, KF Silva, MF Silva, MG Silva, T Silva Fernández, L , 2622 Silva-Fernandez, L Silver, R , 3002 Silver, RM , 763 Silverfield, J Silverman, E...933, 2300, 2619 Silverman, ED , 1310, 1312, 1827 Silverman, GJ...387, 448, 1328 Silverman, MH Silverman, SL , 2076 Sim, JH Simard, J Simard, JF...846, 1072, 1877 Simeón, CP Simeon, CP Siminovitch, KA Simmons, K Simms, RW. 745, 2702, 2713, 2721 Simon, A , 2279, 2280, 2282 Simon, D , 1892, 2130 Simon, J Simon, T... 97, 1840 Simon, T Simon Campos, JA Simonini, G Simonneau, G Simonsen, O Simos, P Sims, R Sindel, D Singer, NG , 1304, 1826 Singh, A Singh, AG , 2642 Singh, A IV Singh, A , 2879 Singh, F Singh, J. 47, 64, 118, 188, 192, 820, 842, 962, 1051, 1660, 2125, 2388 Singh, JA. 170, 189, 190, 191, 195, 196, 199, 1668, 1672, 1802 Singh, JA Singh, N , 2189 Singh, R... 91, 767 Singh, RR.642, 659, 972, 2164, 2848 Singh, S...793, 796, 909, 1761 Singh, S Singh, S...89 Singhal, A Singla, S Sinibaldi, D Sinicato, NA , 1636, 2659, 2660, 2661, 2662, 2663, 2720 Sinigaglia, L Sippl, N Sirajuddin, A Siricilla, M Siskind, L Sisol, K , 2422 Sitbon, O Siu, T Sivera, F... 99, 829 Sivils, KL.. 985, 2430, 2535, 2543, 2930, 2978 Sjöwall, C Skapenko, A , 2845 Skarpengland, T Skarstein, K Skaug, L Skelton, A Skeoch, S , 1464 Skinner-Taylor, C Skriner, K , 2530 Skrumsager, B Skwarek, M Slatkowsky-Christensen, B Sleeman, MA , 2821 Sleglova, O.. 129, 136, 1098, 2422 Sleptsova, T (SLICC), SLICC...865, 2631, 2791 Slight-Webb, S , 2688 Slobodin, G Slocum, C Sloetjes, A Sloetjes, AW...20 Slomian, J Sluka, K Smail, A , 1925 Small, A , 1099, 1112, 2075 Small, BJ , 2058, 2073 Small, BJ Smallwood, C Smargiassi, A Smearman, J Smecuol, E Smerud, KT Smethurst, R , 2370 Smikle, M...6 Smith, CD Smith, CK Smith, D...95 Smith, D Smith, J Smith, K Smith, M Smith, MD Smith, M Smith, R Smith, S Smith, S Smith, S , 2694 Smith, V...737, 1928, 1991 Smith, W...49, 1546, 1849 Smithson, GM Smits, N , 261 Smoktunowicz, N Smolen, J , 650, 906, 1022, 1389, 2029 Smolen, JS...27, 58, 1054, 1131, 1407, 1847, 2358, 2387, 2475, 2495, 2498, 2517, 2907 Smolik, I Smrcka, A Smrzova, A Smulders, YM Smyth, G Snapir, A Snapir, D Snipes, K Snyder, KR...16 So, A So, A...157, 159, 1197 So, AK Sr Soare, A Soares de Souza, S Sobanski, V , 1718, 2700 Sobel, ES Sode, J Sofat, N Sohn, DH Sohn, J Sohn, MW Sohng, KY Soininen, P Sokka, T , 2812, 2911 Sokka-Isler, T Sokol, R Sokolove, J.348, 451, 452, 815, 840, 1470, 1476, 2019, 2456 Solaiman, M Solak, O Solans, R , 777, 880 Solar-Cafaggi, D Solau-Gervais, E Soldal, DM Soldano, S , 1966 Soler, V Soler Palacios, B Solini, A Solis-Vallejo, E Solmaz, D.. 603, 1584, 2611, 2616 Solomon, DH , 898 Solomon, DH , 2511 Solomon, DH...46, 178, 254, 818, 980, 1075, 1080, 1434, 1842, 2036, 2122 Solomon, D...96, 1809, 1911 Soloski, MJ Solotkin, K Solow, EB , 1342 Soltesz, E... 88, 987 Solus, JF , 1630, 1902 Solyman, J Soma, K , 1181 Sommerfleck, FA Son, CN...570, 1241, 2158 Son, HJ Son, MB Song, GG Song, IH , 1545 Song, JJ Song, J...68, 1800, 2944, 2946 Song, JS , 1217 Song, J Song, L Song, M...539, 1554, 1556, 1559 Song, P Song, P , 1752 Song, ST...612, 1458, 2684, 2922 Song, YW.. 166, 1220, 2215, 2347 Soni, R , 1082 Sonmez, C Sonsuz, A Sontheimer, C , 861 Sood, A Sopeña, B Sorensen, IJ Soriano, E. 1438, 2040, 2072, 2987 Soriano, ER...410, 792, 959, 1388, 1585, 1783, 2381, 2402 Soto-Hermida, A. 1121, 1122, 1125 Soubrier, M. 351, 564, 1413, 1418, 1428, 1448 Souda, P...91 Souers, A , 2839 Souliotis, V Soussan, M Southwood, TR.271, 272, 286, 1982 Souza, B Souza, R Souza II, D Sozeri, B Spaggiari, L Spainhour, JC Spalding, DM Spannow, AH Spargo, L Sparks, C , 1062 Sparks, JA...55, 818, 1876, 2008, 2017, 2887 Sparsa, A Spatz, M Specker, C Specks, U.. 804, 808, 1754, 1766, 1861, 2851 Spector, TD Spek, PJVD Spelling, NW abstract author Index 2014 Program Book 335

338 abstract author Index 336 Spellmeyer, D Spencer, CH , 2272 Spencer, D Spencer, H , 2390 Spencer, J Spencer-Green, G Spengler, J Spiegel, LR Spieler, W , 1528, 2233 Spiera, RF.. 781, 878, 1691, 1754, 1766, 1927, 1991 Spijkervet, FKL Spindler, AJ Spindler, W Spindler, WJ Spira, A Spitz, R Spoorenberg, A Spotswood, H Sprachman, M Sprafka, M Spreafico, R Sprecher, M Springer, J Springorum, HR Spruill, IJ Späth, T , 1965, 1974 Späthling-Mestekemper, S Squadrito, F Sreih, AG , 1861 Srinivas, A Srinivasalu, H Srinivasan, M Srivastava, P Srivastava, R II Srivastava, R St. Clair, W St. Claire, EW Stach, C...544, 565, 566, 1945 Staelens, F Staes, C Stagnaro, C , 2755 Stahl, E Stahl, EA , 1219, 2958, 2960 Stamm, TA Stamm, TA...58 Stamp, LK...168, 173, 828, 1214, 1757, 1758, 2377, 2959, 2962, 2964 Stancati, A , 175 Stancati, A Stanczyk, J Stanevicha, V , 282 Stanford, SM , 2871 Stange, R Stangl, H Stanley, R Starck-Schwertz, S Starnes, C Program Book Starr, AJ...672, 1307, 2269 Starr, M. 265, 365, 382, 956, 2411, 2496, 2518 Statnikov, A...81 Staud, R , 251, 897 Stauffer, P , 1756, 1919 Stavrakis, S Stawiarz, L , 510 Ste-Marie, PA...264, 265, 1109 Stebbings, S Stebbins, C Steele, E , 1756 Steele, R Steen, S Steen, VD...734, 745, 836, 1677, 1678, 1927, 1931, 2698, 2707, 2999 Steen Krogh, N Steenbeek, R Steengaard-Petersen, K. 409, 2737 Steenwijk, EC Steer, S Steere, AC...983, 984, 1402, 1970 Stefanik, J , 1083 Steffensen, R Stegeman, CA , 2733 Stehlik, C Stehman-Breen, C Stein, CM...843, 1437, 1902 Stein, CM , 1630 Steiner, CW , 650 Steiner, G Steinmetz, J Steinsson, K , 2646 Stel, A Stelekati, E Stengaard-Pedersen, K.. 349, 366, 1200, 1964, 2171 Stensballe, A...80 Stenzel, W. 1037, 1262, 1263, 1270 Stephanou, A Stephenson, J Sterba, G Sr Sterba, Y Sterpka, J...1, 856 Steuer, A Steultjens, M , 3018 Steup-Beekman, GM Stevens, A , 2738 Stevens, AM Stevens, JA...72 Stevens, RM , 602, 1543, 1561, 1564, 1565, 1572, 1579, 1590, 2854 Stevens, W.. 720, 723, 1682, 1705 Stevens-Lapsley, J Stevenson, K Stevenson, M Stewart, C Stewart, KG Stewart, P Sticherling, M , 1892, 2130 Stifano, G , 2702 Stigliano, E Stijnen, T Stiller, JL Stillman, M , 2856 Stine, KC Stinson, WA Stirnemann, J Stitah, S Stocco, A Stock, A...651, 664, 1941 Stock, T Stoel, BC Stoffels, M Stohl, W Stoica, V Stoilov, RM Stojkovic, T Stok, K Stolfa, J Stoll, ML Stoll, T , 2646 Stolshek, BS Stolwijk, C...574, 578, 2600, 2828 Stomp, W Stone, D Stone, DU , 2543 Stone, DU , 2930, 2978 Stone, JH.. 802, 1754, 1766, 2804, 2805 Stone, M Storgard, C Storti, K Stoustrup, P Stout, K Strand, V Strand, V...458, 2487, 2489 Strand, V...243, 249, 378, 418, 550, 1077, 1522, 1555, 1565, 1597, 2240, 2475, 2813, 2834 Strangfeld, A...491, 1837, 1838 Stratton, RJ , 1721 Straub, R , 998, 1010, 1029, 1959, 1965, 1974, 2349 Straus, WL Strauss, H Strauss, J Strazza, M Street, R Strehl, C Strek, M Stremnitzer, C , 1512 Stringer, E Strippoli, R Strle, K Strnad, D Strober, B Strobova, K Strom, BL Struemper, H Strusberg, I Strutton, G Stryker, D Stuart, PE Stuckey, D , 2863 Studenic, P , 1407 study Group, TA , 905 Study group, TA , 846 Stummvoll, GH , 650 Sturfelt, G Sturfelt, GK Sturgess, A Sturm, MS Sturrock, RD... 41, 563 Stüdemann, K Su, AI , 1885 Su, E Su, F Su, JH Su, K , 1953, 2782 Su, L Su, L , 2646 Su, L Su, W Su, Y , 1731 Suárez, A Suarez-Almazor, ME...17, 111, 427, 970, 1069, 1070, 1676, 2005, 2009, 2013, 2244, 2420, 2895 Suarez-Farinas, M Suarez-Fueyo, A Subedi, A Subesinghe, S Subra, JF Subramanian, V Suchy, D Suda, A...87 Suda, M Suda, T , 1259 Sudano, D Sudini, K Suematsu, E...87 Suemori, K , 2170 Suen, SW Sugai, S Sugano, T Sugawara, E... 2, 2638 Sugaya, M Sugg, E Sugii, S...86, 87, 1762, 1773 Sugimoto, N Sugimoto, T Sugiura, H Sugiyama, E Sugiyama, K , 1906

339 Sugiyama, K Sugiyama, Y , 133 Sugiyama M.D., Ph.D, N Suh, CH , 1509, 1613 Suh, YS , 2356 Sukhdeo, S , 1827 Suksaranjit, P...726, 799, 2531 Suliman, Y Sulli, A.737, 1697, 1700, 1713, 1966 Sullivan, B Sullivan, C Sullivan, KE Sumida, H Sumida, T...82, 85, 86, 87, 2346, 2352, 2467 Sumitomo, S Sun, GH Sun, G , 1289 Sun, H Sun, L.. 635, 654, 960, 2343, 2678 Sun, M Sun, X , 2747 Sun, X , 2844 Sun, Y Sun, YC Sun, Y Sunbul, M Sundel, RP Sundman-Engberg, B Sung, C Sung, IH Sung, PJ Sung, S Sung, YK , 1805, 2025, 2158 Sung Won, L Sunkureddi, P , 175 Supp, G , 1389 Suppiah, R Suresh, L , 2541, 2546 Suri, D Susic, G , 282 Suta, M , 1526, 1538, 2497 Suter, L Sutton, C Sutton, E Suyama, Y , 2727 Suzuki, E Suzuki, K , 986, 1040, 1238, 1398, 1469, 1958, 2479, 2977 Suzuki, M Suzuki, T...429, 2389, 2651 Sveaas, SH Svendsen, A Svenson, LW Svensson, F Svensson, L... 88, 987, 2786 Svensson, M Svenungsson, E , 1877 Svircev, J , 2106 Swaim, B Swales, C... 38, 1446 Swart, JF Swarup, I Swearingen, C...370, 1375, 1580, 2378, 2413, 2528 Swearingen, CJ Swedler, W , 1702, 2799 Sweezie, R Sweiss, NJ , 2799 Swiatnicki, K Swift, S Swigris, JJ Swindell, W Sy, A Sy, T Sylvestre, MP Symmons, DP , 1909 Symmons, DP , 1542, 1848, 2392 Syngle, A , 3009 Syrbe, U Szűcs, G Szabo, D Szabo, E Szczerba, B Szczygiel Cunha, J Szentpetery, A , 2614 Szklo, M Sznajd, J , 1761 Szodoray, P Szombati, I Sztajnbok, F Szulc, P...62, 63 Szumski, A.. 855, 1558, 1893, 2577 Szumski, A , 1847, 2498 Sørensen, GL , 629 T Taams, LS Tabara, Y Tacang, A Tachmazidou, I Tacla, M Tada, K Tada, Y Taddeo, A Taddio, A Tager, AM Tagliaferri, E Tagoe, C , 2252 Tahanan, A Tahara, K Tahara, M Tahir, N Tak, P Tak, PP...392, 1198, 1513 Tak, PP , 2816 Tak, PP , 2463 Tak, P Takagi, K Takagi, K...232, 233, 1460 Takagi, N , 2467 Takagishi, K , 2133 Takahashi, H Takahashi, H Takahashi, M Takahashi, M Takahashi, N..471, 512, 516, 1488, 1489, 2504, 2516 Takahashi, R , 2128 Takahashi, R Takahashi, S Takahashi, T...748, 749, 752, 756, 1724, 3003 Takahashi, Y Takai, C Takasaki, Y.. 87, 1746, 1907, 2728 Takayama, L.. 50, 51, 52, 73, 1824 Takayama, M , 2762 Takeda, A , 2727 Takehara, K...86, 1258, 1259 Takei, H Takei, M...355, 1688, 1906, 2340 Takei, S...143, 1868, 2274 Takemoto, T Takemura, M Takenaka, S , 424 Takeno, M...123, 125, 2763 Takeshita, M Takeuchi, M Takeuchi, T Takeuchi, T...470, 746, 986, 1040, 1175, 1238, 1257, 1398, 1469, 1890, 1958, 2427, 2467, 2472, 2473, 2479, 2521, 2692, 2877, 2977 Takezaki, T , 2274 Takiguchi, M , 2977 Takihara, T , 769 Talaei, N Talarico, R. 2201, 2217, 2656, 2755 Talathi, S Talbert, J Talotta, R Talpin, A Tam, A Tam, LS , 1582 Tamai, M...429, 2389, 2651 Tamaki, H Tamaki, M Tamaki, Z...756, 965, 3005 Tamayo, M Tambiah, J Tamborrini, G Tambralli, A Tamirou, F Tamura, M Tamura, N , 1907, 2728 Tamura, N Tamura, Y Tan, BK Tan, CD Tan, FK , 751, 765 Tan, JHT , 1309 Tan, L Tan, P Tan, PK Tan, W , 2095 Tan-Koi, WC Tanaka, A Tanaka, C , 2925 Tanaka, E , 495 Tanaka, K Tanaka, K Tanaka, K Tanaka, L , 2844 Tanaka, N...232, 233, 1460, 2259 Tanaka, S...414, 1454, 2260 Tanaka, S Tanaka, T Tanaka, Y Tanaka, Y , 2925 Tanaka, Y. 1483, 1541, 1890, 2427, 2447, 2467, 2472, 2691, 2806 Tanaka, Y , 2346 Tandon, M , 530 Tandre, K Tanemoto, K Tang, D , 1540 Tang, F Tang, H Tang, J...48 Tang, MW , 1198 Tang, Q Tang, T Tang, WW Tang, X Tang, X , 2449 Tang, X Sr....66, 1087, 1803, 2050 Tani, C , 2656 Tani, C Taniguchi, A...223, 226, 430, 495, 1061, 1123 Taniguchi, T Taniguchi, T...748, 749, 752, 756, 1724, 3003 Tanino, M Tanner, S Tansey, M TAO, K TAO, Q Tao, S Taoufik, Y abstract author Index Tap, J Program Book 337

340 abstract author Index 338 Tapp, RJ Taraborelli, M...18 Taran, A Tarcha, EJ Targoff, I Targoff, IN , 2210 Tarhan, EF Tarn, J , 2982 Taroni, J Tarp, S Tarp, U Tarrant, TK , 2878 Tarriela, M Tas, SW , 2802 Tasaki, Y Tascilar, EK Tascilar, K , 2754 Tashkin, D , 2995 Tasse, J Tasset, C , 1481 Tatangelo, M Tatar, Z Tatebe, N Tateishi, K Tatibouet, S Tattersall, R Taufiq, F Tauro, L Taurog, JD , 620 Tausche, AK Tavano, A Tavares, R , 1424 Tavoni, A , 2755, 2855 Taxter, A Tay, T Taylor, A...57, 1546, 1589, 1849 Taylor, A Taylor, C , 2147 Taylor, J Taylor, J Taylor, J Taylor, J , 880 Taylor, JJ Taylor, K Taylor, KE...520, 525, 2841, 2955 Taylor, L Taylor, PC...488, 1446, 2822 Taylor, V , 2863 Taylor, W...162, 826, 2573 Tchao, N , 1766 Tchetverikov, I...139, 1571, 1583, 2815 Tchetverikov, I Teal, TH Tebib, J , 2928 Tedeschi, SK Tegla, C Teglbjaerg, CS Program Book Teh, LS Teh, LS , 711 Tehlirian, C Tehrani, R , 1985 Tejasvi, T Tejedor, D Tekano, J Tekin, L Tektonidou, M...958, 2617, 2868 Teku, G Teleman, A Telliez, JB Telliez, JB , 1616 Tello-Winniczuk, N ten Cate, R , 932 Tena, X Tencer, T , 1597 Teng, CC , 1540 Teng, GG , 1873 Teng, L , 1565 Tenner, C Tenner, CT Teo, YY , 2954 Teos, LY Tepper, S , 2856 ter Haar, N. 1231, 2279, 2280, 2282 ter Wee, MM Terabe, K , 2516 Teramura, T , 1885 Terao, C , 806 Terkeltaub, R , 1206, 2949 Terreri, MT , 2712 Terrier, B. 1759, 1763, 1767, 1768, 1769, 1774, 1776, 1778, 1782, 1792, 1864, 2549, 2731, 2777, 2778 Terry, K Terry, KK Terslev, L Teruya, J Terwee, C...260, 261, 3018 Terzioglu, E Tesoro-Cruz, E Testi, A Tetreault, P Tévar, MI...40 Tévar Sánchez, MI Tezcan, ME Thaci, D Thai, J Thakur, U Thanou, A...707, 866, 1605, 1921 Thava, A Thavaneswaran, A...542, 624, 630, 1568, 1576, 1587, 1592, 1593, 2605, 2607, 2935 Thawait, G the CA Investigators Group, F the CARRA investigators, F the CARRA Registry Investigators, F the Vasculitis Research Consortium, F Theander, E...519, 589, 1549 Theek, C Theiler, R Theis, JC Theis, KA... 72, 1092 Theodoridou, A Theriault, C , 2646 Therneau, TM , 1405 Thervet, E , 2549 Thévenin, F Thibodaux, R Thiel, S , 2171, 2299 Thiele, G , 1475 Thiele, GM Thiele, GM.. 348, 840, 1620, 2782 Thiele, K Thielman, N Thiolat, A Thirunavukkarasu, K Thiyagarajan, T , 2741 Thomas, D Thomas, G Thomas, H Thomas, K Thomas, LW Thomas, M Thomas, R.154, 618, 632, 950, 2460 Thombs, BD Thompson, A Thompson, B Thompson, H Thompson, K...797, 961, 2646 Thompson, LF Thompson, PR Thompson, SD Thompson, T Thomsen, H , 1188 Thomson, J Thomson, T...75 Thomson, W...272, 274, 295, 303, 1900, 2294 Thongprayoon, C..726, 799, 1253, 2531 Thorne, C Thorne, C. 365, 382, 383, 386, 421, 943, 1551 Thorne, JC...371, 394, 492, 1387, 1833, 2309, 2410 Thorp, LE , 2245 Thullen, M...25 Thunem, C , 2035 Thurlings, RM Thurman, J Thyberg, I Tian, H , 2125 Tian, SY Tidwell, B Tigen, K Tijhuis, GJ , 2054 Tikly, M Tillett, W Tilley, J , 1512 Tillmanns, S Tilson, HH Timlin, H Timman, R Timoshanko, J Timoshchenko, R , 2878 Timsit, MA Tin, D...371, 394, 1387, 2410 Tincani, A...4, 15, 18, 671, 1532, 1642, 2868 Ting, K Ting, T Tiniakou, E Tintinger, G Tiple, A Tislow, J Titcombe, P Titze, J Tiwari, H Tiwari, HK Tiziani, S Tjensvoll, AB , 2652 Tkacz, J , 1832 Tng, H To, CH To, J Tochimoto, A.877, 1264, 1710, 2991 Todd, J Toder, K Todoerti, M , 2609 Toellner, K Toenhake-Dijkstra, H , 1223 Toepfer, D Toes, REM , 2102 Toes, REM , 2392 Togo, O Toh, M Tohma, S.82, 85, 86, 87, 1842, 2457 Toib, D Toktas, H Tokuhira, M , 1398 Tokunaga, T Toldos, O Toledo Del-Rio, AP Toledo-Garcia, A. 2195, 2196, 2197, 2444 Toloza, S...681, 716, 1673 Tolstykh, I , 1820 Tolusso, B...403, 999, 1639, 1971 Tomala-Haz, J Tomasson, G Tomelleri, A

341 Tomero, E , 2622 Tomiita, M , 2541 Tomita, U Tomizza, M , 1424 Tomobe, M Tomsic, M.. 514, 788, 1524, 1789, 1790, 2041, 2524 Tongu, K Toniolo, M Tonner, C.. 112, 1084, 2048, 2109, 2123, 2124, 2405 Tony, H Tony, HP...497, 940, 996, 2915 Toole, J Toplak, N Topless, R...21, 168, 2959, 2961, 2962 Torene, R Torgutalp, M , 1432 Toribio, R Tormey, V Torner, J Torner, JC...212, 973, 1286 Tornero, J...59, 1129, 2097 Torok, KS , 1324, 1897 Torralba, KD , 716 Torralba, KMD Torras, J , 1659 Torre Salaberri, I. 1250, 1252, 2853 Torre-Alonso, JC... 59, 596 Torrealva, H Torrente, V , 2276, 2622 Torrente-Segarra, V Torres, B Torres, on behalf of the CAP study investigators, J Torres-Barrera, G Torres-López, E Torretti, D Tortosa, R...59, 1129, 2097 Torun, T Tory, HO Tosun, B Tóth, E , 175 Toth, M , 2277 Totoson, P , 2360 Totsuka, K Touma, Z...685, 2634, 2640 Toupet, K Tourkina, E Tournadre, A Tousseyn, T Toussirot, E...991, 2204, 2779 Touzard, C , 3011 Tovar, JV Townsend, AF Toyama, T.748, 749, 752, 756, 1724, 3003 Toyama, Y Toyoizumi, S Toyoshima, Y Toyota, Y Tozkir, H Trabattoni, D Trachana, M...277, 282, 298, 928 Trad, M Tran, C Tran, M Tran, P Tran, T Tran, TM , 619 Tran, V Trapiella, L Trauzeddel, R Travers, T Treadwell, E Treadwell, EL...370, 1375, 2413 Treharne, G , 2377 Trenkmann, M.92, 967, 1977, 2450, 2785 Tresadern, P Tress, J Treviño-Montes, D , 1425 Trevisani, VM Treyvaud, MO Triclin, N Triedman, NA Trinder, S , 1717, 1728 Triolo, G , 611 Trisolino, G Trojanowska, M...764, 766, 1720 Trojanowski, M Troldborg, A Tropé, S Trouillet, S Trouw, L Trouw, LA Trouw, LA...441, 454, 2392 Troxell, M Troyanov, Y Trujillo, E Trujillo, MDM Truong, D Truong, K Trupin, L.98, 420, 1084, 1856, 2049, 2109, 2405 Trzcinska-Butkiewicz, B Tsai, FN Tsai, W Tsalapaki, C , 1466 Tsang, K...28, 1732, 2796 Tsang, L Tsao, HW Tsao, PH Tse, D Tse, SM Tse, SM Tseng, CH Tsoi, LC Tsokos, GC.1033, 1725, 2675, 2677, 2682, 2734, 2846 Tsou, , 3006 Tsoukas, A Tsuboi, H Tsuboi, N Tsuchida, N , 133 Tsuchiya, N...82, 85, 86, 87, 2457 Tsuda, T Tsuji, S Tsukamoto, H , 1952 Tsukamoto, M Tsukimi, Y Tsumiyama, K , 2925 Tsuzaka, K Tsuzuki, H , 1952 Tu, K , 2309 Tu, S Tubach, F , 1385, 1837, 1838 Tubery, A Tucker, K Tucker, LB. 292, 1303, 1304, 1825, 1826, 1870, 2288 Tuckwell, K Tufan, A Tugal-tutkun, I Tugwell, P Tulio de Mello, M Tunc, R Tuncay, F Tunceli, O , 1143 Tuncer, T Turesson, C. 42, 358, 436, 501, 504, 510, 1477, 1596, 1804 Turgut Ozturk, B Turiel, M Turina, M Turina, MC , 850 Turk, S , 361, 362, 405, 408, 1903, 2400 Turkiewicz, A Turkmen, U Turner, JD Turner, R Turner, S Turpin, R Turrent, A...11 Turrión Nieves, A Tuttle, P IV Twilt, M...286, 287, 293, 2287 Tymms, K Tytus, S , 1424 Tzaribachev, N Tzaribachev, N Tzioufas, AG...478, 1980, 2100 Tzontcheva, A Tälli, S...58 Töyrä Silfverswärd, S U Ubara, Y Ubilla, B , 1788, 2203, 2452, 2459, 2461 Ucar, E Uchida, K Uchino, K , 2765, 2856 Uda, H , 1533 Udata, C Ueda, A...123, 125, 133, 805 Ueda, S Ueda, Y Ueki, N , 1952 Ueland, T Ueng, J Ueno, K Uetani, M , 2389 Ugarte, A Ugarte-Gil, MF Ugurlu, S. 1232, 1233, 2043, 2749, 2751, 2752, 2759, 2760 Uhart, M Uher, M.280, 851, 2371, 2422, 2580 Uhlig, T. 101, 356, 905, 944, 1164, 1373 Ukichi, T Ukyo, Y Ulasli, A Ulasli, M Ulmansky, R , 2350 Ulrichts, H Umar, S Umeda, M...429, 2389, 2651 Umeda, N Umehara, H Umekita, K... 92, 2159 Umemura, M Umicevic-Mirkov, M Uña, C Unal, AU Ungprasert, P...726, 799, 2531 Unizony, S...802, 1754, 1766 Unlu,Ozkan, F Unnebrink, K Uno, M Unwin, R...78 Uppuluri, RR Urbanova, M Urbanova, Z Urbanski, G Urbonaviciute, V Uriarte, E , 2622 Uribe, N Uribe Woolnough, L Urowitz, M abstract author Index 2014 Program Book 339

342 abstract author Index 340 Urowitz, MB...685, 690, 699, 865, 961, 1858, 1859, 2631, 2634, 2640, 2791 Urraro, T Urrego, C...40 Urruticoechea, A Urso, K Ursu, S Urtiaga, B Urtiaga, J Uruha, A Usategui, A...134, 660, 992, 1739, 1969 Usategui, R...74 Uslu, S Ustek, D Ustun, I Utku, U Utset, T Utset, TO Utz, PJ...878, 2688, 2737 Uyanik, MS...79 Uziel, Y Uziel, Y.277, 284, 1231, 2279, 2280, 2282, 2899 Uzunaslan, D , 2754 Uzunhan, Y V Vacca, A , 2559 Vachon-Presseau, E Vagelli, R Vaglio, A , 880 Vagnani, S , 2656 Vaillancourt, J , 1551 Vaiopoulos, AG Vakil-Gilani, K Vaknin, I Valcov, R , 158 Valdeolivas Casillas, N Valena, C Valentin, MA Valentini, G , 967 Valenzuela, A , 2996 Valenzuela, G , 2471 Valera, I Valero, JL Valesini, G Valiente, G , 2687 Valieva, S Valino-Seoane, I Valle-Oñate, R Vallejo, AN Vallet, H Valls, E Valls Pascual, E , 2853 Valter, I van t Klooster, G , Program Book van t Klooster, R van t Spijker, A van Adelsberg, J , 2824 van Aken, J Van Assche, G van Baarsen, LGM van Beijeren Bergen en Henegouwen, D Van Beneden, K van Bijnen, ST van Bon, L Van Brunt, D van Brussel, M van Busschbach, J van Caam, A , 1017, 1049, 2793 van de Laar, MA van de Loo, F...638, 1004, 2793 van de Loo, FA van de Loo, FAJ , 1816 Van De Sompel, A van de Venne, M Van De Vyver, C Van De Wiele, T van den Bemt, B , 1843 van den Berg, R , 577 van den Berg, R...540, 594, 2597, 2937 van den Berg, S van den Berg, W. 1004, 2348, 2793 van den Berg, WB van den Berg, WB...20, 76, 1017, 1036, 1733, 1734, 1816, 2948, 2950, 2952 van den Bergh, J van den Bersselaar, L , 1733, 1734 van den Bos, T , 2054 Van den Bosch, F..557, 574, 1545, 2134, 2600, 2828, 2988 van den Bosch, M van den Bosch, MH.. 20, 76, 2948 van den Broek, M van den Ende, CHM , 2860 van den Ende, E , 2249 Van den Eynde, B van den Hoek, J , 2054 van den Hoogen, FHJ.76, 500, 1843 Van Denderen, CJ van Denderen, JC Van der Aa, A van der Bijl, CMA van der Burg, L van der Esch, M van der Geest, KSM van der Heijde, D.2573, 2912, 2938 van der Heijde, DM.575, 577, 1174, 1181, 1379 van der Heijde, D...361, 540, 552, 553, 557, 565, 582, 584, 594, 905, 953, 954, 1164, 1186, 1187, 1387, 1552, 1553, 1822, 1890, 1894, 2137, 2387, 2560, 2561, 2571, 2579, 2586, 2588, 2589, 2592, 2597, 2600, 2601, 2828, 2937, 2984 van der Heijde, DM. 543, 544, 545, 562, 566, 574, 852, 2472 van der Helm- van Mil, AHM van der Helm- van Mil, AHM van der Helm-van Mil, AHM...90, 1174 van der Horst, A van der Horst, C Van der Horst - Bruinsma, IE van der Horst-Bruinsma, IE...580, 2558 van der Horst-Bruinsma, IE.572, 573 van der Kallen, J van der Kleij, D van der Kraan, P. 1004, 2348, 2793 van der Kraan,...20, 76, 1017, 1049, 1199, 2948, 2950 van der Laken, CJ , 2127 van der Laken, CJ , 2093 van der Leeden, M van der Leij, C van der Lubbe, PA van der Maas, A , 1843 van der Poll, T van der Veer, E van der Vegt, B van der Ven, M...139, 1571, 1583 van der Ven, M van der Weijden, MAC.. 580, 2558 van der Windt, D van der Zee-Neuen, A... 70, 2113 Van Deuren, R van Duivenvoorde, LM.. 620, 1916, 1973 van Erp, AE van Eyk, J van Gaalen, F , 577 van Gaalen, F...594, 2579, 2597, 2937 van Geffen, EW van Groenendael, JH van Hagen, , 2979 van Hamburg, JP , 1749 van Herwaarden, N , 1843 van Hijum, S van Hoogstraten, H , 2823 Van Hooser, A... 75, 1619 van Iersel, T van Krugten, M van Laar, JM van Leeuwen, J , 261 van Leeuwen, J van Lent, PL...20, 76, 1199, 2348, 2948, 2950, 2952 van Loosdregt, J van Marle, S Van Mater, H van Nies, JAB van Nieuwenhuijze, AEM van Nimwegen, JF van Onna, M van Oosterhout, M. 575, 577, 2138 van Pelt, PA...107, 300, 1871 Van Praet, J Van Praet, L van Riel, P , 1838, 2524 van Riel, PLCM van Rietbergen, B van Rij, AM Van Rompaey, L van Roon, JAG , 2725 Van Rossum, MAJ , 932 Van Roy, M van Royen-Kerkhof, A van Royen-Kerkhof, A. 1316, 1317, 1325 van Schaardenburg, D.. 408, 2912 van Schaardenburg, D...359, 361, 362, 405, 450, 1903, 2104 van Sijl, A van Sijl, AM van Steenbergen, HW.90, 454, 1379 van Suijlekom-Smit, LWA. 293, 300, 932 van Tok, MN , 1916 van Tubergen, A van Tubergen, AM van Tubergen, A...574, 578, 579, 2572, 2592, 2600 van Tunen, J Van Veenendaal, M van Vilsteren, M van Vollenhoven, R , 2835 van Vollenhoven, R.464, 672, 1350, 1524, 1528, 2126 van Vollenhoven, RF van Vollenhoven, RF.364, 367, 376, 500, 961, 1843, 1845, 2515, 2517, 2524, 2646 Van Voorhis, D , 1882 van Weely, SFE , 573 van Winkelhoff, AJ van Zeben, D , 2815 van Zoest, K van Zuiden, GS Vandeloo, C Vandenhende, MA Vandepapeliere, P Vanderburgh, S Vanderkooi, O Vankayalapati, H Vanstone, L Varela, CF Varela-Eirin, M

343 Varga, J Varga, J.. 725, 729, 745, 750, 965, 966, 1929, 3005 Vargas, AB Vargas, M Vargas-Guerrero, A Vargas-Hitos, J Vargas-Lebrón, C Varisco, V , 2976 Varkas, G Varley, C , 231 Varothai, NA , 1545 Vasconcelos, C Vasconcelos, O Vaseer, S Vashisht, P Vasileiou, P Vassilopoulos, D , 1466 Vastert, B. 1231, 1325, 2279, 2280, 2282 Vastert, SJ Vastesaeger, N , 2493 Vatankulu, B Vavrincova, P Vayssière, B Vayssièrre, B Vazhappilly, S Vázquez, J Vázquez on behalf of RENACER Study Group, N Vázquez Rodríguez, T , 2622 Vázquez-Mosquera, ME.1121, 1122, 1125 Veale, D , 2798, 2875 Veale, DJ...58, 109, 779, 884, 1044, 1195, 1977, 1979, 2181, 2312, 2800 Vedamurthy, D Veeramreddy, D Vega, G Vega, L Vega-Fernandez, P Vega-Morales, D.. 739, 1420, 1425, 1427, 2251, 2644 Veigl, D Vela, P...99, 814, 829, 2622 Vela Casasempere, P Velasco, T Velayudhan, J Velazco-Caspia, J Vélazquez-García, A Velez, S , 2441 Velloso Feijoo, ML Veloso, E...406, 1388, 1438, 2381 Velozo, EJ Velsko, I Vemuri, S Venables, P Venalis, P Vencovsky, J , 910, 1039, 1128, 1316, 1486, 2085, 2422, 2821, 2953 Vencovsky, MD, DSc, J , 912 Venditti, C Venkataramanan, V Venkatram, M Venn, A , 209, 229 Venning, M , 1863 Ventosa, J Venuturupalli, S Vera-Lastra, OL Verazza, S Verbeek, S Verbruggen, G , 2134 Verbruggen, N Veres, G Vergara, C Vergara, F Vergés, J Verheul, MK Verheul, MK Verheul, MK Verhoeven, F , 2360 Verma, I Vermeulen, S Vernet, N Veroz Gonzalez, R , 2190 Verrill, J Verrouil, E Verschueren, K Versnel, MA , 2979 Verstappen, G Verstappen, S... 78, 2031 Verstappen, SM , 2032 Verstappen, SM Verweij, CL Vettori, S , 967 Viallard, JF Viana, VDST Viana, VST , 2933 Vicedomini, L Vicente, E Vicente-Rabaneda, E Vickers, KC Vickery, M Vidal, C Vidal, E Vidal, M Videm, V Vieillard, V Vieira, SM...1, 856 Viger, ML Vignaux, O Vihinen, M Vij, R Vijayan, R Viklicky, O Vila, D Vila, LM...6, 681, 716, 2089 Villa, L , 1316 Villa, N Villaggio, B , 1966 Villalba, A. 605, 1603, 2400, 2513, 2522 Villalba, JM...7 Villarreal, M Villarreal-Alarcón, M Villeneuve, E..396, 502, 567, 1535, 1536, 2569 Villiger, Vina, ER Vincent, GR Vincent, S , 1500 Vinet, E , 2664, 2665, 2666 Vinter, C Viola, S Vis, M...139, 1571, 1583 Visconti, RP Vishwanath, S Visscher, J Vissing, R , 1108 Vissink, A.. 441, 2547, 2551, 2934 Viswanathan, H Vital, EM , 1178 Vitali, C...531, 879, 1675, 1689 Vitielli, P Vitolo, B , 2403 Vittecoq, O...132, 395, 521, 1517, 2923 Vittecoq, O...520, 1140, 1471 Vitters, E , 2793 Vives, F Vivino, FB , 2545 Vizjak, A Vlachoyiannopoulos, P. 1928, 1980 Vlachoyiannopoulos, PG. 478, 2709 Vlahos, B Vlamynck, E Vleugels, RA Vliet Vlieland, T , 2860 Vliet Vlieland, T Vo Hoang, V Voaklander, D Voelker, J Voelker, K Vogel, U Vogl, T...932, 1199, 2988 Vogler, LB Volin, M Volin, MV Volk, R...427, 2005, 2009, 2244 Volkmann, E , 2995 Volkov, A Volkov, S , 1702, 2799 Voll, RE , 2833 Volpi, S von Dalwigk, K von Kempis, J , 2913, 2914 von Scheven, E von Spee-Mayer, C Vonk, MC Vonortas, S Voorhees, JJ Vora, SS , 2318 Vordenbäumen, DS , 153 Vordenbäumen, S Vorup-Jensen, T Vos, P Voskuyl, AE , 2127 Voskuyl, AE...354, 753, 2093 Voss, A Voss, J Vosslamber, S Vostretsova, K Vougiouka, O , 2281 Voulgarelis, M , 2090, 2100 Voulgari, PV , 1170 Vradii, D Vree Egberts, W Vriezekolk, JE Vroman, H Vsetecka, D Vulcano, A Vuolteenaho, K Vuong, TT Vyse, S Vyse, TJ W Waagenaar, G Wada, J... 31, 678 Wada, Y...805, 1235, 1648 Wade, J Wade, S Wager, C Wagman, RB Wagman, RB Wagman, R , 2254 Wagner, C Wagner, C , 1476 Wagner, F Wagner, S Wagner-Weiner, L Wahba, K Waheeduddin, S...53 Wahezi, D , 2903 Wahl, D Wahl, ER Waimann, CA..127, 128, 406, 887, 1388, 2381, 2441 Waisberg, MG Waisman, G Wakabayashi, H abstract author Index 2014 Program Book 341

344 abstract author Index 342 Wakabayashi, K Wakasugi, K Wakazono, H Wakefield, R Wakefield, RJ...124, 137, 2772 Wakeland, E Wakiguchi, H Wakkee, M Wakura, D Walczak, H Waldron, N Wale, N , 1616, 2873 Walgreen, B , 1733, 1734 Walimbe, M Walitt, B , 1106 Walitt, BT , 893 Walker, D Walker, H Walker, M Walker, S Walker, S Walker, U , 2971 Walker, UA...833, 1524, 2699 Walkup, M Wallace, CA , 297 Wallace, CA , 289 Wallace, D...681, 716, 1079 Wallace, DJ...672, 705, 961, 1673, 2646, 2834, 2880 Wallace, D Wallace, Z , 2804, 2805 Wallenstein, G , 2487 Wallis, BB Walliser, J Walsh, D , 2810, 2965 Walsh, DNE , 2331 Walsh, J Walsh, L Walsh, NE , 2327 Walter, JE Walther, T Waltman, BA Wamhoff, B Wampler Muskardin, T Wan, J Wanat, KA Wand, H Wang, A Wang, A Wang, B Wang, B Wang, C , 1116, 1336, 1337, 2065, 2337, 2338, 2858 Wang, CR , 2344 Wang, D Wang, ECY Wang, F Wang, FS Program Book Wang, H Wang, H WANG, J Wang, J Wang, J Wang, K... 66, 1803 Wang, L , 1514 Wang, LC , 2839 Wang, L Wang, L Wang, L Wang, Q Wang, Q Wang, Q Wang, R Wang, S , 2449 Wang, S Wang, S Wang, SX Wang, T Wang, W , 2816, 2919 Wang, W , 3005 Wang, XY Wang, X WANG, X Wang, X Wang, Y , 2843, 2905 Wang, Y Wang, Y...218, 1277, 1278 Wang, Y...539, 1548, 1554 Wang, Y...327, 1013, 1206, 2949 Wang, Z Wang, Z Ward, MM...569, 588, 608, 617 Wardwell, PR Ware, C Ware, MA Waring, JF Warmington, K Warner, RL Warrell, RP Jr Warren, RB Warriner, AH...49 Warrington, KJ , 808, 880 Warters, M Wasko, MCM Wassenberg, S Wasserman, S Watanabe, A Watanabe, H Watanabe, H Watanabe, KS Watanabe, R Watanabe, S Watanabe, T Watanabe, T...2, 5, 1179, 1628, 2638, 2864 Watanabe Duffy, KN Waterton, J , 1464 Watkins, A Watson, K Watson, KD.. 467, 676, 1542, 1848 Watts, G Watts, N Watts, NB , 2268 Watts, R...775, 880, 1760 Watts, RA , 1758 Wax, SD , 2838 Weaver, F , 2106 Weaver, J...48 Weaver, LK , 2281, 2876 Webb, D Webb-Detiege, T Weber, U Webers, C Webster, A Webster, F Wechalekar, MD Wechsler, B Wedderburn, L Wedderburn, LR.. 932, 1314, 2953 Wedderburn, LR...274, 295, 1900, 2900 Weel, AEAM. 120, 139, 1571, 1583, 2815 Wei, J Wei, M Wei, N Wei, Y Weichenthal, M Weinberg, E Weinblatt, M.385, 1141, 1362, 2103 Weinblatt, M Weinblatt, M , 1370, 1485, 1486, 2821 Weinblatt, ME...479, 1335, 1408, 2889, 2973 Weiner, HL Weinshilboum, RM Weinstein, A Weisleder, N Weisman, M...705, 1287, 3013 Weisman, MH.. 446, 569, 588, 617, 681, 716, 1079, 1673, 1904, 1937, 2019, 2880, 2891, 2921, 2978 Weiss, JE , 2318 Weiss, M Weiss, P , 1895 Weiss, PF...279, 319, 2293 Weitoft, T Weitzman, D Weller-Heinemann, F Weller-Heinemann, F Welling, J Wells, A...122, 602, 1543, 1572 Wells, AU Wells, C Wells, G , 1051 Wells, GA Wen, J...651, 664, 1941 Wen, L Wen, ZH Wendler, J Wendling, D.43, 337, 473, 556, 559, 2360, 2554, 2556, 2557, 2568 Wener, MH...453, 742, 1638 Weng, CT Weng, H , 1500 Weng, H , 2493, 2938 Weng, H Were, E Wermuth, PJ...771, 774, 1722 Werner, D Werner, SG Werth, V Werth, VP , 2206 Wessel, A Westfall, A Westfall, M Westhovens, R. 260, 261, 316, 479 Westra, J , 1626 Westrich, GH Wevers-de Boer, KVC Weyand, CM , 1742 Whalen, E Whalen, E Wheeling, T Wherry, EJ Whibley, D Whiskin, C Whitaker, JW , 2816, 2919 White, CJ White, D...66, 1286, 3007 White, DK White, DH White, D White, JC White, T White, V , 1756 White, W , 1619 Whitehead, G Whitelegge, J...91 Whitfield, M...750, 772, 1723 Whitlock, KB Whittaker, M Wichers, R Wichuk, S. 855, 1893, 2577, 2613, 2986 Wichuk, S...591, 2615, 2985 Wick, J Wick, M Wicks, I Wicks, IP , 1467 Widdifield, J , 1833, 2309, 2814 Wiebert, P Wiederkehr, D...100, 1145, 2406

345 Wiemann, O Wiese, MD Wiesenhutter, C Wiest, C Wigaard, E Wigler, I , 971 Wigley, FM...728, 741, 745, 964 Wiik, A Wijarnpreecha, K Wijmenga, C Wikberg, JES Wiland, P Wilbe, M Wilder, E Wilder, T...19, 2792, 2947 Wildt, M , 761 Wiley, GB Wiley, K , 1304, 1825, 1826 Wilkerson, J , 2222 Wilkinson, B Wilkinson, B , 1181 Wilkinson, F Wilkinson, JM Wilkinson, J Willard, B , 2765 Willems, W Willemsen, L Williams, A Williams, AE Williams, AS... 30, 341 Williams, D Williams, DA , 924 Williams, F Williams, H Williams, JO Williams, K Williams, K Williams, M Williams, RO Williamson, D Willig, J Willis, L Willis, R... 6, 2650 Willis, W Willisch, A Wilner, G Wilson, AG.2798, 2817, 2875, 2924 Wilson, D , 1756 Wilson, DR Wilson, F Wilson, G Wilson, H , 3013 Wilson, K Wilson, M Wilson, M Wilson, N... 53, 2842 Wilton, K Wimalasundera, S Wimmer, M Wimmer, MA Winchester, R Windhager, R Windsor, W , 1512 Wing, L Wingrove, J Wink, F Winkelmann, SJ Winklehner, A Winkler, AR , 1616 Winkler, A Winn, D Winnier, DA Winter, E Winthrop, KL , 1546 Winthrop, KL. 57, 844, 1589, 1849 Winzenberg, T Wipf, P Wirth, JR , 1213 Wirth, W Wise, BL Wishart, N Wisniacki, N Wisniewski, SR...404, 1410, 2997 Wisseh, S Witcher, J Witcombe, D Wither, J , 2787 Wither, JE , 2742 Withers, D Withers, M witko-sarsat, V Witt, M , 2845 Wittbrodt, E Witte, D , 1304, 1826 Witte, T.. 747, 753, 776, 777, 880, 2771 Witteman, HO Wittig, B , 1560, 2915 Wittoek, R Wluka, A , 1278 Wofsy, D , 2838 Wohlfahrt, A , 1335 Wojdyla, D Wolbink, GJ Wolbink, G Wolcott, E Wolf, B Wolf, DC Wolf, J Wolfe, F.. 480, 892, 893, 896, 1106 Wolfe, J Wolfe, K Wolinsky, F...54 Wollenhaupt, J Wollenhaupt, J Wollenhaupt, J...545, 1561, 1579 Wollenhaupt, J...548, 1564, 1590 Woller, S Wolover, L Wolska, N Won, S , 2025 Wong, A Wong, B Wong, CK Wong, D. 1515, 1521, 2468, 2485, 2486 Wong, H Wong, J Wong, JB Wong, Q Wong, R Wong, R Wong, TY Wong, WK Wong-Pack, M Woo, JMP Woo, JM Woo, P Woo, YJ Wood, E , 584 Wood, R...325, 934, 2353 Wood, S Wood, SP Wood, TA , 1723 Woods, M Woods, R Woodward, J Woolf, C Wopereis, H Worthington, J...747, 753, 1884 Wouters, C...284, 316, 933, 2279, 2280, 2282 Wouters, H Wren, JD Wright, A Wright, F , 2875 Wright, J , 2862 Wright, N...54 Wright, NC...49 Wright, T , 1304, 1305, 1826 Wrightson, H Wu, A Wu, B Wu, C Wu, CL , 2344 Wu, C Wu, CC Wu, CY Wu, G Wu, G , 2454 Wu, HJ Wu, H , 1424 Wu, H , 2373 Wu, LC...911, 1204, 2686, 2687 Wu, L Wu, L Wu, M , 751, 754 Wu, PW Wu, Q , 1209, 2872 Wu, R Wu, S Wu, X WU, X...66, 1087, 1803, 2050 Wu, Y Wu, Z Wulffraat, NM...931, 2297, 2298 Wulffraat, N...107, 277, 282, 284, 1231, 1325, 2279, 2280, 2282 Wulffraat, NM Wunderler, N Wuttge, D Wyatt, J Wyatt, P Wyman, BT Wysham, KD Wållberg Jonsson, S Wållberg-Jonsson, S Wähämaa, H , 2797 Wöhner, M X Xenitidis, T Xia, Y Xia, Y Xiao, R Xibille-Friedmann, D Xie, F , 498, 820, 842, 1148, 1546, 1839, 1849, 1910, 2388 Xie, W Xie, Z Xing, J Xing, L , 2820 Xu, B Xu, D , 2224 Xu, H Xu, L Xu, P , 2813 Xu, R Xu, S Xu, S , 2566, 2567, 2601 Xu, Y Xu, Y Xu, Z , 1529 Y Yılmaz, V Yabe, Y , 2516 Yabes, J Yachie, A Yacyshyn, E abstract author Index 2014 Program Book 343

346 abstract author Index Yaffe, K Yagci, I...151, 2057, 2769 Yagoto, M Yagüe, J , 2179, 2508, 2926 Yahia, M Yahini, B Yair, S Yair-Sabag, S Yajima, N Yaksh, T Yalavarthi, S...77 Yalavarthi, S , 2867 Yalcinkaya, Y Yamada, H Yamada, H...82, 85 Yamada, H Yamada, M Yamada, S Yamada, Y Yamagata, K Yamagata, K...82, 85 Yamaguchi, KI , 2727 Yamaguchi, Y Yamaji, K , 1907 Yamakami, LYS Yamamoto, A Yamamoto, K. 457, 859, 1454, 2472 Yamamoto, M , 1235 Yamamoto, S Yamamoto, T. 232, 233, 1460, 2259 Yamamoto, Y Yaman, A Yamanaka, H Yamanaka, H...223, 226, 430, 495, 805, 877, 1123, 1255, 1264, 1640, 1710, 1890, 1939, 2427, 2465, 2467, 2472, 2991 Yamanaka, R Yamane, T , 2925 Yamano, Y Yamaoka, K , 2691, 2806 Yamasaki, H Yamasaki, M Yamasaki, M Yamasaki, S Yamasaki, Y Yamashita, M Yamashita, N , 424 Yamashita, T Yamatou, T...143, 1868, 2274 Yamauchi, M Yamazaki, H Yan, M Yan, Q Yan, X Yan, X Yan, Z Yanagida, T Yanai, R Yancey, P Yancy, WS Jr Yanez, D Yang, D Yang, GY Yang, JA...166, 1220, 1403 Yang, J Yang, J Yang, L Yang, M Yang, P Yang, P , 1209, 2872 Yang, S...47, 169, 170, 820, 842 Yang, W Yang, Y Yang, Y Yang, Z Yang, Z Yano, K Yao, Q...832, 1229, 1243 Yao, R Yao, R Yao, Y Yarkan, H , 2595 Yasar Bilge, S Yashiro, M Yasuda, K Yasuda, S...2, 5, 456, 1179, 1628, 2638, 2677, 2864 Yasuhiro, T Yasui, T Yasui, T Yasukawa, M , 2170 Yasuoka, H , 2692 Yau, M... 81, 979 Yau, MS Yazar, M Yazdani, R Yazdany, J. 112, 420, 679, 698, 903, 1084, 1353, 1668, 1672, 1834, 1856, 2048, 2109, 2123, 2124 Yazici, A , 2750 Yazici, H , 2751, 2752, 2759, 2760, 2854 Yazici, Y...69, 370, 378, 1375, 1580, 1844, 2378, 2413, 2528, 2732, 2756, 2854 Ybañez García, D Ye, B Ye, Y Ye, Y Yeasted, RE , 925 Yeatts, P , 1756 Yee, A Yee, CS , 711 Yee, K , 611 Yeh, S Yeh, WS Yelin, E , 2048 Yelin, EH.98, 888, 2049, 2109, 2235, 2405, 2421, 2791, 2827 Yen, EY Yentür, Yeo, JG , 1309, 1618 Yeo, L , 2874 Yeremenko, N , 1973 Yerges-Armstrong, L Yerges-Armstrong, LM Yerramreddy, V Yesil, N Yeung, RSM...290, 2288, 2903 Yeung, RS Yildirim Cetin, G. 2157, 2270, 2523, 2750 Yildiz, F , 2750 Yildiz, M Yilmaz, H Yilmaz, N Yilmaz, S , 2750 Yilmaz, S , 2769 Yim, D Yin, D , 1502 Yin, F Yin, J Yin, Y Ying, J , 1303, 1304, 1825, 1826 Yip, P Yiu, G Yo, N , 2925 Yoder, L Yokoe, I Yokogawa, N , 1773 Yokosawa, M Yokota, K...39 Yokota, T Yomogida, K Yoneda, T Yonemoto, Y , 2133 Yong, W Sr Yongfei, F Yoo, B.571, 614, 702, 703, 812, 847, 2564 Yoo, DH , 1241, 1508, 1509, 2025, 2158 Yoo, HJ Yoo, IS...612, 1458, 2684, 2922 Yoo, KD Yoo, S Yoo, SJ...612, 1458, 2684, 2922 Yoo, WH...220, 1056, 2262, 2356 Yoon, BY , 2025 Yoon, BR Yoon, CH Yoon, MJ Yoshiaki, I Yoshida, H Yoshida, K , 2029, 2511 Yoshida, K , 2214 Yoshida, K Yoshida, N Yoshida, N Yoshida, S Yoshida, S Yoshifuji, H...805, 806, 1260 Yoshihara, R , 2925 Yoshihide, A Yoshikawa, M , 2691, 2806 Yoshimi, R , 125, 133 Yoshimoto, K , 1958, 2877 Yoshimura, A.986, 1040, 1238, 2977 Yoshioka, R Yoshioka, Y Yoshizaki, A...748, 756, 1724 Yoshizaki, K Yoshizawa, T , 1027 You, X You, Y...539, 1556, 1559 Young, A , 1841, 2135, 2810 Young, C , 249 Young, D , 2982 Young, F Young, J , 2309 Young, J Young, J Young, J Young, K Young, K Young, K Young, KA , 2891 Young, N Young, NA. 911, 1204, 1473, 2219, 2686 Young, S. 1798, 2535, 2543, 2930, 2978 Young-McCaughan, S Yourish, J Youssef, H Ytterberg, J , 2797 Ytterberg, SR...801, 804, 808, 880, 912, 1861, 2851 Yu, A Yu, A Yu, F , 2456 Yu, H Yu, M Yu, M Yu, N Yu, N Yu, Q Yu, S Yu, SL Yu, W Yu, Y , 2782 Yuan, J , 550, Program Book

347 Yuan, JM Yuasa, M Yucel, AE Yudoh, K Yue, Y , 2782 Yukawa, N , 1260 Yukioka, M Yule, D Yun, H...49, 57, 169, 820, 842, 1546, 1589, 1839, 1849, 1910, 2375, 2388 Yun, J Yung, R Yunis, E Yunoue, N , 2691, 2806 Yurdakul, S.2043, 2751, 2752, 2759 Yurkovich, M Z Zaal, AI Zaal, KJ Zacarias, A. 691, 695, 1656, 1659, 2194, 2620, 2780 Zacarias Crovato, A Zacariaz, J Zaccara, E...879, 1675, 1689 Zadeh, A Zaenker, M...491, 945, 2027 Zagury, JF Zaid, M Zajonc, D Zakem, JM Zakhem, G Zalevsky, J Zamora, N , 2575 Zamora Medina, MDC Zamout, P Zampeli, E Zampogna, G Zanchetta, JR Zanchetta, J Zang, Y , 3004 Zanghi, J Zanola, A... 4, 15, 1642 Zapantis, E...13 Zarco, P , 2588, 2598 Zarnitsky, C Zavada, J...129, 136, 851, 1837, 1838, 2371, 2422, 2555, 2580 Zazueta, BM Zazzetti, F , 2441 Zbarskaya, O Zbehlik, A Zea, A , 2622 Zea, A , 1643 Zécler, J Zeddou, M Zeft, A Zeft, AS Zeggini, E Zelko, FA Zen, M Zenasni, F Zeng, L Zeng, R Zeng, X , 1949 Zeng, X Zengin, B , 2595 Zeni, S Zenone, T , 256 Zerbe, N , 1262 Zerbini, A Zerbini, CAF Zerbini, C , 2493 Zerbini, CAF Zernicke, J Zeuner, RA Zevallos-Miranda, F Zha, W Zhai, G. 623, 624, 1124, 1289, 2101 Zhang, C Zhang, F Zhang, F Zhang, F Zhang, F , 1597 Zhang, H Zhang, H Zhang, HZ Zhang, J.169, 842, 1148, 1839, 2388 Zhang, L Zhang, L Zhang, M , 2095 Zhang, M Zhang, N Zhang, P , 2591 Zhang, R , 1181 Zhang, W... 18, 394, 734 Zhang, W Zhang, W Zhang, W Zhang, X , 665 Zhang, X Zhang, X Zhang, X , 1751 Zhang, X Zhang, X Zhang, X Zhang, Y , 1577 Zhang, Y Zhang, Y Zhang, Y , 624, 1124, 1289, 2101 Zhang, Y Zhang, Y , 214, 215 Zhang, Y. 171, 172, 787, 822, 827, 923, 974, 1280, 1286, 1801, 1821, 1874, 1875, 2241, 2960, 2969 Zhang, Z Zhang, Z , 611 Zhang, Z , 1953, 2782 Zhang, ZY Zhang-Hoover, J...649, 997, 1495 Zhao, L Zhao, M Zhao, M , 2680, 2685 Zhao, M Zhao, S Zhao, W... 77, 641 Zhao, X , 2949 Zhao, X Zhao, Y Zhao, Z Zhao, Z Zheng, L , 2177 Zheng, W Zhernakova, A...90 Zhi, X... 66, 1803 Zhiyi, Z , 2125 Zhou, B Zhou, H , 1529 Zhou, H Zhou, J Zhou, L Zhou, Q , 1227 Zhou, S Zhou, T Zhou, X , 745, 753 Zhou, X Zhou, Y Zhou, Y Zhou, Y , 479 Zhu, B Zhu, B Zhu, H Zhu, J Zhu, R Zhu, S Zhu, TY , 1582 Zhu, Y Zhuang, Y Zhukov, O Zielstorff, M , 2354 Ziemek, J...758, 2713, 2721 Ziesmann, E Zignego, AL Zikou, A Zilberman-Rudenko, J Zingaro, G Zingg, M Zink, A.301, 491, 1154, 1837, 1838, 2902 Zisman, D Zitnik, R Ziza, JM , 2779 Zobel, I Zochling, J...557, 1682, 2419 Zollars, E Zoma, A , 2646 Zoma, AA Zoratti, M Zou, H , 2909 Zuber, Z Zubrzycka-Sienkiewicz, A.948, 2826 Zuccoli, G Zuccotti, GV Zucht, HD Zuckerman, A Zuckerman, SH Zufferey, F Zufferey, P , 158 Zuily, S Zulian, F Zuliani, F Zummer, M...365, 421, 583, 956, 2411, 2619 Zuniga, J Zuo, X Zuo, Y...6 Zurakowski, D Zwierska, I Zwingenberg, J abstract author Index 2014 Program Book 345

348 Abril, Andy, MD Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease A Barton, Jennifer, MD Rheumatoid Arthritis - Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes Burmester, Gerd, MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems Disclosure: AbbVie, 2, 5, 8; BMS, 5, 8; Medimmune, 5; Pfizer Inc, 5, 8; Roche Pharmaceuticals, 5; Sandoz, 8; UCB, 2 Abstract Moderator disclosure Agarwal, Sandeep K., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics II Disclosure: Adheron Therap., 5 Aliprantis, Antonios O., MD, PhD Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Allen, Kelli D., PhD Epidemiology/Public Health Anolik, Jennifer H., MD, PhD B cell Biology and Targets in Autoimmune Disease Aranow, Cynthia, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis Ardoin, Stacy P., MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Askanase, Anca D., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Disclosure: Exagen, 2 Badley, Elizabeth M., PhD Innovations in Rheumatologic Care Baer, Alan N., MD Sjögren s Syndrome II: Insights into Pathophysiology Disclosure: UptoDate, 7 Baker, Nancy A., MPH, OTR, OTR/L ACR/ARHP Combined Abstract Session: Rehabilitation B Barnabe, Cheryl, MD, MSc Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Barron, Karyl, MD Pediatric Rheumatology - Pathogenesis and Genetics Behrens, Edward M., MD Innate Immunity and Rheumatic Disease Bingham III, Clifton O., MD Rheumatoid Arthritis - Clinical Aspects II: Remission and De-escalation of Therapy Disclosure: **Missing Disclosure** Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions Disclosure: **Missing Disclosure** Binstadt, Bryce A., MD, PhD ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Boackle, Susan A., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/ Injury Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Boers, Maarten, MD, MSc, PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Disclosure: BMS, 5; GSK, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5 Bombardieri, Stefano, MD Sjögren s Syndrome I: Clinical Perspectives Disclosure: GlaxoSmithKline LLC, 5 Bookman, Arthur A. M., MD Sjögren s Syndrome I: Clinical Perspectives Bradley, Laurence A., PhD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Braun, Juergen, MD Spondyloarthropathies and Psoriatic Arthritis VI - Imaging and Biomarkers Bridges Jr., S. Louis, MD, PhD Rheumatoid Arthritis - Clinical Aspects IV: Promising Biomarkers Brown, Lin, MD Rheumatoid Arthritis - Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Bykerk, Vivian P., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development Cairns, Ewa, PhD Rheumatoid Arthritis - Animal Models I Callahan, Leigh F., PhD Health Disparities/Social Determinants of Health Disclosure: **Missing Disclosure** Carter, John D., MD Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease C Chakravarty, Eliza, MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Cardiovascular Disease and Pregancy Disclosure: UCB, 5 Charles, Julia F., MD, PhD Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis Christmann, Romy, MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics II Cid, Maria C., MD, PhD Vasculitis I Disclosure: GSK and Novartis, 5 Cidon, Michal, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus Clancy, Robert M., PhD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/ Injury Clowse, Megan E. B., MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Disclosure: UCB, Program Book

349 Cohen, Philip L., MD Innate Immunity and Rheumatic Disease Disclosure: Janssen Pharmaceutica Product, L.P., 2 Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Disclosure: Amgen, 2; Merck Pharmaceuticals, 5; Pfizer Inc, 2 Conaghan, Philip G., MD, PhD Osteoarthritis - Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Criswell, Lindsey A., MD, MPH Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Disclosure: Amgen-Medimmune, 5; Crescendo Biosciences, 5 Crofford, Leslie J., MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Cronin, Mary E., MD ACR Plenary Session II: Discovery 2014 Cronstein, Bruce N., MD Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Disclosure: Arthritis Foundation, RRF, 6; CanFite Biopharma, 5; Gilead, Astrazeneca, Celgene,, 2; Multiple, 9; Regeneron, BMS, Eli Lilly, 5 Crow, Mary K., MD ACR Plenary Session III: Discovery 2014 Disclosure: Bristol-Myers Squibb, 5; Eisai, 5; GlaxoSmithKline, 5; Lilly, 5; Novo Nordisk, 2; Pfizer-CTI, 2; Takeda, 5 Crowson, Cynthia S., MS Epidemiology and Public Health I: Drug and Vaccine Safety Disclosure: Roche Pharmaceuticals, 2 Curran, Megan, MD Muscle Biology,Myositis and Myopathies D Dalbeth, Nicola, MBChB, MD Metabolic and Crystal Arthropathies II: Mechanisms of Disease Disclosure: AstraZeneca/Ardea, 2, 5; Takeda, 5; Teijin, 8 Dall era, Maria, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis Deal, Chad, MD Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Disclosure: Amgen, 5; Lilly, 5 Demoruelle, Kristen, MD Rheumatoid Arthritis - Clinical Aspects IV: Promising Biomarkers Denton, Christopher P., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Disclosure: Actelion Pharmaceuticals US, 2, 5; Bayer, 5; CSL Behring, 2; Genentech and Biogen IDEC Inc., 5; GlaxoSmithKline, 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5 Deodhar, Atul A., MD Spondyloarthropathies and Psoriatic Arthritis I - Novel Treatments Axial Spondyloarthritis Disclosure: Abbvie, Amgen, Janssen, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 Domsic, Robyn T., MD, MPH Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Dunlop, Dorothy D., PhD Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus E Edwards, N. Lawrence, MD Metabolic and Crystal Arthropathies I: Clinical Aspects Disclosure: Cymabay Pharmaceuticals, Crealta Pharmaceuticals, AstraZeneca Pharmaceuticals, Takeda Pharmaceuticals USA, 5 Elkon, Keith B., MD Systemic Lupus Erythematosus - Animal Models Fischer, Aryeh, MD Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes Flood, Joseph, MD ACR Plenary Session I: Discovery 2014 Disclosure: **Missing Disclosure** Gabay, Cem, MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Disclosure: **Missing Disclosure** F G Gaffney, Patrick, MD Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Genovese, Mark C., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Disclosure: Abbvie, 2, 5; Amgen, 2, 5; Covagen, 5; Crescendo, 5; Galapgos, 5; Gilead, 5; Lilly, 2, 5; Pfizer Inc, 2, 5; Principia, 5; Salix, 5; Sanofi- Aventis Pharmaceutical, 2, 5 Gensler, Lianne S., MD Spondyloarthropathies and Psoriatic Arthritis I - Novel Treatments Axial Spondyloarthritis Disclosure: AbbVie, 5; Celgene, 5; Janssen Pharmaceutica Product, L.P., 5; UCB, 5 Giles, Jon, MD, MPH Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk Gilkeson, Gary S., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Gladman, Dafna D., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Disclosure: BMS, GSK, Eli Lilly, 5; GSK, 2 Goldstein, Barbara, MD, MMSc Rheumatoid Arthritis - Clinical Aspects VII: New Aspects of Monitoring Disease Gordon, Jessica K., MD, MSc Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics I Gravallese, Ellen M., MD Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis H Hannan, Marian T., DSc, MPH Clinical Practice/Patient Care Haroon, Nigil, MD, PhD, DM Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis Disclosure: Abbvie, Amgen, Celgene, Janssen and UCB, 5 Hasson, Scott, PT, PhD Exemplary Abstracts Abstract Moderator disclosure 2014 Program Book 347

350 Abstract Moderator disclosure 348 Hetland, Merete Lund, DMSc, MD, PhD Rheumatoid Arthritis - Clinical Aspects VII: New Aspects of Monitoring Disease Higgs, Jay B., MD Imaging of Rheumatic Diseases: Ultrasound Hill, Catherine, MD, MBBS, MSc Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more Hummers, Laura K., MD, ScM Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Disclosure: **Missing Disclosure** Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Husni, M. Elaine, MD, MPH Orthopedics, Low Back Pain and Rehabilitation Disclosure: **Missing Disclosure** Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Disclosure: Abbvie, 5; Brigham and Women s hospital, 7; Bristol Myers Squibb, 5; Bristol- Myers Squibb, 5; Celgene, 5; Eli Lilly and Company, 5; Genzyme Corporation, 2; Janssen Pharmaceutica Product, L.P., 5; Novartis Pharmaceutical Corporation, 5; UCB, 5 Hyrich, Kimme, MD, PhD Rheumatoid Arthritis - Clinical Aspects II: Remission and De-escalation of Therapy Disclosure: Abbvie, 5; Pfizer Inc, 5 Imundo, Lisa F., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Disclosure: HHoffman-LaRoche, Ltd, 2; UCB, 2 Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus 2014 Program Book I Inman, Robert D., MD Spondyloarthropathies and Psoriatic Arthritis VI - Imaging and Biomarkers Disclosure: Abbvie, Amgen, Janssen, UCB, Pfizer, 5 Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology: From Genes to Cytokines Disclosure: Amgen, Janssen, UCB, Abbvie, Pfizer, 5 Jackson, Shaun, MD PhD B cell Biology and Targets in Autoimmune Disease J Johnson, Sindhu R., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Kalliolias, George D., MD, PhD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II K Kalunian, Kenneth C., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Kamen, Diane L., MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Kang, Insoo, MD T cell Biology and Targets in Autoimmune Disease Katz, Jeffrey N., MD, MSc Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more Kavanaugh, Arthur, MD Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis Disclosure: Abbvie, 2; Amgen, 2; Janssen Pharmaceutica Product, L.P., 2; ucb, 2 Kay, Jonathan, MD Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis - Late in Development Disclosure: AbbVie Inc., 2, 5; Amgen, 5; Ardea Biosciences, Inc., 2; AstraZeneca, 5; Bristol- Myers Squibb, 5; Crescendo Bioscience, Inc., 5; Eli Lilly and Company, 2, 5; Epirus Biopharmaceuticals, Inc., 5; Genentech Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, 5; Roche Laboratories, Inc., 2, 5 Kermani, Tanaz A., MD Vasculitis III Klein-Gitelman, Marisa S., MD, MPH ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Kloppenburg, M., MD, PhD Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Disclosure: AbbVie Inc., 9; Arthritis and Rheumatology, 6; Dutch Arthritis Foundation, Pfizer, TI Pharma, 2; Leiden University Medical Center, 3; Pfizer Inc., 8 Koné-Paut, Isabelle, MD Miscellaneous Rheumatic and Inflammatory Diseases Disclosure: Novartis, Pfizer, SOBI, Abbvie, Chugai, 5 Krishnan, Eswar, MD Exemplary Abstracts Disclosure: **Missing Disclosure** L Lafyatis, Robert, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics I Disclosure: Shire, Sanofi, Regeneron, Roche/ Genentech, Biogen, Lycera, Novartis, Celgene, BMS, Amira, Celdara, Celltex, Dart Therapeutics, Idera, Inception, Intermune, Medimmune, Precision Dermatology, Promedior, Zwitter, PRISM, UCB, Actelion, EMD Serono, Ak, 5; Shire, Sanofi/Genzyme, Regeneron, Genentech, UCB, HGS, Precision Dermatology, Biogen, BMS, 2 Landewé, Robert B. M., MD, PhD Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment Lang, Bianca, MD Muscle Biology,Myositis and Myopathies Disclosure: **Missing Disclosure** Lassere, Marissa N., MD, PhD ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Disclosure: **Missing Disclosure** Lazaro, Deana M., MD Education Lee, Yvonne C., MD, MMSc Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Pain: Basic and Clinical Aspects I Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Levy, Roger A., MD Antiphospholipid Syndrome Disclosure: A ACTION, 2; Inova Diagnostics, Inc., 8 Liao, Katherine, MD, MPH Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease

351 Lim, S. Sam, MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Disclosure: GlaxoSmithKline, 2 Lo, Grace H., MD, MSc Osteoarthritis - Clinical Aspects I: Imaging in Osteoarthritis Losina, Elena, PhD Health Services Research: Improving Clinical Practice Lotz, Martin K., MD Pain: Basic and Clinical Aspects I Louie, Grant H., MD, MHS Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk M Mahr, Alfred, MD, PhD Vasculitis III Makris, Una, MD Health Services Research: Improving Clinical Practice Malfait, Anne-Marie, MD, PhD Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Marder, Wendy, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Cardiovascular Disease and Pregnancy Markenson, Joseph A., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis - Late in Development Disclosure: Amgen,BMS,IROKO,Anteres,Celgene, Abbvie,and PFizer, 8 Matsumoto, Alan K., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Amgen, 2, 5; Ardea Biosciences, 2; Astellas, 2; AstraZeneca, 5; Auxillium, 2; Boehringer Ingelheim, 2; Bristol- Myers Squibb, 2; Cardinal Health, 5; Celgene, 2; Centocor, Inc., 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Hoffmann- La Roche, Inc., 2; Horizon, 5; Human Genome Sciences, Inc., 2; Janssen Pharmaceutica Product, L.P., 2; Medac Pharma, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5; Regeneron, 2; Sanofi-Aventis Pharmaceutical, 2; Seikagaku, 2; Takeda, 2; Xoma Corporation, 2 Matteson, Eric L., MD, MPH ACR Plenary Session II: Discovery 2014 Disclosure: Ardea Biosciences, 2; Biogen Idec, 2; Celgene, 2; Centocor, Inc., 2; Genentech and Biogen IDEC Inc., 2; Mesoblast, 2; National Institutes of Health., 2; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2 Maz, Mehrdad, MD Miscellaneous Rheumatic and Inflammatory Diseases McInnes, Iain B., PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development Disclosure: Elly Lilly, 5; Galapagos, 5; Pfizer Inc, 2, 5; Vertex, 5 McMahon, Maureen A., MD 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Disclosure: Glaxo Smith Klein, 8 Mease, Philip J., MD Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; Covagen, 5; Crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5, 8 Michaud, Kaleb, PhD Epidemiology and Public Health I: Drug and Vaccine Safety Disclosure: National Data Bank for Rheumatic Diseases, 3; Rheumatology Research Foundation, 2 N Navarro-Millan, Iris, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Newman, Eric D., MD Quality Measures and Quality of Care Nguyen, Uyen Sa D.T., DSc, MPH Epidemiology/Public Health Nigrovic, Peter A., MD Rheumatoid Arthritis - Animal Models I O O Rourke, Kenneth S., MD Education Oddis, Chester V., MD ACR Plenary Session I: Discovery 2014 Disclosure: Genentech and Biogen IDEC Inc., 2 Late-breaking Abstracts Session Disclosure: Genentech and Biogen IDEC Inc., 2 Orange, Dana E., MD, MS Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II P Paget, Stephen A., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection Disclosure: Crescendo bioscience, 5 Pap, Thomas, MD Rheumatoid Arthritis - Animal Models II Passo, Murray H., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Disclosure: Pfizer Inc, 2, 5 Perl, Andras, MD, PhD T cell Biology and Targets in Autoimmune Disease Disclosure: Pfizer Inc, 2 Perlman, Harris R., PhD Rheumatoid Arthritis - Animal Models II Disclosure: **Missing Disclosure** Peterfy, Charles, MD, PhD Imaging of Rheumatic Diseases: X-Ray, MRI and CT Disclosure: Amgen, 8; Spire Sciences, Inc., 1, 3, 4 Peterson, Erik J., MD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Piva, Sara R., PhD, PT Osteoarthritis Porter, Duncan, MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Disclosure: Pfizer Inc, 2; Roche Pharmaceuticals, 2 Abstract Moderator disclosure 2014 Program Book 349

352 Abstract Moderator disclosure 350 R Rauch, Joyce, PhD Antiphospholipid Syndrome Reiff, Andreas, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Reveille, John D., MD Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Richardson, Jan K., PT, PhD, OCS Osteoarthritis Ritchlin, Christopher T., MD, MPH Spondyloarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines Disclosure: Abbott Laboratories, 5; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P., 2, 5, Novartis Pharmaceutical Corporation, 5; Regneron, 5 Rose, Jillian A., LCSW Health Disparities/Social Determinants of Health Ruderman, Eric, MD Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis Disclosure: AbbVie, 5; Amgen, 2, 5; Celgene, 2, 5; Lilly, 5; Pfizer Inc, 5 S Salt, Elizabeth G., PhD ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Disclosure: NIH, 2; Pfizer Inc, 5; SmithKLine Beecham, 1 Sawalha, Amr, MD Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Schmidt, Wolfgang A., MD Imaging of Rheumatic Diseases: Ultrasound Disclosure: Esaote, 2; General Electric, 2; Siemens, 2 Shadick, Nancy A., MD, MPH Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions Disclosure: ABBVIE, 2; Amgen, 2; BMS, UCB, Crescendo Biosciences, 2; Genentech and Biogen IDEC Inc., 2; Merck Human Health, 3 Shahrara, Shiva, PhD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I Sharma, Leena, MD Osteoarthritis - Clinical Aspects I: Imaging in Osteoarthritis 2014 Program Book Shelef, Miriam A., MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Singer, Nora G., MD Pediatric Rheumatology - Pathogenesis and Genetics Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Singh, Jasvinder A., MD, MPH Orthopedics, Low Back Pain and Rehabilitation Disclosure: **Missing Disclosure** Systemic Lupus Erythematosus - Animal Models Sivils, Kathy L., PhD Sjögren s Syndrome II: Insights into Pathophysiology So, Alexander, MD Metabolic and Crystal Arthropathies II: Mechanisms of Disease Disclosure: AstraZeneca, 8 Sokolove, Jeremy, MD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Soriano, Enrique R., MD, MSc Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Janssen Pharmaceutica Product, L.P., 2; Roche Pharmaceuticals, 2, 5; UCB, 2, 5 Spiera, Robert F., MD Vasculitis II Disclosure: Roche Genetch, 2 Suter, Lisa, MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives T Tanner, S. Bobo, MD Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Disclosure: Amgen, TEVA, Anteres, Celgene,Pfizer,Navitus, UCB, 5; Merck, Lilly, GSK, Pfizer,Novartis, UCB, Astra-Zeneca, 2; Pfizer Antares, BMS, 8 Taylor, Peter C., MD, PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection Disclosure: UCB, 2; UCB, Pfizer, Merck, AstraZeneca, Abbvie, BMS, NovoNordisk, Celgene, Lilly, 5 Troum, Orrin M, MD Imaging of Rheumatic Diseases: X-Ray, MRI and CT U Unizony, Sebastian, MD Vasculitis II V Van den Bosch, Filip, MD, PhD Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment Disclosure: Abbvie, Celgene, Merck, Pfizer, UCB, 5; Abbvie, Janssen, Pfizer, UCB, 8 Varga, John, MD ACR Plenary Session III: Discovery 2014 Vazquez-Mellado, Janitzia, MD, PhD Metabolic and Crystal Arthropathies I: Clinical Aspects Vinet, Evelyne, MD Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus W Wallace, Daniel J., MD 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Warrington, Kenneth J., MD Vasculitis I White, Daniel K., PT, ScD, MSc ACR/ARHP Combined Abstract Session: Rehabilitation Y Yazdany, Jinoos, MD MPH Quality Measures and Quality of Care Yelin, Edward H., PhD Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease Yunus, Muhammad, MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives Z Zeft, Andrew S., MD, MPH Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Disclosure: Merck Pharmaceuticals, 1; Novartis, 5; OPKO, 1

353 Enbrel (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months). Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months). Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years. Other Malignancies Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown. Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was cases per 100 patient-years. Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin s and non-hodgkin s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 1140 pediatric patients representing patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Reactivation Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe and the needle cover within the needle cap of the SureClick autoinjector. Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions]. Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated. Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNFblocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener s Granulomatosis Patients The use of Enbrel in patients with Wegener s granulomatosis receiving

354 immunosuppressive agents is not recommended. In a study of patients with Wegener s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions]. Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza. In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/ Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials. In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6% 8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials Placebo Controlled a (Studies I, II, and a Phase 2 Study) Placebo (N = 152) Enbrel c (N = 349) Active Controlled b (Study III) MTX (N = 217) Enbrel c (N = 415) Reaction Percent of Patients Percent of Patients Infection d (total) Upper Respiratory Infections e Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. b Study duration of 2 years. c Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 359) Enbrel a (N = 876) Reaction Percent of Patients Infection b (total) Non-upper Respiratory Infections Upper Respiratory Infections c Injection Site Reactions Diarrhea Rash Pruritus Urticaria Hypersensitivity Pyrexia a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. b Includes bacterial, viral and fungal infections. c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis. Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure. Adverse reactions are listed by body system below: Blood and lymphatic system disorders: Cardiac disorders: Gastrointestinal disorders: General disorders: Hepatobiliary disorders: Immune disorders: Musculoskeletal and connective tissue disorders: Neoplasms benign, malignant, and unspecified: Nervous system disorders: Ocular disorders: Respiratory, thoracic and mediastinal disorders: pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions] congestive heart failure [see Warnings and Precautions] inflammatory bowel disease (IBD) angioedema, chest pain autoimmune hepatitis, elevated transaminases, hepatitis B reactivation macrophage activation syndrome, systemic vasculitis lupus-like syndrome melanoma and non-melanoma skin cancers, merkel cell carcinoma [see Warnings and Precautions] convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions] uveitis, scleritis interstitial lung disease Skin and subcutaneous tissue disorders: cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B Pregnancy Surveillance Program There is a Pregnancy Surveillance Program that monitors outcomes in women exposed to Enbrel during pregnancy. Women who become pregnant during Enbrel treatment are encouraged to enroll. Patients or their physicians should call AMGEN ( ) to enroll. Risk Summary There are no adequate and well controlled studies in pregnant women. Based on limited data, etanercept concentration in cord blood at the time of delivery showed that etanercept crossed the placenta in small amounts. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Human Data Three case reports showed that cord blood levels of etanercept at delivery in infants, born to mothers administered etanercept during pregnancy, were between 3 and 32% of the maternal serum level. Nursing Mothers Limited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. Caution should be exercised when Enbrel is administered to a nursing woman. The development and health benefits of breastfeeding should be considered along with the mother s clinical need for Enbrel and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Women who choose to continue Enbrel treatment while nursing are encouraged to enroll in Amgen s Lactation Surveillance Program. Patients or their physicians should call AMGEN ( ) to enroll. Pediatric Use Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions (6.2)]. The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. Geriatric Use A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. Use in Diabetics There have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. Rx Only. This brief summary is based on ENBREL prescribing information v.53: 11/ Amgen Inc., Thousand Oaks, CA All rights reserved. US License Number Immunex Corporation. All rights reserved. US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. For more information please call or visit R5-V1 V53

355 IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefi ts of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients In patients who initiated therapy at 18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin s and non-hodgkin s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants. NEUROLOGIC EVENTS Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURE Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored. HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed. HEPATITIS B REACTIVATION Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients. ALLERGIC REACTIONS Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated. IMMUNIZATIONS Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin. AUTOIMMUNITY Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops. WEGENER S GRANULOMATOSIS PATIENTS The use of ENBREL in patients with Wegener s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended. MODERATE TO SEVERE ALCOHOLIC HEPATITIS Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis. ADVERSE EVENTS The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials. DRUG INTERACTIONS The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients. Please see Brief Summary of Prescribing Information on the preceding pages. References: 1. Enbrel (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, Calif. November Data on fi le, Amgen; #1 Biologic for Rheumatologists: May 2, Data on fi le, Amgen; TEMPO CSR yr Clinical: June 21, Amgen Inc., Thousand Oaks, CA All rights reserved R1-V1

356 In moderately to severely active rheumatoid arthritis (RA) Help patients get back to many of the activities they love ACTIVE MOVEMENT ENABLE EXPLORE SUPPORT ENBREL ENBREL + MTX achieved signifi cant improvements in physical function vs MTX alone as measured by HAQ-DI by Week 2 and out to Year 3 1 * Whether your patients are practicing their putt, spending time with family, or walking their dog, ENBREL has been a symbol of change for your patients with moderate to severe RA. Since 1998, ENBREL was the first and is still the only FDA-approved soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL is the #1 prescribed biologic by rheumatologists today. 2 ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection. Important Safety Considerations: ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis. Please see additional Important Safety Information and Brief Summary on preceding pages. *In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n = 228) and 1.8, 1.3, and 0.8 in the ENBREL + MTX arm (n = 231), respectively. 3 HAQ-DI = Health Assessment Questionnaire-Disability Index. 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts. Visit Booth #943 to see how you can help patients get back to many of the activities they love. Enbrel and the Enbrel logo are registered trademarks of Immunex Corporation.